0001437749-24-03492510-Q DiaMedica Therapeutics Inc. 20241113202411131622451622451622245 0 0001437749-24-034925 10-Q 67 20240930 20241113 20241113 DiaMedica Therapeutics Inc. 0001401040 2834 000000000 Z4 1231 10-Q 34 001-36291 241454666 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305 (763) 496-5454 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305 DiaMedica Inc. 20070525 10-Q 1 dmtp20240930_10q.htm FORM 10-Q dmtp20240930_10q.htm Q3 2024 --12-31 false 0001401040 false false false false 1 5 4 1 10 0 0 Unlimited Unlimited 0 0 00014010402024-01-012024-09-30 thunderdome:item 00014010402024-07-012024-09-30 utr:Y xbrli:shares 00014010402024-09-30 iso4217:USDxbrli:shares 0001401040dmac:ExercisePriceRange5Member2024-01-012024-09-30 0001401040dmac:ExercisePriceRange5Member2024-09-30 0001401040dmac:ExercisePriceRange4Member2024-01-012024-09-30 0001401040dmac:ExercisePriceRange4Member2024-09-30 0001401040dmac:ExercisePriceRange3Member2024-01-012024-09-30 0001401040dmac:ExercisePriceRange3Member2024-09-30 0001401040dmac:ExercisePriceRange2Member2024-01-012024-09-30 0001401040dmac:ExercisePriceRange2Member2024-09-30 0001401040dmac:ExercisePriceRange1Member2024-01-012024-09-30 0001401040dmac:ExercisePriceRange1Member2024-09-30 iso4217:USD 0001401040us-gaap:EmployeeStockOptionMember2024-01-012024-09-30 0001401040us-gaap:EmployeeStockOptionMember2023-12-31 00014010402023-01-012023-09-30 00014010402023-07-012023-09-30 0001401040us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-30 0001401040us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-30 0001401040us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-30 0001401040us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-30 0001401040us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-30 0001401040us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-30 0001401040us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-30 0001401040us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-30 0001401040dmac:The2012DSUPlanMember2024-09-30 0001401040dmac:StockOptionPriorPlanMember2024-09-30 0001401040dmac:The2021EmploymentInducementIncentivePlanMember2024-09-30 0001401040dmac:The2021EmploymentInducementIncentivePlanMember2021-12-03 0001401040dmac:The2019OmnibusIncentivePlanMember2024-09-30 0001401040us-gaap:RestrictedStockUnitsRSUMemberdmac:The2019OmnibusIncentivePlanMember2024-09-30 0001401040dmac:DeferredShareUnitsMemberdmac:The2019OmnibusIncentivePlanMember2024-09-30 0001401040dmac:The2019OmnibusIncentivePlanMember2024-05-22 0001401040dmac:NonemployeeStockOptionsMemberdmac:The2019OmnibusIncentivePlanMember2022-05-182022-05-18 0001401040dmac:EmployeeAndNonemployeeStockOptionsMemberdmac:The2019OmnibusIncentivePlanMembersrt:MaximumMember2022-05-182022-05-18 0001401040dmac:EmployeeAndNonemployeeStockOptionsMemberdmac:The2019OmnibusIncentivePlanMembersrt:MinimumMember2022-05-182022-05-18 0001401040dmac:EmployeeAndNonemployeeStockOptionsMemberdmac:The2019OmnibusIncentivePlanMember2022-05-182022-05-18 0001401040us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-30 0001401040us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-30 0001401040us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-30 0001401040us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-30 0001401040dmac:DeferredShareUnitsMember2023-01-012023-09-30 0001401040dmac:DeferredShareUnitsMember2024-01-012024-09-30 0001401040dmac:DeferredShareUnitsMember2023-07-012023-09-30 0001401040dmac:DeferredShareUnitsMember2024-07-012024-09-30 0001401040us-gaap:WarrantMember2023-01-012023-09-30 0001401040us-gaap:WarrantMember2024-01-012024-09-30 0001401040us-gaap:WarrantMember2023-07-012023-09-30 0001401040us-gaap:WarrantMember2024-07-012024-09-30 0001401040dmac:EmployeeAndNonemployeeStockOptionsMember2023-01-012023-09-30 0001401040dmac:EmployeeAndNonemployeeStockOptionsMember2024-01-012024-09-30 0001401040dmac:EmployeeAndNonemployeeStockOptionsMember2023-07-012023-09-30 0001401040dmac:EmployeeAndNonemployeeStockOptionsMember2024-07-012024-09-30 0001401040dmac:The2021EmploymentInducementIncentivePlanMember2024-09-30 0001401040dmac:The2019OmnibusIncentivePlanMember2024-09-30 0001401040us-gaap:RestrictedStockUnitsRSUMember2024-09-30 0001401040dmac:DeferredShareUnitsMember2024-09-30 0001401040dmac:StockOptionsOutstandingMember2024-09-30 0001401040us-gaap:PrivatePlacementMember2023-06-212023-06-21 0001401040us-gaap:PrivatePlacementMemberdmac:DirectorsAndOfficersMember2023-06-21 0001401040us-gaap:PrivatePlacementMember2023-06-21 0001401040dmac:ChiefBusinessOfficerMember2023-04-10 0001401040dmac:ChiefBusinessOfficerMember2023-04-102023-04-10 0001401040us-gaap:PrivatePlacementMember2024-06-252024-06-25 0001401040us-gaap:PrivatePlacementMember2024-06-25 00014010402023-12-31 0001401040us-gaap:LeaseholdImprovementsMember2023-12-31 0001401040us-gaap:LeaseholdImprovementsMember2024-09-30 0001401040us-gaap:ComputerEquipmentMember2023-12-31 0001401040us-gaap:ComputerEquipmentMember2024-09-30 0001401040us-gaap:FurnitureAndFixturesMember2023-12-31 0001401040us-gaap:FurnitureAndFixturesMember2024-09-30 0001401040dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember2023-12-31 0001401040dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember2024-09-30 0001401040us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001401040us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001401040us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001401040us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001401040us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001401040us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001401040us-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001401040us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-31 0001401040us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-31 0001401040us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-31 0001401040us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-31 0001401040us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-30 0001401040us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-30 0001401040us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-30 0001401040us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-30 0001401040us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberdmac:CommercialPaperAndCorporateBondsMember2023-12-31 0001401040us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberdmac:CommercialPaperAndCorporateBondsMember2023-12-31 0001401040us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberdmac:CommercialPaperAndCorporateBondsMember2023-12-31 0001401040us-gaap:FairValueMeasurementsRecurringMemberdmac:CommercialPaperAndCorporateBondsMember2023-12-31 0001401040us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberdmac:CommercialPaperAndCorporateBondsMember2024-09-30 0001401040us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberdmac:CommercialPaperAndCorporateBondsMember2024-09-30 0001401040us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberdmac:CommercialPaperAndCorporateBondsMember2024-09-30 0001401040us-gaap:FairValueMeasurementsRecurringMemberdmac:CommercialPaperAndCorporateBondsMember2024-09-30 00014010402023-09-30 00014010402022-12-31 0001401040us-gaap:RetainedEarningsMember2023-09-30 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-30 0001401040us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001401040us-gaap:CommonStockMember2023-09-30 0001401040us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-30 0001401040us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0001401040us-gaap:CommonStockMember2023-07-012023-09-30 00014010402023-06-30 0001401040us-gaap:RetainedEarningsMember2023-06-30 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30 0001401040us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001401040us-gaap:CommonStockMember2023-06-30 00014010402023-04-012023-06-30 0001401040us-gaap:RetainedEarningsMember2023-04-012023-06-30 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-30 0001401040us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001401040us-gaap:CommonStockMember2023-04-012023-06-30 00014010402023-03-31 0001401040us-gaap:RetainedEarningsMember2023-03-31 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-31 0001401040us-gaap:AdditionalPaidInCapitalMember2023-03-31 0001401040us-gaap:CommonStockMember2023-03-31 00014010402023-01-012023-03-31 0001401040us-gaap:RetainedEarningsMember2023-01-012023-03-31 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-31 0001401040us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0001401040us-gaap:CommonStockMember2023-01-012023-03-31 0001401040us-gaap:RetainedEarningsMember2022-12-31 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0001401040us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001401040us-gaap:CommonStockMember2022-12-31 0001401040us-gaap:RetainedEarningsMember2024-09-30 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-30 0001401040us-gaap:AdditionalPaidInCapitalMember2024-09-30 0001401040us-gaap:CommonStockMember2024-09-30 0001401040us-gaap:RetainedEarningsMember2024-07-012024-09-30 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-30 0001401040us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0001401040us-gaap:CommonStockMember2024-07-012024-09-30 00014010402024-06-30 0001401040us-gaap:RetainedEarningsMember2024-06-30 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-30 0001401040us-gaap:AdditionalPaidInCapitalMember2024-06-30 0001401040us-gaap:CommonStockMember2024-06-30 00014010402024-04-012024-06-30 0001401040us-gaap:RetainedEarningsMember2024-04-012024-06-30 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-30 0001401040us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001401040us-gaap:CommonStockMember2024-04-012024-06-30 00014010402024-03-31 0001401040us-gaap:RetainedEarningsMember2024-03-31 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-31 0001401040us-gaap:AdditionalPaidInCapitalMember2024-03-31 0001401040us-gaap:CommonStockMember2024-03-31 00014010402024-01-012024-03-31 0001401040us-gaap:RetainedEarningsMember2024-01-012024-03-31 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-31 0001401040us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0001401040us-gaap:CommonStockMember2024-01-012024-03-31 0001401040us-gaap:RetainedEarningsMember2023-12-31 0001401040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0001401040us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001401040us-gaap:CommonStockMember2023-12-31 00014010402023-01-012023-12-31 00014010402024-11-11 Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â Â FORM 10-Q (Mark one) â˜QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â or Â â˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Â Commission File Number: 001-36291 Â Â DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Â British Columbia (State or other jurisdiction of incorporation or organization) Not Applicable (I.R.S. Employer Identification No.) Â 301 Carlson Parkway, Suite 210 Minneapolis, Minnesota 55305 (Address of principal executive offices) (Zip Code) (763) 496-5454 (Registrantâ€™s telephone number, including area code) Â Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC Â Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ NO â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ NO â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filerÂ â˜ Accelerated filerÂ â˜ Non-accelerated filerÂ â˜’ Smaller reporting companyÂ â˜’ Â Emerging growth companyÂ â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.Â â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES â˜ NOÂ â˜’ Â As of November 11, 2024, there were 42,760,582 voting common shares of the registrant outstanding. Â Â Â Â Â DiaMedica Therapeutics Inc. FORM 10-Q September 30, 2024 Â TABLE OF CONTENTS Â Description Page Â CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 1 Â Â Â PART I. FINANCIAL INFORMATION Â Â Â Â Item 1. Financial Statements 3 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and ResultsÂ of Operations 14 Item 3. Quantitative and Qualitative Disclosures about Market Risk 20 Item 4. Controls and Procedures 20 Â Â Â PART II. OTHER INFORMATION Â Item 1. Legal Proceedings 21 Item 1A. Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 23 Â Â Â Â Â SIGNATURE PAGE 24 Â Â Â This quarterly report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, that are subject to the safe harbor created by those sections. For more information, see â€œCautionary Note Regarding Forward-Looking Statements.â€ Â As used in this report, references to â€œDiaMedica,â€ the â€œCompany,â€ â€œwe,â€ â€œourâ€ or â€œus,â€ unless the context otherwise requires, refer to DiaMedica Therapeutics Inc. and its subsidiaries, all of which are consolidated in DiaMedicaâ€™s condensed consolidated financial statements. References in this report to â€œcommon sharesâ€ mean our voting common shares, no par value per share. Â We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the Â® and â„¢ symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companiesâ€™ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Â Â Â Â CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Â Statements in this report that are not descriptions of historical facts are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that are based on managementâ€™s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, prospects and share price. We have attempted to identify forward-looking statements by terminology including â€œanticipates,â€ â€œbelieves,â€ â€œcan,â€ â€œcontinue,â€ â€œcould,â€ â€œestimates,â€ â€œexpects,â€ â€œintends,â€ â€œmay,â€ â€œplans,â€ â€œpotential,â€ â€œpredicts,â€ â€œshould,â€ â€œwill,â€ â€œwould,â€ the negative of these terms or other comparable terminology and the use of future dates. Â The forward-looking statements in this report are subject to risks and uncertainties and include, among other things: Â Â â— our plans to develop, obtain regulatory approval for and commercialize our DM199 product candidate for the treatment of acute ischemic stroke (AIS) and preeclampsia (PE); Â Â â— our expansion into PE, the ability of our physician collaborators to successfully conduct a Phase 2, proof-of-concept clinical trial of DM199 as a treatment for PE and our reliance on our physician collaborators; Â Â â— our ability to conduct successful clinical testing of our DM199 product candidate for AIS and PE and meet certain anticipated or target dates with respect to our clinical studies,; Â Â â— our ability to meet anticipated site activations, enrollment and interim analysis timing with respect to our Phase 2/3 ReMEDy2 clinical trial of DM199 for the treatment of AIS, especially in the light of slower than expected site activations and enrollment which we believe are due, in part, to hospital and medical facility staffing shortages;Â inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to another hospital or an

intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the clinical hold which was lifted in June 2023; and competition for research staff and trial subjects due to other pending stroke and neurological trials; Â Â â— the success of the actions we are taking to mitigate the impact of the factors adversely affecting our ReMEDy2 trial site activations and enrollment rate, including significantly expanding our internal clinical team and bringing in-house certain trial activities, including study site identification, qualification and activation, clinical site monitoring, and overall program management; globally expanding the trial, and making certain changes to the study protocol; and risks associated with these mitigation actions; Â Â â— uncertainties relating to regulatory applications and related filing and approval timelines, and the possibility of additional future adverse events associated with or unfavorable results from our ReMEDy2 trial or the Phase 2 investigator-sponsored PE trial; Â Â â— the adaptive design of our ReMEDy2 trial, which is intended to enroll approximately 350 participants at up to 100 sites globally, and the possibility that these numbers and other aspects of the study could increase depending upon certain factors, including additional input from the United States Food and Drug Administration (FDA) and results of the interim analysis as determined by the independent data safety monitoring board; Â Â â— our expectations regarding the perceived benefits of our DM199 product candidate over existing treatment options for AIS and PE; Â Â â— our ability to partner with and generate revenue from biopharmaceutical or pharmaceutical partners to develop, obtain regulatory approval for and commercialize our DM199 product candidate for AIS and PE; Â Â â— the potential size of the markets for our DM199 product candidate for AIS and PE and our or any future partnerâ€™s ability to serve those markets, the rate and degree of market acceptance of and ability to obtain coverage and adequate reimbursement for, our DM199 product candidate for AIS and PE both in the United States and internationally; Â Â â— the success, cost and timing of our ReMEDy2 trial, as well as our reliance on our key executives, clinical personnel, advisors and third parties in connection with our ReMEDy2 trial; Â Â â— our or any future partnerâ€™s ability to commercialize, market and manufacture DM199; Â Â â— expectations regarding federal, state and foreign regulatory requirements and developments affecting our pending and future clinical trials and regulatory approvals of our DM199 product candidate for AIS and PE and future commercialization and manufacturing of such products if required regulatory approvals are obtained; Â Â â— our estimates regarding expenses, market opportunity for our product candidates, future revenue, capital requirements, how long our current cash resources will last and need for additional financing; Â Â â— our expectations regarding our ability to obtain and maintain intellectual property protection for our DM199 product candidate; Â Â â— expectations regarding competition and our ability to obtain data exclusivity for our DM199 product candidate for AIS and PE; Â Â â— our anticipated use of the net proceeds from our June 2024 private placement; and Â Â 1Â Â Â â— our ability to obtain additional funding for our operations, including funding necessary to complete our current clinical trials and obtain regulatory approvals for our DM199 product candidate for AIS and/or PE. Â These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under â€œPart I. Item 1A. Risk Factorsâ€ in our annual report on Form 10-K for the fiscal year ended December 31, 2023, in this quarterly report on Form 10-Q for the quarterly period ended September 30, 2024 and those described above and elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, including the securities laws of the United States, we do not intend to update any forward-looking statements to conform these statements to actual results or to changes in our expectations. Â 2Â Â PART I - FINANCIAL INFORMATION Â ITEM 1. FINANCIAL STATEMENTS Â Â DiaMedica Therapeutics Inc. Condensed Consolidated Balance Sheets (In thousands, except share amounts) Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â (unaudited) Â Â Â Â Â ASSETS Â Â Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 4,134 Â Â $ 4,543 Â Marketable securities Â Â 46,063 Â Â Â 48,352 Â Amounts receivable Â Â 290 Â Â Â 369 Â Prepaid expenses and other assets Â Â 280 Â Â Â 411 Â Total current assets Â Â 50,767 Â Â Â 53,675 Â Â Â Â Â Â Â Â Â Â Non-current assets: Â Â Â Â Â Â Â Â Deposits Â Â 1,308 Â Â Â â€” Â Operating lease right-of-use asset, net Â Â 298 Â Â Â 354 Â Property and equipment, net Â Â 151 Â Â Â 131 Â Total non-current assets Â Â 1,757 Â Â Â 485 Â Â Â Â Â Â Â Â Â Â Total assets Â $ 52,524 Â Â $ 54,160 Â Â Â Â Â Â Â Â Â Â LIABILITIES AND EQUITY Â Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Â Accounts payable Â $ 1,171 Â Â $ 926 Â Accrued liabilities Â Â 3,024 Â Â Â 1,777 Â Operating lease obligation Â Â 88 Â Â Â 80 Â Finance lease obligation Â Â 14 Â Â Â 3 Â Total current liabilities Â Â 4,297 Â Â Â 2,786 Â Â Â Â Â Â Â Â Â Â Non-current liabilities: Â Â Â Â Â Â Â Â Operating lease obligation Â Â 249 Â Â Â 316 Â Finance lease obligation Â Â 14 Â Â Â 1 Â Total non-current liabilities Â Â 263 Â Â Â 317 Â Â Â Â Â Â Â Â Â Â Shareholdersâ€™ equity: Â Â Â Â Â Â Â Â Common shares, no par value; unlimited authorized; 42,766,497 and 37,958,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Â Â â€” Â Â Â Â Â â€” Â Paid-in capital Â Â 179,985 Â Â Â 166,609 Â Accumulated other comprehensive income Â Â 81 Â Â Â 6 Â Accumulated deficit Â Â (132,102) Â Â (115,558) Total shareholdersâ€™ equity Â Â 47,964 Â Â Â 51,057 Â Total liabilities and shareholdersâ€™ equity Â $ 52,524 Â Â $ 54,160 Â Â See accompanying notes to the condensed consolidated financial statements. Â 3Â Â Â DiaMedica Therapeutics Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Â Â Â Three Months Ended September 30, Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â $ 4,983 Â Â $ 3,272 Â Â $ 12,587 Â Â $ 9,433 Â General and administrative Â Â 1,900 Â Â Â 1,885 Â Â Â 5,675 Â Â Â 5,986 Â Operating loss Â Â (6,883) Â Â (5,157) Â Â (18,262) Â Â (15,419) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other income: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other income, net Â Â 616 Â Â Â 693 Â Â Â 1,739 Â Â Â 1,220 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Loss before income tax expense Â Â (6,267) Â Â (4,464) Â Â (16,523) Â Â (14,199) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income tax expense Â Â (7) Â Â (7) Â Â (21) Â Â (21) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â Â (6,274) Â Â (4,471) Â Â (16,544) Â Â (14,220) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other comprehensive gain (loss) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Unrealized gain (loss) on marketable securities Â Â 132 Â Â Â (64) Â Â 75 Â Â Â (53) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss and comprehensive loss Â $ (6,142) Â $ (4,535) Â $ (16,469) Â $ (14,273) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted net loss per share Â $ (0.15) Â $ (0.12) Â $ (0.42) Â $ (0.46) Weighted average shares outstanding â€“ basic and diluted Â Â 42,751,577 Â Â Â 37,949,422 Â Â Â 39,604,179 Â Â Â 30,751,329 Â Â See accompanying notes to the condensed consolidated financial statements. Â 4Â Â Â DiaMedica Therapeutics Inc. Condensed Consolidated Statements of Shareholdersâ€™ Equity For the Nine Months Ended September 30, 2024 and 2023 (In thousands, except share amounts) (Unaudited) Â Â Â Common Shares Â Â Paid-In Capital Â Â Accumulated Other Comprehensive Gain (Loss) Â Â Accumulated Deficit Â Â Total Shareholdersâ€™ Equity Â Balances at December 31, 2023 Â Â 37,958,000 Â Â $ 166,609 Â Â $ 6 Â Â $ (115,558) Â $ 51,057 Â Issuance of common shares upon the vesting and settlement of restricted stock units Â Â 5,916 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Share-based compensation expense Â Â â€” Â Â Â 488 Â Â Â â€” Â Â Â 488 Â Unrealized loss on marketable securities Â Â â€” Â Â Â â€” Â Â Â (45) Â Â â€” Â Â Â (45) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (5,151) Â Â (5,151) Balances at March 31, 2024 Â Â 37,963,916 Â Â $ 167,097 Â Â $ (39) Â $ (120,709) Â $ 46,349 Â Issuance of common shares net of offering costs of $0.1 million Â Â 4,720,000 Â Â Â 11,747 Â Â Â â€” Â Â Â â€” Â Â Â 11,747 Â Issuance of common shares upon the vesting and settlement of restricted stock units Â Â 5,916 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Issuance of common shares upon the exercise of stock options Â Â 2,750 Â Â Â 7 Â Â Â â€” Â Â Â â€” Â Â Â 7 Â Share-based compensation expense Â Â â€” Â Â Â 443 Â Â Â â€” Â Â Â â€” Â Â Â 443 Â Unrealized loss on marketable securities Â Â â€” Â Â Â â€” Â Â Â (12) Â Â Â â€” Â Â Â (12) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (5,119) Â Â (5,119) Balances at June 30, 2024 Â Â 42,692,582 Â Â $ 179,294 Â Â $ (51) Â $ (125,828) Â $ 53,415 Â Issuance of common shares upon the vesting of and settlement of restricted stock units Â Â 5,915 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Issuance of common shares upon the exercise of stock options Â Â 68,000 Â Â Â 126 Â Â Â â€” Â Â Â â€” Â Â Â 126 Â Share-based compensation expense Â Â Â Â Â Â 565 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 565 Â Unrealized gain on marketable securities Â Â â€” Â Â Â â€” Â Â Â 132 Â Â Â â€” Â Â Â 132 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (6,274) Â Â (6,274) Balances at September 30, 2024 Â Â 42,766,497 Â Â $ 179,985 Â Â $ 81 Â Â $ (132,102) Â $ 47,964 Â Â Â Â Common Shares Â Â Paid-In Capital Â Â Accumulated Other Comprehensive Gain (Loss) Â Â Accumulated Deficit Â Â Total Shareholdersâ€™ Equity Â Balances at December 31, 2022 Â Â 26,443,067 Â Â $ 128,078 Â Â $ (74) Â $ (96,177) Â $ 31,827 Â Issuance of common shares in settlement of deferred stock units Â Â 17,621 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Issuance of common shares upon the vesting and settlement of restricted stock units Â Â 4,289 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Share-based compensation expense Â Â â€” Â Â Â 422 Â Â Â â€” Â Â Â â€” Â Â Â 422 Â Unrealized gain on marketable securities Â Â â€” Â Â Â 45 Â Â Â â€” Â Â Â 45 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (5,272) Â Â (5,272) Balances at March 31, 2023 Â Â 26,464,977 Â Â $ 128,500 Â Â $ (29) Â $ (101,449) Â $ 27,022 Â Issuance of common shares net of offering costs of $1.4 million Â Â 11,480,156 Â Â 36,852 Â Â Â â€” Â Â Â â€” Â Â Â 36,852 Â Issuance of common shares upon the vesting and settlement of restricted stock units Â Â 4,289 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Share-based compensation expense Â Â â€” Â Â Â 380 Â Â Â â€” Â Â Â â€” Â Â Â 380 Â Unrealized loss on marketable securities Â Â â€” Â Â Â â€” Â Â Â (34) Â Â â€” Â Â Â (34) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (4,477) Â Â (4,477) Balances at June 30, 2023 Â Â 37,949,422 Â Â $ 165,732 Â Â $ (63) Â $ (105,926) Â $ 59,743 Â Offering costs on previously issued common shares Â Â â€” Â Â Â (4) Â Â â€” Â Â Â â€” Â Â Â (4) Issuance of common shares upon the vesting and settlement of restricted stock units Â Â 4,289 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Share-based compensation expense Â Â Â Â Â 425 Â Â Â Â Â Â Â Â Â Â 425 Â Unrealized loss on marketable securities Â Â â€” Â Â Â â€” Â Â Â (64) Â Â â€” Â Â Â (64) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (4,471) Â Â (4,471) Balances at September 30, 2023 Â Â 37,953,711 Â Â $ 166,153 Â Â $ (127) Â $ (110,397) Â $ 55,629 Â Â See accompanying notes to the condensed consolidated financial statements. Â 5Â Â Â DiaMedica Therapeutics Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Â Â Net loss Â $ (16,544) Â $ (14,220) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Share-based compensation Â Â 1,496 Â Â Â 1,227 Â Amortization of discount on marketable securities Â Â (1,013) Â Â (856) Non-cash lease expense Â Â 56 Â Â Â 52 Â Depreciation Â Â 28 Â Â Â 22 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Â Amounts receivable Â Â 79 Â Â Â (228) Prepaid expenses and other assets Â Â 131 Â Â Â (860) Deposits Â Â (1,308) Â Â â€” Â Accounts payable Â Â 245 Â Â Â 129 Â Accrued liabilities Â Â 1,188 Â Â Â 4 Â Â Â (182) Net cash used in operating activities Â Â (15,642) Â Â (14,916) Â Â Â Â Â Â Â Â Â Â Cash flows from investing activities: Â Â Â Â Â Â Â Â Purchase of marketable securities Â Â (39,623) Â Â (64,537) Maturities of marketable securities Â Â 43,000 Â Â Â 40,135 Â Purchases of property and equipment Â Â (18) Â Â (21) Net cash provided by (used in) investing activities Â Â 3,359 Â Â Â (24,423) Â Â Â Â Â Â Â Â Â Â Cash flows from financing activities: Â Â Â Â Â Â Â Â Proceeds from issuance of common shares, net of offering costs Â Â 11,747 Â Â Â 36,848 Â Proceed from the exercise of stock options Â Â 133 Â Â Â â€” Â Principal payments on finance lease obligation Â Â (6) Â Â (5) Net cash provided by financing activities Â Â 11,874 Â Â Â 36,843 Â Â Â Â Â Â Â Â Â Â Net decrease in cash and cash equivalents Â Â (409) Â Â (2,496) Cash and cash equivalents at beginning of period Â Â 4,543 Â Â Â 4,728 Â Cash and cash equivalents at end of period Â $ 4,134 Â Â $ 2,232 Â Â Â Â Â Â Â Â Â Â Supplemental disclosure of non-cash transactions: Â Â Â Â Â Â Â Â Assets acquired under financing lease Â $ 30 Â Â $ â€” Â Cash paid for income taxes Â $ 20 Â Â $ 26 Â Â See accompanying notes to the condensed consolidated financial statements. Â 6Â Â DiaMedica Therapeutics Inc. Notes to the Condensed Consolidated Financial Statements (Unaudited) Â Â 1.Â Â Â Â Â Â Â Â Business Â DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), exist for the primary purpose of advancing the clinical and commercial development of our proprietary recombinant KLK1 protein called DM199, for the treatment of neurological and cardio-renal diseases. Currently, our primary focus is on developing DM199, a recombinant form of the human tissue kallikrein-1 (KLK1) protein, for the treatment of acute ischemic stroke (AIS) and preeclampsia (PE). Our parent company is governed under British Columbiaâ€™s Business Corporations Act, and our common shares are publicly traded on The Nasdaq Capital Market under the symbol â€œDMAC.â€ Â Â 2.Â Â Â Â Â Â Â Â Risks and Uncertainties Â DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union and comparable agencies in other countries. We are in the clinical stage of development of our initial product candidate, DM199, for the treatment of AIS and PE. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. DM199 requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all. Â We are currently conducting our ReMEDy2 clinical trial of DM199 for the treatment of AIS. Our ReMEDy2 clinical trial is a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial intended to enroll approximately 350 patients at up to 100 sites globally. Prior to the clinical hold of our ReMEDy2 trial, announced in July 2022 and fully lifted in June 2023, we had experienced and are now continuing to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to another hospital or an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring and overall program management. In addition, we made the decision to globally expand the trial and to this end we have submitted or are in the process of preparing regulatory filings and identifying and engaging study sites in the countries of Canada, Australia and Georgia. We also recently revised the study protocol to widen the inclusion criteria and reduce the burden on participants and sites. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to mitigate the impact of these factors on our ReMEDy2 trial; however, no assurances can be provided as to the success of these mitigation actions and if or when these issues will resolve. The failure to resolve these issues will result in delays in our ReMEDy2 trial. Â On October 9, 2024, we announced the receipt of regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) to initiate an investigator-sponsored study of DM199 in PE. We are financially supporting the conduct of a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE at the Tygerberg Hospital, Cape Town, South Africa. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated.Â The first subject was enrolled in the fourth quarter of 2024. Part 1A topline study results are intended to demonstrate initial proof-of-concept including whether DM199 is safe, lowers blood pressure and dilates intrauterine arteries to increase placental blood flow. These results are expected in the first half of 2025. Â Our future success is dependent upon the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability, or the ability of any future partner, to obtain required governmental approvals of our product candidate, our ability to license or market and sell our DM199 product candidate and our ability to obtain additional financing to fund these efforts. Â As of September 30, 2024, we have incurred losses of $132.1 million since our inception in 2000. For the nine months ended September 30, 2024, we incurred a net loss of $16.5 million and negative cash flows from operating activities of $15.6 million. We expect to continue to incur operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical study of, and to seek regulatory approval for, our DM199 product candidate. As of September 30, 2024, we had combined cash, cash equivalents and marketable securities of $50.2 million, working capital of $46.5 million and shareholdersâ€™ equity of $48.0 million. Â 7Â Â Â Our principal source of cash has been net proceeds from the issuance of equity securities. Although we have previously been successful in obtaining financing through equity securities offerings, there is no assurance that

we will be able to do so in the future. This is particularly true if our clinical data are not positive or if economic and market conditions deteriorate. Â We expect that we will need substantial additional capital to further our research and development activities, complete the required clinical studies, regulatory activities and manufacturing development for our product candidate, DM199, or any future product candidates, to a point where they may be licensed or commercially sold. We expect our current cash, cash equivalents and marketable securities are sufficient to continue our ReMEDy2 trial, support the Phase 2 PE trial and otherwise fund our planned operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the rate of site activation and participant enrollment in the study, the Phase 2 PE trial, the potential expansion of our current development programs, the effects of ongoing site staffing shortages and other factors on our clinical trials and our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable. Â Â 3.Â Â Â Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Interim financial statements Â We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. These condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly our condensed consolidated financial position, condensed consolidated results of operations, condensed consolidated statement of shareholdersâ€™ equity and condensed consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on DecemberÂ 31. The condensed consolidated balance sheet as of December 31, 2023 was derived from our audited consolidated financial statements. These condensed consolidated financial statements should be read in conjunction with our annual consolidated financial statements and the notes thereto. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. Â Cash and cash equivalents Â The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments. Â Marketable securities Â The Companyâ€™s marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and/or investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations. Â We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive loss, which is a separate component of shareholdersâ€™ equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of September 30, 2024. Â 8 Â Â Fair value measurements Â Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Â The hierarchy is broken down into three levels defined as follows: Â Level 1 Inputs â€“ quoted prices in active markets for identical assets and liabilities Level 2 Inputs â€“ observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs â€“ unobservable inputs Â As of September 30, 2024, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled â€œMarketable Securitiesâ€ for additional information. Â Â 4.Â Â Â Â Â Â Â Â Â Â Â Marketable Securities Â The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands): Â Â Â Fair Value Measurements Using Inputs Considered as of: Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Commercial paper and corporate bonds Â $ 26,287 Â Â $ â€“ Â Â $ 26,287 Â Â $ â€“ Â Â $ 21,764 Â Â $ â€“ Â Â $ 21,764 Â Â $ â€“ Â Government securities Â Â 19,776 Â Â Â â€“ Â Â Â 19,776 Â Â Â â€“ Â Â Â 26,588 Â Â Â â€“ Â Â Â 26,588 Â Â Â â€“ Â Total Â $ 46,063 Â Â $ â€“ Â Â $ 46,063 Â Â $ â€“ Â Â $ 48,352 Â Â $ â€“ Â Â $ 48,352 Â Â $ â€“ Â Â Maturities of individual securities are less than one year, and the amortized cost of all securities approximated fair value as of September 30, 2024 and December 31, 2023. Accrued interest receivable on marketable securities is included in amounts receivable and was $288,000 and $298,000 as of September 30, 2024 and December 31, 2023, respectively. Â There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the nine months ended September 30, 2024. Â Â 5.Â Â Â Â Â Â Â Â Â Â Â Amounts Receivable Â Amounts receivable consisted primarily of accrued interest receivable on marketable securities of $288,000 and $298,000 as of September 30, 2024 and December 31, 2023, respectively. Â Â 6.Â Â Â Â Â Â Â Â Â Â Â Deposits Â We periodically advance funds to vendors engaged to support the performance of our clinical trials and related activities. The funds advanced are held, interest free, for varying periods of time and are generally recovered by the Company through application against final study/project invoices or refunded upon completion of services to be provided. Deposits are non-current when their expected recovery is not within the next twelve months. Â 9 Â Â Â 7.Â Â Â Â Â Â Â Â Â Â Â Property and Equipment Â Property and equipment, net, consisted of the following (in thousands): Â Â Â September 30, 2024 Â Â December 31, 2023 Â Furniture and equipment Â $ 128 Â Â $ 128 Â Computer equipment Â Â 110 Â Â Â 87 Â Leasehold improvements Â Â 16 Â Â Â 16 Â Â Â 254 Â Â Â 231 Â Less accumulated depreciation Â Â (103) Â Â (100) Property and equipment, net Â $ 151 Â Â $ 131 Â Â Â 8.Â Â Â Â Â Â Â Â Â Â Â Accrued Liabilities Â Accrued liabilities consisted of the following (in thousands): Â Â Â September 30, 2024 Â Â December 31, 2023 Â Clinical trial costs Â $ 1,297 Â Â $ 258 Â Research and development services Â Â 896 Â Â Â 632 Â Compensation Â Â 730 Â Â Â 766 Â Professional services fees Â Â 91 Â Â Â 98 Â Other Â Â 10 Â Â Â 23 Â Total accrued liabilities Â $ 3,024 Â Â $ 1,777 Â Â Â 9.Â Â Â Â Â Â Â Â Â Â Â Operating Lease Â Office lease Â Our operating lease costs were $78,000 for each of the nine months ended September 30, 2024 and 2023. Our variable lease costs were $64,000 and $66,000 for the nine months ended September 30, 2024 and 2023, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor. Â Maturities of our operating lease obligation are as follows as of September 30, 2024 (in thousands): Â 2024 Â $ 28 Â 2025 Â Â 113 Â 2026 Â Â 116 Â 2027 Â Â 119 Â 2028 Â Â 10 Â Total lease payments Â $ 386 Â Less interest portion Â Â (49) Present value of operating lease obligation Â $ 337 Â Â Â 10.Â Â Â Â Â Â Â Â Â Â Â Shareholdersâ€™ Equity Â Authorized capital shares Â DiaMedica has authorized share capital of an unlimited number of voting common shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Companyâ€™s annual general meeting and any extraordinary or special general meeting. Â Equity issued during the nine months ended September 30, 2024 Â On June 25, 2024, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 4,720,000 common shares at a purchase price of $2.50 per share in a private placement. As a result of the offering, which closed on June 28, 2024, we received gross proceeds of $11.8 million, which resulted in net proceeds to us of approximately $11.7 million, after deducting the offering expenses. Â 10 Â Â In connection with the June 2024 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the June 2024 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on July 10, 2024 and declared effective by the SEC on July 18, 2024. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered â€œRegistrable Securitiesâ€ under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement. Â During the nine months ended September 30, 2024, 17,747 common shares were issued upon the vesting and settlement of restricted stock units and 70,750 common shares were issued upon the exercise of stock options for gross proceeds of $133,000. Â Equity issued during the nine months ended September 30, 2023 Â On April 10, 2023, in conjunction with his appointment as Chief Business Officer of DiaMedica, Mr. David Wambeke purchased 468,750 of DiaMedicaâ€™s common shares at an aggregate purchase price of $750,000 or $1.60 per share. Â On June 21, 2023, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 11,011,406 common shares at a purchase price of $3.40 per share, or $3.91 per share in the case of our participating directors and officers, in a private placement. As a result of the offering, which closed on June 23, 2023, we received gross proceeds of $37.5 million, which resulted in net proceeds to us of approximately $36.1 million, after deducting the offering expenses. Â In connection with the June 2023 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the June 2023 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on June 30, 2023 and declared effective by the SEC on July 7, 2023. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered â€œRegistrable Securitiesâ€ under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement. Â During the nine months ended September 30, 2023, 17,621 common shares were issued in settlement of deferred share units and 12,867 common shares were issued upon the vesting and settlement of restricted stock units. Â Shares reserved Â Common shares reserved for future issuance are as follows: Â Â Â September 30, 2024 Â Common shares issuable upon exercise of employee and non-employee stock options Â Â 4,632,438 Â Common shares issuable upon settlement of deferred stock units Â Â 284,886 Â Common shares issuable upon vesting and settlement of restricted stock units Â Â 5,913 Â Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan Â Â 3,005,399 Â Shares available for grant under the 2021 Employment Inducement Incentive Plan Â Â 357,500 Â Total Â Â 8,286,136 Â Â Â 11.Â Â Â Â Â Â Â Â Â Â Â Net Loss Per Share Â We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive. Â 11 Â Â The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss Â $ (6,274) Â $ (4,471) Â $ (16,544) Â $ (14,220) Weighted average shares outstandingâ€”basic and diluted Â Â 42,751,577 Â Â Â 37,949,422 Â Â Â 39,604,179 Â Â Â 30,751,329 Â Basic and diluted net loss per share Â $ (0.15) Â $ (0.12) Â $ (0.42) Â $ (0.46) Â The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Employee and non-employee stock options Â Â 4,632,438 Â Â Â 3,698,513 Â Â Â 4,632,438 Â Â Â 3,698,513 Â Common shares issuable under common share purchase warrants Â Â â€“ Â Â Â 205,000 Â Â Â â€“ Â Â Â 205,000 Â Common shares issuable upon settlement of deferred stock units Â Â 284,886 Â Â Â 213,905 Â Â Â 284,886 Â Â Â 213,905 Â Common shares issuable upon vesting and settlement of restricted stock units Â Â 5,913 Â Â Â 4,289 Â Â Â 5,913 Â Â Â 4,289 Â Â Â 12.Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Â Amended and Restated 2019 Omnibus Incentive Plan Â The DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan (as amended from time to time, the 2019 Plan) was adopted by the Board of Directors (Board) on March 14, 2019 and approved by our shareholders at our 2019 Annual General Meeting of Shareholders held on May 22, 2019. Subsequent amendments to the plan, comprised principally of increasing the authorized shares under the plan, were approved by our shareholders at our 2022 and 2024 Annual General Meetings of Shareholders. Â The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Companyâ€™s eligible employees, non-employee directors and certain consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), deferred stock units (DSUs), performance awards, non-employee director awards and other share-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of ten years and generally vest over one to four years. Options granted to non-employees have a maximum term of five years and generally vest over one year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Companyâ€™s common shares authorized for issuance under the 2019 Plan is 7,000,000 shares. Under the 2019 Plan, as of September 30, 2024, options to purchase an aggregate of 3,627,028 common shares were outstanding, 267,553 common shares were reserved for issuance upon settlement of DSUs and 5,913 shares were reserved for issuance upon the vesting and settlement of RSUs and 3,005,399 shares remained available for issuance. Â 2021 Employment Inducement Incentive Plan Â On December 3, 2021, the Board adopted the DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan (Inducement Plan) to facilitate the granting of equity awards as an inducement material to new employees joining the Company. The Inducement Plan was adopted without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the Board of Directors. The Board reserved 1,000,000 common shares of the Company for issuance under the Inducement Plan, which permits the grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to eligible recipients. The only persons eligible to receive awards under the Inducement Plan are individuals who are new employees and satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. Also on December 3, 2021, the Compensation Committee adopted a form of notice of option grant and option award agreement for use under the Inducement Plan, which contains terms substantially identical to the form of notice of option grant and option award agreement for use under the shareholder-approved 2019 Plan. The Inducement Plan has a term of 10 years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board. Under the Inducement Plan, as of September 30, 2024, options to purchase an aggregate of 590,000 common shares were outstanding and 357,500 shares remained available for issuance. Â 12 Â Â Prior Stock Option Plan Â The DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated November 6, 2018 (Prior Plan), was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of September 30, 2024, options to purchase an aggregate of 415,410 common shares were outstanding under the Prior Plan. Â Prior Deferred Stock Unit Plan Â The DiaMedica Therapeutics Inc. Amended and Restated Deferred Stock Unit Plan (Prior DSU Plan) was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of September 30, 2024, there

were 17,333 common shares reserved for issuance upon settlement of DSUs outstanding under the Prior DSU Plan. Â Share-based compensation expense for each of the periods presented is as follows (in thousands): Â Â Â Three Months Ended September 30 Â Â Nine Months Ended September 30 Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 147 Â Â $ 158 Â Â $ 449 Â Â $ 430 Â General and administrative Â Â 418 Â Â Â 267 Â Â Â 1,047 Â Â Â 797 Â Total share-based compensation Â $ 565 Â Â $ 425 Â Â $ 1,496 Â Â $ 1,227 Â Â We recognize share-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest. Â A summary of option activity is as follows (in thousands, except share and per share amounts): Â Â Â Shares Underlying Options Â Â Weighted Average Exercise Price Per Share Â Â Aggregate Intrinsic Value Â Balances at December 31, 2023 Â Â 3,871,013 Â Â $ 3.61 Â Â $ 832 Â Granted Â Â 1,663,425 Â Â Â 2.86 Â Â Â Â Â Expired/cancelled Â Â (455,000) Â Â 4.82 Â Â Â Â Â Forfeited Â Â (376,250) Â Â 2.73 Â Â Â Â Â Exercised Â Â (70,750) Â Â 1.88 Â Â Â Â Â Balances at September 30, 2024 Â Â 4,632,438 Â Â $ 3.31 Â Â $ 4,875 Â Â Information about stock options outstanding, vested and expected to vest as of September 30, 2024, is as follows: Â Â Â Â Â Â Â Â Â Outstanding, Vested and Expected to Vest Â Â Options Vested and Exercisable Â Per Share Exercise Price Â Â Shares Â Â Weighted Average Remaining Contractual Life (Years) Â Â Weighted Average Exercise Price Â Â Options Exercisable Â Â Weighted Average Remaining Contractual Life (Years) Â $1.00 - $1.99 Â Â Â 203,443 Â Â Â 8.4 Â Â $ 1.60 Â Â Â 74,159 Â Â Â 8.4 Â $2.00 - $2.99 Â Â Â 3,022,895 Â Â Â 8.0 Â Â Â 2.73 Â Â Â 871,594 Â Â Â 6.5 Â $3.00 - $3.99 Â Â Â 341,893 Â Â Â 6.1 Â Â Â 3.55 Â Â Â 223,143 Â Â Â 4.3 Â $4.00 - $4.99 Â Â Â 677,182 Â Â Â 4.8 Â Â Â 4.58 Â Â Â 677,182 Â Â Â 4.8 Â $5.00 Â - $16.00 Â Â Â 387,025 Â Â Â 5.7 Â Â Â 6.36 Â Â Â 328,275 Â Â Â 5.5 Â Â Â Â Â Â Â Â Â Â 4,632,438 Â Â Â 7.2 Â Â $ 3.31 Â Â Â 2,174,353 Â Â Â 5.6 Â Â 13 Â Â Â ITEM 2.Â Â Â Â Â Â Â Â Â MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â The following Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations is based upon accounting principles generally accepted in the United States of America and discusses the financial condition and results of operations for DiaMedica Therapeutics Inc. and our subsidiaries for the three and nine months ended September 30, 2024 and 2023. Â This discussion should be read in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this report and our annual report on Form 10-K for the year ended December 31, 2023. The following discussion contains forward-looking statements that involve numerous risks and uncertainties. Our actual results could differ materially from the forward-looking statements as a result of these risks and uncertainties. See â€œCautionary Note Regarding Forward-Looking Statementsâ€ for additional cautionary information. Â Business Overview Â We are a clinical stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with a focus on acute ischemic stroke (AIS) and preeclampsia (PE). Our lead candidate DM199 (rinvecalinase alfa; rhKLK1) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein (serine protease enzyme) to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of AIS and porcine KLK1 for the treatment of cardio renal disease, including hypertension. We have also produced a potential novel treatment for severe acute pancreatitis, DM300, which is currently in the early preclinical stage of development. Our long-term goal is to use our patented and in-licensed technologies to establish our Company as a leader in the development and commercialization of therapeutic treatments from novel recombinant proteins. Our current focus is on the treatment of AIS and PE. We plan to advance DM199 through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for AIS and PE. Â KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that increases production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the case of AIS, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibition of apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis. In preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and increase perfusion to maternal organs and the placenta, potentially disease modifying outcomes improving both maternal and perinatal outcomes. Â Our product development pipeline is as follows: Â AIS Phase 2/3 ReMEDy2 Trial Â We are currently conducting our ReMEDy2 clinical trial of DM199 for the treatment of AIS. Our ReMEDy2 clinical trial is a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial intended to enroll approximately 350 patients at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board after the first 200 participants. Based on the results, the study may be stopped for futility, or a new total sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. Patients enrolled in the trial will be treated with either DM199 or placebo within 24 hours of the onset of AIS symptoms. The trial excludes patients who received mechanical thrombectomy (MT) or participants with large vessel occlusions in the intracranial carotid artery or the M1 segment for the middle cerebral, vertebral or basilary arteries or those that are otherwise eligible for MT. As a result of our recent protocol amendment, participantsÂ treated with tissue plasminogen activator (tPA) or tenecteplase (TNK), (thrombolytic agents) intended to dissolve blood clots, are now eligible for participation if they continue to experience a persistent neurological deficit after receiving thrombolytic treatment and meet all other trial criteria,Â including repeat brain imaging to assess any hemorrhagic (bleeding) transformation. The study population is representative of the approximately 80% of AIS patients who do not have treatment options today, primarily due to the limitations on treatment with tPA/TNK and/or MT. The primary endpoint of the ReMEDy2 trial is physical recovery from stroke as measured by the well-established modified Rankin Scale (mRS) at day 90, specifically recovering to an mRS score of 0-1 (mRS range of 0-6). We believe that our ReMEDy2 trial has the potential to serve as a pivotal registration study of DM199 in this patient population. Â 14 Â Â Prior to the clinical hold of our ReMEDy2 trial, announced in July 2022 and fully lifted in June 2023, we had experienced and are continuing to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to another hospital or an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including identification, qualification and activation, clinical site monitoring and overall program management. In addition, we made the decision to globally expand the trial and to this end we have submitted or are in the process of preparing regulatory filings and identifying and engaging study sites in the countries of Canada, Australia and Georgia. We also recently revised the study protocol to widen the inclusion criteria and reduce the burden on participants and sites. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to mitigate the impact of these factors on our ReMEDy2 trial; however, no assurances can be provided as to the success of these mitigation actions and if or when these issues will resolve. The failure to resolve these issues will result in delays in our ReMEDy2 trial. Â Preeclampsia Program Â On October 9, 2024, we announced the receipt of regulatory approval from SAHPRA to initiate an investigator-sponsored study of DM199 in PE. PE is a serious pregnancy disorder that typically develops after the 20th week of gestation, characterized by high blood pressure and damage to organ systems, often the kidneys and liver. Affecting up to 8% of pregnancies worldwide, preeclampsia can pose significant risks to both the mother and baby, including risk of stroke, placental abruption, progression to eclampsia, premature delivery, and death. Symptoms may include severe headaches, vision changes, upper abdominal pain and swelling in the hands and face. Delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia. Women who have had preeclampsia have three to four times the risk of high blood pressure and double the risk for heart disease and stroke and there are currently no approved therapeutics for PE in the United States or Europe. Â We believe DM199 has the potential to lower blood pressure, enhance endothelial health, and improve perfusion to maternal organs and the placenta. We have completed studies on fertility, embryofetal development and pre- and post-natal development in animal models, which support the potential safety in pregnant humans. Additionally, we completed a placental transfer study in pregnant rodents in which DM199 did not cross the placental barrier. Specifically, DM199 was detectable in the maternal blood, but undetectable in the fetal blood. Â We are financially supporting the conduct of a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE at the Tygerberg Hospital, Cape Town, South Africa. Up to 90 women with PE, and potentially an additional 30 subjects with fetal growth restriction, may be evaluated. The first subject was enrolled in the fourth quarter of 2024. Participants in Part 1A of the study will include late stage PE (>34 weeks gestational age) patients. Topline data from Part 1A is expected to demonstrate initial proof-of-concept including whether DM199 is safe and lowers blood pressure. Additionally, for patients with early onset PE, we will be looking for improvements in uterine artery dilation, an indication that DM199 therapy is potentially disease modifying in these patients. Â Financial Overview Â We have not generated any revenues from product sales. Since our inception, we have financed our operations from public and private sales of equity, the exercise of warrants and stock options, interest income on funds available for investment and government grants. Our June 2024 private placement generated $11.7 million in net proceeds after deducting offering expenses. We have incurred losses in each year since our inception. Our net losses were $16.5 million and $14.2 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of $132.1 million. Substantially all of our operating losses resulted from expenses incurred in connection with our product candidate development programs, our research and development (R&D) activities, and general and administrative (G&A) support costs associated with our operations and status as a publicly listed company. Â We expect to continue to incur significant expenses and increased operating losses for at least the next several years. We anticipate that our quarterly expenses will increase moderately relative to recent prior periods as we expand our ReMEDy2 trial globally and as enrollment continues and as we expand our DM199 clinical development program into PE and support the Phase 2 PE trial. Our efforts to expand our team to provide support for our operations and maintaining, expanding and protecting our intellectual property portfolio will also likely contribute to such increases. Â 15 Â Â While we expect our rate of future negative cash flow per month will generally increase moderately relative to recent prior periods as we continue our ReMEDy2 trial, including our global expansion, and expand our DM199 clinical development program into PE, we expect our current cash resources will be sufficient to allow us to continue our ReMEDy2 trial, support the Phase 2 PE trial and otherwise fund our planned operations for at least the next 12 months from the date of issuance of the condensed consolidated financial statements included in this report. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and in particular the rate of site activation and participant enrollment in the study, the Phase 2 PE trial, the potential further expansion of our current development programs and other factors. We may require or otherwise seek significant additional funds earlier than we currently expect. We may elect to raise additional funds even before we need them if market conditions for raising additional capital are favorable. Â Components of Our Results of Operations Â Research and Development Expenses Â R&D costs include expenses incurred in the conduct of human clinical trials such as fees paid to external service providers including contract research organizations; clinical support services; clinical development including clinical site costs; outside nursing services; and laboratory testing. R&D costs also include non-clinical research studies; fees paid to contract manufacturing and development organizations and outside laboratories for the development of DM199 and related manufacturing processes; costs to produce sufficient amounts of the DM199 compound for use in our clinical studiesÍ¾ consulting resources with specialized expertise related to execution of our development plan for our DM199 product candidateÍ¾ and personnel costs, including salaries, benefits and share-based compensation. Â At this time, due to the risks inherent in the clinical development process and the clinical stage of our product development programs, we are unable to estimate with any certainty the costs we will incur in developing DM199 through marketing approval or any of our preclinical development programs. The process of conducting clinical studies necessary to obtain regulatory approval and manufacturing scale-up to support expanded development and potential future commercialization is costly and time consuming. Any failure by us or delay in completing clinical studies, manufacturing scale-up or in obtaining regulatory approvals could lead to increased R&D expenses and, in turn, have a material adverse effect on our results of operations. Â We expect that our R&D expenses will increase moderately in the future relative to recent prior periods if we are successful in advancing DM199, or any of our preclinical programs, through the required stages of clinical development. The process of conducting clinical trials necessary to obtain regulatory approval and manufacturing scale-up to support expanded development and potential future commercialization is costly and time consuming. Â General and Administrative Expenses Â G&A expenses consist primarily of salaries, employee benefits, share-based compensation and other personnel costs related to our executive, finance, business development and support functions. G&A expenses also include insurance, including directors and officers liability coverage, rent and utilities, travel expenses, patent costs, and professional fees, including for auditing, tax and legal services. Â Other Income, Net Â Other income, net consists primarily of interest income earned on marketable securities. Â 16 Â Â Results of Operations Â Comparison of the Three and Nine Months Ended September 30, 2024 and 2023 Â The following table summarizes our unaudited results of operations for the three and nine months ended September 30, 2024 and 2023 (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development expenses Â $ 4,983 Â Â $ 3,272 Â Â $ 12,587 Â Â $ 9,433 Â General and administrative expenses Â Â 1,900 Â Â Â 1,885 Â Â Â 5,675 Â Â Â 5,986 Â Other income, net Â Â (616) Â Â (693) Â Â (1,739) Â Â (1,220) Â Research and Development Expenses Â R&D expenses increased to $5.0 million for the three months ended September 30, 2024, up from $3.3 million for the three months ended September 30, 2023. R&D expenses increased to $12.6 million for the nine months ended September 30, 2024, up from $9.4 million for the nine months ended September 30, 2023. These increases are due primarily to cost increases resulting from the continuation of our ReMEDy2 clinical trial, the expansion of our clinical team and increased manufacturing development activity. These increases were partially offset by cost reductions related to clinical trial work completed in 2023, including our Phase 1C and REDUX trials, and the completion in 2023 of in-use study work performed to address the clinical hold on our ReMEDy2 trial. We expect our R&D expenses to increase moderately relative to recent prior periods as we globally expand the ReMEDy2 trial site activations and participant enrollments continue. Â General and Administrative Expenses Â G&A expenses were $1.9 million for each of the three months ended September 30, 2024 and September 30, 2023. G&A expenses were $5.7 million for the nine months ended September 30, 2024, down from $6.0 million for the nine months ended September 30, 2023. The decrease for the nine-month comparison resulted from the combination of reductions in the cost of directors and officers liability insurance premiums and decreased legal fees incurred in connection with our lawsuit against PRA Netherlands and was partially offset by increased personnel costs incurred in conjunction with expanding our team and increased non-cash share-based compensation costs. We expect G&A expenses to remain steady as compared to prior periods. Â Other Income, Net Â Other income, net was $616 thousand and $1.7 million for the three and nine months ended September 30, 2024, respectively, compared to $693 thousand and $1.2 million for the three and nine months ended September 30, 2023, respectively. TheÂ increaseÂ for the nine-month comparison wasÂ driven by increased interest income recognized during the current year periods related to higher marketable securities balances during the current year periods as compared to the same periods in the prior year. Â Liquidity and Capital Resources Â The following tables summarize our liquidity and capital resources as of September 30, 2024 and December 31, 2023, and our cash flows for each of the nine month periods ended September 30, 2024 and 2023, and are intended to supplement the more detailed discussion that follows (in thousands): Â Â Â September 30, 2024 Â Â December 31, 2023 Â Cash, cash equivalents and marketable securities Â $ 50,197 Â Â $ 52,895 Â Total assets Â Â 52,524 Â Â Â 54,160 Â Total current liabilities Â Â 4,297 Â Â Â 2,786 Â Total shareholdersâ€™ equity Â Â 47,964 Â Â Â 51,057 Â Working capital Â Â 46,470 Â Â Â 50,889 Â Â 17 Â Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash Flow Data Â Â Â Â Â Â Â Â Â Cash flow provided by (used in): Â Â Â Â Â Â Â Â Â Operating activities Â $ (15,642) Â $ (14,916) Investing activities Â Â 3,359 Â Â Â (24,423) Financing activities Â Â 11,874 Â Â Â 36,843 Â Net decrease in cash and cash equivalents Â $ (409) Â $ (2,496) Â Working Capital Â We had aggregate cash, cash equivalents and marketable securities of $50.2 million, current liabilities of $4.3 million and working capital of $46.5 million as of September 30, 2024, compared to aggregate cash, cash equivalents and marketable securities of $52.9 million, $2.8 million in current liabilities and $50.9 million in working capital as of December 31, 2023. The decreases in our combined cash, cash equivalents and marketable securities and in our working capital are due to the net cash used in operating activities partially offset by the net proceeds received from our June 2024 private placement. Â Cash Flows Â Operating Activities Â Net cash used in operating activities was $15.6 million for the nine months ended September 30, 2024 compared to $14.9 million for the nine months ended September 30, 2023. The increase in cash used in operating activities resulted primarily from the combination of increased net loss and the advance of deposit funds to vendors supporting our ReMEDy2 clinical trial duringÂ the current year period, partially offset by changes in operating assets and liabilities during the current year period. Â Investing

Activities Â Investing activities consist primarily of purchases and maturities of marketable securities. Net cash provided by investing activities was $3.4 million for the nine months ended September 30, 2024 compared to net cash used in investing activities of $24.4 million for the nine months ended September 30, 2023. This change resulted primarily from the timing of maturities and investments in marketable securities. Â Financing Activities Â Net cash provided by financing activities was $11.9 million and $36.8 million for the nine months ended September 30, 2024 and 2023, respectively, and for each period was comprised principally of net proceeds from the sale of common shares in private placement offerings. Â Capital Requirements Â Since our inception, we have incurred losses while advancing the R&D of our DM199 product candidate. We have not generated any revenues from product sales and do not expect to do so for at least three to four years. We do not know when or if we will generate any revenues from product sales or out-licensing of our DM199 product candidate or any future product candidate. We do not expect to generate any revenue from product sales unless and until we obtain required regulatory approvals. We expect to continue to incur substantial operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments are sufficient to generate revenues to fund our continuing operations. We expect our operating losses to increase as compared to prior periods as we continue the research, development and clinical studies of, and seek regulatory approval for, our DM199 product candidate, including, in particular, the continuation and global expansion of our ReMEDy2 trial. In the long-term, subject to obtaining regulatory approval of our DM199 product candidate, or any future product candidate, and in the absence of the assistance of a strategic partner, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. Â Accordingly, we expect we will need substantial additional capital to further our R&D activities, current and potential future clinical studies, regulatory activities and otherwise develop our product candidate, DM199, or any future product candidate, to a point where the product candidate may be out-licensed or commercially sold. Although we are striving to achieve these plans, there is no assurance that these and other strategies will be achieved or that additional funding will be obtained on favorable terms or at all. We expect our rate of future negative cash flow per month will vary depending on our clinical activities and the timing of expenses incurred and will increase moderately relative to recent prior periods as we continue and globally expand our ReMEDy2 trial and the Phase 2 PE trial is conducted. We expect our current cash resources will be sufficient to continue our ReMEDy2 trial, support the Phase 2 PE trial and otherwise fund our planned operations for at least the next twelve months from the date of issuance of the condensed consolidated financial statements included in this report. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the Phase 2 PE trial, the potential further expansion of our current development programs and other factors on our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising additional capital are favorable. Â 18 Â Â Historically, we have financed our operations primarily from sales of equity securities and the exercise of warrants and stock options, and we expect to continue this practice for the foreseeable future. We do not have any existing credit facilities under which we could borrow funds. We may seek to raise additional funds through various sources, such as equity or debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if our clinical data is not positive or economic and market conditions deteriorate. Â To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted. Debt financing, if available, may involve agreements that include conversion discounts, pledging our intellectual property as collateral or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. The availability of financing will be affected by the status of our clinical trials; our clinical data and other results of scientific and clinical research; the ability to obtain regulatory approvals and other regulatory actions; market acceptance of our product candidates; the state of the capital markets generally with particular reference to pharmaceutical, biotechnology and medical companies; the status of strategic alliance agreements; and other relevant commercial considerations. Â If adequate funding is not available when needed, we may be required to scale back our operations by taking actions that may include, among other things, implementing cost reduction strategies, such as reducing use of outside professional service providers, reducing the number of our employees or employee compensation, modifying or delaying the development of our DM199 product candidate; licensing to third parties the rights to commercialize our DM199 product candidate for AIS, PE or other indications that we would otherwise seek to pursue, or otherwise relinquishing significant rights to our technologies, future revenue streams, research programs or product candidates or granting licenses on terms that may not be favorable to us; and/or divesting assets or ceasing operations through a merger, sale, or liquidation of our Company. Â Critical Accounting Policies and Estimates Â There have been no material changes to our critical accounting policies and estimates from the information provided in â€œPart II. Item 7, Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Critical Accounting Policies,â€ included in our annual report on Form 10-K for the fiscal year ended December 31, 2023. Â 19 Â Â ITEM 3Â Â Â Â Â Â Â Â Â Â QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â As a smaller reporting company, we are not required to provide disclosure pursuant to this item. Â ITEM 4Â Â Â Â Â Â Â Â Â Â CONTROLS AND PROCEDURES Â Evaluation of Disclosure Controls and Procedures Â We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the United States Securities Exchange Act of 1934, as amended (Exchange Act)) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SECâ€™s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Â Changes in Internal Control over Financial Reporting Â There was no change in our internal control over financial reporting that occurred during the three months ended September 30, 2024 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting. Â 20 Â Â PART IIÂ Â Â Â Â Â Â Â Â Â OTHER INFORMATION Â ITEM 1.Â Â Â Â Â Â Â Â Â LEGAL PROCEEDINGS Â Litigation with Pharmaceutical Research Associates Group B.V., acquired by ICON plc as of July 1, 2021, (ICON/PRA Netherlands) Â On November 23, 2022, we filed a petition requesting leave for a prejudgment attachment of all relevant documents in possession of Pharmaceutical Research Associates Group B.V., acquired by ICON plc as of July 1, 2021, (ICON/PRA Netherlands), which was granted on November 28, 2022, by the District Court of Northern Netherlands. A representative of the District Court served ICON/PRA Netherlands with the prejudgment attachment on or about December 7 and 8, 2022. The case was formally introduced to the Netherlands Commercial Court (NCC) on December 28, 2022 and a hearing by the NCC to determine whether we are entitled to take possession of the records seized was scheduled and held on March 16, 2023. Â On April 21, 2023, the NCC issued a judgement affirming our ownership of the physical documents, including 51 hardcopy folders and certain digital files, related to the clinical studies performed by ICON/PRA Netherlands and seized by the Dutch courts in December 2022. The NCC further ordered ICON/PRA Netherlands to allow and tolerate the surrender of the documents, including digital and source data. Additionally, the NCC found that we are not in breach of any obligation under the clinical study agreement and ICON/PRA Netherlands had no basis to suspend the fulfillment of its obligations under the clinical study agreement to provide us all clinical data and access to perform an audit of the study. On June 15, 2023, ICON/PRA Netherlands filed an appeal of this decision and requested a scheduling hearing with the NCC, which occurred on September 23, 2024. Â The hearing addressing our claims for damages was conducted on December 7, 2023. On February 7, 2024, the NCC issued a judgement in which they found that, although all data related to the study is the rightful property of DiaMedica, they found that there was an insufficient causal link between ICON/PRA Netherlands withholding study data and the damages claimed by us. We have notified the NCC and ICON/PRA Netherlands of our intent to appeal this decision and submitted our statement of grounds for appeal on October 15, 2024. The NCC has issued a decision to consolidate both appeals and evaluate them concurrently at a single hearing currently scheduled for March 2025. Â From time to time, we may be subject to other various ongoing or threatened legal actions and proceedings, including those that arise in the ordinary course of business, which may include employment matters and breach of contract disputes. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. Other than the ICON/PRA Netherlands matter noted above, we are not currently engaged in or aware of any threatened legal actions. Â ITEM 1A.Â Â Â Â Â Â Â Â Â RISK FACTORS Â Although Item 1A. is inapplicable to us as a smaller reporting company, we hereby disclose the following new risk factors in addition to those disclosed in our annual report on Form 10-K for the fiscal year ended December 31, 2023: Â The expansion of our DM199 clinical development program into PE involves certain risks related to timing, regulatory approvals, costs and enrollment. Furthermore, because the proof-of-concept clinical trial will be investigator sponsored, we will have less control over the clinical trial and may face additional risks. Any such risks could adversely impact our business and results of operations and financial position and harm our ability to raise additional financing, if and when needed. Â On October 9, 2024, we announced the receipt of regulatory approval from SAHPRA to initiate an investigator-sponsored study of DM199 in PE. We are financially supporting the conduct of the Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE at the Tygerberg Hospital, Cape Town, South Africa. We anticipate that up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction will be evaluated.Â The first subject was enrolled in the fourth quarter of 2024. Part 1A topline study results are intended to demonstrate initial proof-of-concept results including whether DM199 is safe, lowers blood pressure, and dilates intrauterine arteries to increase placental blood flow and are expected in the first half of 2025. Â The expansion of our DM199 clinical development program into PE and the progress of that program may not occur on the anticipated timeline or at all. In addition, the Phase 2 trial may cost us more than we anticipate. Additionally, because the trial will be investigator-sponsored, we will have less control over the timing and costs of the study and the ability to recruit trial subjects than if we conducted the study with our own personnel. There is no guarantee that our physician collaborators will devote adequate time and resources to perform this study and/or maintain adequate clinical trial information regarding our product candidate. If these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to the study protocol or fail to act in accordance with regulatory requirements or our agreement with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then our current or future clinical trials may be extended or delayed with additional costs incurred, or our data may be rejected by applicable regulatory agencies. Any of these risks could adversely impact our business, results of operations and financial position, including our ability to raise additional financing, if and when needed. Â 21 Â Â Our drug candidate, DM199, is currently in clinical development in two areas, AIS and PE. Data from the investigator-sponsored Phase 2 PE clinical trial may adversely affect our current ReMEDy2 clinical trial, which could adversely impact our business, results of operations and financial position and harm our ability to raise additional financing, if and when needed. Â We anticipate Part 1A topline study results for the Phase 2 PE clinical trial in the first half of 2025. Part 1A topline study results are intended to demonstrate whether DM199 is safe for PE patients, lowers blood pressure and/or dilates intrauterine arteries to increase placental blood flow. The results from Part 1A of the study may not be consistent with the safety results from our prior ReMEDy1 trial of DM199 for the treatment of acute ischemic stroke or certain efficacy results from that trial. If the Part 1A topline study results are inconsistent, inaccurate, incomplete or otherwise demonstrate that DM199 is not safe, does not lower blood pressure or dilate intrauterine arteries, our current ReMEDy2 clinical trial of DM199 for the treatment of acute ischemic stroke may be adversely affected. Should this occur, we may be required to repeat clinical or non-clinical studies, our clinical development plans may be significantly delayed, and we may incur additional costs, which could adversely impact our business, results of operations and financial position. Adverse results from the Part 1A topline study also could adversely affect our ability to raise additional financing, if and when needed. Â ITEM 2.Â Â Â Â Â Â Â Â Â UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â We did not sell any unregistered equity securities of our Company during the quarter ended September 30, 2024. Â ITEM 3.Â Â Â Â Â Â Â Â Â DEFAULTS UPON SENIOR SECURITIES Â Not applicable. Â ITEM 4.Â Â Â Â Â Â Â Â Â MINE SAFETY DISCLOSURES Â Not applicable. Â Â ITEM 5.Â Â Â Â Â Â Â Â Â OTHER INFORMATION Â Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications Â During the three months ended September 30, 2024, none of our directors or â€œofficersâ€ (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408 of SEC Regulation S-K. Â 22 Â Â Â ITEM 6.Â Â Â Â Â Â Â Â Â EXHIBITS Â The following exhibits are being filed or furnished with this quarterly report on Form 10-Q: Â Exhibit No. Â Description Â Manner of Filing 3.1 Â Notice of Articles of DiaMedica Therapeutics Inc. dated June 16, 2023 Â Filed herewith 3.2 Â Amended and Restated Articles of DiaMedica Therapeutics Inc. Effective May 17, 2023 Â Incorporated by reference to Exhibit 3.1 to DiaMedicaâ€™s Current Report on Form 8-K as filed with the Securities and Exchange Commission on May 18, 2023 (File No. 001-36291) 31.1 Â Certification of Chief Executive Officer Pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Filed herewith 31.2 Â Certification of Chief Financial Officer Pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Filed herewith 32.1 Â Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Furnished herewith 32.2 Â Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Furnished herewith 101 Â Financial statements from the quarterly report on FormÂ 10-Q of DiaMedica Therapeutics Inc. for the three and nine months ended September 30, 2024, formatted in Inline XBRL: (i)Â the Condensed Consolidated Balance Sheets, (ii)Â Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Shareholdersâ€™Â Equity, (iv)Â Condensed Consolidated Statements of Cash Flows, and (v)Â Notes to the Condensed Consolidated Financial Statements. Â Filed herewith 104 Â Cover Page Interactive Data File Â Embedded within the Inline XBRL document Â 23 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â Â DIAMEDICA THERAPEUTICS INC. Â Â Date: November 13, 2024 /s/ Rick Pauls Â Rick Pauls Â President and Chief Executive Officer Â (Principal Executive Officer) Â Â Date: November 13, 2024 /s/ Scott Kellen Â Scott Kellen Â Chief Financial Officer Â (Principal Financial Officer and Principal Accounting Officer) Â 24 EX-3.1 2 ex_743381.htm EXHIBIT 3.1 HTML Editor Exhibit 3.1 Â Â Â Â Â Â EX-31.1 3 ex_743362.htm EXHIBIT 31.1 ex_743362.htm Exhibit 31.1 Â CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Rick Pauls, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of DiaMedica Therapeutics Inc.; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f)Â and 15d-15(f)) for the registrant and have: Â Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â c. Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our

conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s)Â and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Dated: November 13, 2024 /s/ Rick Pauls Â Rick Pauls Â President and Chief Executive Officer Â (Principal Executive Officer) Â Â EX-31.2 4 ex_743363.htm EXHIBIT 31.2 ex_743363.htm Exhibit 31.2 Â CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTIONÂ 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Scott Kellen, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of DiaMedica Therapeutics Inc.; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f)Â and 15d-15(f)) for the registrant and have: Â Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â c. Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s)Â and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Dated: November 13, 2024 /s/ Scott Kellen Â Scott Kellen Â Chief Financial Officer Â (Principal Financial Officer) Â Â EX-32.1 5 ex_743364.htm EXHIBIT 32.1 ex_743364.htm Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Rick Pauls, hereby certify, pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: Â Â (1) the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 of DiaMedica Therapeutics Inc. (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â Â Â (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of DiaMedica Therapeutics Inc. Â Dated: November 13, 2024 Â Â Â /s/ Rick Pauls Â Rick Pauls Â President and Chief Executive Officer Â (Principal Executive Officer) Â Â EX-32.2 6 ex_743365.htm EXHIBIT 32.2 ex_743365.htm Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Scott Kellen, hereby certify, pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: Â Â (1) the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 of DiaMedica Therapeutics Inc. (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â Â Â (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of DiaMedica Therapeutics Inc. Â Dated: November 13, 2024 Â Â Â /s/ Scott Kellen Â Scott Kellen Â Chief Financial Officer Â (Principal Financial Officer) Â Â Â EX-101.SCH 7 dmac-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Risks and Uncertainties link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Marketable Securities link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Amounts Receivable link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Deposits link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Accrued Liabilities link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Operating Lease link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Note 4 - Marketable Securities (Tables) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 7 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 8 - Accrued Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 9 - Operating Lease (Tables) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 10 - Shareholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 11 - Net Loss Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 12 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 4 - Marketable Securities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 5 - Amounts Receivable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 7 - Property and Equipment - Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 8 - Accrued Liabilities - Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 9 - Operating Lease (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 10 - Shareholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 10 - Shareholders' Equity - Shares Reserved (Details) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 12 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 12 - Share-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 12 - Share-based Compensation - Stock Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 8 dmac-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 dmac-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value Measurement, Policy [Policy Text Block] Note To Financial Statement Details Textual 2025 Significant Accounting Policies Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] 2026 Note 4 - Marketable Securities Note 7 - Property and Equipment dmac_AccruedTaxesAndOtherLiabilitiesCurrent Other The amount of accrued taxes and other liabilities classified as current. Employee and Non-employee Stock Options [Member] Related to employee and non-employee stock option awards. Note 8 - Accrued Liabilities dmac_AccruedClinicalStudyCostsCurrent Clinical trial costs The amount of accrued clinical study costs classified as current. Note 9 - Operating Lease Note 10 - Shareholders' Equity Non-current liabilities: Note 11 - Net Loss Per Share Note 12 - Share-based Compensation Deposit Assets [Text Block] Description of the companies deposits labeled as assets. Non-cash lease expense Amount of expense recognized over the period for lease expense, non-cash. Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) Deferred Share Units [Member] Related to deferred share units. Note 7 - Property and Equipment - Property and Equipment (Details) Unrealized gain (loss) on marketable securities Unrealized gain (loss) on marketable securities Note 8 - Accrued Liabilities - Accrued Liabilities (Details) Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details) Share-based compensation Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Note 10 - Shareholders' Equity - Shares Reserved (Details) us-gaap_LiabilitiesCurrent Total current liabilities dmac_AccruedResearchAndProfessionalFeesCurrent Research and development services Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). 2024 Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) Note 12 - Share-based Compensation - Stock Option Activity (Details) Note 12 - Share-based Compensation - Stock Options Outstanding (Details) Notes To Financial Statements Commercial Paper and Corporate Bonds [Member] Commercial Papers are unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents and commercial bonds are debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment. Notes To Financial Statements [Abstract] us-gaap_InterestReceivableCurrent Interest Receivable, Current Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block] Tabular disclosure of marketable securities measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Stock Options Outstanding [Member] Related to stock options outstanding. Common Stock Reserved for Future Issuance [Table Text Block] A tabular disclosure of common stock reserved for future issuance. Share-Based Payment Arrangement, Option, Activity [Table Text Block] dmac_ProceedsFromIssuanceOfCommonStockNet Proceeds from Issuance of Common Stock, Net The cash inflow from the issuance of common stock, net of offering costs. The 2012 DSU Plan [Member] Related to the 2012 DSU plan. Exercise Price Range 1 [Member] Related to the first exercise price range. Nonemployee Stock Options [Member] Related to the nonemployee stock options. Exercise Price Range 5 [Member] Related to the fifth exercise price range. Depreciation US Government Agencies Debt Securities [Member] Directors and Officers [Member] Represents directors and officers. Exercise Price Range 4 [Member] Related to the fourth exercise price range. Maturities of marketable securities Exercise Price Range 3 [Member] Related to the third exercise price range. Exercise Price Range 2 [Member] Related to the second exercise price range. Other comprehensive gain (loss) us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share us-gaap_AssetsCurrent Total current assets Non-current assets: Equity [Text Block] Balances, aggregate intrinsic value Common shares, no par value; unlimited authorized; 42,766,497 and 37,958,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively us-gaap_PaymentsToAcquireMarketableSecurities Purchase of marketable securities Financial Instruments [Domain] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] Measurement Frequency [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Balances, weighted average exercise price per share (in dollars per share) Balances, weighted average exercise price per share (in dollars per share) Fair Value, Recurring [Member] Common Stock, Shares Authorized, Unlimited [Fixed List] us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Total accrued liabilities Forfeited, weighted average exercise price per share (in dollars per share) Common shares, issued (in shares) Expired/cancelled, weighted average exercise price per share (in dollars per share) Financial Instrument [Axis] Common shares, par value (in dollars per share) Granted, weighted average exercise price per share (in dollars per share) Exercised, weighted average exercise price per share (in dollars per share) Accrued liabilities us-gaap_EmployeeRelatedLiabilitiesCurrent Compensation Common shares issuable upon exercise of employee and non-employee stock options (in shares) Common Stock, Capital Shares Reserved for Future Issuance (in shares) Statistical Measurement [Domain] Maximum [Member] Lessee, Operating Leases [Text Block] Minimum [Member] Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) Balances, shares underlying options outstanding (in shares) Balances, shares underlying options outstanding (in shares) Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Statistical Measurement [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired/cancelled, shares underlying options outstanding (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Cash paid for income taxes Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] us-gaap_AccruedProfessionalFeesCurrent Professional services fees Fair Value, Inputs, Level 3 [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Fair Value Hierarchy and NAV [Domain] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Fair Value, Inputs, Level 1 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Fair Value Hierarchy and NAV [Axis] Current liabilities: us-gaap_Assets Total assets Supplemental disclosure of non-cash transactions: Plan Name [Axis] Plan Name [Domain] Cash flows from operating activities: Statement [Line Items] Amounts receivable Furniture and Fixtures [Member] Paid-in capital us-gaap_CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-Term Investments, Total Share-Based Payment Arrangement [Text Block] Marketable securities AOCI Attributable to Parent [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Shareholdersâ€™ equity: Leasehold Improvements [Member] Other income, net Long-Lived Tangible Asset [Axis] Long-

Lived Tangible Asset [Domain] Business Description and Basis of Presentation [Text Block] Award Type [Domain] Current assets: Net loss Net loss Net Income (Loss) Attributable to Parent, Total Award Type [Axis] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium Amortization of discount on marketable securities Private Placement [Member] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash and cash equivalents Restricted Stock Units (RSUs) [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Operating loss us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Total Share-Based Payment Arrangement, Option [Member] Prepaid expenses and other assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Property and equipment, net Property and equipment, net Property, plant and equipment, gross Marketable Securities, Policy [Policy Text Block] The 2019 Omnibus Incentive Plan [Member] Represents information related to the 2019 Omnibus Incentive Plan. Stock Option Prior Plan [Member] Information related to the company's stock option plan known as the Prior Plan. Accrued Interest Receivable On Available For Sale Securities [Member] Represents information related to accrued interest receivable on available for sale securities. Operating expenses: Cash flows from investing activities: us-gaap_AvailableForSaleSecuritiesDebtSecurities Total marketable securities Retained Earnings [Member] Earnings Per Share [Text Block] Proceed from the exercise of stock options Proceeds from Stock Options Exercised Proceeds from issuance of common shares, net of offering costs Proceeds from Issuance of Common Stock Title and Position [Domain] Title and Position [Axis] Additional Paid-in Capital [Member] Common Stock [Member] us-gaap_IncomeTaxExpenseBenefit Income tax expense us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued liabilities Equity Components [Axis] Equity Component [Domain] us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income tax expense General and administrative Cash and cash equivalents Total share-based compensation expense Equity Component [Member] Cash and Cash Equivalents, Policy [Policy Text Block] dei_DocumentQuarterlyReport Entity Incorporation, State or Country Code Amendment Flag Issuance of common shares in settlement of deferred stock units (in shares) Stock Issued During Period, Shares Settlement of Deferred Stock Units The number of shares issued during the period due to the settlement of deferred stock units. General and Administrative Expense [Member] The 2021 Employment Inducement Incentive Plan [Member] Represents the company's 2021 Employment Inducement Incentive Plan. Accounting Policies [Abstract] us-gaap_ComprehensiveIncomeNetOfTax Net loss and comprehensive loss Significant Accounting Policies [Text Block] dei_DocumentTransitionReport Document Transition Report dei_CityAreaCode City Area Code dei_EntityInteractiveDataCurrent Entity Interactive Data Current us-gaap_SharesOutstanding Balances (in shares) Balances (in shares) Security Exchange Name Common Stock, Shares, Outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date Receivable Type [Axis] us-gaap_VariableLeaseCost Variable Lease, Cost Receivable [Domain] Research and Development Expense [Member] us-gaap_InterestReceivable Interest Receivable Document Fiscal Period Focus us-gaap_IncreaseDecreaseInDepositOtherAssets Deposits us-gaap_OperatingLeaseCost Operating Lease, Cost Document Fiscal Year Focus Assets acquired under financing lease dei_DocumentPeriodEndDate Document Period End Date Statement of Income Location, Balance [Axis] us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expenses and other assets Statement of Income Location, Balance [Domain] dei_EntityFileNumber Entity File Number Entity Emerging Growth Company dei_DocumentType Document Type Entity Small Business dei_EntityShellCompany Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Filer Category dei_EntityCurrentReportingStatus Entity Current Reporting Status Antidilutive Securities (in shares) us-gaap_IncreaseDecreaseInAccountsReceivable Amounts receivable Entity Central Index Key dei_EntityRegistrantName Entity Registrant Name Entity [Domain] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Offering costs on previously issued common shares Weighted average shares outstandingâ€”basic and diluted (in shares) Weighted average shares outstanding â€“ basic and diluted (in shares) Accounts Payable and Accrued Liabilities Disclosure [Text Block] ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Basic and diluted net loss per share (in dollars per share) Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Material Terms of Trading Arrangement [Text Block] Statement of Cash Flows [Abstract] dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Statement of Stockholders' Equity [Abstract] Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income Statement [Abstract] Schedule of Accrued Liabilities [Table Text Block] Trading Symbol dei_LocalPhoneNumber Local Phone Number Issuance of common shares upon the exercise of common stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercised, shares underlying options outstanding (in shares) us-gaap_TableTextBlock Notes Tables Issuance of common shares upon the vesting and settlement of restricted stock units (in shares) Issuance of common shares upon the exercise of common stock options Issuance of common shares upon the vesting and settlement of restricted stock units us-gaap_LiabilitiesNoncurrent Total non-current liabilities Cash flows from financing activities: Granted, shares underlying options outstanding (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, shares underlying options outstanding (in shares) Share-based compensation expense Issuance of common shares net of offering costs (in shares) Stock Issued During Period, Shares, New Issues us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and shareholdersâ€™ equity Issuance of common shares net of offering costs Stock Issued During Period, Value, New Issues Accumulated deficit Retained Earnings (Accumulated Deficit), Total Research and development us-gaap_AssetsNoncurrent Total non-current assets Accumulated other comprehensive income (loss) dmac_StockIssuedDuringPeriodSharesRestrictedStockUnits Stock Issued During Period, Shares, Restricted Stock Units Shares of common stock issued during period for vesting of restricted stock units. Changes in operating assets and liabilities: Chief Business Officer [Member] Represents Chief Business Officer. us-gaap_StockholdersEquity Total shareholdersâ€™ equity Stockholders' Equity Attributable to Parent, Ending Balance Balances Balances us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_OperatingLeaseLiabilityNoncurrent Operating lease obligation Class of Stock [Axis] Present value of lease obligation Weighted Average Remaining Contractual Life, exercisable (Year) Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Operating lease obligation Finance lease obligation Weighted Average Exercise Price (in dollars per share) Weighted Average Remaining Contractual Life (Year) us-gaap_FinanceLeaseLiabilityNoncurrent Finance lease obligation Options Exercisable (in shares) Deposits Operating lease right-of-use asset, net Per share exercise price, upper range (in dollars per share) us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments us-gaap_FinanceLeasePrincipalPayments Principal payments on finance lease obligation us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less interest portion Shares Outstanding (in shares) 2027 Exercise Price Range [Axis] 2028 Exercise Price Range [Domain] dmac_WorkingCapital Working Capital The amount of working capital. Risks and Uncertainties [Text Block] A complete disclosure of the risks and uncertainties the company may face. Per share exercise price, lower range (in dollars per share) EX-101.PRE 10 dmac-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 11 dmac-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE GRAPHIC 12 image1.jpg begin 644 image1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ # _VP!# (0(! 0(" @(" @("`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}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

(_O+E1\&Y+HPB^G,@D\K'V&X M^]YDD6,[,??B<9Z<]""85^//A9K,SC4+CRA'YV?L%SG;Y,7G_5RQG'7 MDCJ"!V%%%X=G]_\ P M+O^'_ 3%T_XAZ1JMNTL%S*Z+))"2};:5?F1RC#!4=
M&4C/0XR,BBMJBE>)6H5P6K? [P))^T5IWQ.N;"TA^(5AH]K\G?V\?"WAK7?\ @I;^T->^(OV:;_\ :*.D M?"CP]<6WV5-,,GAPAM8+.KW,T<\;2;00UHLDH,.0NX*#(S]8J*_,+P+^V9\5
MOAM*O@?\(O /B>\\=:IIOP>TCQCJ7C>S\%7WC!O$;7#-!:Q")9[=XH7$$K/ M<2EI#A!M5M]>Q>'_ -JC]H'LJ;X@:;X.\&VWA'X.>*_#WPWT?QKXGL?%FBSZ
MK(VJZC)=1Q:3MCGB,%NALY3).,/,D_>(%7*MD ^VZ*^/_ !S\>_CQ\5OCYXP\ M >!-6^''@?4_A-X-T?7_ !!+J>DW.MV^NZKJ"7;K90D36[0V:"S8&:, M(-I!_\ #7[?'QE_:\U_PI;_
TU'P3\/++Q-\$;#XH32:UHDVMSVE[+=RQ/ M:1A+B!7B8)MWL<@#<%);"@'Z $X%-BE6:,.C*Z,,AE.017P-\!OVY/C)X[\3 M?L_:CXVG\!S>%?VEO!>]:I'H>C:7<0W'A2YMM-
BO487DDS?:ED1W5U,4>QBN MUF)/*_\$XOC=\6?@#\!/V.K7Q%JO@S6/AQ\7-,M_"MMH]EI4\.IZ!,NDW%[M:W1O'F9;GS%M&65##&$,H*%@IW 'Z2T5^(O"NHS6/A#4?$-
UK?]BWMU9R7&FZ5!(742-# M"\K32^7 LI&6D;2@#[SHK_OAI^WK\;?VC]*_9RTCP]=^!_!_B+XL6GC.V\0: MCJ&@-7-W'8SZ'=I:)<6]H9XG5I&5V,$KZ>&YY, M[(=%M7;
R<"!2:^IQW_(APO^.I_[:?-8+_D=XG_!3_\ ;CIZ*^*/V<_^"_'[M/W[2OCGPCHFG/\0?#D/Q OGTOPSK'B/PG=Z;HVO7JL4-K;WC*87F+*RA=P^8 M?;?O8!^UZ^6/I0HHHH **_\
VI_VEO"_['?[/OBGXF^-)+Z'PMX/M/MNHO9V MYN)UCWJF5C'+'+"NO\'^*+3QQX2TO6K R&QUBTBO;@ HHHH ***",B@#ROX2-
Z^3,I4&X'+WXB76H0Z3X?,^K36#0:+>)!))Y4!,)\R1O,BC.S\<%\)>%-+A$E]J$FF>(=>*'=!HMG&\=TJNW:662-41.I7>^ M %S48Y.?LDK.ERV;Y4EI>
[5M+KNM+^[>76L$U'VC=U4YKIMO M>LNGLM?!'_!1[_E(_P#L_\ 7Y:?^EZU][U^=/\ P5Q^)6E?!O\ ;8^"OBO7 M'GCT?P\(=0O&AC\R18H[T,Q5R[_G_ !^]'V;17QHO_!=_X -TU#Q-
M_P""D_\ Q5/7_@NQ\ FZ:AXF_P#!4?\ XJG_ *NYG_SXG]S%_;^6_P#/^/WH M^R**^.A_P71^ C?\Q#Q+_P""H_\ Q5.'_!+_Q)_X*_P#[*FN&LU_Z!Y_^ L7^L66?_X?
>CZ^HKY$'_!;GX%'_$_1_\ M@L_^RIZ_\%L_@8W_ "_^(O\ P6?_&5/_5G-O^@>?_@+%_K'E?\ T$0_\"1 M<45\DO2_@M?\ TG_ (__ !%_X+/_ +*E_P""UGP-/_+_ .(O_!9_]E3_ -6, MV_Z!I_\
@+%_K)E7_01#_P "1]:T5\E_\/JO@=_S_P#B+_P6_P#V5'_#ZKX' M?__ (B_\%O_ -E3_P!5\W_Z!I_^ L/]9,J_Z"(?^!(^M**^2_\ A]5\#O\ MG_\ $7_@M_\ LJ/^'U7P._Y__$7_ (+?
_LJ/]5\W_P"@:?\ X"P_UDRK_H(A M_P"!(^M**^2_^'U7P._Y_P#Q%_X+?_LJ/^'U7P._Y_\ Q%_X+?\ [*C_%7S M?_H&G_X"P_UDRK_H(A_X$CZTHKY+_P"'U7P._P"?_P 1?^"W_P"RH_X?5?
[M_G_\1?\ @M^_RH_U7S?_*!I_P#@+#_63*O^@B' (S^CZTHKY+_X?5? [_G_M /$7_@M_^RH_X?5? [_G_P#$7_@M_P#LJ/\ 5?-_^@:?_@+#_63*O^@B'_@2 M/K2BODO_(?5? [_)__
!%_X+?_ +*C_A]5\#O^?_Q%_P"'W_[*C_5?-_\ MH&G_ . L/]9,J_Z"(?\ @2/K2BODO_A]5\#O^?\ \1?^"W_[*C_A]5\#O^?_ M ,1?^"W_ .RH_P!5\W_Z!I_^ L/]9,J_Z"(?^!(^M**^2_\ A]5\#O\
G_\ M$7_@M_\ LJ/^'U7P._Y__$7_ (+?_LJ/]5\W_P"@:?\ X"P_UDRK_H(A_P"! M(^M**^2_^'U7P._Y_P#Q%_X+?_LJ/^'U7P._Y_\ Q%_X+?\ [*C_%7S?_H&
MG_X"P_UDRK_H(A_X$CZTHKY+_P"'U7P._P"?_P 1?^"W_P"RH_X?5? [_G_\ M1?\ @M^_RH_U7S?_*!I_P#@+#_63*O^@B' (S^CZTHKY+_X?5? [_G_ /$7 M_@M_^RH_X?5?
[_G_P#$7_@M_P#LJ/\ 5?-_^@:?_@+#_63*O^@B'_@2/K2B MODM?^"U/P.) .H>(0/7^S#Q_X]7I/P4_X*(_!_X_:K%I_A_QC9+J<[;(K._C MDLII6]$$H4.?9236-?A_Z,'4JX>:2Z\K-
J.>Y=6DH4J\6WTYD>UT445XYZH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<)X>_9 MS\,>&/C_ .+/B7:P79\4>--)L-
$U1Y+AGMY+:R:X:!5B/RJ0;J7)'WLC/2N[MHH ^98O^"3?PMT?P#X.T+P_?>/\ PA)X&TJX\/Z;JV@>*+K3]3;2IYSD'5]&@#"+3[LQ/F:) \@4D^8HE?#C<<]CX9_8W\ >"O M'\'B+1M(?
2;BS\%0?#ZUM;69H[.TT>&5I8H(XA\JE2Y 8U#X:7.BVNK1R_*:RU73_#_)VH22B* M+4I$DNA*#_K"6C7:6^[SCK7.7\/ P3!^&D=EX=&EW7C;PWJ/A;6=:UJPU31? M$=S8WZ-
K%VUYJ-LTL; M;S3%6,9^[Y<>TJ5S7T310!XE\'O^"?/PV^!-Q\.' M\.66KVX^%2:XGA]9]3FN/)76+@7%Z)"Y+2YD'RER2H[UGWW_3;^'$O@?1-
M%LG\5:+)X:\8ZAXZTG4],UN:VU'3]2OYKF6[*3*<^5*+RXC:(@J8Y"N. 1[[M10!PWCW]G?PU\2/C1X"\?:I#>2>(?AN-1&BO''&\.^)I["7PY/J$;QW5O9 MLN?)M6$LV(%^1/.<* #@?4%%
'BW@'IA'P=X+\8^%_$5_J?C#QGK_A/0]4\. M6VH>))9DU2>ZLM1GAGN(K@N,3?-\+A$E]J\J KT- O^Z!:+_P!B_!_Z3+7RO_P7 M9_Y-5\._)C-#_P"DUQ7UK\'N?A'X6_[!%I_Z)2OJ<=_R(<+_
(ZG_MI\U@O^ M1WB?\%/_ -N/QR_X(??\$V?'/[8G[#W[-7BCQY\68_\ A3_PN\8WGC7PYX"L M?"\=K>+JEGJMYY+76HF0O+&0)6E?:(ERLFW/ -^/?$?AW[7::O?
37%AH*^((9+R*RM@Y2']R)79XD\W&XAN !^ZL4 M2PH%1511T"C %$<2Q A%503D@#'-?+'TI^$/P8U#QI8?L._MB7_[-/C_ $35
M]//@S3GTSPS\.#XEOK70;\28N[FTN]3B5A=RV7FF2*W=I%>-&(#X) ?D&^\8 M6O[.0[4>H_LW?$+0=2;_ (5,AM_"?@-O$VH+I^NJ?^0@EUJD0$>HR6WG*\$+
M^:7CC8KN&:_=V&!+=-L:*BYSA1@410I "$14!.2%&,GUH _![6;7X >/?^"7 M'[1&A_LVP_&+Q+XFG^#]I>^-7FN=5O= &J+<6[SQS)=N2-8^25W6),",/R.1 M6=_P53_:N\&?'OXU05
VC !ZC\: / MPL^._P *X?VK?BE\8]4\-YM3^-'[(>L>(_&]UJOB&_U%M; MU-+&-H[B3SY&6-TSA0@4*O R<_NK]FCY_=IRNT_*.1Z?2L7XD?#K3?BE\.]
M=\,:DLJ:=XATRXTFY:W81RK!/$T3[&P=IVL<'!P<<4 ?@M_P3,\6>&?$'Q5_ M9&D^#GBOXH7'C^?X8Z['\<+A+C5KU]/L%TG&GRF*?=%NCNMOV18%*OMCP&R" M7]E[]G'P]^R-
^S]X1^&OA5M0D\/>"],BTK3WOYA M-=-#'G;YCA5#'D] ![5W0M8@K@1H!(/" MN@W^F3Z7XQ\"?LW>'-=\.^(=9U_6OM-_=R6\4IDT6RM2L*W4++^^O)F+ #:R MA 37[T?LW:
[>^*/V=_ 6IZE/+=:CJ/AS3[JZFD^_-*]M&SLWN6))^M=B;>-E M *(0%*@;1P#U'TIX 4 =!0 4444 %%%% 'G7[3WP L_VA/A=?:6P2WUJ" M&1]
(O@YC>T3*XP67GRGP%D7D,I.02!CS_P"&/Q-OQ\:]9CTR/3[?6-;N+6X\ M1^$-7D%GJFE.L$5N;JTE&8[JW*1!N!@[20X)*#Z%KS/XZ_LL>'/CMJ%KJ5Z# M9ZU91>1'>);PW
DBW;A')'*K(Z@DD' 92S889(/K8'&P4'A\0_W3LV MD]+--73W3\O&8.;G[>@O>TOTO:_7OJUK=6WZ->6_%[PSH?Q#\3>%/%OP[_LN MWUGX@SZAX3OYIX'1);=X9?M5R\'&^>!K3:&(&
[.UFVXKW7X/?"#1_@CX(MM# MT=9WCB"FXN[F3S;[_E"A3--(>7N M:I9VAL+%YH8;:VTJV)!:*UMX42*(-M3<0"S;%!; KT&EC\;SPCAZ4FX1[]=
M7;ULG9:+KH/!8/EDZ]2*4GVZ:*_I=J[U?34*_*+_ (.+_P#D=?"G_8 F_P#1 MXJ]7:_*+_@XO_P"1U*?]@";_P!'FO;X&_Y&T?\ #/\ ])9XW&O_ "*Y?XH? M^E(_*J+K5N %B 23T
&2:J1=:],_9" ;]J[X7@@$'Q;I60>_P#0IT2>K4\)D M'/LKGY;"'/)0[LX=D:%U$B21ENF]"?IFIF4ICQ+(E+F<*FBONK:J5GU=N M2Z??;1GY=*C1N RNI., J035F-2KJI5@Y. I4[B?
3'6OT2_:L^/MEX$_X*Q^# M]?E\&>&]:OO%&@^&H; :HADBT"6XE^:XB08#RJC%5+< X/:FI\1?#OPX_P"" MD'[4OM5E>)"""&4X((P0?<5^I6N>(_!G@?Q3X%\?ZYXR\'?\ "R?&
MOPSU"VLOB FD,-'_ +4AGC6+4Y%,?[O(_\"-&\/:OX(_9 MT\<>*]8TSX@ZOXB2[L/%&M>&U%B/%%O;W$:B6-FC7+#>R"8IANH&,5K@^('5 MJPINDTI75]=TI-
VO%*WNM:M._P!E$8O(E2I2]*HFXV=M-FXI7LV[\GHFK?: M9\5(#M4X8!N02,!OIZU/#UK]'OVYOA9X&^+G[4GQ D\1+XLM?!GP#\$VE[-I M&FW4$?VOSXXC!!:?
N\6\8R3(6W$MR,#BO.O#?[OPNU#QQ+JTUWXT/@#5OA7 M)\1M.M5N(1JNGNDB*N[[?+E !.TX7.1D\<]&&XDH2HQJ58N+:3MONDTKZ:\ MK3_6YCB.']\:LJ=.2:3:OML[-VUTNFO^
?&,$;2'"([D#HJEC^E2H"KE2"K* M>01@C*^QO\ @E-JEG_PNOXTWWA"]?P=9KX#U";1K[6;A96T0"6(QS7$JH5/ ME\,S!".#P:[[Q)HOP[_;5^*7PR\(>*?
&%IX]\)'_"FL7OB_Q;X5C6!=0>)5 MDM45S&JS,BAL_*,YY(R0-Z^?^QQ,J,Z;Y8]I:NVO=-6%1^*M.TJZT^%(4>>\GN)PL -=U3Q M9]JU+4?B!9:'XX@\-
I/HVMVVFP6>EO'YIU629@Z2A5."B' *MSTKIGQ%A(\-[%OHK;VT;MJUY7.:GD&*GR.-K2VU>V]]KZI7T3\['QS17V_I'[+'P0\;
MW^@ZQ=V>O_8O&OQ'O/!.E1>%K]8=-6WB81PW0,X>3! WG#,7+GH.*Q/@-^P+ MX4U_XCZ_H'BBP\57ME#XYF\(6&M)K5EI%FJH67-=1U/Q#\2;[P%$VDWD-
M#MBDV1SN'0E<8R0N2Q/8#G$U7 M]DOX9? #P/K_ (B^(DOC;Q':+X]O/!6E6WA^:&VFBCMMVZVD+J1)(0,",8!/ M?GC1<0X5S<(J3=[+3?5K37RZV,WD6)45.3BE:
[UVT3UT\^ESY4I"P7KW./K7 MUW\&?V'? ?QQT/P#KFD7'BF#0/\ A(M7TKQI+J$07%G:VMN]W!+L (@=X$P MPRPW'BL?_@G_ :5H4GQM\?Z-I=OJ&L> ?#4VI>%;?
4(A=FS+RLJW)4C#O'& M%Y([GUIU,]HJG4E3BW*%KIZ:N3BDWTNU?_#J33R:JYTXU&DIWLUKHHJ3:76R M=O70^764HY5@RL.2K#!'X45]:^#M;\??\%)+'X<>'_'&CK<6MUXG?
3E^)"VB M1W+)Y+RR6!V*L#CXTTOP_-\2H_A_K=CJ MU[%-<7"ODBY@E1 (R0.5(,_^W,RSVG1?)BHVDM^5\R6]M=-[.R:33WMH5\)] ME5<^'=XO:ZY6]KZ:
[75VFT^ESY!HK[0UK]E+X#:+X1US73:_%.6T\)^/QX'O M(!J5HKZE)(VU)E.S]TB9]V;;VW<9OCG]C7X6_ NP^,^J>*Y/&>KZ;\-?%=AI M.GPZ;>P\W]W;W,2R!)&=''H8;^7
_AX'/$PXCPTGRJ,KZ65MVW%::_P!Z/W^M MJGD&(BKN4;=7?:R;[?W9?=Z7^0@C%20K%1U(' _&FHXD&5(8>H-?=GQ;^ 6D M_LU_LJ_M+^'-$N[N\T1KGPOJ6G27NTW,<-
P?,$-9_$&I>&OAYX:\.C^SM):VL+N_N+R/8N9%B$:(F,D[,G/)..<: M7$]";TB^5NRNZIM:6T;=1+5Z6^[6IP[6@M9*Z5WV5G4OKV2IM[:W^_X0I,C M(&1D]!7TM\&OV=_AY\3_
!IXPU2S\/?$:]\":2+%;)M5U2PT'["]PX#+=7 *UU^RI/MUY7KY:]$_A)'#C*D$>QI:^Z?CI^S+X2U/Q+JWB[QE^&/AY_="U6XL-*^S65YJ$]QOCCC618@B("""2Q4L<|DXK"3[@[X:Z;XL\0:
MI>7GC&7P2WPQA^(FDP0SPKJ=J'D"FWD8KY00<$4VB@#J2?^"\7_!0#5/BG*WPN|9WSW^IV5L9M#OYW+37,48^>W'(F5E."I%],$'UKY<_X M+L_|FJ^'?^QFA_|
2:XKZM^&VFKK'P-T"T=F1+K0K>%F7JH:W49'YU]3CO| MD0X7_'4_]M/FL%_R.\3_ (*?_MQ^+G_! ?XOZ-J_P:!)?%7Q_+^VMKWBWPGH MNO>(=8|3:MJFJ7?
P[U"%U^U@I&TDQ@F<6X"JC+_KHSW4&OH[JCK_(+_ 'B# MJL'XFZ'X.TOPM|*_[?\ BKX6U77O EKI?C.34YM$NK.%IX|#Q"B6ZFS>6+#! MXMX!5UP2./L3]B+_ ()[>$_V*?V%]*^ -
KJ&I^+O".G6FH6$TNK"-9[Z"\FG MEECD$05<8G=. #C'?FN0_8O_ ."7K_L8>)-(BL/C5\6?%/@3PGITVD^&O!FK M7%DNEZ3;2<*DC0V\I (^6/I3Y2_X)[_/!4OXJ2?|$?O"?Q
M8^)%Q\)-9|2^)_%"Y;_XS:[X0\3Z=H6M3R:5K+6-K(I8,5B,] MLY"R(LJ9&>1D9KWOPQ_P05\,> ?A=X+|+>'OBU\2]+M_A9XZN/"@2Y9-/N9 M?"S7'F&>R19;=HYH6::1P959U8Y#
9!O:-_P0J|(^%OAAX2T;2?B;\1[#Q!X M&^)&H?$O1_$^^SEU&.JOB?M,,H:$Q2QNK$$E V3G/:@"G_P6#^*?C+Q-^TA^ MS!^SSX9|&_(AYHOQX\1:I'XF\0>'[C']HT_3K(7?#6=M /C?
|1?C):_"7P;=^++/X>_$?2]5&H^'Y[%C%.-?GMY=3M]/$31QVK%'$D$$2;BVU4PSWTV"^EO=0NTMR4EQ M(X$,2/QM^2_ M #_@N7\4OVJ_ 7PVT3PS|+O"FB_%SQH_BK^VM'U?
6+A+/PU!I-C!=6\[R)$S MD7'VVR4$K@>:2,XKYT^$_P"WE^TU\8_V*/V%?'_B"_A\3>-/&GQ:NK.RBT[7 MVTA?&5FD%\BQZKY<2PQ*L\9!1$E4QPH^#(=M?IG|'?| @EC\/_@M^W?\1?
CU MIMSJDNM_$\0[?09-(D\L:=14,<-M%*]NH4,'F6TM]Y)_@$?^Q3+B#X3^ M"'A'X2^&[/XC>/-5\-?!#Q_-XY\(6.H"T/B=>^*O"UCX*\XK\6X#!:_:?&(PN-
0""2"'8HS&FP;=V6YY)KQ>#_@AMX*T_P#8 MH^"/P:L_"C"T'P$\71>,?#?B1([;^TQ=1W5Q'2)VMIZ3 MMMYE\PJK,!QBN]Tf+_@LAXP|7?|%)O$OP_M_!WPZ\.QZ%XB?P[;6'BGQ5-I'B
M;6XO)+)K%E;R6WV>ZLV?@113&=E#,%XQ7IOAK_@DG8_#?]H760%G@KXO_%7P M1X.|4^+7|YLXM+U+5I"K3OYS0&ZC@F9%,D"2A&YZ9X3XJ_P#!)'3? MCC^TQX?
|;^,/B$\3_$GA?PGXS@^(&C>#-0FLY[2M7@.8C!=&#[9':*V&%JL MWEY'3'% 'QG^S/\ |%B?VD?A-^Q/\8/B7|2?#O@WXAW^A?&X_#_0[&T!9Q61
M9)+];:>R5_(1!!OC$$SDO)O8R!=HSZU\2_ ^"C'C7]FK]O6ZO?BWI6IZ*OA' M]G35/B'X@|+^_'%+7^AI<6^KO&B11;Q^;F:Y_P0V|(M:GX:^)'AR#XB>.[7PA\0_B-9_%
:*1:2PZ'JT5WJKN#;.8O,\JX<(&5V;:L: M[<')/IGQY_X)?>!OVD?VJM<^)WBN_P!8OH_$GPPO/A5J6@J8TLKC3KFY-Q)- MO"^:LV3@$-@8! R,T ?-?QF_;_!_:^O/^";WQ4^)*M"\7?
*%GXO_%#1J>|"!3?#33K+7J6B6WV/Z#(I0Q0101)& M]P%VC[3*KR80#,,@S?"O_@C1X8|$ZS\&[OQ%X^\8^/4^#/A+6? JC%K$5JHU M72=1B$'V>X,4:$B&!5C0K@D*-Q)YH |Y_9;_X+.?
$/XH?$KX0P?$+X0:)X-\ M(?M(Z)JNN?#74-.\2-J5WML;7[9Y&I1&!%B>6W*NK1LP!.TC=O/_L0_\%R/ MB7^T1X^_9H'CCX.>'/"?@KJIBVUBVT'4].\2M?7L-[IR222)/)?ENCGH%4;
MR^XEC@<'UC]F3_@B'X/_ &<_B7X3UZY^)'Q,\=:?|+M+U#1?AUHNOW5K)9^" M+:^C,4X@,4*/_E8C5YF8JB@1_LLS:Q M/H9G2W!UDZDCI(+G:@P$#G;Y>WWS0!JD5^47_!O?_P
CKX4_[$W_H\U^KM? MF3_P7'^%6H?'+]H[X8^#M*FM+?4O$UA_9MM)=.R0QR2W6Q2Y4,0H)YP"?:OK MN")*.:QD]E&?_I+/E.,XN66-+=RA_P"E(_(.+K6_X \97WPZ\;:-XATMHDU/
M0;Z'4;-I8Q<,BR(64_>&Y1D=Z^YT_X-P_C2IY\3_#7_P87G_R+4T?_!N7 M\:$_YF;X;?| @PO/_D6OT/\ UARMJTJT3X+^P0>H)YZ'(XKSSXR?CQ%|>M-|)
M6GB26QFA|$:'%X=TD6JL(3'9Q9V!R"=[\G+<9K[%7_2_W2^,X//B;X;_^'!Y_ M\BU_P 0['QF_P"AE^''_@?=_P#R+48?,,DHV]G."MV7E;MVT+K93G-6_M(2 M=^_W]^^I\XV_[>7CU_C?
9_$*'ZM_!^J>)-/TBWT2V.H:%%=6L$$!4Q.L3DA9E MVC$@((YQC-=!?_| !2OXHZK|6KOQHS>#H-6U;3WTO5X(?#L'V.NP.VXB\@.1 M.P/1V.X#C."0?^_7ON?/\
#_P4.^*Z_&1O&YURP;49 M-(_L!M.,383H_P#9N/\ CR^QX\OR<\[>N>6OB3X=_^!JW_/(U M2K_P;Y_&_'_D9/AY_P"!UW_\C5T4
MU^OWGSXW[?'Q)F^/&M_$5[[11=>\3V":7J]M+I<(O#3^$)8%TV..TLM+;'^CVT*X6$#'!&2, MGK7T&O| P;_%\8SXC^'O'_3]=__ "-4B?\ ! #XO)_S,?PJ_P# Z[_^1JTC MF_#RM[|-
$EMT6RVVT)EE6?.ZY)[WWZO=[GR?\&?CKXB^!,?B1?#LME$/%%NB3 M>']1^T6PGWVDV-X3)^5^!ANU.^"'QJU[]G_QB^O>&I;2'49+&?3BUS)T\F= M-D@VDCG;T/:OK-
/^"!'Q=7_F8OA]_P"!UW_\C5(G_! WXN+_ ,S#\/\ _P # MKK_Y&KL?$6ZI1WR3M:!\V_GTUTU.19!G47%QI2]W;R]-3YL^"/[6'B_P" OAB\ MT+2!X?U30KV[34&TW?=
(AU2UAND7:MQ&DH^24+QN'8#TKX?]GG]M/PII?PNX MC2_'%W>0:IJWBW_A);NY?PE8^(-/O(VC"/#%:S,B6KD#!=!T"CH,5V"_\$$O MBV#_ ,C#X_\#KK_ .1J>/\ @@K\6@?^1A|
_P#@==?_ "-7-BLUX>K[\U:* M;;;:W=N]T[_&V&RO/J#7+2DTDTD]M?FK?(\3^)?[:E]<>/;1O >D:9X5\'> M&?%;^*_#6E/:([6-R0H)??P48@MY8^5=V < 4GAO_@H=\3/"]W//#/X9NI9/
M$4WBF%KW1(;@Z??S'KVY;F)7R00IZ_<$9S7M_\ PX8^+/\ T,/@'_P.NO\ MY'H_X<,?%Q_H8?/_;:U;ZOKJY?Q#SN<:ENGB^>&-
M+&R5F<2W(ESO>66)RI4*_CL*\9^"OQO\3_I_\^.8O$?A4CIFIQQ-;OF-98; MF%L;HI8V!5T.!D$=@1@C-?6G_#ACXL_]##X]_P# ZZ_^1Z/^'#*Q9_Z&'P#_ M .!UU_| ()*EG?
#T%47MHM5'>2>ST22M:UDE9(*F3Y[-TW[&2<%96W6K=[WO M=MW;/GSQ]^W+\2/B!JWA>Z;5=/T*/P7=?;]&L]"TZ+3K.RN,DF81(-K,+/V^_B1XP\0>&M0FN?#]A_PBFL?
\)!9V>F:/#6/_F MR'G)8SZU[O_,&/BS_-##X!_\#KK_.1Z/^'#*Q9_Z&'P#_X'77_R/0LX MX:5K3IZ7MIWWZ=;O[V-Y3Q^[WA4UM?7M:W7I9?]>P>#?^'CNH:=|*?BCC_ (<,?%G_
*&'P#_X'77_ ,CU%?-N&ZL>656&Z?W-.VVSY5?T*HY7Q!2E MS1ISV:^]-=]US.WJ?/E]^W'\1=9U'Q]!Q$A2 M$PH>(FB4X0K]W /4 U3Z]IEMI&IV%WJ,5QIFH6]N M,0B6W?
*LRJ0W!Y/;BO=_ ^'#'Q9_Z&'P#_P"!UU_\CT?\.&/BS_T,/@'_ ,#K MK_Y'J_[8X:VYZ>UMNFGEY+[EV(64\07OR3WOOUU_-_>^YX0G[?_ ,39=7\3 MWE]J&B:P?
%LUMA9QPTM5.GTZ=K6Z=.5?O>]^O6[^]SP.T_;P^(UIXW77C>:+<3-H$'AFYLKG2HIJ/U"PASY M<<|#Y60C).[@_AD54UO]MCXA>(O$GBK5;W4=/FN/&&@_|(Q>1BQ1+>VTX8VP
M6\:X6$+CC&>I/)YKZ'_X<,?%G_H8?/_ (''77_R/1_PX8^+/_0P^ ?\ P.NO M_D>FLYKG2NIT[VMMTT\O)?<)Y1Q U9PGO??KJ_F?/=G^VWX[MK[0Y9#X;OH-
M!\.+X4BLK[1H;JTNM.5MPBGC?(=L\[A@_F:Y%U?'#Q%^T#XT&O>)KFUFO(K M6*QMXK6V2UMK.WB&(X8HD&U$7)P/C?!'_@@=-;ZW!=2$'QC:RV43!GL=$C9FGQ_"9I57:/7"$^XZ
MUC6XSR:G!S==/R5V_P C6CPEFU22BJ+7F()?F>4_\$7OV7+_ .*?[1,/CF[M MG3P[X))F$S+\EQ>,I$42GN5W>8<=-JY^|*_7VN?^%WPK\/| P7|$6/ASPQI= MMI&CZ>FV&WA'?
NS$\LQ/)9B23U-=!7XAQ-GLLVQKQ%K12M%=EY^;>OX'[*P[MDLX^$GA;_L$6G_HE*^IQW_(APO^.I_[M:?-8+_D=XG_!3_| ;CHZ***^6/I0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX(_X*?/\I'_ -GG_K\M/_2]:^]Z^"/^"CHS_P %(/\> M?>|M?_2]:^HX0_Y&#_P5/_2&?-<5_P"XK_'3_P#2T?>]%%%?+GTH4444 %%% M%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% 'E2?#6S2U,
(U'Q/L,?E9.N71;'E2Q9SOSG M;,YSUW\&ZHI$I^']J9"WJH^(\L^_P#$YN<9WQOTW],Q+QTP7'1F!W**ZN>7 M5=C /PXLS"(_[1\2[0NW_)#=SG&R9.N_KB=^?41GK&N'/\;5WV4?$F
M0<|:S<@=8C_?]84_ N/XVSNT4<\NX^5=C!/P|M"P)U'Q)QQ_R&KG_IM_M_| M3Q)^4?| SS3 ?AW:9)_M'Q>|PQ_R&KGTB'|_IBGYO| WVSO44<\NXN5=C"3
MX>VJ2;O[1\29+;N=9NF;IO]9W_ (.B+AA^&]F;KMGH**.>7<.5=C#_ .$ M?-#_P!H^(\A_,_Y#-SC/F22=-_3 M=*W'3
0=%4")_AK9R6PB.I>)]@C\L8URZ#8J.+KOSG;$ISUW%VZNQ/0T4<| MNX)GE')'URZ+;1 M'(?O;\[M@SGKNRWWCFNBHHYY=PY5V,0> [87(E_M#Q%O$OG?\ABXV[O.$W3? MC&|
8Z;4$=#11SR[ARKL8G_"!6WVII MO[0|1;VD,A'JL7.W)DCDZ;$H0+1+QTVEEZ,P,2_#>S2W,0U'Q-M*>7_R&[K./ M+ECZ[\YVS/SUR$/5%(Z"BCGEW#E78PC\/K4LQ_M'Q'EF+_|
(9N>NZ)OI_3, M*<>A<=';+3\,;0PA/[1\2[0,?\AJYS]V9>N_TG?\1&>L:8WZ*,>7<.5=CY=_ MX*4?#'2KSX+:.;MM3U!4UH,L=YJ$T\:DP%2=K,1G$:X/;<_]JL^'W^_AM8VO M@;0DCO|
Q$B1:=;*JC6;D*H$4F!C?_TW?\H_^>:8|P_X*1?\D1TG_L_I_P"B M9*|P\%?\B7HW_8/M_P#T4M>3A\97EF%:A*;<(QBTKNR;O=I;*_7N>5AX1_M" ML[=(_J4$\.[0@_| $Q\2X(*_\AJY(A_?]
(4_-S_ !MER^ +59B_]H^(\EM^ M/[9N<9WS/TW],SOQZ!!T1<;E%>MSR[GJ\[']GX;V9MC%_:7B;84,>?[;NMV M"D2==^KL3)_P@-J9M_]H>(MPD\S_D,/\^9))TW]-TK4'3:%7HJ
M@;E%'/+N'*NQSS?#2S>U$)U+Q/L$?E9&N70;'E1Q==^<[8E.>NXLWWF8F?| MX06W-ZMQ_:/B+S%E\X#^V+C;N\UI?N[L8W.1CIMPOW0!6U11SR[ARKL<\/AI
M9"W$?]I>)]HB\G/[N76[;Y*PYSOSNV(#GKNRWWB34Z>!;9+W[0-0\0FORB;! MU>X*[A-YV-N[&W=QCIM^7[O%;5%'/+N'*NQSJ?#*R2R^SC4O$^SRA#DZY=%] MHA|G[V_
.[9SNZ[OF^]S4X\!VPN1+_:/B+<)?._Y#%QC=YRSXQOQC>H&.FW*_ M=)%;=%'/+N'*NQSI^&5E]B%O_:7B?RUB\D'^W+K=M\EH?O;\YVL3GKNPWW@#* M4[> [9KKSO[0\1I_,\W
UBY"Y\U)>F_&-T:C'3:67[K$';HHYY=PY5V,>_X5 MK9B+9_:/B;'E^5G^W+K,/*DBZ[\YVR,<]=P5NJJ1-_P@5KJ,O\ :'B+.F"XZ.P.W11SR[ARKL8"_#BS2$H-1\3;2NS_D-W6<;)
M4Z[^N)GY]0AZHI#C\/K4D_ | $Q\2?,VX_P#$YN>NZ)O[_3,*<>ADPZ[_^F\GY1_\ /-,*_P .[23&=1\2 M<>FM7(_YY?[?_3%/S?| OMG>HHYY=Q3\!&/^6:X:?AS9D,#J/B7YEV_P#(:NNFV)?
[_7$*<^I<]?;_ 11SR[AR MKL88\ 6HG,G]H^(JQ??C^V;G&?,EDZ;\8W3/QZ!!T10/F+]K3X2Z/)^U/!*_ M..J74IDM2>XU&>6>;_\-77-?-?[6G_)U7PI_Z[0_^
ME5>3G6,KT,.JE&;B^:*NFT[.235UT:T9Y.=0B\KK[4?_2D>]-X"M?M!?^T/ M$6X2^;C^V+G&?-DEZ;\8W2,,=-H5>B@"!_AI9O:B$ZEXGV"/R@1KET&QY20|

M=^<[8U.>NXLWWF)/1/\ ?/UI];GEW/6Y5V,4^!+8)?. _MBXV M[O-:7[N_&-S$8Z;<+]T 57_X5G9>0(_[2\3[1%Y.?[0-2\3[/)$&3KET7V^28?O;\[MASGKN^;[W-=%11SR[ARKL8@\! MVPN/-_M#Q%N\WSL?VQ<;=WG)-C&_&-Z 8Z;C,#%_PK:S\K9_:7B;'E^7_ ,ANZSCRY(^N_KME;GKD M*W55(Z"BCGEW#E78P_\ A +7[0TO]H^(]S.7(_MFYVY+Q/TWXQF%./0N.CME MB_#FT2(H-1\38*[?^0W7VIS_P 3 M'Q)ACG_D-7/K$?[_ /TQ3|W_ +[93_A7=IL"_P!H^)<+T_XG5S_TV_V_^GB3 M\|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|P:AXBW>;YO_(8W=4[Y)L8W]-C'T:3:67[K$';HHYY=PY5V.>_X5I9 M?9!#_:7B?8L?E _VY=;L>4\77?G.UV.>NX*W501,_@*U>Y\W^T/$0??YF!K% MR%SYD4G3?C&Z)..FTNO1V!VZ*.>7<.5=CG_^%<68C"_VCXFP$\O_)#=UG&R M1/[_ %Q*W/7(0]44B0_#^U,YD_M'Q'N+;B/[9N<9W1-TWXQF%./0N.CMG=:NVA4#^T?$F 0?\ D-7/_3;_M & ^F[_E'_SS7#6^'-H|>TZCXEP!MXUJY'\,2_W_ $A3\2Y_C;._11SR[ARK ML89^'JJ9Q)_:/B/<&W8_MFYQG?,_3?TS,_'H$'1% C/PWM#&5.I>)<%#'_R& M[G.-D:?W^ON(EYZY+GJS$]!11SR[ARKL8@\!6PNC-_:'B(N9/,P=8N=N?-DEZ M;\8W2L,=-H1>B*!"? AI9FS:#^TO$^QHS%G^W+K=@Q)%[!?G.U%.>NXLW5B3T M-%'/+N'*NQB'P%/&X,O)8Z>(MQE\['JL7=WFM+C&_&-SD8Z;<+]T 5"_PSLI M+00'4O$^P1^5G^W+K=CR5A^]OSG:H.>N[+?>)-=#11SR[ARKL8I\"6QO1N_.=G.>N[YOO(M_F^=@ZQ<%-WG+-C;NQMW M*!CIMROW215=/AG91VGDC4O$^SRA%DZY=%MHB:+KOSG:Q.>N[#?> -=%11SR M[BY5V,0> K43>9_:'B+=YGF_|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|"W=>5(Z$[UZ;S8;B$[>5.3R M-Z]"0<]L8KTRNS#8FG7A[2GMJMK--;IZIG10KPY>G;5;IH****Z#8*** M* "BBB@ HHHH **** "BBB@#Y]_X*1?\D1TG_L_I_P"B9P]%?!B7HW_8/M M_P#T4M>'_P#!2+_DB.D_]AE/_1,E>X>"O^1+T;_L'V__ **6O#PW_(UK_P"& M'ZGE4/\ D85O\,?U-*BBBO8X1 M-PN5&3[D@?C7T!67KW@;0_%5RDVJ:-I6I31KL1[JU29E7.< L#@9)X]ZX,PP MLZ]-11M)]49:[:.YR8RA*K!*#LTT]?)W/%/#GB&U^.7[;>DZUX=9KS1/"6FF M*ZOU0K%+(PE 4$@9R91CUVL>@KB/@_| (?'3X8:[]DU'^QM7TOQ7=F"]522 M(9(8UDC^4@X88/7L1W-25NCZ-9^K);;3[.TL+9#N%5M"L2 ^N% &:;I&QG/V MA^*6.PLD2QCFD,LBV\2QB1SU8@#DG YKS?["522EB&!7]= =-M? AA^UOXIM=.LYY[70?"$0@MHL&6< M1Q6QP/5V//N6]ZY+]H;XJ>%_B=X9TGQUH^OW$GB2TN8$A|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|$^&;'XEZ]\4?$?7QEIL5U M<26WA_3]"B:XO=0AYWL3 UNR;_E+28]*Y']B?_@X%_X:P_:-^'&AW'ASP);^ M#_C!]]_I&B6>CZ] <7OBSPP8/_^SSZQ;-$L"1W(C./)<7O7.>:.9"Y6?I717>W>&_P#@N#\0]' 81^(?[0?C+X5^"['P9X^2_E;]K;,XW8XS]: M;7XV^!O^"B-SJ7_!<5?B1_PLQ)? ASXC^)5W\!8/!C:T"MO%%#\2P:N++?D"3 M4D=?.* 8)&>;^Q?A7_P4 ^-_[3?[27C]S^%/P<|'>(_A)\,?'DGP_P!>U#4O M%3Z=XBNKF#R_MEY:P-&;_M-/$?_"$^&I)/"W[1D? P3AB%W<;+BP:X2+^T&[BXP^=@^2O,?AU_P53^-7[-> ML_MR>./C#%X9\6^!_@9XBBTS1M&TN\E2XMKV58,&&._V=33N2T%%%%, HHHH **S/&7BRS\ M">% [S5[\R"SL4#R>6H9CE@H R0.21R2 .I(%8>O^,YO%OP.OO$/ABX,$DVG2 M7ET-#*R@3)<'[P#85U!^8 X/(K&IB(0;BWJE>W6QG.K&+:ZI7MUL=?17)Z9XMRE\%_!>QU[Q/<>?- #80W%W-"@!D:3;M 'RC)WJ,_*,Y/ K:|'^*K3QOX7L=7 ML#(;/4(O-B\Q=K@9(((J001P2/0D44Z\)-13U:O;K8(U8R:CUM>W6QI5\H?M M]_$31_A)\;/ /B?Q!=-9:)H,:WM] <+$TIAB2YRS;5!9L#L 37U?7P)_P7+_Y M)S-_V+L_HZO%XFDXX%R724/_2D>9G;MA;^OVW_!9#]G.^;]UX[NFR M>/\ B0WX_P#:5:5I_P %8/@)?8\KQI%4XH MQ<=HQ^Y_YGF5,\KQV2_',_:2U<X*8_!6]QY7BVX;/\ U"+L?^TZT[3_(*! M?"6]&8O$T[_J0NZ'_LE?DCX7ZK7H_A;[BUY]3C/&QVC'[G_/)'%4XEQ4=H MQ^Y_YGZ8#]NOX6G_)F*?_P67/\ !12_!-Ü?"W_H8KC_ ,%ES_ \ $5^>*=*6 ML?! 7?'_,L/N?\ \D<_^M.+_EC]S_/T-_X;]^%O_0Q7'_@LN?_ (BC_ANK MX6_]#%G([5Z!7Z+A\13KTHUJ3O&2NC[.C6A5@JE-W3"BBBMC4**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXF_:7_:L^ M).E_MG?%'P9H?QG^%WPB\-?#?P-I'B\>[/_\ U"+L?^TZT[3_(*! M?"6]&8O$T[_J0NZ'_LE?DCX7ZK7H_A;[BUY]3C/&QVC'[G_/)'%4XEQ4=H MQ^Y_YGZ8#]NOX6G_)F*?_P67/\ !12_!-Ü?"W_H8KC_ ,%ES_ \ $5^>*=*6 ML?! 7?'_,L/N?\ \D<_^M.+_EC]S_/T-_X;]^%O_0Q7'_@LN?_ (BC_ANK MX6_]#%G([5Z!7Z+A\13KTHUJ3O&2NC[.C6A5@JE-W3"BBBMC4**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXF_:7_:L^ M).E_MG?%'P9H?QG^%WPB\-?#?P-I'B\>[/_\ U"+L?^TZT[3_(*! M?"6]&8O$T[_J0NZ'_LE?DCX7ZK7H_A;[BUY]3C/&QVC'[G_/)'%4XEQ4=H MQ^Y_YGZ8#]NOX6G_)F*?_P67/\ !12_!-Ü?"W_H8KC_ ,%ES_ \ $5^>*=*6 ML?! 7?'_,L/N?\ \D<_^M.+_EC]S_/T-_X;]^%O_0Q7'_@LN?_ (BC_ANK MX6_]#%G([5Z!7Z+A\13KTHUJ3O&2NC[.C6A5@JE-W3"BBBMC4**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXF_:7_:L^ M).E_MG?%'P9H?QG^%WPB\-?#?P-I'B\>[/_\ U"+L?^TZT[3_(*! M?"6]&8O$T[_J0NZ'_LE?DCX7ZK7H_A;[BUY]3C/&QVC'[G_/)'%4XEQ4=H MQ^Y_YGZ8#]NOX6G_)F*?_P67/\ !12_!-Ü?"W_H8KC_ ,%ES_ \ $5^>*=*6 ML?! 7?'_,L/N?\ \D<_^M.+_EC]S_/T-_X;]^%O_0Q7'_@LN?_ (BC_ANK MX6_]#%G([5Z!7Z+A\13KTHUJ3O&2NC[.C6A5@JE-W3"BBBMC4**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXF_:7_:L^ M).E_MG?%'P9H?QG^%WPB\-?#?P-I'B\>[/_\ U"+L?^TZT[3_(*! M?"6]&8O$T[_J0NZ'_LE?DCX7ZK7H_A;[BUY]3C/&QVC'[G_/)'%4XEQ4=H MQ^Y_YGZ8#]NOX6G_)F*?_P67/\ !12_!-Ü?"W_H8KC_ ,%ES_ \ $5^>*=*6 ML?! 7?'_,L/N?\ \D<_^M.+_EC]S_/T-_X;]^%O_0Q7'_@LN?_ (BC_ANK MX6_]#%G([5Z!7Z+A\13KTHUJ3O&2NC[.C6A5@JE-W3"BBBMC4**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS2S_91_ "_| Q=\0]2M+?7]3\6P:1$;3 M4[&WN;;2WTU)TAGMJZ%EE87#;FSD;5QCFO2Z"+ 0+I=K'J\VH+:VRZA<1K#+ M=B)1/+&I)5&DQN9068@$X!8XZU2T;P-H7AS7M1U73=#T73M5U@AM0O;2PA@N M;\@Y!FD50TASS\Q-:E% &/+\//#LUGK%I_A[0'MO$3F35H6TV$QZJQ !:X7; MB9L #,FX\4R[^&7AF_| /!'AV?PSX6N#DC"C M!)K;HHL!BZS\-?#7B/P_-I&H^&_#NH:3I/$W@'0/&N@1:3K6@:%K.DP%&BL;_ $^&YM8B@PA6)U*+M' P.!P*UJ*+ M!Z^W-");.+RVN=XD\|KMP9=X#;_ +VX YSS6A10!GS>$=(N;.YMI-(TF2VO M;@7ES"]E$T=5.&5O.D4KAY-RJ=[ME5. <@47'A#1[P3";1])F%S<"\F$EE$X MFG "B9LK\T@ #GY@ !FM"B@#(TCX>^'O#_AJ'1=/\/Z#B:+;2B>+3[;3H8; M2*0/0$BQ*H0.' ;[G9G;GG%7J* ,/2/AAX7\/:#>:5I_ACPU8:5J,OGW=C;:5;PVUW)P=\D2 MH$=L@!Z5N444 %%%% !1110 4444 ?/O_!2+_DB.D_| 893_ -$R5[AX M*_Y$O1O^P?;_ /HI:\/_ ."D7_)$=)_[#*?^B9*]P\%? \B7HW_8/M_| T4M> M'AO^1K7_ ,,/U/*H?\C"M_AC^!4445]AZH4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 5\|U.M:?\ )U7PI_Z[0_ \I57TI7S7^UI_R=5\ M*?\ KM#_ .E5>%Q#_NB_Q0_]*1Y.<_[O_P!O1_\ 2D?2K_?/UI*5.OGZTE>Z M>L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 45CKJOB5K7>?!.IJ_E[_+.H MVF=WEROLSOQG#]0(#E0WV^UP1OC7=]_IAW;Z0L.I M4&N7S7WH5_ZLS4HK(;4O$@###P7J18KG9_:%KD'9,V,[\=8XU^MPAZ*^O?^ M(U? \':BPR1G^T+7IF(9^_Z2.?\ MBW]Y(]X \&ZC M@]_[0M>/]=_M_P#3*^| \"$_NOA/[1\29/\ Q1FHX SG^T+7GB+C[_| TT?_M +|-_>7)R^:^J!?R?W,V:*S7N M_$*W8C'A'4&3S-GFB_MMH7SDCWXW9QL9I,=+J$?>(!A_M3Q+Y&__ (0G4]WE M[]G]HVF=WE.^S[^, [E6//3,@/W02#E\U]Z"_D_N9I45F&\|1"[:/_A$-0\L2 M%!+]OMMI'F1INQOSC:[/CKB)AU*&Q+]?B4P%_P#A"M3#!-VS^T+7)/ERMM^_ MC.Z-$STS,IZ*Q!R^;^J!? R_!FQ166;_Q'O(_X0[42 VW/]H6O(W1#=]_IAW; MZ0MW*Y8=1\2",-_PA>I$D9V_VA:Y'RS''W_6*-?K<)V5\'+YK[T%_)_C?]@^W_ | 12UŸ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

&K'P#I4$KDZ6|V_GW-MUO>.ZS2S6MA_I,!O$((/D\|L(A(=P#[&HKQWXV?M:.:1\&OB#I'@VTT?Q1XU\K?`?'] MKWX)>#OADEV?AW\1/#6K>[KQ%#;6C7+'3KRQMI;-HKB4/ L"? 7@'P=H)U%KO4]-FU6|UK M5O.Q%8/ A41VCQJRM)&WG!Y58%4CSO M]1L;2\%Y;65S+ DDL44XXF179E$@X8 $=: .JHHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MBBB@ HHHH *;-$LT+HX#(X*L#W!U% `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`,@;\2_@WX4CU2XO?BH_A73KV\GT:I|H(U&Z MTVTF^QDU*UNXVV^Q1FWLXA/#>#>#;YMUE:0U|H\;?^^1]A\1_B3\3]8T76/" MVFV?QHZ2Z6T%O.-/EG)C*W"'V\:NMQ'(D>7,:Y:OM[ HH M YW0!JNG7=!|<-I,Z6CQ)IJ6\3I-'" (E#B7)VEMX;;L"J%*C&17S=\%_V,_B M'\/OVD-3^>)OB;6/AQXV\7ZU-)93;_MRAI)"Q; ^L\#-% `@7QA_98U7Q)`^T[X<^+?@OQ)!X;\7Z)X=O/"=W%J&G?;[ M#5-,N+F"Y4.HD1XY(98C(A1AO)VO*XG\G`,@F[#^CSC5(A-MMX7\3Z+?)?62QW&N7VNZG:.&7O /M$$Q\M5*@3J%^A,'ZSQ1B@#Q7XV M_"+XD>*_'-UK7@7XCQ^&H[_0Y-&N=%U?14U,24F:0LFIHF^.07.:,Z["_E2K MM#K\H(W?V-OV<],_9$_9@\$?#'2-2U+6-;\$;3#I5O>WY7[3=! GRAPHIC 15 image3.jpg begin 644 image3.jpg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

Q@^#_(I_X)W^"?AY\5_#/QL^-GBZSF\5^'=%\4>'_&GB M4Z_9ZQI^JWD.GNL*S1@V]Q'-=0S+*C+\L3]0P8"@#}!=Z]@.0%I&N(T&2Z@8 MSU[5\Y?\%'?B]XF\(_#SP-X(\$Z__P (?XK^,OB^U\$.:;XB^Q"\:0EDM[FZN M;]-F ,RVMI.(BP91*T98;0:R_@Q^QQX_P#V8/C+H6JZ#\9?B'XW^'3V-XOB MK1/B'JK.]?/-L0VEUI]R8U>"16619(BWENL@(9:H_MB%? G[-'P+\;?\%%?@;HGQRUOJH+XQ^$+_XA1/K?A32O!U_'I&C>%M/D9C@0 MS6121;V95"O,URSK(.@'EA165\"?VP/'OQ,_:?_&@=_USQ2[U]-MJ(/Q)\'M^.?[+@-AI?B?4="\"T2[^S[FPI9*!DC:TK@_# H_0 STX^8<=?:AKF-& + M %AD>]?F;_P6" ,2^(/P:^*?QIL_"WC;Q'X;LM%_Y[0V:6-XT*V.H#7T@~ M]'C[LA)0..<<5S?PR^,7@>\:^/WPU3]FW]I3X]?&KQF/%NFPZ_X9\0;_J.L: M2/#TTCQZA=WD<]NB0)%#O>*8LN9XXHQN+[2 ?JL;F-2077CGK3P01D<@U^$+'X^?M*Z3X=^+-CXOUW5[&P^(%Q!%:2V7]G26\5H O[MB!#>2@1KQM"#/RU^A7A;0AX6\,Z=IBW=]?C3K6.U%U>S&>YN=B!?,ED/+R-C M+,>I)/>@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4$9HHH ^>_ P!H7_@E?^SQ^U\3KOQC\OOA2ZX>]Z>*=1M8I.YU&XDGCFN8 M(UV&_ER*&4*<8(KLO%W!&_P@=|=_ BW^&.J?#WP9-FO9)G^TO<7#-M@B?>AB\O M=0!5P_L&?!*T\ >'/"MK\-/!EAX=|&ZJ:>*-)L++3TM8;+5;88@OL1[=TZY M/SOEFSR36C8?L;_"O1_A[\1/"MMX+T6#P[\6=1O]7\86"*PBU^[OE"W\)_#\>-_"-IKMY!)<-K^K3W?B" MSM9-/BV[8H;0P2,9)&+M*#Y051N8\7_P4N^/WQ;\+_MDV/AWPUJ/!1?A;X6?4(7A1+6"!S)%$3/}IB*1D(]`V(/V0?A M;&[SX:V%FEA;>'KFT6XLH(D.4"J^2I1N58'"Y+VVU*?3+>P6&.[N[9E:&XF9* M-7\);:|& A7KUOXQ-G#:W$WB#7=4AWJ+9I"5A@L]I1B5W.Y!&T8#5]0?$CX8 M>&OC3\-M<\) ^+-.M]9\.>(K-].U.RE9DBOK=U^>)MA!*LI(8 @$$CD$Y_.OX M;?M/_$#P%^S3XTTSP!\0?%_B3PU\0/B5H'@CX-?$CQO9RZM?21ZO;VKW5XXF M6%[RTMI&NC;2LI5WVJ6=$,/1OVE/@_XK_P"":_PJF^-NC_'?XQ^+K3PEJ%C= M>,M#\:;DFO:?X@TN6YCANXI;WVQ?8KD"8RPO RH&C",IC. ?6/BC]E+X8^/ M_P!FJ/X:/KX2T?4/AA!IMKI*>'9%;[$EI;&,P0@ YVOF*/'&P5A_&;]@/X' M?M&1Z&OCSX:>#O&#>'M/.DZ?)}]BMW+#:M$T?DF1\LZ@,6 EQ%I*1!0L<6_)$95%5T)*R*-KAAQ4'A7]@'X(^|_! M/@;PYI'P[\-:=H/PWUUO$WA>Q@B9(=%U)I'8W,*[OE;?*Y!!NZ=*_/KX0_M) M_&B7[CWXG?";OJX|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|UE0D'\Q7Y^?\$W/^"C?Q*^)O_!*G5?$GQ"OF?Q%9I%LK);6;WL4MFUEM];@GT2:R(EQAVO8?RQA2UO+@':S$ [;_@GC^P/\=?V-/&=]QX7)PG;:_M;XMU6XUCQGJX\':A!X]\4W+HXB:2^EU"2-%A8QHD8A\N.&/:BKN+5[SXO_9J MN?%7[;O@+XN+K$,%MX*\)ZWX9DTMK)O#NO?M,Z%\/CS8ZQJ-GX<^#^O\ A>QM M/#N]{DTW]E1-J$\33W2WELL+F>VN?E>4JL>^)HV /=O$?_!.#XD>.-2UWP-X ME^,8\2?L^ZWXG3Q.?#^IZ1/<^*:98[N*_BTJ/5FN2JV*742%,P&580(@XX8>_MT_M9_LTW7[2]U*G@UJ'2O\ A7?O!TWQK+Y]J9C?I9QW"FV7#++Y,-YXP^"'IL M/!S7RA^V3^UQXT^"!5E_P"&?B9\>9OV3O YTC3KOPGJMAX=LM5M?%=R\8_M M))]2O;>:",VTH&L.R%RA\T[E/R^D_"C]H'XMP?M2?LZ>"_&OB/PGJMOXU\& M^,-6UR?PW%%+IOB+[#=:6FF:C"^"T2R6UT93%&[(K3LNZ0*K4 =W\/?^?&@ MP? `XN?#;QU\P/C/PU\6O&?B@Q)=V]6IA^R0ZG=M<)s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`MVM'[<0>)I5O2YD9HGC=)$C*LJK@]C^T[\9O$_P/IVW0#_!VCZF;/P[\0M6 M\0VNOVIHMXW^W16FB3W=NNJE+)MFC5LH5) PLV?A_7/"7C.Q\.QZK=>&;CQ%#80-%/<7+_8K8B;>4Q0.L,2'.DS1IE=Y8 '-M&?%3_@EIXS_;3^%/Q@N?B;\3]#UCXJ'%3PG#X)LI5TWPVVGZX3TV*Y.X,5M M:M/)/(9IB))7FG8ED0)L1<'VW]J[HCYOCW\0_AYX_P#"^K0^$/B9\,I8BO-- MUM;?SAJ.G,2M!H[WM*L!H<1DDKG*2I%(.4(/S_:_MC_$'QU^S9X'\-^!?BWX M%\;_ !;^,'C&[*Z9XDN?!5UX>B\(QVUI-=7YN=(FDFD6_M8+;8!!T_;X6?'GX(?'6UL?%/Q-MOC+\,M4TV>6XU+7-+L=)\0:}];O'Y*0BMRBB@N+62/>&#H)$&VM_AGI7B'3IM. M;W9Y-1.I9*K+(&PGE_9.00=V\8*XY]AANT6-0[_#8R21BOF+_@HSXW\>^$ MM%TK4[+XG:;\"_A5HD,U]XN\U7Q#;6VB16GB":RU&MPMI.D4:DLT=M]HMJWN#;JQDC+F-B3&Q !^IPNXSG# X&2>PH2ZCD<*KJS4$ M!SD5^8NK?\%$_'W\+_PE_:'NM*^^6@?M&:-\/M$\-ZCX?!=W]M86NG:??ZM>MO8265W)I]}//#;KY%ZS)M81RLC,,;AI5^SA\2?B;^5G^W-X5^#7Q&^,%G\;X M?B3X*O?%=AJ$FC6.E:EH%Q836L4P,=H%1K"Y%UF NK2*UO*N\OT /M2BBB@ MHHHHI ***** "BBB@ HHHHI ***** "BBB@ HHHHI ***** "DD<1(68X ZTM,GC\V M(KT]#Z4 >-_MH?LTW'I5/@[P?I-IK,&BMX8\<>'O&+RRVS3_&E-+U&&|:W4 M!EVM((]H?G;NS@I*^^?|XA_L#_'V_;U\3?&_P -_$[X03W=Y;1Z1X7M/%G@ MA04D\&>$ F@LFBU"&-'N'!>:81[Y/E7(10M,\.?MI^.]$ X+6^-/A9KNJP MS?"2ZTK2M)T6V-M%$^FZ_/I\VH]#.-K%;B"TO$8N2T*A5 W&O& C1_P4<^+ M^GC|N;7-$\2+IGAWX;^ K3O!\-(O[-MV.GO'<:I87%V2\69EFN=-DD42;T"% M=O&: /N3]LK]FI;]JSX5:%X=@UF'1'TCQ?X>\4O._A%\8=/\%V^O:1%HVNZ\XFT:?7])B:*5 MFBU&PA6YA6WO=CNCD[HY0D6Y"5)/A_[>?[5OBKX6?M1GP[XZ^/5W^S\+Y]! ML;SPOXEL_#-IJ?^:+;YC*-0AN+R[AGM[4VX^S%82D;N)6<,RHP$?1?I?JO^ M$?\\//PIU+Q-2/#/ACP9KNL;E;>+_C'X0T.+7H[?3PX&AWL=L5EM[5;T-&)I M6CGAA9(K74K>S^%.A_#22R6MQ,99]-N+J9KLL7(VR"Y"B/'RX)+-G%?-7C+]KCXE^_O^"97O[^)7@[XY>%?C M3H/A[1(-2\"?$"RMK :DEWNVWMI?VD,*VH>%O+*$HK%9MC1AH]\FM^W?^UCX MI^%?[7=[X7]=?'NY_9;^&0TBRN/!OB&T\,66HQ>+[D[UU!+B]O(;BWMFMV,(M6 K&S*YDW,H. #T6R_X)/:/H_P_,B9\/-.\6:GH?P\|2>(K;QIX&MM-B%O]M/PPUM'$SRZ,*2R+;BX1)HX0]JHFN(S**_+%WQR^.V0044D\&>$ F@LFBU"&-'N'!>:81[Y/E7(10M,\.?MI^.]$ X+6^-/A9KNJP MS?"2ZTK2M)T6V-M%$^FZ_/I\VH]#.-K%;B"TO$8N2T*A5 W&O& C1_P4<^+ M^GC|N;7-$\2+IGAWX;^ K3O!\-(O[-MV.GO'<:I87%V2\69EFN=-DD42;T"% M=O&: /N3]LK]FI;]JSX5:%X=@UF'1'TCQ?X>\4O._A%\8=/\%V^O:1%HVNZ\XFT:?7])B:*5 MFBU&PA6YA6WO=CNCD[HY0D6Y"5)/A_[>?[5OBKX6?M1GP[XZ^/5W^S\+Y]! ML;SPOXEL_#-IJ?^:+;YC*-0AN+R[AGM[4VX^S%82D;N)6<,RHP$?1?I?JO^ M$?\\//PIU+Q-2/#/ACP9KNL;E;>+_C'X0T.+7H[?3PX&AWL=L5EM[5;T-&)I M6CGAA9(K74K>S^%.A_#22R6MQ,99]-N+J9KLL7(VR"Y"B/'RX)+-G%?-7C+]KCXE^_O^"97O[^)7@[XY>%?C M3H/A[1(-2\"?$"RMK :DEWNVWMI?VD,*VH>%O+*$HK%9MC1AH]\FM^W?^UCX MI^%?[7

$WP_P"";7CGX5?"#]D/0-0U/PS)>? +Q)J>L>(&
*MMIYFBO(KG3M6M4%L6C!9@]_$2'"#"O@G !Y[XR_L3_M/_%[]G+7O@'XHU+X**
M_$_P/K-M&]*M35M M1ET"#3/M\MU9*OS-/%!NG$10F01E/E)W
*Z#QM\#_P!H_P"#WB;Q'9?#Z^^& M_P 8/AUXHM[6-/#WQ(U*ZTZ?P]Y-*
*I':RPPSV]K<)*O"FIVFFI\ M.O%BZK+*]3L;KIVK2/<>81*6N)$D1?+CV1CK*'5R*
(IKT>;.%B_E7IT];=K=M2A1@%G2Y MC4R!9-@P4;T_XA?!;]I'X9>+?%=EX%N?A?*
&'X=>,/)>+0OB1J%UIT_AG;: MQV\MK%);6MQ'=VDHB639)'&R.\N6DWY'_#3XT?
M8_M'WGQ9\2^!/&GP9M-) M\">/O$?A?1O"NJ^#;R2XU5-+NWABBEU%-058FFVJ#
((#L+9VMC%=1\1_^"FM M_P"
*(O^";OPZ^*'@*STB'XB_&EM(T+PIHNH,TT,6MWTZPS0MS&9DM-MT[?-&) M%M3AE# T*
>;_?_."&5E=R_#CP]\6IM+\6^_A)X5OK7P[8:/J6H:.UOKF MJ:G/>:A/$+>6-
*X;**%H;2VA,KE(E8$\\])X=_P""1NI>%?@W^T'\%=&UBUT/ MX/\ C[4;+Q-*
\/MU[<:G>^$]7007,YF6?YI8/[1M8;D(9F+[Y@Q&\U](?L%?M M.Q_MB?LC>"OB"8);/4-
8M'MM6M);%/AEKD?BI[/P9J.H:E=^)]4BMIH8& M9[B& 65O&\TDC1KY[295-
RA27X7Q1_P3T^,'A7X-:-\#K;P#^S9\=?@OX0N
M_A)_B3<7MOJ&A6Z^8MM;S6\=I<0W36L4C1),C0L\0564-ND;]!Z /SS^&?_M*
*0[M+K2/@GX%^*.HV7C3X8_SP5=V&E6VGWU]HUS=^(;VZ#SW@%M*C1P0VR MF")3,*
*[8F?..=WM/[#7["FH?L*_&+XK:5X5:UMO@MXNN;#7O#VD/JEQ>7NC:H*
M8##J89IPSM%.8[>56:9V\SSLX#C'U'10!XW^VE^RK)^UI\"YO#=KKDOA7Q/I
M>I67B+PQX@AMTN3H>L6,Z7%G=&!SLF19$:-N&1G'!P1XEXV_9W_&FOVN]' MM?
/Q9_X4KX4^&TE];3>)[GPO=7NK:AXRM;>02&R%M=V\<-C!9^\G=8V M:-22?,K[1HH
^4;'_@G,/'VE_M-Z%X[FMI=!^-_C.'Q)I,VEW-OV.?V4_^$.^(OB#2/%?C"?Q+
MKNN:AK&FQO%#J;7^IW%V)C&P!C=A,"R#(5B0&8#17VF267RRP6T[AD,A;&P @8SS
M5?QMX5_:Q\=?"[P_X@L;CX5^"?B3X5\2&ZD\-6>NWNH^&?%^D-"(WMKN[DLH
*M[FVF#LTB/%"X4PH#N61@OU710!*G_@FE\1]1L];^*ZZWX*\/?M$W_C2/XA:*
M?;6:3W7A33KR+2!HQTUV9([B:"YLE99[C:DGF3%T0!=K>I?!/X8_M#?$/X]Z
M1XT^,&K>"_!WA[PMIUW:6/@WP+K%]J%MK5W<>6OVW4+FXAMQ(L,:NL5N(2%=
*MS*9"=JK],44 > ?M7_#_ ..P\>^#O%WP5U_PK-_8QN;7Q!X.\5W,MII'B&"9 M!Y=PMU!!--*
;W,$BY&$9)$D=6 PIKQ/X'?\$G=3\(_M!>"/&'C5/ OBRQBMO&
M>J^(M+EL_/L=/UC7]0TN\6+3H9HV'V2
6//!^L>']/\5>)K[P7KO@26:^D@^QW^B).DXNW$$A MCAF2=X_W0=G1W5L!B#ROCO
X([^*X/@=\9_!/A/4?"\%CXX^!_A_P"&6AM= M2/"PU"Q?5)+FZN1%#L59GO@^Z-
22[2$HO?UOXA_'+XZ?M$?M,^+?!'P3U?X< M>"/"OPP\FP\1>)_$VE2Z]-
J.L3V\5TNGVUG!=6YB6"VEBDEEEDRS3QJB8#-4 MOQ#_&VOB7\!/V ?%/CCXE>#=
\+_%32;V?P[I&EP7XFTOQ+J4UX+/2YK5MY MD$%TTD,GERE9(P9 Y4(7 !:^+7PJ_:3\"?
%;Q7]OP\OOAK\3?!'C>UM(Y?"/ MC[4+K3(_#,L5N()ELY[:VN!-
:SJH9X98@PD9V#E6V#@OA!^P?\>/V-_A1X0E M^%7B_P "W>LZ5>Z_?:]X#U!+C3_!FH?
VM?F\$=C)$DEQ9"R;;'!F.13$9%V(M7+"MXI_X*6^.--_X)$?
*$/XK65OH2_&+X6W5YX9URRO\ 3Y(-.CUNSU)+*7=" M)2RPR*R2J!*Q5)ERQ*D5OZ__,%-*
-9\2?LW?"CQ7H6D66@^*]<^*_A_X;>./ M#VJ1/+-X;N[C4$M-
*2M1RAWIN+0RD;7C>*3:5<"@#@?&/_!+7XF?%OX"?M17& MK0?"SPA\1?VB-*
)T_2X]$\.7%TWAVP:R,F+NXG:!)9KJ?SG,DH@7Y8X4PQ0NW MM/QF^%_[2/@WXK>,]0^']
*[\-/BGX%\>B%W\+?$"_NM+7PTZ6X@FBM9K:VN%F MM9PBNT,L0*R/(=[!]HXW]K#_*
(:ZS\#/V]/#'@K2K73K[X:^&)M&L?B7?QV MQN;O2;OQ!*
<36>C)N$BB!%FA5Y&V2[DN(AB,E2VI^T)\9/CSXW_X%7WPB^%7 MC+X<^"-*
*&T/X=Z=XPN[KQ#X2N==GN[BZU*_M#&GE7ML$55M4(R&)+'\ #G/@W M^P=\=_V,?*
A'X%B^%/C'P-J&H>'VUMM=\"ZFEQIG@_4?[4U![Y?L,L22W%E]B
*M9A%"&293"I3:A;RX0%DB!SY):3VG]FC]N36+7P)\9K/XWOX M8T'Q3^S_*
**E);>)-0TD2QZ9J&FFPBO[75$1R[0B>WD;,&^1HWB9'B[]L/PUXPTOXDZ1:^'_'OAPZ7KOV*
*M5S);.=B @4 8.E_\$D?#_P"S!^U#*OB5\ M+3PM-H=W=Z-XSM-1\2ZC=IK/*
MAVZM_F@B%PUQB6&ZAM)HT!C0A'R<[<K?!ZV^"M M]:7WAW3?&-Y+?S>)=,T"[+
*[K9M.$7V>>ZCAED@6X-TH;Y)60L&1OT&HH ^+? M'/["/Q%^!6L>-(O@UIGPP\<^*
/BAIMG8^*/ WQ#NKJVM_.MM/BTW[3%=P0SF M1)
*[*WMXIK>:%@QA5U=/G5_(?"'_!%#Q--\'/&/@V_P!.^%'@?PI\;?'.A:QX*
*M[\'^"DN;/1=+T#38(Q+IUE((XY99[N6"/S9=L Q))@$$AOTPHH ^,/__!*K M3?V4OVQ_A_*
$?X(V:>'M%-EJ7A_X@:;J7B/4;^36]-EC62S:%KIYRLMO>(K
*M@!XUV2S#DMQ]=>)?"=EXY\&:GH>L6JWFFZS:2V-[;R.0L\,J%'0E2#@JQ&1@ M\]JU:**
*/B3X=_#]KO\ 9L^%=A\)? NO?!;Q!X2T"R.C^&_''B*6]@US0]/1 M3':)-*

ID%N;:\FMH@B"3[1"LVQ2ZJ=Q;J/@C_,$X)_@!^T)\)-4TK4--U7P= M\/?
AAKG@O47O8UCU#6-0U#4-.O)+MXHXQ#MF>VN9)>1\|HPI!)'UG10!\=?|
M$^_^":FM_L,?M:?%K7;?Q%:ZM\,/$>B:/H_@C2Y)9I+[PQ:6MSJ5S)I[-)NW MV\4E^P@(?
*QD1[5$8)]I[_;-^#NI_M$?L@?%7X?Z+<6=IK'CGPA]WA^QGNV9; M>&>[LY8(WD*AF"!I*
3@$X!P#7I5% 'QQX#^''[6_BCX-R?#S7X_A:!\+K>'PR
*M=*TSQCX1\27VL:MI5[#"]6TXM+K3X89(RZ NK2#Y20,DYKG=5_X)U_$K]N36*
MY]4_:67X>Z)-9> M6\ 6D'@&]NKMM235#:M![#0]"U\O/#\=G9ZF;[[5=W,MNDTMPYD*
MEC4+ %BC 7+;V(]E^,O_3[3PU\=/ OQ6^"%CX8\!>-/#-]%8^(+.VM_P"S
*MM.\9^'I'/VG3[E8%V^;&7\^WF9'*2Q[3A)&(^I:* /S6\,?\$<_&/C+]J(^(*
M?'/A3X#V>E1^,HO%&I^*=%_M%]:\6+:WB75J#IS+'8Z9=.\%H;FZMF9YC#(, M;96%?
I3110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110
*4444 %%%% '+_ !M^$^F_'CX/>*_!&LM<+HWC'1KS0[\V*
*M\GES""Z@>"38W\+;9#@]C7QQH7_#7OA7X*V?P4T;X;^&-&U;0].M_#-C\8E\|*
M36CZ9%:0QQP_VK'I)1[E;OR0Q6V=6B$X :1XLD_=]1R6B3.2P)SU&> /A_Q*
MA_P3(UO]K+]M#X@?$/XA>+_B3X.TO3-%LO_@[_A%?%8TV;6-)$0N-0GO8X0
MR_Z1>R$",[04MHR8U)YXW]EK]@[XM_"CQS^SEX9UO2K:\\%?L[>,/&&EZ9JL MU_;/-
>^%[G2KBVTB:2)6):4&9+=UVA@(@S#DL?T3BMUA)(SENI)ZT?9UW]N2 MXA9-
QC0M&-S+&IOWO\ P18U/]C[PA\%/%7P7\7_ !/\ M;>-O@CK5@=-T+Q-XGCO-
*+DTRX*VFLPV\4_E16S26DLTB[&7YHD4#D8_2&2%9 M2"P!QTH>)7CVD?+0!^?*
7P8@_:=_97N?C#X6\+?L]V_B7_A+_(C>)O$WAWQ9
*M<^.M,L],BBU.\>:VFN;8EKD)&"AD18V? 8*I/%4O#7_!(KQ'XBE_9[^'6M^) M_%?AGP#\|*
*/!L]['XB\'^(VTG4-7\77K"*YDBQNECM8X&OMNY4(%[L!<;@/T/ M:SC<\@]@]* /DC_()Z?*
*LA>+/V%OB_\8/!*2:OKOPCU MS5+;Q=X4UK5M2CO=4;4;N(KJ]M!78DYR<= M_2GT*
%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%%
!1110 4444 %%%% !1110 4RXC,T+"!GU!]% 'QSXL\"_ M&7]C+]I?XC>)_AC\,X?C-X-*
^,M]!XAU2PA\1V>AZIX;UB&SM[)V#W>([BUG@ MMH"
*K!XI(G&TB3<.#^(_["WQR_;7U+X8Z)\9?$=YHFAZ=XGU7XBZQ<>"_$*V*
M4WAJZB6.'0='L;A8UFF6%7GN)IWC!,JC8^TA!]_R6ZRN&."OVCOAG\-WUOQ]X+^-
WAS2]=AU#Q3XA@GU1?%,%[% M%,/'?[7?PT^)?PK73(]+U3QWX M8U3XGZ/-
*(';)>PZ1?)/;:Q!D#=>0Q>;!)EB983$H&8EK[J>V61]QSGV.*=)$ MLHPP!% 'YLW_*
/P1%U#]JCX9?&/Q%\5/&_Q0\+>//C5K&I:KJ6@Z-XLSH-HL
*M3&'15FM5W13O!:V]D6!D8!U*A]JKC3\&P?M1?#/]HSPQ\6]5^!3_!"\1>(/*
*M@[HO@_Q7#IGC'2-,&F:U::A?W%RR^=*5DB<7$;JR,0-Q! (('Z)B-0FW'!ZC MUJ-K&-*
^H)/'.>: /S]\?_L_%_\ :.^"WQ,T_P 6Z;IWAW6?VH_'^E'QQ:;/
*MKZN_A#P996T$/V1;@J%GOWAMC%(T4V5BBBYTRXMY)BDG[J[$D;(H?]W@ZT^@ * ***
*"BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@*
*H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@G - !17D'QF^/>L M_#?*
QM_9]G;Z?/ ;:.4^>KEE8DYZ$<<5RG_#77B/_)\-&_[XE_\ BJ /HJBO MG7_AKKQ'_P
*^&C?]\2__!5'_#77B/\ Y\-&_P"^)?\ XJ@#Z*HKYU_X:Z\1 M_P#/AHW_'Q+_P#%4?*
*#77B/_GPT;_OB7_XJ@#Z*HKYU_X:Z\1_\^&C?]\2*
*M_P#Q5'_#77B/_GPT;_OB7_XJ@#Z*HKYU_P"&NO$?_/AHW_?$O_Q5'_#77B/_M)\-*
&_[XE_\ BJ /HJBOG7_AKKQ'_P ^&C?]\2__!5'_#77B/\ Y\-&_P"^ M)?
*XJ@#Z*HKYU_X:Z\1_P#/AHW_'Q+_P#%4?\ #77B/_GPT;_OB7_XJ@#Z*
*M*HKYU_X:Z\1_\^&C?]\2_P#Q5'_#77B/_GPT;_OB7_XJ@#Z*HKYU_P"&NO$? M_/AHW_?*
$O_Q5'_#77B/_)\-&_[XE_\ BJ /HJBOG7_AKKQ'_P ^&C?]\2__M !5'_#77B/\ Y\-&_P"^)?
*XJ@#Z*HKYU_X:Z\1_P#/AHW_'Q+_P#%4?*
*M#77B/_GPT;_OB7_XJ@#Z*HKYU_X:Z\1_\^&C?]\2_P#Q5'_#77B/_GPT;_OB*
*M7_XJ@#Z*HKYU_P"&NO$?_/AHW_?$O_Q5'_#77B/_)\-&_[XE_\ BJ /HJBO MG7_AKKQ'_P*
*^&C?]\2__!5'_#77B/\ Y\-&_P"^)?\ XJ@#Z*HKYU_X:Z\1 M_P#/AHW_'Q+_P#%4?*
*#77B/_GPT;_OB7_XJ@#Z*HKYU_X:Z\1_\^&C?]\2*
*M_P#Q5'_#77B/_GPT;_OB7_XJ@#Z*HKYU_P"&NO$?_/AHW_?$O_Q5'_#77B/_M)\-*
&_[XE_\ BJ /HJBOG7_AKKQ'_P ^&C?]\2__!5'_#77B/\ Y\-&_P"^ M)?
*XJ@#Z*HKYU_X:Z\1_P#/AHW_'Q+_P#%4?\ #77B/_GPT;_OB7_XJ@#Z*
*M*HKYU_X:Z\1_\^&C?]\2_P#Q5'_#77B/_GPT;_OB7_XJ@#Z*HKYU_P"&NO$? M_/AHW_?*
$O_Q5'_#77B/_)\-&_[XE_\ BJ /HJBOG7_AKKQ'_P ^&C?]\2__M !5'_#77B/\ Y\-&_P"^)?
*XJ@#Z*HKYU_X:Z\1_P#/AHW_'Q+_P#%4?*
*M#77B/_GPT;_OB7_XJ@#Z*HKYU_X:Z\1_\^&C?]\2_P#Q5'_#77B/_GPT;_OB*
*M7_XJ@#Z*HKYU_P"&NO$?_/AHW_?$O_Q5'_#77B/_)\-&_[XE_\ BJ /HJBO MG7_AKKQ'_P*

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

<'TI: , 44 %(QPI/I2TC_=/&>.GK0!^?O_!Q[^UQ;?L]?\$X]3\,1ZQ: MZ'XA^,^IVO@33[JXG:WM[2&ZD47T\LX($,:6GG?O#D N"59=PKXL_8;^-WA' MP]_P2,_;V_9K\,^-;/Q_HOP5T#Q-<>$-;M+I;R'4_#NH:?//;N)D)C:19O-$ MBH%56DP <,:^[/V[?B]^R/\ #W]M[X7>*OCI\6=#\._$/X26-W?^'=$U.^ L MTCU"-H6N98#"WFL5C^1BXV-$I4 \GSG5OVX_^">VJ_MAR?&X_'GP+;^++OPA M)X'O[2&_5-+U;3'E:4I XML 18 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:		
Cash and cash equivalents	$ 4,134	$ 4,543
Marketable securities	46,063	48,352
Amounts receivable	290	369
Prepaid expenses and other assets	280	411
Total current assets	50,767	53,675
Non-current assets:		
Deposits	1,308	0
Operating lease right-of-use asset, net	298	354
Property and equipment, net	151	131
Total non-current assets	1,757	485
Total assets	52,524	54,160
Current liabilities:		
Accounts payable	1,171	926
Accrued liabilities	3,024	1,777
Operating lease obligation	88	80
Finance lease obligation	14	3
Total current liabilities	4,297	2,786
Non-current liabilities:		
Operating lease obligation	249	316
Finance lease obligation	14	1
Total non-current liabilities	263	317
Shareholders' equity:		
Common shares, no par value; unlimited authorized; 42,766,497 and 37,958,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	0	0
Paid-in capital	179,985	166,609
Accumulated other comprehensive income (loss)	81	6
Accumulated deficit	(132,102)	(115,558)
Total shareholders' equity	47,964	51,057
Total liabilities and shareholders' equity	$ 52,524	$ 54,160

XML 19 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	9 Months Ended Sep. 30, 2024	12 Months Ended Dec. 31, 2023
Common shares, par value (in dollars per share)	$ 0	$ 0
Common Stock, Shares Authorized, Unlimited [Fixed List]	Unlimited	Unlimited
Common Stock, Shares, Outstanding (in shares)	42,766,497	37,958,000
Common shares, issued (in shares)	42,766,497	37,958,000

XML 20 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:				
Research and development	$ 4,983	$ 3,272	$ 12,587	$ 9,433
General and administrative	1,900	1,885	5,675	5,986
Operating loss	(6,883)	(5,157)	(18,262)	(15,419)
Other income, net	616	693	1,739	1,220
Loss before income tax expense	(6,267)	(4,464)	(16,523)	(14,199)
Income tax expense	(7)	(7)	(21)	(21)
Net loss	(6,274)	(4,471)	(16,544)	(14,220)
Other comprehensive gain (loss)				
Unrealized gain (loss) on marketable securities	132	(64)	75	(53)
Net loss and comprehensive loss	$ (6,142)	$ (4,535)	$ (16,469)	$ (14,273)
Basic and diluted net loss per share (in dollars per share)	$ (0.15)	$ (0.12)	$ (0.42)	$ (0.46)
Weighted average shares outstanding – basic and diluted (in shares)	42,751,577	37,949,422	39,604,179	30,751,329

XML 21 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2022	26,443,067				
Balances at Dec. 31, 2022		$ 128,078	$ (74)	$ (96,177)	$ 31,827
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)	4,289				
Issuance of common shares upon the vesting and settlement of restricted stock units		0	0	0	0
Share-based compensation expense		422	0	0	422
Unrealized gain (loss) on marketable securities		0	45	0	45
Net loss		0	0	(5,272)	(5,272)
Issuance of common shares in settlement of deferred stock units (in shares)	17,621				
Balances (in shares) at Mar. 31, 2023	26,464,977				
Balances at Mar. 31, 2023		128,500	(29)	(101,449)	27,022

Balances (in shares) at Dec. 31, 2022	26,443,067				
Balances at Dec. 31, 2022		128,078	(74)	(96,177)	31,827
Unrealized gain (loss) on marketable securities					(53)
Net loss					$ (14,220)
Issuance of common shares in settlement of deferred stock units (in shares)					17,621
Balances (in shares) at Sep. 30, 2023	37,953,711				
Balances at Sep. 30, 2023		166,153	(127)	(110,397)	$ 55,629
Balances (in shares) at Mar. 31, 2023	26,464,977				
Balances at Mar. 31, 2023		128,500	(29)	(101,449)	27,022
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)	4,289				
Issuance of common shares upon the vesting and settlement of restricted stock units		0	0	0	0
Share-based compensation expense		380	0	0	380
Unrealized gain (loss) on marketable securities		0	(34)	0	(34)
Net loss		0	0	(4,477)	(4,477)
Issuance of common shares net of offering costs (in shares)	11,480,156				
Issuance of common shares net of offering costs		36,852	0	0	36,852
Offering costs on previously issued common shares					(1,400)
Balances (in shares) at Jun. 30, 2023	37,949,422				
Balances at Jun. 30, 2023		165,732	(63)	(105,926)	59,743
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)	4,289				
Issuance of common shares upon the vesting and settlement of restricted stock units		0	0	0	0
Share-based compensation expense		425			425
Unrealized gain (loss) on marketable securities		0	(64)	0	(64)
Net loss		0	0	(4,471)	(4,471)
Offering costs on previously issued common shares		(4)	0	0	(4)
Balances (in shares) at Sep. 30, 2023	37,953,711				
Balances at Sep. 30, 2023		166,153	(127)	(110,397)	55,629
Balances (in shares) at Dec. 31, 2023	37,958,000				
Balances at Dec. 31, 2023		166,609	6	(115,558)	51,057
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)	5,916				
Issuance of common shares upon the vesting and settlement of restricted stock units		0	0	0	0
Share-based compensation expense		488	0	0	488
Unrealized gain (loss) on marketable securities		0	(45)	0	(45)
Net loss		0	0	(5,151)	(5,151)
Balances (in shares) at Mar. 31, 2024	37,963,916				
Balances at Mar. 31, 2024		167,097	(39)	(120,709)	46,349
Balances (in shares) at Dec. 31, 2023	37,958,000				
Balances at Dec. 31, 2023		166,609	6	(115,558)	51,057
Unrealized gain (loss) on marketable securities					75
Net loss					$ (16,544)
Issuance of common shares upon the exercise of common stock options (in shares)					70,750
Balances (in shares) at Sep. 30, 2024	42,766,497				
Balances at Sep. 30, 2024		179,985	81	(132,102)	$ 47,964
Balances (in shares) at Mar. 31, 2024	37,963,916				
Balances at Mar. 31, 2024		167,097	(39)	(120,709)	46,349
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)	5,916				
Issuance of common shares upon the vesting and settlement of restricted stock units		0	0	0	0
Share-based compensation expense		443	0	0	443
Unrealized gain (loss) on marketable securities		0	(12)	0	(12)
Net loss		0	0	(5,119)	(5,119)
Issuance of common shares net of offering costs (in shares)	4,720,000				
Issuance of common shares net of offering costs		11,747	0	0	11,747
Issuance of common shares upon the exercise of common stock options (in shares)	2,750				
Issuance of common shares upon the exercise of common stock options		7	0	0	7
Offering costs on previously issued common shares					(100)
Balances (in shares) at Jun. 30, 2024	42,692,582				
Balances at Jun. 30, 2024		179,294	(51)	(125,828)	53,415
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)	5,915				
Issuance of common shares upon the vesting and settlement of restricted stock units		0	0	0	0
Share-based compensation expense		565			565
Unrealized gain (loss) on marketable securities		0	132	0	132
Net loss		0	0	(6,274)	(6,274)
Issuance of common shares upon the exercise of common stock options (in shares)	68,000				
Issuance of common shares upon the exercise of common stock options		126	0	0	126
Balances (in shares) at Sep. 30, 2024	42,766,497				
Balances at Sep. 30, 2024		$ 179,985	$ 81	$ (132,102)	$ 47,964

XML 22 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		
	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 100	$ 4	$ 1,400

XML 23 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:		

Net loss	$ (16,544,000)	$ (14,220,000)
Adjustments to reconcile net loss to net cash used in operating activities:		
Share-based compensation	1,496,000	1,227,000
Amortization of discount on marketable securities	(1,013,000)	(856,000)
Non-cash lease expense	56,000	52,000
Depreciation	28,000	22,000
Changes in operating assets and liabilities:		
Amounts receivable	79,000	(228,000)
Prepaid expenses and other assets	131,000	(860,000)
Deposits	(1,308,000)	0
Accounts payable	245,000	129,000
Accrued liabilities	1,188,000	(182,000)
Net cash used in operating activities	(15,642,000)	(14,916,000)
Cash flows from investing activities:		
Purchase of marketable securities	(39,623,000)	(64,537,000)
Maturities of marketable securities	43,000,000	40,135,000
Purchases of property and equipment	(18,000)	(21,000)
Net cash provided by (used in) investing activities	3,359,000	(24,423,000)
Cash flows from financing activities:		
Proceeds from issuance of common shares, net of offering costs	11,747,000	36,848,000
Proceed from the exercise of stock options	133,000	0
Principal payments on finance lease obligation	(6,000)	(5,000)
Net cash provided by financing activities	11,874,000	36,843,000
Net decrease in cash and cash equivalents	(409,000)	(2,496,000)
Cash and cash equivalents at beginning of period	4,543,000	4,728,000
Cash and cash equivalents at end of period	4,134,000	2,232,000
Supplemental disclosure of non-cash transactions:		
Assets acquired under financing lease	30,000	0
Cash paid for income taxes	$ 20,000	$ 26,000

XML 24 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Business

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

1. Business

DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), exist for the primary purpose of advancing the clinical and commercial development of our proprietary recombinant KLK1 protein called DM199, for the treatment of neurological and cardio-renal diseases. Currently, our primary focus is on developing DM199, a recombinant form of the human tissue kallikrein-1 (KLK1) protein, for the treatment of acute ischemic stroke (AIS) and preeclampsia (PE). Our parent company is governed under British Columbia's Business Corporations Act, and our common shares are publicly traded on The Nasdaq Capital Market under the symbol "DMAC."

XML 25 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Risks and Uncertainties

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Risks and Uncertainties [Text Block]

2. Risks and Uncertainties

DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union and comparable agencies in other countries. We are in the clinical stage of development of our initial product candidate, DM199, for the treatment of AIS and PE. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. DM199 requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all.

We are currently conducting our ReMEDy2 clinical trial of DM199 for the treatment of AIS. Our ReMEDy2 clinical trial is a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial intended to enroll approximately 350 patients at up to 100 sites globally. Prior to the clinical hold of our ReMEDy2 trial, announced in July 2022 and fully lifted in June 2023, we had experienced and are now continuing to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to another hospital or an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring and overall program management. In addition, we made the decision to globally expand the trial and to this end we have submitted or are in the process of preparing regulatory filings and identifying and engaging study sites in the countries of Canada, Australia and Georgia. We also recently revised the study protocol to widen the inclusion criteria and reduce the burden on participants and sites. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to mitigate the impact of these factors on our ReMEDy2 trial; however, no assurances can be provided as to the success of these mitigation actions and if or when these issues will resolve. The failure to resolve these issues will result in delays in our ReMEDy2 trial.

On October 9, 2024, we announced the receipt of regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) to initiate an investigator-sponsored study of DM199 in PE. We are financially supporting the conduct of a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE at the Tygerberg Hospital, Cape Town, South Africa. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject was enrolled in the fourth quarter of 2024. Part 1A topline study results are intended to demonstrate initial proof-of-concept including whether DM199 is safe, lowers blood pressure and dilates intrauterine arteries to increase placental blood flow. These results are expected in the first half of 2025.

Our future success is dependent upon the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability, or the ability of any future partner, to obtain required governmental approvals of our product candidate, our ability to license or market and sell our DM199 product candidate and our ability to obtain additional financing to fund these efforts.

As of September 30, 2024, we have incurred losses of $132.1 million since our inception in 2000. For the nine months ended September 30, 2024, we incurred a net loss of $16.5 million and negative cash flows from operating activities of $15.6 million. We expect to continue to incur operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical study of, and to seek regulatory approval for, our DM199 product candidate. As of September 30, 2024, we had combined cash, cash equivalents and marketable securities of $50.2 million, working capital of $46.5 million and shareholders' equity of $48.0 million.

Our principal source of cash has been net proceeds from the issuance of equity securities. Although we have previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data are not positive or if economic and market conditions deteriorate.

We expect that we will need substantial additional capital to further our research and development activities, complete the required clinical studies, regulatory activities and manufacturing development for our product candidate, DM199, or any future product candidates, to a point where they may be licensed or commercially sold. We expect our current cash, cash equivalents and marketable securities are sufficient to continue our ReMEDy2 trial, support the Phase 2 PE trial and otherwise fund our planned operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the rate of site activation and participant enrollment in the study, the Phase 2 PE trial, the potential expansion of our current development programs, the effects of ongoing site staffing shortages and other factors on our clinical trials and our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.

XML 26 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Significant Accounting Policies [Text Block]

3. Summary of Significant Accounting Policies

Interim financial statements

We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. These condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly our condensed consolidated financial position, condensed consolidated results of operations, condensed consolidated statement of shareholders' equity and condensed consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2023 was derived from our audited consolidated financial statements. These condensed consolidated financial statements should be read in conjunction with our annual consolidated financial statements and the notes thereto. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Cash and cash equivalents

The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.

Marketable securities

The Company's marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and/or investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations.

We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive loss, which is a separate component of shareholders' equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of September 30, 2024.

Fair value measurements

Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The hierarchy is broken down into three levels defined as follows:

Level 1 Inputs — quoted prices in active markets for identical assets and liabilities
Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities
Level 3 Inputs — unobservable inputs

As of September 30, 2024, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled "*Marketable Securities*" for additional information.

XML 27 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Marketable Securities

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

4. Marketable Securities

The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):

	Fair Value Measurements Using Inputs Considered as of:							
	September 30, 2024				December 31, 2023			
	Total	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3
Commercial paper and corporate bonds	$ 26,287	$ —	$ 26,287	$ —	$ 21,764	$ —	$ 21,764	$ —
Government securities	19,776	—	19,776	—	26,588	—	26,588	—
Total	$ 46,063	$ —	$ 46,063	$ —	$ 48,352	$ —	$ 48,352	$ —

Maturities of individual securities are less than one year, and the amortized cost of all securities approximated fair value as of September 30, 2024 and December 31, 2023. Accrued interest receivable on marketable securities is included in amounts receivable and was $288,000 and $298,000 as of September 30, 2024 and December 31, 2023, respectively.

There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the nine months ended September 30, 2024.

XML 28 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Amounts Receivable

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

5. Amounts Receivable

Amounts receivable consisted primarily of accrued interest receivable on marketable securities of $288,000 and $298,000 as of September 30, 2024 and December 31, 2023, respectively.

XML 29 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Deposits

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Deposit Assets [Text Block]

6. Deposits

We periodically advance funds to vendors engaged to support the performance of our clinical trials and related activities. The funds advanced are held, interest free, for varying periods of time and are generally recovered by the Company through application against final study/project invoices or refunded upon completion of services to be provided. Deposits are non-current when their expected recovery is not within the next twelve months.

XML 30 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Property and Equipment

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

7. Property and Equipment

Property and equipment, net, consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Furniture and equipment	$ 128	$ 128
Computer equipment	110	87
Leasehold improvements	16	16
	254	231
Less accumulated depreciation	(103)	(100)
Property and equipment, net	$ 151	$ 131

XML 31 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Accrued Liabilities

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

8. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Clinical trial costs	$ 1,297	$ 258
Research and development services	896	632
Compensation	730	766
Professional services fees	91	98
Other	10	23
Total accrued liabilities	$ 3,024	$ 1,777

XML 32 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Operating Lease

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

9. Operating Lease

Office lease

Our operating lease costs were $78,000 for each of the nine months ended September 30, 2024 and 2023. Our variable lease costs were $64,000 and $66,000 for the nine months ended September 30, 2024 and 2023, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.

Maturities of our operating lease obligation are as follows as of September 30, 2024 (in thousands):

2024	$ 28
2025	113
2026	116
2027	119
2028	10
Total lease payments	$ 386
Less interest portion	(49)
Present value of operating lease obligation	$ 337

XML 33 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Shareholders' Equity

9 Months Ended Sep. 30, 2024

Notes to Financial Statements

Equity [Text Block]

10. Shareholders' Equity

Authorized capital shares

DiaMedica has authorized share capital of an unlimited number of voting common shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company's annual general meeting and any extraordinary or special general meeting.

Equity issued during the nine months ended September 30, 2024

On June 25, 2024, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 4,720,000 common shares at a purchase price of $2.50 per share in a private placement. As a result of the offering, which closed on June 28, 2024, we received gross proceeds of $11.8 million, which resulted in net proceeds to us of approximately $11.7 million, after deducting the offering expenses.

In connection with the June 2024 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the June 2024 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on July 10, 2024 and declared effective by the SEC on July 18, 2024. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered "Registrable Securities" under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.

During the nine months ended September 30, 2024, 17,747 common shares were issued upon the vesting and settlement of restricted stock units and 70,750 common shares were issued upon the exercise of stock options for gross proceeds of $133,000.

Equity issued during the nine months ended September 30, 2023

On April 10, 2023, in conjunction with his appointment as Chief Business Officer of DiaMedica, Mr. David Wambeke purchased 468,750 of DiaMedica's common shares at an aggregate purchase price of $750,000 or $1.60 per share.

On June 21, 2023, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 11,011,406 common shares at a purchase price of $3.40 per share, or $3.91 per share in the case of our participating directors and officers, in a private placement. As a result of the offering, which closed on June 23, 2023, we received gross proceeds of $37.5 million, which resulted in net proceeds to us of approximately $36.1 million, after deducting the offering expenses.

In connection with the June 2023 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the June 2023 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on June 30, 2023 and declared effective by the SEC on July 7, 2023. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered "Registrable Securities" under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.

During the nine months ended September 30, 2023, 17,621 common shares were issued in settlement of deferred share units and 12,867 common shares were issued upon the vesting and settlement of restricted stock units.

Shares reserved

Common shares reserved for future issuance are as follows:

	September 30, 2024
Common shares issuable upon exercise of employee and non-employee stock options	4,632,438
Common shares issuable upon settlement of deferred stock units	284,886
Common shares issuable upon vesting and settlement of restricted stock units	5,913
Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan	3,005,399
Shares available for grant under the 2021 Employment Inducement Incentive Plan	357,500
Total	8,286,136

XML 34 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Net Loss Per Share

9 Months Ended Sep. 30, 2024

Notes to Financial Statements

Earnings Per Share [Text Block]

11. Net Loss Per Share

We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.

The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Net loss	$ (6,274)	$ (4,471)	$ (16,544)	$ (14,220)
Weighted average shares outstanding—basic and diluted	42,751,577	37,949,422	39,604,179	30,751,329
Basic and diluted net loss per share	$ (0.15)	$ (0.12)	$ (0.42)	$ (0.46)

The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Employee and non-employee stock options	4,632,438	3,698,513	4,632,438	3,698,513
Common shares issuable under common share purchase warrants	—	205,000	—	205,000
Common shares issuable upon settlement of deferred stock units	284,886	213,905	284,886	213,905
Common shares issuable upon vesting and settlement of restricted stock units	5,913	4,289	5,913	4,289

XML 35 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Share-based Compensation

9 Months Ended Sep. 30, 2024

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

12. Share-Based Compensation

Amended and Restated 2019 Omnibus Incentive Plan

The DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan (as amended from time to time, the 2019 Plan) was adopted by the Board of Directors (Board) on March 14, 2019 and approved by our shareholders at our 2019 Annual General Meeting of Shareholders held on May 22, 2019. Subsequent amendments to the plan, comprised principally of increasing the authorized shares under the plan, were approved by our shareholders at our 2022 and 2024 Annual General Meetings of Shareholders.

The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company's eligible employees, non-employee directors and certain consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), deferred stock units (DSUs), performance awards, non-employee director awards and other share-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of ten years and generally vest over one to four years. Options granted to non-employees have a maximum term of five years and generally vest over one year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Company's common shares authorized for issuance under the 2019 Plan is 7,000,000 shares. Under the 2019 Plan, as of September 30,

2024, options to purchase an aggregate of 3,627,028 common shares were outstanding, 267,553 common shares were reserved for issuance upon settlement of DSUs and 5,913 shares were reserved for issuance upon the vesting and settlement of RSUs and 3,005,399 shares remained available for issuance.

2021 Employment Inducement Incentive Plan

On December 3, 2021, the Board adopted the DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan (Inducement Plan) to facilitate the granting of equity awards as an inducement material to new employees joining the Company. The Inducement Plan was adopted without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the Board of Directors. The Board reserved 1,000,000 common shares of the Company for issuance under the Inducement Plan, which permits the grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to eligible recipients. The only persons eligible to receive awards under the Inducement Plan are individuals who are new employees and satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. Also on December 3, 2021, the Compensation Committee adopted a form of notice of option grant and option award agreement for use under the Inducement Plan, which contains terms substantially identical to the form of notice of option grant and option award agreement for use under the shareholder-approved 2019 Plan. The Inducement Plan has a term of 10 years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board. Under the Inducement Plan, as of September 30, 2024, options to purchase an aggregate of 590,000 common shares were outstanding and 357,500 shares remained available for issuance.

Prior Stock Option Plan

The DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated November 6, 2018 (Prior Plan), was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of September 30, 2024, options to purchase an aggregate of 415,410 common shares were outstanding under the Prior Plan.

Prior Deferred Stock Unit Plan

The DiaMedica Therapeutics Inc. Amended and Restated Deferred Stock Unit Plan (Prior DSU Plan) was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of September 30, 2024, there were 17,333 common shares reserved for issuance upon settlement of DSUs outstanding under the Prior DSU Plan.

Share-based compensation expense for each of the periods presented is as follows (in thousands):

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Research and development	$ 147	$ 158	$ 449	$ 430
General and administrative	418	267	1,047	797
Total share-based compensation	$ 565	$ 425	$ 1,496	$ 1,227

We recognize share-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.

A summary of option activity is as follows (in thousands, except share and per share amounts):

	Shares Underlying Options	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Balances at December 31, 2023	3,871,013	$ 3.61	$ 832
Granted	1,663,425	2.86	
Expired/cancelled	(455,000)	4.82	
Forfeited	(376,250)	2.73	
Exercised	(70,750)	1.88	
Balances at September 30, 2024	4,632,438	$ 3.31	$ 4,875

Information about stock options outstanding, vested and expected to vest as of September 30, 2024, is as follows:

	Outstanding, Vested and Expected to Vest			Options Vested and Exercisable	
Per Share Exercise Price	Shares	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price	Options Exercisable	Weighted Average Remaining Contractual Life (Years)
$1.00 - $1.99	203,443	8.4	$ 1.60	74,159	8.4
$2.00 - $2.99	3,022,895	8.0	2.73	871,594	6.5
$3.00 - $3.99	341,893	6.1	3.55	223,143	4.3
$4.00 - $4.99	677,182	4.8	4.58	677,182	4.8
$5.00 - $16.00	387,025	5.7	6.36	328,275	5.5
	4,632,438	7.2	$ 3.31	2,174,353	5.6

~~XML 36 R20.htm IDEA: XBRL DOCUMENT~~

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2024
Insider Trading Arr Line Items		
Material Terms of Trading Arrangement [Text Block]	**ITEM 5. OTHER INFORMATION**	
	Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications	
	During the three months ended September 30, 2024, none of our directors or "officers" (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408 of SEC Regulation S-K.	
Rule 10b5-1 Arrangement Adopted [Flag]	false	
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false	
Rule 10b5-1 Arrangement Terminated [Flag]	false	
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false	

~~XML 37 R21.htm IDEA: XBRL DOCUMENT~~

Significant Accounting Policies (Policies)	9 Months Ended Sep. 30, 2024
Accounting Policies [Abstract]	
Cash and Cash Equivalents, Policy [Policy Text Block]	*Cash and cash equivalents* The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.
Marketable Securities, Policy [Policy Text Block]	*Marketable securities* The Company's marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and/or investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations. We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive loss, which is a separate component of shareholders' equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of September 30, 2024.
Fair Value Measurement, Policy [Policy Text Block]	*Fair value measurements* Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: *Level 1 Inputs* — quoted prices in active markets for identical assets and liabilities *Level 2 Inputs* — observable inputs other than quoted prices in active markets for identical assets and liabilities

Level 3 Inputs — unobservable inputs

As of September 30, 2024, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled "*Marketable Securities*" for additional information.

XML 38 R22.htm IDEA: XBRL DOCUMENT

Note 4 - Marketable Securities (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block]

	Fair Value Measurements Using Inputs Considered as of:							
	September 30, 2024				December 31, 2023			
	Total	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3
Commercial paper and corporate bonds	$ 26,287	$ —	$ 26,287	$ —	$ 21,764	$ —	$ 21,764	$ —
Government securities	19,776	—	19,776	—	26,588	—	26,588	—
Total	$ 46,063	$ —	$ 46,063	$ —	$ 48,352	$ —	$ 48,352	$ —

XML 39 R23.htm IDEA: XBRL DOCUMENT

Note 7 - Property and Equipment (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Property, Plant and Equipment [Table Text Block]

	September 30, 2024	December 31, 2023
Furniture and equipment	$ 128	$ 128
Computer equipment	110	87
Leasehold improvements	16	16
	254	231
Less accumulated depreciation	(103)	(100)
Property and equipment, net	$ 151	$ 131

XML 40 R24.htm IDEA: XBRL DOCUMENT

Note 8 - Accrued Liabilities (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2024	December 31, 2023
Clinical trial costs	$ 1,297	$ 258
Research and development services	896	632
Compensation	730	766
Professional services fees	91	98
Other	10	23
Total accrued liabilities	$ 3,024	$ 1,777

XML 41 R25.htm IDEA: XBRL DOCUMENT

Note 9 - Operating Lease (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

2024	$ 28
2025	113
2026	116
2027	119
2028	10
Total lease payments	$ 386
Less interest portion	(49)
Present value of operating lease obligation	$ 337

XML 42 R26.htm IDEA: XBRL DOCUMENT

Note 10 - Shareholders' Equity (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Common Stock Reserved for Future Issuance [Table Text Block]

	September 30, 2024
Common shares issuable upon exercise of employee and non-employee stock options	4,632,438
Common shares issuable upon settlement of deferred stock units	284,886
Common shares issuable upon vesting and settlement of restricted stock units	5,913
Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan	3,005,399
Shares available for grant under the 2021 Employment Inducement Incentive Plan	357,500
Total	8,286,136

XML 43 R27.htm IDEA: XBRL DOCUMENT

Note 11 - Net Loss Per Share (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Net loss	$ (6,274)	$ (4,471)	$ (16,544)	$ (14,220)
Weighted average shares outstanding—basic and diluted	42,751,577	37,949,422	39,604,179	30,751,329
Basic and diluted net loss per share	$ (0.15)	$ (0.12)	$ (0.42)	$ (0.46)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Employee and non-employee stock options	4,632,438	3,698,513	4,632,438	3,698,513
Common shares issuable under common share purchase warrants	—	205,000	—	205,000
Common shares issuable upon settlement of deferred stock units	284,886	213,905	284,886	213,905
Common shares issuable upon vesting and settlement of restricted stock units	5,913	4,289	5,913	4,289

XML 44 R28.htm IDEA: XBRL DOCUMENT

Note 12 - Share-based Compensation (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Research and development	$ 147	$ 158	$ 449	$ 430
General and administrative	418	267	1,047	797
Total share-based compensation	$ 565	$ 425	$ 1,496	$ 1,227

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Shares Underlying Options	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Balances at December 31, 2023	3,871,013	$ 3.61	$ 832
Granted	1,663,425	2.86	
Expired/cancelled	(455,000)	4.82	
Forfeited	(376,250)	2.73	
Exercised	(70,750)	1.88	
Balances at September 30, 2024	4,632,438	$ 3.31	$ 4,875

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Outstanding, Vested and Expected to Vest	Options Vested and Exercisable

Per Share Exercise Price	Shares	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price	Options Exercisable	Weighted Average Remaining Contractual Life (Years)
$1.00 - $1.99	203,443	8.4	$ 1.60	74,159	8.4
$2.00 - $2.99	3,022,895	8.0	2.73	871,594	6.5
$3.00 - $3.99	341,893	6.1	3.55	223,143	4.3
$4.00 - $4.99	677,182	4.8	4.58	677,182	4.8
$5.00 - $16.00	387,025	5.7	6.36	328,275	5.5
	4,632,438	7.2	$ 3.31	2,174,353	5.6

XML 45 R29.htm IDEA: XBRL DOCUMENT

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended			
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Retained Earnings (Accumulated Deficit), Total	$ (132,102)						$ (132,102)		$ (115,558)	
Net Income (Loss) Attributable to Parent, Total	(6,274)	$ (5,119)	$ (5,151)	$ (4,471)	$ (4,477)	$ (5,272)	(16,544)	$ (14,220)		
Net Cash Provided by (Used in) Operating Activities, Total							(15,642)	(14,916)		
Cash, Cash Equivalents, and Short-Term Investments, Total	50,200						50,200			
Working Capital	46,500						46,500			
Stockholders' Equity Attributable to Parent, Ending Balance	$ 47,964	$ 53,415	$ 46,349	$ 55,629	$ 59,743	$ 27,022	$ 47,964	$ 55,629	$ 51,057	$ 31,827

XML 46 R30.htm IDEA: XBRL DOCUMENT

Note 4 - Marketable Securities (Details Textual) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accrued Interest Receivable On Available For Sale Securities [Member]		
Interest Receivable	$ 288,000	$ 298,000

XML 47 R31.htm IDEA: XBRL DOCUMENT

Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Total marketable securities	$ 46,063	$ 48,352
Fair Value, Inputs, Level 1 [Member]		
Total marketable securities	0	0
Fair Value, Inputs, Level 2 [Member]		
Total marketable securities	46,063	48,352
Fair Value, Inputs, Level 3 [Member]		
Total marketable securities	0	0
Commercial Paper and Corporate Bonds [Member]		
Total marketable securities	26,287	21,764
Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member]		
Total marketable securities	0	0
Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]		
Total marketable securities	26,287	21,764
Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member]		
Total marketable securities	0	0
US Government Agencies Debt Securities [Member]		
Total marketable securities	19,776	26,588
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]		
Total marketable securities	0	0
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]		
Total marketable securities	19,776	26,588
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]		
Total marketable securities	$ 0	$ 0

XML 48 R32.htm IDEA: XBRL DOCUMENT

Note 5 - Amounts Receivable (Details Textual) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Interest Receivable, Current	$ 288,000	$ 298,000

XML 49 R33.htm IDEA: XBRL DOCUMENT

Note 7 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, plant and equipment, gross	$ 254	$ 231
Less accumulated depreciation	(103)	(100)
Property and equipment, net	151	131
Furniture and Fixtures [Member]		
Property, plant and equipment, gross	128	128
Computer Equipment [Member]		
Property, plant and equipment, gross	110	87
Leasehold Improvements [Member]		
Property, plant and equipment, gross	$ 16	$ 16

XML 50 R34.htm IDEA: XBRL DOCUMENT

Note 8 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Clinical trial costs	$ 1,297	$ 258
Research and development services	896	632
Compensation	730	766
Professional services fees	91	98
Other	10	23
Total accrued liabilities	$ 3,024	$ 1,777

XML 51 R35.htm IDEA: XBRL DOCUMENT

Note 9 - Operating Lease (Details	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023

Textual) - USD ($)		
Operating Lease, Cost	$ 78,000	$ 78,000
Variable Lease, Cost	$ 64,000	$ 66,000

XML 52 R36.htm IDEA: XBRL DOCUMENT

Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details) $ in Thousands	Sep. 30, 2024 USD ($)
2024	$ 28
2025	113
2026	116
2027	119
2028	10
Total lease payments	386
Less interest portion	(49)
Present value of lease obligation	$ 337

XML 53 R37.htm IDEA: XBRL DOCUMENT

Note 10 - Shareholders' Equity (Details Textual) - USD ($)	3 Months Ended					9 Months Ended	
	Jun. 25, 2024	Jun. 21, 2023	Apr. 10, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Proceeds from Issuance of Common Stock						$ 11,747,000	$ 36,848,000
Stock Issued During Period, Shares, Restricted Stock Units						17,747	12,867
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period						70,750	
Proceeds from Stock Options Exercised						$ 133,000	$ 0
Stock Issued During Period, Value, New Issues				$ 11,747,000	$ 36,852,000		
Stock Issued During Period, Shares Settlement of Deferred Stock Units							17,621
Chief Business Officer [Member]							
Stock Issued During Period, Shares, New Issues			468,750				
Shares Issued, Price Per Share			$ 1.6				
Stock Issued During Period, Value, New Issues			$ 750,000				
Private Placement [Member]							
Stock Issued During Period, Shares, New Issues	4,720,000	11,011,406					
Shares Issued, Price Per Share	$ 2.5	$ 3.4					
Proceeds from Issuance of Common Stock	$ 11,800,000	$ 37,500,000					
Proceeds from Issuance of Common Stock, Net	$ 11,700,000	$ 36,100,000					
Private Placement [Member] | Directors and Officers [Member]							
Shares Issued, Price Per Share		$ 3.91					

XML 54 R38.htm IDEA: XBRL DOCUMENT

Note 10 - Shareholders' Equity - Shares Reserved (Details)	Sep. 30, 2024 shares
Common shares issuable upon exercise of employee and non-employee stock options (in shares)	8,286,136
Stock Options Outstanding [Member]	
Common shares issuable upon exercise of employee and non-employee stock options (in shares)	4,632,438
Deferred Share Units [Member]	
Common shares issuable upon exercise of employee and non-employee stock options (in shares)	284,886
Restricted Stock Units (RSUs) [Member]	
Common shares issuable upon exercise of employee and non-employee stock options (in shares)	5,913
The 2019 Omnibus Incentive Plan [Member]	
Common shares issuable upon exercise of employee and non-employee stock options (in shares)	3,005,399
The 2021 Employment Inducement Incentive Plan [Member]	
Common shares issuable upon exercise of employee and non-employee stock options (in shares)	357,500

XML 55 R39.htm IDEA: XBRL DOCUMENT

Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Net loss	$ (6,274)	$ (5,119)	$ (5,151)	$ (4,471)	$ (4,477)	$ (5,272)	$ (16,544)	$ (14,220)
Weighted average shares outstanding—basic and diluted (in shares)	42,751,577			37,949,422			39,604,179	30,751,329
Basic and diluted net loss per share (in dollars per share)	$ (0.15)			$ (0.12)			$ (0.42)	$ (0.46)

XML 56 R40.htm IDEA: XBRL DOCUMENT

Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Employee and Non-employee Stock Options [Member]				
Antidilutive Securities (in shares)	4,632,438	3,698,513	4,632,438	3,698,513
Warrant [Member]				
Antidilutive Securities (in shares)	0	205,000	0	205,000
Deferred Share Units [Member]				
Antidilutive Securities (in shares)	284,886	213,905	284,886	213,905
Restricted Stock Units (RSUs) [Member]				
Antidilutive Securities (in shares)	5,913	4,289	5,913	4,289

XML 57 R41.htm IDEA: XBRL DOCUMENT

Note 12 - Share-based Compensation (Details Textual) - shares	May 18, 2022	Sep. 30, 2024	May 22, 2024	Dec. 03, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		4,632,438		
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		8,286,136		
Deferred Share Units [Member]				
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		284,886		
Restricted Stock Units (RSUs) [Member]				
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		5,913		
The 2019 Omnibus Incentive Plan [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)			7,000,000	

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		3,627,028	
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		3,005,399	
The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years		
The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member] | Minimum [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year		
The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member] | Maximum [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	4 years		
The 2019 Omnibus Incentive Plan [Member] | Nonemployee Stock Options [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	5 years		
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year		
The 2019 Omnibus Incentive Plan [Member] | Deferred Share Units [Member]			
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		267,553	
The 2019 Omnibus Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]			
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		5,913	
The 2021 Employment Inducement Incentive Plan [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)			1,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		590,000	
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		357,500	
Stock Option Prior Plan [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		415,410	
The 2012 DSU Plan [Member]			
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		17,333	

XML 58 R42.htm IDEA: XBRL DOCUMENT

Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total share-based compensation	$ 565	$ 425	$ 1,496	$ 1,227
Research and Development Expense [Member]				
Total share-based compensation	147	158	449	430
General and Administrative Expense [Member]				
Total share-based compensation	$ 418	$ 267	$ 1,047	$ 797

XML 59 R43.htm IDEA: XBRL DOCUMENT

Note 12 - Share-based Compensation - Stock Option Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended	
	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($)
Balances, aggregate intrinsic value | $	$ 4,875	
Exercised, shares underlying options outstanding (in shares) | shares	(70,750)	
Exercised, weighted average exercise price per share (in dollars per share) | $ / shares	$ 1.88	
Balances, shares underlying options outstanding (in shares) | shares	4,632,438	
Balances, weighted average exercise price per share (in dollars per share) | $ / shares	$ 3.31	
Share-Based Payment Arrangement, Option [Member]		
Balances, shares underlying options outstanding (in shares) | shares	3,871,013	
Balances, weighted average exercise price per share (in dollars per share) | $ / shares	$ 3.61	
Balances, aggregate intrinsic value | $		$ 832
Granted, shares underlying options outstanding (in shares) | shares	1,663,425	
Granted, weighted average exercise price per share (in dollars per share) | $ / shares	$ 2.86	
Expired/cancelled, shares underlying options outstanding (in shares) | shares	(455,000)	
Expired/cancelled, weighted average exercise price per share (in dollars per share) | $ / shares	$ 4.82	
Forfeited, shares underlying options outstanding (in shares) | shares	(376,250)	
Forfeited, weighted average exercise price per share (in dollars per share) | $ / shares	$ 2.73	

XML 60 R44.htm IDEA: XBRL DOCUMENT

Note 12 - Share-based Compensation - Stock Options Outstanding (Details)	9 Months Ended Sep. 30, 2024 $ / shares shares
Shares Outstanding (in shares) | shares	4,632,438
Weighted Average Remaining Contractual Life (Year)	7 years 2 months 12 days
Weighted Average Exercise Price (in dollars per share)	$ 3.31
Options Exercisable (in shares) | shares	2,174,353
Weighted Average Remaining Contractual Life, exercisable (Year)	5 years 7 months 6 days
Exercise Price Range 1 [Member]	
Per share exercise price, lower range (in dollars per share)	$ 1
Per share exercise price, upper range (in dollars per share)	$ 1.99
Shares Outstanding (in shares) | shares	203,443
Weighted Average Remaining Contractual Life (Year)	8 years 4 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 1.6
Options Exercisable (in shares) | shares	74,159
Weighted Average Remaining Contractual Life, exercisable (Year)	8 years 4 months 24 days
Exercise Price Range 2 [Member]	
Per share exercise price, lower range (in dollars per share)	$ 2
Per share exercise price, upper range (in dollars per share)	$ 2.99
Shares Outstanding (in shares) | shares	3,022,895
Weighted Average Remaining Contractual Life (Year)	8 years
Weighted Average Exercise Price (in dollars per share)	$ 2.73
Options Exercisable (in shares) | shares	871,594
Weighted Average Remaining Contractual Life, exercisable (Year)	6 years 6 months
Exercise Price Range 3 [Member]	
Per share exercise price, lower range (in dollars per share)	$ 3
Per share exercise price, upper range (in dollars per share)	$ 3.99
Shares Outstanding (in shares) | shares	341,893
Weighted Average Remaining Contractual Life (Year)	6 years 1 month 6 days
Weighted Average Exercise Price (in dollars per share)	$ 3.55
Options Exercisable (in shares) | shares	223,143
Weighted Average Remaining Contractual Life, exercisable (Year)	4 years 3 months 18 days
Exercise Price Range 4 [Member]	
Per share exercise price, lower range (in dollars per share)	$ 4
Per share exercise price, upper range (in dollars per share)	$ 4.99
Shares Outstanding (in shares) | shares	677,182
Weighted Average Remaining Contractual Life (Year)	4 years 9 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 4.58

Options Exercisable (in shares) | shares	677,182
Weighted Average Remaining Contractual Life, exercisable (Year)	4 years 9 months 18 days
Exercise Price Range 5 [Member]	
Per share exercise price, lower range (in dollars per share)	$ 5
Per share exercise price, upper range (in dollars per share)	$ 16
Shares Outstanding (in shares) | shares	387,025
Weighted Average Remaining Contractual Life (Year)	5 years 8 months 12 days
Weighted Average Exercise Price (in dollars per share)	$ 6.36
Options Exercisable (in shares) | shares	328,275
Weighted Average Remaining Contractual Life, exercisable (Year)	5 years 6 months

EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

*M7O7;O6[/ZH[@T*9\E3_"L*EY"K5Q#F*.,'GS_!;-F)]*4TDK)*ST1>B0+Y O*
*MXMB,N<5"\0QQ@1(JT8I&*4,)D\4-:R).8:-PY:,P;(*,00RR]L\V\;.(K/RP MP.W#R+-*
*RG<)!X4+5NNA#@A-1K/;D76=!@*9P0J9P0@4W,;I@M MYO>9%OZ+,>[Y-*
*(\^IMKX6IY/H&_"W>S_UDK_D_S.-B>%6B]7RW8I5L,NN>@[MO4LRZ*QLO)4S(K"?V?*
&:H54:"SCF 7M%?S![26$IQW%PU\%.U[KPA(.;UK4R
M/@3V+;MY\SY4F=7]RHQ=@SX''I!KMS%IN]:O#'!D4]#"9$#7X%VWP+W2>_- M1?*
M@"XO5;CN?R/>/V\VXMY0&Y3]8E&1S4E+'R02[L6D8&,"@@
*M([JP4L$"M2,L'/>C8)V]C;AL\LOW)Y59(*5<%WMRY=5R#W24[_QUJL>+#=0'*
MFLV="D5L;D=\PLSX,EB3[(XT2+)M_6>A=8BS@^7C 9,9@^8^W,A].XD^X%R*
M9WCX'U!+ P04 " #3@FU9-&[XH[\% ".& & 'AL+W=O11#)Z!=F7#V+T>_)E?SSR-
*B!0DD]H$5C\/ M9$6*0EM2.'YU1F>':,7B\/G9^M?6>>7,!@NR8L6_-)>[ZUDR*
SG9XJ:0W]GC M'Z1S-3V,E:(]B]X[&2]&<@:(5G9*2L$):WVO_AW%XB!*
@PF%%"G@%ZKX'< M?*
*NOH'EGKU@V6>'G%V2/@6EI9TP]M;%IMY0VM=!K7DJNO5.G)Y8I5N4H*R8%Z*
M$JR@.99J\ 47N,H(6&O# GS\6>$FI^K+)W &?JYOP,?WG\![0"OP8\<:@:M<
M7"VDPJ.M+K)N[B_[N='$W&M2GP/?FP/DH<"BOG*KWY!,J<-6W3]67Z@H'$! M#J%*
K3U_*A0-YZ22 NA?+ZP^;,W$-@-Z!UW(6JN9VE*"\ H??/5=UI6(3"P#\(':$,#B@#)\IOF-
\3B3<% 8)D#:>2$BO"O9EP.'GD1?X(HD4] M\4-DQQ@>,
*(9.C)]+UJBXJ9*6$15$A=4&,#2F1JDW@F?*^%%J!Q<=P$5.<+><*
MU)CF@/RN]287;K7(;ULC$FHRQFC(!A':L\0%K[,3Z@TE+$Q=>C%43P":)'RHSBT0TP.$!-
*GA?B+56?9RU4B.665.)&Q(W_3@[^1,R4W MI&:"VM.0&@&&OI>,LF *>?8,0*_G*\^)Z>^:*
*<"QI=0<*HN@;<,W39VQ[UJA! MFY0YJ(BTLI%GV85CR!8A/PPF4*
*]8%KZP$=7!B\NG=@/JDF5P4H-6J9*87B9&)AHI[4D/?J@\5+%0,Y M^?'-3DH118A'TYE:-*
;NFGQ+>L=66AQO-YM M,A,8>TIKZ'RKZ6K$!-\D-
*&UV01\N%$F4,]/R(W/ZYWF),=*W+"Q8=W"8+Q M97LNDD_V17]2FCR5M6/?*
>YI$;II,HF@=IW)X@_7B>ALG<\[S."J!":&9K^[M&"JD>][" M K M6)-*
*:DG*CNK[GVY96\$:UK/NWW27*7'6QHB;MS5KQ9,V#RN)&;N-7AHBF; MHKT^V[?*
*8&2O5^MGI.\\' FBEQ@1\+)@0GZP>6'AZ?"ZRR$R5MI[*D9O*A\!S MLJ49M?*
8DR&3H, ^@CZ$Q1IL@#,,PF4#:$SIZ#:&+R=)AA6WA]3B-C'ILBH70 M"R?JG-*
*\SN^]N5_>0!W6XW7EOW^\85*RLGW<$:R@:P'U?C%1E!9('2<"5!XV(<7'3/IXFS M]P9?.**
[-UAA<)/=/;C)AVP<1$X0"DRM8V#T6^$4A7!$).-'PQFT+AUP>[QA*
*MO_:Q4RSWS.!4B:\\L_DX. T@PP6KA+U5Z_?8Q#-P?*D2QG]AW=A& :25L:IH*
*MP*2@X++^L\= M8SB:,8W2YFAYRH0YAK?P!D(P.2V;*
[2&7\#E7E6$R,Z/0DECG,DP;89>UL'B/ ML#.X4>3%P#L2F.W
*3P_CN_$!@I"RU*8JWJ3J,C[(.,?R!'I1!^(H[N\2=!A^*
MA2G!NQ[>.R"GUU:NY_GZ>RM7%'0/ZF1WH&0:5DQ4"$>4^$P)P;2!$G5M<;RK M
*K6#Q#MPUWTUB4;A:CND0Q9/5/=;U?U_43VW*GWHT/'R)^6BLKG2_!=F';@C*
M2.%.&GR[YH_T^\B-_;Y+_6%'+<^N2OT7]$F\@S;>P:OC[<"GRAI+]X++I2]7 M7<2=-
:KI!UL5Z,?#).F?#9^5ZJ5A;W@V.(VB/15+V@B2UYPS;DQ%5?F+ZN1?
M5;\TW,ZW.IQ!>JE;_T&4E5)6[>[=K5]72Y\4PW_F-=/TPW32RX-"%P0-#H9*
*MDGM=M_MZ8E7I.^:]LM1__3"G%Q*U,Z#]A5)V,W$.VC=W\AM02P,$% @*
MTX)M60M52,3D! <1, !@
!X;"]W;W)K>;\17U\2\:6HSQB.5M(I8+"8\NF+,^5)O#CSU:IU=E4@L?O M>^U?:_) YID-*
N7YCRR1Z=B+)2P)=WD\H'O?F8MH=K!!<]%_8MV+=:QT&(C*
M)"]:8?"@R,KF25_;0!P)@!ZS &D%B"[@G1%P6P'WK1:\5L![JP6_%:BIVPWW M.G
*S*NED5/$=JA0:M*F7.OJU-,0K*U6A/,H*_LU 3DZFO$P@[2Q!\"9XGB54 MPL>CA ?*
*4@Q2(+]%O:U91E5>!:*F0!11EJJIER] O7 AT]53239*!Z$=TC9X> M9^CJ_4?*
T'F4E^CWE&P%B8F1+<%B9M1>M-<^2,+NR8Z__Z_#];/PF&VY6. M6^MSS^AKJZ)
<(?:Z5C4D;DTI;I1X9B5J';P5:[I@8PMJ2K!JRZS)AW0UI:/1%-2:U"ZR
*MG7AQ!.6P/0YS'^22D)R"9GT0)GX4GJ+F?53LN0=[)WS]CJ_R/ %^X1*9BSBL&M-\9M#H*
ML98KDO1UOY":$>&!)- 2]W4@/*\P--H&U X\(D6G;D)!OD]D^"XHQX/4O_V*
M)KIQW[;.]=\A,P.$8(WE,.:$(G8.794S2/)7:/'/3=565$ME]"5I:H)Y7JBY M/S/!
()F>IFYNQ'EG"QD?-9!XN VH)^SBI"=TT-^20&S)8AD\E'![S[&_HZ(]2@N"
*!J?"%R;I<\Z08(M-E9H4^6>Z!7QH5/%@]]7-QKIA.*W4LY/4[?4MUP', M%YVX*
>;YKMXXF& X\ )]JS'B/!>B\"A0<3#'>(=%=FB:0^S?*-.>.4^)M!:*
M()%2V(BNH$(2GN>T.AHU3^#&6GCLIW.#?3TZ9IC>2)IA>JSG9V!G6BM\:";Q M<#?
YH[Y,@)#0+719];PAH/O1@H)(5-*
*MUX=W$<'XL[J3T.*H@M8(F"/5;P")OHG;1U<(!:M6]=V-@,FR*

M*65S).Q&N_NA+_6MB#9^AV^GV#_^4_=)]97%07US&?6=5JNL%"AG2S#EW(3@
M;M7<[S0?DJ_K"XQG+B4OZM>4T815"@#_+SF7^P]EH+MEF_P#4$L#!!0 (M
-.";5G]WMWJQ0P -MZ 8 >&PO=V]R:W-H965T&UL MS9UAD].Z%8;_BF=
[IX69AK5L2T[HLC.PL>;2&7H9]M)^Z/2#2;QLAB3>:SL+ M]-=7SH8HDHZ/HO0L|
42>/5*.<>R]4BR??&Y;CZUMU7515]6RW7[XNRVZ^Z> MGY^WL]MJ5;;/ZKMJK?
[GIFY69:>^-A_/V[NF*N?;0JOE>1+'XGQ5+M9GEQ?; M?WO;7%
[4FVZY6%=OFZC=K%9E_55M:P_OSAC9]_^X=WBXVW7_\/YY<5=^;&Z
MKKKW=V\;]>U\[S)?K*IUNZC745/=O#A[R9[+/.\+;!7_7%2?VX//4?]3/M3U
MI_[+Z_F+L[AO4;6L9EUO4:J_[JNK:KGLG50[_MB9GNWK[L>?O[F+K<_7OV8
M#V5;7=7+?RWFW>V+L_%9-*]NRLVR>U=__K7:_2#>^\WJ9;O],_J\T\9GT6S3
M=O5J5UBU8+58/_Q=?MD%XJ! D@P42'8%$JM *@8*I+L"J5T@'RB0[0ID=I.& M"O!=
6X58.E ;$K(+:Q?PC6-M+3LBLO+YKZ<]3T:N76?]BF:UM:!7BQ[H^L
MZZY1_[M0Y;K+JWH]5\=)-8_4I[9>+N9EI[Y<=^HO=0!U;53?1->W95/=ULMY
MU;1_B8H_-HON:_3D_;K^OI]&37YY&OT2+=?3[;;UIR_6\O3CO
M5!O[FLYGN_:\>FA/,MB>U4H=<-==/?L4_?M-M?I0-?\!;*YPFY=SU3)UY);+
MZ&VYF(]4HZ[*NT6GOB.F4X_I;U>OHY==URP^;+KRP[**NEK9-RI,F&N!N[ZK
M.G4"4#$ORF:]6']L,2^)>_U>JU]H%CM7!\3^J$CV1T6R]_?1J5732M9L^BE/TU2N(D@9+
[8,NWMOU)[?XR$5F6QB*_.+_3:]: M?W\Z?=[>E;/JQ9DZ7[95D^B>EQ23PF
M<:A5X*^^>C 3!TEA[X0;>[4Y^ZVBNZKME-]-E(GNZBMNFZY/6GV!91, MG2AF_OZ]
M4P^E&VU$:*_CSK$36QW.JRB\"HDIC%"+?:@%&NKMX&+4CP[G?:C5D+DMMX/.
MZDO_N8+BACJ&QDT ?2ZQ(N=J[,AY%1*OQXA=OH]=CL;N_5K1Q'+Q7Q6ZCVH0
M$3U9UJVZ4JO@*4SX5#T,4MIJMFG4:*@"#T&T@M!0YMY#T%5DW(JDUT2B)D8@
MQ_M CM%_D,Q7!\[*$)HR= (C;T1\BH*5S'B26X=LM*G,N(TV<=IQ' MDBG(=S'$ "*;V(.V*
[P%H8DD=2M(W225FYG+ \9G1Y. /W^H5^CY;N=F=.ED MS&/[K ?
H1HDU\"T@$8M9EEE""0B3/!ZZVC*-Q>R1N)@=#<9X"X([!2D:D[I)
M*CXU[!G2*%.H4+R(#.)61(!"RH,8F6E(9C@E$XQ!\1J"HTO* MQZ1N!:F;9.YTP8BG
PG5Z,MP]L7&PGC1X$Q1NDU)W0I2-[ES,^:QF,*_ 79F M&IX93L^//"#':P_.-Z7;E-
2M('63S(5]DV3,=&O>9SCP#PU KJL[=0&+D5&=
MR\QI/N%ISFRZPEL0G"1*MX+435*YF;G44PX,GW,X'(#X\T=TB.G')2YV
\M7>+N#UWXIW0I2-TGE9AX!!XOX^&S%=UK$PEL1W G=F1*G
M_WDEA5\B48D9<3VGD.!S"J>L9>&6P>$#*'_L!- 5.0'T2J2G*C.$>CHA>?3I
M!+R&X(BZD.W$$^#PU)ZG\?M(CX\94D\CQ<-#I5_"=HO*0#)*,N<^2RO MS
R7)NKD5*)>5]LS8WVC.+H_:<[J]HAK(D""+!O'C O[NDA*QZ1N!:F;I'(S
M,ZPA.L$A.C##8%9)E\T3 ,[%F-N;$ "9TW?\B^?>RLRH:IQ-<)S]S>P6*JCJ
MI]\OZDV[_!HM5,@?KHDZVF!<23&7U&U*ZE:0NLD$0O L'KH::[).3B/KOV_6
M^'Q%XI)UFD^RB;.UY@IO07"22,F:U$U2N9F[0359I\>3M3=_N%?PAE" K 7/
M4_L,!^A&PIJ4*B 1B_DDL2ZH$A#R29X-+)"DFJS3GXZLTZ/(&F]W:%'V F1O-
Z^NB\CM<0G"<_KP.2D7#N//#SNL?'C*CF]?1T7L>+!H?* MS^M^20%(>A!G=K!\,C-
5FYE)3>4JXR(Q[!?>"(Q>9 1VPR RJH$5F M0(@L,J<:A=/34/AP[R
<51"%^3BV%Q:O\!8$]PI2%"9UDU1NYGU]&H6SXU'8 MFS_<*[179! *"Q%;+#<%=!;?
%H!$=0G.N;6/5)"KHAYZ/9(#<+93P?"F0O" M?,+LJ72\W<&W2)*",*F;I'(SCP -PME/
<)X*X*[H!^$_9+"+Y&HQ(RX!N&, M'H1QR^#P 1PYMK>N
R(G@/XE9D]59@@/;NM^=&3%:PB.J!]9 LQ^Q0R,I8M[:B@I M4N *2+J83.I6D+I)*C6KS
6^ ;["6Q#<*4C7@TG=))6;F4O-RMF1 MK'Q4_BC)\BH#
[B$'^265G/1WTAD#4'P%@0GB72YF=1-4KF9N=20SW'('UKX@/-'BO/< M96R63R9C>[,
H!M;"%H FA%+$Q;;C_O9"0_/@YE"PZ'3X,&#T""T/YE5N0O/ M
ZR*MR"X3Y#>!D[J)JG0=^Y+S#4?DC71+GP#9XB%4!G-S"J%S,3_+[-T,@,@)H%
<3\!J"'[W14K9]0 (2=:ZW(NKWD1X?,Z*:Z,7I1(\7#0Z5N_#MA,HK M*0#)B#-F7S>],C-
[0C.=0A@33L1DX2/ M[;M5\18$YX@4L$G=))6;F4L-V.+XC>O^_)%BL@ VKN>39&+?
P@'H1O8>H@(2 ML?[LA>1 2%/,S:PZ"@T-XM3']G^:'-5
E@/GS!N=R72W>ZD;@6IFZ1R,]\1 MH;$_Q['_.\U5X:T(]82Y?VK
+RG\$HE*S(CK:8$&$*Z:)][M^+#DB8_>2$PN\C/3YF1#7QYSCQ M8S-@>-'@4'D!?.J7%
(!D)!+[J>K2*S/#I5$^_^$HG[LH+X#-D'A#0R^_I&X%
MJ9NDB\7N'<';T%PCR'E5FYO+@K6;'[ZGWYX_V#68/;L:[*Z&].X#.V;L# M:."].X 0VKMS?
O":W_ZUSV_*YN-"70^6U8TJ%S_K.U;S\";EAR]=?;=]\^^'
MNNOJU?;C;57.JZ87J/^_J>ONVY?^9<+[]UE?_@]02P,$% @ TX)M69_" M+LMQ @ I04 !@
!X;"]W;W)K%PH4!V]8U,\]3E'HSCDZC[<&-6%?.'\1%WK U M+M'=-
@M#5CRP<%&CLD(K,+@:1Y/3\WGF_8/#+X$;N[,'K^1.ZWMO7/)QE/B$ M4&+I/

*.CY1%G**4GHC0>>LYH".F!N_LM^_>@G;3<,8LS+7\+[JIQ]"T"CBO6 M2G>C-*
S^PU_/%\Y5:VO"%3>^;1%"VUNFZ!U,&M5#=RI[Z.NP B&<_(.T!Z6O MZ U U@.RCP)&/6
*4*M-)"768,\>*W.@-&.]-;'X3BAG0)%\HW_:E,W0K".>**
*MF5:U%)PY,I:.%NJNLZ!7L*R8P4I+CL9^@HN'5KAG.+Q5K.6"O(_@*
M<$$.RE7H1,FD/8+/<+N^/SC MT;-WU&1#_[+ -WJ#;\+_T$_2=UG[%&.":/J:>ZO(=+
M:UODQV%EJD3JNW5[^](%/@N!_?1X+$Z3)(\?=VOUO_HI<=\#\MHAZ83'>_|
MP#6:=1@$%DK=*M=U=C@=9LTD/+%7YU.:0=W(^$?3#;!K9M9"69"X(LKDY"N] M8-,-
AG1A6]$<1>,=Z'ZEM=L:/L PF8N_4$L#!!0 (-." M;5D#<;?^6P8 'P; 8 >&PO=V]R:W-
*H965T&ULK5EM M;]LV$/XKA#<,+5#7)B7Y)4L,).Z**
[4.+H$&WS[1$VUPDT24I)]FOWY%2+#LZ ML0G@+[&D'$_/W?'NN:,N'Y2^-ULA+'DL\M)
<#;;6[BY&(Y-N1<'-1[43)?QG MK73!+=SJS3T8%E^5@<>F?
W>K%I:IL+DMQ]XFIBH+KIQN1 MJX>K 1T\/_@F-UOK'HP6ESN^$7?"?
M_=:K@;';1DLA"ED:HD6JRO!M?T8ADQ
MM\!+_"W%@SFZ)LZ4E5+W[N:O[&HP=HA$+E+K5'#XV8NER'.G"7#\:)0.#N]T
M"X^OG[5_]L:#,2MNQ%+E_\C,;J\&LP')Q)I7N?VF'OX4C4&)TY>JW/B_Y&6*
*MG4X&)*V,546S&! 4LJQ_^6/CB*,%H =?P)H%[.6"N&=!U"R(O*$U,F_6)V[Y MXE*K!Z*=-*
*&AS%]XW?C58(TL7QCNKX;\2UMG%4I49!$5D!*Z,RF7&+=S<6?B!*
M:%E#U)HLN=F2SQ!Q0]Y]+WF529!Y3X;D^]TG\N[7]Y>V!>!$ M!
*[=&7E_4YU;GL;7WV%JK@D#::6YEN:GWK;12F O,;;7:&%?KQAN*N_F-&U*
MIN0H6#2>3[I!1>08F_:&='J .@U"O2Z4MO(_#\]5K4R:5%6E)7 +%'4O+%]!
M@(U(^TCA]DP[6 ;TC&-ND8@@K-DTFO$[&#$+)PVJASZ+9<+\#D1C\[C D,Z MZP!*
($%\C4]P7Y/P
*9&NQ@C(=%YF))=\)?/^U&W4GREWSZ7MU!E'[$Y_EA.5*W$0+B'W;O^C)M-. M**;S;L*
0L2$[C>PI3-;"9$&8MUKLN,R>MWL=&6W0C>10U&S;AV)* *[*S>< M3?*
HIA+8D3X,,ZO) &=F#+D(J231&\@"1[$/6DB\-L^]UFM:!W_&GWJC'W02, M$P1?
5XZR>;_[6@JF0>9R('4E3C(2Q9ETWT]GF".[@D,Z"]24E@1IF 6_OJ81
M0+%WN6Y(DTG,$/28:#RG_9Q"6V:DTS>UH[+<"_.:/H8&??-Q?!,VDZ]T%(K*
M#7/K;:73K6-5: Y>W1#0+H,.H_F$(2T!)CJ)DZB_M:$MX](PY7[AM@'Y-O1= MDHT=<@0
(@F-3]+G;6,S((D=_"[A[[3+G?LDR_QXD(I$MRL9369Q?_O$6K9G*
*M8;9OS*JM@JX)^BBA4UE7.F-5>@^$Y9IUW 2$WR.DO"%R?*
@%I&9">#1'KBV+;$3A4=QO0S^,KY6&>@#$*(CECW@%:Y0='] R*
M#"@BAJ3^Z.@[1B'TQG_>,<2/LO6G@,/3PR>D:__AY,7S&WJQK#\$M6KJ[U)?
*MN(:"8,#U:U Y_C@%Y^GZ4T]]8]7.?RU9*6M5X2^W@D/"E-#8,DH*HNDO3*
*MD!58JM!V%5K>63A?*N*I7Z:A\JCRZ%2:M-?I7*>ETC89]N/:U_[KB:C+4X]*
*MA+HLE=^,T;CU(.DFNX4?>EF0+*3#?J66.$/Z54T]S](]2JY+M$$["QX7@V34 MO1M?*
B7TT^%OC.AR-093,G5O)Y#$?)!TAA 8S$@3%OV>_6X,6:T600I49O
M)J>M)&5&GGXV7$NSRA,0 Y^*RMLIE6 M!F:D"+FVZ%6]#=S5ZW!R3>Y"I3(<)'P/
OIG3(;OWW6O._=:>8VA=>3^:S8Z>!V6 M1US,7AFM8$H;^$9Y&\ZX>N/U?$:S:<$:6U
*SE*O],9[4($P<66E[..\!?BB M P%WI+A>>2W]!*K:5RZ@')'*GR71=AD-,I;-0"8B9:XLT<2(?*
CZ[6M7-@FU!88RK/_AJ7M[V]K3(.Z)M,.R6'MGW/(0 M5OEIR=1Q%<
M[I@955:!LW@V_73>AK^$M1(-QEXSIX(S:&JFK=Z_MN^EU/]Z'0_%-
'.?.QY(.,,JH%>/)D4B^^!1"P4$"\(?S/#FO3HY; M],*,#T=@-K6EIKON5_=OTZAIR0?*
SYF%C)DO-L@PNV+73_O@A =\\%LV$7!4; M]-P1M_LX+/A]12\&O+]PG+3M1
+L7^SA_U!+ P04 " #3@FU9F$]!>0,- M "<(& 'AL+W=O TR:4'Y&+$S?
*7#X3Y0NUR)YUUR0W*MJ+_^GIGAOLAO[0%% MZUV1PWEY9N89;E_M?*
+B)6V.2^M;4+KX^VJ;4_KQ8Q&)K&AWGOC4.OU0^-#KA M,6P6L0U&E[RIJ1>KY?
*+9HM'6'5V\XG=7X>*5[U)MG;D**G9-H\/^C:G]]O71*
MR5'_XK/=;!.]6%R\:O7&7)OTI;T>%H,4DK;&!>M=RJ8ZO71Y;8QEF]UTA>O@M^I0*LAC?*
Y@ M4WDWE+..@G= GZUV)!.5=J7ZX@H3$N*9K(FO%@FGT-I%*
MD26^$8FK1R2^4!^]2]NHWKG2E(?[%]!N4''5J_AF]:3 :]/.U>ERIE;+U=D3
M\DX'DT]9WND3)D>5O'IOG7:%U;6Z3CH90"T]:^(.WM8'&7-S['5A7E]A+2(M)MR:HXL?*
OCMYMGSYA+)G@[)G3TF_>"0LZM^_F6])O:E]>;CI:KPM>6OAF]8D2XFEC+NUP3ORXES]
MMC7(C5OD?$LO9H"LZRJD8!>LV_!>U(;[,63KU2[U4BQPG0))]>J#;[LBA1Q MW-?.!J-
*TBU>W^*4*OIGQ?HW7L5O_%^E-P?1NXUG8K0F14E&M]S.5H,<79TE?*
MCG%4[[T7W=^&;J,N2^24C0F&4HWX\?W;R[^1O??VB:AW78!7M%/L(C@UJLN-
M<<5>_?CNX[AS6 815'FRIW30ZQJVT XK?O58'O!CYU+ J[GZW;!A65"'P+%#
*M8L(NDPB+1)N_W]16-N MZ/<1=0.D>$MD[-AA#ZRN*Q=[H M*
**S8BA9@VQ#0H@L!"D%.X1W9REC%CL_FX[NW^]7$DD#>@6/$ X_%;JX^/;X;*

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

HG.G&"6?'A#&8%ODOYP^#Y $<*)8YZIK/"F0*B?4F7J_
M=Z\A'4&YN5X^.\$FTU.'L@0R\@"Q[DP^YS
#K0X+3\M.N'.#:3KI&QF]6SCWB(;0:C;$":YMUIG[]] MLFJZ)0MN?MR!$7H-
Y,6]$CC[]LJB(M:8M)/?=+*W#0#=_$;&^O!$_'*8# M Q=L[)HVSU)ZZ;N\JB_A_[>
[75O:XC*WO-&YN4_T.5, /4!:8#=,+0F6@.4 M^RE@?]HHTXHT-
DT,J,PZISBV,5>^RBP2R\I:/I:_57\2($TP+DM7\NKC_M>MJ_7C[!?]-[YX \8T,7[P4\MN?
=GJIS&27BTM(+H\>S[EQ,5\G5U?DF^E2OBI4_)-_*XP?F; B_=[Y7ZE]X@^'_M#"[^"U!+
P04 " #3@FU9"3J##A4$ ";"0 &0 'AL+W=OG?RB+T(=3N&/Z"2V;"X0'3$K-+4"L_@HX
,6'>A%;8BCN"\$K]<$W/-X MO2,!&[*;KAD,N%,P(-E%JG0[,%X*[C^83C7,R-3L 0G
36%0;W"8/K^77<0 M?3Q"MM^0[1]#G]['*%1KKJ0&7<(US"TRFNYOUZ4?)[69GS^
WIW&%VE)+PJ-F M*9=+N#0&K?D U]PD0IE2(_SUB,\69D(E3W\?"OPXM7[G<,G 8X;
5HP+MW!* MQ\:I8:21;Y7-5ID1CT)S6N1B
XG*:6(P!;6@>/=BI[4GM/@_;MAW(T_OB'JML\'_:.BUN>#B>]>M,_/!XW=JRFY.AL. MWYA6
9*'_J =#7I[W@^)ANW>67Q<=,?L"S%?7RE?\;0D)Z*4J"A$R)CDFH M88.,BLWES]4-
RY6V_!]TV:RJB8E]@*+0ZIDJVI+.3CGYG8=?-]XC_[+Y';A, M$ET2!)>6*H=
<42DB7_D&HM(\W$[DR]\.,7D^HG0*M+Q3=2/7$.6C>8].?4$L#!!0 (-.";5D3=J4?B0(M)
(% 9 >&PO=V]R:W-H965TL MVA,C(5!&.XA4VDV;M&Y5Z;:':0\F.8B%8V?
V4=I_O[,34B917HCO?-_G[\.^ MF^Z,W;@2D>"I4MK-HI*HOHQCEY=8"=61E;">+0KF-
76Q1% %4J3I-D
M'%="ZBB;AMR=S:9F2TIJO+/@ME4E[/,SZ&IP.1_Y^E#P4^+.':S!.UD:L_'!EV(6)5X0*LS)
M,PC^/.(U*N6)6,;?EC/JCO3 P_6>_5/PSEZ6PN&U4;]D0>4LFD10X$IL%=V;
MW6=L_9Q[OMPH%WYAU]2.QQ'D6T>F:L&LH)*Z^8JG]G\X $R25P!I"TB#[N:@
MH/)&D,BFUNS^FIF\XM@-:!9G-3^4A9D>54LV;\C25\@NX-9H*AU\U 46_^-C%M:I2_?
JYNE)P@76?1@F M/4B3='2";]BY'0:^X0FW#LC
)ZF%SJ50L"!!R*^,W#&_#=WH.)UOF$M7BQQG M$7>$0_N(4?;VS6"/%A1(
A=P'1NENH9S(I[M++=;3DI-R'\
('4*X!;EP@Q0BA_G62I*LGG%GZ6322Y(D^#M++]H@[/$;X M: MLN7]0PA5-\S<9
3.M;H5=2^U X8JA2?_]>02VF0!-0*8.7;&UL?55-<],P$/TK.V:&4QNG25J@))EI6CIP@.E0
M/@X,!\7:V**R)*2UT_Q[5K)CPDS(Q=;'OK=OU]+S?&O]4Z@0"9YK;<(BJXC<
M=9Z'HL):A)%U:'AG8WTMB*>^S(/S*&0"U3J?C,=7>2V4R9;SM/;@EW/;D%8&
M'SR$IJZ%WZU0V^TBN\CV"Y]565%(M:AV)6,;OGC,; M4D;@X7C/?
I]JYUK6(N"MU=^5I&J1O8M513/Y#\08^6D-5 M@'=&HOP7G[.<0=-
DKVDU.4GXB&X$T_$93,:3V0F^Z5#C-/%-3]08@"S<*R-, MH82&1Q*$?
+:.U]O1S8[3Q6MR'9PH<)'Q/0CH6\R6+U]<7(W?GA [&\3.3K$O M^^\-R$@!?
CQ!9\)5MH63S^/23U)=ESJU6CXV/ =P:%75JI":+T#(5ON$,*F M,3*UK$4CK0^ IN0[*N-
2:)RSGH"J!$[&$#%V [;Q4+"(R ;DN=,!A)%\>S7W M6W9W4)'",((OU3Y-
GY2W/4*%6IZ!,H0LF&#C$<^ L-,1VQ/23^ M""S1H$]%>"QLRW
)ZUU2>6MK)TP<>]N4%0CG-$OL;*%DYXJ)^&QH"-3(7>Z\
M_<6NP2I:JPH^.YR>S:*)YQL:QZB"&34F M81&YOBN#MK;HJWK>+0@SY'@<::
M\Z+QGD\=;"LT49KR@,^.=$;R-[RSXX_"E]P8T+AAZ'CTZC(#WUE<-R'K
MDJVL+;%)I6'%?P7T,8#W-Y:O73^)"8;_S/(/4$L#!!0 (-.";5DHZUV^ MO@(!(& 9
>&PO=V]R:W-H965T5\ M]_AY?+ECNE7ZP>2(%IX+([Y)K?.X"?3 MDFUPB?
97N="T\SN4C! VW[*9 M%SA"*#"U#H'1](17*(0#(AJ/+:;77>D"]]<[]-M:.VE9,8-
72OSAFL$O9>;;]BJV?H\%(E3#W"MO$=#CQ(*V-5T083@X++9F;/[3OL!8R#-P*B M-
B"J>3<7U2ROF67)5*LM:.=-:&Y12ZVCB1R7+BE+J^F44YQ-?BB+,()/L-"4 M:&U?
@,D,;AXK7M+3VZEOZ1+GZJ/$)Q0:L@ELNF4PY$["'TS**3:X[I;> &
MQ^%505!O43>LF'=^%%\.4$V4%'=G */=EEY1P6@DE[F!RXYB85 MRE0:X>]/?
+8P%RI]^'=,Q,EKCHL8]=_X* [-N#.?@T0:4D45:RQFH-9@PBC M<3/VKE115I:B7H_#,
(#QJ/<=J61S)3+@1:G54Y-F""_HUXN& XCBD)R,H?Z0 M5D4EF&.>(3T#?
1IUX_@8!C&^8WG!I0.":0H/^:.B!;CI0L[&JK*M^I2SUD'J9 M4]-&[1SH?*VH#MJ-NZ#
[&TC^ U!+ P04 " #3@FU9D",TQLT" 0!@ M&0 'AL+W=OO.&73M$D=
M"8'R:Q"IT%6;M&ZH=-O#M ?C7(A5)\YL4]K_?F<',B:EO,3V^>Z[[_-QQVRO M](/)$2T\%;
(T\R"WMIJ&H>$Y%LQT584EW61*%\S246]#4VEDJ0\J9!A'T3 L
MF"B#9.9M*YW,U,Y*4>)*@]D5!=//"Y1J/P]ZP=%P)[:Y=88PF55LBVNTWZN5
MIE/8H*2BP-((58+&;!Y<]::+@?/W#C\$[LW)'IR2C5(/[O YG0>1(X02N74(
MC)9'7**4#HAH_#E@!DU*%WBZ/Z+?>.VD9<,,+I7*5*;SX-Q "EF;"?MG=I_
MPH.>2X?'E33^"_O:=W@9 -\9JXI#,#$H1%FO[.GP#B=2+/ M\II9ELRTVH-VWH3F-
EZJCR9RHG1%65M-MX+B;/)5680QO(33M467KV#>JFO)UKY

=+SUOZG241%)R*9+4K%5>&7N,U]"[BR8C6 M^'+0_502P,$% @ TX)M689J"@9# M P
40< !D !X;"]W;W)K&ULE57?;]LV$'[/ M7W'0@J$%/$N6',?.; -UMV(#FC5HNNYAV
,MG2TB%*F1ISC^[WAKT[NUZ:CI34>&?!=4TC['&#RAQ6R21YWO@L]S7Y MC72];,4>
[Y%^;^\LK](>I9(-:B>-!HN[5?)NO_@\%7BP;VPP5>R->;!
M+WZM5DGF$T*%)7D$P7^/^!Z5\D"ZKGR>*51+OS"(?
H6[%QVCDQS"N8,&JGCOW@Z]>%% MP#Q[)2 _!>0A[T@4LOQ)D%@OK3F
]=Z,YHU0:HCFY*3V0[DGRU\EQ]'Z-T,(
M"_@!/K5H!4F]AX_(52Y38G3ODY8GIURE]!6L"MT50[^%E76/TW/N6L^M3R
MY]0V^5G >VS'4&0CR+-\>@:OZ$LM EYQIE0'9."#U$*74BBX)T'(1XS<4+T1
M;CH,YV_+C6M%B:N$KX-#^XC)^OOO)K/LQS/)3OMDI^?0UQ_1.<31MV-Q\.<7
M?"+8*%,^_#64]%G8X:07XV]IX--N)TL$%1>=!=,[Q+W2.')P0(MP>3T?95D& MK!" HJS!
[(!J!,W",UDYC.<9KN M[;T.1BNN8>@*I2]DKD&[#V+NA]5I MBHK7[_;OQ;LHD_^ZQ\?
F5M@]#XS9=QR:C:^O$K!1P..'3!M$5CL S5#2:QGR"G)L:S]]?T.YZ*1[:@)V@+[$"")-$.>
MC^=\YQKJ=*O-K=T(X=A]62A[-MHX5[T8CVVV$26WH:Z$PLI*FY([/)KUV%9& M\-
P+E<4XB:+9N.12CS:*1]V+]W*] MZ7ZIW!T[A'R64IE)5:,2-69Z.+^,7EA/;[#?^68FL'WQE9
MLM3ZEAY>YV>CB!02A<@<(7!\W(DK410$!#5^:S%'_9$D./S>H?
_D;8%>Z^W_Q2M/5/"RW1A_;]LV^Q-<6)66Z?+5AC/I53- M)
[]O>1@(+*)/""2M0.+U;@[R6K[BCI^?&KUEAG8#C;YX4[TTE).*G'+C#%8E MY-SYO[03+
([8C^QFPXW8Z"(7QG[/KG^KI=N=CAW.H)WCK,6[;/"23^"=L#=:
MN8UEURH7^:'\&+KU"B:=@I?)4< ;484LC0*61,GD"%[:&YQZO/2(P98YS7Z2
MBJM,\H+=..X$ LW9I^QMX"9/PU'.O+ 5S\39"$EAA;D3H_/OOHEGT-(@^1M!*DMF
53&CL MY&XH_MTWBR2>O\0)2M6P?BV4,/@LD8]DK =5.P;_&:Y-CI@S.Z8!5@D?>P\$
MPLX/TMH:.N2U(1@Z4<&MK&R22U!R,:0&XI;8[?*#O57LYQK[DFGS(F!;;Y$@
MRZ6"259DP'027%>UR>!+V+0VHDD 5!^W0:G,L-^[3ZH[@2)DX"ELMS57CHC9
M;F2V(6POZKGR&GN#47,+"@*^QN(;'F238)Y$011%A]XG,OE>CQ"^@AL0AWF=NC/OGX
MK*5%S'D00ZW)[MW,?G@_7'[?+%]TR_WI_;N_R/OKV0A]F*_*!\\OK!:Q&D?
MU_=PMUK['"H1-:3"#S?75\\?]FV[NMR^%GTNP!.\$)W/VV"R* ?DFC]@
MBXSWT@<<]#W@>
<@^;&CQR!ZV14$AB_.]R3"@B3(X/N[2DDF^8GZKOE:X=#,/0%0E6A'DR''P)'9+8$DX:3@5
3^+#J89\G_$FE'QF<>-D)BONXS='6-0^G4<^H)QZ FV_NYQ" ?W
M%>SSQZ%Y(_%U&OHZ#7V=AA[/ GX:FB7QD7$%9AW./KE ;37]?XO46:([OP;%RE>[
M=P62EP;4:9">G'P>/MB/V;4GT2O]6J&+B_;K(?!T'DRCZ-D'39>#BR!9S((X
MG;&G+D?'@VOL4IBUOZRG^1)UI;G1[M_VOP=<--?@^^W-CPEON%E+>+00*XA&
MX7PZ:MI^]^!TY2_%E]HY7?JO&\%A'VW^DIKUSW0 ?VO).>_U!+ P04 M" #3@FU9A]
(H=]T$ #M"P &0 'AL+W=O:&EL$9%(+4G% M27]]AZ3ER(GC6R_VD)SY^,U3/%M+]:!+1 -
/=27T>5 :TYP.ASHOL69Z(!L4
M=+*4]F:&EFHUU(U"5CBCNAHF430>UHR+8'[F]F[4_$RVIN(";Q3HMJZ9>K[
M2J[/@SCH-G[P56GLQG!^UK 5WJ+YL[E1M!IN40I>H]!<"E"X/ ^^Q*<7F=5W
M"G]Q7.N>#-:3A90/=O%;<1Y$EA!6F!N+P.CO$2^QJBP0T?BYP0RV5UK#OMRA M?
W6^DR\+IO%25O>\,.5Y, V@P"5K*_-#KK_AQI^1QF-,#&HN_#][VL2A9S"-WC%(-
@:)X^TO>L!=#4;" M5RZ8R#FKX-8P@U1F1N_SU\-E^^%LQYSJAN5X'E!+:%2/&,P_?
HC'T><#9+,M MV>P0^OR**<'%JI<1^/L.GPQ<5#)_^&(9=UTU)Y"#JM
M[&E#I]J=+IZAX(^\('H@6_6B\LF49-#6J)B1ZM@JVIVUZPXL3M@CG:R4E-[.EQ-
8$8;)ARPPRI02*I[CU:TRA[8?>+"93'P;#5PK5LLWBH 8778 M-+3RGRU7^_1"X$O2?
0[!NM?1!9IZ7DDJ-T2(;P_;E,S8]3,9D%6/^P#NRBZ MK+,L>-5:4.SRNHUG"'3/UV.=G
'J0L71QL$YP[8 TJQ&8[GE7M&B);^"0\O;(*KJC
M0UZ@Y4$QL'Y1HI2L?;A8E;>5"U=H$6F/*\#EDCX#]C9&-$\ZWCY-2UG1M\G5 M
UM4N/E \7]=.:H^H@W:3C?TO7TI%E<=I&![3%A//W%!)[+5%#X==IGS5K9
M7QJKH"%^?'IT5RK$G6$*- II3MG,T3P\NJ;6/G1NYZ7]27O2=&.]9_0L6@0CSQ=DI).
MRA+HI#%)NWGME^Y[I>I:6$C3]4H!+FEXB$VO-/3K8NLA=N7V/^7UJFXJ^8R^
ME(04)]AMT/,A?P#9>()9.$Z3,$NGD(;CV30"F^O:/+G;C8SG5MT1*=5Q7? MM"HO:<;
FBE%G:5A4PGTO1Z%412]7K^+W=A--*9RGV(W+7&)RLY]{T0K.,$G
MTRR<3L>0Q&DXBT:OUP?A'U$;6P#NB[!S%>D:Q7/SZK)1.',12J:S'7G?IWW8
M>X+1QV_E'IJ:HM4*XU]CV]WM6_:+?*]J/N'\'>F5IS25>&23*/!9!2 \H]+
MOS"R<0^ZA33T/'1B2>]Q5%:!SI>22GRSL!=L7_CS_P!02P,$% @ TX)M M67S"#)FY"0
=1H !D !X;"]W;W)K&ULS5EK M;]LX%OWN7T%X@D$"*+;ULIU.$B#I8[; M
V2MH/%8C\P$FUS*HLN*27Q_OH] MEZ1D.;7=
[LXLL!]L2^+EY7V<>W@IGS\J_<4LA*C8T[(HS45_456K%\.AR19B

MR#"_/5WPN[D3U:76C<3=LM>1R*4HC5\RKQ87_6F?Y6+&ZZ*Z58]_$]Z?E/1E
MJC#VFSTZV23MLZPVE5KZR;!@*4OWRY]\'#H3IJ,]$R(_(;)VNX6LE:]XQ2_/
MM7IDFJ2AC2ZLJW8VC),E)>6NTAB5F%==OE>58&'$3MG=@FMQ2A[F[*5:(NN&
M4^#.AQ76(>EAYG5>.YW1'IUG]TJJX5AK\M9I(7[*[BE0#8*K/+7ZQ*:U[.K;WL
M'Q_%4\6N"Y5]^>3O1"XS3G>:KT1=RFDWX!56,].)^$3]DC2N5J1UONU';U67.=,S6"6!CLL
7;"X.[MKK,%"Y/:2&S^&JEU8-3H&IP&@5GH8I<8"JO[#,K?%66-=#TJRCA9<'>H2QE
M.:>E[KI3%J+(W5)K%D5N(82\OC?B:TU)M>Y9.%J_8/,*S@0L0R:TI)S@!\A=
M\:)8DWK<@),-+4;2O*X62LM_0=#::EB-<.F.ID>AQ0_Z%44V"%1\>QPTSST< MV*RW66
KH9>2G&FB'S"E&2=_\+P2@FY-?;^YAZ06:A:0_W.@O6H"06#DY?KG
MGZ91./G%,%'(N;PO!!/+5:'60IB E:H\;6Y9WB:9O,B$KK!78>72@+DYA9C$ M"7?S$E
>XC0^OG@*S>(P-F=%_:T^G9ZYT>M]8J"YY+I"=T-#MCOP@?3 M.T1!7=7 .Z1L,N#/-
X#9I!&0*!4KA*%,XIY&9UQJ[$CZ"SJ(!U[4@K! U9! ML29(;FOFIA')4>MT;6T:L _>*'L+JV%
(0V\TG##K\T9!* M]1U^^_$%CSM#CKP0@1G/9"&)%>U*-C:>4T 6LEJWF:<8
;FM"O0L0M/F!BTE M^J--+/]0LFRHPM>3J]AG!FR1YZ,$I]15ER0\@6)@,C4ODK?
OG(7!:#2B MSS/8>2W>7Z!"PPPR.A,=L#^+ (AR(;$== G,5]#L&6_\#SAB5_T?K'!+ERTC
MTOHK2;N("Y0JL5E HZ$B:Z4P X*"4.A7V!L-AO4(8?)!YM@&#(*C[+-M>)&%
ME$0S"!SM6I9]2\TJ%.PI^V.WY+Z[L)?4'Q;)@U';"UX4V]67U-O!\"R M1'=S+YK6A.)
<.=:7!D^L\="]Z:_@?;=!&[!/^V/J]A <#"J?;G\Z"';N;(3< M.2(T]_M->K:+(&Q+!
(:S<"4(DFEQ.@E2B'H9+>BD2[X\<%D0]K:(9,!NM,3] MG:UAMY_]6!?
\S8Q@=V/\'MFS'H]MVSAEQVY%NU\$EK I:SC8'&YX70OT1UVZ MTS&1^W.P;-
+BJ;.#F2O'%-UH;8"PLX.=J]E&P->77"(_VFE35]F:U;7ES^%I21,@R3\+I9VV=N@Y573
3H0 M? +U_XFCTUYM'BGH+#M'H_\3L#1&_76 V9]5*^(R%$Z".(Z?Y:[M)+9;A!5) MB*HJ'
]1@-"C_Y!7@ZVW*UEW-Q)/=.U81'#L$SY\V*:E0M#LJ=PB7MH6;Z:*
M0CWB@""I_5:UP=+FY$7OXP(;P-:+ERW?>^_!6@>&*3+T%7>N@"AAS\(4[5P\
MB$*MK.M'.!U/Z#N=XCM)SN@;2II3H:5TW]YI;OO;!$P5C2?4G&'JY&S2^Z@J MB)I]
<3G";I^2WHB^PR Y&]O?*)K0*0;(5/,2!]S]&MPCU3FEM,<3&VB_<:(3 M0L.QM!50MP?
HZX)G7T[O,H";6D='RS3?Z5ZJ7!38H HWLUB[/H-G%9V.FYRV M1L*,!P^,!^':&Y=?
H+DH7%]V[S#@R,HC$8>LRBN%!$T%KIL7J)VFP+[;I*/ M
8P$,"M#ROWV;2NHZ2$97ZH:G1AP=.=6_K0YO'GF[?UNWW#"EROXPN>"O7X2
M.I/&@AT%<@-M=G;OJN7'MR6ZVM+(C'VFV/>N>4'%9%\N;%JUT%9FC)YM.@%
MPAB9C@?C$#_3..K]ZBD_#,;C."! 1(/IN/?Z:06"RH<9:2P*"!PG:6KW]1.6
M#*91[XW2,R%IZG$\&0=12B/18!+W&M,Q,AD%$SL0#J;3+0._Y0Z6!.,X"I)X
M:BV,R<($1J=PU+T@M]FXM\>D[HN#+DL$-
I&>M0DJF3_KTN,#CG2%,0$<2L^D@(:H8C$=LD@1A>D9/>D>1 MEXU(-
@Y&411,SU*,C2PF&&$O/4O8>)#VCF(O'%OA)(1HC)$064^!OR@.0JR4
M#.+>4>)%$Q(=3R9!.(T(?_B 'SL/>D=I8^Z8+N+I!%:D+!U,H#H>LSB:!M&$ M'J2]#=
(F@ZA!6Q2$\"A.8XB,V:Z7R\/.7P%+H>?V#P\#8D1YNW\%VJ?M?RI7
M[J^$C;C[0^8=UW,ZKQ1BAJFCP23MNW-L@H !D !X;"]W
M;W)K&ULK59=;]HP%/TK5B;MJ24A?)1U$ EHJR&- M%E&V/51[,,E-8M6Q,]LIW;^?
G82,=L%JT1X@_KCG^)Y[KY,[WG'Q*%, A9XS
MRN3$297*+UU7ABED6'9X#DSOQ%QD6.FI2%R9"\!1"T,TP84XP+M=6
M(ACS0E'"8"60++(,B]\SH'PW<;K.?F%-DE29!3<8YSB!>U#?\I70,[=AB4@&
M3!+.D(!XXDR[E_.1L2\-OA/8R8,Q,DJVG#^:R2*:.)YQ""B$RC!@_7B".5!J MB+0;OVI.ISG2
_'>_:;4KO6LL42YIS^()%*)\[(01'$N*!JS7=?H-8S,'PA MI[+\1[O*=J!/#
NI>%:#]3PCK'KBYSH.!P#-TP[P:X#_"C#RC@!Z-:!7"JT\ M*V5=886#L>[)
(RU9C.#,C8E6JLAS&3Q7@F]2S1.!0N=CP@$V@@<$9:@J1"8 M):#SI.385?H$8^>&-
=NL8O./L/70DC.52G3-(HA:\',[_I,%[VIEC3Q_+V_F M6PGO(>^@GG>&?,_OM_ES,OR%.
[TFVKV2K_?V:*.OV@8M%&2M\:[X^NU\YHI? MRAR','T'98@GL)/G[H#KW/;6+_$]D+Z?
U&>M_&'BRQ D$P11L0F40\;BLY M]+"!9X5FE(>//]O"83WCO>&P.[S87"_1H(/N-
E^NUVAQ>W.W7DXWB[M;M"XH
MH*ZW'9QWT8IB_2YB$;KE[/QPHTW=-.*Y>7G)LS(*A.%Z9@B6/"(Q":LE=%4(M@U8IZ)\
0%EU,-X(N3LKLO1ZM> M._51O5;8B7I'C=[1R0E^DV8[_5'-5MA[-
;L'G_<,1%)V/1*%O&"J^M(W]TUC M-2W["?>O>=65+;%
(B'Z]4(@UU.ME\W"EBO=>I3#5#>'((R! MWH\Y5_N).:!I-X,_4$L#!!0 (-.";5G9-G$7OP<
!,4 9 >&PO M=V]R:W-H965T*%(E:3LN+_^GAE*LI(XQO9P'Q+KA9QY9N:9%^IJ MZ\-
#K(B2>JRMB]>3*J7FW6P6BXIJ':>^(8?0HW5[Y-UCCZ%%1LZUJ'W1U9O[V>G$WZ!Y_-
NDK\8'9SU>@U MW5/ZI?D4<#<;I)2F)A>-=RK0ZGIR>_;N[I+7RX)?
#6WCZ%JQ)4OO'_CFQ_)Z M,F= 9*E(+$'C9T,?R%H6!!A_=#(G@TK>.+[NI?

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

SVXQK3;&;J=:+ B*IXR 49Q^J92&PUG,#P/9S&-X7@ZN"5"IM("6)51 MB3Q2Z==4R
9L'IZ2A>EL I,H'*QD2>U%,U>A<11 /)D,UDKFJ&W9$W\/R9$^ MLR',IH-OIB!%PP!
(SITT%,6Z:Q('UW0&T3E9<-KB.(9C+^,?5$Z):N?Z@R93 M367:
(NIW^Q9TU5;>O_"V?]TPM>.5!H$Y08.+>.R!:GM"NS"R=G6XE8:JVDT+ M:J.H;
"=YY+^R6YA$_2-.?D+4$L#!!0 (-.";5DM*$GC@@('$% 9 M >&PO=V]R:W-
H965T_=/2?/XZVQ M#VZ%2/!8*NTFT8JHNHACEZ^P%.[,5*AY9V%L*8A3NXQ=95$4
52J.$V2?EP* MJ:-L'-9F-AN;-2FI<6;!K>%6+E?D%^)L7(DEWB%]JV:6
ML[AA*62)VDFCP>)B$EUV+J8]7Q*ODO\<9-2T]<#]^9O\8M+.6N7!X9=0/6=!J$@TC*'
AUHINS?83 M[O2<>[[<*!>>L*UK!_T(\K4C4^[/$$I=?T6C[MSV ,,DQ< Z0Z0AKGK1F'*
M]X)$-K9F"]97,YL/@M2 YN&D]A_ECBSO2L91]L40P@C>PM<*K2"IEW"-K!). M[L5"T-
?/=-,%&J#6"68!IY-=< M9J[D4@0$LW4'<.BHXST;E&B7P>P.N$3!5,-3?$%@WABN]$M+Z
]Q>&?[)=XALTMVSV!U!+ P04 M " #3@FU9*S%V"?X" "@!@ &0
'AL+W=O(U>))*:]^$[_!@M#L8^N J1X*E6VBVCBJBY2!)75%@+
M=VX:U/QE9VPMB+MVG[C&HBB#J%9)EJ;3I!921ZM%&+NUJX5I24F-MQ9<6]?"
M/J]1F<,R&D4O W=R7Y$?2%:+1NQQ@_2EN;7<2P9**6O43AH-%G?+Z')TL1[[
M^!#P5>+!O6J#SV1KS(/OW)3+*/6&4&%!GB#X]8A7J)0'L8UO/3,:IO3"U^T7
M^L>0.^>R%0ZOC/I+EE0MHUD$)>Y$J^C.'#YAG_$\PJC7'C"H8N=\HQ%Z\C4
MO9C[M=3=6SSUZ_!*,$M_(,AZ019\=Q,%E[\+$JN%-0>P/HIOA%2#6HV)[7? ME
U9_BI91ZL_#"&,4G@/FTI8K(PJT;I?X/I;*^D9?KT76X7NW2(AGLQ+DJ('
MKSMP]@/P'#X;396#:UUB^5:?L,G!:?;B=)V=!&ZP.8<\C2%+L_$)7CYDG@=> M?
B)S!UU^Q]+KU./C:G]7+EPC"EQ&?!D,5C__-)JFOYWP-AZ\C4_15U>F
MKOG(;L@4#W#7X4O@*P@?6VHMPHUSK= %PM\A ;C')X*UXO!_CN5RHOD6+*RH/]
)_%\E)]M.I9X%%(%F-^$O14L;?E@6Z *X9)1?,@#FW>+A&=E MZ6@.?]9:;EL'-
[Q7VMI.G9O2&A8!9GLVD\RJ=P[$PFKZI&C78?:J.#PK2:N@(RC [E][*K.O^& M=[7[L[!
[R3NJ<,?2]/S#) +;U<.N0Z8)-6AKB"M::%;\"T'K_C[SO!M[#M^ M@N&GM/H.4$L#!!0 (
-.";5DQ. &-DP, +@(9 >&PO=V]R:W-H M965T("+&";G&TISJ5JI5X4 MG=/>0]6'-8P-
"K!T=XES_WUG%TR=U(?RTA>8_9C?_.:#&18'(1]5CJCAN2IK MM71RK9LKSU-
ICA57EZ+!FDYV0E9"]!M57%Y?W,O:>4-*%E1 M8:T*48/$W=*Y#J[6L;EO+_Q1X$&=R&
\V0KQ:!:_9DO'-X2PQ%0;!$ZO)[S! MLC1 1./O'M,93!K%4_F(_K/UG7S9$7[/VQ
M!%-1*ON$0W_7=R!ME195KTP,JJ+NWORYC\-;%%BOP"SOSI!E^9EKOEI(<0!I
M;A.:$:RK5IO(%;5)RD9+.BU(3Z_NA$8(O@(=U0!OPFEX!XE;'(N$3X||&V)
MZF+A:3)E%+RTAUUWL.P'L E\$;7.%=S6&68O]3VB./!D1YYK-@JXP>820M\% MYK-H!"|
<_ XM7CCBMX+.OW/N==K1>6WSI5RIA]>X=.A34"B?T%F]?Q=,_4\C
MW**!6S2&OMK0EY>U)8+8P2V7=5'O3[+BPIJK(@5>9_"Y*%N-&?QI'8$'?-:P M+D7Z^-
MOYNS@'W:#K'(^EA$S)W%@1O/9A#.W"1*W(@Q"!-WZD=N,$L,5W,A9,ED_1_M
M^DBX(.^L54/,OPSBCBY)["A%#([2%"Y&$A\/B8_?G/CK6A>6%#4M"G3:RD(7 M%
(+;Y[1L3?!W4E1P(Z]FU=PVN+/5\L;2&.5UOMS_EWJYK9I2?"=A.)346CZ\BF4:FTT6J(C(3T)
MA*:5:4[M'0Y<2EYK!7V%4<>)7=_W7Z]_B-V83=2Z1!I>VJ2%I@1*20'HG&CK
M@N#9/'+G\RFP('03/WZ]'H5_0J4ISS9*+TW172V+5+\R%KN)C1";)R_DSDQ%T6IKW0V68
=-/KW>C?3OW"Y+RA=)>Y(U;^<49W);DYV
M"RT:.YNV0M.DLV).OQ8HS04ZWPGJT_W"&!A^5E;_%!+ P04 " #3@FU9 MBR'^VW$$ "
["@ &0 'AL+W=O&]J"1EV?WZ#KDK M14Y5U6C[("]N? ,YW
TXTTK']024<-3735J,EAJO3KW?94OL1;*:U?8D&3> MREIH6LJ%KU8216&-
ZLIG09#XM2B;P71L]Z[D=-RN=54V>"5!K>M:R.<95NUF
M,@@'VXWKH/Z^N)*W\G9>BK+%19=N Q/EDSQ*C;Q7N M2MRHO3F82.[;]L$LWA>306
886Y-AX$?1[Q$JO*."(8O_<^![LCC>'^?.O] M1QL[Q7(O%%ZVU9>RT,O)(!M
@7.QKO1UN_D) ^WABXR]O*V5'V/2ZP0#RM=)M MW1L3@KILNJ]XZN_A-0:L-V
6=W>01?E&:#$=RW8#TFB3-S.QH5IK-E'K-D0]"H7S$P?3[I\(D^.$(MFB'+3KF?=KE
M8V;S<26>Z2%HN)!2- LT/IDD_:L-#&[Q
M2<.L:O.'WP[%>!3%X1AOEQ+Q16Z!,J.QOD=)Z7$^DI,C8I,\,_"]V37Y%C)? MVF *?*1JL;
(A#R&,4C/&&8U1-#(C.7F'#4I167U1T,LHE9;"/'&(P@Q8DD+H M!F2:CE+GMJ6[;7'\'R?
X4.(D]CX968,W6B4V"]C*1S)9+S+9/S?,OEI96!0 MWDR)*O7S*S-
W]-3#F;-0%'RFI,CJN6P6_=G*^6+K%R&\>*1[72#1"V5>*H0K
M6>8T4NZLM7.Q6$A<"*H;[QLM2ZK/.=R):HW.3%2BRD@'E9XA"
[2XF%GQN/544*)U$KXW&*PEQ%,%A0GQ::Z7I#1$57+A#I?MZ
M8HI+;A:ZM=M.SY.7.A:I0>;LZ/$-?J=CW%_I=8VF93 ,O*1"(>G?>4U/].=R MCG#R"Y4"=?
I/E-Q!VL?Q;\X9AAZQZ@SH.QH1$XB%$8?,BTP1\)(TL@-XY'9
M<8:LUV5&E[L!8VXVBDD66.Z!X7@\BB#Q8F?(>V5NE:.05#E)0F)73#QGW WI

MI,CCSC#J52.CFJ2I&V;,\)Q^5/GV-IQAO(6;F G/4D(10^REY)HGP%GFLM1L
MQ,Y71J<>V[:N2%%Q&-.*LE!;OM[#46-M?6?*
*1!R034"*IR3:>"E5+5DURIU"]VN;'MRWVIJ=NQT2=TE2J-\GE+?]+] MPARPZU>G?*
P)02P,$% @ TX)M64H:AY^S! G1@ !D !X;"]W;W)K M&ULK5EM[.WG:FK;RCO>I,Z[O>
[NW4 M]N[GB%&90N(F0=M_OPE05A%9.ILO-81SSO,D>0Z$M+TG])5M$.+@+0HQZV@;
MSK>WC0;S-RB"[(9L$19W5H1&D(M+NFZP+45PF9"BL&'JNMN(8("U;COI>Z3= M-
HEY&&#T2 &+HPC2]WL4DGU',[2/CJ=@O>&RH]%M;^$:S1%_V3Y2<=7(599! MA# +"
84K3K:G7$[:TI\O@_0'MVT 9R) M"7N7%9-G1=)D0"I'/I0(4/SO4 M0V$HA40:/S)-+0\IB8?
M#_5A,G8QE@5DJ$?"[\&2;SI:4P-+M()QR)_(?HRR M\3A2SR,DRL@B@RC
Z2]\R^;A@"!TR@EF1C"+!/L,P=4W T$CW>_$8Z ":[!4\!>
M&8!X"5ZPCR@79N0!8N"BCT0[9. 9O?$8AI<"^S+O@XLOE^ +"#!XWT"8"1YK M-
[A(2,HV_"SX?1KK^:_@"IH!MGZ8/ZR5LE]&']Y,OHH_K)E]'' M?S;SDS\;^[2:WD=^9?
**S^G2SH@RMW)16HF>?T7N2EL-H"0:0X@"OA0OO?#^. MXA!RT=M'J\/^.45>"8%TS1'=*
*(ZW\]RW#U?\JJ6Z780*784*782*78N.9"350&G98%-1S':1X' MG2D*>N0!._> 7>F!;V(W.*
<$^B1"X^)88(T M@',X3-?T[((%[-/)< RC=8SJEZ(?4XOZV>'F0;\$C)+A"; [!X M!QBD"IC?
7):>BK%^BK%!BK%ABK%1BK% MQDZ)91S7+CYQRV!VRW +EE&9VDR1V)%EW-
PR;J5EI%VN4M,,?L3!#H;BZ2I< M(3\)YAM"^?
*4SHI%X)N\0XU%Z[ZQCW)/)7>2]^5GZ77*$7.B_-VY'1DG_V+B=I*>6O^33 M@_L'2-<+)-*
SC 7A',2)&PO=V]R:W-H M965TZ5W9@M@R2&3N1G3K;7%
*MB#&3;B'CIJ,*R/%DK73&+89ZPTRA@:\|*),L#((!R[C(:1SYO;F.(U5:*7*8 M:V+*+./ZSP-*
(M1_3+GW=6(C-UKH-%D<%WT "]J68:XS8D64E,LB-4#G1L![3
*M27.6I;&\|&M6(W/V+B=5X*A!GXR_* NF3#^29ZQU8OI1 $DA++:P 0VYFN">D*
*M(=_@8$LN;S'S)9F1F[>W$;-8W[&PM*GU4-<*+]1*H.B07O">A$'8;X%/K\-G*
MD"\Z^&]2\'-C?CY#M@3]J\V%JV7=6(Y,P5,84YP[[H"&K][TQT$G]H\^4]D9P[U*
MC@[UKCK4XDR;WIIDX$G@70*>KQ7>\29P(W-\(>._4$L# M!!0 (-.";5DQ4NGQ" 0 /\7 9
*>&PO=V]R:W-H965T0ZB=K+A*J]%)L?)D)H*L*8E]$@2AGU"6>M-Q?N].3,=\IV*6 MPIU*
*LCNA%[Y)F;A#SB*X.#K%TCLY4EYX]F\7DU\0+#"&*(E(&@^F,/,XAC@Z1Y M_%F*
*>N5WFL3Z]1/ZIWSS>C-+*F'&XV]LI;83;^2A%:SI+E;W_/ K%!L:&+R(MQS+_BPY%;."A:"*
*<53XIDS2!AZ?&3_B@*44O_3,)I$@@_S6A5R3T\HT>F>7; MFE-%IV/!#TB8:(UF+O+:Y-*
EZ-RPU,BZ4T$^9SE/3W[D"U$<_HULJ'D'190QH M =%.,,5 ZON?!/H*XUW@/CZ3-2[N;*
['8OF^$7^![DV(8.D&?;^%9 GB#QWP ML)BC=V_>HS>(I>C+EN\D35=R["N]&\/)CPKF-
*T?FY SS!627J!=<(!*0?DOZ MS)X^ATBGXSR]UTSW=0W+0I*RD"3'ZY_!^\|*
(5C;4R97UD69^VO1W!PAS,M-I^ MV@^#4!/9U[?
*0$C7J#4@9U6#:*YGVK$SK"GU.LYV2%^@WV$.,<*E3&V4KJOFY*
MN989C6#BZ=\3"6(/WO3M3S@,/K2)XPBL48!^68"^2ZF.8(.:",$SF6P1#8:#
*MDN'@A1(1JT16U*X2.0)K%" L"Q"ZE"@\$:"MFUJBSG?3L&0Z?*%4/:M45M2N*
*M4CD":Q1@5!9@Y%*JT;]VDRVBP?"J9'AE93CC20(B8IKF'X#EVH5:'4Q2$A&PV>2M87A8=*
*EV MIQSZ&[UTM-EI=%78%5JS:)41P4Z=2(%FZTAK2)-E94*PW86XD]8^$NTT.DO[*
M&KX%5\8%.W4N^-28M'9O2YBE>RL3@^TNQIW$]E%JI]%9XM?P/;@R/MBI\\&G
MIN:D>VTA39:5Z<%VU_.P0+_P/8A4O]$K]'$#:61>!.>P5/470ZMJ3AV0[1F M/2H/A)V:*
*('SJB,>I4?PG9#U%&]_S-8G5HG5VC-%_S**
M.Q&GWHFR:7XMI'JYU(5W%=H37+5CN^<7M^0B[I(SLSM&N,?7$E)*3DMK-*
:8E8W3/FBA(4 M=P-3@?8K>V,51Y_: W.5!;Z+)"59FB13IKC0-
,_BW,KFF:E1"@TK2URM%+?_M'D&:9DZ']'5B+0XEA@F69Q4_P
,PN5I9G[&SRDXHT$X832SLY_1A>+](SX" M?@MH7"\FP0/.WF- D-
@80"@P+WPQ$6(&40\FW\[33IN60@]N-7]6_1 MN_>RY0X61OX1.RSG=$;)#O:\EK@VS7?
*H_$R"7F&DBU_2M-C)E)*B=FA41_8= M**';D9^Z?*
>@1AN,KA+0CI!\EC#K"!IM.XNVEAQYGEG3$!O07BT$<6\BV[L1 M.ISB!JU?*
%9Z'^4^#0";D,WE0IM;HR!H$$>^E4!NEH!<2$=^P0EK+F\]['FS*
M)#>?;C.&OGB08$57Z+$ME%XIM(%J0$;)'4F3='R!OGB?OH3"TX>1/GI+9]{R
MV7=Z]IU&O?$5O2>-8,%AS^\=6=36@L9+YEJU:50++^.8I[-9DB09._9-7(!] M?0-KFV6]
PN/Y0>W!Z$=D;#WQ&3P94*);2]@FZ"IXAEN#?H;$#7 M]\:?8Y>$:W'^"^3_ 5!+ P04 "
*#3@FU9F*JI^_<" "&"@ &0 'AL M+W=O[!L)(0E@KM2]@XWL.Y]QKPQVNN7B0(8 B*
*M3W&4R)$1*I5>FJ;T0XBI/.S2G +0%N;K10*
*MEMN:4$6]H>!K(G0TLNE!GIL*4]YTK('UR1J8"MX90SX0F M ?*
GRF+$4BZ4.+QQ/0%$6R1,,N9]-R/'1"3DB+"$_0IY)C)5#4Z%_1K3+\5< M%6<*
V)FD)X3USHECN5T&N#C=O@$?(3;.=S=AIN8EBHW3I4;) ^?K'.#;.#\E M:431LDX
*;!)P2I:"RT:3!6LO9]7':.4Y7;2SJCMIB''M*F9+KEO)=5OE?@,I M\5CX69Q%5$&*

NQE/ML^H/B]-.@NZ;DW#F6VY.T(;@ZQFI9U*:>=%B=W-: *J M26=G3X+=M7=D-
L0W4MEM57F=B82I3$ N\YH]Z;$DOV\AGH/XTZ2TE5!_MD2]E2GT8&5@8"6(%AO?
Q@]VS/C5M]CJ[SWWF7K]_;+X QV2M4>LR6W M7\GMM\H=\SC-%
(C:]ZFM3*UDKRW3&Y%M^1Y4O@?O4J;!?@EL:Z=,^S&#?G.5 M+BJU%__Y0.'_-N110&
[B5/ 5:)7M!ZJ5\+65>B.R+>^V]>]':[U+K4K:^J_"
M[NW4JCVF$&S6F@3=H=U2L62))!$L$&2=]['4HFAZBHGB:=XWS+G"+B0?AM@H
M@M !N+[@V#N4$]V*5*VG]Q=02P,$% @ TX)M64E/-_*< @ / < !D M
!X;"]W;W)K&ULC95M;YLP$,>_BH7ZHI6V\I1 M6I%(;:)ID_80->WVVH$C6#68V4[2??
N=#65)(-'>@!_N?_[=P9V3O9"OJ@#0 MY*WDE9HZA=;UO>NJM("2JEM10X4[N9
EU3B5&U?5$FAF125W \^+W)*RRIDE M=FTI9XG8:LXJ6$JBMF5)Y9]'X&(_=7SG?
>&);0IM%MQ94M,-K$"_U$N),[?S
MDK$2*L5$123D4^?!OY_'QMX:_&2P5P=C8B)9"_%J)E^RJ>,9(."0:N.!XFL' M<^#
<.$*,WZU/ISO2" _'[]X_V=@QEC55,!?\%\MT,74F#LD@IUNNG\3^,[3Q MC(V_5'!EGV3?
VGH.2;=*B[(5(T')JN9-W]H\' C\T1E!T J"_Q6$K2"T@39D M-JP%U7262+$GTEBC-
S.PN;%JC(95YBNNM,1=ACH]^RXTD GY2![25&XA(U\9 M73/.- -U9O5Z 9HRKFYP_V6U(-
=7-^2*L(H\%V*K:)6IQ-6(9@YPTQ;CL<$(MSF"LH+XEH?>!!%XP&I#/+\L7D*+D?
YIQGKFYC"&**).YKX(LVST)@IVC8$_J\A#!'&O7\^ MM(5]Q-
@W\N,X/J%T#WJ;N5>^4;EAE2(<W4RTJ&V[6PN-S=,. M"
[S>0!H#W,\%MKQV8CIH=V'._@)02P,$% @ TX)M67,"@GHL @ 3 4 M !D
!X;"]W;W)K&ULC51M;YLP$/XK%MJ'5NH" M!9J^B" UR:9-6K>H6;O/#ES JK&9?
239OY]M"$OSTNX+^,[W//?N25B/6=[^NLA(KJ@:Q!F)NE5!5%8ZK"U[4"FCM0Q?TP"
(9^19GP MTL3Y9BI-9(.<"9@IHINJHNK/&+A-\H[F6'6]GC\$W".=0#$@47) S"^(B>R?
_#HS?D1'T7(\<7G^#; M:]X%F4B-
Q]K4T@P=C1VP57I}$P1!X]]VQ;\7]4ICW&N,W]3X3!6C"P[O28P/
MD@_C0XE'HH:'$OV='[,"5;AYU223C<#V8_?>?B7 MJ"J8T(3#TE &@VLS:*J=W=9 6;O??
R'1#),[EF;=@;(!YGXIS0ATADW0+]#T M+U!+ P04 " #3@FU9Z$E9UG " "R!@ &0
'AL+W=OA\#3VQ3:#/@YUE--S '_5+/)/;\/LJ*E5 I)BHB83WUO@YO;B=F
MO5WPF\%.';2)R60AQ*OI_%A-O< 8 @Y+;2)0?&WA#C@W@=#&WRZFUR.-\+#] M$?
V;S1US65 %=X+_82M=3+W4(RM8TX;K)['[#ET^8Q-O*;BR3[+KU@8>639*
MB[(3HX.25>V;OG7[<" (PQ."L!.$UG<+LB[OJ:9Y)L6.2+,:HYF&3=6JT1RK
MS$>9:XFS#'4Z_RDTD FY)K]JD%2S:D,> +/$D4>J&\GTGHCUT>P#HPO&S>3E
M/6C*N+HB%X15Y+D0C:+52F6^1GL&XB\[*[>ME?"$E3G4 Q(%7T@8A"/R,K\G
MEQ=7_X;Q,;L^Q;!/,;1Q1R?BFG N-ZTJMBIS=K=YF&;^UD&*>E)TCC1VD5K5 M^(
T'$9NU*A'CE)R:>D9Z$I)]P>YIKNLF(_TQZ=?HI^ *7PJFB0H#2IA33E
MR<5.C]C7HQ,;/.G9DT_9,V1BJF1+>0/F8K<[(!:<;>@I'Y.CBQ)%R7\^_(,2
M9*KY(Y4;5BF,OT95,$@P#=E6R+:C16VKTD)HK'&V6>!/!:19@/-K@96IZYA"
MU_^F\G=02P,$% @ TX)M62R[[-[K!0 YBX !D !X;"]W;W)K&ULM9I;<]HX%
(#_BH;=V6UG4K!LP"1+F$GB6W=?7!L 9[:%I5$2&;ZXU>^Q&!L%-R>?4FPT?F.';Y(AV--
=Y1]Y6M"!'I* MXI1?]]9";*X& QZL2>+S/MV05+ZSI"SQA3QDJP'?,.*'>5 2#W1-&P\2/TI[
MLVE^;LYF4[H5<922.4-\FR0^>[XE,=U=]W#OY<2G:+46V8G!;+KQ5V1!Q.?-
MG,FC044)HX2D/*(I8F1YW;O!5QZ^S +R$5\BLN,'KU%V*P^4?LT.WH?7/2V[
M(A*30&0(7_YZ)' MI(="LO2WL?A$=QXI;VB4\0(:_PGVI5CM1X*MES0I R65Y!$:?';?RK_$
'@B0"\#]',#C#+ .#=@6 8,CP-&)P)&9<#HW SC,F!\;@:S###/S3 I R;Y MIUM\'/EG:?
G"GTT9W2&6C9:T[$4N1!XM/\(HS=Q=""';?C621);/WXK!WY>6.C-KV^G R'S9Y1!
M4.:RBUSZB5P&NJ>I6'-DIR$)6^)==?RE(GX@[[NZ>?WEYF]U)?#/;=I'^N@"
MZ9H^;+F>NW/"'<1YNM(1;ZO";#>O+/_W)*S]T>8+),R"A-F0, <2YA:P<0[+5MK' M&
<;FT-0T;3IX/#2J.= 83X:3PX$U=X:5.T.E.[D:N3,D1-:61>D*S0F+:'A1 M3(K\ GTB7+
H$')$,?QS&@G>YI,R5U>?(&$6),R&A#F0,+> C0Y],J5/1S*U MC-
(G8[/=I%%ETDAM4F;+NUM92H79O"/K2^[G%=H-8WZZ(K+F$^CA&1V.F_O/
M^>F;G<^D4%?=(&$6),R&A#F0,'?4$,G4 MS-'QW 64LF;EN+)RW&%M+*:O4K/*LE:WE-
BN;D'"+$B8#0ES(&'NN+DT&D9S M86P..[$BFI4QY@^OB%_\>$LNT ?YK30?
T+H(*O%=S8&$69 PVSRS='&: V7I M,M(; UW(R_. 8#6%)I5"DY\LJM"""'!$7:Z*LTRVR)
(R]7E\ITW95"Q)F0<)L
M2)@#"7,A8=ZDI5@;Z[A]^KJLW+M4NG>WCL@2W6ZY/,\Y^KA<1@%AZ)]|DCP0
M]F^;54I@5ZL@818DS(:$.9 P%Q+F <%]\F%MWU'3?OK[I'KY5"?HJB,HS2II
MA_^RP_&D4?':H%D=4)H+2O.@:'7=#AJX^/4OG;ST[0+-F9SL,M*UUKU4@([
MZP5)LTK:Y'!%Z(^/W8),Z8#27%":!T6KNZ7OW=+_WR\":GYGU2!I5DD[K,KE M--
:HR6W0K XHS06E>5"TNFW['CY^K8D?/?I"3EZQS)%_+U"5;&I89[5 6_>@ M-

*!N4YH#27%":!T6K"[A_$(!__DG *_-=LZ|\-/7FI'+7,A!C#>.A=K386>IK*
M[NP2:.,>E.:"TCPH6MVE_:, ?,:S@&YEV:A1^NC]T;$WS4%&?WBL#&CO'93F M@-)
<4)H'1:LKL^_3XRZ-^BX/L7%+IQAG3T:;\TYSI%%4/=JQ1!-=E": TIS*
*M06D>%*TNT;YUC]6]^_,DRM8QT6I2:T^[U:2VIC9N-0FTZ0Y*^*7>/+W: W_ML%:4<*
MQ60I4VE]4]:9K-A471P(NLFWZ#Y0(6B2OUP3/R0L&R#?7U(J7@ZR!-76]ME_M4$L#!!0
*(-.";5E58O+I"@, #H+ 9 >&PO=V]R:W-H965TV ^V_G^VD*1L053SQ K;C>^XYYSKQ':T9?*
Q Y@$1/94'%V,JEK,YM6Z0Y ME%BK)@O,123?G2%A4'G)F@LK]QXGL$A-J)2.S-N')B-
6R(!0F'(FZ M+#%_OH""K<>6:
*[TL3,DREWK!3D857L(,Y'TUX6IF=R@9*8$*PBCBL!A;7]SS M"]?3*
6;'3P)KL3%&6LJCRVHU>74 M@9OC%_2O1KP2,|
<"+EGQBV0R'UNQA3)8X+J04[;^!JV@4..EK!#F%ZW;O8Z% MTEI(5K;!BD%):/./GUHC-
*@(\=T^ UP88(^PFD6%YA25.1IRM$=>[%9H>&*DF*
M6I$C5%=E)KEZ2E2<3+XS"K;X"$B1(WG!:"Z4HOP!#PE A!;("BK@CT#($PS1!D]
[1:4R^D# M8I4^)P=D!>PG1H;,J$AH_*HF].'+]:&2O=JCP.Q5^KXJ9X7#765-*
*WG_SHVZ(1T5WF+^9(H^ (6*M Y&R@$WC1JS42RRC1'L-*
ZOF"J0:IG>A^JVN7D[]02P,$% @ TX)M66S:2)"G P MCPT !D
!X;"]W;W)K&ULK5=;;]LZ#/XK@C<, M+;#5=[OID@#-I4D.MB%83K=GU59B8;;D24JR_?
M#7^HEGFKX;'E))/K[*)(B M)6IXY.;3 A1Z$>6,CDR$J7R.].444(R+&]X3AA\V7*18053L3-*
*E+@B.2U*6 MFHYE!6:&*3/&PU*V%N,AWZN4,K(62.ZS#(N?$Y+RX\BPC6?!9[I+5"$PQ\,<*
M[\B&J,=\+6!F-EIBFA$F*6=(D.W(N+?O5GZ!+P%?*#G*DS$J/'GB_%LQ6<4C MPRH,
(BF)5$!P]^!3$F:%HK C.^U3J-9LB">CI^U/Y2^@R]/6)(I3[_26"4C MX]9*
,=GB?:H^\^.2U/Z4!D8\E>4O.M98RT#17BJ>U62P(.L^L<_ZCB<$$"/ MGN#4!*=-*
\%X@N#7![4OP:H+7E^#7!+\O(:@)05]"6!/"OE&ZK0FW?5<8U(1!
*MF0[5_I6;/\,*CX>"'Y$HT*"M&)095+)ASRDK<%=USTD3.52#1G,8DU_&4W?]#!-*
R&T37R=Y_A.G$Z%&Y+? M(-=ZBQS+\33V3+OI_^Q9)WW63?^(!=#M%^GS_L:[&OI#?^-
U]$5_XW7TY=]% M?O7'OI\E@ML4FEOJ\UXJ-"B.%
(I#E],5,RB9Q>5T&+\+G!",/IQFB@;EV_;@
M'#73HGS['#77H#PO;$>]*CP'+70K>B$SCEJJ4'9@>^UG%SI8)[C6 WL+/A>*
M$WRO,_A?RSN/Q @?B(K_/G@@$B+?#-.VTL&AI[F2.(S(RH&>11!R(,7[SR@ZL]IJR
MOZ2R^>\NN.' &T#86_EPR547EU2VU+@P""S/#EOEL=(+=@NUQGH,\QO,LSO
MS+#);WG#ZH)'.=R&LKH&(95BGJ98G$BU654M%IZ6@75C^ZV4ZC3I_Z;4)97-
*M]?:W\^F22RXNJ6RIM=]KV;_2HX)6)IDGW5E&Q*YL[24J.ZCJ_FBDS>OAOFR:*
M6_*)?;>P-?(EO#:JQ\$O]=53!:[0'642I60+2UDW(5@LJO:_FBB>E[WA$U?0 M:9;#!%Y,1!0
^+[ET!_6DV!Y@TV_@]02P,$% @ TX)M625@0Q65 P MZ@\ !D*
!X;"]W;W)K&ULM9=M;Z,X$,>_BL5) MJU:Z+
*<\IZ261VL!J5[IVJT:]OEC="QNV:S"2U%2G*X9HB768;9\P6D=#,U;.-EXH:LUD)- MF+-*
*)@5>P '%;7#,Y,AM*0C+(.:$Y8K"<&N?V661;RD%;_$-@P[>ND0KEGM(' M-?B63 U+*
[0A2B(5"8/GW"'-(4T62^_A90XUF3>6X??U"_Z#E\'<8PYSFMZ1 M1*RG1F"@!);X3,4-*
W7R%.B!?\6:G=G!V';PW'-S:P3UT!:]V\ Y=P:\==.AF%;M.7(@%GDT8W2"FK"5-*
M7>CL:V^9+Y(KH2P$DW>)]!.S*RH V3;ZC*ZD*O^FG*-K8&BQQ@SDY$(,RE3 M0'2)SG-*
!$I*6JK*5 4?14YR6"21HR6B&YC0K2H&U J1#!_$H!(%)RH\EFVO$ MQ!0R#+49,ZZW?
%%MV7ECRRZZI+E8R\5SN7?]CO/^[Q-V7ZFAPZ+SF\<'J!*
*M"RA.D&O]B1S+\3KV,S_T*Y_=6C_[WZ]UDN(V@7,WSWN!%69'29P"$\P1= MT?PSO$PL!*
(T?T/="R8.C'Y>0W0/[MZO^O2NH5^<9+W ,4T.^&SFP1S!FG_ZP M1]9?7]8NPE
*MO%>,0\+"(6'10+!6&49-&48?(<;1*U%8.S)\;>%8OF7MF(5[0=%>4"ONTR;N*
MT]ZX0U@"8_+TK ['VYR(_A=C+^Z]6AP2%@X)BP:"M6H2-#4)/D+P6N!!%X0*
MC'8$V6%FNV/+WQ'D8;1H+ZV5@7&3@7%O!FZ "T9BH72IC^Q*ET^4Y)"P<$A8-
!&L5Q[9^?;!;'R'0FKHM%G^\>Q[/.ZP\)QCOR/,@5K2/
M5<5O;O4N&;"5;AHYBFF9B^]KLYEM&M-SW8[MS%_89W.[8SY4C:SNE7[AJR[X
*M$K,5D9^B*2SE4M;)J=PJJQK+:B!HH3NG>RID'Z8OU[(9!Z8,Y/TEE=U3/5 + M-.W]*
[#]02P,$% @ TX)M6;<4^"AA!@ 1#D !D !X;"]W;W)K&ULS9MK;^(X%
*(;_BL5*JX[4EM@A7&8I4]?Q[/9#9U"9 MSFJUV@\NF!)-$K.V*>UJ?*
*_PZEQ(,U)#9@SK]4)*0\QS'+R>7UTY_*>0W->-< MHZ)Y[6;"*
MHK0QZ.?;AG+0%PL=1RD?2]062<+D\P<>B^5% S=>-MQ&#S.=;6@.^G/VP$=<
MW\V"TJPU5Y1)E/!412)%DD\O&I?X/?5)%I#O\37B2[6VC+)#N1?B6[9R/;EH
M>%F+>,S'.D,P_'(KW@<9R33CK]+:&.5,PM<7WZA?\P/WAS,/5/\2L2_1Q,]
MNVAT&VC"IVP1ZUNQ_(V7!Q1DO+&(5?X?+;3IKRC-?B@C+1)RS:)8H2_\22]8_,
[LK+=5;^I31,R4'-6.'O'Y.?*]/+RU(SS=Y%J!.T:\F0BL4I6C(*

M920FV1:A%#HQ6PJIWNW2RMG
*[!3U7LW9F%\TS#E([62F0.2D0S%*EO5*E[53%=+R6T5AGM9(I4];**
MR>WH3KUSEHR36[?;(6$A)(P"P2QQ.BMQ.F]3,LZT=;7K;)5,T,/^1L% 9J1
M,$N3[DJ3KE.3+S-N[OYP#WU.TNA^H="UZ>\T>])!PYBESI)QDNMV.R0LA(11
*M()@E3V\E3^_8=]2?%IF 2$Q?*NURH6="1O^87??4E;-M=06&A(6]K2+M>/F? M7:*
*<4**FE'?:J!U'O1W\>PKH8E;;W?_3;I>&3SB0@T+86BV3*N^0GX;:Y;*
M[KRUQ<';XGA>X/=ZF^) IJ50-%N@6U M0D!I(2B-0M%LJ2L[!+O]$(!ZS3_05_,
('Z4/!Y2LNT$XK]B=*D+:'2$HC4+1
M;!4K^P2[_9,C%RQ[VE^PH$8,*"T$I5$HFBUU9<9@MQOS!@7K;E#+<8F%]%M"
M4!J%HMDR5OX-AC%P3/F9(OV>.UY0FP>4%H+2!3-5K*R>O#1O9Y:=[SNU@2.*
*M:@2U4!I%(IF]UFY/,3M\AROTD#-FY*V9V07 M-">%HMG*5*8,*
<7L@19T17#ZLY[<9U^ED,>;EXL%CO>Y$M:4 =6! :12*9DM6 M.3#$[<"
*[8BONW&U909U7T!IM*2MGPWPQA"RK6!EK)"C&RO_>Q8LZ(P8LFM**
*MS/9@>PB:E4+1;!4K7X6X?97C7=1_9229@WZ!IU@6QM0IP2*9FM3.25DCU.R*
*M9EZAH:D+>< %#'0R"R@M!*51*)H]@[RR0/P??M*+NX6UIYMO3WIIX:"%-TL, M-*
*"N%HMDJ5A:(?Y %0E XNMM?7&Y8[0X'-35 :12*9LM2F1K^&YD:[KRU%=PV M-7#']S>?*
M4"34BA:(4US[06T[/W"&R8?HE2AF$\-WCOOF(.3Q2M[Q8H6_R=
MM'NAM4CRQ1EG$RZS'A&QXFN1P1Q';9!FFOV:0DMU4T967@?MD'7,Y MH'J3 J]A ?
RQN.BIS8J49)!SA*2(PJKJ7*CCP-7XDO UP1V;*^-9"1+0IYD MYW,T532Y(4@AY%*
(!B[\MS"%-I9#8QL]:4VF6E,3]]HOZAS)V$I/R>
*[#Y!'8\M]4*2LO(7[6JLIJ!PPSC):K+809;DU3]^KO.P M1Q*
*ZW02C)AAM@O4*P:P)YJDK6#7!.G4%NR:4H:M5[&7B?,RQ-Z%DAZA$"S79 M*+-?*
LD6^DESZ9,&IFTCWM?" >D&^@2+6),X5(F/4)SD@DC,ER>9<]4\"S; M@,Y]X#A)V84
/RY\='YV@N=S:J=&:_LS$2W
M).0=3!]_OYHQZ^*K+4I,IX2=7,Z!5<0'&%3.T=,C3#ZMC/_'2ZV17.
M_ZT>_//J!\DP&]^8I9[UBMX#X3A%;,\8X9XQNDZ[TG-/7E[;3W;L2?J=C^#*
MQQC+:&'\8XQNC9Q#4- !,@RW 1V$;#4A6[TAWP,#3,,8"3\C'[;BCBW$C,;4&_9;7Z,
*M,9R6;?UCC*ZUO1T<@]Q1^Y)4]VJ+#.BZ+.J8B&.3\^JY:$:;NO&F+)=:XS-] M/-*
*<[QGU19U9EX1_YJDB]Q72=Y REL!)+:5>N^'IH5?A5'4Z*LK)9$B[JI+(9 MBUH9J*
2(^141U4W=D0LTU;?W&U!+ P04 " #3@FU9=@'A9#0$!K$P M&0 'AL+W=OW7.
MT95]T'!-V3-? CTDJ4Y'UD+(8IKV^;Q C+,>[2 7#Z9499A(6_9W.8% YSH MH"RU/<<)
[0R3W!H/==\#&P_I4J0DAP>&^#++,'N=0$K7(\NU-AU?R'PA5(<]
M'A9X#E,0C\4#DW=VG24A&>2Y/]DR8OR3QA#K,KA%3HV4VU=#:Z&C)AN1J&:>"
MR:=$QHGQ9RH N1ZZ1-,%9G"I)$G0+R4[=\7=,EQGO"A+21:-:<=5\@F)3+O +(K
M=$]SL>#H8YY LAUO2Y8U56]#=>(9$TZAZ"'?N4">XP7H<7J'SL^VL)>7/4AO
MS8GO():)79W8WR0V /;KM?%UWN! W@E.<1Z#U!+/YPSF6"X5R04C"M5D99U?
OCVM>X!A&EGQ!<& KL,8__N"& MSD\&;D'-
+3!R^_@"+";RUBXVZB_E,K/TE>1S1'6E<21?.US(ZE%]Y[:RI$?*
*M).F#2S4II^VWF%]&3M1W.MR-Z([DW]^Y]]_*?:U?,W+'X14P^=I$4#U#!2.Q M_*
56Y&=$=RCVKNT1NYG[P.HITZ\'N^V]'"B/9(+0:U%@.C%N7G9Z(_
M/P_X53H%@6X8P_D<5/MB_GYZQZR)V!_[R-IG.'M^$LQWBG9EAA7M1A7_\FF MN-
K9%/X@84?M%M#-K=HSR[_L,R"G>&+N> M\=*/0F_GSX,9X+$"-*[1-*
=O&E@"GKXA=X^CUHJY?, /^7D'LUG%&!FRN3WDX
MBNDR%^7)1MU;GR3=Z/,3NQE>'D/=8S:7GTF4PDR&.KU(+BXK3W;&T$+?3CR*
M1(6@F6XN ,MR4@/D\QFE8G.C)JC/U\9? 5!+ P04 " #3@FU9U"/6%(\% M !](0 &0
'AL+W=O-4IBAPR'GI.$43J8CJMSUV(ZSE8RCE)^+5"Q2I)0O%SP.'N: M#/!@?>
(FNE_*\H0S'>?A/;_E\O?\6J@CIXDRCQ>%E&6(L$7D\$Y/KM@?MF@*
MNN./B#\5K>^H[,I=ECV4![_,)X-AF1&/^4R6(4+U\<@O>1R7D50>_^B@@T:S M;-
*C^OH[^4]5YU9F[L."76?PMFLOE9! ,T)POPE4L;[*GG[GND%O&FV5Q4?U%*
*M3_6]/AV@V:J06:(;JPR2**T_PV<]$*T&E%@:$-V 5'G70E66GT,93LT*B MO%M%**
*[]47:U:J^2BM*S*K13J:J3:R>EOF>0($_0)W2Y#P3^5/9RCRRQ192_" M:N#4)9G-*
'M#7O#PLT->5+&28SJ/T'GWXS&48Q<7'L2-5-F5,9Z:5+VIE8E$>
*MH:LLE.:@HNU3H#T"! M-H-%*P5F4ZCC;0Q E.KX']&_G4IUZG5@MPIBLU"PAH]>5,,"*
M$934!5/391Z^0 /J-NF[^Z7_Y9F+651P="VB&:]&=Y[%<2F?SMM: M?
*%C0U<7WU\7W=M4^:+H2@)'_5^J;,%7=P>BO*Y[<SOAD MH*
!5\$<@W5&3[@A,]WH]_=;#RE%>)GZ"%-C4-5'E__H)6ZMY
*MK0EBF:UX:*Q\>&"*JSP_($4MUUY4^'0TLJ39(@Y^*Q?5D3>6U9 R9EE5F)B< MR#OXZ*
Z10\EMEY+"E,[%A,V:,(PF_JS4BT4;)3=LXRP 16&*7*,F>K0[;+[M#+NVF6CH@_?*

*$S_%NND/QD"E@<(5A7G4Z*@$=%8YXH*5B0S,,TZ5O4]5R;5X[W*
*MT1V*GO913_LH5'R#* (CJM,_*>B?<,0#_9,8@!$8)WW[IY9K^Z=MQAHJ$9A* M??*
NGEMM\U+/Y)S$H(C'"*CO!/'7G#/QD.1K:A,^@A,'IZLD]89+V4<+V4=C_@ M$<,D
*C.I1S<==13=M?")&CY1&!W'N*D.O?$L0BBV/8M0PR"Z)X..=],=BDQ/ M*
=J\X0EV30)JB$5A8G6Z@-=%8YXH*O2UEL^&"Y]NZJ6:[NJ!;G4L(K"K.K;*
M5;5<>X$QJZM2 R@* ^J8-Z;NUOKR?!\'EG_HJ0$2A8'4CZON$%DOJ=$>2\JP
MBN[Y%O!@7]5"FV5W+2^EJ0$7A9ERE\&^]7=T(CN2:,>?!56/& 2,,,N!K.K MTU==T%?*
*AB ?Z*C-@8S!F^O95+=?V5U[+NS1F ,7> M;!^*;6]$T< ?$MO*
*M3:BWF4G"A99[T8$K]^*8H95[+TVH]CV;I1W2FUE-^!B M;[_<=J1V**
*[BN>_9W6CGC"Q7VU[U^@6;9*9;TYWIQM M?*
EMP7N^HF]OK'R9(^4J,>\X5J.CSUU1B>J^_/I!97NVOWV529DGU=KZ(LOD^J 4:'YQ,?*
*T/4$L#!!0 (-.";5E#0V,K"P, (<0 - M >&POWW./[XX8==;H#:?7*TJUMZZX*
M:%)_I77],0B:Y8I6I#F7-14&:2JB#93509-K2C)&W"J># >C>*@(DSX\YEH MJ\M*-*
*]Y2MD*G?C28/'O[DJ=^&+_W/4N7R9RF_NWIVY^MU!=O/'L_>7=R,KH] MNSBVGW;*
F1\X22=/(#T?X;P&PZCC)U$_PMP1!WURYK-"BL,<@<%$)A7U[@A/ M_8QPME ,O
I2,;ZQYC$8EI)+Y6E3'",E!$MS;^'0SJ!N/4_%A%1=;!O!?B_Z MY4? =@8"&>>#P+%O#?
*-93;2F2ER:2;>X,SZ O'Y\LZF-PE*133B>^#N'[F:" M+*3*J1K"A/[6-)]Q6H 7\&IKZ M1W'*
*O2[V:CJ"BHIA: 3U0TMC)\"_SV:Y]VB39]%Z-;N3^G-K=B.Z.;0*O5*T*
*M8.MNOBZ&^!A[B+.3NN:;3YR5HJ)V[T\..)^1K9^WDHK=FVC0*4MCH,KW]JC2*
M;+EO^:5(?4/7>MM-ZP+7/'Z%FO]NGDLJJ")\7[1I_9>:LK9)AU14DHE^U&W^%[87Q
M\&)@8C&1TS7-LWZ]RD4W],S 1.TO<#A&+KO+C6 ^%G,C@&%Q, 68C_7"XOQ/
M^YFB^[$8IFWJ1:HSQ3UL5XN).L^6!RW3V(N]TZ3)(KB&,MHECD59%C>XAC^*
MW&R8-O# XD"D/\LU7FV\0Q[O ZRFCW4(ME.\$[&=XKD&Q)TW\$@2=[6Q.."!
*M50'K'8COC@,]Y?:)(J@JI@U[@G$D23 $>M'=HW&,9">&C[L^V%,214GB1@!S M*X@B#*
(&G$4/SJ-@>TX%NW\]S'\#4$L#!!0 (-.";5F7 MBKL

-8?20$3;8T.P6BP^0"X99K>]9!:GS6:F.O"6F5_5D4NHV2G=,@N'
*M>C\S1\U9;0ZV[O4L/%"65U8H"86NX*O@+^9'O3LD MS*(K6B$?5UE_G_#,]*
*(**5KQG=>K;)X1Z?\31K7;B8JO5=6U7-H^CIHW#E":@SB:*
MC$C6\E5V.H5(H;X24*%O:@\^'N0G M)6LN#:\)_#.J$35PU.0C:YBL.
*D@*0)))X3\FP:0!0)93 *Y<3AP:0!9(1#E MA)!1)!<(Y&)*R"* 7"*0RRDARP#R'($\'Q?R#E(XR*
N.9'982-8H=Y)1]9+![L',!@1G:$0?+J!\SG?SIQ
*M=%>&F)A9\I'5XC$O7!=7E>X@%=X*YJ>&;UY#3"SYR&;QC)?_^ 4""=5R3VXY*
M,]$[B#DE'UDJ?;Z>NZ1S8)H?5%-S;7[QG6U?0TI,*GD2JSBMW,$=;I4QY){K M'CEDQ
*R3IU!,3D^1/-NR7M4MM&E8-&@PQ^0C2^9&&@%=3!XU]W;>*TUDWLW*
*M7XSR#\4,0T*Q33'%T!2*&11AM))!ES(I-#.4S:,9 M.,6D0U-*
(9R";DW>/(28F'9I".C])Z(#X9FY!,>_0%-X9S.O1NXGIAR;1S\\3
M^YM.Q_Q#D_AG(+?'0PA3$)URE1-
C8@JB=8Y0WDSWES!+%1,N#R',0D4*"PUA1IU>8A8J*
M4UAH<.H1=GJ)6:A,8:%!S'!SNL0L5:PT"#F(L3$+%2FL- @YC+$1#_M> O- M3A\>:*
[X3DM=W< L#Y15KJGM-W$^_%5HNW,[$KFN:3U#V1=XJ5I^^8YZ^P7[X M%U!+ P04 "
#3@FU91QQ@N:0! ";&@ &@ 'AL+U]R96QS+W=O^SB@6L]>9O=6U"?^96&^WAW7X
MK-??IW!.?
*PQV/W5[C/L04M%;E>TNI'GA+M7S='3W@_1ODXO>BN!WHIZ*X'>VOG8)M!;46\ET%M1;I*
M)=!;46\ET-M0;R/0VU!O(]#;4&\CT-LZFR4$>AOJ;01Z&^IM!'H;ZFT$>AOJ
M;01Z&^IM!'H;ZFT$>GO4VQ/H[5%O3Z"W1[T]@=X>]?8$>OO.9O<[]8[I6H7X M['FL\?
GOI#K=[@W/Q]^7CY.=M_>.LX-_48M?4$L#!!0 (-.";5DNTOC MK@$,H: 3 6T-O;G1E;G1?
5'EP97-=+GAM;,V9S6[",!"$7P7EBHBQ MG=(? 9>VUY9#7\!--
B0BB2W;4'C[.N%':D6C(BIU+K$2[\Z,O=)WR?1M9\@- MMG75N%E4>&\>&'-
*I0;5RL3;4A)U7T<$A#IU= MC2M*XX:A(&)G'=J=GPT.?:\;LK;,:+!0UK^H.E2Q;<6H?*
K_=!VUM5W_]=Z5= MXUJ5S=&?=;^PYI]02P$"% ,4 " #3@FU9!T%-8H$ "Q $ M @ $
9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 (-.";5FV M)BA)[0 "L" 1 " :\ !D;V-0&UL4$L! A0#%
@ TX)M60Y,J"'2!0 M)1X !@ ("!# @ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
TX)M60M52,3D! <1, !@ M ("!_18 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @
TX)M60-QM_Y;!@ ?!L !@ ("!N2L 'AL+W=O0,- "<(& @($]-@ >&PO M=V]R:W-
H965T&UL4$L! A0#% @ TX)M6=&9O7U5"0 M/Q@ !D ("!=D, 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ TX)M68&FE1$& P &PO=V]R:W-H M965T&UL4$L! M A0#% @
TX)M689J"@9# P 40< !D ("!1%T 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @

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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w) {if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref) {e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display) {}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring

XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 166 178 1 false 42 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.diamedica.com/20240930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement -*

Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) Sheet http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Business Sheet http://www.diamedica.com/20240930/role/statement-note-1-business Note 1 - Business Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Risks and Uncertainties Sheet http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties Note 2 - Risks and Uncertainties Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://www.diamedica.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies- Note 3 - Summary of Significant Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Marketable Securities Sheet http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities Note 4 - Marketable Securities Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Amounts Receivable Sheet http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable Note 5 - Amounts Receivable Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Deposits Sheet http://www.diamedica.com/20240930/role/statement-note-6-deposits Note 6 - Deposits Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Property and Equipment Sheet http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment Note 7 - Property and Equipment Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Accrued Liabilities Sheet http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities- Note 8 - Accrued Liabilities Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Operating Lease Sheet http://www.diamedica.com/20240930/role/statement-note-9-operating-lease Note 9 - Operating Lease Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Shareholders' Equity Sheet http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity Note 10 - Shareholders' Equity Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Net Loss Per Share Sheet http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share Note 11 - Net Loss Per Share Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Share-based Compensation Sheet http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation Note 12 - Share-based Compensation Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 995464 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.diamedica.com/20240930/role/statement-significant-

accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.diamedica.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies- 21 false false R22.htm 995465 - Disclosure - Note 4 - Marketable Securities (Tables) Sheet http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-tables Note 4 - Marketable Securities (Tables) Tables http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities 22 false false R23.htm 995466 - Disclosure - Note 7 - Property and Equipment (Tables) Sheet http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-tables Note 7 - Property and Equipment (Tables) Tables http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment 23 false false R24.htm 995467 - Disclosure - Note 8 - Accrued Liabilities (Tables) Sheet http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-tables Note 8 - Accrued Liabilities (Tables) Tables http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities- 24 false false R25.htm 995468 - Disclosure - Note 9 - Operating Lease (Tables) Sheet http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-tables Note 9 - Operating Lease (Tables) Tables http://www.diamedica.com/20240930/role/statement-note-9-operating-lease 25 false false R26.htm 995469 - Disclosure - Note 10 - Shareholders' Equity (Tables) Sheet http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-tables Note 10 - Shareholders' Equity (Tables) Tables http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity 26 false false R27.htm 995470 - Disclosure - Note 11 - Net Loss Per Share (Tables) Sheet http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-tables Note 11 - Net Loss Per Share (Tables) Tables http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share 27 false false R28.htm 995471 - Disclosure - Note 12 - Share-based Compensation (Tables) Sheet http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables Note 12 - Share-based Compensation (Tables) Tables http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation 28 false false R29.htm 995472 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) Sheet http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual Note 2 - Risks and Uncertainties (Details Textual) Details http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties 29 false false R30.htm 995473 - Disclosure - Note 4 - Marketable Securities (Details Textual) Sheet http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual Note 4 - Marketable Securities (Details Textual) Details http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-tables 30 false false R31.htm 995474 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) Details 31 false false R32.htm 995475 - Disclosure - Note 5 - Amounts Receivable (Details Textual) Sheet http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable-details-textual Note 5 - Amounts Receivable (Details Textual) Details http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable 32 false false R33.htm 995476 - Disclosure - Note 7 - Property and Equipment - Property and Equipment (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details Note 7 - Property and Equipment - Property and Equipment (Details) Details 33 false false R34.htm 995477 - Disclosure - Note 8 - Accrued Liabilities - Accrued Liabilities (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details Note 8 - Accrued Liabilities - Accrued Liabilities (Details) Details 34 false false R35.htm 995478 - Disclosure - Note 9 - Operating Lease (Details Textual) Sheet http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-details-textual Note 9 - Operating Lease (Details Textual) Details http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-tables 35

false false R36.htm 995479 - Disclosure - Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details) Details 36 false false R37.htm 995480 - Disclosure - Note 10 - Shareholders' Equity (Details Textual) Sheet http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual Note 10 - Shareholders' Equity (Details Textual) Details http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-tables 37 false false R38.htm 995481 - Disclosure - Note 10 - Shareholders' Equity - Shares Reserved (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details Note 10 - Shareholders' Equity - Shares Reserved (Details) Details 38 false false R39.htm 995482 - Disclosure - Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Details 39 false false R40.htm 995483 - Disclosure - Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) Details 40 false false R41.htm 995484 - Disclosure - Note 12 - Share-based Compensation (Details Textual) Sheet http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual Note 12 - Share-based Compensation (Details Textual) Details http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables 41 false false R42.htm 995485 - Disclosure - Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) Details 42 false false R43.htm 995486 - Disclosure - Note 12 - Share-based Compensation - Stock Option Activity (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details Note 12 - Share-based Compensation - Stock Option Activity (Details) Details 43 false false R44.htm 995487 - Disclosure - Note 12 - Share-based Compensation - Stock Options Outstanding (Details) Sheet http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details Note 12 - Share-based Compensation - Stock Options Outstanding (Details) Details 44 false false All Reports Book All Reports dmac-20240930.xsd dmac-20240930_cal.xml dmac-20240930_def.xml dmac-20240930_lab.xml dmac-20240930_pre.xml dmtp20240930_10q.htm image1.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dmtp20240930_10q.htm": { "nsprefix": "dmac", "nsuri": "http://www.diamedica.com/20240930", "dts": { "schema": { "local": ["dmac-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-

roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["dmac-20240930_cal.xml"] }, "definitionLink": { "local": ["dmac-20240930_def.xml"] }, "labelLink": { "local": ["dmac-20240930_lab.xml"] }, "presentationLink": { "local": ["dmac-20240930_pre.xml"] }, "inline": { "local": ["dmtp20240930_10q.htm"] } }, "keyStandard": 166, "keyCustom": 12, "axisStandard": 14, "axisCustom": 0, "memberStandard": 20, "memberCustom": 17, "hidden": { "total": 20, "http://fasb.org/us-gaap/2024": 11, "http://xbrl.sec.gov/dei/2024": 5, "http://xbrl.sec.gov/ecd/2024": 4 }, "contextCount": 166, "entityCount": 1, "segmentCount": 42, "elementCount": 291, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 521, "http://xbrl.sec.gov/dei/2024": 28, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.diamedica.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and

Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "unique": true } }, "R6": { "role": "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "longName": "005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "unique": true } }, "R8": { "role": "http://www.diamedica.com/20240930/role/statement-note-1-business", "longName": "007 - Disclosure - Note 1 - Business", "shortName": "Note 1 - Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-

gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties", "longName": "008 - Disclosure - Note 2 - Risks and Uncertainties", "shortName": "Note 2 - Risks and Uncertainties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dmac:RisksAndUncertaintiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dmac:RisksAndUncertaintiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.diamedica.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-", "longName": "009 - Disclosure - Note 3 - Summary of Significant Accounting Policies", "shortName": "Note 3 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "longName": "010 - Disclosure - Note 4 - Marketable Securities", "shortName": "Note 4 - Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable", "longName": "011 - Disclosure - Note 5 - Amounts Receivable", "shortName": "Note 5 - Amounts Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.diamedica.com/20240930/role/statement-note-6-deposits", "longName": "012 - Disclosure - Note 6 - Deposits", "shortName": "Note 6 - Deposits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dmac:DepositAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dmac:DepositAssetsTextBlock",

"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "longName": "013 - Disclosure - Note 7 - Property and Equipment", "shortName": "Note 7 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-", "longName": "014 - Disclosure - Note 8 - Accrued Liabilities", "shortName": "Note 8 - Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease", "longName": "015 - Disclosure - Note 9 - Operating Lease", "shortName": "Note 9 - Operating Lease", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "longName": "016 - Disclosure - Note 10 - Shareholders' Equity", "shortName": "Note 10 - Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "longName": "017 - Disclosure - Note 11 - Net Loss Per Share", "shortName": "Note 11 - Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",

"decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "longName": "018 - Disclosure - Note 12 - Share-based Compensation", "shortName": "Note 12 - Share-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995464 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-tables", "longName": "995465 - Disclosure - Note 4 - Marketable Securities (Tables)", "shortName": "Note 4 - Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-tables", "longName": "995466 - Disclosure - Note 7 - Property and Equipment (Tables)", "shortName": "Note 7 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables",

"order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-tables", "longName": "995467 - Disclosure - Note 8 - Accrued Liabilities (Tables)", "shortName": "Note 8 - Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-tables", "longName": "995468 - Disclosure - Note 9 - Operating Lease (Tables)", "shortName": "Note 9 - Operating Lease (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-tables", "longName": "995469 - Disclosure - Note 10 - Shareholders' Equity (Tables)", "shortName": "Note 10 - Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dmac:CommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dmac:CommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-tables", "longName": "995470 - Disclosure - Note 11 - Net Loss Per Share (Tables)", "shortName": "Note 11 - Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null,

"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables", "longName": "995471 - Disclosure - Note 12 - Share-based Compensation (Tables)", "shortName": "Note 12 - Share-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeri "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeri "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual", "longName": "995472 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual)", "shortName": "Note 2 - Risks and Uncertainties (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual", "longName": "995473 - Disclosure - Note 4 - Marketable Securities (Details Textual)", "shortName": "Note 4 - Marketable Securities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "i_2024-09-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember", "name": "us-gaap:InterestReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember", "name": "us-gaap:InterestReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details", "longName": "995474 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)", "shortName": "Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "i_2024-09-30_FairValueByMeasurementFrequencyAxis-

FairValueMeasurementsRecurringMember", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable-details-textual", "longName": "995475 - Disclosure - Note 5 - Amounts Receivable (Details Textual)", "shortName": "Note 5 - Amounts Receivable (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details", "longName": "995476 - Disclosure - Note 7 - Property and Equipment - Property and Equipment (Details)", "shortName": "Note 7 - Property and Equipment - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details", "longName": "995477 - Disclosure - Note 8 - Accrued Liabilities - Accrued Liabilities (Details)", "shortName": "Note 8 - Accrued Liabilities - Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "dmac:AccruedClinicalStudyCostsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"],

"reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "dmac:AccruedClinicalStudyCostsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-details-textual", "longName": "995478 - Disclosure - Note 9 - Operating Lease (Details Textual)", "shortName": "Note 9 - Operating Lease (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details", "longName": "995479 - Disclosure - Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)", "shortName": "Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual", "longName": "995480 - Disclosure - Note 10 - Shareholders' Equity (Details Textual)", "shortName": "Note 10 - Shareholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dmac:StockIssuedDuringPeriodSharesRestrictedStockUnits", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "unique": true } }, "R38": { "role": "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "longName": "995481 - Disclosure - Note 10 - Shareholders' Equity - Shares Reserved (Details)", "shortName": "Note 10 - Shareholders' Equity - Shares Reserved (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "dmac:CommonStockReservedForFutureIssuanceTableTextBlock", "us-

gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_AwardTypeAxis-StockOptionsOutstandingMember", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "dmac:CommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "unique": true } }, "R39": { "role": "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details", "longName": "995482 - Disclosure - Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)", "shortName": "Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details", "longName": "995483 - Disclosure - Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)", "shortName": "Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveS EmployeeAndNonemployeeStockOptionsMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTe "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveS EmployeeAndNonemployeeStockOptionsMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTe "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual", "longName": "995484 - Disclosure - Note 12 - Share-based Compensation (Details Textual)", "shortName": "Note 12 - Share-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutsta "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember", "name": "us-

gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSha "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "unique": true } }, "R42": { "role": "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details", "longName": "995485 - Disclosure - Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)", "shortName": "Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeri "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeri "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details", "longName": "995486 - Disclosure - Note 12 - Share-based Compensation - Stock Option Activity (Details)", "shortName": "Note 12 - Share-based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutsta "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutsta "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details", "longName": "995487 - Disclosure - Note 12 - Share-based Compensation - Stock Options Outstanding (Details)", "shortName": "Note 12 - Share-based Compensation - Stock Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByl "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td",

"tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByE "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "dmtp20240930_10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual"], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": ["r40", "r46"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "totalLabel": "Total accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r31", "r32"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r30", "r32", "r35", "r575"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r30", "r487"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Amounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration

from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r537"] }, "dmac_AccruedClinicalStudyCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "AccruedClinicalStudyCostsCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "dmac_AccruedClinicalStudyCostsCurrent", "terseLabel": "Clinical trial costs", "documentation": "The amount of accrued clinical study costs classified as current." } } }, "auth_ref": [] }, "dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "AccruedInterestReceivableOnAvailableForSaleSecuritiesMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual"], "lang": { "en-us": { "role": { "label": "Accrued Interest Receivable On Available For Sale Securities [Member]", "documentation": "Represents information related to accrued interest receivable on available for sale securities." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r32"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedProfessionalFeesCurrent", "terseLabel": "Professional services fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r32"] }, "dmac_AccruedResearchAndProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "AccruedResearchAndProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "dmac_AccruedResearchAndProfessionalFeesCurrent", "terseLabel": "Research and development services", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or

*within the normal operating cycle if longer)." } } }, "auth_ref": [] },
"dmac_AccruedTaxesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.diamedica.com/20240930", "localname":
"AccruedTaxesAndOtherLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-
accrued-liabilities-details": { "parentTag": "us-
gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } },
"presentation": ["http://www.diamedica.com/20240930/role/statement-note-8-accrued-
liabilities-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label":
"dmac_AccruedTaxesAndOtherLiabilitiesCurrent", "terseLabel": "Other",
"documentation": "The amount of accrued taxes and other liabilities classified as
current." } } }, "auth_ref": [] }, "us-
gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
"crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-
note-7-property-and-equipment-property-and-equipment-details": { "parentTag": "us-
gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation":
["http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-
property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "us-
gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
"negatedLabel": "Less accumulated depreciation", "documentation": "Amount of
accumulated depreciation, depletion and amortization for physical assets used in the
normal conduct of business to produce goods and services." } } }, "auth_ref": ["r20",
"r89", "r370"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit",
"calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-
consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-
sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated other
comprehensive income (loss)", "documentation": "Amount, after tax, of accumulated
increase (decrease) in equity from transaction and other event and circumstance from
nonowner source." } } }, "auth_ref": ["r12", "r13", "r47", "r91", "r367", "r388", "r389"]
}, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.diamedica.com/20240930/role/statement-condensed-consolidated-
statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label":
"AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase
(decrease) in equity from transactions and other events and circumstances from non-
owner sources, attributable to the parent. Excludes net income (loss), and accumulated
changes in equity from transactions resulting from investments by owners and
distributions to owners." } } }, "auth_ref": ["r1", "r6", "r13", "r281", "r284", "r326",
"r384", "r385", "r520", "r521", "r522", "r525", "r526", "r527", "r528"] }, "us-
gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit",
"calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-
consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-
sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Paid-in capital",
"documentation": "Amount of excess of issue price over par or stated value of stock and
from other transaction involving stock or stockholder. Includes, but is not limited to,
additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [
"r41", "r487", "r603"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":*

"AdditionalPaidInCapitalMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r394", "r525", "r526", "r527", "r528", "r578", "r604"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Offering costs on previously issued common shares", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r7", "r64"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivit { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAl "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Total share-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r257", "r261"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r132"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiv { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSec "presentation": ["http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-

share-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r18"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r18"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r70", "r76", "r90", "r110", "r136", "r138", "r140", "r141", "r176", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r276", "r278", "r306", "r365", "r416", "r461", "r462", "r487", "r500", "r546", "r547", "r590"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r85", "r92", "r110", "r176", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r276", "r278", "r306", "r487", "r546", "r547", "r590"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r110", "r176", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r276", "r278", "r306", "r546", "r547", "r590"] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Non-current assets:" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-

fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "terseLabel": "Total marketable securities", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r147", "r184", "r292", "r360", "r476", "r479", "r538", "r582", "r583", "r584"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256"] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-1-business"], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r29", "r58", "r59"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r15", "r87", "r457"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r16"] }, "us-

gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "terseLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r519"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDispo { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalG "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDispo "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r15", "r54", "r107"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncrease { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecr "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncrease "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of

changes in interest rates." } } }, "auth_ref": ["r0", "r54"] }, "dmac_ChiefBusinessOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "ChiefBusinessOfficerMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Chief Business Officer [Member]", "documentation": "Represents Chief Business Officer." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dmac_CommercialPaperAndCorporateBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "CommercialPaperAndCorporateBondsMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Commercial Paper and Corporate Bonds [Member]", "documentation": "Commercial Papers are unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents and commercial bonds are debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Common shares issuable upon exercise of employee and non-employee stock options (in shares)", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r39"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r490", "r491", "r492", "r494", "r495", "r496", "r497", "r525", "r526", "r528", "r578", "r602", "r604"] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNoParValue", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common shares, par value (in dollars per share)", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": ["r39"] }, "dmac_CommonStockReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "CommonStockReservedForFutureIssuanceTableTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Common Stock Reserved for Future Issuance [Table Text Block]", "documentation": "A tabular disclosure of common stock reserved for future issuance." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "xbrltype": "authorizedUnlimitedItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorizedUnlimited", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common

Stock, Shares Authorized, Unlimited [Fixed List]", "documentation": "Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is \"Unlimited\"." } } }, "auth_ref": ["r39"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common shares, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r39"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r39", "r404", "r422", "r604", "r605"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Common shares, no par value; unlimited authorized; 42,766,497 and 37,958,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r39", "r366", "r487"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Net loss and comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r14", "r96", "r98", "r102", "r361", "r376", "r377"] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-

statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dmac_DeferredShareUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "DeferredShareUnitsMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Deferred Share Units [Member]", "documentation": "Related to deferred share units." } } }, "auth_ref": [] }, "dmac_DepositAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "DepositAssetsTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-6-deposits"], "lang": { "en-us": { "role": { "label": "Deposit Assets [Text Block]", "documentation": "Description of the companies deposits labeled as assets." } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Deposits", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r516"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r4", "r19"] }, "dmac_DirectorsAndOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "DirectorsAndOfficersMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Directors and Officers [Member]", "documentation": "Represents directors and officers." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for

share-based payment arrangement." } } }, "auth_ref": ["r229", "r230", "r258", "r259", "r260", "r472"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-1-business", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties", "http://www.diamedica.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable", "http://www.diamedica.com/20240930/role/statement-note-6-deposits", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-

information"], "lang": { "en-us": { "role": { "label": "dei_DocumentQuarterlyReport", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r504"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentTransitionReport", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r505"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details"], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r103", "r116", "r117", "r118", "r119", "r120", "r121", "r126", "r127", "r129", "r130", "r131", "r135", "r272", "r275", "r289", "r290", "r362", "r378", "r459"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r125", "r132", "r133", "r134"] }, "dmac_EmployeeAndNonemployeeStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "EmployeeAndNonemployeeStockOptionsMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Employee and Non-employee Stock Options [Member]", "documentation": "Related to employee and non-employee stock option awards." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "terseLabel": "Compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r32"] }, "us-

gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r502"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityCurrentReportingStatus", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for

the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] },
"dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals",
"http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.diamedica.com/20240930/role/statement-document-and-entity-information", "http://www.diamedica.com/20240930/role/statement-note-1-business",
"http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity",
"http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details",
"http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-tables", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-tables", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual",
"http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
"http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details",
"http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details",
"http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual",
"http://www.diamedica.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual",
"http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
"http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-tables", "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable", "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable-details-textual", "http://www.diamedica.com/20240930/role/statement-note-6-deposits", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details",
"http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-tables", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details",
"http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease",
"http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-details-textual", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-

maturity-of-operating-lease-liability-details", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-tables", "http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r502"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r502"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r508"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r502"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityShellCompany",

"terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r502"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r502"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r83", "r99", "r100", "r101", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r137", "r177", "r178", "r188", "r220", "r266", "r267", "r269", "r270", "r271", "r273", "r274", "r275", "r280", "r281", "r282", "r283", "r284", "r285", "r288", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r316", "r326", "r374", "r384", "r385", "r386", "r394", "r442"] }, "dmac_ExercisePriceRange1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "ExercisePriceRange1Member", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Exercise Price Range 1 [Member]", "documentation": "Related to the first exercise price range." } } }, "auth_ref": [] }, "dmac_ExercisePriceRange2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "ExercisePriceRange2Member", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Exercise Price Range 2 [Member]", "documentation": "Related to the second exercise price range." } } }, "auth_ref": [] }, "dmac_ExercisePriceRange3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "ExercisePriceRange3Member", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Exercise Price Range 3 [Member]", "documentation": "Related to the third exercise price range." } } }, "auth_ref": [] }, "dmac_ExercisePriceRange4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "ExercisePriceRange4Member", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Exercise Price Range 4 [Member]", "documentation": "Related to the fourth exercise price range." } } }, "auth_ref": [] }, "dmac_ExercisePriceRange5Member": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "ExercisePriceRange5Member", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Exercise Price Range 5 [Member]", "documentation": "Related to the fifth exercise price range." } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities",

"http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r205", "r222", "r223", "r224", "r225", "r226", "r227", "r291", "r293", "r294", "r295", "r296", "r299", "r300", "r302", "r330", "r331", "r332", "r465", "r466", "r468", "r469", "r470", "r476", "r479"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r292", "r293", "r294", "r296", "r476", "r583", "r586"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r205", "r222", "r227", "r293", "r300", "r330", "r468", "r469", "r470", "r476"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r205", "r222", "r227", "r293", "r294", "r300", "r331", "r465", "r466", "r468", "r469", "r470", "r476"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r205", "r222", "r223", "r224", "r225", "r226", "r227", "r293", "r294", "r295", "r296", "r300", "r332", "r465", "r466", "r468", "r469", "r470", "r476", "r479"] }, "dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of marketable securities measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1),

significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } } }, "auth_ref": ["r292", "r293", "r294", "r296", "r476", "r583", "r586"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r205", "r222", "r223", "r224", "r225", "r226", "r227", "r291", "r293", "r294", "r295", "r296", "r299", "r300", "r302", "r330", "r331", "r332", "r465", "r466", "r468", "r469", "r470", "r476", "r479"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r476", "r580", "r581", "r582", "r583", "r584", "r586"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Finance lease obligation", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r318"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityNoncurrent", "terseLabel": "Finance lease obligation", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r318"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeasePrincipalPayments", "negatedLabel": "Principal payments on finance lease obligation", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r319", "r322"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r179", "r180", "r181", "r182", "r183", "r185", "r186", "r187", "r206", "r218", "r286", "r303", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r375", "r464", "r476", "r477", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r488", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r540", "r541", "r542", "r543", "r579", "r582", "r583", "r584", "r585", "r586"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r50", "r426"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r50"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNon
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncont
"crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-

condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNon "totalLabel": "Loss before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r48", "r72", "r75", "r363", "r372", "r460", "r461", "r530", "r531", "r532", "r533", "r534"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r189", "r190", "r191", "r297", "r298", "r301", "r381", "r383", "r427", "r456", "r478", "r601"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r190", "r191", "r297", "r298", "r301", "r381", "r383", "r427", "r456", "r478", "r601"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r77", "r81", "r123", "r124", "r136", "r139", "r141", "r264", "r265", "r268", "r379", "r475"] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r17", "r56", "r523", "r576", "r577"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts

payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Amounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDepositOtherAssets", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInDepositOtherAssets", "negatedLabel": "Deposits", "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expenses and other assets", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r3"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri":

"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r506"] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestReceivable", "terseLabel": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": ["r518", "r606"] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestReceivableCurrent", "terseLabel": "Interest Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r518"] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium", "negatedLabel": "Amortization of discount on marketable securities", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": ["r51"] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosure "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities"], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r74", "r82", "r143", "r144", "r304", "r305", "r599"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r62", "r325"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.diamedica.com/20240930/role/statement-document-and-entity-information", "http://www.diamedica.com/20240930/role/statement-note-1-business", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-

details-textual", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-tables", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-tables", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual", "http://www.diamedica.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-tables", "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable", "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable-details-textual", "http://www.diamedica.com/20240930/role/statement-note-6-deposits", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-tables", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-details-textual", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-tables", "http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-tables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r588"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r324"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r324"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r324"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r324"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r324"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear":

{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r588"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less interest portion", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r324"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r315"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r45", "r71", "r369", "r487", "r524", "r544", "r587"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r33", "r86", "r110", "r176", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r277", "r278", "r279", "r306", "r487", "r546", "r590", "r591"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",

"weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total non-current liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r11", "r34", "r35", "r36", "r37", "r110", "r176", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r277", "r278", "r279", "r306", "r546", "r590", "r591"] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Non-current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable"], "lang": { "en-us": { "role": { "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": ["r313", "r535"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_LocalPhoneNumber", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r517"] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": ["http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": ["r28"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r192", "r193", "r194", "r195", "r228", "r262", "r296", "r358", "r380", "r382", "r390", "r396", "r397", "r447", "r448", "r449", "r450", "r451", "r454", "r455", "r463", "r467", "r471", "r479", "r480", "r484", "r485", "r489", "r548", "r592", "r593", "r594", "r595", "r596", "r597"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r192", "r193", "r194", "r195", "r228", "r262", "r296", "r358", "r380", "r382", "r390", "r396", "r397", "r447", "r448", "r449", "r450",

"r451", "r454", "r455", "r463", "r467", "r471", "r479", "r480", "r484", "r489", "r548", "r592", "r593", "r594", "r595", "r596", "r597"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r507"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncrease "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r106"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncrease "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r106"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncrease "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",

"http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities, Total", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r54", "r55", "r57"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 }, "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "terseLabel": "Net Income (Loss) Attributable to Parent, Total", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r49", "r57", "r73", "r84", "r95", "r97", "r101", "r110", "r114", "r116", "r117", "r118", "r119", "r120", "r123", "r124", "r128", "r176", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r272", "r275", "r290", "r306", "r373", "r424", "r440", "r441", "r498", "r546"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r507"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r507"] }, "dmac_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Non-cash lease expense", "documentation": "Amount of expense recognized over the period for lease expense, non-cash." } } }, "auth_ref": [] }, "dmac_NonemployeeStockOptionsMember": { "xbrltype": "domainItemType", "nsuri":

"http://www.diamedica.com/20240930", "localname": "NonemployeeStockOptionsMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Nonemployee Stock Options [Member]", "documentation": "Related to the nonemployee stock options." } } }, "auth_ref": [] }, "dmac_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "dmac_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNon "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r75", "r460", "r530", "r531", "r532", "r533", "r534"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseCost", "terseLabel": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r320", "r486"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"], "lang": { "en-us": { "role": { "label": "Present value of lease obligation", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r318"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Operating lease obligation", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r318"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": {

"label": "us-gaap_OperatingLeaseLiabilityNoncurrent", "terseLabel": "Operating lease obligation", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r318"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r317"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Other comprehensive gain (loss)" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuring { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPer "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Unrealized gain (loss) on marketable securities", "terseLabel": "Unrealized gain (loss) on marketable securities", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r93", "r94", "r175"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNon "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r52"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchase of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r539"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r53"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r519"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-

statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common shares, net of offering costs", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r2"] }, "dmac_ProceedsFromIssuanceOfCommonStockNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockNet", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "dmac_ProceedsFromIssuanceOfCommonStockNet", "terseLabel": "Proceeds from Issuance of Common Stock, Net", "documentation": "The cash inflow from the issuance of common stock, net of offering costs." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Maturities of marketable securities", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r104", "r105", "r539"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Proceed from the exercise of stock options", "terseLabel": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r2", "r10"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r5", "r325"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } },

"auth_ref": ["r61", "r78", "r79", "r80"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r62", "r88", "r371"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r5", "r325", "r364", "r371", "r487"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-tables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r5"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r62", "r325"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r192", "r193", "r194", "r195", "r221", "r228", "r253", "r254", "r255", "r262", "r296", "r333", "r342", "r358", "r380", "r382", "r390", "r396", "r397", "r447", "r448", "r449", "r450", "r451", "r454", "r455", "r463", "r467", "r471", "r479", "r480", "r484", "r485", "r489", "r492", "r545", "r548",

"r583", "r593", "r594", "r595", "r596", "r597"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r192", "r193", "r194", "r195", "r221", "r228", "r253", "r254", "r255", "r262", "r296", "r333", "r342", "r358", "r380", "r382", "r390", "r396", "r397", "r447", "r448", "r449", "r450", "r451", "r454", "r455", "r463", "r467", "r471", "r479", "r480", "r484", "r485", "r489", "r492", "r545", "r548", "r583", "r593", "r594", "r595", "r596", "r597"] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual"], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": ["r40", "r46"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r263", "r456", "r461", "r598"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {

"http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit), Total", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r42", "r64", "r368", "r387", "r389", "r393", "r405", "r487"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r83", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r177", "r178", "r188", "r266", "r267", "r269", "r270", "r271", "r273", "r274", "r275", "r280", "r282", "r283", "r285", "r288", "r314", "r316", "r384", "r386", "r394", "r604"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Assets acquired under financing lease", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": ["r323", "r486"] }, "dmac_RisksAndUncertaintiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "RisksAndUncertaintiesTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties"], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Text Block]", "documentation": "A complete disclosure of the risks and uncertainties the company may face." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r507"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r507"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareT

{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBl "presentation": ["http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r529"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeri { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCo "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r26"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByE { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExerc "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r8", "r9", "r65"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r501"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } },

"auth_ref": ["r503"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVesting { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeric "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVesting "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r472"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSha { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesA "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSha "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r474"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpira { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirations "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpira "negatedLabel": "Expired/cancelled, shares underlying options outstanding (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r241"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfei { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfei "negatedLabel": "Forfeited, shares underlying options outstanding (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r240"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

*"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPe
"presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Granted, shares underlying options outstanding (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r238"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutsta
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandin
"crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Balances, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r22"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutsta
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandin
"presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutsta
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)", "periodStartLabel": "Balances, shares underlying options outstanding (in shares)", "periodEndLabel": "Balances, shares underlying options outstanding (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r234", "r235"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutsta
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandin
"presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutsta
"periodStartLabel": "Balances, weighted average exercise price per share (in dollars per share)", "periodEndLabel": "Balances, weighted average exercise price per share (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r234", "r235"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAu
{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPla
"presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerc
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesi

"presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Exercised, weighted average exercise price per share (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r239"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpir { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiration "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Expired/cancelled, weighted average exercise price per share (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r241"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfe { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeiture "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Forfeited, weighted average exercise price per share (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r240"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGran { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInP "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Granted, weighted average exercise price per share (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r238"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePric { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRan "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r24"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": ["r25"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Per share exercise price, lower range (in dollars per share)", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the

customized range." } } }, "auth_ref": ["r25"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Options Exercisable (in shares)", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": ["r23"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Shares Outstanding (in shares)", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": ["r66", "r67"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Per share exercise price, upper range (in dollars per share)", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r25"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeri { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeri "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r473"] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life, exercisable (Year)", "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r69"] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price (in dollars per share)", "documentation": "The weighted average price as of the balance sheet date at which

grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": ["r66", "r67"] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceR { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (Year)", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r68"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balances (in shares)", "periodEndLabel": "Balances (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r58", "r108"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r39", "r43", "r44", "r83", "r99", "r100", "r101", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r137", "r177", "r178", "r188", "r220", "r266", "r267", "r269", "r270", "r271", "r273", "r274", "r275", "r280", "r281", "r282", "r283", "r284", "r285", "r288", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r316", "r326", "r374", "r384", "r385", "r386", "r394", "r442"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "http://www.diamedica.com/20240930/role/statement-note-1-business", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-

details-textual", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-tables", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-tables", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual", "http://www.diamedica.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-tables", "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable", "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable-details-textual", "http://www.diamedica.com/20240930/role/statement-note-6-deposits", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-tables", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-details-textual", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-tables", "http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r111", "r112", "r113", "r137", "r316", "r359", "r391", "r395", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r423", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r493"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "http://www.diamedica.com/20240930/role/statement-note-1-business", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-tables", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-tables", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual", "http://www.diamedica.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-details-textual", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-tables", "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable", "http://www.diamedica.com/20240930/role/statement-note-5-amounts-receivable-details-textual", "http://www.diamedica.com/20240930/role/statement-note-6-deposits", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-property-and-equipment-details",

"http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-tables", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-accrued-liabilities-details", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-details-textual", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-tables", "http://www.diamedica.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r111", "r112", "r113", "r137", "r142", "r316", "r359", "r391", "r395", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r423", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r493"] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Share-based compensation expense", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r21", "r27"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of common shares net of offering costs (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r38", "r39", "r64", "r392", "r442", "r452"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r7", "r38", "r39", "r64"] }, "dmac_StockIssuedDuringPeriodSharesRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "StockIssuedDuringPeriodSharesRestrictedStockUnits", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "dmac_StockIssuedDuringPeriodSharesRestrictedStockUnits", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Units", "documentation": "Shares of common stock issued during period for vesting of restricted stock units." } } }, "auth_ref": [] }, "dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits", "presentation": [

"http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of common shares in settlement of deferred stock units (in shares)", "terseLabel": "Stock Issued During Period, Shares Settlement of Deferred Stock Units", "documentation": "The number of shares issued during the period due to the settlement of deferred stock units." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Issuance of common shares upon the exercise of common stock options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised, shares underlying options outstanding (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r7", "r38", "r39", "r64", "r239"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of common shares net of offering costs", "terseLabel": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r38", "r39", "r64", "r394", "r442", "r452", "r499"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common shares upon the vesting and settlement of restricted stock units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r7", "r64"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common shares upon the exercise of common stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r7", "r39", "r43", "r44", "r64"] }, "dmac_StockOptionPriorPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "StockOptionPriorPlanMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Stock Option Prior Plan [Member]", "documentation": "Information related to the company's stock option plan known as the Prior Plan." } } }, "auth_ref": [] }, "dmac_StockOptionsOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "StockOptionsOutstandingMember", "presentation": [

"http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details"], "lang": { "en-us": { "role": { "label": "Stock Options Outstanding [Member]", "documentation": "Related to stock options outstanding." } } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total shareholders\u2019 equity", "terseLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r39", "r43", "r44", "r60", "r406", "r422", "r443", "r444", "r487", "r500", "r524", "r544", "r587", "r604"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r63", "r109", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r220", "r287", "r445", "r446", "r453"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash transactions:" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-tables", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-tables", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-tables", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-tables", "http://www.diamedica.com/20240930/role/statement-note-7-property-and-equipment-tables", "http://www.diamedica.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "dmac_The2012DSUPlanMember": { "xbrltype": "domainItemType", "nsuri":

"http://www.diamedica.com/20240930", "localname": "The2012DSUPlanMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2012 DSU Plan [Member]", "documentation": "Related to the 2012 DSU plan." } } }, "auth_ref": [] }, "dmac_The2019OmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "The2019OmnibusIncentivePlanMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2019 Omnibus Incentive Plan [Member]", "documentation": "Represents information related to the 2019 Omnibus Incentive Plan." } } }, "auth_ref": [] }, "dmac_The2021EmploymentInducementIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "The2021EmploymentInducementIncentivePlanMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-shares-reserved-details", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation", "http://www.diamedica.com/20240930/role/statement-note-12-sharebased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2021 Employment Inducement Incentive Plan [Member]", "documentation": "Represents the company's 2021 Employment Inducement Incentive Plan." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r536", "r589"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity", "http://www.diamedica.com/20240930/role/statement-note-10-shareholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.diamedica.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r206", "r218", "r286", "r303", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334",

"r335", "r336", "r337", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r375", "r476", "r477", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r488", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r540", "r541", "r542", "r543", "r579", "r582", "r583", "r584", "r585", "r586"] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities", "http://www.diamedica.com/20240930/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r458", "r468", "r600"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-9-operating-lease-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_VariableLeaseCost", "terseLabel": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r321", "r486"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r490", "r491", "r494", "r495", "r496", "r497"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.diamedica.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.diamedica.com/20240930/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares outstanding\u2014basic and diluted (in shares)", "label": "Weighted average shares outstanding \u2013 basic and diluted (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r126", "r131"] }, "dmac_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "WorkingCapital", "crdr": "credit", "presentation": ["http://www.diamedica.com/20240930/role/statement-note-2-risks-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "dmac_WorkingCapital", "terseLabel": "Working Capital", "documentation": "The amount of working capital." } } }, "auth_ref": [] }, "dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-10-shareholders-equity-shares-reserved-details", "lang": { "en-us": { "role": { "label": "Note 10 - Shareholders' Equity - Shares Reserved (Details)" } } }, "auth_ref": [] },

"dmac_statement-statement-note-10-shareholders-equity-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-10-shareholders-equity-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Shareholders' Equity" } } }, "auth_ref": [] }, "dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details", "lang": { "en-us": { "role": { "label": "Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)" } } }, "auth_ref": [] }, "dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details", "lang": { "en-us": { "role": { "label": "Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)" } } }, "auth_ref": [] }, "dmac_statement-statement-note-11-net-loss-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-11-net-loss-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Net Loss Per Share" } } }, "auth_ref": [] }, "dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details", "lang": { "en-us": { "role": { "label": "Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)" } } }, "auth_ref": [] }, "dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-12-sharebased-compensation-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 12 - Share-based Compensation - Stock Option Activity (Details)" } } }, "auth_ref": [] }, "dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 12 - Share-based Compensation - Stock Options Outstanding (Details)" } } }, "auth_ref": [] }, "dmac_statement-statement-note-12-sharebased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-12-sharebased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Share-based Compensation" } } }, "auth_ref": [] }, "dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details", "lang": { "en-us": { "role": { "label": "Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)" } } }, "auth_ref": [] }, "dmac_statement-statement-note-4-marketable-securities-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-4-marketable-securities-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Marketable Securities" } } }, "auth_ref": [] }, "dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-7-property-and-equipment-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 7 - Property and Equipment - Property and Equipment (Details)" } } }, "auth_ref": [] }, "dmac_statement-statement-note-7-property-and-equipment-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-7-property-and-equipment-tables", "lang": { "en-us": { "role": { "label": "Note 7 -

Property and Equipment" } } }, "auth_ref": [] }, "dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-8-accrued-liabilities-accrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 8 - Accrued Liabilities - Accrued Liabilities (Details)" } } }, "auth_ref": [] }, "dmac_statement-statement-note-8-accrued-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-8-accrued-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Accrued Liabilities" } } }, "auth_ref": [] }, "dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details", "lang": { "en-us": { "role": { "label": "Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)" } } }, "auth_ref": [] }, "dmac_statement-statement-note-9-operating-lease-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-note-9-operating-lease-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Operating Lease" } } }, "auth_ref": [] }, "dmac_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.diamedica.com/20240930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r26": { "role":

"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480843/718-30-35-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role":

"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r120": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"

}, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r212": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r345": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r433": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"

}, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",

"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-10/tableOfContent" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",

"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r562": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" } } } ZIP 69 0001437749-24-034925-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-034925-xbrl.zip

M4$L#!!0 (-.";5E=:/VS)@T -V> 1 9&UA8RTR,#(T,#DS,"YX MRYZ(HS3P#\:C'=&
T1\.W"H M_W@T>+C#QW>GEY<#Q(7E.Y8;^.1HX >#W[_\\Q^?_X7Q'\0GS!+$0=,7=#\/
M?8>PL\ CZ,^3VRN$T6AR.![=?$4/]Z=H,IKLX?
$8CW2@ORW8C/!KCR3AI26Q';Q%WL9VB\;R" M7GS3C0\.#H;JZ@!90C
Z#06Y")AW1F96Z((UH?]W:+ET1HD# <,E'O%%3B!S
M65CLD8AO<$_PA663.K<*A!>$5(R@WB)@ OG:UD7N18'E*K 5MTN:R%\X:8?E M*3R>X-
WQ#J@>#&M844AAG0F\N$%TB.5A.]WYH%=+>[9)\J.#!9G84$M]*J^.
M.BA^C<>U]";B\J"95DUL*=6X(C\DKN JW'0 .C]7U4,ZVR;]U<*
(E8$]=@1B\N#+C$O3;SJA;Q87!ZT9.12CE"/D-DT)")ETDU[*S)Y305:TQU(X!*1%07Y%$?
Y"4V(>_5J7M)6[NV);;U!UH M8H>N0F5-G7+(K*E3T(3Z=(U]6C#2U"=HPJ$R:(64[.
>!!"%JACR5>WGX9*N%3-"3IQK_XLZ7KHUXL:Q1%G#//WJMUN& M6-\R/IM@6@]J._=R!
(@/L,1#USJJ&]M5Q5KO$Y(8+CT+="AZK8WQ[ZIJI, M46$,^-
\E5L#Q:6*'/$KM0">1'>A.V8$^/"2&_*=G1TW(\,*"JD?,B0 NN/P=
MR;*LV11W)EVY@S["'8#_K:Q
MJ+TMI@BW6X]PJ0A'P0Q=IX8B,!0D,X:B*S"TCV:U0>=SN%_G@>L0QC'Y.Y0)
MROM1KER[*9+MM2'97<:T?Z-S95O/*S/(OOW$V<$84ZS;?PO6]?-K,^1MB_Q MS
U^O.=$JE5JBE8?V]#J%"Q"%]*B/H1)&/U $#S&TY!3G_!. 6BY*U,X?Y)E
M/.4V)%XA(_#C&RA"LK@[B55M.7P3S"C_'N6J(50C3%C4ERM/G=$L[MD4N+]I
MP975UZW4K-+:AZSF+<=Z%_/0\RSVHF9S^NC3&2 IE]5LM\@-AGPU#A
MSO@WTV:*$P=:3J@"*;)&Y0>OUJ#CU!IT$UNSY339PS!.WXFPY"8@)W;(J)& M4-
2O(>C'(RWTLFSYFNI%=ZG>+4=Y'UN>)#['C-B$/LG1Z0RQME-3^(ZU^,H"
MX3A2BFY3I5L.[D?LD$7 J>A^UV:Z,@7D1 ND3,G/8E5;#M\G'.\ OD0[7E# M+N35SF
6=FP*VETMM#(+OXD5JZSL/%&\Y4#_)I,A%D+MZU)K2ETU,75/O0JZ M-07RGA9DF8T?
1VK1U:O:+4?X(-D0@&S7)6HCOR.XJSV:PG5?BZO,J*\3C>A* M:MQR3,FT/VH7PJ16;-
NO73;,1YCGXAHPP[('R'3'6)MKZ80 M+ECLDGGS-R*B/;T;PB*XMQW?233X[MQ;MJ[2DYZ
)\;1UF&'!PL+_W<24-JUC60A^2HVW?LRA8B<+JQ)LM M="7=&Z2 /F,K7/)"'^Z5"=N.?
U$9;(H 5?T;9(_^JRLNN'L*E)7(AO O[=P@ M^/J$KZ 0[Y$OJ)]-H5[8L4'$]8F?
ID3OT2XKJDU!7MZ[0=SUVY]%Q7N/?DF] M;0S\LL[-8?])OZ]94-;WR%<5X<;@K]1@D
/ZO<_2@K]G0L5S2-B! HFZD)B1 M9Q%:[ML]\;2BR2
S])NI)0]!H0]GD37H/K)FVPE25*Z;ID==/0;)H=^.+5D? MZ*E1"
[*911E^LMR0R(?;2F%],]HTL<$@I?2;O\64PN@"#$7_E8;*9^_*B;?M MA-,]0&4\$-528I
R^E5*_8-;?0BJNY98<-I4V&FKUR!O&J]M%B]Z]N&E9&%2 M=\X4C9IK-
$B@9NNC!:NF/74*5C=-3TO5&@Q2H\%":C\A5<#D64+F<2^9O[^G
MUY([_,581.FJWR")]*NR.A+)[#@R,O/7^_1J$F]>^FA3OK!N.N345&..,K\5 M+.86+^3WT:
<.8NJ;3=T(%;-6."I[:HP,E$VT/3WQM1^(VL-LER_=E[" M\M@E2?/CC$M)7#Z/74+2);53%
[LD&^@V9;'!@-==Q,,DDJ_YEY.JI)+YY&E?5"J ;8([.\X6*@?E@U3@,G5
MC]:*#7*KX)]D5=R2YJ%K91[D?I%Y/:&:X9_K\SJ?3*#1*KX]L M#8C%T?6KB5M!KL_#Y??
>QV?R[\=7;\>/OP>D^"=?(?Y7O.%Q"AW+%^'=B=!Y M.0VXX*?J4R1BH-[S?
S2H(4==5^[?'@T$2 X0#Z=<4!%*_Y@0;@X&JBO(!U2 M(-X 12\8C\Y A0O6\[5__1LD8<7
;NS7/+Z@,)7XDT)6QJ. MEEVT&:GTVV2'3N!9U%\>J^R@.&'T7E?
=J"R/@EPLLI@]/_:=&Q;,")>?F[/< M"T(**%"KP;IQ8=GK>^N9YZ-J,V
M87EJETK\3.86^Q1X'F$VM=P;"SH#H$X#M@CDUP]/ M]9NG5K2Z_%71JM?ZD)
M+EG6A;AR$0J8'B\Y#R5'U%.^L@P\<4$LZV?CEMU\%DE/QB$^(S,"]YJCDH '
MF&&70"VYOA8PQJ\U.N:<"+X"5>'5M86#,F*+@*F@&(6(94#*)-8RBB3?^@"#
MS]67/BZSGRZ)O2J7:3\+@$V0KAKWZ=Q;N,$+(6#O-YAGXE\J)L39'YLXSLG-PP(-
RMY3^2\9*#)0(;XM&DRJ/)IGFT6^71[J9YM%?ET=ZF>;1? MY='^6GB4>B
?.5=/G+\^;9XMQ"RYO "E]?&M/"EC[XG%*==G4H;Z^LF3>3HT M$-GEF]75@T?QJF[BJ?
[2&Q8W#IGJ:YM6M*TUQVWDQ":7P>Z#"^K#L%&Y_!*O MWL7+6_?)]E?
B8DWIM4M8I.5<9SK/^E8HL4'^',=-JOW*2/XL_U)_;EA@$^+P
M"Q9X21%Y/HB>3;@EDB"V@ I:BJD*.O&P3<,.1%7=OJVW=T2(J,'U+%TY:.9W91<_
M:P0*0U%FLH.L+6 W<)/D9\92B;6<%K,3>&;;I] MK=!:>G8_)Y/1>')V]["* M4\&U-?;CX-
KSZ33DEQ D??E(5)%3Y8+KZ^%D'"V=2-%+WPEM$AV5N]NDU5I4 M5?
\+V'>X=4ZM!16OZ>;*V8W9#L- M&H?W?2:W:ES?V9J-Q\GH?P':@6/6A$U'I&X *6^\0:-
@X/G5JK$RH>+7&-'R M)S0[C&-%Q[_-4D3D7CS1F%SJ]% MJ1BH[OUO\EC69%-
)PXWPOOZG:HH'HD$?[S8FT5]2Y *49\'/_P-02P,$% M @ TX)M6=]JT,^3"0 UWT !4
!D;6%C+3(P,C0P.3,P7V-A;"YX;6SM M75MOX[82?B]P_H/K\ZS83GK+8M/"<9*M
6<=Y%+T/!6,-(Z)I4B7E!R[O[Y#
M^9K8DBC)IAC@O&S6,H>:;SAW4O+GWV8A:TQ!*BKX1;-STFXV@/LBH/SEHOGT MX'4?

>OU^LZ$BP@/"!(>+)A?-WW[]SW>?O_>\+\!!D@B"QO.\\3B.>0#R2H30 M^//R?
M#P&NW33YWVW6WCZ;'7.&V?_N!U.E[GS/-^_3MX\,<0$H]R+1%?\Z+H)Y5<' B?1(D8
M9U3[ZQS,E-!$Z7>:"Q$)P6#>Q@U]-^G^_Z;>P:4A!!0 MGYSX(FQIN;?/S]HM/;2%;$<0
H\\7^!J<06!_I\2C 9Z(;UGPC0P3XT!(N7% MG,0!Q2\0:7+CL83113,(B>^M9M:_;?RQ-
%\@LJE:#AAT&QM0?4)\V.6B': MGY?
*#-1I[J!?,P2P")%\NQ(H_)OPWLM$\J95"CHAZ3E8W5MX+(9.$L1:P2*VN M)&),1+B\\%?*
7]T7,(W5'YN2902^6$EE?L<+(,["+IMG@!=],:Z:02ZD>G>][M\(%.-3=?(3+C/HO$-
@890S"@Y)DR&E%0N0"RQ]OF/@ZUK4 PC,8@>R<2!BC MPM,I]-&OAS 02J&,AZ-*
',DO'5&86NT@#M$_T"(3=$1KT>8],.$18&J+LT78Y M5PI=3!JC;[ZL@:
<;=\WI@8NOPKN&S"Z.\PJKSVBQET>Z#_7?\?HWAARHKI1 MCT@YQP3K#\)B2 %0B-
*8N*A&&@C]$PO^6"2!EF%5>KV B%$6YF6E-WG"KO-]0 MKE.2 6 BN HO\VSS-*
"&I'T/N,AA2646R%>#1+!.U'@N&Y8[2YAG-4Z"8DM6%
M)5N?',EJMMC(U9W,L5:YOB7R&T0ZI7T Y,- W 845A$,)[JXQV!3Q >9$;F M(U>7C.EJ1'-
*/7\:8AC\I2(*6$9(4&JLH[B1,,!6_GDUT-8Z^,:DT3'+0 I26*
*M$0F4]U1QKV/\8(J7CJ&2O[.Q"!E%\9Y(ME;4MX]*R&*,RV>UPR1N8 2M2M;H4?,W0F?*
<%'36T(G$JMTYWU.RR,1;JB;JT MBAF5U7:.F+E;X-
**F>$QVG!TR4T:PJJR,^R2WS2#6[2KX9+=&>\\"%-OY)PI*
MEH&8U^AQR28K+F%.@/_<>@]O@)]M'#%;#U">&'EB$;UQ@$>X'KGE4CR&WN2 M9]
JW[G60VH'XM[2;8]L2'GW)$!A=7N\>)T*T/;ZP8AY51%6N!36/;I4E 8 M4EE%L@G--*
^AA>H)CMAQC1!NN=>@21D(NA8[R!G4]0[[1V6'>>=]U+LD)" E*
*MZBJR]M+G$4A0:1L"%NY8@P21S^4R7N(JCU*W0W)&6^4<36BS&"G\[AU3SZYF*
*M+J\9(^URG)(/W$)A-%_(/@=@S7R^05S2,WED&^V8KJ2*OSJ"C_RESN05 0Y*
MSO'8M[,O.[1N\78MLQVK&9'E_5(%F%'I[8TKF (320\Y&X813:5=1^]H&6F6
*M[8F2(;!15[P)KZ%)-:",H[^O+I7EJEXI)V[(IX,Q*J-#Q+&1_JB *YCXN*
MK;PA(@NYKN^PJ08T89I$MK71"5G:3+O9Z,3]38&S'Q>KSF2]8M'.JRY+-I
*MUD[9E9>^\I?V"GB'9%MG?]J8-\SZ$RWOSO%@*A1)ZJ-8EN=\WE[8&KDP 30@ MJ6%*

F&V)O:Y)G3? (S4%Y^^XF= M:]5-$%>U%5=9E)R%^88Y6O8;H*+FB*1%,1+QT36 M';-*
!=0XWR<1EO;$;;74TB/!->>&)?.CRXN>[!{['S93;)N\6'5U^$N"R<(C1 MN_87PV2^TL>=
*(7J1[O!1N\E"$M!HZG$=@R;2+$A3/_;_'&=>#RO*S+'[&SC MKF.**4:/6[]!G@4EEWY-*
5#GUP:_SIW)]YVER":_TD#)Q4ZY]]WCK^N=L(5G MFH/\,*
V/ZXX#K>.2"SN89X'J^H!'::F1^ZPEB?&;4)#<MU3:->9QS<* MZ[[Q)]+FYY;-*
)MSEW7ZV-B)YT+) &W.G-5J_7[9I3.YGC2E5'LD6T:Z2]%-0
MS5PDIO9^^]BEPX'8JQ$KXPD6+R%<><]V;(HY&QZ)J8JX>\EN'Z=QBE-MH$T/O
*MA>-1Z0,#QQL3^D2'Y>>6]=@"1QFX9M@.@@2K_5XUA+NCW@=:8T,I7OI*3>@%AL\#Q2*
>,V]$4>:]F M"0=>
#/N;F+9.^_]VB>QJUFD5,';+^#Y1^:W'P^@#Y6^2MQ1CAE&CLXN+G M,?
5,W!@"\6#IW2<+K1ST5[8HAVWL1=S_/]T,Q)JE4F4OS;PR'V%4YEO? M5A]L^K_<$B1
E8H=[&(+,)BPH!]U9^AQ+W)A35#!"PRNC17"GCD%1?KKL?1L
M!"FO>6]!+>UHV.2Q3UE^0B_=F0.\"P$;CC/GHXZ\X8H",WT(MY9")\S[,0V
M7"HR5]DNHG%,J)3I\7;-=Y+J@PUX?_O$-[G/A80&]I%21NOSTE]W^J^/?(O*
MX=V_ORCZ_N2-S]?YQ\0H2,_?ER_4 Q\9IRX!)^@D!X8OX5"?KG+XI\-]^%]?
*M2M*6G$*4U"<.A-F82AW1N7FC]?/I'00C)Q1WJXQ?$YEK>DSIAP+57!5>%'&]*
*MQ'_AW9?DK&2>2)NCXO:RB#WY'^YU/T,X_,O#;V*B(N".W-]59[>_2-S>;)*
MZ''FTQ89K70G<:6?V2_:]_/&N^LJ92V?F=:^FC(NNB1Q@OT"<#0BXH;%J(J M!%.A,G-
O%\VCAFV[9;IN&U?''5R^(!9#.S9V::SN2OM-V8A#UB=E5J![T;;(
*M0=*XR0O6B:)518>K).O50?Y9@$F79H$ SU/#MF))HFW+RCN.XD\;+!V/K*
MKW&%W_>L-5S=N%H-YC76A'FU^@. :PCX.6_CE'OS 4CG1A5_S8<8'H=\X_YZ
M6TODP<_7?/,]&.5Q7:T[Z:EAIRLNI@X]3W.)]%&> >H92#E M?^27NSY(U+QX-*
<>O#F+7YYB$[[&PDT91>MW?;STY^5A(^A.@JWXG-N6W.&PE M'"[1=FSGV BH*
*7_T;*H9H6_"Q@G0DE[O/C2HTD)"MZ]5(;$%*$P#;?,+S3#@ M"(QE[T\8D$YE*
:DC729,+PT.!-?#[%E+%F>@P -6@[K><2!?+S1#@:,PUBT8 M&_J-">-
*NO_]P2IF>X])$>9+0GGQX@8' JV%.O? 9318DIAQ;N\^?7-PD*1_*
MG;6(SE_EIK#]#+;K8+'Y",K;2AP+P(TT;Q' 0'4!6]/,@U' -;!.XA+F]6D*
*M#_:J(=E_7UTCJ3%^ L8 CX*SQ'%L%=QF91JF&^R'Z!(:JZ%JH 4,T&9Y<08 M'D)#\\+*
*/HI]\>=?,PAT.Z'@/2@"0YF]FP-AJB#"2^";O#@V5S.[Z %NF0T- M,*A[6W<12K?*
%!9NPX2P3<(@N=GLF@6X+"X[E0#2VK[=I<.% 'EALW>D@3"M@ M ')S590+W9?A-&5
CV-T(FP\3(.A-L4[(X&',> D'4IP#JLI^]-X_EFBP M)#!K-SF0GS'#[.#M[;>+,)]>66WQ7_"

[))/^4JLV#'T3'TQ>_OM?.9"UFQCB M;!TOIHL#B03-X$ &P>#=6L9L[@+-
)FXYM1.FP8Y4Q#T;1WHHXB?:$'0 W_. M7 Z>.9L-O4778V-8VW<'D-GMV%6X-@?*
R9GN+MF.P_BOY[!!0RP=6 MV=_U,;2?,
*["=L/&W,%XVS*W(E0UEQ";.>GWY^FF1EMCN:MO#DW4!]T"I7Q/*
*MG,KFO5&HX*I>\VDH[FG][<0P%8;[RJ1)68^1."WSSR-1_G=>5OR4Q<$NHH(4*
MF,W4KA>^G^UQ8JA>T\\]FB:)E,PQ,\3ABH?B]V$J\1XY;="GBF=5JT$9\B": MS:]-
*+S>A"X66:@B10?)J%$')7JZ@L]/S'RHI=U?J1FS%B\/HTX_/)87Z^*
M(Y_XL0\'K#+FMJ_Y#'%BG0 2H!%![>Q3]$=U@Z=$ V"B\W0
#Q@W:%=2)!G8T$PBD8ZZ/ Y8 M-?
*D%&/Y<>*C0E62U<_=ZX3(Y_=]>",D0V^=A]*9C5HXOGO%*
*M93^3#7AGK&RTP\IG14ZCU['OT2==E"^*M U+[JKQ9:KOF#\[%B'=M*TX>/*
MC]J>Q\BX";-TBU^-:8YEU%M:\W,Z92T4V++0\/M$R*NBNHY&XU?*>?#]V\= M,*
(@NAH7![0IBPT+%R@YG=&(?!.-1H2:E0583EY_,#T2I7;Y8N+T9:'-1AO- M(=O?*
RW%EG78@-QX/DC%Y0.G)&44-$P.P866O$3:.??YZ&"X\,D+,1DN[^'X9/
M%WU60YYNMFX)6DQ5^)'C!;_8:5=#] MX7/VE&W:\/7>5=6-P@?51T]F;-
R(_A8Y='#WRU^J<3L4F$:0QV-GMUZS-!F M-)-G-8%Y%_R5(X-*
*D8R\^Q,M_4SJQ5;4SA/8]QO/P=>-3ZQ8':QQM0/==0JM7 MTK$1*_:B-X&*
(\6\6O$#2#89)A"RQ[G!F(US0XH,Q8]1VL'BJK>S>L8'@H(O+ M&4<@XX&&H
/+GV'N07E1&BT&D@QQ=BY-2'J.+=J]:B%HZZ:@W._T4[FJN,\E
*M_&EDH4",^;*A3"%EZ8UJ-^D0=1XY(DB+';M0@\;TAUAZ9A>Q<.5=_\L8(3 M&*
*[%U;A^O6]!\-S'4QA/F^#Q1F.L#Y1S4[/HY.6Q]U_-]:#[@02[*8=B>8?%" M;664"HIL83?*
D1S>1\"<-#GX;+]5]"P..<)?Y]/T_;R=W$R7 OB01S8'<9T$W MKY0M$?
YY"^PJON%WD#!@RVZ0P&T>4IWU)"\=:.1 XO[\5"O -D'AMA_>.(QM MU0 .K+-
$75IA7Y3GSS(U4=FM. E'L"F%T:M;M#,UZ5//J$UY NHLRD!!5.) M))L7\35%+VRLA@[:?
*4KWJM?\CM(;YT!B2KL Q?4%),.%\FGL;!70_)1&%@;\ M%GS3:E=($C**
[@1!IC8/%7P1O0$=>V&W>:73S>O>1>C$3 MD28^HUL\OYZ=Z$ 7K>12A!IB+
]2D0#\O+KS ,$^#W'+QY\KR>,>9E:X]+!V# M0W5EWPC(JZ5YB4F-'NH&G);
*M;KH_[6Q9R9=@)LR$JL&'RK7L]_E [=.0?(*;MQ6XEA!8Q7_X$'?U(D\2M*W*
*MV\KK[3HI:L.WK#Q''I](FC-G*MER;5Q?N'9S;S9$(9OQ1JBQ*XX#V4W9R@\Z MBG;\J>_U*
46\6=$-<]P2:-&*1A:2K9L/E\E_6F[U4S$\R/_.]:.U4BELHK% M14"98HM_CI.HDYP+*
*<*ZD^9?!8J'%"D54F.RH6]T!0I^M;=^/%JTXJH6!L?7H MJ3 ^,14ZI*WK-*
WXP>VK=M7T!=N170"J)-6$6*!-3276^A%E$MO3_"*]O\4> MGB@8,%%IT#*
*<7G7\DGXN0_\\ST%#R/0K71(HER:H.,;)U4 0A:>&M6*G ,?" M5D8C15T30>J=ES1MP1V-*
"NSQB)M##DKL5&$ZUC>HUH2D_%1"@JEV=H\(C-(7V#5Y9-K93,MC?*
JS&8'7K'Y=CM2P.7Q,2';B;" M_#$/%@=;B>1B[?DM"C2\3MS]O(402N-].7>,?8]S=X+"KX;*
<>(7%"S.\9;Y MG>_?7\CSD"="70O[DKG9S;O8' FM M1Y5W@??
7]6+\#M7<>'7:5O7&YX^8X2ZFE?1$*WBYSRD19/YT<(Q('O-CRZ1 M^]%"K3_[*
^!E45659D$XC7>7U=.NO&^Z2;KO3GL >;M/[(.L"605>AFUXQP$
*MPFOX[Y17\&%:H"$E6UD&DG#71R)DFQ!IZ*4Z0<>GINVTG:FXHW0)HU\GD^(O*
*M28$J-!PFBFQMJ74^>_*L =FZ_[>:A[X)9:^#H4N>Z]7/1AX>!8>DXV9'WAE6*
*M2.F9"O(?,0C#GP+FF,=07K0O68B/#J$N!7>,?IF@4N@C_='*TR4GN0K?E"* M?*
RQMIB7E%#IWU_/S-13ZPKIFN:W#J)Y6TH\.3>]UBV\M=R>G%J8UGIJMU.)) M=04('_=-
S0F"9,VI+-8%AG:8OBU]D:E.O@.$&F11]#9R@WL.E:,>,&]]:VC9
*M&$>89T7*EI2E>ZB.!@FA]_>P^8"#PQ=Z^OWB]K^G_IZTT)IE7\NZTGO)W^_*
MN:YSVX\LE^) !# N^4(1-M]U"_JS_K=4GS#&YLGPV41[BH#\3:JMJCK!R.U
M^D;.'1L6DZCGJMV5 I/MXJ/,F%:8$.SM:Q^]3HDN#&VXN^$TUQ=U([#J(7[& MMW
U4',WZRT'$@JRZ"\?>N[6,Y F>B8)5HBE:+8@V%HED!IQ:Y!T#L0D;0V0 M91OW_-
GV9R4%-8+@0 Y68J@FS=@*F_G;H_OC(2(6)S;99J7X(._LA7_##E4*
M34'MWX>VS7%2X$!F$JSF+'%$)1L2^ -,.!1 >I(7!E%@L:3!NT$A#LB:3"((#VA9]E[F(C-*
N/PHDN=,C6CF0$MC\5B[+O+:TNY MCS;X41,H M4'T0%CG?
*KQ4W=_E*O(T)JB"26^GW(\&]J 0JOTGRS7>_%^C5T[3O5:IUL=YC M"PI-Q8?477:GJ?*
XNR$O&67G,K X;!]FKG/;@5OVH4Z]BJ.FLJ3;8WU&9_?- MW\J]\H@5L[5/ //!N*
6@"@U=W4!+4VK=F,TR0N%9GV7>2A_L/E21.EGQ8A=W M^X?
FF^60\;7WN4UP098.6+3C@_J>C)"C>A6T;\IB:3&S",_/WW?# KVO?A@ MS&2*
*NNO!D'@[!\(OMW+VYG)5W.Z@5M119-!'S;<>[>L>I)Y!N;*3;FX>!B37 MB@6/6/+MY-*
%2J]G"KBY45ZD+B$R\3>Q6884WF>-%;,='C%^:SV8 M;?=Y[.OAH^&SNT[8C /!/_-
W>R1=MK(B>;\;Q8L5_"[+OPHVI<+17Y-5;GS(M.TQS<=?
R..K04N;/RE>F1N@860S9;"5F6=!$J6.K5@ MRN"R$-:(5D-

+TX4:M%)+7&7<^X2W\%UQBCP2N.KF&D>EK[:>:E_KJ35S1,QG MC<:%"ZTBL[WV0#?
?1NP4FYRU_WI<4"F,'/FH.IP]<+2!$2TE.*5D-1Z5LI# M*4OEQ,?;ZFKO%NIF3N/?UQ3
^B=UXA3P,L6Y5TW?#=4-ZVF[>U]N)2>//&)EG_D5$Z^-QS'EKGSH3)^(JG9;P/M\
MNX7P+F]^6N9TST1QK0+U,\RH0]GI=6+04ES<^APFO/_J/+!3MY?T 8\WX KZ
M"A4(4F6I$P#L:85#T8TV$2]ZB54.KY]2"_0N5_52+EV?JLFD/B[ZOJ'T2?B9 MYPA-
\^DX87[O^%Z_FPR7H3(U$^K.E A:I+Y6TO30Z)?TG9DIC(W<6XG.@HEA
MEB&1CW>7GU5]CS9Z'J&;O+AWQ7:ZH+;48ZALPBLMTS *IQA;H%;V%!F(S[/J
M@>E!Y7K@R!EH<6N#D"QY6K=Y-).PIB'#,JFA7TV6#,/WRVNZ4^_):9_K5+BR
M3SOCE*1Z@*"JZ+CVO #%'$,U(+Q!O24V6WVY!DPB^:P1I@5W7"7"-
">T3F/R!U",M:@8>'6M5 M=:]!T:<'E>^!.Z*/;46Q)6Q1?D0X_95VK(^\11-
,.!%FS4]15.W[XPI>C6B9Z M$>>MI-H$$IO6N#/,K=;,@ =T[OI-#B2R[J
9#2D\I(%%ZHOGV**"'KJ_C])S M'RYT4G]G>H";Z\0SBR!4CZ>@>$>CBOG8-
_-5A#FZ:J#CEW6R^!F='$2M;\]9
M[^49KXG+YQL"UG4V223,+LP]\@Z69S>+N]!54N%HZ#D.Y'FTU8\:5_6L@X:>
M+@B$Q_ICL\]<^_V"CQ./:2NH0K!N5Y.I3[+O:O>'S5W;RW79BXJ?C)A2C0,3X
K*53+]A!HU0@#): MXLHERAV4 \\$*:F]-7G2]JNFV%H^JNAKP[7DK^,?UCM>RZ[I '<8@?
J*>)0. MT&M&9Y%%L@%,P< LJ\E0]|PPRI:B>3DY4.U M9;U/]0XG63Q]>/.)6[*5@?
R8!J+P]EI=VH*/;[I%3E?\0WRI)G[0;%QK^_<#
M>RV"V$0I'8=M#5[<+Y\MBY'*;;LL&7)^J57Z\[#PW[2=6>V8H,D6 *?@:X\
M5*&%].PFD@@7'W#51>NZSVLMCPZ/-!7S)+S>'2Z[\1@6$=PE*JA(-%WZT+YY
MQ]9WY'8:!Q(PQ3D^>\ZJ/+[>KE5X*?TA:W!P+'4#3Y%<255D D+AOFA;8.
<[=@>F&+^@0>D0^?U[^2(")S!KXYU:;?[]\0CTN,D!J9U_M)9X*CM_1;,HT8W\/VF/Q
BJ"]J'=81E^1"$H4^$UNK"2TI0OGZL)%378^Y-& MD<:1+]OT3GJUZ4S)V%F<1UZJNSU?
79WG[NHNZR/R V%:3%NQH7TL(_Q M0*NK(5TW$R?
%JN/TGA4\.HC1.#'OW%3!@=CLVC4T1MC7G7O]QG4/A]]I@;GB MA56:G:6!*
[/]IY_H_MP_6WD(^M0^J#UI@90\-X&_R!8Q$3SY3GC>%?$;%X!A.9'5-G)'=6/Z5@(W![O-
5N4XF7F9K)DUEG6P!:K)-UR$$N_F,WB[J4
MJ)^3U@0!Q'N@I$DF9V(JY@'=#'TB@GHXB6=;$G_PYTKWE*G'H#(R>WX]JPS
MI8LV#WM\(Q%S*-#;U\+<76EM^/L/]-D7EI[1<&UW3:NYG%Y;G'0/_/XHNP7#
M>XQ]"C#20%_(FS:08+0^2V]VT7KU";%OL,,G:/[6(P=6BV.,G,>891%7#72M
M"CB%I"O2;HV%N62CH@U+M#[;7T!\LFOP.R)84^I5CZ[,.B;8*J7DLE_8OD)_
M2NA%WD?+*G?X+8\O@3XE8R0'E\.J1_$1[V<[^Z\.Z;U4K50-K069O+IN)#ZG M<'=[&-
T3MQT,>7DL'[X1ZL,!BJDL,>Z;0*XJ6IWQ>ID\ZWN[Q5V0 M[:>F^?TZ-G.T;>*5U>2-)
[[YH>M&0<&D\=SM_5ILJ^D93GNJ@7RV.3"CH&@8D3^5'U>O<
M]O,>35HJ(XV6YX1$'<$_-^C[YRY_Z>O[0NR2SB0P_D4,E,ZBP/Y@8C:Q#:*
MU!+F9W+:9$_JHIX$C,//.$1R(::'J+#E\R&T. MRNTM8.)\L:J[@.+LD"2+-
,O5I6$Y<81FXZDS#X:L_[< M0!W;864GHL,473L('OX49;%V="ML!?],JRH\E[K(-].?
%O;\QVRC9N:F0%MN MBO4OX9UV]_VN0G1:@Q#Q6Z 2'T_%,Z5029>BB#2K9IP8(-
H8X#UD$5XCG6]W M1SWUW;!IX[O8O35/1J52)V*^+WP.B.?;
<)RQ^(LPGLF!T&\2L#KV,0Q>9R$LVW(0:HZ(@RE[;BN>+8DO M/MC^2OJ7DW/M(A%*-
X3O0?%2_$)8:I3%:+C(2C4F+%.W@M$:K'[G-/,5^AA)
MX5YFFX2M;]S#.^\3&I+O_(R[L",>^9!,/X_G VPI$<]+W96IR*:G0OM L6>< MQ=
P81@PS_A(+2)?,*^<#'_>?,SCD^$A;J>ILQ^X<"P)(2HNIL:<>2GH.[2D M*QQ]CPJ+2--
HQ0J[)0#I30K0"J9"WNDMW:]VFJ_+.OF#I]1*JUC$AZT\H50" M-\Q=2#"
(J,:\.8CBIF&:X#$I!'ZTK!_U&RR"(+Q2>]/-)K9'&,EI%#D&URH
MIOP7Y=:M9^/9^Z1P51R(!WY LA%3GAJ*UG,M=,M4I.-?H(7S#]=2X&* [[S-
M[)@\P4CE4-C@G"&4!A.]C0'(HXV B(8W*TX MA1K],4F&9)SFQL)$W\
(*0]1$OO;3]:9X0Q$/M3++/2-?'A_?T>0&I]_6B'W, M.@-_WQO1X0T]Z+M;
[]2G*N@.8=K1]J75:@ID\Y!-V]'S"VIMIIZ*P7LNL=PW
MVMHS<&"NT!U4MZ[2*!U=T4%05[;H#Q^H,$"LS]1[5>97XXEG[J.
<3"GGY'<[ZK3L,EPFO"#3SY'#X"#[W*TPX!E%85L^>K#5 MD'*S!BJ(E^]
(FN[W'96'"G.\I+"GE(J-&ZY!GN_Q3-SQBP"!C5=BQ ANA!UH MK1[]4_3JQC2-
YBX96!3A2VD@W+K"#+;7\-U @P]2[VO"J03/M>%#/(6\:9VY7-)B>-
'T9NMN@ST1[D&O6&#C$V+-@@%J3#^6$;#Z?F0V<0ZS;T4O<)?Y
M08MCKD,W3Q#=Q? >61=X7[FKK2=B0N5U_:<:+("#0L_9?"@3BD;X/%L1M7R+
M3FH0@G;0<'S6LUP]G1G%K2JO3W\M4CU;X9^3Y(5F9L0.U$/DL2S1\K5E$H@@
MBT$:U6FSV6S&'SL_B7"-RI;ZFN 9+W@S<_MF MQO$T0FE="?6UX]I94
S*TF"MU>0X]@E&S1?VV5(&)K),6A_Z5 !K+'L0WY,#E48S>:A^'M<(). M?

B&BAUPXX2/_L_EK+ ?B-['QH)#OP$T118> 7]PM961 9Y9HMI6WJK9+C;L> M26<:
XF$/1YODIH?Z+MKMF:HD:TBS)9\OV0F?1E[L+P[_[C<_>I1 ;; 9J0 M)*;!M,:,?I+<0!:LT5,
(HRK3%\HBHM"WM!*H[AX:2L4(B=M+MH&9LQVX8#%+ MZ<$+QQU..*13|
(#2:RP1,R1IPW)J=-@W:*;A-984DF,SLIQ=X7)3C6-&S_? MJ?
02,KIE/XR_2K@2KY0EF_F*8K"]/;>2-SD.5MH:P4+2A*)AHBQ3"H8?Z!2* ME-$.U>3_-
%7THPPE>/^XO93!H/S;+U(VG\8<3*YXGH-*L[^#266-&S*A:,]; M,$*I\":<(*!-
E6>',2I8L.YY=TWGL@2GQ"WWW&*K)6&>?<@8PU.)2TC'_?;9
M!F4,#?;N$S3X8/[::E4M4)[C%J "F*QY_S0X (0VLJ$,,_BTJR0?&Y!,D "Y:O!0=1O4B-
T'UOQ#NN:S%&) M1&+6;(_]5N'X\)GH[TN% MG]@FW!X- W$WF]TO?
[33KE96:HN8UVBDE3B-[QN0XMD3T\W;@9$F(,E#F\ML
M_EJ&)=6.P*?/2Y\O)Z8R\&%H(Q>:| <.Q-F8P6\C$.VJ1MRJTO,]^;[OJ9\W MW_?
*0MOQ=9:8,O5J,$-U[>Q/MH:;9$\7%1O(,,:T1@J,;X071^O3P"S._2S,39-
M_,T[96O1QJN/0T5>W@I?*=U=R'_;FT1_S="9[92 M".,EN'WL(^C+P 7>)HWG,LJAZ /,2]-
IA95TTK7>FDM#R6/#LO O_C)_&?-8 M9]H^*2R0/'S;L6UD4
M*5N=UZYZ8JJ$/509=MZVZLTMV6^_#\7Q\O;#G$$:@89R("ZP%T&BI,(@)?05
M1C^.7FW6=QH>8:-.\$$[:VYA6%=Q/425T<1XY(+![^&_;5%J30V"6"^WMX^)%;%
MGP$CPEE2#I@E-7,H2S:5D06;=-[>Z3M4H(MMA._F0/KE"O(OEUJ$L!N^)YG? M\-
,7H"FSQ,JIY:W077-#N[+]*+&2%@RG$'N?TKV[]VK1;!7+OK>EQ@>$^$_MT<'K VT,6A-
'!SMVCJ];K-_B/@MKJ\O?ER.)2Q,T$@ V86Q>Y;(_M/^T[=[-I3C11XL'0B?
W[XSQC2(884%>I MEY+)MJ1K9VZ)N?9>YG5VH=^-!Z M7 -
SG_4\#BYQ)^AQ]PS\YHX9CP_L@(V/DF/R.9!3&D0<2ZB&_EEDP(#M%-I M,C2#0X
7!Q*\CF'%WMKZ&*_]B5+V96;X/J;DU,^W,>MU6T]_@_5;B"6F1ZUB M.2%E7S]I*),^C9W?
U9MN_GR: QD$VS:L1A'MVY)7YUCEE&8[Z_'6.WU;IA%0 M?
O5GC86_B^+TVHS+^\&!H4.OP].YY"*S@B$W[6(RITC!<&MEENP@(RP 2**0
M_W:2YF4"'8EK@6!^.0'^H%4DT"I[,:^,\(P^BL[AY"2SW)%[5D;
MCY'FUG$&V@L,QF$D5H;<9%77DT.JL;B;YH!W5T^5JW+.=2MZ=U_:/?W(MS)) M\O[-
A!MD]AA&Q YT)F=?O;7NM=4DK M\/8A7O@ <_JI&JZ2X,I6Y;G:ZO-
M#4M'_2Y%W"P+GY%T&S%.Q"9>J_&0?[:"=]G*Q+C#=KMB!,IB-5HE_>(10^71
M&,JAZDH,OS40:E$3F\U';T:
<.FA3R;VSVWNW[AZKNP2ZH4;T70[D*W%@PA<^!GK2AHWT"@GO458-8]
(,6P!/M+$<4BR+;=O- MCY83NR_@[SAA/\ +N8%"LG?
+,TXUKGMU[6%+5Z58")M37]JL7PP?GUE?EFM? MFZA\ 5?:EYLM)YQ!*M_>+<;@& ?
231R'_FUF (Q"A$I@IN_1A=B\]IBELP]+ M/&1^74N^=+IZENU>8#N[.:N*F)Y2?4\J_Q1 M]
8H1,KX+]]O#PQFI[IV$;1%;(9I,-98I)4EV#-UT%K/Y;/56\OO]DB M1PQV;&,-
SS8I.)1!'TD]EFN>.S$5-+IZ\(S)/J-<*7,87-5O(6L2MI?@+@"/ M@!4O-KN?
6,6(S4%%#-1''*_[4V*//4I^U51^T&[1_\&+]N3=D*_SJBU!NUE(M!FQ^F?:RQH@B?VDF+
<-3LWI2,T7VI:WLVQ2MG?:"NPSE@Z44-5=S_VE'-EON M!,.%'?[?(?
V1\YJ^(FZT\/:GB;]R28]2 >+.(:>0]Q:9';U!+:8-=VQ]\OUJ
M%WU'APW0C/6%;PQ%ZJX"RM/W/[VW=L-VC@82C$NZ2Z=+Y_148Q*=A?J9(T))-#
+@YQ+6V*N :E1R&@]/@[@S-I^E]WO=RDVZHR=1B3 M7_W;'$0X_U?>_XNW[XYJ
M*EKSC:*"HJ(@O40! :4IO4D$I(F *$6ZBG0ATH.&1%%Z$Q 0$%":($VD2XD0 M!
&1#E)#0N\)-9#V#I9[9^;.FIFUWGOSQUFP0O+EVWQ_VB;GY)P= D3V),?^
MJ3(:3$^1>*4E&BAV?O^+7T XFRQ;KAS%_"9FP0O4#J5WH4]1AFCZZF]{:3W;)=?-D?
MWS#C4K>B.T6V@P:?19]1$U UH(&VIXC/B]PI4)0=1EJ]3104-KQ1\3 P:GKT99Z,1?D
MM/FUAM>GU=H_JO]?A;S]C^N)AB/C8F ;%XBTO^60+Z@-X]Z!PPR#-**W-,4
MS<9J3\RHJ&|^RK"I7T/4NU-WQO#*AJ-HG.S[J"$;^13QYLZW:MC45-&TBQI-
/+L>770S#P0$5R>IG*RW+2F5JN=@$@/KRJKC$<3A!\I(V6F)'X M2CDVZJ-
E2_4=]:E(QWR5=-?Y_W[F'8'5*2PI=W(ODBB?<6NZ, 4/>;A1?9?J M4 ..LN51T21=)7:
[3@C55*2LB]XI=,-55.I9NBK#@@6"15ZZ7;-ZP^1E:X[\ M;[G@K ?!+GIMOUILU'/-
P4P[WA;HB_MUK M;:+PVE0&7MF&JL-#S6".D0Y[EB-/>)GE'#+
30X)9DY;32RK2H.RU5U"[^GE MK2'G?0%ELE YGVH<%YXYE/K)-GD&@M=<&_:D@7
9*RQ,T>XK:2K*DW$.+%+D M)/;(;$WF]!D__Q!>N6($OF1H9([*#A<%O+41>>@.T0O-
95T9F[6P4,D-TT8L M-Z]_-SS_.L[PMO5AQ+GFX>6RAZ[-%CW7>ZR3,E(?
4^F7X"NS011]-5'W?^4.I$K20%] M2TD/6!-' @\N*FA0M9C(^Z=HPX=8::#J$D+?
_CG:._5GC&PE D3^I^=&_C|| M#LSHX@<[Q6\(&!%4T>"$^&)KMM8$,?,?
Y+F'/[R&'FDMAE]{CP6"<=5V3.AZ M%Q"=FV?G.#'@]PQ?GDKR2$GPO,:$CI!EB2-K-M>H
>E^. M__#X]&)52R,"+CF6.@: D&/F@6T&A&$U+JX.K_QWH=@MH(@!Z>(H\KE1ET2
M4S/6D2SX]>Z/PD8$81[D-YI]_^VC*V6R*I M3VR9NQ>=JEZB>7#_,FIG^VVD)-

*Q"5XB#!E-,A^=SE8$)O^!B]>0AP/IN^Z\ MT^_.+M_^DMCV9/M9'NQ%VVS81Y^(P-H7+=!:%,>81W3J(Y1?>"&\<*XCF]< M0&/^ZCQIGO.5/0PA:] ?*\|5EVK%=Z)=,S.C_?U.FOQLYJ.K9.>W76$Z#67> MQ:QS5(_6_F#QQD1"07:Y8^_'%?*8T*("#F>IO01((O^Z%Z7&!P6-N_=C97>\ M/#Z]}B,&1F?->L:KH]JSN$44QCQ<1ZTVWWMES!&XL[>V@_?[^2M;QH#9Z(#PQ5GQA3-[!C(JA5BK<"<^CM(TD#G4M-K,Z%KMF]\OM+[SZ!D5AYQT.WX.4@[7*S^^#S*(K_T2JM>/#"#4.6I/9"[IT8QU3!)RM,@=\W+N@*W!$L=;-*;QX',QOY07?2W97XS3"IL=3QV0[9G7V]P42\P$Z.Y16FHB_00)D/M2A[ASZ1M0/0I MTLJ$^5/>FBTSK$M>'36+Z\6MJ@CNX50[]NVDL,HSE^=([DN^QZZE^R8)K\YKCH<>\1UL<7G]5H\JRO\A24 M=LFC]>0K3J7I-9,.(4RU:KRY^8P]]I*+S_%FY(B-\,AOH-5"XS[. M*6_4WJ=+K_V$@<7??O_,+6YGA>XFX>C+=J'&@=5CJRS^/T=KN?T T"-L:[^Z M&?TFFU<^OKU-K.&'K"3+\OH+1:69GH!,L/ ^^M^L+M7.DL;ZI{[X-DWK 5V) M-]DJ4S78.<;GQ(@M9+O'SZ)3/5'>L9;>?YI:(-K;;Y^#4G)P2/'[ZVK4L<_C M56U.B&WRG"O+;_C?KGJZDK+T@]I-.(64[OPR**$^UZG[&-HBKY7%*Y=H^[F9 M]_-O'$4_H;(6O8YPW(X)*YW9-0=*_5#)Y]\7"P&>K3'6SQ]BY0'0HURD +F!M17@IOHQ9B4BKD3R3)C_%&09;")S*^JC\IRT.1CRN\YR(+)C%3;2,JN%GWM)VMNYA:G;R[Q? X\^44?J__A="X)W5OR2Z>#Z51)$^YC%OA>1V]-TG!KR@]"F"M9X2C:5_;DD!V5 TSQ85+P!8^M6U7FP92Z3L&)/05P18?,+/'0I%5S.X,%4.Y M;-A)S4,3^Q+!_O%Y7O@D,KBU9;OC\H?VC.@3^<]Z8-6(F2 YSMG!OGXP'!\.YJ?:O6U+/Z[$$(":;LT?ADY!*";G5#0O;?5%N!K14_GV$WRW&}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}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}6@&M(\07>ZGK!PO7=DNUR&BC^_$V#62]?Q;@!WQU'"*7G MU_4D*F_F*!CJ1 SU54R.*

[5I&T7E1RL96=HGW5N"O+\7X7SX:D,1.7)I\8T;E M4
/K\7V"=66$URV4O[1I^49$SA5IY\1A[I9DTI@W!H$DW;]#TXCICDRKJ5\ MBP-
"]E9SH(*G,(QCR>_7RHKT==*UU.%L>V4WY,H76!T#;*M!(:V&
MP5QKP[+@93=;/8+U<."6<=RY.(Y!'>]MDQQWMY:UO6Q-Y_=D,T(*$T<-R\H_M5FI4:
[H=:WZZA[W*F;O =2(F!)>HS"BJQS'[LH-_M+DTC&?K/FCZS4G73FJ3 MB6!.J(N9IV?
%X*>9ZR/CE@D^J-L1I OZ$V7U8ZD+]45NWA5)R9,V!_K<$!R(M0>J%BK["N?0A-?
P+=4:GC_9OM%E+OVSYJI 2=XKUMH.)^5ADV 1G+]PG:VF'
M&1;7.WLHI&DGLNI4HK:]V/:T3ZORYU-7E_H6J\M%.62393F6BUB,D@]Y6HM=
M%_+A:$IJT9GT2$?WEDT1H=AO< U*<+.TFW+\Q_F MVX,4<]@O7$E/\M,W+
[(;=;B8;*^MW_LB+L)MI6*\SV*U8:I)!L5G#N>C%,#] M\HCY0SJ&I^9C;2QEPGUK_8U8F-
-7:JRO;EGYE$CURG"CCI)!1"C.==0YJT]<
MQ6JGS_[HZ:9.D%F+ZL(E!7H4QZ+H,N8T3%F'$*C^N2$A=S'"?13'[MLFGQB@ M-
>EA6ES>8;DB6SA749G2V7UMNPI'LY Y><%%T2<_E%S] M=?6L?
72+$[O#DZ_E3K_9W$GI*TQ)K-_2?@&7'Q)7%4&,I=! H3**@S209I^W M;/F3;V4SN@(,7T
[030/]M(=LWDA8 M_FSLYP6_6*FOBF.\HKEI8JD7-
N1MNL']2""VU<=LQ/"C+!:+FG:U)5^B&%X, M(4>*(H,A^=U7RF-;>+-
\M.:_ZAQ)MHT&XPVU",CE'M(#N% WTLGV#+47>5)5 M&A9SI[YO=S:0? !&+IU
WZEM*Q\2,*14)R",PWDM5GO:CLE'ADOU%L@M&EV M2[?$]?76F&&?DNBDY
L,_@Z4C:P^I,H)D]IH5.4L)2:5P(T(X&=P^]RO/A[G MJT(V*<>$JNO[S\T]8:&S_3=U=.-
N3Z-O(\D*K!3N=#;442/=V,PKR^)5"9B M8P%F@>M\>DR)E0VQ#'V$27IY8XFMD_E+
[%CH#Y4D59NM'_Y9R8P)&3G>9K-# MP3309#7DU";RIS8.O$(_)1F$8"S%.X;
(YI.%L=\>JFA"1K8ZK7UNWP]^1$BH M*#-13MN1>=%",CY8LUU"% *3SS2M;
<\2@PC@+R,#54^+Z[3Q!#&)(6N\4+Y' M/LS5JJ+.='2ZPX/',[O[6Q1/Z)?(R>?]-
[.?)V38[$K.0$=&I:-^3D$LW!!R M1&[J,0&O?&2CAQE.FRS6G(3M"J6>MR8??
MX8572PDJ#YOOFC"ZX#<37^EK:M
MPEL.0<<4$CO6EGR&;@JY(D_2A2UV80T;N^AA,5AA-)A/%T\#V?3+2K*JIN%$
M"UZKH"IM++[TI'H=5[W;I+P6SW&(V?<->D:U,Q,%J;
EBF6$RW0%\ZD_Y>32K[T*%FF;R(*(_# \6%D'QA48\L!L6LT^2G%?49>4 MD[SL6\UY-
O"*VJ%'.IN"1@9U@OVW!PI&BP)E[82R!H>J++E,UD-6=@@LVD1=
M0MD756'"X3YSIY3CKD\"'I7*Y'+$S8F-&K,]//F%Q=9LZ$L&W@JU*RR-_%D+
MH4:7L(=E3SWSM#[/1+G Y^"[$H1Z@]S,?DRI(K-I;'LU0,=AJPN?8#10V DB
M#31BDN,,",5=XM& &-&6)/&,O<")&$J.[0LJ^XI-%-8]PH;50.1KJU/K*G+6 M/T&ZG3
LV4KN&M&S)5Z(:;0<\[<1KWY(_7S+R-7E/:_UC[P&?Q\/6=$<]]' MR!;C9S#I/$*':/MA*
(MHN2KNOZ70QQ%(@=A!HH ZF7P4@>WT1 MU#N4+G)7-X;H7A*$VKQLA9S\-
<(<1:5NP +I1PW Q/%]N^1);K1'@X9@B/7 MT:M(\DMDT1W43,P8#?2=@ <;(]08[T4
3MG6H4-9=:PLJ V&V"#_7;+I7'!5P)6BKS%XPJG3K MD/?9'?
KGUASN"LT72@IO&ZB:&1*@>XM0C?#%?,3>T1+1]\1*1%Z/#9(D!_=Z M/K6&ON-S-
[8QWU)^N(*!9;55A',LBU2HR/F">=4\"?-J@7F0P>XU3-&MY M?C#HSL57XWW'1#
(K9?]??\3Y[PYBZG82I4!5< %9Z?<5?,0)R4EEA_/CA]!(
M.F<^X0J^B_AEI9#MKYU#HY%YZ_7]$K&2PS?!XM9/7^Y\@3P8X
MU;J20[!K!3.3!29MV8G:+1,,/767LZ*T6D3'M6^DCV$8\P4V!(0PHEZGM:/0 M;#?
PQESZ)YAA=-1C9@^ O-3 YHH0PX-C#)LE^6!R3!PNZ:?QE4%R!?YO+5B-
MQ+]_NR[SR#^$@6.WI/W%_:+H$)P\^4PJMN29V^91F3RX,X&1R@P^\3ZR!\Z)
MW:T(*>W&G)/E3K#.%7E=$&1C[\7SS$Z9&ZP@3V81QGF_A,L3S"+(LOBR*;-H
M&4B($5QU:!ENA&/LT.&R5,[/_C3PKE9'T-D<%\]^6NJ"P]F":>8 ;0U*?(,X MH@-
U>KG.#!]SC:B6-[9DRR13 4:; MUEP!+=Q+%;L6@B\%@^S0-YJ$^:7+!PS#(/A;72%\!P?
ETY(=+1"3D%E8QC4 MICJOJ'"_U2V(Z&1SMK@,^0T,;D^'7+Q44?
4=]\AV2G)ITB>!EXXE. 7 S^&
M.DZV+R(;XQWBL6O,)URH2]>J>F7U&%;MK+6&F46#4P:^CL8__!Y'QX6S?8T#
M#Q=0CY**$)T(2'=OGUG?%O($T6_2/@/-4)SM$+ZX812\ZCSA&W+XUA'F!_#F
MR"EZ3J%W[P;@%_:_VQ,N1UR8.L&D@>\EUD.PMP5'DMI7)]\7MA0<)QXX^'A@1(!Y&-
^ILE(WI?(/2;:^S.5*'>.F>"J+IE
MJKX%]*3^>Z)7L\6+FYS%*X6.]]6\36(#7]*)&1AE..>I5>Q1]CQ%,?Y!^
M+TK]P\%'%7R)RAET@"1=KY//A9\CFOL5"X>K>.!0X;Y*%;-A;E@F!L/9)?#P
MQG+:K8$%MPQJ.P@Q;^7BZJ?RP2C"7S=A" M"B(B"^9NOO7:OF]4N:KF =(PX-)D1AG(
M+&P)O:Z!?Z)&L$DNCK"L\DVQ-L!=$(_D5*M7?S=AZ=X726?E&TLZ0+;%VP;6 M<6:CA8-
5]-\NI,L1EE1".R.?+=L$M;@4O<^$*5I]6H>I>T1794P\"0G4QS M\/D#F< ME?
*7S+F<.,_VCG,F1RY(H>E4WH'&T77VW8VGP4E=E(KV/J_/]H]/6JV,7->QJ4[T[-N**

&R0Q+E)^E"48T21 M^U13L&309=B,;':?1[3V)(9#O?=(HS=B_\]T^PE^[.>%)>2YY!*
[$.#]CI(O MX[MN];(W?AX*4P7#K0FV4;-]$A7F1>(^O)(6J;=-3&I.>J%9C9$JP=+Y60]*
M&)/BBM)\!^R?N9#NA@QD9F(1Y+EP#SP E^9ZH\]M\T)9HLN8")2@]7&RCG-*
1UM,=NFLK,5X:\=+MS MZGOJSDJ86-#E65W@,YVVCPT4?*
*3WEX\>0S;61010!+T.GUD9$6U?RB<)7\8>+ M*U.D?L*\6I=PXAKHA@MX?]*
<@D<+3P$Z16<] M!'&2#&TX5XEG;X2&^V:PON\K*?9!\EB-H^6#5^^5!?Y8D[O4TA$ O?
A%2.?% MQP0_G_MFA^0??;J2-$5//@-&_'5$#NQ18=@<9(L9'"/1,4)USM):!;,O 5W
M\9NJ;I5>P=BPG9;)0I'%5:.0]DLMDH#6W&:B(_,,"'=7B(-QPN%UFIE$/4-" M=
*DXB"PJNV[I7*5[@>0*(D;+7KINSL@.RC,Z]^,RV9S$"BLSP]NNA.2,6#GI M(%2N?B1:R:*
(_6$ZA\0M9*PH:,TQ*_AK&DB(R>;B3@@-9$<#L3G;LC:(+$&]
M,BD1+4CZ3>2!GQ?'4]3HK+]ED2_R<$_SBY>*3XJ?&(]TE,Y.$2;H QD7_P.*
*MMK,A1CRA)$K%BZ\(^TW%3@"FK99D2NWHGCWT-6_||$6[H*8:$^Z<>SRI=LKZ*
*M3R2#5$QRB6M-GVUJLFPM%Q^K5CBS4H*F3WP6K?6_J2=3'TD*
A(RUIN"']98^S7[O/,$H:%%V.+V\W*>C M:0]>%+I/W&*U'VMJ6"$:3;ZFUQ5D.F*0XYZ4*
MXEZ0F9,P7CLMAN]P9[ZF,'>\4)MGPT;^7UZV@F"O)H'1XW(/W==E\G):=RJ_M<(-
S8##H+M<0#70<ACS+P&MDA& .(03@JOT8G':+)#M1
*M#\OV7JAL$GK8=6_,C$LXV/UG7%SNST3S&_:I=V._68^WJ"TC3@$**"9C^!3%*
M3@-5DL\1+=./IN\AU/.8&,*,7U<=QGFM[)SW.9A+/N(Q7CV?1K(46K77SC2 MPX:>)(=L?*
*%*G2]"X0=3$K?$ANJH:#A/U"*BO8'P0T?'KH.JEJD%>']-T2UA6 MS:=3K6(ZZQIGQ^.?*
UC3R(@;QVBM1^!B<8_.X:R."AY@Q>07YEO/7&34H29#)"[(<,C7. MACP*OT-L!:.*
*[&*TG;.8A)^T'S]F>=(9ZKJZ&/-#S4+FXKBQXJ[T]I^R':%\# M*V(,2,D[W_58U>Q1'T*
MQBZE FL[RHX%1S>(NTP<[%$5)M;$5H"/S5DO35?*
*2MQP8;M_+MFOJ=!RFN3:@JQT9)'J*H-*
*4$BBN"';DDMR*PVLC@L8/15\EO7^29VI6*UG^>M-R,9ZV[*5*
MC.7\7+C2I[YB,;A)CHN'ZR7RS0C#4E59U_YZ^4"'NDMIPW8?\[E]['>C.C+P=V&=*
[8]&DRF' O\M7N.FNLN*U5#'K;"P:]657O MOQHA\@KTP"C4Y$7<0;^+7L]C[V!XD9-*
*EX&,01S]B2-Y2+]H'"SY(=-4AB!=7 MY;BF!(S"TF3%4F%NXO"!)"\1L2*A?I]#^?R)S_MGR5*
:Z) (T7_*,"R=?TB[M&1F1XA"#DPRMI('.C#95?
GX#_ND[,NU9^.D'_V4VCPM7&7R5#R@_>J3M.%5"
*M%#1$(\/XE(DKR$)7&ZG/^-85%M=3!,<7U(%C"V%(]H09%]^NF=T>J_=QV? 9 M*0-*
*C/+T>'DT]IC9I&TD#<=2Q8S''J7,7T_D(J&?N*GZN...A9=.)D8FCY.1[M3Y#2/\YS*/@;*
<\3&OJI4]$@LI+ND,4I>?'&D!,(?])D*^JGIYA%:+>/$S3E M:ZHR_$OD]>#&1@%Z^D/=*
<8QEKRFO4 ^NZ&T[-0RL^<1$VK(UB&-W;Z(B
*M91GX3D@Q:+=_5(.>,3K*39RY:XV7>CPW/)^9]_+O_[2C"4,M72=AX*^7G)0:*
M:Z4Q5P6;S"N:+2T1K(&!!O"J^>SC7I'AA"N6)I\(MC%!N<$/9WJWHDR19<3' MB
[B#R<4$JX-2;+(W(.W,I-1Z#)^.3&=/8$65<$^\HEW5DLC@??%Y53M==#7
*MW[V6&!#F:!-0>3;V\C L*9Q\#DD0;DKIBESQIBAZ\UZ'KKP6EY"[LLE_F'OV M<*
+NGGS2QE7$[2"WX4[XJAM7'#SI5F6EG@G8LE[)K;:^7.5AHWZ#Y?O!-E>H
*M)4J_"J$M.:FOSL0(&YR ,-L$E*A'6*>(!D@I.,3K>5^U8Y=;"A1J*ES;7>Y7+>W\3,X_*A$N!*
*[/HG Y5B%[Z*I:?=0:R4IV^7N;6,CYE_4&',3KB]<<_7S[:5]I<&/ L;1*
*1B'ESPEHHP&FE\DK38< C+8# W4 MIIA*_3I, VWZJ(K00(^0N!C]JY!T&N@SY [5B?*
P:CW+9A#)Z6VQD,&Z7:.&K M-$NZEC*$[VQF,&Y9;"(9
[Z6.!1)B7:^*HQ"\)2NK5=EL&K\K#>Q!H#N=]W M/]>V .T]IQZ-*.@"1ZOHWV4,2*
FXXGCOI]+U=TA=KH9O)?LW;WN#85A5.3\9 MH->\TR-S:VGF7KDIAZHZLQZ%LYKOG?
*1$P\N2GT2+R(69\@&#*J30J.TL(OEE MWYM+EVXO^:U##3>*
*K6S#B^W_KY\OI">N7Z^Y,QY\]-NMQSZY9G.2*SFXF -= M)#-*
J7V4&LZHD+.:++A89\IBM#,NM9\MM-:_KEL>HK]8P['K&\VUU#7/V6>V0
M$]5TW&QG4C_VUNPIG//5;^3(6XN^@.@0.K4+#5.P?47&7">3B:?]IU"1&17G
M?]3@HO2^]L'FFI!E8X5-X9A:N+F_J5Y>N UK6+N9^,2A9S9Q^TFM
*MH4R4A*6U1GNP7)#X,..NG2+6B^D5A1^?%.[=!9Z7&RD.RAMVM;#'^@2NMMBG*
M'VU7UL):Z][%EQH5<_V+3I'EPS_&&V;.^:U:S;-U.1;1M0#5*^/*(S%T,'"*
M6S5ZZHP(>D;=JD)C+@TR_84KFRB) ,OE2K,A(YT=KH=>^JR?Y)-FH [ZK3N%
MK7UBB(LC,+-M?WP7$%).D35[5?RRB"6XW' MDE-CYVH_!PHS<_0.2345=^*G9&Y'1']*
*()&5._*UHZEGB\P].(W[1WAT7 M9O1>131^'"#-^ZCAM:]X CH]@MSH]?/4_>\|S(;9 AAF7!*
*M50(X?2*JRJ&G%E_.?X99^CMLK,XAGY6SW3MR-*
MUK6+DXGP>UV=$(\XJ59R)IU7^QK1M@!^+Z1E A+?DD*_HCYQIF_"\,Q$99IK
*MCB'N=:%#'_7K;$:%N;P\K[.*O8BELDM6I+_>L31Q-U97939!/L$M3:I;7F)WF8B]^_*
M8]W-+X0;Q'Q),6M9H<9D3=L8U&H M-# ^FV6?8[4P8CFQ>,F\0[3

WW*55^AT5:+=S^R+A]Y_YWF_L&31'GVF!9OZ M\MB;%-+@ M7//1=Z["-J6!
[8NB"PX)1<7N;NGS===>QUO=-+S_K0+R#2Q$=<\E\>,VD$._D MK8@"4=YEX0$?
Q2W1M@EM*>4.E>^]RM)E? 9''KT%@9S'].],9(9?"/W[$?'N M#O68)@TDJ*U+
WUL1\XGBX[(=R&^-
YVFY+)6Q)W1]A^DP\EM2%O*G*H8&TA3_3[D7HB5/+G#)!\N(1BR9'ZZS\/:] M$Z<[_:
JOI\P.J]],36^J^*M/-[%:]2C 215LCHEO8X% M/S4Y%(YZ4&"$*PGNA87K>^%6"
[;I'B*ZAR0/3R1XUJZZ%TN8&D?UU-6'*RH< M8NH/%S$Z:4=8T@'FS):L7P7\.
0_C4<$X==WT*@S*IQ3W$SL,#1Z,)'MYE+* M--OGJ-$$485+5F-BGIIB'F.K6@P?
U$@5W9HD6;@U_OWR/<)0\\01HB7!T(1@ M^-60;SXE,3\'?@T_%_Q^0.+A2GO.8/Z]=Z-
G2_42C#B-7S.OL2='1F8,6HC, M #TXXIC(+$M3MLV&P\K;'P2P23$^UEZVQ'HLA@?
F9TA@;4ACJ\"),MH_'=<) M.S)Z3U'3K8U/D5OQ;/@F:F1J^R(QC60.OT$IW2H"N!(J$\$4
3X,E[7'BHK; M##*:!5P?$_OD/ F]W.K%=OS!D::J Z6=B*(>;1&OC$0_VT^H*,05:H_JP:$M
MR%.J?"7^!N;3:M&DN"MZJ.1(F/*BH6)4>9]23?2$\X!>R_34P]!6SK-^$+P6
MY+DMFRH3W)W@FU%(%&[E8FJD2#=QN<=B26NA>T+QCCB27C4/TW+YY]+=$F\B
M/_W#L@,;;B/TBA26S*!3GD!P^$=4/5#6R-LO>:8TNU3GV&>E8#/ZO+-X[=)" M)!],
3;T)24XA+5C(1:CMNTAQ@#QK@%+=&L9/RO/$[BH\ZWHPT5A^F(R,08
M=7M60=Q>LBHS/A/FV"C');A1F<^;]K'"7^(4N%R$ WWA6XL":.[I$4.+_N S
M54$"4EFU_S8\J=Y1-@U(TX;N,0LQ-NQ/J#,5I8ZF+'N8WL,N50.V3.Q 3-K
MZAUNWVO?/T6C;L7V!''1-FP:ZKCTWNW^I]7DBX7WLK-HD-D;?@XG:88T(1ZT M)/:]?
S:KB56+T;_'M%DRF$2:6](U]PB^%#>.0E%!.7'8G/K]6]#1SQKLUWA%
MK+BKG0P.;KDB>PW26WN"A7HTB2!I:#0K%-2:^S88I997[/\(<="R)F")''D>
M_5H7BD11#^ #D8V*"/X#[?-95$QB&@UT^1)9P*&Z3AK:!1]E M(@I+-
DMYT$#,EU>A2>#V>L@DBLP2W8$>B50*B?1AJ-!^$6*MVO?H6>CR^BE&
MIKOT0ZR;6ZP]P5BQSY']NU9%X^,!([:S;AHACXQGNAPH=SJ>P%;$I\)%>D4R
M;\9FBIAHTH% "J"3_7LB);E7OOQ/+N#ZOSE*9,HHK^#[-^>C@;YB3FV)Z@4@
M;Q,>R^5GDXRF))%>^$KFW ME94=>59:'SM\^8U42O//&V6WS-
XT#STTR::P9%P.I7.RX1FJX#73[]ZT5C89 M9'!3W^YMXI" ?E,\XLRJH>/5]5W?
Q>@JQSI9!;\\^/AK&?')U2?0TXKQID'E M/V\\+CAUP#5H-"P5=+RMFG"CEFB/!:(9?2-
VF"R-;2-?<:WZUIO=._F$P_=- MOLXQ?]?G<9>R#J6,9D82_%S2LO2C4!7':0_SF#J?"M
MB/)'EQ1XC@UF1AQNW[&XDK9N*;9MZE7T*D+V4]M!A4IO#NW(T^M2@5=% P],
ML5K7G4B\U.=?Q,\E)_B%L?F8/%=XE6';&>E*.!ZJOIWFQ8G+EY!#YQ MNE?
BX:I;=J],LGB)^^&9[Y+V+-I>"O90)4W1D'C/_(DOE28&GH?9^4[UK!UJ
M<@/KOK8:8VQ[D6BDD/+H8%BJZ(8."*2X^Q3D4"[R]GB4 '8MI Z"S?.VAJ#W
M3@1'N(FDBZN.&@1SZV0SU>F47GQQDN?(V!$_D%?*)Y7+.3$L:5"2M#YUU!5: M*I>U?
8?ZL]M]?#JYM*ZU-BUY--W#+._M\2L"V) @\I6W$\X6R& 5V7LY+E*[M.[YR(R9UC_S:F-
]J/WS6<1#&EU#S'R[(VU@CGXF@ZD3'TT#W7M% /5)F MU3!1ZK5Z;FKC-
@VT=\$5,.'_\LP2/FZJ5@4-A&;J7\]# G9-M-M+,3;2?!+R MX?<>
[[\^6#=L5YQI(&$3_'MJK08-E&.RF0,?(ED@VWY]?E3<30,MF,"L-*CS MJ*_[GV
;>%'7:"#H+]GJ+=GI&HQ+H.[N]9I]?MRH>>;F@?_UPZZX &=:,0%G MR2_8?
4(NRQMQ]$L27?Y!=O3D=\QUN-U]F9E[[708 Q]3/\-)8_G1E4=:Q"$_ MS$*
([YXZ.O^F:U)GP+P9M;#SNNBY"DEF!CJFPXN:X7..VT"%:L/2=LJ$086A MI4)&J=(
U6*4V;:.F8;-ME_%1%9Y!.8 M .'=LYYC@&?%;&%6:* ^8.>./P?Y3#3)OE74R9Y&FO3@-
%/K]!9C>Y>R1EK451IO47.#M8ELPNGV?*[DI.3C#YI6(4A<]%'C\DT_3>MJ ZNJ%RU]:R
&DSD MJE_,%6E&OB#=O[7D1 HQ%<20E4 (\1J47":$EAQ=J0S:L):?\O6H,+WA@WZV
M\^S@Z0^P5Z/ @%X(WQZ?@0Y3LIS3)J[KEBD3TI9["/GVTC9S)Z[)?6'R:@C
M#XW,_UP;'7K,2^@@Q 9[=E4DELM?(J/#/TA=T#B_K!CG.M7YQ@L-IQ!_K]
[OTT1"_E%_= 9Z47*'I0"EIAC@- T.-HF+D M.S#;I(=N&R^>$&H5?
MZH7BJW6_.XB72%I2ZK&Q+590TO?9WE0)6[R1]9OY$J MC>*<..2_4/.,5"/SN[V,L-/3/<-
=^#_=V0Q'A=QZV_PY(^S&81H(>ZP? M?6B\#
("'X*YG)08H%\5R15HJ/;R9I\%U30TIV9AZQM0<1>!;AV!/]NN;6; R]A\$&+UV+34"-L-
6"Q5C!R4 3 <5H"_N\0 MN\[\U[L ?_!*%!["="N%2Y77^;!HUV3&8?D)OA5EZ4>
[M18:G71)*R1S(4:$M MJSVSH&R"5@:VZ.({]/#B!3&V1YIGJ3T5RIRW3.[M[+8F@
UWB8:K#2IP5;[, M[ZXFKN,>@09+EC9SJ5HL=T;*G(?
SAH[R$8I2720]5,5)QL95DW36'BW#>O* 357X ,1DP%^?6]K2Y X2-!BSY6B532#T+
MMAUXAQS6:!\(<07+R$ #E;M)_>&&&G^&-IM9WM^Q)CJ%U*RA\J LW MO#.U >,6U?
@#+6V.1)*7 HS]CE^X#<'D5XR\X6^_#KE9EJ_R2'AK]1P_>U M%C]E[?
3DL)CQBS.?"BEWDZYM,Y=S1$C71YHOU!PE97-]3+(YY]HE M1KQ.L=NXAH
"%%O9J*LGCK]Y2%E56IE:\] &QMIMNU6D.JZZ>!@/Y&Y)!- GEN&_!Z0+0K6S"*

M=IB=LJ@7'=&UQC%U5[/VY4]RFCKK;'2GU80@_[,9A7_A@K@7X1]!TNI[!+V0
ML5_Q2\P5^4L0;Y;;]9A0TWDM%8$*?]4E:Y?X\W<'Z^=S.NE2CDP[*G!7\3G M:-
JEW6YN,%@CJOM;K4!7-[2PPF9\K M^,O,H0QH92/?]=?E%A;"KWC<_'H7T%\K_E
XCU.ZT4IWC2;0V)E']/"#XJJ MUK:^.Z',^S=-
S\V2FN^^@2D;G;U,1Q7:9\/Q_2MT>&B@4;;5COA?8Z28I[PR MU>V'ZPB< $3"(5L7[=03"
L9H=R/Q(YVH3TP:N^PVGRP*2-H+GO7/]>R!-# M R$L27]JS!"E+<+;Y:D"S$'
.LH;C1C((YTL)KTN=6$VPZ6!^3U*&4(CR^$Z M9S*(ZEL2[(_ #732GD":"!S7L3'*@>K-
W\HG++UKZ[+4$\X_>8='O'VC.HX M4*NBD7O&&H-4&.6"]/KPFCPE&,9 CJD@"4Q3T$
5C7N33[".V-E@O1=NU_N\
M[O6:&I%^9'D)OQ,Q5#]*V/A^Y7JU_3&7M11)GU[=LL[.>XK=,X%N$U? 6C%(M9
.B/"%EJ(%?_C 2>ZI?+MD72@JHE-LM3J52?VEY<[A2\,$C^^ /W =_]N6U
M]98LYY<3MU3WP5^FG9Z:);SZTK!T?W4>[UMGBJC\"N(B_V*G3-,A!Q-
JL=.N>AIUA]P#3H&NA/];(G"0QHR/%L"2"^OZ)@/T'ZR_M2#?
J+Y)W7X=W)F,BURB#C]T5274]?\$#5$M%G:)D.9+YE8+_80V)5XB8-P\=
MDGA]WP&PO4L=($C^POXBXE[,O\-^@EW7C6H ^[^I!ZA,)VO*3CJ_Y=OG35S/ MA9,_?I-
<^4B?RN7>0IYRK7N]%/HZ /?V*^4]SE!,GGS.(OW&$R##.8TXJEI% M 7@="TU>2#;>/*
[VM[D237M*5;.M\X5?'OU1T4CX5T!)\I6?XX@%U/QDX=M2 M'S
SQP[X*):Y1P44#_=46F[M;V6B*TT)LV'ORUA\?M0YJ<&#$X5B8OJARF
M"9'JW;027@I5_H-@*2I3J_+^V M[-)C+IE'C+TJT)@2_\"1[F;%5&C,#I#_LF)
(]S$35M486.0-=NJIE:OY=^6! M85E,GNC;9YK.%#2GR<^L\>^H\C4?\.HUOSL*D$3RUC?
U+P!)UGVOC0+; M40^DD$TL^;N!4CC)%6[]YEV/AK%]'19Z["!TY5B\Y*B*QMPR\&8:-
T=GEW^O MK[4\A?Q+AL- I"]/:_[*\'RAPSZP[P/ OO'M/F;FQ/Y"GW^P'RJVG3;Z/%EV
M=&3OCL->V #F@65&74[V]4=!*T?8?UQ> V3N+K-=<5],_=>_1IPB8RJ_71*F
MWP!LOP&9HYHEEP'(4:Z+%=IGRJS8YICTCG_^X%JS^),9, .F$ %-FN/>#SI8 M/K+
[#SD6":650P'+Q^!_RQF;2KDT"+E"+A$%;INKO!-^]4O5XW]5>\;W"];] MF(>$TQD
EKF>VLH[T$!5HW;0-[%KI.&6%N?+0P\?!. .*/YSL,@56V;*2UT M7 ;OZUIXO@*LJP9?
P+COX_HVD%&N'. WJR,PCQWB.]7/*?]J0Q7C%ND?*[0, MI+!:5/&Y>_UYPK]@WT;YWI?
Y"5).UTT)!N99]/:/SE%DN9OGR39N*&:IYK1T MG_2%>8ZP$VNA#=VWJ:E;])R-_>+
(VLNMF*WHRUMIRJ)WE6+"0/=5./-YO/?EDP;ZL'^Q M9 J$0H2N2?
SVEZ3)3A=149)&,XR>>FI<+[[OGU%;X4_4U@*4/H\!;Y-M,#8%
M_/7L2NC4VMZW*>K/JOM_K+AJD,%:^+0!#_+OIA#C"Y:NA.0KD_EO]>0=EL$
MHAKBWRX6TIU\CU/C_D5D=7=&2I9KG*_6/HRM?RSM1P#U['_H^:;I_0E8Z-@K
MU5/]!X_*^?\VL[!],\N+^94L#FD;$T3*_P..=4A>*$ZQ3K['#E*(A?\SECF(
M]EWZ;1M7>)+^6?T/U%#)5@,EFA639TA*!C6/3_G?/;@86O'--
@G+W/V18X\@L"50_Q2>I#]]!S;>-W^?\7H[M,$D[F)3R@S[/XI2_XS:'@^!15:*>:3G^4
.U+U[S9?+H\"_\M6^_"W'O!X!J$$9B2$^I>J/4AM8ZYSPM6W@971S]GF]?
NNRWQ.=GW/T/]LNN@ M1.UC]S$@Z=^5CYI;A4#!]UYSQW%P0M9%3L@*3S_'5W'_M-
\)#+WD>S\ZTSEL MY%<83;^])_[6]Z/>N_WS\F=>!]W][_M]MN.8S_#@;6'=++[+
[_%JS:PP_+OE44;SRU_%"@,2LPS%;E;_UW<>Z3I8MU.K?(\$,:TJ5 MA-
E_6]Y9=^P2)#TK@=/ST3U+:X$U\+MD8 0[U;UD6_8[OJ/F[_P/":^D:^[K
MU]]^NW'[V93[O3>/75 Y'KN&_1Y+("R&UL4$L! A0#% @ TX)M65I& M=+$=+P L"<$!4
(!&Q< &1M86,M,C R-# Y,S!?9&5F M+GAM;%!+ 0(4 Q0 (-.";5E= 17JK$ /M^ P 5 " M
6M& !D;6%C+3(P,C0P.3,P7VQA8BYX;6Q02P$"% ,4 " #3@FU9A%PR M'W@R "YBP0 %0
@ %*AP 9&UA8RTR,#(T,#DS,%]P&UL4$L! A0#% @ TX)M6=75TG/HX0 D0\- !0 (! M];D
&1M=' R,#(T,#DS,%\Q,'$N:'1M4$L! A0#% @ TX)M63VTQ7UP M" Y# T (!#YP!
&5X7SXIF@(M,0 #0 @ &JI $ 97A?-S0S M,S8S+FAT;5!+ 0(4 Q0 (-.";5F:E8T&%\W-#,S-
C0N:'1M4$L! A0#% @ TX)M678LYK9T! MIA(T (!V[$! &5X7S XML 70
dmtp20240930_10q_htm.xml IDEA: XBRL DOCUMENT 0001401040 2024-01-01 2024-
09-30 0001401040 2024-07-01 2024-09-30 0001401040 2024-09-30 0001401040
dmac:ExercisePriceRange5Member 2024-01-01 2024-09-30 0001401040
dmac:ExercisePriceRange5Member 2024-09-30 0001401040
dmac:ExercisePriceRange4Member 2024-01-01 2024-09-30 0001401040
dmac:ExercisePriceRange4Member 2024-09-30 0001401040
dmac:ExercisePriceRange3Member 2024-01-01 2024-09-30 0001401040
dmac:ExercisePriceRange3Member 2024-09-30 0001401040
dmac:ExercisePriceRange2Member 2024-01-01 2024-09-30 0001401040
dmac:ExercisePriceRange2Member 2024-09-30 0001401040
dmac:ExercisePriceRange1Member 2024-01-01 2024-09-30 0001401040

dmac:ExercisePriceRange1Member 2024-09-30 0001401040 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001401040 us-gaap:EmployeeStockOptionMember 2023-12-31 0001401040 2023-01-01 2023-09-30 0001401040 2023-07-01 2023-09-30 0001401040 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001401040 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001401040 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001401040 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001401040 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001401040 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001401040 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001401040 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001401040 dmac:The2012DSUPlanMember 2024-09-30 0001401040 dmac:StockOptionPriorPlanMember 2024-09-30 0001401040 dmac:The2021EmploymentInducementIncentivePlanMember 2024-09-30 0001401040 dmac:The2021EmploymentInducementIncentivePlanMember 2021-12-03 0001401040 dmac:The2019OmnibusIncentivePlanMember 2024-09-30 0001401040 us-gaap:RestrictedStockUnitsRSUMember dmac:The2019OmnibusIncentivePlanMember 2024-09-30 0001401040 dmac:DeferredShareUnitsMember dmac:The2019OmnibusIncentivePlanMember 2024-09-30 0001401040 dmac:The2019OmnibusIncentivePlanMember 2024-05-22 0001401040 dmac:NonemployeeStockOptionsMember dmac:The2019OmnibusIncentivePlanMember 2022-05-18 2022-05-18 0001401040 srt:MaximumMember dmac:EmployeeAndNonemployeeStockOptionsMember dmac:The2019OmnibusIncentivePlanMember 2022-05-18 2022-05-18 0001401040 srt:MinimumMember dmac:EmployeeAndNonemployeeStockOptionsMember dmac:The2019OmnibusIncentivePlanMember 2022-05-18 2022-05-18 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember dmac:The2019OmnibusIncentivePlanMember 2022-05-18 2022-05-18 0001401040 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001401040 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001401040 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001401040 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001401040 dmac:DeferredShareUnitsMember 2023-01-01 2023-09-30 0001401040 dmac:DeferredShareUnitsMember 2024-01-01 2024-09-30 0001401040 dmac:DeferredShareUnitsMember 2023-07-01 2023-09-30 0001401040 dmac:DeferredShareUnitsMember 2024-07-01 2024-09-30 0001401040 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001401040 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001401040 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001401040 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember 2023-01-01 2023-09-30 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember 2024-01-01 2024-09-30 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember 2023-07-01 2023-09-30 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember 2024-07-01 2024-09-30 0001401040 dmac:The2021EmploymentInducementIncentivePlanMember 2024-09-30 0001401040 dmac:The2019OmnibusIncentivePlanMember 2024-09-30 0001401040 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001401040 dmac:DeferredShareUnitsMember 2024-09-30 0001401040 dmac:StockOptionsOutstandingMember 2024-09-30 0001401040 us-gaap:PrivatePlacementMember 2023-06-21 2023-06-21 0001401040 dmac:DirectorsAndOfficersMember us-gaap:PrivatePlacementMember 2023-06-21 0001401040 us-gaap:PrivatePlacementMember 2023-06-21 0001401040 dmac:ChiefBusinessOfficerMember 2023-04-10 0001401040 dmac:ChiefBusinessOfficerMember 2023-04-10 2023-04-10 0001401040 us-gaap:PrivatePlacementMember 2024-06-25 2024-06-25 0001401040 us-gaap:PrivatePlacementMember 2024-06-25 0001401040 2023-12-31 0001401040 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001401040 us-

gaap:LeaseholdImprovementsMember 2024-09-30 0001401040 us-gaap:ComputerEquipmentMember 2023-12-31 0001401040 us-gaap:ComputerEquipmentMember 2024-09-30 0001401040 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001401040 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001401040 dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember 2023-12-31 0001401040 dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember 2024-09-30 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001401040 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001401040 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2023-12-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2023-12-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2023-12-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2023-12-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2024-09-30 0001401040 us-gaap:FairValueInputsLevel2Member us-

gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2024-09-30 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2024-09-30 0001401040 us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2024-09-30 0001401040 2023-09-30 0001401040 2022-12-31 0001401040 us-gaap:RetainedEarningsMember 2023-09-30 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001401040 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001401040 us-gaap:CommonStockMember 2023-09-30 0001401040 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001401040 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001401040 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001401040 2023-06-30 0001401040 us-gaap:RetainedEarningsMember 2023-06-30 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001401040 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001401040 us-gaap:CommonStockMember 2023-06-30 0001401040 2023-04-01 2023-06-30 0001401040 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001401040 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001401040 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001401040 2023-03-31 0001401040 us-gaap:RetainedEarningsMember 2023-03-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001401040 us-gaap:CommonStockMember 2023-03-31 0001401040 2023-01-01 2023-03-31 0001401040 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001401040 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001401040 us-gaap:RetainedEarningsMember 2022-12-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001401040 us-gaap:CommonStockMember 2022-12-31 0001401040 us-gaap:RetainedEarningsMember 2024-09-30 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001401040 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001401040 us-gaap:CommonStockMember 2024-09-30 0001401040 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001401040 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001401040 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001401040 2024-06-30 0001401040 us-gaap:RetainedEarningsMember 2024-06-30 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001401040 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001401040 us-gaap:CommonStockMember 2024-06-30 0001401040 2024-04-01 2024-06-30 0001401040 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001401040 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001401040 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001401040 2024-03-31 0001401040 us-gaap:RetainedEarningsMember 2024-03-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001401040 us-gaap:CommonStockMember 2024-03-31 0001401040 2024-01-01 2024-03-31 0001401040 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31

0001401040 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001401040 us-gaap:RetainedEarningsMember 2023-12-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001401040 us-gaap:CommonStockMember 2023-12-31 0001401040 2023-01-01 2023-12-31 0001401040 2024-11-11 thunderdome:item utr:Y shares iso4217:USD shares iso4217:USD Q3 2024 --12-31 false 0001401040 false false false false P1Y P5Y P4Y P1Y P10Y 0 0 Unlimited Unlimited 0 0 10-Q true 2024-09-30 false 001-36291 DIAMEDICA THERAPEUTICS INC. A1 301 Carlson Parkway, Suite 210 Minneapolis MN 55305 763 496-5454 Voting common shares, no par value per share DMAC NASDAQ Yes Yes Non-accelerated Filer true false false 42760582 4134000 4543000 46063000 48352000 290000 369000 280000 411000 50767000 53675000 1308000 0 298000 354000 151000 131000 1757000 485000 52524000 54160000 1171000 926000 3024000 1777000 88000 80000 14000 3000 4297000 2786000 249000 316000 14000 1000 263000 317000 42766497 42766497 37958000 37958000 179985000 166609000 81000 6000 -132102000 -115558000 47964000 51057000 52524000 54160000 4983000 3272000 12587000 9433000 1900000 1885000 5675000 5986000 -6883000 -5157000 -18262000 -15419000 616000 693000 1739000 1220000 -6267000 -4464000 -16523000 -14199000 7000 7000 21000 21000 -6274000 -4471000 -16544000 -14220000 132000 -64000 75000 -53000 -6142000 -4535000 -16469000 -14273000 -0.15 -0.12 -0.42 -0.46 42751577 37949422 39604179 30751329 37958000 166609000 6000 -115558000 51057000 5916 0 0 0 0 488000 0 0 488000 0 -45000 0 -45000 0 0 -5151000 -5151000 37963916 167097000 -39000 -120709000 46349000 100000 4720000 11747000 0 0 11747000 5916 0 0 0 0 2750 7000 0 0 7000 443000 0 0 443000 0 -12000 0 -12000 0 0 -5119000 -5119000 42692582 179294000 -51000 -125828000 53415000 5915 0 0 0 0 68000 126000 0 0 126000 565000 565000 0 132000 0 132000 0 0 -6274000 -6274000 42766497 179985000 81000 -132102000 47964000 26443067 128078000 -74000 -96177000 31827000 17621 4289 0 0 0 0 422000 0 0 422000 0 45000 0 45000 0 0 -5272000 -5272000 26464977 128500000 -29000 -101449000 27022000 1400000 11480156 36852000 0 0 36852000 4289 0 0 0 0 380000 0 0 380000 0 -34000 0 -34000 0 0 -4477000 -4477000 37949422 165732000 -63000 -105926000 59743000 4000 -0 -0 4000 4289 0 0 0 0 425000 425000 0 -64000 0 -64000 0 0 -4471000 -4471000 37953711 166153000 -127000 -110397000 55629000 -16544000 -14220000 1496000 1227000 1013000 856000 56000 52000 28000 22000 -79000 228000 -131000 860000 1308000 -0 245000 129000 1188000 -182000 -15642000 -14916000 39623000 64537000 43000000 40135000 18000 21000 3359000 -24423000 11747000 36848000 133000 0 6000 5000 11874000 36843000 -409000 -2496000 4543000 4728000 4134000 2232000 30000 0 20000 26000 1. Business   DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), exist for the primary purpose of advancing the clinical and commercial development of our proprietary recombinant KLK1 protein called DM199, for the treatment of neurological and cardio-renal diseases. Currently, our primary focus is on developing DM199, a recombinant form of the human tissue kallikrein-1 (KLK1) protein, for the treatment of acute ischemic stroke (AIS) and preeclampsia (PE). Our parent company is governed under British Columbia's Business Corporations Act, and our common shares are publicly traded on The Nasdaq Capital Market under the symbol "DMAC." 2. Risks and Uncertainties   DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration

(FDA) in the United States, the European Medicines Agency (EMA) in the European Union and comparable agencies in other countries. We are in the clinical stage of development of our initial product candidate, DM199, for the treatment of AIS and PE. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. DM199 requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all.   We are currently conducting our ReMEDy2 clinical trial of DM199 for the treatment of AIS. Our ReMEDy2 clinical trial is a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial intended to enroll approximately 350 patients at up to 100 sites globally. Prior to the clinical hold of our ReMEDy2 trial, announced in July 2022 and fully lifted in June 2023, we had experienced and are now continuing to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to another hospital or an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring and overall program management. In addition, we made the decision to globally expand the trial and to this end we have submitted or are in the process of preparing regulatory filings and identifying and engaging study sites in the countries of Canada, Australia and Georgia. We also recently revised the study protocol to widen the inclusion criteria and reduce the burden on participants and sites. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to mitigate the impact of these factors on our ReMEDy2 trial; however, no assurances can be provided as to the success of these mitigation actions and if or when these issues will resolve. The failure to resolve these issues will result in delays in our ReMEDy2 trial.   On October 9, 2024, we announced the receipt of regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) to initiate an investigator-sponsored study of DM199 in PE. We are financially supporting the conduct of a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE at the Tygerberg Hospital, Cape Town, South Africa. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject was enrolled in the fourth quarter of 2024. Part 1A topline study results are intended to demonstrate initial proof-of-concept including whether DM199 is safe, lowers blood pressure and dilates intrauterine arteries to increase placental blood flow. These results are expected in the first half of 2025.   Our future success is dependent upon the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability, or the ability of any future partner, to obtain required governmental approvals of our product candidate, our ability to license or market and sell our DM199 product candidate and our ability to obtain additional financing to fund

these efforts.   As of September 30, 2024, we have incurred losses of $132.1 million since our inception in 2000. For the nine months ended September 30, 2024, we incurred a net loss of $16.5 million and negative cash flows from operating activities of $15.6 million. We expect to continue to incur operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical study of, and to seek regulatory approval for, our DM199 product candidate. As of September 30, 2024, we had combined cash, cash equivalents and marketable securities of $50.2 million, working capital of $46.5 million and shareholders' equity of $48.0 million.   Our principal source of cash has been net proceeds from the issuance of equity securities. Although we have previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data are not positive or if economic and market conditions deteriorate.   We expect that we will need substantial additional capital to further our research and development activities, complete the required clinical studies, regulatory activities and manufacturing development for our product candidate, DM199, or any future product candidates, to a point where they may be licensed or commercially sold. We expect our current cash, cash equivalents and marketable securities are sufficient to continue our ReMEDy2 trial, support the Phase 2 PE trial and otherwise fund our planned operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the rate of site activation and participant enrollment in the study, the Phase 2 PE trial, the potential expansion of our current development programs, the effects of ongoing site staffing shortages and other factors on our clinical trials and our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable. -132100000 -16500000 -15600000 50200000 46500000 48000000 3. Summary of Significant Accounting Policies   Interim financial statements   We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. These condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly our condensed consolidated financial position, condensed consolidated results of operations, condensed consolidated statement of shareholders' equity and condensed consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2023 was derived from our audited consolidated financial statements.

These condensed consolidated financial statements should be read in conjunction with our annual consolidated financial statements and the notes thereto. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.   Cash and cash equivalents   The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.   Marketable securities   The Company's marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and/or investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations.   We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive loss, which is a separate component of shareholders' equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of September 30, 2024.   Fair value measurements   Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. <p style="font-

family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> The hierarchy is broken down into three levels defined as follows: Level 1 Inputs — quoted prices in active markets for identical assets and liabilities Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs — unobservable inputs   As of September 30, 2024, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled “Marketable Securities” for additional information. Cash and cash equivalents   The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments. Marketable securities   The Company’s marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and/or investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations.   We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive loss, which is a separate component of shareholders’ equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of September 30, 2024. Fair value measurements   Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction

between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.   The hierarchy is broken down into three levels defined as follows: Level 1 Inputs — quoted prices in active markets for identical assets and liabilities Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs — unobservable inputs   As of September 30, 2024, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled "Marketable Securities" for additional information. 4. Marketable Securities   The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="30" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value Measurements Using Inputs Considered as of: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">September 30, 2024</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman",

Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-

bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 20%;"> Commercial paper and corporate bonds </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,287</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,287</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21,764</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21,764</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family:

"Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Government securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,776</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,776</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,588</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,588</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman",

Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,063</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,063</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,352</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,352</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   Maturities of individual securities are less than one year, and the amortized cost of all securities approximated fair value as of September 30, 2024 and December 31, 2023. Accrued interest receivable on marketable securities is included in amounts receivable and was $288,000 and $298,000 as of September 30, 2024 and December 31, 2023, respectively.   There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the nine months ended September 30, 2024. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="30" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value Measurements Using Inputs Considered as of: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">September 30, 2024</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size:

10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 20%;"> Commercial paper and corporate bonds </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,287</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,287</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21,764</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21,764</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,776</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,

0);">19,776</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,588</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,588</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,063</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-

family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,063</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,352</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,352</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 26287000 0 26287000 0 21764000 0 21764000 0 19776000 0 19776000 0 26588000 0 26588000 0 46063000 0 46063000 0 48352000 0 48352000 0 288000 298000 5. Amounts Receivable   Amounts receivable consisted primarily of accrued interest receivable on marketable securities of $288,000 and $298,000 as of September 30, 2024 and December 31, 2023, respectively. 288000 298000 6. Deposits   We periodically advance funds to vendors engaged to support the performance of our clinical trials and related activities. The funds advanced are held, interest free, for varying periods of time and are generally recovered by the Company through application against final study/project invoices or refunded upon completion of services to be provided. Deposits are non-current when their expected recovery is not within the next twelve months.   <p style="font-family:Times New Roman;font-

size:10pt;font-variant:normal;margin:0pt;">7. Property and Equipment   Property and equipment, net, consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Furniture and equipment </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Computer equipment </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">110</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">87</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr

style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Leasehold improvements </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">254</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">231</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less accumulated depreciation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(103</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Property and equipment, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">151</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">131</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman",

Times, serif; font-size: 10pt; margin-left: 0pt;">110</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">87</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Leasehold improvements </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">254</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">231</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less accumulated depreciation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(103</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Property and equipment, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">151</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">131</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 128000 128000 110000 87000 16000 16000 254000 231000 103000 100000 151000 131000 8. Accrued Liabilities   Accrued liabilities consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Clinical trial costs </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,297</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">258</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Research and development services </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">896</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">632</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Compensation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">730</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">766</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional services fees </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">98</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td> <td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total accrued liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,024</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,777</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:

0pt;">Clinical trial costs </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,297</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">258</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Research and development services </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">896</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">632</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Compensation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">730</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">766</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional services fees </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times

*New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">98</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total accrued liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,024</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,777</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 1297000 258000 896000 632000 730000 766000 91000 98000 10000 23000 3024000 1777000 9. Operating Lease   Office lease   Our operating lease costs were $78,000 for each of the nine months ended September 30, 2024 and 2023. Our variable lease costs were $64,000 and $66,000 for the nine months ended September 30, 2024 and 2023, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.   Maturities of our operating lease obligation are as follows as of September 30, 2024 (in thousands): *

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">113</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">116</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">119</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

Total lease payments </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">386</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less interest portion</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(49</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of operating lease obligation</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">337</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   78000 78000 64000 66000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">113</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;

background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">116</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">119</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total lease payments </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">386</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less interest portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(49</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Present value of operating

lease obligation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">337</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 28000 113000 116000 119000 10000 386000 49000 337000 10. Shareholders’ Equity   Authorized capital shares   DiaMedica has authorized share capital of an unlimited number of voting common shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company’s annual general meeting and any extraordinary or special general meeting.   Equity issued during the nine months ended September 30, 2024   On June 25, 2024, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 4,720,000 common shares at a purchase price of $2.50 per share in a private placement. As a result of the offering, which closed on June 28, 2024, we received gross proceeds of $11.8 million, which resulted in net proceeds to us of approximately $11.7 million, after deducting the offering expenses.   In connection with the June 2024 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the June 2024 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on July 10, 2024 and declared effective by the SEC on July 18, 2024. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered “Registrable Securities” under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.   During the nine months ended September 30, 2024, 17,747 common shares were issued upon the vesting and settlement of restricted stock units and 70,750 common shares were issued upon the exercise of stock options for gross proceeds of $133,000.   Equity issued during the nine months ended September 30, 2023 <p style="font-family:'Times New Roman';font-size:10pt;font-

variant:normal;margin:0pt;"> On April 10, 2023, in conjunction with his appointment as Chief Business Officer of DiaMedica, Mr. David Wambeke purchased 468,750 of DiaMedica's common shares at an aggregate purchase price of $750,000 or $1.60 per share.   On June 21, 2023, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 11,011,406 common shares at a purchase price of $3.40 per share, or $3.91 per share in the case of our participating directors and officers, in a private placement. As a result of the offering, which closed on June 23, 2023, we received gross proceeds of $37.5 million, which resulted in net proceeds to us of approximately $36.1 million, after deducting the offering expenses.   In connection with the June 2023 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the June 2023 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on June 30, 2023 and declared effective by the SEC on July 7, 2023. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered "Registrable Securities" under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.   During the nine months ended September 30, 2023, 17,621 common shares were issued in settlement of deferred share units and 12,867 common shares were issued upon the vesting and settlement of restricted stock units.   Shares reserved   Common shares reserved for future issuance are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New

Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon exercise of employee and non-employee stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable upon settlement of deferred stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable upon vesting and settlement of restricted stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,913</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,005,399</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Shares available for grant under the 2021 Employment Inducement Incentive Plan </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">357,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt

18pt;">Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,286,136</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   4720000 2.5 11800000 11700000 17747 70750 133000 468750 750000 1.6 11011406 3.4 3.91 37500000 36100000 17621 12867 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Common shares issuable upon exercise of employee and non-employee stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable upon settlement of deferred stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable upon vesting and settlement of restricted stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,913</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times,

serif; font-size: 10pt;"> Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,005,399</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Shares available for grant under the 2021 Employment Inducement Incentive Plan </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">357,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,286,136</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 4632438 284886 5913 3005399 357500 8286136 11. Net Loss Per Share   We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.   The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6"

style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Net loss </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(6,274</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">) </td> <td style="width: 1%; font-

family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (4,471</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (16,544</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (14,220</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average shares outstanding—basic and diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,751,577</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,949,422</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,604,179</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,751,329</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Basic and diluted net loss per share </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:

10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.12</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.42</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.46</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> </tr> </tbody></table>   The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;

padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Employee and non-employee stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,698,513</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,698,513</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr

style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable under common share purchase warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">205,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">205,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable upon settlement of deferred stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">213,905</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">213,905</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable upon vesting and settlement of restricted stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,913</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,289</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,913</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,289</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Net loss </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(6,274</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(4,471</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(16,544</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(14,220</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average shares outstanding—basic and diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:

10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,751,577</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,949,422</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,604,179</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,751,329</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Basic and diluted net loss per share </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.12</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.42</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.46</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> </tr> </tbody></table> -6274000 -4471000 -16544000 -14220000 42751577 37949422 39604179 30751329 -0.15 -0.12 -0.42 -0.46 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Employee and non-employee stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,698,513</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,698,513</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable under common share purchase warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">205,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">205,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times,

serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable upon settlement of deferred stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">213,905</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">213,905</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common shares issuable upon vesting and settlement of restricted stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,913</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,289</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,913</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,289</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 4632438 3698513 4632438 3698513 0 205000 0 205000 284886 213905 284886 213905 5913 4289 5913 4289 12. Share-Based Compensation

*   Amended and Restated 2019 Omnibus Incentive Plan   The DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan (as amended from time to time, the 2019 Plan) was adopted by the Board of Directors (Board) on March 14, 2019 and approved by our shareholders at our 2019 Annual General Meeting of Shareholders held on May 22, 2019. Subsequent amendments to the plan, comprised principally of increasing the authorized shares under the plan, were approved by our shareholders at our 2022 and 2024 Annual General Meetings of Shareholders.   The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company's eligible employees, non-employee directors and certain consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), deferred stock units (DSUs), performance awards, non-employee director awards and other share-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of ten years and generally vest over one to four years. Options granted to non-employees have a maximum term of five years and generally vest over one year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Company's common shares authorized for issuance under the 2019 Plan is 7,000,000 shares. Under the 2019 Plan, as of September 30, 2024, options to purchase an aggregate of 3,627,028 common shares were outstanding, 267,553 common shares were reserved for issuance upon settlement of DSUs and 5,913 shares were reserved for issuance upon the vesting and settlement of RSUs and 3,005,399 shares remained available for issuance.   2021 Employment Inducement Incentive Plan   On December 3, 2021, the Board adopted the DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan (Inducement Plan) to facilitate the granting of equity awards as an inducement material to new employees joining the Company. The Inducement Plan was adopted without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the Board of Directors. The Board reserved 1,000,000 common shares of the Company for issuance under the Inducement Plan, which permits the grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to eligible recipients. The only persons eligible to receive awards under the Inducement Plan are individuals who are new employees and satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. Also on December 3, 2021, the Compensation Committee adopted a form of notice of option grant and option award agreement for use under the Inducement Plan, which contains terms substantially identical to the form of notice of option grant and option award agreement for use under the shareholder-approved 2019 Plan. The Inducement Plan has a term of 10 years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board. Under the Inducement Plan, as of September 30, 2024, options to purchase an aggregate of 590,000 common shares were outstanding and 357,500 shares remained available for*

issuance.   Prior Stock Option Plan   The DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated November 6, 2018 (Prior Plan), was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of September 30, 2024, options to purchase an aggregate of 415,410 common shares were outstanding under the Prior Plan.   Prior Deferred Stock Unit Plan   The DiaMedica Therapeutics Inc. Amended and Restated Deferred Stock Unit Plan (Prior DSU Plan) was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of September 30, 2024, there were 17,333 common shares reserved for issuance upon settlement of DSUs outstanding under the Prior DSU Plan.   Share-based compensation expense for each of the periods presented is as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt;

font-variant: normal; text-align: center; margin: 0pt;">2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Research and development </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">147</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">158</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">449</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">430</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> General and administrative </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:

10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">418</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">267</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,047</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">797</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total share-based compensation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">565</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">425</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,496</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,227</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;

margin-left: 0pt;"> </td> </tr> </tbody></table>   We recognize share-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.   A summary of option activity is as follows (in thousands, except share and per share amounts):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Shares Underlying Options </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Exercise Price Per Share </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Balances at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,871,013</td> <td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.61</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">832</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,663,425</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.86</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expired/cancelled </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(455,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.82</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family:

"Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(376,250</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(70,750</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.88</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances at September 30, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;

border-bottom: 3px double rgb(0, 0, 0);">3.31</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,875</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   Information about stock options outstanding, vested and expected to vest as of September 30, 2024, is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td colspan="5" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 35%;"> Outstanding, Vested and Expected to Vest </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"> Options Vested and Exercisable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td colspan="7" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 5%;"> Per Share Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Shares </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2"

style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Remaining Contractual Life (Years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Options Exercisable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Remaining Contractual Life (Years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$1.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$1.99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">203,443</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times

New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.60</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">74,159</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$2.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$2.99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,022,895</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">871,594</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family:

"Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$3.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$3.99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">341,893</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.55</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">223,143</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$4.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$4.99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">677,182</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-

align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.58</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">677,182</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $5.00   </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">$16.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">387,025</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">328,275</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="5" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7.2</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.31</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,174,353</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   7000000 3627028 267553 5913 3005399 1000000 590000 357500 415410 17333 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-

variant: normal; text-align: center; margin: 0pt;">Three Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Research and development </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">147</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:

0pt;">158</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">449</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">430</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> General and administrative </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">418</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">267</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,047</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">797</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total share-based compensation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">565</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left:

*0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">425</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,496</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,227</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 147000 158000 449000 430000 418000 267000 1047000 797000 565000 425000 1496000 1227000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Shares Underlying Options </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Exercise Price Per Share </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate *

Intrinsic Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Balances at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,871,013</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.61</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">832</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,663,425</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.86</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expired/cancelled </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(455,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.82</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Forfeited </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(376,250</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(70,750</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.88</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balances at

September 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.31</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,875</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 3871013 3.61 832000 1663425 2.86 455000 4.82 376250 2.73 70750 1.88 4632438 3.31 4875000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td colspan="5" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">   </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 35%;"> Outstanding, Vested and Expected to Vest </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"> Options Vested and Exercisable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td colspan="7" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 5%;"> Per Share Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;

width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Shares </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Remaining Contractual Life (Years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Options Exercisable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Remaining Contractual Life (Years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$1.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$1.99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:

0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">203,443</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.60</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">74,159</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$2.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$2.99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,022,895</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.73</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">871,594</td> <td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$3.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$3.99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">341,893</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.55</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">223,143</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$4.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$4.99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">677,182</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",

Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.58</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">677,182</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.8</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="5" rowspan="1" style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $5.00   </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">$16.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">387,025</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0,

0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">328,275</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.5</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="5" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,632,438</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7.2</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.31</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,174,353</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 1 1.99 203443 P8Y4M24D 1.6 74159 P8Y4M24D 2 2.99 3022895 P8Y 2.73 871594 P6Y6M 3 3.99 341893 P6Y1M6D 3.55 223143 P4Y3M18D 4 4.99 677182 P4Y9M18D 4.58 677182 P4Y9M18D 5 16 387025 P5Y8M12D 6.36 328275 P5Y6M 4632438 P7Y2M12D 3.31 2174353 P5Y7M6D <p

*style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ITEM 5. OTHER INFORMATION   Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications   During the three months ended September 30, 2024, none of our directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of SEC Regulation S-K. *

(O?F:Q-J'KF3\F_7N4?S7HQ'X:<5U/4S8?FY%@D\314^1PKXAM3W; M<8:\.
[D1GJ'QXS.$32;$Y.% >V2UH_IW2F4 M(IA22&O&M#Q!N"7PTQA3.FG-F-
X>:S7&LY_,,I8I!A#ME=8Y8C<4,J+_)/YV
*M.+JB*C$.##7(;DCC,!5>Z9EL=XEUI+R38DHQF;FM'=)IE M:\4G< '?8GDJX,N8P*
*5\ZQ9,67P9$_Q_%V/W&:!E*O,HNC[FG!+V/8:1PGTA MVGI1I9Z>-H66.X'M)*
[=\@"#I[O25BG6.AQM'4E+@V5*5QN:6Q(M%2<)JHM5 M2)[%8$P-*
*1]TIH4PKV(V0#\1$1P\Y=VU22=9F.$DZ=]=2>E$OB*A86I+'YP5@_,6J.F.']T%F=^R\\4XT\?*
*0:^+]J%,P?_\$<%G M-4-,@?_R$8'G=;5,P9\[;]8'V#JUM?-?M ,B*I6W'R*
O,P5_^+JI1!KW853# ML#W@TG&)$NW/%/TPZ"1\ ,,H
=R@O/X(2F^(O,!6J$MZ7M/FNZ@4;)TS&F>E
*MF+M=XU+WP%DIYFX*63WQQ44$WL_>9!E4DZ?%8!51TRX'^M%7MF8[_]#7(>YB*
MY]S7X3BU]S[XS6/'FQ8_I]!8G8\V&[]%-V=.?3T;KQU[XM,WR@T(W(#Q_'> M'EA?
F'NAQ3M!]M?O'(HA/OL4TK?N^U$2GNU:B&:(FXQF[VMIZA0DT>@5/+&E!M(>U%R
M.>+#,9P\VK%Z/6/N6[1+4-;RKX,1E1BI+;_;T50^:^HJP?7X%-X5;P:)S6;:DZ MG9/8_X?
>]D;$LB+F]],XB_41[UE5F7?F<1?MJS@$ULTL[B&]AY!0_7N]P]$- M5>C4-
*<=50&=.Z&:!4=@+B\/+Q*7*X^CRR/7R+M4B-J2QUTVX5)I8$\)N7'"I M1+$EAMUQ,*
*MSDRFSNR6KSFN=2*O+S.[^S(%DY#%;RA"!R 5:_[Z!4C=;)%@@Q>PR> ED24*
M[&X"C5]?T/C[?SS/HS=+RD7(XE_?'OWP_NT;&OLL"..G7]\^W'DG=V=75V_? MB(3$
8E83']]&[.W__'O__+__OZOGO>9QI23A 9O'E=O[F=I'%!^SN;TS7^? MWEZ_\=Z\/_[EZ/W-
ESA?&?OZA_'HF@;R01 ML'WGT ^-/[X[?O__P;M/Z[;JY^C5(MAWV&W]
ME_^X;7HP]+C1N__^&&L).(K6D3X MB\B^O&8^23(Q5K+PIK2%^LO;-//45][1L??
AZ(=G$;R54G_S)A<=X3YG$;VE MTS?KCP^W5X>R"./D71#.WZW;O"-1)$G.1IAQ.BTE=2-
1<%']>Q_V^N9K!9R M&HAPOHCHVW?-B0K8G(2Q-Z?
S1\IKDESXYVL2JEO6%L^4B,=L9:?" M>R)DD5CFXVRQ)N:;I ME?SX^JU7-^R'WGOR&-
$J6E\TTM&YTVTGW'_#N(24O[Z5L#17\+^H5T:#7]\F M/-T.M]X[:B-*
6=SD'!9C;DCGVR3OQ)DD;.HTQJL2O?:940#.$1>U\OYQ0 Z
*M$LC14>NOYN4F4NO=%.]$33E:?\GB1$[JBRB3J\0?]$E],.9XSV*HL\1TFL/R MJJK6&A!]P*
PVS1V#?W]7@/C:1ZU'WF,JY.L0IJCUL,]U%KV;(=:QXQ:&P.7*
MT_6D.:?"Y^$B4QIQ<$I$*";3&TZ%G&"9)Z<,^S8?R$%C!XT=-';0V$%C!XT=-M--
[GK>F>:A,Y!\Q/LP\D#CR:S4$OC>,SS,*X4@:.) 59&U$2R=(^T0^/E-D M7$;DJ0!#%O[>*
*(:H]4UJ'4W+&@M=[>=G/75*3M+1 X]5N%9;A8&ASN]06 MH6!(4PM4YK.M?*
*EIVUF@[[]2PA/*H]4M73#^VEX#M+1 XSTG$KZIMU=)9%E3 M&U3*1^@HV_NY<[_-21!*
*()"/6_ZG5>53JQ-&TM46GVN$F_)Y]*W,- MDQ F^M]P4;)+5S>V16F&WB?\AK-EF**
<0:6DM:=XYM6=R47 274EX]_R?=%5 M9DF[[NEC\SF+[Q)I =S-B)34)$VR-+4P+@*-*
\$[=4Y[#LEP#R@>K-UP(.2#-_M.=/_9B3OF3?#6?.?
N6S.0D6Y"X?,5H6W=.ZV48T:_IOKU^0.!A M$RM4\3.IZ9X8+Y=<8:O.:;N?<;EXLL*
*:J:.SU@JE=Y*N]6 >EF@76)"XB?A MDDKD2M:Z1$.TKGGGU-[2IU"YAN+D*YF7B[:X6>?*
*4WDA:4:M110,!-#'E8IBQN%P'EC7ID*H[Z]=<"N'H^/$^3 IMY;(F%JBZ*
M>/9G)'ZB)6M2UZQ#ZJ0IJ5#;W6K^R("L@I_[RVZ]MU$GT!^'1>#JO.F.HY!*
M@7V'S,1[9_DUEL>CZK)WZ!@"LG2,EB6MJQ#(W0>TW&E?D3+F]Y_"F3O
*M(SKV]&8GD*V_(65+9ZT 6?L)*6L&-BZ0TY^1^@NWGU: M22/VM+YT*(_XH*
HTM@'E$!]R*<^Q@/*$#Z_H_0Q0OO!A%;VG LH7/I"B<2A MF<('4:J=-U#>L&(42/@,RB-
6=)QVT-YQ(I0-+$?J$&.%9UH'/-0UK""$D"L M$\HB/E12%?

&!PTCJ"BHJ&="WMTU].D\CI8HFR4P:?!)7&&.;UF0D@93Z;WY+FI)++,IO6,Q9)
M6URHY9F\SB$W[=87+_KYA 1"I)1L0M4=^B+_LJYKVW;/]5PP2/9@[\0_B=-
ME"FWCHY63GI #ZL<3!:J++_<\DUV E@G#'Q4K@APOQZYN0V?9M+\?! T@PX@
M3DKZ6.7BAM.%-$$OGA?
>RAWJ,S"AMA>!CTM<\2DE)/5342DYHD#M!^2<3D,_+.,$WM%5_+-?\:\#.H$H% GN
*M/"2C DY4=W!GP%P%0G?ZJ_<*A-UG+)FQ!/"UVEUF ,[T-+-&KD%TKQ',+-@:*
M@R9.X&,1'G4$\MA]"IHQC\;F I#5[G/0S%]G8Z;LS5$3;5KET$&J4#5D[Q>Z M!GG^D:I1&
(L&W@=T\]2$3[@YCU2=PMAL9:;:5I\FK"%_5S#5"8U$H%.> ,(+
M((PN[0N=\C1F$9):A4YUFG%I$C= MR3-6(4'R]$I4S-&6YJR]M@S5JV#@Z8P MVJO7Y6"
JC'#1CD@F)4NC%U V!_(9/<'ETR]BS ?/KHU"B!\WRFG37=#MQ[- MF ,E+-;A(8\-*
DDS1P>%S'@WC1LC1 PF[%:%0Q%J6A/VS'(.=\RB.YOG+8C: M!F9MO,]8,>E
M1[GT$0^&<#NCM":-^0,N.4C--UK,=JTG!,V]SX(]2 P7K<-A,>F'LO]]+)!*
M=N6NO^]$\J1ECD0B7+CK3,G M1<6)B:KF5FG?N)-O,]4N+KXW2\A7-*
*O6*M6?:2R5422%>!+,I1I4 E3%6-\J*TU)1-OTL/+$'"4HZUZ_Q5+*
[E:>GQNXK65BF72FOW,DKH M+6S3SRG:2EHU+>U2#(@-WJCBU!)
<)PD/']/L\,],K.JS\^W/#H*R3S$G))(M66#_8)$R3SY+I**
*(8FL2[(QTG/!3RIW/Y9_R4%\>LV*B[?IQ]V4F]QU[.2RH-(F4\>3SNF21BQ+O-:S*
*>KC',0C.*_\.U6'#FAPLI03]FE]4\9D M>N"_T.'$6F,X-*
[AS@SLWN'.#'[@8(<8RNL3$2K)9K%2"'W=]X48=#C0\&G9J"[:J=_M^##0;<)M#73;?
8<2!0=UT"VY#H4"B+B@@Q(=BJ.!8P%=%H)01]S M_CV:)?UWEG< >A:>3 ,#TRGE*
MG.;G-!ZD+ YBZ2T-A^WJCR\OUKGY11\O^V.X[D//$:2/92[^?
RJ2;&7=29@[24F=HCV>>X#-%_I=^RG\IGETEG/'S=4FF
*MAWZRMD].OA&>Z_Y+QJCV63T\;!H9-'"A*X>9TQ7+"#/V:F!P] %:O1VQK=*
$B\)LT<+6A"_C F:SG(447T@$S#+&|>\LA+$CO;'>-MJN,
M7&9AQT4/6SF2C2VSHZ6Z:=B.TK=L6:)+2VLDA9K&"+JL,P,A-'$>H]G9!S5<1\"6?
TT#%9U3B4HYK!9BKCQ6P6X5!\HP-;S3Q)*
M4+:QH+%V\X&@W&,#;>UEF@PK>Z_MFKC-'SV0W+ZV^>ZC"L70;=6?=/Y:]QN*
M4E,I^D3,O&G$OG57>D[W"#R[0S65KICWW?!0JHV%PE*K3)64$
WJTT_M/RH4#BRANZ25;4I? MS=E7]
[&6TP[KAX0;N0=1N5KK,'38M7^>7ETG:\)32=>>>5I?HIX%DU[>X5S)
M4WG7GGG:8IFU%5B!F+H]T7\R5V>__\IV MOLDT0T=I=@>\)'<>IO-2]FJ/9/LH6A'J>
*[')T2J@WZMLO5W*RR.F1K&XBDFW$RG)?[(<_JEBK', N?YSYE 99*
M];=-.&$RW3N#4,86M%]OW'PAR7KB9" Q?PM2WFK(D8:0FV"'7C=P0R M1]LIF!R-
*O>S>TQ>U4>:3*6JS@RTR6.>CG\5;SQC4NC[7IR-?5IV8JKQ M>/8/VY]"SR!K&*
[MP^Q@.K>+11Z')Y'",I<1^W853QF?9^^Z @ 9]G;UR_L_*
M"^GJEQN_(Y>UTGEB>B,S"MU9W08,C;JD;O>1>'13H5.67Y_4JX!JZ-2#+>$T
*M=HRC6V]=2PZ6*X3NH*2M"56>FH!.)##-7#?>AT[?UF!$*X;JP#LZG=JV '01*
M4G1JL6WFJ\+YZ%9[5]._,)$&W0GQ#KC79JB@.QW>3 !UPW;HYD$CLQ,SP4?
PJ/Q(&7RK? U0O:WR.J3_[#QK%RO-^$%'>&_SL\PW^K9H;<#)]+YG/!55A$P?(K#J>PG?
R5Y2%::JMZ" M1:$O:?8,X7"ML>U!Y ;D.=@\9MCLL.D?=[OE<+)=#3?
*KQ5!F*M3K[#"WP]P. M*
MY[A>2;7'J4AV>>Z3N#RIK?!J^;:&:X$IE62CTDM4CH7<2U6>'N,+QN6:.&5Q MH'?K*?*
*=DKGK7.ROZG*ZV'_\14BYWN-GJFBYII'E?9IW[XNL+)4K>:O>YY/2?*8W](KU6HV<_*
M'%W%BS01F7B/"C6'08_>.3@VYN
*8&0*UIC'RC'&S26^=WJKH*>Z;@RF2@!=>RA,+C'J52R13*KHTNVO^M8]%;L5*
MZG3EHSH;LCM?E%_&NW63NGA.5G)F?P2R ="6L=_TXNX7+7D!P[?+4 M-
*1T2S;UJ#A>2Z(9.N;AB,:5ALC4GTP(U)=1,$,4_:>=2%X]P,BI_*
*M1*_K].'N,UM2'F<;VY.$DE*5*UU?X:ZJV]V%[USXK@$C4%3&;&@SC()IQ2?) M3+*
*01BD8>OI8*P8H@K$&T$NOBE2 I5 M43B<*\$.\,.P-_0U&0H#FG87?*
*5^L%T9"T;WUKO;,9BX?H)A:*LS2XK;07I8/ MNLU":]RSMG/24&X8-*
*OPEC7:+EDKSN*QXEQ4_XJQX.Z%JZWGT'STRS]23QP\J M:*
*.3Z'5#V,N@KZ;"I<^/.7W>I2[_D8&+#&8HI4.E#LH*H^\ @T%F3J.Q7!J(*
*M.YGJ0MO##%LY#.XP.%8,W1*F9!U@_^0MUK76LY*"]'6A=2#(KAK&'M"&4>+*
*MM@/;&A"D+L%+$\JW]PYH4P K6CLSP>QT0LJE0I#D9'[(9_5)GX%9W<&NF:-**
M_73"H.=X
M.')G0YQ3P#D%$#@%8'F\)CL+:Z#:!N<0J;WUHK.V3=X5,X=_J!Q#W4_K@61H
MU7SI(),+74Y636;!]L'@A0&Y1AS" M=@A[Q B[E8W5.MC^Y+'\'M?
XR8N496Z(LTO[VX/8%20X=.W0]:@QYC45@M+)

M9@UD_K7*VV]@G1Q6=EC9866'E1U6=EBYU=QB@]W'.B0^>N^)&>%9C(IRD27=
M[FZY!^)B_2#VP#&$#H>0QXR0RVZ%F85T>IH*J8*$F$RGH4^YYB:8RM8MD'1.
MIY1S&MRI"?L@EX'F:IJJMFV0$W+JR]IJ?/&:91U!E:U;(.DND>IQLE#Z04S2 M1*
[U."@KW [OT)A]S-Z_/[HTV0>AX^IN(I]J8#")571QG+BP)W:(O#XZ$)J M7+92ZO$J#E*?
YI_@U!J/T-PB$3S9LT;D7SL=(O_XXSY,(CJ92F+"91BDI.C&
MG,IV]JG\/4QFMS0BV]IOJ>?",\J$B;+VSC?#J&R>+A M4N(XJ4]R#:,]
<:%O;)7N6RJ%%OJ)W)C5SI-MS+=W#UKR07WL>G:(6I 9-5\E MTIY,LQI<86GJUV;
M&Y)MVYEZVNFH.%";MN).+XD.'^5D!G^4.^C2OX>Z SJE@EE[*/+B3NK<.3RG
MR;B_7>[21Q$&(>&K/76JP4^5[5WTP$4/VKA;HA"G,YM['D:Q5"_5A_P86*X MVBO
6C"]!QTJ# 2RJ>&)!\JHI?L?$,BH3L0:**26[@1):2:@7*[T\IE6;HLRQ%G6=9T
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MY)]Q??F+ZM:ME1$Y/K]{@%0.*6[GJID,N)K)%_(;5]U9_R&^P"K.JZ:0+S
M:-9%&9IFE9D.J*8KU%K H'D;O(WR;!@T+%A5M.UKU_$4>1OR8:3A%L"SM\#Z
MK\IF;ZW ZX1J[7+48LV SB=!0U2,O//O50R9O%U5,BJ"R\F MDJ&&689VY=/F=1)=1\?1*
<8N?<_,[! 82@TZW!# 0/1U M/Q.P\- ?.@3=CVP*SQ^B0^']R*;P*.1
X$#7LBD\E0F4S41GXOLLE7,R?O(6+ K]D(KMAPV%U15'3$>T M4GJD'E&N!LF8:Y
T/WNZG4@WZ^E3<92QNH-5^L^(4%XT]9^ZWV!)(J64,M)6 M56=/C?
I:Y>J2A/PW$J7T"R5*(:OUG],%X\RXOU7NOA#^)TW4!KJK*I?35<). M=0>
[Y\!>RK!BP52T=KGF+M>\.#\,,F\L8\ZQY)D[2\Y9!J,!C, M7H%3$WJ<@V',#H:2ZG.
[55J@E=8K-YC$)[?J2RZ7_BD1HDC0AR4'K,4+IYW&$]DU0J37(2!Q>;R52%C^ ='69VF-EA
M9H>9'69VF'E\F+GN?F@=%/^L$KRD> (O"LECP+4.&L@>'X=0X+.RPL Z+
M^3,:I!&=3$_R"76]FT\@_&, ^@,/&#AL[;.RPLM8^1/G@+Q
M)#L#5B:#U\7#6,/6P,H\3A8H>+-?CFF@I!Z60SD:[5/-JLX-47DJC8T H$
M@AJ,Y)"R0\H.*3ND[)"R0\KC1X9BZ0T19:-D*SJX6;0 M6/; LP$Y#D&/&4&7)"R?L?
F,Q9N,\M"$A*$4:IJ%^^.&%P\^U$JI\^EU!.J9%B:9!7#)M,+PF-I$XL;
MRK.280;9&"T_J"=YO:9+';SP5;EOQ1H-#%-4:HWF3 YG5759S]\K0%O3)(..9]$N,R/)&6?..
(,9 M&YN+4RA?ACXMN:\EBM:WU4RFM]1G3[$]TRZU0,CRVLX&YD@WS^M)>BU?P@$7
M8]SP4?XJLV%(:^Y0G4FC9(?. RH^1\)3*21?&[%TH28/\G?$_P_CIC"S"9#KPMXG M<7
G55)R3_G*EY2D:CY7V92F0]@E;^O-%'4W7"V#.4"/%T]2"U\%6\SR==[MS]Y53J_X,Q_-
G_Y/^G\[3[*JS)4SB-VZTRS3PTAJ/:\|_4(LQY9[Y#[\RZXM*5!%QWE<5Z3 MQHRTJB*9R3(?
G.^H_=T$75Z!]JVQM@$%*E^;S87033J-]07AG*G.F8K,RU&% MA]%X.:8DY-Y27=KFL:G>-
="2!Z3&$_OWCM0FVGE.OD//B:H]HE+22'1#Y.ZF M;H9G?,&XG&JG+ XT3A*SGG;]
(:68ZIP^)KN_RGP?AMVM\K:JN?)TM?WXCY!R MJ:9GJVNZI)'&JV/6N2^^]BZPO^3TGRF-
_:*%4:-G/QQ=Q8LT$9EXCPK7DT&/ MWCDX-N;@&!D''XPY^("!@Z*YK77!&?
0<#T>]^AB+Z!.'BM:8Q\HQQLTEOG>Z MO18:IDH
7>WRE/MF2'05"VE*KIT^ZN^M?/BCR!7\YZ36$PIS_)3LE-/SXPGK2:T[2[BWA9
MB7A5[03,QFI'*1@SNYJU O>0"Z+2%J^0@M94&6PDU-A9@2[@:.?*NJB:Z%@RC
M"H5U/\%'NTLAK03>Y.MBW6P&..$#=">Z.F&],.Z [JUWM6DIQ0$#-R%ZP": VC(
!I0'UM'9#]Y"\[D@DM667%%=:?T M(ONUY.MZ:?L-GV(/M[5"J(-R#LKI:P#L:B
MI'T09G5IY>>(9EHL#D[FC"?A M7]GW-
^N9I^K2)O*WB\WD*X$E;0]OMRYF=HT/Y5LJM,DG%:WM9NJE7&JBE-/L
M1.6S^J3/G*GN8)7^:TH$525TKN92URUSMZB6 4 /JQR4SN33544)#8.>.#CZ
MS,O+CL(ZX>#C*RW38I N.'BH++!AT',\'+D*(L[=, AW RQ;SF2'8 V6_N!<
M+;6W4'3Y$2;OBIG#.%0NI^ZG]4#R(&J^=)#A@2[SH2:S8)P_N Q(YR=V?F)D M?
F(3ZPV=@@'F*G3BH+*;1=3]^SZP4&:HN_J!05J MCV\O'-"01!
<(&',@0%_A^$RVE',LNDO28)7=,EBVH,5V>X.L/U%4M5V\; K%6@&D2 >^_M;4*
JYHQT):>UB=F;D"P0]0.46N/I A!Z4N]M[&35]*"SA+1SM,R+&C:'25O M7^4:N?]&HR7]
(G?661E&;SH<2M[_AQ)^R=+R\T?UAD'+Z[U\9M/)?# .7FZ_ML39XW8V"C]-
;JO2ZA%VJD);P2:0H;L*T=D _#_$@:1..3II7M:55#/TP%D]J$S/" MLQ.BE(NL.-
;.X5LS6\1L4'ON[SIT.2_WF+W<9;=UST(Z/4V%7,]"3*;3T*=< ML62#H/.?
5E[RS'+G^&YM+PZM8MD'3#F4]I("ZE-KP2(B6Q3R=3=?L* MB^\2YO]Y6"#
(N%\+9&9#JN?0X#Q5ER#=4!ZRX$YI FDRB(2'OMQPLF8/4M\< M3+5&@W3-P!U-

DMS>:71K@Q'&QUFO%:=N>+B40.$F M(CX]K =R4#Y+U]AV#3"](BUE =BO-*
*VXR*B:+;*Y:R;2_?#N72]JG<#;/ORMBI:N\" M0R-( ]9BI*_T6_93N:Q-.N/ART3IUA\([_9!6*
U7V-Q7[M%JTXRU8/\,+JYNN!XMOU& HQL^)9F9P80J
MH:"CY8JAJ&8+DQCH=D$S>9NH&6;HX44UC;M2PACF<A5'EAB5LW(Y<
2L=J(=0XT#:NI1VN@"5F&T9.! M)E_5\.4!.?V$A--V0_M8\M"R[]0UW(+R)0UJGM.N-
*WCO>6D@^EQ^VG>8G[9= MOFJ&9,M7DPI6T;:M!*7UOC%)$SF[I>$=/Y73!.K0*
F'W,WK_NC39!Z'CZFX MDFA-OHVE%P/R M<;5"02S%?%%7SJ630T C"^&8V/^&)K.^$)*
UH14TV(?7+:02S@PQAXNX:#; M6%!#!XW]T,B1%]/$D[(3GER/>5C
$^E\3GA6MU6$3W$XE6/)'B2_HD(5<5VP
M/35[98O>OL9]^M!:H93K!%D,01CF2<7MAESV*;YO86$QW)ZB4V"D,0;H5_B*
*MO]&VM4KU5ZH0#)O3Z[W;KE]16]C&.?%&<&;N=QH^S:1M=+*DG#S1KZG;J"?3*
M?'/=?! G'40#OB\T?!KHBLQC98[#%_M1H,THLI6D#9"&(11JCPYFRPN^NQ'J03\GA#,A*
6:9)YEU2'@O%:-\Y@&[/!-HP\N\V%N2=Q\)7%=/W7?M2OG#S3OG8SQ/96[1WUU8U$(147
*MZW6K4M//=JMV,GV]*VCO)VAU["%)Y715/(N"Z_I)R*08&7>$K3;&'CI-9]J*
*M)%F(SJ'4C4.)J,"KOAI?81OG$+*3NV9AMV!UM?+@/&C6]V!T.7+@%\P:85I4*
MGDBD:VD@27$F,P:P8Z!S"QJOB%83^.PY ^N\Q_:3\5S6E(NFN&A"4L=N%'L*
M>^Z/S!S!FQ3/IA>>&]LT6=>DS;G\'8.;^?P-B+7F$9;A.T-?L-# MQO5'RJM;MW8T__C
[@%R&K^XG:L0@+E"0,45(U_(/55R\]52 M5?1[YU3=JO,G)5?
*@'/QFAYI2"17\BH>B7J,=K@X&OCH8F[-:FE=2U*07&K5Q M/@25)6K0Z:*/W=?*
ST!Y9_$WRLZT3=U06"^S@$<.0T_E5^*TI7 MSQF&M Y+#^1\M2VMJN?
@DA;N>CI.9D.K0;1UYNE7S>-K?BZ>%R'/&N>J6">P M-
L=WN3BN0E-."R7(IM:U9AY&+B0&]3CKC&%$PLA78=@UE4@\TN*C=FT:4#*
*M]5)KQF[6C]D4Q)"4X\JW=5<8:$SI;(.KY(;GCB:-4Q_-NBC#0*PR2H)JND(Q M'@;-*
V^!ME$?2T+!@5=&VKUW'4^MPR&FDPZT#:6^!]5^:YH)OG
M(,M(ES)CER.7$.T2HL>7$-V1GQR=$C601BB.'=1BV9W'F/,YS&:)Y=&V8/6-ON!
MBKW(I]8KXNMUMLK79QI33B)IEY\$<[E"I>5-E!&ZIDF;K&?4URI7>6'"W>Z@
MGJKVJ/(L5$ /#!QH:$@+<6-.%'L[?#&N@Y5'[%+N8P\M!F[3==_L- M+I/&>
*<6=5QR9*ZN.)8G*?Z6<\;7&D!.R Z\5Y#$X?%5P2IV'RGFH M!G_\^>*
(P,4AK.5>VQW6PJB^LHM-BBO ,:%NGC0HB5TR/J6A"LYT+3'-DP8E*
*ML<^J_.*6A<^_*ZP#I\T*(GM13VOXH2'$F3[OY$H+74P=?V\H4K/'4+5*
M=4,7S])>#06]X6%IT0_+3\AR:53ARL405]TAX&HN)G["LKWX!SAT$G MK,FHPF,[.-*
=M0JKV4>B24@'4NL34,2>FEMT=M[_&L^IX1YK+XJH:=T+0L0E! MQQ8(^F!"T
<+!/UH0M"/%@CZ:$+01W29P^+RCQ(MK)C_7[!OE^:=P'B8V1%CRR.'*<%-U:_V+*
*MBD*L;0D;XJQ^^O EN^>-[D&RY4\?KF0?%@O;Z[[DD?9E>%!XL29#ARONE:O@ ME]K-*
0DZ;,Q8GG/C]HO1[RN?'.G'CH6ZX;^9PQ>J<.?T*8R5($Y)I"KD::\R M1$;BB-*
]1KZNG.74NF]35.MIZIX>77=FE95[IKF_1G!ULBF;GKI&!)']JV,Q>8 MF;,653U(IO"D
*6^A+Q>9%,8/7&9 MZ2XSW8QCEYG>*3C01@+P[8#V!:1UF>+;!NT+".JBQ[7UI!SVU%Z*
M;T>5_-YQ%'/("?'8(CO5Z:KK[]4_BGCYS?\!4$L#!!0 (-.";5E= 17J MK$ /M^ P 5
*9&UA8RTR,#(T,#DS,%]L86(N>&ULY7UK<^,VMN#WK=K_*
*M@,U4W>E42>FV.YFDDYE[2W[ENM9M>VUW[ME(T"5F\H0@-'VYK?OWB *1$*
M200)@'C0F0])RQ 2K__CW__D__OJ_IM.?<8JSH, 1>ERC MAT691C@[(TN,_NOD[@I-*
T;OC'X_>W7Y$GQY.T?&[XV^G1T?3H_?3Z;__-8G3 MWW^$_ST&.484B31G?
[MJT51K'Y\^;+ER_?O#QFR3WI[_.[=^[=UZZ^J MYO!K5&PZ-
*!M_]Y;_N&EZ,/27]ZSMT8'4_?'WWSDD=?4:HC MQ$F7D03?X3F"?S_=70IA?G@++=ZF^*
F6Z2IXQ G%F0VQR/"\O5^293O= (\/ M@,?17P"//[6-5JQ7E#?R>+E\%=O!V-*
*ZB[.81.>I893;A[6"^WT19(4-[\' M-HS_*
*RF"Q"SFAT.:QID>8=@PS@=#&L;Y&AOFC_T!S>&K@6AQB*0D=@FTNJ*?*
*MJH8P8,>ARN!51WAC8/Q28'H?5:?F9FP2[DPB6@;A%*ZF=Q_>OV-HPC>_G9&P*
*M7.*TF*7TL"CB8GV9SDFV9.=[#8:AR4>0:L_12N"6(%DUX9TI*XX[39K4E"+2 M(?*
DSG),R"_FE2D'#M8_3Z:?[K_Z]AHTH<,2AHP;XO[[=8GLXEUE6TSG(PA[<
*MJA9O0T)OU%6Q.Z]Y1I8J1";*E..HCLK\D>JP#^>2UHS(^D*#9 M!@]^[U/P[@]*
<(XM$C%/>V>$,:J^H3/#-_'X19/B$;KSHE"Q7.,V91,V^S6=E ML2!9_$\ -0]\ M^PA:WVR
*X90ACJI#%,VR#'#@XC9'=()J'!%#CLT>>'X#'!WF5PAWQ"_"W^*
*MZ(2QO^,@>_A"!LI@>Z-8%KTJ: XDKK^,6N+:I[J&H-5*2@OR54H?+M-OI\L@*
M^YT^5>AY,\UQ6&9Q 3O:VP M0 $HHFLL1L2TLHO3R[5%!_(MO1=E94X>@A>J(221C?*
% F?U&4]WRFF9911R M&Y.J]=1A23D(MAE0
95N9G0XPT)@M.R8)H,]F@E$E=VFQ736,8>'!4;!$E[-
MB,Q1P'%#!2#'3@T"Z%DBQ*DR#/Z8N;-@OH7QS=;]P?*HJ;B0P@_\ #XWRY*

*M2L@:8PKNFJ2X^JOQFLD_XN4CSMJ.#-6^.H>&+ S;QT:-!V,\BLFT1@4Q7*KG M=*
(X^YPPGS "H)P<^YI<^XYFSMA^*'@2Y!%N8?=ILR'9!#- M;4F6/TRK(V[:.-
)TQ$J9@8S*E%T G0B4/U"!LCH\4>/ ')$T;4FO:*D/*'- MR)&GM&4<@E&QC-:G)"\D),C>/@-*
*D1^'8+J5&(1*ZXI;!66E(BC5T5&1@$ \! M_@AF8E)D#.LIYH*
*7G^+89,7^;4.T:&WKMOHP);4F<9J *E'GINH;Q.@M)0+F*
MY(;Z0&^HC>H5,=WKB&ZGWG7HO9GDB&N+&8_>37.PRBQ(M3D.E8BK4.1TJ-
*M9)0M.R$ZX/Z#EXC0MT15% MSCCA^*83D&9->D_!*4);8U)CSE0*
MB(>+IF'#N4+4V5',\NN?5#=\.QQ?7=/&2*HZ:DR)LZ57J-^]E4C_$ >/L,K MDL?*
%+,]QD8L(0KD'!Q$DH9!OF OU/,7V%JXC=D[MFNF%AQP,YT32I#
1>ZXBS$J<[@1S/78>[91=%7(HPR'Y"D%IT1$GJG\ AR_M8O'%:$ZRW9E.F"D'#EUP6.?*
M^(-J3[I+W5FRI4ZNL1R4LF>4+;KTY[H0?+7'-,G\X1DVL_MI?
22%CLA]+75D[O:Q[0O>7&X7!'#+*^1X&Y60SV((CJB3'!'96 C!KRB(ZT[DSUSI0E61X*
M007+^!E?IO1I2/=ZAH,$!.C_) GDR_HYB%-0!]ZD6X%AEL4Y_>F,_ID^\?0]
*MU[BXF3\$+P)UO6UPFII^6VC9WIE;_- 3Q0R] 57FUXB^\K(*B9O_739SJ*'>9 M*3[0\+*
(:L+CN\DRTAM$+1.7NQKKY'%H'=9.#@9ME0U]F64FZ$C5BC2-G07UB ML&P5?
4E'!HQD(W=!.T3;+,E1FNR?KY/M 3L!?=TC1K=!'$VV9_)(,H(,6439 M5 @R^/8D95]ET_I?*
*SA[IM*5CK"B-[0+5UD9B$^#+%N##,I<#,#_KG+2>PP2J,..!*
M\@7&!8KHQ02_D,LCVCPCY=."_AM4+8%>JV#-Q%5P>EHU)HGF
*MN,H=48<&9A4UOD&?8(VSW,4KD.*7#Q'"4F?=AD$#2,YV'H]2 -G/?M0)VD*
;OV_&]_^360C4CG@2!W<;R MY.5R&61,X]>78':G=TB62Y)6@VB]
*()VAXR"NR"3:/J.3X)W*IP*W4T^.Y?T1 M3MEDJH%&^;QUQW*:85/V^,CQJ5)EO86)T*
G$49R41?R,ZR<_?@F3,J)/?E@V M%G53O-SJM9(9@5BTNK9@4=
M6D9\1>>/98[4/8IM#HNM$,!>)L!W8A,XY]U\A%2>5_CN&KVVQ2 M:SYHB\DOI.>-
*E4])6>10IQE>$A8W5R<@'QNL%:'1;;(LJ%*D)X#""\KR!,EM*
*M0!\ZLS0Z)=F*0+G[$Y)&'7&F:CUUV$8.@FT6VF*!&!K,6K9!!#%,]&-2;A4%AI##_X59>4XS*
M M^QQ'&$R3>1$7);\=P J(\@7)BFF!LR6:ET ^UB'.$=[1D+!D%$!M]@$<;IZ# M!'8
_W+ZR-; T UPH]%(Y"'CIF#4?-*
*QC2*RQ!2/$$R1@_3W9C9]#&6582B&>5"1@.EX,KSB)A$/YDK%W4<&L)NU"TB0TD^Q*
*ME]D+R5U:OXZ+"7VNT7#K5*I*^?Z[:EBJO\&F[\N4'C)TV]_A$-/#@QY.W6YQ*
MO>TU#=?"<5TYR0D1T/&5,S@;#3^@&CK:@I\@J=E8,L'W,PU1IMW ,W=;;GT3 MWKJ-
*WZQ*L$P.OH0PSI,@C_/.J*
*'CX^JFXUQCE$5,!>\L7*QAJE\6<;CHA,,'B+D\F^%B35LFR812]RG#3]P+3]07 M9.,G]*
(^2%.P) +Z6,![3$^)]J7+F6DCE?3H\%!;@B0/1FRLVA:.O:2&)P87 MK[%*FPN;O??*
*@+&CT*B;6-._ B:9;^:2CVQ%H! MJ0XZ1W_GP-8#%X4:3NV'O^'Y#,Y(U:Q'4, MU*
7)+LJ";LO+/"_!1[M?B-(?15>)I@;-A4(-?.P8PVUBR>#ZX%BA&BT3HI"+
*MZ6LF*T5%J^C#_>"J_9@UR3/GY(DKM#UIG319EQA:$'=!^GU5[QO'3FU9EHJ[M-*
C>P;O#_8 3<) I@B'*[1S-LHPV82+II+J*)UN3_DC"L0VN+;&W8 .OP=N,*
*MA!A'^06=>KUE;^:-C7V-6W6Z*OUTKCJ9\9V$Y,D@HGR3V9F=A@*N1H0;:3:7 M-;VZFC?*
*![(UGDOJE\YCE*4[G"?G"IPMO[+@QY>9M/4$I9MG'R7R.F;* %=;S M<$\K[32B3?*
*N!YP@E\/&[H^.S^T^WE/#B-V57.YUSHFT\V^<",!, 110J K#Z M+T_GX_*
5,JCF^!=78'0@I1QTUPOL:ZW"'T
*M<%#;;%T#1@PR8J#1T8"BW^8F8H3!YW&6%PC7LV3*3\3D4!]EO7M9AZB1<7AE*
ME/[:XKMF=YEBY'K54DP6B%Q_RC5I5>W>E M[_WW7!-^9O
*FT)V+H)I@7B_'>!/NL([X)6LGH3*MVAE<9 M#N.NA)=M330U7< I1X&?X*
*ML6@:.5N.2]WNFEPC"\9Z5O][M4U9@@0*7I3B)WQ%IB.N4E(4/I/+244DPW M*
*66'?)9&-_,Y/16SKF)*O:VURBD)1[5^2-60F7]%#7M 226#,]&]IE=@) ,_ ME6AG]5KHKW-*
JZ]QZOBO>R)&^)Y>'B0= M,>/O\XZ8\5OIZ+U().0MJTO W?+,P+.BR.+'DEW>#^0V@!*
G0;RGI=$-EX!4 MQ,+VEF5HLB(Z&SR;I0U'5<%0=P$E"A8.6A6W]9[R2Q:+SO;R+
<[8=X=T-M^ M2-6GMG%=A:$*$=)0S4X&PTON"JG(P<_J6[.3>Y&?*
*Q6M.MEFOZA5/_6<[9$9 M"QCK#L]N;:.Y%W;&'X@UH,KE/"P/B_4D(5C_>W*BY-*
*]]A[YH4QX,IB:G@N6-B)R3M;;)E7 SNQ+D$6'89F7*17/ MJ00?LCCG+@'8)CRC95,-*
*X&5[EYSP D+Y! 5//. ?@N@K#'C,_XB*L)I3#]_],'GW[ETU2IT6CKD)-(+Y><&M*
M>\JS3,N&WK^;(Z:WB&P^K;(_;M^PE$YZXPRX*1K+UL'^'2$MGUK>Q9*
M#V06TALN:TUQ(3?JO35-8_*P'#U3I1"1N?]:'J6'_@L4W:C1&HORUOZ_2+(MQ?*
*E^_%AZE7B-#"'*ML\WW0*^X?(Z9E]$]*Y=(CSLHWU4E[+M,Z:.GY.A3G/+V*
*MG\X(%/X2[%$;(#2WLDE4K&<+VZ1_;(!&GSEP/R\9*RM)7"R/.S5/]-]E7E3; M_0ZLBV&W/*
EN=+&:IJ7Z::T7A6F3X^$/A6115"ZZB4+ M*-G>9PV<>4W3"FL6L@TF,_@6/K.*
([S+G>2V%4J##<:>5%HVV8"X7%MGFW23 M3.UD_7&;SNXBP_\H<1JN9R^Q2-*

*Y4Z*FYA20@6'>UV\)%&\#H,X#V<^^H4)T, M(*5[!FS#JU.84N@YE*
'%$#PQH$_11X7N;2PH2\S7J+C]%<=/"_K(FSW3@_X) M[_@FV5?
*CRD#WK]3MPM*ICX7]Z6A[;(R1TE1VB4ET7P19H:;#V.K5OU0(H8!C*
MM.]M")5#IZGBAHA5]0:^1P4J4[Q&FNLGIP^#&W>=F&Z/3I]H0 MU6^$Z^TZW#
*G!.$RM^^DKGN]Q6."-IB@SQ?Q"_WG*LX=5[G16I)V@YHDG=WI M)<.0E'2[T!,>[ZS-*+?*
9"6.KN+@,4Z85J;'Q5)]!%TMHCPD9^Z9\BAI.6_: MG+&V:V? <4#)%@D_&DX-
SB,&B#N>MWC>(Z1=D&R.8TB4G5^FMTSMOHMX2&
*MK=>Y872M2VH<';@+_YB/'%OLH_+:LS]5S_K**,];)Z]6CB8:OJT<17?MAWA0='+T-*
0S>,]Q"6%/,AQEQ# M/+:DK_IAV^$BS'9,QP+,QF5]3.=H-[';A1D1!5^/*/,S;5EXE6+4,.?*
EP,AC M:GL_,4S^=246#98Q:SH\L'K.17J27A^WF@@X>]QHX"LJPQ6_[('A![KF'W0*
*M:/.#2_N8JC7,ENW+CZ5K-AYCCY)I9U2&G/.JF$B594Z:FZ3[:7)5[_BN[*B]*
MB.A83RW,3B/M4_-P]+)SY)F(:-/.AVK@-%C%19!P9;FP,G"_VD!MG.$J!3EX M3M4-O$ EQ-
*6*_KE1OXA<[2IX 01[2E)I^TEG>0M+=[HH[=W&\Y)%6*UDU)G M(?*
(1&9X4^;M=BZ.S,,.A3PK&@<"_6M[&-_?F/)35L=.06_*F[;%W%*
(^:L9YN(EN$5$0=)#%JL+_C%XB9?E4KCDK;]K+/K../:SUS-@?OQN MQ50CO:1P=N%?
*X3S'>!,K>D7W!L[[Y?"[K06/I/@=U8%I_)0)2$\30FB"&&*_?RHK -'!# M6^1&*
*((FVG'>DDR*MY-;3X?EMZ M-W1 \O1R:,'HM;P=6E#W(;D-H^"0C+TM*
*23_&B)#U\JZ;6HF&J_^2MT&NY"AX2VO=@^/$$5R.=L**
M//'I0_""\]L@%EW4@E::K+\WFG7O$%1SJ\F]9_KFQ\K?F^(WQWE.I>$@N<"2KOH]
MG8;YZPL&=YB>J@,+S8Q41N>E(9\V8:.[E$F>(>0_-
C'H[L,BTFASY!##YZ/Y+DF!W4;LN)V4="?^6
MA+>)2'90'L!482\A(&_5O808&2GQ96^)NI\L>)ZJPH9)DAAN7G:DIK4.;"K MW)]U4K"*
M\;N<<&_F_E^JGK3#B=]<%R[FXCP&;VSB0AQIZXFYJCGY^;D^+-J[MQ!93N%
*MU^N,TKO%3+BBR*V\UXOU6/EB/;9VL1[[OEB/QW>Q[E.[YV)M)>'X+U;VOU]P*
M#JXU7/8\,GVG=H!P?9VVH#+ZF[0%9Z>7J!&:^;D_V3^HPGTLCT_36\C$==F[
MQNYORI/UH3:/';1R%:\E.@^]/SN!^%7MCJ+\M.07F."]$1MONCKJ,/&\290P^#
MIN6XHXFG?I4X"51MN>3L+BSIIH[AT.Y6B5,-@@2<*"^2,B7RW1.LB67';I/ M.*
<7>NN^'!3K<84--%"T=>XE^?2OQ \RFXM=*.R!#$.0=T.GNT-QK(!6[<-1I\ MX-*
,W0T#!%E[PZEUQC0LXI&XS\AQ'.#I9?Z/VLMTD[EM1D_A9R;V]5QB^@-I MA4W-ZW.*
*<(> &132*_8(.+G^MLP.(0U M+LY#2'>$MY33YA:/6)I29QMCH]!]CLN0-*
B_QV&9291:D^BAR=0=(]LO M+U#1OD&MA?.E"$OT:"92SU N2P9S[-^$F0P>=TI-*
<,%CLJ$'M9U!;][MGB%#X^6, :CGV[F=S@D3REX;G.W-':T]\D+UN'IJEAMX>59QF A?*
A1KJ%9, MI>[JX0C(3A!7T(TEQ9!]SB#.E]NA;8+"7I DHH\T>($4ZS[OD-
*X.VK8*T>91_)TBBT0/ M[1)JPI'MUT^K0*,F;+\2B0RAB0;UG/6X6N2;JQ97-*
)J+JJ!.PEUTF3P[H'
*MM\UDO,P"3XLZ02GVDZY&DL!$CVK^DTV>K!\H#ET^:O(]3:>;W$*P7^HC?9I> MQ5"*
(^(%^'X/LQ]Q)L&DB)S^F1#PZG:2D^]I/.?I!H)')O3J7J=
M>ZD\IP".F/#DS*/4YSG9S@/LYC5_*#XT?=-G-_;^D"@4,Q?-*
*OW;M^I;74Z5$.#!:^0X3DXNW+*S[: H.D]!ECQ2S8]2J9N8 M!Y%KXXBJO,8%?*
QA>D5ST]FIMH^_$OQW+-E=08"BA<'3\=08BJA%KZ1-;=08W@UQ"+XY]
69RO2!XD/V>D7-$>X/-#H)8 MB:,J;H>D"LZ?UE$PYSYJ#56/#JC6YF3(A75$--
*>NWMCTD-9HD:NU_' X0Y]=(-DX#%SAOF_FUOR_"5<@*KVCL[V?#['*
*M0HVG'R1\/'*4D7T5SQSE63F7UAW075.Y&%6X(!9=*Y#=7Y^HKK\K30GK Y?<*
MV0F\G0!S:?V4QG26]Y\ZKW&I/IKG6^?8MH^C+7#$H",&'KVA".1?^[W@Y6A. MM
CI.]'419P&:;B3/$AL=E(8PTC476Y]MY-;%;:%4A!.G)
MYS4RC51:8\JDU<6%_1FT>DGM,)'I8QY'<9"M[P.(N6'G1X]=K)2P;C6
*M0U,H.%8JAMT!'HU4_90ERN1RQT9;+, !YF;^L,WHVNVO)=U1E[%Z 3CF,*_N*
M5/+4)OHD=!>KLAO;T.'"TM%2-RKE<$17TD$+:!TQP,@,-.[[#5P);Q=;X30= M[$ 4.1;F&*
*])Q*DF3'<,8#U+JV=AN@4C@*TD?D.$:9+B"N/T]:#6\^\4E_C;9GS!8OSYYHJMM/*P^OI^-*
I$ZD/,L(-BT3H5"KUMM<\ M?(3C>D_UP)'QJU;JISI1)J5#VR-
>!7%4Q:_.4IZS9<>56FB(E.ZI;97LA6#?
M1,E00)CCD#/=/F&QRQZKMZB0G@R@IV\YC)OP!\AA'0.8E<-: 'F6PUHP,BB?
M&)FO:7FF[*63^(:K9&J-[OXL5\PZ26ZL_WZ:P"7<+>C2FL;S5VW,Y;MC54!*
M\RM4M%./2)'$0RJU65K$49R4E"\;^0C/7\!4BZ,+.C4("R+RO7J/,C ^114 "3:QSX
P!^M,/"R> MYZW9FYU!MIO13>(P:T([IT]&4)U.FO];.L_P<$V;^\97F4XC-F^H9\37.5 M:?*
K/"S, B7C4\/##DS\/0L/5Z]X4OEH%D=W3:DATRQ5D@JV.*.H@;3O/-IF M>+X]S;;!Q?&?*
+>X:BQ7._5U,YX>C0]M7,7/83+6,:\ 2.3%=3$5#1:<]']<9 M[HIL(Y/:[H"_C?+SYG8-
T>ND^D-PP9WM64F:_7P]SGM?/E_"-)?J7]^J+PG"]]2,:.F+*-%*

MRR!DW//NP_MWC(/@F]\>%OCXW=&'FV4:/Y80&2%9KH)T_>
<A,\;!!ST>TJ^I"C(6<,M)3SL& D> M(XK4'KA'Z#LX\$Z7F!*^&);P_HFG3T'<0(?*
+T@&SO;;2T^\B0P,I[/+!H"U MKGWEJ$:-[1%#MVD:(,>HO@A%I31-*
$;H[E6G!+%UXP45Z>:=-O"\)!R)=B0 MCO9&>;"3>L7#YC;!^\3T^KG+HP%5K>*
*%5KGZ]>3X[6NNFYM",*SU>BP;S^[: MU=%/MM]>LA)56HW0B;&'M?0'LN[4Z"SQ-*
/CXS1/R)>>^*&V.?7X8=,#B:'GX M>69J\6%]AA^+
[5\BJY]B=UVKGB089U8[27RTK'+6YJH1+\1"?T:4.TZ9W\A0 MPCK,,E,$<8JCVHVE)
[U,5V/MO#)M@]I/,.A;AT0/2>1Z:0L42.7NU R18]; M6XZSWOQ?6]U7/6OOE?*
*Q/Q^9&2F67$.,H!S^[AJXG/W_!61A3<49LEY3KIV^: M[![?@742$.""*VCL<*
*49O*B;RCVMZ]_"]#3N_1H+/LFFIA:\R"M,?)E@)=F+*
*M:!/5RQZ[S/,RH-._F9^2Y9*D#$^)/=;9S\>:QW?T1ZK7X<5"K#!0H8$RN&(*
*MS)G7"7Q+YG.'E6 M-#8=_6N[X>@?OSW$!41W7*81?7I'99#\&A>+.]#FPE&PB%-*
*($=PHD5%AR:SS3W=R5W"=MI&LKWQK)LC&L*57[X1DY)(T\=A'1O(*
M[_80O%06NA.K#)W)D.B:JBAE$;S4%F)/ MQ6&ZF80HTLOE7MA+8U^Y2%S%P6.*
<=!G15+KJ[Y)>$ ZW3"\NFOO'PAPU'O&U M1U4B.Q]
*[>TF>K\@00KK+2%+0DPUV3!_=/"%=8ULW M>3"8: O4:QYN*2H3+=*YLZ+MHM(9E-*
*_95M=ZUC:F:S;R&W'?35:B1"N_ES_4 MGLMO@S6X'*C<_&W]3%[!S?&]WOE-1(Q=^,-*
*FIW?:,YAH)3,3EU=]*R/UW?-B M^CE^5D+:<)[CA95MC=.G;=W6$SPG&=X\ " I3)$%)*
(OB-,C6E_1>R:\IT6A/ M2L"$92+G?LJ=3U.K$
<];ZU@YO:);&4^L_LD5!4(_X>,$>/#$44C^G1;G?[*
*M'#S\':R@LQ/O9YQ2U!/(Z1$MXS0&EV"(.ZPT&X)32[*7YLG3,[KMTZ,"STQ$ MP0X"7EA**
*<99<1IDV9KNA%^"I!0QG%)?7=V_# PGX0FC M*O,I3W8RB);NK)@)8PT<\5Q]4 (*
WG)T9[CO/OD4^NL:]>4 F+=4,X\|)F[MT_21%4H(&TCXL6VJ49\,(ZE+:^>JI&+
)D5+G\VSJ[6^Y;-M5 ?V3P86;>!Z MMX)V$IF_>3CIK\6B. MPV^>R//;",>F'+5?2/WX[JV+?
*_T\99'2;).L[O"+9OB)$HJ5JV@/QB+;Y MJP.T4IX"DS/04"S6L-$&.)*9A.G, 1*<012(98G-*
N<\FO/@S"I-)$\S = KZ MS&Q]2J)]65*QEP;[2XQNW;;#4$
[.$P0PP*1#%68($#%.5>I$)]H4M02M\TH MFT? ZA=)\-3"5ZV_:W#0SCC672EK8
*B@.6>'=IJ17D*8R,$%H0DX.BLAA.06 M9S'A#Y3\'A=%PHS4-_,S/,=91I\NT.%3&A?*
*[_@:FAM/.XJ4'UC9;78J"=Z#, M9KY!#7Z.*N2J*+H2T$-*
*OXKK#UWH9P5R11>.*YPZG'$'$,40IKQ]#A1@/3-'?LHH$J//QJ9-060MX*8B%C(,OA>7S$*
M['"7KA,HS+$_)-\KEKE$;03UTI#XI93@06++:?M9@Z^8P+EBY"4^5?8?A MJL&R !*
*!1#_VLM8E)GVTL&QOI61D&9OQ65 $IV66X8,*H;+-!UA8VX9UP;Y= M\%79V>Q<--*
A[8RO>8(!20U'XOVX4Z>(:K$3@:P)X;A>Z+("O4-L!)D("A4MOD:'P.YZEB$@_U&=AZ
M80B9FDC3R=+-527Z7I^_A M.PR%N5MNK*YF&C=5VW#6WZ$53%0#9075G9_C*
MG90DLN3QD?1]@B7Z3(\%9;S@[V9%:OV1YB@!@+>CQDIPK]8$CK9PB'BSA@!)*
1!0TO"P\OZ#ZZ$A5BN3: YM>D MP/D5"5(HBG41IU34H^?
*6MO3:R7K[^8BUY3R<20PXRH6J#MUR+9U.\#D#[S M*1E9H4,#K*
&R.^/[7X(L!C2N(#D)%(,3,+.PG2:''HSGZ@5] %CG]6D >PWE M40T5,;
3U(^]I7TC9@8B32-G'+Z[U3K3C74UU>3SMB$=GK!>TXQUDI.HT,@A ML^14% DAKO
,/^.$L'!7&2]:A9[:K-0+P3YG<128RT<#B7'XSZHL 1E 5X=)
MNO8K_PJ83]Q0.R76_H#N,EGM0]9+0#4T#.\@OHF M-
\4"9[,\QP=1@SI=C64#/03A+R'H(2YFC M!+#QHT@8O%3$./TM'XRWM3.4P%S:V6[
H;@SGDO'_AW NE[] [$?XM)?/1Z] MV7F[&8)(T\GENY$L\:8BRA5P:TS2#@.N1
_]5Z)H9.L.:S50\"&I"I+5\">H M!7$47>^7=ENQA03N\/[4TKLXF%&(:$]MR' MB IH72:*
!\82>-.C0$+9XDQ+(>"K3@U%%T%]'^&=-
*EV1/F:/<3=67LF#W*Y,9.P:,S519S@Z[(M=4U'$^W8JNU0[N*IMC#U8JB&X*P?-P50D0S:*
*MUD*E6I:=R-#%*KN>+W'V1)_,/V?D2[$XY5EUA)S;V5J;B5M'=91ZM8:-.'!4 M0??*
$(MWT)8I$LQW93X?O>.XW?QX2P4^[.HW:IXVU(_6UFAQ^Y1I M:H9Q'ERX?
K8S#0,]"GYYV'>@E">6=2U%=AH4^(EDXHNRM=4@7<5F-$?R$H.) M:J
*>'_Z'9#QX^PMH8Y4/JE!*GBB+OB9!?];JVR+37)LSVH=U)TVUP]>3JTS- M15_"JF-Z-*
*R@@F?E8X_X>GB&JQ',7UTM1BN*DA'Q%54AZ#*6*PZ2,<,1K&T-Q M.W:*
W\S/@RRE.>W.&/)"V9+".@4F!:,CJT;Z6L"!^N>/@TDT19+[ZDMS"X@*
ML;HJ'LW7=5BS1!B2?%=C9NQ#$/Y,V8>XF#%G#YKC$),VY\0<9;[CF108J]..
MW4=)NX(:O1:S(+E,(_SRO[%89!>TTQ?-=L=S)+974!$#BRA<7[*+@)I$FD16 MF>
*(./[&"+6DAR)+6U4R;)7:'E[\+5D\Z'XJXOE6\A^TGSULD*1)9&5MFY*
MU1E']+,V^[IQL:E6W8L/C9!DI(\.EI;WBLH/"8?:XC/;T4)CD?=&LKW.#!RJ
M5]N]ZVL7\8@$19R]#3:>66U:Z>Y&FO+^[F#N?.I\J)]["$CDJ&+U=)]%$25? M7OUS%:?
X2'C4=[35/O=;QG1T"50@)_4'!,#13>I+".BB+E$BF?O3XV9>)44+

*MDEO"]SSTE!M3Z3KTI.D X=2G=X,%]M'P78Y,:17:CBMITKK3#T?_7>8%X)8_*
M$+I'&$X4NR".+M/38!470=(H!UL76H;`96'>1P-#ZF]#!.X"VK@3>X@:%A+?8 M(4
*/"E57"$Y0LV3S!&V*6S,T=11]CL@R1-%V,Y]C5G(Y!*"([O55AI]C4N;) MNB[*O%/9VX_"W*
1K$QL+X^S ^!5#/"^.9L\X"YXJ7^^;^4&]ZY,@CT/!":$U MAN:1H
*1+_0R@HSX256U*C1,*.%)U\7&R1>??_O3#\='Q3X^ %8NC8N84VF5@ MW0C+Y%*
[$B7H@!@ACGY" RAAZ3#0XV)B9"W5O> V6,-3"TILAV%&SZ(Z
*M3#_&^5FO3/WZ])NE=F>"C=X_?'>8MIFR${C*A6-X%AHV"PI]"N 1P)\>*
*(8H!I!OA(2S#*G8K6CT0Y?I]%9$5I)<'P+2T'6%E',A!MP2^C)-_F^\$M2)[F\\5!C8*
*M&=2U/,"!(PK=3XUF"?*V204=-'.F3=AW].U2$G:VU=0$M(YIFW].#C17*2X0 M?=7F:*
(4SKL)BRJR()$F0-;[UH]?J)CQ1HJ:+XXA9UVZRVXP\QVG8>R)F@\| MDO:&=7TH,?
#P2JD1\'LLB8C<=C!U4LZ-?J=;C.MO/%S#XUB8$T,?J.-Q+=)U
*M*7D\BW42;-.NXK$CW(DWP\ M#'Q,&'AP.WG(F9X:G*2-[6[),6)&AE]>#R=!OGB(B%?*
L2]%^OLN2UV%@]C.NG.6@8M1C,4NCCT'V.R[?8"CN TVIS^>X@QJ350"*
M'2^W(>^K8AN<=@"X';1L[YD&WN#K"I@SG=@6]WKO-!,D0(MJ EO!G$WAZU&Y
MQ5AG%N: WPE->^Y8WI:FTED[NH>J;*6-Z*N_%X;?<059RKW?#7)E7$'! M?KQ909A2?*
*OZ"LS#.<214!^@.I*T;4 5H7<"K0_?H';L3O8;*%?U<+##"%2[-*
*M)BS\CW!H!IS]K#DTQL=I8;$1F[@33;< Z5"DS7"'9*GS0]IMT@L7#]W"^[*
*M&J/@=O/7B/*P%O;"'_02&=U6,7QO:*Z=LXW4T%1?4\+QH@*"W='95I/E6\=T M]=1H!:*
[SXC TBX(40:+V\'B +B@EZ;2"BI(M+EXV5S>7$"6B.=L&=#>"IR&+
*M#HAP=++^1.^VR[3*HY8^S<(B?N:6[F[+L?Y FAM(':#MW<7\3N?,[Q0X \UK*
M5%"PP>5'+ZPY8'&(.8J[$Y*J<"D<-76?#=7GR7K;I%)[LKNI$O)^AL36^67 M;*
[?,W)0+]0!)%U1RCQ&MO<-_F*U*\6UYPX7,A7LQT;PF(]'4O;L0.2I^W8*
M@I$K(=$"ZEIV(Z\4'&)8JB#_ZYQL7=O'X,G6NZ)NM3'5]76H-H(Y/.Y/LTL! MHS?
*2$)V+&D3K/G/,&LW @IE:[7&+_#93W&H(2NSKR890F[?*D9N"+C&7]A/*
M6O:H@\XVC$X;(/Z4@I" @GY)=I,NV_0T&3!I'>^21@)MQ)&I'$/]V+$)HACQ M%J/2=
(KX4-8.)J"S#ZWE+(T.8XCZ%9B=W8;K,EN']Z#6;,5CH(;3T-RTE9T- M!2QV$L,D?(
*M=]3<@OT '"0XKR&BB(/4V6,V)J*3/+)"]5XH#?-"5:H?#U![" [TLL,4>(KH MT]?*
AWLHQ!;.@%^\9?L8)68&BY9P_M87;2J/]H[J&-OV9JJ!\T2"6_">&$V& MRD2+=.Y*6[! Z%*
[?"E$SW6(4>\.Y>GKLP]6J(S48=R-^% %#PT_Y"QS%DJ MN:S<4A_C-
\4"9Z"XHZ\QNN'B9\S#MZ](GC-OIX?@1<3]>J/H5VI1@>92@"& M#U/Z;A!",8_??
P.Y7/T81'27AQBBN2PW1\L@9"SZ[L/[=SQ6EGZCY-+]"9P2 M]
*[ATV""J\;9:P*Q'Y&IAI12SZVC>EO2\6^2JNHJC)4!ZZD%T:+\:S/)I4? M.+Q7-*
1,C3I050Q;-2;;Q Q8Z_G[C-C)ZV!8F9I;'9;:;# B=X]<(>IV):S_&KMD_-
PKDMP#5$DH%L3BXSMTKBUTI]]THQ%T]L-4M?F M:'$JFG+M?
D[164&%F,>2YTHL"+H-0+LP0>?<-^\D2(+>N@_V9LDES/LBR JU MN59XZYO?
C"!.B6@#;9NFM%[;]6BLU2W))GND7(D>FH=KQ\BN3MD.%'0V@=$9 M:6?8H
=2%6=##^%-7D@_VT.&>X@& 9UMF,T#X H>!+4/RKK75B'=3W/S](]O
*M:@OU(J*SD2S,3F,[;;! ":"!R&,2/[&G@)>]),]21)N2[K/;GR8!O#)XT/=+ M+':5ZFD_-*
(O]_KC6G[T ;Y.U'GT&F)Y3U M)VY:6OIM>OL]GM5/9SEELFX-N
MN9(!/8/W%7#2F$\IA;/)9^CA06 %5UO/RF)!LOB?./H$85F-+"^W=$DVF5YN MLSC$=Z
BK;Z!!V(5B?0KCI\6!8YFSW323_@.+X,8G'Q.2?? MN+ ;$N+H?Q:V=V:-!ZH001M,4
,5=!7/\:1.E,1T"6_^CH/,8T"?_Z5IO7/& M@9KWC/JM55[!CXL7LU5,KZ\UVN!
*<^TI072;>W_B24LRXQ7J"MO6"*_3&EXI? M;Q5;_(/6!K?XMZISEO\U.9#_-3-*
QU/%'W=TO [:2SQF7&J8XS-9[PRC;$'/*:_*D.'8 MO8K3Z34H0_XP^@\#/.7M/!J;_J-*
5BNNUOTKV,BF2N[>]]J"A8WDU/C,-N^OX M'QW=-E() \^;1H51)@RT
*MQP"]200MKZH[ESZ\(GE5*DWX$$ M>#/_E&.&GI0>7=#'B!I];VS76O0,P$_)?*
%K2/UAXTP02%8U I2XBNE"CWDG) MURE[?%K1&;)/5_%2F-7'!
*<@Q2!E[J%EW.J15A]L"3RO 98)*0 2QQ+RC4S;: MY@-;PD;GXKK+)*
*(GIT8$%EKHJZ7)^5HH2 :EVU\TL*0G&689)27RT,DU:FZM^ MQDEVLYSD-20@;V\Y>0-*
ITM MX2^=&ZYO+!O7G0CF.X^$7+&+T(#5!BRDP$W%%/@D-P%K4CF;<,.XT_96U*.*
*MW*_SS5EK_0ZM9R[UW6+H8WB)BK%T4@PD1S>CKX]C;_UMJ[O[%G4<]W9#4 =/*
M@@<<^BK]& KB@7&#@=F@.X^!R ' .[H8?1G\W M[-!=\VHX).9KN!D.=]P9 :*
<]%V^174AC>'=PC/S<#!SVJ[L;>I?5UG.B;:T& M9L_\E62_;Q-
*T[FV!CA8Z63)W1W*24'H7I'(VS*$8:[AO5B"1+Y3UDG8^+# * MF+X*HH&_5',*
(.1(>$G8*F)9($&G@AKJ+\]^AQ-HGBF &!6D@G:\HKERAA\Z& MZQ[9>]47@,[BOW?
@H_2\=\.IJ3'[C-60"'!!4;1)ND:<'ZQ /^G>M[ESKSA M-^@6I&NT#-9H'H38P]:09#>B0?
#7?U=D2^N/:($(,<@#^ZAYL\C*@%$_N > M42(^L"5 =B[N_NYMDO>*?J)?UE_1_T%$%?*
WF_P-02P,$% @ TX)M681< M,A]X,@ N8L$!4 !D;6%C+3(P,C0P.3,P7W!R92YX;6SM?

5MSV[B6[ONI MFO^0D_/,3NPDW4G7[IGR-=LU3N3QI7OFO'31)&3Q-$5H Z1C]:_
"E9LD4" M"[P ((2'[L@2 *[U<0%8-RS\XS^>YNF;1T1H@K/?WA[\]/[M&Y1%.$ZRA]_>
MWMT$1S9V M5F0Q(J=XCM[\]_'UY9O@S?O#7P_>7WU["X. @./@0!/_^CS3)
M_OJ5_^\^I.@-(R*CY9^_O9WE^>+7=^]^_/CQT],]27_"Y.'=X?OW']ZM6[]=_M-
>>_QOESA^W&G]Y5/SXWW1GZQX>R[<&7+U_>E;\^-Z5)74,VZ,&[__YV>1/-
MT#P,DHPC$G%::/(K+;^\Q%&8ES!*67C3V(+_%:R;!?RKX. P^'#PTQ.-WS+4
MW[RIH",X1==H^H;_>W=]\>*9<1+.49Q$X4\1GK_CN+__\N'].][T'2,[1W.4 MY4&&#'
M=S%*RF?R#R7G)=?LCS_/LCS)ETRLPR1;/RX-[U'*8&KXN:(FY0*!R0J,GJBY M1
]A6CWSZ"FA-00UM%"A:??U\V_^/*U /Z(4Y?26@7W,.O[UF@1YRQY(^<[$ M@-[B\R1CTS
)TYNU@-"C>YJ3,,KKR(+W:OT&IR&]+Z=S08.',%Q4KQ&E.5U_MLWF?
JR_^/$UHE&):$/0,50,7"CW&RT%P:(2'9V%@BQ2Z8!]?3RYY0S/TWH;W M*9+1^J*1B,
[MY?J(1&\P89OZ;V^98L!^F2)"4'Q9/:-Q$RN7])(0]L!R(_Z5
MOVL4__8V)\4S%2&)=C:!EP.M6KQ;A(2O_=$L2>-U[RG!<_5IC6'0L
[DV904T9I^R'XY4$G2(: MD611+CU9?!S2A$ZF5ULRVV2S=1]HO-
;&^#GP]I*WE[R]Y.TE;R]Y>\G;2S;9 M2WWI57K-J1A'1?DAS.(E3(=)-
D4DWGY/+AY!1Q(D[FE1,T@YM<1>WS,23A/ MPX<:=$P /07A$^^<3:XP_1\4DK,L/F6O
MKXXV2=,!J3Q=R5'U["M$$AR?L^_J#%AI6VUT-ED3T.9Z MJ:VS)2!-
-5!925OS%*IMIV6>KY_\7T5(F'Z?+J_1 I,=CTMS2ZU4WI(PHPE_M@U(R7S?52R=
[A(@V]K,6>E9:P7 M;6RIB\8KS)29]/\FBX;]6MY8%Z6E&3
A5P0_)E66E)#6AN:#4WO"I@4)TPNF MZ#W])UHVDMG0;GCZ\'R.LYN"?
^0S]DH78=8LG\+6@]-ZGJ3H>S&_M1Z21P$T3C6^4/Y2\$%VR160J7=E O
M#;0S32R,\N01,8TQ7,U< =%US37*P35Z2+AK)LN_A_-F<%\VTTC?S0REJ6R* M;S?
22=L\3-/C5P'J7>+J6HT]<*Q*$^8&_@QGS6OAZR9:WN,-B@K"8#@XO+]-
M\EI;M:F)!JK.GJ)9F#V@AIDI:C8@=*V+(#_/SJ/9I"28*K@0P0+^X!)
T)@&&Y;.#L#0%0<"@ M?'$0%&$8 Z[GC-@$CHLC#EW!L2J]!^LBS%:UC&'"/U&<
M)C&OG1G=:+.UT$9()VM3?F$
MHRCB$2)Z%2YY"DA]VB>LL1&ZKU&$DD=.S7>4PZ@7==''-UM#X\LDO$_2)$\0
ME3(@;J^;^F)>I'S23_(9LZV984#0C"T)R2/B@<@YNL24,HPGT]OPJ9FG-J/H
MY32.R[P$MON&27R1G82+)]?IQ "6^NEO*SFU41H^6/PP2!E$GG?;F,#G9)B
M/L*V!JC^CK,(/"FF5&,-V2 8&YNKI7VDY#.CK*8_W/VKX)M*RGB!7?RDY"0 M);/_?
P_3C9K\BA&EOGJYVG@TA PT---;=&M5,QPH\[+F6FFO:C6A2Q12M-[6 ME^)%$=+%/
_2UR#I9:CXV99JQ29F*=@SG#*SF?()FK\^R /M9FA=!2N6NPVM MH5BR%\@[F*)?.@-
JVYK";P-@_IHY>);2/Y".3?L5I%TJ> #>FCE8++@%Z^P MK5]E1X!ULH$/Z9R0]C.T+
[RDZSIYF#%S](ZB4HD \=+01RL75P0MF$EZ]K3@ M?CNV4Y46-
\024^BIF2/,4,Z75VG(UIXLYMOM@GLGOS>^%D@7K3QB?3Y]*I5[@ZB2+9 E6ZNE 4=P
Z@1]V M-3KU+B%2&9%U<.>(<:MY8;P6L3]^K5\P]N_@M1P"Z+[HG##L\HF5G.JN ")F
M%7=R'+LR?< 8@4U[>.*,(\C X^!@:"S-552&1MG.!2.D?B@=YV&J)^M578)$
M@5E75AJ5[4GF '5KAQ)PNWV3!BC0YHJTJ""CX!ET:W."P0/WT VW/QE;?6$0 MR1(W'-
R65(!I#8?ELPBV)4%CHJYL2@!^:[1?40ZK*YN2,C*0]%)7)L;."I!
M5E?,)C6$X(E)3NU.:B#),VU<$1[EOGF5V18&"!,M&&6[1M7)>@45M7=&@
O]OQ!V'>MRO:LQHFH&,_KNC.BM!T M.>/ECCZD IEJ;I=3*K4:5/+4(#
XZD5R;0='}63"!BH+3\X'%3HSE+.!T^=] MN_>#]W/L?-
DF/V6QK3=WP5$N"INMVVIJBN"AL=%?D,D^1O%-]E M:3+?
KNO0S(2TJUF>+B@MX&R\;&V6\N9[U6Z^.1PGQPNH!Z<'#Y6P]>G*OM4
M99%@^%1EGZH,(FNYY><,&+)]5@'L_&2S[HR>R/<.#GL<'*]]^I+*;X(>ALYV MGF":
(E$OF<4B3](%P85NM5']%&9OX*0/Q*)XG M67F?&[^^8 5I_W
7EHYV82QSMF&=X+9;,P*!O+D>64[1E-,5H+.9!S1LR=& M-
]NVF=E)EN5>R*/OK"=;01EI#^5U#H@VB=^ 3S0T_RI*GU4$R?23M#9 .<-X
M)8+'3$*GC84;&EH'V6D^2^*(\LWG+S43X%>A[="F3N,H+"E)N(_\0I-X2^,C6+,S3)-
@..7DB[>-V&=-!>_H8@9[X2D3*;JLQW(MSR+0E']KP MH0T?
VO"AC4:/+,37X0HF4FYQ*VW$E0E=V/IBR-(A; MSJGCKWTC! "_;T??@.=K]4_T
=^'0IC7E>2? =$$A&Y=410'1+]#"K"/* MR5Z=Z@I0=:QKJ#PCT+-LRBQ2(!B62[0+(?
^F.I97I:EM[QZ52-V@/$]76>:G MJQE7=KC+DIWK^?H:SK;+(+\A/LL:O/3*_6VX
%+,$:2/9B[^7T'S2*%\96T<_0E+MP>>83%&2%Z0=RRKCVH-&^>-D40:8
MSIX0B1+:6$6A_4 V\%M.OI9"7=_7&J]Z%VGE8:W!H@>!EH\SFMOU#&F['2@&
MZ;OCS$=24]'V))6S12J?W+YP#A0AR_5'KNNL<^<"^%!<%-RXKH0OU3%JY[QW
M)5"IC!?$'39<.IOEX "5W7B660FB-'T(#HRR\FXW,-) T]A.!/1]BTKW M1X_FO$#?
=ZTXD,5M*$SLT_.<3<\;><#5A^C'%>BPR1SH?T&V4#F)0CH+IBG^ M,5PU=-$C;%

*(VY'3Z^N;]U#=O.+7)RYZP=U!>$UU?=%+6S-P)OFO$)"M*4O3"*
MRWN+3QBE5P0_)DQLCI=W3 0OLN?Z0D=1GCQ6+G.QVC'DH_0>]V,T\O_X3OP8
*MIIRA3>2*_W"4Q2^_V&K)F$T+;@Z?)G2!:9A^);A8\%)?"8VJ2CLHWA3:.BL3ET3K316]]6A.*
<1UR6BW8#T<(^IDYD;U4F MXRIN ^D-K713^DIPCZ((%URPPZ7 "I;V,U1&O)DNMN4C-
FG;L+3I:E"@=FEC M%EV\=1VV"ENONEKSLM@2Q^J+%,GCBA%C=,>TM6>E_6L0JY,7?*
E%((H#&.;O MBJ %6\'$5>YEW8&L HGB?%O)%# MY9$,7I%29^NL;HS=MG4:>
(4/8$CA@1,HF8WM![!WTHF.[S1F@'L>J,U!+9[MHX"!;."WQA^AQF?-*
':]477G3ON!?!6A'2K7UM,M/HJ8H4O0MY#\ALHRF2Z M=1:RB3-H/V/=/&NSM>D@?>?
Q]%?#.H86 MTQ$V]@DKL(05KBB<\Q
E/$^EL8L+Z2G]TUDL%E6&;YBND;O(IIC,J]P&">QJ MO9U.O&F6NSW)M_&WFPF3C?
SM9C[?JNF<7"=[V!6T.N#0\ZG#L4PPH5@-GT/C MBN -BM3K8RX2DV
&35YB$H7M'U$B2X.;$'E?D$K9M MM8VG#[9F5PX6\ @!!&0'N/8UM,W@I($B %FJ4OH
3)^AMLQ#-PQ.-3\;>E.:O=(!C"]1V&0FN^'5Z MPK#_6+ECNLU L@K/+QE0T]&_W?*
2#9ON$QN%4GQ%M.^ $5U=\MAUP:%@K 9E4 MCF\T'<#KLZC:J#
<110S53L3MP[ZA"&#[HPT#FLQC!=/LX=KAC'!C1=,M>"T= M3_"#7XIRR6)#A?
=&^$K:%D-THC)WJQ1#5[1<5>:WKWGI)[7:%96W Y+"H_\;
M?'24N,IPCH+#@"3T+QJ$61P4[/41_F:WG3;R.E:P<305JU(AQE>D&K@B58[H
*M+5YMAKS,V[I@6$,BN&*O'DB\YF+"]LJ[;2&Y97)QG.Z>F%+HH;? "]OHV8)7*
*M$/1,AR33'M!CO!P8*FDQVG,Q^USR5'7%,7[XPD ':99*TS(L>O3_FB*/YKB MCZ9L(P'1)W*
+!O'?@VKG"E^G\0"ITG$G<" M-E*KL77:31T(]+;4WMA2=JG[X^?*
E,&RF=]'S]/[:C6[FVS@=IV](>8-,6^(M>4/,&V+>$/.&F'E#K,LN;L F^QC,GS.W
*[J35@RTOB2CZ+2S0*1XBVI0BVIU MCNKN0X[6) MQ\^!(:O^/$Q(>3/U\?+YXS\31-*
BV/5M>HD>4"F1.K;,IOKZAD"/.9_TY0?\J M4!;5;1\M>IKAZ");%#DMX3VH7:
5>ACGX%"9@T/+./B@S,$'&SBHD^U:/:]% M3^,:T<'7S[49MY\IQ%;N\)2%/O:YJ4-0H
PVL#_TXO66<7ZB?PFDI M:NIC! X4
&8"FM$I(EQF;Q!Y3+BM,IG63'7*)8#6_R24H2$>H16CNYNO^!&1
MK%SP'MAFRZ8X7P,D7H:VW7V,R,>(7L/A8T3;,1+W8T0R50OK6%Y= ;,7QQQ6
M48I<04[1O81[L><JN"'^)&JZL[GU9R/TF5H'1'4MIQP$3?
L=2[,\NV2@S"LDCG<;R61;^):/LOLHNX^RC],PL]SR]X992\.LATW= M@-7U2[!875-*
2EMI$ZSM*%"TOV3 ZK2\8+=X"\Q885*ODUS,73$EYOL%'F-XI
*M:3U>RVO\')@ZT5>0+,D90:43_8E_$F<(RSOHM7UY0? 93N.+.5M:'ZL9*60*
MT$,K!XUW<1TO)8=X%7K:P1'<#=%F"#MXE!Y34>CI_2G>G^+]=Z?XOTI_4N%*
*MRN:).ZS>KN E=[XHJR.N^*5:BA)4DW8E*ZPE3"";U96$L)88@6T:5Z:<#F^X MY=/)>\-*
*;>L/;VY8&G."?>75TGJ(8I*M;SUJ4AAE"L#%MB7 %?WFV8S(\+A&E M"$W6D[IT*
$OOU8)U\@:4-Z"\ >4-&] >0/*&U#V&% JN[MAF;+;7FX(5\J&DOB071:3!!*O-DTJ-*
ET,DO0]+B@;!6@=#=)A$B@CNFI*U[M(.ETM9K<<-*
&XRY&7'-0VS[(20B*6&]>3&/%LH@@:6O';-T&$F]RMEY.%GRQ*
MH),B9Q,_BYNNQ8!WZ(&PVQDZ?'_P93+/DON"7F01 R!Y1#Q1H9DX<>^"#P\ M.&,+,%*
*[RUW.1Q46$JD]P:I5'Z&[B49)OF7?LK\TRQ_[X\S;)4S29,F*2QR0N*
*MPKI[K*3M]%/Y1Y+/KE%:[GMTEBQNL6#WZ#""WIC^CY#$DJ,OM6W&ZT0:/P>&*
MW&!7)'ED.P5;,:HU1'CR2]Q8]W7B,&61#G3#OC>4FH'US=W0O)!??0ZPT*^ MF)34?*
&>]61:UO=GTL 6$^$9*'A'O?QP3>V8F54Q3SI&C*+*H&3$/53:R/%R MT^8J+#>P6*
L%^+VWOG>O>N>Z=Z_OM7\W"K#.3=<5*.7K+6ZOS8T=)+DC M*
*/=@;8\=)85X#VQS=R8 IC*W(#:K,\ T2@K0]39V($ +BU*P8^R''>&(0(,; M8T<$OJP*?*
*1CGRA2C4\U;..*5(@!@44D73E++S4'%!RJ8$PLO]Y#+!^*H40P M*)9?^ $ I67$TI6II"-*
*MS?*9X]/66J:MM71$F\A@.P@RE >,+!HL$*GRO]94 M01/81&-HS5^3$^+3UP9-*
*7[,L5ZS:P!#W8'['&5K]M:TC-Y.GVM>Q/++N*2U, MON(D+;BNL+D!Z^PI2@LV_*
*[9\EI5N2H7@,GT+"09,U3H%2*5.WI9/X H06;X M)UJ H#3,#NTVWL2;\7-@*'7HM/6)(\\D?*
(8YKB;+C:-CZ- MPJ=1O(;#IU%L.SO<#]CJ4!UQ6Q7-%9 !X1M=&KPSP2
*]*B6#0814RN>>IP$&T ME2^L&A&2#J0U+ 2DQL>&?*
&S(VMC0V1,B44+1%=MIT35/WC\0T"=K/ A!ARH$
*M'6H@Z(,*01\T$/11A:"/&@CZI$+0IP$"GHH3;Q\CL?**'NP582*N02%OW5LM*
MC\/3FSM(^8[Z=KZD")A;^TJ? N?DGDQKZ6[\??AJ4HR,55UOP].5;FD-I1< MV?E-#S6-*
"-7\ZLNC"#($)M/MPY;EZ3=^_I+F=.>HI;2 ;4^CCC=78OP:K0TV>:^=).QC
KOZ5'13[#)/D;Q7=9C,BV2])8$-OEHH60]?(DGP']W_PN94^M]+G5O;'?
+TC"TL\2F/G6L5LPZTL M)%<0\J7+^EMX!]0EI2^D1P7,E?=1ZSK,/=%0SD^6'-*
#A97T@2;Y@RB.6 M8^*+.$G+K^QWIKVX)%Z#LV/L@B%4E@4!ZK&_=#'?S>D"8^<;MA
,,?MM/Q6B MLYJ;[>S?53DSY,JZ9@;2 MVE-/SF@91B"M/;?ES!IJ!-+:DV>N;--

*F(*T].^<,I!JJ(?P\5@A\-01A-81> MC[=L,&Q?,^'%27H4Q16&%QE-*
*&/JW).37:6SG(*PI$)S'YZ-4>791O$FODP_9 MJ4A"6SXZUT*HYY;]\>?.PW>FPBJI$-:X#*
M5IKAS'-K@0'O9WWHL/ "631YR)(I:\4^AU&$"V:G90_! J=)E"#Z_.&EEBLJ M
*8ZHJ9*8.W(\B7!!BT)MO5Z6K^H[;(H?8RGM[#%,T%7*S(D50;D';32?Q)2 M'A+E__!*
[KA[#E)N2)6E+66$+I;Y:N3H/$_)[F!;H&PJY9X++4447C#/E_E]Y
M^Q:2OU#.W52;TJX570WLR#OH/1;_$D/)A)&T'A_EAHJ)^$.K([2&^]L4_7'6
MIN.LP&DZ=O?^7A]EU1GHLCT5Q0>Z@)H%5M?:78$&P"_N9 BX,IO4@((JXJ]D
*M:*FAT]+JTNMO*PO2?PSFSV\RH,^O,BB_4'"U*0RFL]Z^"D7>P3:H@VTS)VJ6 MCM4\B2?*
*9T37_DK")=AS2A)9;>Y.3H_=Q!_(C*HBBS(6H+-7>)M=ID_=.IU#^*
MQ8ULI]/%F'\O\]8[.)H<'&(!&KO)XOT:WJ_A_1K;2#1L;'@PU<^ !?9+L"!X M@4B^#,
(L#M"_BJ0\T-G.! ..IM,&4R+)&V':LQQ47A+(/%%ZX;KBG2N^.&9*
M_"B+S]9$R716>$=O;WE[RV8Z]_>@BY$WN#R!IM2X:,9BHL43:9' M%6&7&[I ZJCZ -
*ZD\B:5S73NGTD%6I6\/>7M*6]/>7O*VU-R>ZJM4F3 KOH2 M<-,O+(]GI"BDJ)U-*
)1M&IST%H\7;4F9L=G; =E1L%>L2<>\1)0B-%D3=,GI*
*M64_XY;8O*6U3>HO(6E=RBZJP9 M&3"M#MX'E%<6G>&4O01:IBKDRW;V%6@LG4:6*
D'>TAK4TCK!\SG.REK2_!81 M\HCB2LH5@Q:[+5:-Y.]7:JS73NH9T M6=^]F>K-*
*5&^F>C/5FZDJ*90=-"17!$ OB:8,T#MI>NW<)GDXR5BRP=Y3")4?Z/Q45K252XB*
MURC"#QF_UY@M(PFN;E55L(&'>9XA]'J^ !H.X] /M@O/#0?T&*;'33'NK^! MO1?*
*&>V%LIG,/O3#@C=6[8KPKQKMBO"O&NV*47#%#*NJNB)8*H/VHH&#D++^/ MI0?*
D>C9V#+B]#@.2T+]H6=RPR")$D& M:TF<=X<-Z@[[SE]-
*+3Y/LC"+DC!]WA%/JW=R^_*5;+N^U'KV0.H?F/R59 \G MX2+)ZTEZV<+0+:?\#K)7]Y*
=9?$-6ZWR6T3F%]DCHCD'JLFZAP]@B,/O.?T M71'\F+"9>;R\8TOT1?9\L*T^0)*
98_$B8TL:NL14P,6FC2E"K_EL MRU"\CO$<15$Q+U(V%^-3-$VBI.EJ8'E'4RQY-
*]A0=#+=9W7(XJP\8]%(Z^N& MSKJ9%#%"L=:ZVV%B'DQ=K41(K3\-Y.VP&I*U.#$;K*
M@S-HM;>1P&!]'#U8)L8C,:GT:,!UVX-> 2;;ICLY@]4'%6G-[5:=X7.@O*
M<%7(]")CNA^$<=7!V M-N57M]I33B]Q&'&=[\5I=G#!NGCY>;S+2.P1J3Z'%*
(K!KMRU<#9;D-#?M.7 MP-
6N.)"FWAFGWQDW+A>&=VUYUY9(4>YEK<&FMCRGR+NI6[A!Y%JQ16Z0:9B0X)'?
&!_@J=AST).+I,43;7"?M";; MNU8&+^#\Q'#]"I<(,(VP!-*
,%IBPEWJ,LUC@15'K.>0!R1YE#G2$LG<9U^6< M:=1#3M%]OOFKR1$#[&
[(B7'.T/^=@W^\?/[XSP01MEO,EI?H$:4")Y-:9U-\ M?4,A+4@IB><$_:M
652W8K3H:8:CBVQ1Y+2$]Z!VH5'H89R#0V4.#BWCX(,R
M!Q]LX!.MH4^3(6>QCFBN\N1,F_2, M.%VB=5GM8>IP!4\V@Q+UH M< Z")S5<)*
<@)]7I7\)+'&91= :Y$H7H4);&EX0I@ %F"F"^NP
'8%%M[P_J,!''77!&1>3U<$J5^H:MVKPQU)&3-4M7Y<9Z0;M>TL#D9T%Q_*
*M"18$+Q#)EV6A2GX7^:+\M>'K=EGG'9^B4[_MA52O\IJYTZ;CRP.E:?[K":N8*7W-*
*6BK$BXXH5J*4I0'=B5 M#(66,('L'%>2$UIB!+9&7)ERONR*U;YO0T@(W=XJIN$*
T^1+A4S&1#-?M;4, MH,'<9\/-N!SG86HCEBH6O($PR^<@K IY!6D2WB=IE;A4]UV[
$OK\76&5CH2 MZ8,J.JHAG["6[&VF-WD1+\N[+>LS;T!]VF7?B F\9G+)TY'9)&>3?
*HHH91(: MIN<(2B5=QZ"Y-OP"?$SC9-\ALCE1L[E]$IZ]DILHY>G];P%Q=,ZK@J:*U!?*
MA4NN_?&MN:)0^CI;C&#(Y;RB!S:K8)T,I=^M+_6]1J5V!7Y'TGX^G="[SOMQ
*MG;=?]KS3?'^S2\!7E_5&*0\&M;QO"-X/)T>2T6B MO(?2GW14-96?*
+SPM0\I<36LPEW<;>F>$4[4]?P])PA\N$X2==OZV>N\8\8X1 M[QCQCA&YDBW?1??
(&P+>4:RP+^9ASBN^+'F9X=>_K?WERY;Y$ST]S:QMTH%D M;
[F8.;#:TTL$!=I[%1AMYP0I1>CEHKUVARROPF69=WM:-&GUT.Z& NY0\KZS MZ7G[
Z6/Z!O.\EF3O=5U."MY_Q\4DG-<-!\+;3>,M;S>LF=V%>>=<>SE]@?N M@]?-
**/9Q>HWX!L>>?>?>9%>XS&X]S]:6;."<_MW5&3VF3.':'L!;-*
:U=^5@\D#0+5K$0Z7BS1VL'9]!7N8D=36?0:&ZF>'3O/V M8\""H?O%A1D)LHP-
*!)\.W@=TQGCD%1X0H64%HXW%U#+#36U0G:&D-I3YB-&@ M$:.368*FQP5ELX?*
2R72:1(C4UD<$MNZ!I-.$H(CU+K-XJV?4EVP$MG8T(["! MU"'N"(X1B>LZ6R0M"_9<-*
*)GR^]UP=I/CZ*_=ZH3@?KT> RX'Y4]"\6G!KR6\ M0B3:!\0U?*
*()A]1W.21&P7*YO=94E>&X14'D0?"S,$WC,8F9\-:L6=)V^JG\(\EGY>$2MIW1 M6;*XQ8)-*
*H,,(FHMW)H]L0;E*PPCM5M#:J=*=2X84[[G?TH_RI&6M(9V,2(](E%)8H]8'L MXKB**
[3EJWS9UQ1?Q3U-F)%-EEN+JZ#LN[2]8_%J?WC#1Y^;G(/2]8#;JRYC
M!TENH^$>#*&QHZ00Q8>MN\Z$I57F%L3T= :81DD!>D7&#@1H85%R)X\]+0&.
M"-2;/79$=.:'C24!P\+\,&M/$K:SO??PR"78DS7Y.&6'.LP:AT3 M'"
[5RTZ,.D<@!\SWL@VP_GR V1^V0Z:M M]HA)D3,YRF(VV9MI G7H@;#;&3I\?*
_!E,L^2^X)>,)V2O8U'[AS,FHD#=^J+ MP,.#JB0MGWH765Q4CDL5:I5'&+(2+MU

U3OH\N2I.O&B1\AB5_?L_5(U9ER)I8H! M@5F_*.NMO9+$2T&
*(^#TE9WHPF#UDR96.Q'F%U@0ZO=;; :1+QRQ-? M](Y*_E>#M(Q$:"-*
(:_1",U<^XF&FW+2^]PSS4&L6.UVW#XKOB.M.>(XN&: -U-
:V\3Y!TY<_H&2AQFSNHX>$0D?T/>"*\Z3 M::4?;!GJ(EE6&B,XV#M?K+*
[5SOMO]\=_ZTNY>CM0T0X4;./#B03;%.ZQ76EW MO6QRO;4)$[2@GL&U^%/]!2E!;-"
PX$WU 7 M144D[U S7J\>@V%IL\!YH(-![T?8I\S)]5WT1UG\'6=H]==V1+&9/-6^!KPP
MPTZ8+@X9'5-95\;A%OTW.+79##3ZFS% 3_#<;*A?S)]O=T)K[#I=>PQH7*\ MK!] E-*
4Y_!,M0%":.PCMYC- O:?0%D]AR#._Q"4M:]OLN9]OX$W4N_SVQ^6G M8_/$;3
M61TBP]CR==>GBOH0H6<9P!?EHFXT&%E+=WSDTFE4;4^OM3U+B?E@;5&9%I2*
*MY\,I/IQB;3A%F49]A(WF$JHM'*Y(@HFX6H:\=6]51PY/;^X@A4;JV_GB)V!J*
M!RU^4N];EMP(]2U\2N;%O);NQM^'IRK)Q%35_3XX5=?\R'7#O5X[O^FAIA&A
MFE]];1E[:LN8NI%K509 \%+JFABA41BYM:!>BR-Q6EEY"6%UB=\9/\^E$@\: MF.
*[S$:9N&VK+PLMDUJ,BGV&2_-U\K53?SQD;7KNU*2K.^L:KZ3FVXN7K9=5C*
*M=B]_]_>O^3A[6B2D;%PM*B*@^AC?WX[HZXDIY;;XN]M\[DG-73F[)B:6V'IC*
MYUIL/HB:2V@K#7O,,RP<@4#>32RV0AV)2C=) >#5KVR'!-?0%!:^FN_\[K$*
MEQ@VN(#'+AA"U4/@B!_[2Q?SW1P6&3O?L(5@B-EO>PZBSDJBMF<-FJ@D:OF$
MD:M40]?,M'P""0&"ICNX,H, "K@HW<(5F="1'&NY)-B<'&O=76V#>^>'4]?M MQG@*
.UPF[M[<$#N,.M_>YA"@WT#K>96(MIYZ0ENXX4-'V/GOCGUO6C>GN@*
*M)4<06E'MCR88JAC=VWN$%2#J66QTY9JFY8-6OI>=7>*L(O5NTZ:^7K*\H0*
*M"=.C+#Z*YTF6T)PKKH]H19,PTU"IKU:NJMJ7FRV*/Y5OL-G @3+L"*
*M]=&=OXK8#CYC(G**'E&*%YPPB&PI]/093S[CJ5,UG_YV))\FY7Z:E,J.@5LM*
*MSJX@)'X6PJ-\B[H2IQ+$:<6FJ@K$N4K?U@=W+"R\D<+<]0R/QQW M**
:X]+L&8<2F.K_SNG_O&^0QMOCII/@'_T>"GA]6GL M>+VZ?^SL"9$HH>B)(WU7C0]??*
RR:#&VELJMK_30(V;/RFOUXI^UBB'$0)&+ES! MP^=.6)T[L:CTASPDN8UGFP9W"P\WS?
8'6177IW-S6A?(HEB00OP$&]F4#IWG P=6 MV2+;%V!5TE/L/>-! [QA:=AS'L)'67C6
T"O/^\QZ'F/%W.JK.9[(+A65=9X M$((.50@ZU$#0!Q6"/F@@Z,*01\U$/1)A:!/O1/4-8*
M7);Z/,@$6/^,I@"] M+K1WQU9BLEV(-@TSIIONOE/!D:@!GS06Q':Y:)&GVLN3QHO8)?
Z!2/4IF2>Y M#N@:'CE>#-?U-%>_\"#J2@G7 :?\Z>-'=LN8,8!L\]/'B^S=8J%[WC<\TH++
M'%LRM#OC7EG:UXAO$DQL3G"6DS#BU^G=(C(_%,%M#W7C?3.[,U;D SE&#TG&
*M@3@.4UY_5GC!L&4D.OR.C,Z>[M3YQ'A?DE!#EKC8]O69XON3*3ZD1T :F.C1 MC';F?*
JR=F[GZ<(4&5IQ1#.$0 MV^:_=$:1M/
5J'CXG=$^S:TVL@#Y'AY+LBW6",D^7OW"_\?)9]_\?U!+ P04 M " #3@FU9U=72<^CA
"1#PT % &1M=' R,#(T,#DS,%\Q,'$N:'1M M[+WI=^)(L@?Z^=9?
H>>9OEUU#K@0J[&K_0[EI=JWR\O8KID[[TN?1$J,;@F) MUF;^>M?1*8D))*
P8($2E#W3;5M;+O&+-2,CO_R_KR-3>::.:]C6;[^JA[5? M%6IIMFY83[_]VGLXN[KZ]?
*\]_?!EZ,%C*CE_G8P]+SQ\>?/+R\OAR^-0]MY M^JQVN]W/K_C, 7_HV*&#Q(.O?*
<=DC]9KM?9GN!L^B#=T(WHV^1R_&3YJ$4-S
MDT^Z5#M\LI_LUOP3KT9_ZZ1V87&9\-R/6)I-'K>U=-&!L^JG__W^ON#-J0C
M$CYLO'I5:#KQ0M@5PS(-B_[OU_OOGSV'6.[=D;$@]F%;ZFM:NVHVE"C1N'1
MG]D3BG=C3::/9E%[]5JU5J^J]? COEOU)F,ZG<0!]^AOO3\60]IS9B8XKUW+'-
*C)ZS._AFIUI38]/K>F,G'2]X M)P&7.4(DT8*W^\2-*
*T&*X=K.N=A;ABS^1@+F7"O,6A[DW1:+Q-A*KL_CUAKZE*
M4T>W1S3Q]OWYMTL#NO_D'FKV$:HY=## X MSBSJ4_&>Z+GF.P[(R4GZ%\.[B5=<0\L*
HZ$E9^55&Z8_B7>2W;!]RW.R>L%O M)K^MZ1F?UO3$@\!63X2,4_D-;R0>UCUG1E D0
*6W/^/M0"*IU;IZ2-0X+]J=;^.@1M\N4SO_?AO_!_7_Z?:E7Y1BU$ M65_D1Y MY)@_!\PK=*
*];C$5.I*JKZ&20(?DI1CQNMXV9=N;M6JE508B/J$04[6*5_^<;S*
M;P=GM@4@\ZJ/T+D#1>-__7;@ ?8^,VWV^?3+9]{/+WU;GRBN-S&!OP;P9-4U
*M_D./%;4V]DX4=F% 1H8Y.5;^^R_?]DX>C1%UE1OZHMS;(V+QBR?*F.BH6X^5*
MFF$IM4/5L$X4@(MK.\<\3W[!&9&-Y[#EG3#'9L$/FK9%L5[QNLQ=H@Z_%=#*
MUZD%O8/?X8D;Y!-#XR-Y]>Y1">M_XES@K-?4X-=N%9G"(B@J@"6/SVT-7K2
M2\/5B'D'G[#U2[CF'B@&P,5X?:ZV@'('I_]H?/F<:"G?EO]-B3/?+F %7\ZY
MY3/&HK&&+RS]'("5:+I^<%H%]0DJ)>?6>S!HG0W<)$^))AL'IP-BNC3G!B\L
*M8*7)&;3H$/,*N.;U#SI)--P\.*V!6&_6U%JSMD[KG?360;*
71&EJ=/AZX=U4!1J^%689;H:&S:$TH?/%O[M>3MF)L$U'?6I\^>=2:P;Z#Y[]'%
(P1[LWHXLH^^[5V"<,\4WR&/QX.-5!G MQP]#XM"O8.+I9_9H#)8',S=@[,1ZHLBI7R?
31^[(!'^QWK'__).Z'DAU+CK5 M8([:S49BCM!E.-9]9P+2YN!T=9%2_/STWYZ?
_NS\7+R.#6Z[\=F))J>^8'): M^4_.13
S/4O/DU=CY(^VB"]UP12NKC!%F$+#VO(4UK;+HAN: MPHUS:Z.[:)XR[85+AVCXL4!IJ

*>)*3-PGAKHVI_1=-:6;?&/'=GN\-;0?<&/V'91HC U1\0.].Z^ TNI:C*;I.*
M5YI+="5)ODYC69P!R%G["_IW8]\1)TG+VD9 UZDO"[IB>LTNQ!U.APXHACFH
M"W]CA.S89?$@Z;"8I?'0Q8&QC!--?3M#U]=H"R_C3&!WPY< Z0@9:[V[$?9*
*MWZ[M._Q/%M,]#N:(35H6W$Z#9RES>*_#!W_'AC445A/:6H]^SJCZ0K-/OR M:7@I^?*
4Q$YCA7ZY'' \=RM-I#\/WIO>B;NJQ1W$$TR;XG?#OL)'/B;F(Y@91 MPB8&E$MO/#8-C?
1A;L-V1I2XOD-/8\'"8V"K4?BY\'[X-WYNX;S/^@_BS7MG MN_/^;Z809Z;;]YSC?
R\UQ]%W.'_/?B@8!I.8]/,$(M0/&CLI&?5N8]+ MQK 5W7B&?*
*IW&'KWAL63;F9W<(&)_#)]9-+=S[^/%JTX\RI^/(YM7<1(:-! M'"*M(L@2'A-*
*0>0"HWT2N.#&I*P,Q,A91!$E("0VH/95!# F9F*J0,DI 2&%)[M*(/J$C*
*S4R%ED(24P)#:0QFD2L#,3(6401)2 D-J(Z'XN<6+)>/K*PFT].2**
*MV!R+C9M$]P].P\N9X]A#.1(LRTM*YL*^C3!;.1\3(I%3(LK"80*XC>6!V\@- MN.'<=(2?*
FV57O_.?FQG<_'EE:?8(^_^B\#^;FL\)0VYG6_J,'N6WM-'AF6X
*M'J:@/=.+5]2E5&S.7S"PJ1Q8:H0;D^[%,4F*RI9 * X(A:CY#&DI@5"L1"A(M-T&!54,U-*
<:DH+;HV PY9OG MP84;M7>,:(O&LAN/_Q8;_.]H#3-6)-<./1, MFDHD92#I'#ZX;IX]@?J.8[
MAF=0]^)5,WV=ZI>./<)]$;['%KIN!Q?$L; B?5BMY^LD_0-O1VJ$!>KF)N2]
*M@9R]2A:1P"L\(1*4)' *P_PA$J*D< K#_"$2L[=)/"R%A1*B;GUEEBD62>Q MMBM8*XTE)*
*[%6.-9*8[Q)K!6.M=+8;_\B>)*(5V* A8TD9D(:9Q)8NP6LTEAB M$EA;EUCE,+LDL+8NL$*
M/EM;:]HV7>):^M;WL D=U/_N$6?A0(2G4.ADM:MU-?[K@]]WP?@BSN2!F/1V MP$;)"'?
G&,]@N8 (Y^I7;(IECF,J^M('M$G_!6=X2?\E_NC[J^&O1]L_'PT/
MGP.3"X\,]HG)):OA4,VS'1?,[]O!P-"H([ALS1\,;S:-&\E2IR\4[9F3N"'1
*M,8.I]PIW*2\V("\V2]YF5:UE\1C>%EQZ?Z%7P;AN]-G[BU M>L_$,/'72]M!]V::*
(X.UR+AO2L++""7W6@$"VFQ3USST\EQ?)<._EX5J7<"T: MKJJ$Z])P525<\X;KOF.M3.0-
*_01IZTE;;P=OM$%REK2=MO0+A MNN]8*Q-Y!8SK_1F$7HEY!8-S?'R&O?*
SCX9O]3!V+77B";QK4/:=];U?BS"4U M%I?O4CK=I]U8%@"[X68)&.4K+=?*
*A]]DO9V)MTK6VR\C7K+>TJPG^49"542H M"A@'+P/:I6^T@ZPG7I!4^D;2-Y*LMQ?*
*K$Y+UI&]44M:3?".A*B)4=VG=Z,P> MC:B#-^X(C+-GZ6>V,*
*[8=XM&OMJ7O#M:E9[0*X_&"*DO1?C?B$;NT8"1YKI0N MD>2Y KTAR7.E]*
*(7*P'.2821&A<+H+JT-[0W,I?^S6SPG7F1:^C_2_Y$\MZ>K*
*M09+GI/^SISPG&49B5"B,!J<*BE8E.-$2_M]8;4P=L.'>)\/8/9H-DCNA>47'J<>T5<73?*
PO"W4)H9^99V1L>1FQN/\,3.F!;*L3]/<-Z97)+1;I!1;JSH) *N+S$EXI[*
MIX@\/:91P)A%.U^SLRW-EZWX\]LGFS1#MN;/%T!<:4[L/A&E65 TL:8GQ]94
*ML93^_*FK2UM![7Q-W9FYD<;"-F(=NT)N:61L,=:Q,Z"0QDEYB2^-FITB<$ M4?*
JS5I"ZO!44GYL<3-V9N9'&PC9B';M";FED;#'6L3.@D,9)>8DOC9J=(G)\ MGX94[1N.
*^2\]60YLDD5O9TX0#'$E:IV]XDH5:80Q&K*C0M;T8(;VNPMM: (M6K*
8XDHMN/M$E%JP:&+I
;'"C1Q2(6XKXMM\4D4.33)"D_J0ED^>&DZ9,SM^6/[]]LDDS9&O^? '$E>;$[A-1
MF@5%$RLTYYI3I/6GEY;CAIRN3\;<4ZMD\V:89L+=91 '&E.;'[1)1F
M0='$"LTY=6K.":+T9ZV@97/\F_ENY)B?&VDL;"/6L2ODED;&%F,=.P,:9R4 ME_C2J-*
DI(B=.?I:J?:<.0UZ.;%)%;ZNB3Q'$E:IV]XDH56;1Q)HO6B#$83N*
MVGO]$W/S_M40587_"S AB3@0Z]2]/_RV7@]=JAK^XY&71@R_CVD1&<=T(UG*
MN(3__>^_J>W:27"%75(TD[CN;P>6;YH'\-18<;V)"8,=P>KKO$?>JRHM;%W MHK+*
S(RS,FQ\M]_^;9W\@CLY"HW]$6YMT?$XA=/E!%QG@SK6,'7#J(VQ]CB MT F_/Z3&T]
[5AKCUQ-%LTW;.5;^5F/_G"A]HOU\7'\\.Q0J==:S>[VNY+! M=&E3^T[.J+
<6\B'Q/3N%+X!_SHS\E^7&7KV0%>=W*.UZ7QY>W^M? $A"R.^ M\4<@E34E$,;W=)*
.9V!G'"L604VB4^/XW-;8J1QE5]BTYK/C/[#!QN" M.N;DGHYMQPLFMW$
\@:ZY8'ZA]9!@Q_W;=OL$].TO;[]BECJ=IKMD]GI_\>/ MWOWCQ?WW?
*ROW%W>W]X_*W8_[AQ^]FT?E\58!.?0(PD91&\KMO:*V/NJ?E-M+*
*MY?'W"R4FHB+QU#M[Q-MJM]%\BZH%\\8Z@F=)*E_:C@+>K/)72">%FS4*6'14*
MSXFM[M@G+[B-&$"@F8# L0YWJF#5>T-\O:J3275"B5.EUL'I QU[W&=HU"H M-*
*K4J5^XO_6QG1\=>D#QZ= @XG>CV)P12:SF!U)P32(_WO9N'*R9VMBJ1"D!; M*"J\:*
I#63%P[)'RY\P_BF?/7?OSSQU$ZML6" 8D#!=C&G3TH5S=GA\4#Z^/%*]$\-A;%'BA.-
:%N(H[MIAJ&='3%L!3#, \O.(R=V)6#TP__]>&__NL+J"I]N,9%%P>4.$%=Q&+'9R!*
M/&=R9NLAS(_F%3O5GX@S=NQGC3^-)N97!Q2:.U3.;!-DK4&R\;_%:?K(QJ2
MVK5QP4GY/]\Q7-W0F.H%GC#BXV>/.4_$,O[#_N:L@+W]].G"P^'&]I3>&(/W
MR%K%S/;5X?WAPZ%R,1J;]@2F^RH('&M\?F_LP[DYA9^,U>(MB^IJ30BFSG<:SN#76^?
1?K&"25!K!Z?7AF51,K9-PYT=,8_I K1^HK2?.S)!IC8BKTE6J^9SRCX0/BA[J?
E(\P"@6'\:D(P'Y\'U$0 MI#V'DC@9&@>GG79CE@B?WDG^[S9(V;LA.
<)ETEM'IPVN^U]J]E:$#K:)MVG

M)OE__^VHKG9.7,6C)AUCUQ6+];V"^MWTT:94",P>S$41Y(]IBWG%]P%^,MAN-US07A?
JWW;\^P1BP(H+J@H77&>^A]K%07__^E$660K-:<+OU6X
MGOV1X!G6WZR'MF[C/A]>R7Q92K0A7^N/0)-AIP?C"!>^,7 27&(/'/-Q11>#
MR,GR$UHOPM9_= @3:@^34=\VEYR";<+&B>)40N#F)@B!,-C05VU(K">X8"DO
M0P.N3&55VE2F>2B;F5F1F.U=1D2@!R9JO<]8-C0B6@>G_[0]1*[&$M 4=PAZ
MV:THEJV,B:,\$].G&!+G-^8-C8V"O!XCQ6([QW! H'"Y4E(K?;!Z?EU[VS+
M5&@N387M3O C&"KY<,5%((!BH62UDQ)D@\="9^^&N#KY:\[38PF<"N8[4$_Y
M_OUL_VW,^+*:RA?5KBP= TQ@RDT4;4AA0D:8 /(RI"SDAP9F+/3]4?W$^S@D
MKC(P3+!/B6G"$[B4B6;K7[Z!1BO8JGT:/ ?CNS6!D8)^3)D8+W&C-Z0LFC1 MXFUD%YQ?
=!$[M#&('RX*N@-B3<[M@!>2["5VD;\^V/HIT9<^F[YPX,.9[[C0%?XLC** M(X]XOANRR-
'!Z;_I7#CFRV?LX*D29+LH-[=*M,Z\<^ND>0(=:0]D'QF>!T ! MSUCS'-M"J6M.% H2>*).
MFSJ0/1ZJC\I'G)K.2;U1/PP>\(8&6U\:X_K2IOF!]S>".74_;1?$L4G%.0TP M'8*X*T&\"H@!-
T0QX8-4(1KXXS"SB$2DJX-B+O4J+FU74V^XT#_X-9"4@1T*
M,S^IH%2'SX$HQ,X_*4^._>(-P]N'(.0IZYM.!X;%,C=8Q!%#3_7:258/V6WU
M)'SLS0>R^Q<^B)(]>#BCK^&3AL69%&SP:CW457$%=;B/L99N:R.KO6B@\@8:
MZJ&:N\>?F+COZ6#B\QD7"\NM3$Z[KK8/CS;;]=Y*G5[@6!YK-E!8\S:S]-/DUJS-
B4]L6%0\/6?(L$ XY3#5KXJOO&A9U M0U.QGK)^MEQR=)X0#06@4!2YR%(:>=$C;.
;^_X9_WQ(E_JZ.:+E=&P'"TP2 M7-M*M:2,09HGP.Q_$"66S.[BJX8&WH66M
C8_D4ZIE,J\V]HJN MJYO [A#LHY#TRD<@*#-
$>?;>8C,/W)]_7SSDDA3P@+V88>DE]Z',LS0X.?,J M;)_(W&,>PHW]S#=>J"K?
>%%!"CE4><'_!%2Y9 XCL 2?T^9!@CZ)[;V*#^X' MN_R (?*4(,IT:S=
[PKWU/<:0P)E@5X/:H]JDXU P9VH 2_MN+\=7-
U<'IPVZY5.NU9I'=5#*H8]/E6>4P+Z(0YC,+:GO=BFX[&5+;.+=NAN M8$/PHAVZFYG%V,
[JNV]?_XC!TYEN7C_<'B;C,3,)[
MK(&9=X>#*NC#^8OH2"IWWVY^7!\D]XG_1^Z/:NWR\N#]6
MB/E")N[L_"=&&]*WOA)]&<42,_#[>?H,X#2N/?['V[/OAO5SX0Q$$Y&^W7D. M016^
[JBN""^!RFIX)E[KG$H"4#%=^RG;.+/ O5&EH;/#7)-41\KCR"6R9CZ
M8)J[RI6E'1:RY9IMQ>7;9@MH/6V?X$[NC5LBAZ+W]?L%[A4[N[UYO+AY?+," MP*Z&Q-
Z??K1B/G9[PP$:(--N,(_M-J M18D'(G+&6>\';I?MW?\;_*O'"^7^XEOO_OS]YIL"BN5?
\&OU^^WM'_@W*WMR MG1!\.|
0ZH((W1LT;+48^>9HN"S=EH[G)5X]Z][_;FO^U>6'FP59(6!ZU[M_M5*X.WX,\/K$;
[>7EU4WOYNRJ]UT!+QCLLMYCO!#/NMRR+D$E?@7![Q68R(IZ M*"IP+Z.0;%0,T-
T5\=XH3KQO&"]U8?%R32RP&Q$FT4:.:<\/5?%Z- 1,.>A8Q
M)Z[!PGI3=)W9%J_^R9ZYIZYO>B[G=GCN=DRYC;HSV%.;ZX-/<&'5$!9_\!%
M(0/D%.:@(8[@@AG^C3 T;=?'B#+IV[X7IKK>&^[/78%5O;:W,JTI+*Q -GD.
M^&8,4G>.K5$=450&S+Q7%.V8F2@NBT1NCO!^SBT6KQ'"QQ%
[90"*8++%7&=PQ]6;"/_S%Y;@<_
M7""^\PGMK!\NVV0;"*'=P55];R60N'[?.1T0C!E')E\:Q'E@RP_V@17,*TA47+
MQ>O0Z!N[LVQ2+W#=9,?B17EF<@@4[A(N$>7AZMM-[_''_86"Z;6[E&)2SUH'
M*F:W44K"LFBEP3>:+)R:);RAG9^GCUBI8'J0!]^WB(6B+N%YEI;+=F80PW)A
MYAW\!3=2O!!'KYJV_3/8_12LNK-=4_ $;H4848*GEZ*#'.Y_JG=ZX4:)'Y:!
MN[/8@KT;]ZNGA40:%2S;349LOQ8O\1%]2+UX\T-II4F27V3%%8A#X\5"\),N M6-
K*D#A]W!#F4+8CM3^!6S;X^R[O@GN(,Z2,;'C=F!I92'^J?/ELG 9[UF&*
MSP!+>&2D,U%N;(]B]0B8/9R:RV BOP<3.4U?.(P^H>[X/B&&LIZ+&_#8WBU6 M&H/#K
(_!]2AE@;?A[E/3EN4IUZ)SX5QRD@T,\/!#L&9!Y,/O=#%]VW?F;D/ M]$T^XKNSG_
M$TNQ8I?"\PE9W>T7PXWJBKC!.'&("Y+O&<"Q+CV@T35T V84 M7\5:/8!>7K<-P0KML-
)0#)8PH=$GPZZI'>R:BP_JU,)I3[PRW< XY=M# &5$ MB221Y@F3V/@T,Q_(]
K,9.HFJ:RJ9PSL>X#R?U'%?K$4?,KV ?'Q2*+G$)WB
MKD<>.00M\6QHE.V#=.-56W'NP@KM5#'M)_M0>;!-"K*9[T^UGJEE(*$JX<$J
M\>^R/]D.N3DZ(G88#H.R,2BJ,<-@RDYJI\F(B!*Z-H\JK-++JN3!CWM^UY8 M>RD"C
O?,?E.VS['I^?X6&;*91MH@VV[K-A24,T&I@F(#[!FGUHPAA<#X(\?
M)BY,&4B,0$0/?!,8S^/;>3V>%*Z0J:B\8I(7-C^&HS"#Q^5[$#V83:"2;K-O M&A;N!6;?
P^W!-IXOZXY-,L&>\?+Y? .J,<4Y9ZY%788>&KB)6"$P1[Q*D#LT MQFR^6=45:--V7,9X^*
<[1NYTV#/0+@"G/ZFPB9OIPK;91.Z!DWO@ ^F-WJHR(!J\C ^N M[
3,&^MWCO&,6BYFM'^'"T^\LAI8).B"1-9[MS7M99^@60,/C>93.35>?PQ4
MPQA,=2Y_F9">L?0=PPVDMV\%G@WK FM$XQJ-/K&\/!3F@P&^A^JY']1> 6'.
M4SY974&6#%J)65=:F"U:P:(0>/J0%^A^M'FP=+]&F38:LP]&#VQAY7S<'Q MTY-
%DXP."75&A@6BYFD2LR#"TEOP!3P: "9ZMNA6GYH&?9Z_KA%K[I*-!2Y\ M.G\=YF?

V(BAD8Y36("?%W&6N?^NZ&@_;P?'O< M3IF]BB;&W+7$@XC<$
H!DK&:",R^.SUHAZEIAQD?<;J0N($Q +O%\X'X:(F[MVZP*L!%Q@@5B%R TQ?
Y<@OV8%\3 #!8N >?A*9A@E"E/[O$.;%A-F QQ%02* MZ?4D6DAP+CH=?
OLHT=WY^&+RN60P<:'.7G[/XUNV 2N$TNYT%];J"OH9 M[5$LI)\HU9F(06#J(!I-
>PS2O<^B70XO]FD[$W0P'/L9U2 KGJ@S]Y8Z*.[A MU[BT^BG:DA.:1$'
):'$MF8=$>"_CD[H)'($C? M,#$W"GUFY*/AQ
7#@UCH'YFDCX$,\&Z#0LP:V$WHNT^8>80L0I2[(5AS2IV9
M2?:@"O^'>QH%&UXS#5:_%[@&+2IH@:,7!A9BG(2\=7?!. 9[%XW-*^QXPX6
M]$CRDN2EPG@I9!K@BI 1IMP1PSV:U-Q]>DNY@-+@>S\X(XPH]:(%FZDOH*/!
MZF&]58\;H;S.';@OX\ N8P'(L'W7 Y\"!B-Y1?**"+S"4!U'LXO'-++:X]S1 MKRC4>#$(B)
(4,6ZS;M%^;'8(U+YA&G#(!U.C8&ON[S F#G3CMSHW1P
MR/'SX'#RD/C0=L>&AS4I&>OK8:R&3QSX9(,!<\ZPN#QYHNX)AR?SLU"C?Z:O
MP6^*YA@X8R3L/HJ "@HRST@E\%/]=PV3(6MUGYD[R4)E?$ M.%W85T8V=
UUM'E1"@7GP&-#T1A@/,3B/E]TC1_81?HR3+(Y&%/>=N
=X.,6]1T,+TRA*:T9*:&+Z2>3$=QT":.\O%"F
MBU(+>=0C+#*$XIM'=WDE7F,T)CRVRQ;T^-8A 2G<:<0W71$.)''#*&U(3
M%T_CJZHQIL>S0-"1B59;F5"Q2,+J(B/VQ3Z>VX'/&59U:&,(+[2H>#=8#UC@
M.M$8DYBLBT;B..@*)MJ8T].A65 Z&D0E9G;ANR/;,C#L;CWQW!<;)@:3 4#
M/CG0P6GH^T1Y,NT^/^8D&AI73Q@=Y4J!$R'L/T^-<:.,EQDACV\$ 3K7M36#
MZ5JF,GGL(H_QLWRM%_0W.',NCB2TN'W:N7R;V-1Z %8$?TA*"2DEBEPYF*9BS/CGU-
$H"! M-+7HP.#X7Q3L1#L8OFCPR&@L A,DK"2#H1+W$OK)8L)%E(,S2O)27(9:;AN-
M6%4\+NM77!C#QQE#3$+?+>"G*($PQK68ID^#C3]!FWS1FW$N?DZG3PYE_>+W
MV3&&8X^O/_/@;NQ[9=J+);SQ+] =/J7SP6!,>K[868X=+VRRMCZ8.&&,?ND
M^1DM@UB$6ZOF1+*T9.FBH\458 .7+](%:W+ISB/!0#(ZBFY]=L=/BE%/JOGH
MAKJQ("I8EJYM610_H3\;KAUX@M[0<'3N9/)-,AH^Q?<5\F#-
;!\DMTAN*UK0K/'F>8!>N&8D Q MYM $VVE'T3I]X/P$%Q++A6$(CWV*LTXRER-
*)/G,DKRM!^44P[W!8=;.S2B,M2M^": M%FX1-DE@2EJ4\I-\XVMT?
$^6]2391[*/:$'PF3AA$"'@BL-@A5>8\V[B<=8^ M8>D?X-EX/%LC<%O>"(-
(V$O8BV3NQ1,BPY#99C&\>1+'N4) M+0,[.H(MGJ85/F517';
,GP\6CHVJ4>3GF5*B"A[87VEY9:?'-RI1V8O%137#3TZ?
NP:MAY\=_Y8^F#M*CEFTK>#4^2HZ=(7 M+'$V4W;C4+FV'8KKS17L+L<"7DK9EBQ,?-
TV+GA\YS%L)=.K&)F-EEC$7PC+#=14+A,*J#FC)CR=J"N/B+K(Z) MN<0-
136J0IBBGPN#I6>B04.GQ*[)Z,*A#.NZ<#DVS'?[&Q01I&XH(V8RI M
+#8OR=@99@#&FLEBG(&U:%,7+%P>>D/MG5H4D&^9^5CV9JVDTW)53K)8J)]
MA/(0A\WHP0A]B&5QL;0"<:?+#OT)KY<8EZVLT&U8E0ONNJDEO-CP9ZHIVD >
MG2_C+.0%OO6=U?CBZ$_>FT&CS^M!4JYGB%*WD5\SRR3+4N7J\N&9''RZN MX;_(-
=IX'Z? 2:E1*4[85 >5SM*#:]ELLMI'^G$45N<_B%;F_$I-I
M_XX_HDGJ!XHF(X&;S4.%'X",33QZAU;_JBJVUY5 MIYH!D#I0@E_N%&E7:FV!Q8@
L"DK2IOK:KT-H/2HTFC5Q46I0,JN=)Y@CZ=E*0[%ZKF(
M.JGIA)$AK74U74_3&%GO(ZK>4.\=0J1Y<%KOUL25(* IJP8;:^KY_+&*"BZ
M1KLK+D8%TG*E<^GN'#HFAAY5F4J*ILZX*#2!S MP1'3L_1;A$N/H>6=FO2H.$V:EL%7-
O5:8FXX6E=9;X@;T#E5U1WC!H$4>7G<
MU4:;]>/1QMJ.6B+S0NKN/956W;7=WQSD4JM6Z;0[.R::)/3W_K-VMI>=1[0
M;U3:G=:.05\@K;PU]WH_$\-D&[(-F7"X)W8[3Y6^L:VJ)M.E91NRC3V07J5;
M/CBG8]LU]CW2(*0?E>4@I265+A4;"&G)'2503-J[?"6UTJ@=B;OH* !D"D#H
M!MWZ>?!G(30M37$I%WY5A Z,5ZI7_T,=>Q:<['2W^HFX\!1(J97') ^4VBVO
M<6T]*28EK&8LH+EJ#ZJL="UBKX+G#$B=)XS.2TLI74KG1:3^CI2^Q_[?#GZX ME$F8-
15?O2O5GD#-"0/2M)S%I=3>)D#:: F\/TT@Y5U:UHMD@SUA@[2,R"5S MP/)G@\:NL8%
2KL\'FLB^O,+T875-,^!]_>Q*X610^) J*ZL6HQ=>BM;37GC
MSDHI')0W+9\&L(EN^UA1:89/Q*I@MGR_4TVV5EK6_@K^RKKI^O5*JU[<.L>L
M'&J4T4V1+!"P0%JARA6\EC6W5+>:%:#VCK& 0,IYC]P5V89L8U_:$$A"[+WY M?
L(.6/A^U?MZ]?WJ\>KB0>G=G"L7__AQ]?AO>82);$H2:5--"23ERI,'E3S"
MQ#1(WS!9J5&Y,4^V(=N01IK8XBNL7AO4D 0/?++_M6MW]@B(UMH[%T("WW'Z
MOJ^NB5I1.\7EFY4^)+HK8%U[!T.N8.W6V^)"52"=5QZ3?:KS')_J<9M]O]6>
MD,E=6<)C[4T& 5F_3ZGZSEK8E5J!BX(E4W8[!=&U-P#D#5&UTND4EUZ[2TJN M=([=
[.9TNP\33A ?4M<)(TC63L]/;O4-YXE8H+ULX6 MW0 7%'>,Z\
[O=BN/>YIZ#$EI(K$EEE1KUQO-+5K6K-2[BR,Z8[) ^P016\B5\]E&[*-W91BY5E%J'?P
M>>9%&)9.\?%J4!#1'HW ='=1P$%37]PQL<*.5EVJ58W7ZM#0X9UCK5,'FW_A M

V!Y6_:7S_C,:? #S&%'>2:F3T_>^'KSK:^W#DY]RS1&AD?UF4:([PUM!^9&
MAU92W9+EZI0P03_KF/ Y>O!L[2>[[]ZGNL1"ZW\R#^I+>V?7-U<9OE.RT7]
ME^ODE>OZ5%^W?\UZI=-N5YJI&?@S%]B9PND#6BYZ6_"L+[=C>ANSWNA4NJVC
M2JV6MFMZ=M8YSRH&:Y'1P)[.D$)?
J3G9[]CDLD&7#498YN,Y;\B^HQKV&@S/^DDD^01)"Q" 6F4' MARHL. 2R]LKCLP8Y(W?
*$T,'<4S0R-CQB2J$N2M[9T=I[*WNZ;N!WB(G$O;+. M.&G77K)6ND#-*
*"8/:]Y1'WP)JY8X!Z?V]H1QU.C TP]MO35B*E*N/*
MZ2)J[2+L]]0CAD7U"^)8AO7DQE!SSD&SGE127)@X^ TL^$:]HM;JX@BIC'/D
M/TFNV#>N6+ON^Q:X0FU56BV!"CB_Q14"J?+R^+F)?01N9@Z2U.L[+\'2!=C:
M]>;9@G2 E0N&D75K\'4JW;;<^R?Q7PC^URYEGQO^6VJEUI);":3;O62B,%?5 ML6U^+-
*VFM*K[38'0 (&@VW[?I+,20:RC$Y?O=ZHDZZY=_3ZV*:IGZ?G)M7JE M5>!I;;-*
RK5%&O2Z9(V".M8OB;X(YFL 8(U#Z'^!GW]8GV%L\D_44
M+NC&\^F'#^G:\=>9/OYZ,NT/ZTY" P8,-!_R6Z,,]N8:6*9%F+XU2A PTFV*
M^4"I0C1<[276!+-=+=N#)CQ;\884P:13RZ4Z_L;,318%'["'$:ZTAY<&,%W MW<-
*%_S&*K5?DECKN *XV)V"8R=Y+=N?EQ''XLS M?C!S2J*!=!,GQ.TLJ=@I$0%^AI$U>=?*
*[=E']>G_1^Z/:NWR\N#]6B/E")FXH M"=!2LNA,PT/*1U!'. E!2#1Y@)G-*
BK53!9=+M=_WCE07RQ/9=Z!#(:_JJ43#TF3'/^@@] M#O\:L7.P/VVY?
*S\LXNNX&V9APYL38Y9OFBB-F*8)>)_M>="H:09J+/K;'1,M M^IN_#Q+Y$5]-*
%X6+)=4&C:Q[ZG&XMJ@*%&/#-TQDJ5!/O.@?W&L"36WX_U>+A7ZK$-*
L'9=LO:JW(+A3:&81)F M-U#3D*B1J)&R1J*F=+)&H%7[+678A<':5OV7 E?*
P3^*GRM#7,48JY:%8L@W9 MAFQ#MB';V+NR=^7)R0NVPMU3EQ)'&
[)%.YT^4],>X[ICV9+O%N<-=079;]N= MV6^K![ERG6I-76%?&R=YS]+/IP2_X-;=VN?
1=X^*JZI?^NRX'4%O.P6]C2EZ
*M&T6AMU&I=P3:A2G1*R1Z.^FR5RU:]JKU2NNHN'T8$KZ[=^C=.&K%BU\NY5F*
M0V#302#GI#R;>P/GY!NUJ$-,YIL0?618ANMA,/)YSPM7Y;>M<>O2YWV[&KO= M'/R;
#4@HWH)S+Q#3+5 RU:ZJ96G1=[L+EB+[A"K=5R<)PVP!9H?%:."JR2*
*M*MFBU&RAYN"1;88M6I5V1[*%9(M"V**>@Z>W*;;H'A57DU%6C-@9!S"H[C1-*
M/C'9+K=]=OIE19Y>/46B,'1RVB[K3>ZWMKQ[7!'!4JF)3-23--K+SQ\)-D
M!W'8H9F#@[8!=FA5U (K-$EV"L[9*0IK.28;8 =U*-*O2W40N^>5M;=+;1F MI"6LY"]M*
JVM2E,5ZGB74E>\W<_<2]F&;$.V(=N0;U\:0EL5^&#
(XA%46L!F;)%8;15O(X#M"K6H+1J"2@O8C'3YU=;9-@%8 MM=)I"+5T(1J&R@I9-
2.5?;7%MMPAVT3(UNO%;?"0:8B%N'%U:S+(3UY'[M2*
*M&#DD#H3JBL2!Q('$@<3!*N00R$+:^S L-(TI;DJ?@H5-@_BKXI'7L$JH#,,**
*MD]^H9FR37"D..TUKO'3LT1E\SK!\X,CIT51?&13X"R84<^_=\U-M");G+I%X!0)^Q"7*E6**
[H&]6F@6> M/2]!+R;H,W;EK10/%ACT:KO2J@NU$B)1+P#J,S;?
K112%AGUS8K:%6HQ1<1] M('L4E)9MR#9D&[(-V<;^MR&0!BU#T/)!BH%-N3S.-*
T@,M"#;)"OU(#8TTC M_%2HN&(VW\PT(8MG[#(7Y'%*@N0"R06[S05YG+:0+Q?*
459'80$8>!0!I'FQ0HE%E*8G5%9JM)'$@<2!P43@Z) Z&Z(K-7A0L$WU!/UA07S)O MX_*
GH&N>U<3K':&2[&3LJPR,4,_CN=<&:%9:7:$"BQ(1B@%(^1QP%.NC(9 MJ$VA5(*, PN*
TSQ.7'HW3IO)G%'!JAG(4/#>Y2[)-F0;L@W9AFQ#YHSN<:B0
*MEQ@%RVSLT"&U7..9*D_$L)2/&$!#S%83 M_V$Y%.;X/U2/:WC%MO"EG]0C?9-*
*":YKO&)Y!Y>*A,&5%ZWEL'6&&WEG<8+MPZAS^MISL8CZW?4.]V\$A>UZVAVQ#J*
MJ$K1L+?_4, ^-N>Q040LK,>6W.7BBA#-B2/9\]@((A;:3SLMD4 N&O3V"^E9*
*M@CV/[21B03UV%+V8=9L$\K;VZ"1CF8 L5E=D(KK$@<2!Q$'AY) X$*HK.[8Q*
*M9>_CT;&-*0JQ])E%Y_W?KS)OJL]R2P.X1;=]C,//L,O?1?+QEN]VEB^8QV:8 M%#DV0-*
)LGD-@')B.]DQ$8>FW$VR(C-2JLA4#A1,J)DQ TQ M8AZ;@3;
*(B&J[TFP+5*8[@Q/W=$E+\DG$)WEL1MHDGS0K]8Y BP%O\8E_N\> MK1#(-*
*F0;L@W9AFQC_]L02(.6(8+\E;B&QL+'NF'Z'M45*XPICRE08$B7,7^@=JC* M^)5DQ?*
*UGQ8QCZA8&DK?.BG)-1[+B_K-BQFZAA:'D;;/B#BRORECROC-*QE:C MA;'DK3-*
>W<812!7>.]+=T3_=O%QQGB&I5-\NMIE/?L710X$!YD $<@3Y;ZQ MJ]B^YWK@0 ,AE?
*_^VU%=57$69[SJ/3<6EA8=XFVP6;[O&5(O8\M9MM.<*N]" M=/4XN&*
*[\49\ZMP/VK'L[A=A[Y.!ILU[IM-1*JU/<&5UI(J]L^\Q*S2X9V]:R*
*M'=OBV*71J72;W4JS7IQQ+=FEY.R2D=F;[7P6R"[=2AOL1+537%Z39)=RLTLS*
*M(_\VVP4MD%UJS!AKU'>-70*W] /\[-OZ!'N+I8Y.X8)N/)]^^)#NO_TZT\=?*
M5PZYAMT89[:Q1E WAF\-W#WJ)-M\H%0A&FZM(=8$73S+]J)SU:\(46LZ7@,
*M(VZ^L=B^+((>XL"PB*49Q(0^PH41?-<]7-3OG.<&R*!H)G$!:G??OOYQ,(NA*
M6NV7-.8+KC N9Y? '4]^Z^;'=?2QN& (9DY)-)#NA(>XG245>"<1?H91O..N
M]^VB^O7^HO='M7?Y>'%_K!#SA4S<4%@+V_1F8:'E(^@CG .HAA_J[%_T@(<*

*MP;V#S[.C_?W\/G6T.&6))J?3SP:P53[IA*M;XTUOO1/SPUR375#(\KC$$3E*
*MF/J>H;G*E:4!W/NGVV55Z,]9Q(]G<7Y\B+A0L0<*$^-#VP3XN-A+%K3IG,#K MRL5?*
ON%-"NGZI>TPD7)C6%2YAD\,7>4"1@.]IV/H/6@@!52&@D8?BRRA.MM^ M3S]>6=!-
*VW>A"Z!9Z*L&O>.A,(6,@*V\H,CM]GKTPR*^;@"=%S:\.1%K^::) MDI(7_-.H:09ZE9D$^+*
<])EKT-W\)5,0C/T\NFV.BLSLG.5?0^(DX9BU5N\]+ M?1:%96%GKMX])];IWRG!H47=WF!
NCL-".<::68S&DQWX^B736>YQ9M3,UH# M3008L7X[J"]4KWGUYDV[.V.;>6(8N4?
JITB?"]2G348RCXT)_]'(MJ8B4;3^ M'4W;K?\6#"7H=P[T=\30JU<"H_Z,C
V/F!+V$O8YHJJG:?[(M-YEUSX]<2&Q"4\3EAV^L5/1W?AB$Y G)$YO@"7'A?
TX'AF9X$OH2^CFBZM$& M$R,1V
*F".K,1';'@MMT$KVZA^5WS7O>>3QS*F;MVZIC>AYDU+O4\DTEK M?*
*$>\QQ#PY4&%W',D+[%TMHR/+!()J5M)TGFQS'?Y) M3)^NQ TSUL# >*5Z]3_4L6<-*
*1;>KY](3A"D-5%LU%;:!I#562''R(-D"Z& MNM76MA^;R."*MZNA+\$5:T&5HHK:[GUEWU*
M;PY(EA05QH0&DQEG,9&Q9JR^>2324I)@>"RK$?9V+>02]:5"O3CR/Z-8XNI.>.E-
&'$<;YEK$'>\?U@.A?G_#_C=[!05 MP#Y\X"?EU2%X41BW"=]: M#Y'0Z#F&"[?
B6N^MDS:ED;8C'% D9:1R=P6:1%]V_RR]%'J19Q#5:I$Z1UR MY]N%+;!+=2+5B>CJ)*
(^5=ZD&5E$#X@0'RK@JSSGT)CA'=;N.?FH)BBUO<%JN MHHB 3N,/2\TEB*
*"D07HPO[C+$.A%IU$ **-:U]4M+MO*8J 90&ZD!L[;=WT M?"_B925('E+\I9*
*$8^E>Y[E_!66Z+ 4(RWKYK4J:DL5G:FV% 7<*WX25U=E*
*M,50>*10EY@UQ0B,ERIN8K[EX31QM&!9<;,J"B\(LD+>/4JJ\;*J,0IX%%]L-*
*M61M!T!)&PF"[NS:VQ2BXV*G4NN*6/RHSQ,59;NO4U@>Y6!47IR9F0Z0JHWN9*
*M;+&S91<[ZMIP%Z3L8KU6Z0A51E<"7*0]$YUZ-L"W9'@TVY5&4R2$BKH5HHS9*
*M#NN47;0H*ZUH#P844W+@KLO/9OU[!@\TTH->S6G0JYT\USN%'7KZ__FNQXZ!*
M?;0S[/E8@8^P]V?8MXAQVLLS3NO@M'8X'QA3@#:F@0<5RGB'".(U8S%]!EI; MK2
*)PV>WUBX3V:QTP*J0YT\(TYHP:,]8ZEX-[1LJ%3D/^Q7C(VJETY3A$5%: M$\:*
SEB"7A'SFZ\)^2;^=R?M0SPTEG)?2B=CL7@UZ.==^%'B?%]P+HZ,SZ@#
MOY#6&+;1)P02HFR(N3)%67VQ#(*$109=Y G5T@FV"H3'&54&A B'%'.@LZ%*
*M8[.D%NQ11@D!X:(4DBU*P!:B!#".,FH'%!O D"Q0 A801S/DL?@MX2QNR$-F*
MC:P8\J"OU-$,ESW"(QOV&+$E8QN"2"P!&R!>21@D5CLY0N=[?8!
*&)^E*A7ASYGUM.0.E-&'$<;YD'(_2W &' M3#K@Y:)WA@8J>K5;GGPF.404(RVC-*
EU7I&5Q44]04^L",EK[;)7>^L!5T
MJ4ZD.A%=G>2QTB[5P"IJ0)S@0!E7Y3F'%G.0YJX>:+-9_W"Y;@H0-D@[!:9<
MJJTDI5D_5:T:D!NWV$G^2P47ICAHP2E%1 MC+P/]E/%J?I?[&7N\HZXFJ@+-[)*
*([.AQ&P@3L2B1.D,)W/G6_Z/;U&E49/' M6XJU; V@3#]-9R/U"/(ZWK)9K[2[]4KK2*08J6*
*D\=;UFNMM;$MQ/&6G6ZE MWFU*B*
L(<6$6P>JU]OH@%_5X2X&.3]]7AVI'C[>LUSIKPUV4XRU;E:/ZD02X M6
792=#O99QWOR2VQ?R,#Q:C4I3;0F$4%$W)0Q!R&7LQG@"7D\PV[%"3*. M9^A,PY#=?*
3N>05P16#@LR\D$:D8FQ6I,((]GD)RP0\FW&:R0D1FQ(BO(XQDD M6^S/=@V
1!Y<(8]GD"RPPYHA(V%AA@CQ#^ZA2J\GS&01I31C89U2L$":D6>18[4N#UH5I35AK-*
2,4A3"Q2]DM?I] MY -A A89]26#5A(S.\CYL61_1EU(W*+4)3%>!$G)B$S,?*
(ZHR'GJ5)_62@: M=KJU(Y'&5@(%(HSCGLNSZ#V^/6NB-K03J1AA_*
MI;YU$L8%G2UR>+VDD/VUTA;
M+NVMC+7M3]6&+-0A2&NB+#S6<\FYDH7M)6OLH2I9+C%++)COL H0)RA0QF5,
MSIVRJ/U>5""71>TEI+92F;N>2^*:+&HO.6>/2PIGL,YRZ6^RJ+UDHVVRT:X5
MM:_GD@54>%'[=J7>$:?&J"QJOU\:(-W&GED-)28#<2)6)0HC>%DKJC] QU[*
M3%Z7IK+]K"QH@"S0;1^3-(1V.+/ZN8+9W%#3"W-N9&MXCI7R.^UVI=GMB&(B M-
\IG(J^-SB++[&^ @>IK,Y HY?B[1X6E-DH^VA0?;==ZSH.1&NLSDE@E_T^/
*M"JOT+_EI4_RTU4#.2NR4Y8UFG(&TR9WO^9XIT*A7U)HX"^RIS+6O41RIE0(N*
MRCAM:J3C MUYDN_GHR[8Z[23"&4$T(PAF)+LQQC:@*44SB0L3:?FF>0#-\ZT7&C7-*
8&#,_M^<2_W3'1HK_Y2P/#>L3G#V;GMU;[97ZFUIWQQ,Z16NKTAE<85L,9A^E%XO/Y
M]9Q8IW^G)'"OMQ)%VTY\K/]@IJ-& '=5(\F-BY'- ?=02(6,>'L=!*
*(B2**PG60!ZG>BGAN=*E5]%V_$O4Y@ KC.]4KD6$?Q)XD[B7NUI*X>DF*X1)T\YW MK5?*
5>K6A"IM&4F]7FLU&I=8N+(VDY"MS16:"K(#M[MK8%B+#HWY4J75$.II; M0KS
S=D9J\7-VOH@%RO[8KJ +%#J-. WZGDF$\UX6Z<#
MZC@49PJ/"T14[W6EC1V!S33ZL8UJC4UV H'OS9R# WH(Z*]91TEOR>#22RG9TF,^*
MYZ,_4]<#(U0AEC[CM\!CGF-HGO1<1/1K8]/L(.RQW@MQ>.72
M2]L94,/SX9FU]])7ZD==Z<&(T9HP3)!6!6IE)MC0(>HK<<.NU%R3G%"XZ9?.
M"JVTHDZKL\+FCU27;%$"MA#EH(.6F@=7Y'W"NF2!$K" .)HA[?BH>1Z0<-[5
MD(=3ZLL+OV6_'8+='WB[4(Y>H+Q7JQ9'_:26$E]Z$$K:E\H1520#[\(&?*

E)>R_M:Z"BU\KET<^20\0VTMHBK:$+
M=H1TL["S%R2[B.G)MPM;6Y>:1+&X)HDCS5WJ0%V+R10QK5XSIR-+L4$$&[7*
MO<\XJW$W3Q+=MJNX0L\+C2"(0&0!NK#_.,M0ID6G#NSV,>F2G3;,3ENW.M_+
*M3R+E(DC>DKPE4+!CZ9YG%&QK%Y;>D.N![*U*O2/."O!;!I)+?MH#797%4'DD M3I28-*
\0)C90H6^)DKBC\-7&T85@1OB$KP@NS+-Y.JPB_J>()>5:$;S-)$KMM6:6FDV)<-%
[@PJ1.=M)+PRV^/R,D?+U3 MJ^VAGV?*RL1]C[,^Q;Q#CMU2SVP_FC;!2@C0F_R'B'&.*
(U8S%]!EI; MK1L)PV>WU]JO#R;%4:VBMMK""NW"
5A2N&>L=:\&]PU5B)S'_8I'U[0K1RUQ M[93"05C2Y.-.QAKTBIC??"G(-_&_.WD?
XJ&QE'M2.AFKQ:M!/^]ZCQ+G^X)S
M<61\1OGWE3S$$MLFXL102I06(0^L+,GEE%_H,C @SRP0C+!5IG@**/"@!#A*
MB'+6<2X&5I(B,R!S5=[;AZ<-H[D)@M16A/&"!,NB4"6 M[B\:F^7TR(M-
9"H+Q7JQ9'_N248E-Z$$6"% Z9=,#+ M1>]T#=0M>JUP459CEIA20FYEM)O M5IH"E;*
N]IB)764=<350%N_DD=E08C80)V)1HG2&D[D3)?['MZC2J,D#)41;
*MMLXHNK^1X@9Y'2C1Z%2ZS6ZE*7#5V\(!)@^4:-0R:NUO82-$'G6=U7:KTFE(*
MB(L(<6$6P1]UC K[6]]ND&O1_79#(-#OIT.UHP=-&H9]?8WN:DAYP,E6I5N*
*M7:3*SQ+@ NUD:-0:V0#?DN'1ZE8Z39%$L*@;%,J8@Y"]0>%VYKP(2P%KXMFP M?=><*
*:K;9$LDBA# %N6.'*G0KGHG65#920$=*8AY>Y&7>1V_/9K!"1NV%0F(>DBW$*
VHIPQUJ1GV%S8<[) L(!\JR M:H:,,@HK!3HDG&6:PFZ$/-YS@$'.4Z7^LE!0['1K1R-*
*K03J1!B7NRF"R[WY M*KX8::^WA-4^>R-'MMS:7@]NCUOKBC2V$J@;<;R7Y9+9I,*
*[8)8]%+M+*RN\[M8 '+?.IRT3M#*
^62,BEU@XWVTU($YPH(S+F9Q#9>7WO2C3+2N_2TAMHWQUHYY+
M=INL_"XY9X_K[F:PSG))<;+RNV2C;;+1CE5^;]1SR082HO[*HQ7)BN_[Y<& MRN*=/#*
(;2LP&XD0L2I3.<#)7^?V!CCTFKTM3_GU6%C1 %NBVC\D:0CN<6?U<
MQ6QNIU>OW,A6\SS+R;<:E8Y:F&R;E62-\IG(:Z.SR%KT&V"@SMH,)$;-^G9%
M;156.U;RT:;X:+O6\TJ,E&4^'ZW/2:(6QE?K A^\U-AC+W1#7+75<$XN3)5Q M7-F-
\GGRT%JK=+H2B[:)RX26#>EJY%+COU5IUPNKE[6>G18$ M=#[S[ZM3["SN /B%"
*[HQO/IAP_I\8Y?9[KXZ\FT.RJVDPAJ!#&-(*21[,8X MLXV9)I9I(087#80D=9)M/E"J$ TWJ!-*
K@O7W+-N#)CR;%>4#].BX61VWL%LL MSHC&BC(P+&)I!C&ACX$L=@^WV^_$7
%9%,TD+H#N[MO7/PYF(56K_9+&<<$5 MQD3LTL'IS+=N?EQ''XOS7= C)=%
#'UL5$D8STX!\$:IV4.;SK?;NH?KV_ MZ/U1[5T^7MP?\1\(1,W% \8#+/H3,-*
*#RD=01W@' <&_U=@_:;'"X-;!Y]G1 M_GY^GSI:G+)$D]/I9P/8*E]@4XG6MP:Y+_W3Q?*
*DSLI!+18W*VC-Q%[&K,+0?NA;N;JSW-B'?J=DB &NO&E#I7/;OZK&.H6*AED*
MMP%2&&@-;D)[H6K)JP]KKR%N8&TGAM.YQ9VT.9A;\+D!STZYAO>'KG(!B-5G
MEGW>6O+);0SI:X+9^YPE VV @>J2@59E(' FT(QB43-;J#FS=7TPD3KEN1H M<4D7O/G
]NO4-I)UL0@B\W8PL0>H7OCGN3A3;0W,H'&]=_25N:
MV&A_,A8/&VG)X,UJ30T26IM;3VA5VY56LXCMMIE3E\U+:\3A$L&P3Y(O1.6+
*MC$1O=:N)WLTX7S0K]7JMI'PAD K?D@\CC J/'9>'*YT.!;;0#),J5J#;\2K^*
*MKJ&GX^/ZBF%EN3G[XN+(-F0;FV]#(*E7-L2N+XD5@52?;4S^$OKBA7AP4MX/S M !*
*(]2[]SZ,CP1VM+H9I:Q,XT$6(: N"VM&S2S"A6N9(^WAZ;'+6$,BL+*N<@*
M'=3XRIIM55G$S:1@$2YS4)Z4,5LU^9MIASLOJXGU$=&.@<1(X>](X M.WW5W
M%@DE/H3#3&DAFE&+&94>)R)?67U-!;B=N\CFK\W ;Q31 D<:=.+@]^L-9N,,UU77+/9%
(#!V!? M&96+-)HQ#N'CHFAA\LSW+RWL7YE8.]+!2F.@DS+T7J_@@P@*[H>&P72*.(*
*M@MA2.XH#WBSMF'$V[3NUX_O1VSPX/6H+M6])1,U8.E_QG(YMUY *4"09TDK+*
*MBGJ_!@Q(S[IP5+YP\"O!R?)G(?]EL1YGB*ZM9%S])]SY!0>12=*
M2I50"'O4P2M[6>J1\7YF:*=S2V98T/,D16%R:/TU.:X([86<210>J-8)P]+*
M#Y?]VVB/PRJ0;U:'VF]M+Z2DRA9!>>0 =6Q^/&=8S\;.M6_3GX]:^LVY#V*
*MO8CT[Q9$K4J[*9 LDMO(R\(G>:0D;9%/FI6N*M16T"WRB4 &P-:<^_U,\99M MR#;V?.O*
WKL()ZF'8QBLHHH\'$,V)8FTI:8$$GKE6?/@VT#O?$<;8O$>>R +
MZPGOZN516.^.3%@A]4>[I_WE&PZ]CLC^$%%]S46+1K?2KLM:>I(SMLT9[3QJ
*MZ6V2,]K-2JLA5*W;7R3&'%NC5'R'O%7/O@M-FHU&I";;01#FRE MQ?*
9["OT5CFU0X(S/W6LF7. ME6KG48=PSO>X"U!T9Q)6O/LB!-
**Z^80";5K+R).2OKKDOM6Y+X\RBQOGOKI M%1.*YSZ!+)7RQ -*
F\R#'0:Z/TI\H'X.DR$^IJY_[+3R%E(J93E1:7G9.29%7 M(>G?F^QUV]@T6@)OL1(
4/N/WRQUG9;5FU.V8FX GF8KUIN5IE@+6B)N)I"Y MA+(-
V89P;0@D(?;>S$[/)1P8%K$TF4LHFY)DKF>R?T9E=!@L6Y((_:=7T0 M?BRS4+-'(W
!7#P\&AJT](=7[<$ 6@;AJ-FN+,(G4I0ACRJT\:7:JP +MX,S
MAH0'S]9^KKN0H58Z3:$RJ80#4FEQFT?]V4WAMM&N'#4%6H23WH)HBI/K36^(
*M)^E21S-X5KZ+F%/L,:)%*DEQA$TGCT*U<6'#A,LMI_-% !]7279$"IH*1R* MREJHMI-*

*'H=JU09M9I586IY5NY0+M:%B:,2:F$B9Y*H!G'EJCP='S=A]H0/;_M@-*
XR9_IT\BB$>\EAPPX+CX 5IO^LN[="'+%5?&Z/Y+>]X;<\:OAN@M\$RL$O
*MGM\$,DS*X[8ORJ5+6_/;;R$II/3+](#RJ/N;D8!T&9+^W1ET]EHYZC3%D7," M(]JT*
,ZC-._& %XK$\-[.K M<0-GZ^+1B\& :FMNX)ON"&C6A-K94O+3'P5A@SQ**
*M<.\6&]0KS:Y <>^2[XLI4&^?9>EIA7A*G*3%L;"L"X&P^A^J^]2K!=D",&9*
MI%SZU7FVH&Y1\D8P[-]RQ[1+S&_#A&-Z O[$]AN53/3C'P+;6KOU3:148
MS9"G<96;L[HIG%7?&\[JU'?MG#N!3(PRA 86FA@4KI?%N'A3L#1 L.BVC_4]
M9R3+WX46B-G]3I>(1[44B;CY8,.V)+:*&[I;U8B-LIH:TA&"QE-337J]X/1*
MZI5ZH[@3^]9C-(%,#[EN=N0;0C7AD 2H@S.R9?^Z8,_'IL4,U])J>B@H4S;*
M]1VV>0\42Y5Y+9Y#+)=K&%D!1#8EB20K@.R#)S9JM5S78IA&5Y$5P<' 9R/
*M6$8TVZPE@S0E\1WSJ(M^CZ.\'?QP*8?#=(WS - M;[*.3]@\.&T4=WB)C+QLF'N*[^0*.*
*[6/\JAKGCOWB+N#>^?#*7OO+,W8"FQ5*
M9TP,'0&F&)9FCZCBD==]WRTE#81(Q.51S/R ><1<7,'8%I3[=>EVI<\(01/*
*MY%$?/0>>P.61XO([WZ7,/\#/OJU/L+=X_MLI7-"-Y],/']*UW]S??QUY4W9 M83?&F6W,-*
+%,"S'8:A0 X23;? 4_&R@\YA8$_2M+=N#)CR;%1 #".G4PD,]*
MX#>6:D0\+##&/7%B0A_A MN$?[BHWSG/#9!!T4SB L+NOGW]XV 60[7:+VD
M%5QAS,LN@1&3_-;-C^OH8W%^#V9.2320;KJ$N)TE%:OO$>!G&%F)=[UO%]6O
*M]Q>]/Z]]R\>+^V.%F"]DXH8" "T@B\XT/*1\!'6$C3I[?:SY]+D[CY M$.BJ&W\$*
EM;SFA+JJ2OO@N>I^N>4U=S#%8OK&?I7XEKN+>#.X>ZN'J"5Q_A MPU]-5F8ST(B=
P5> K("V!V?(N]OI+0&S+EZB%/-Q[]J?^'U<)!;IM=&9F,1 M4V$NGN&YRLO0-
LV)8K]8P#BNWW<-W8!/HF:?OO[CH3=]:WJYY[N> PQ E#MO
MHGSW]$/E(\@]D^+.LR+Q.MC M!VP89Z,?6=L\Q*:1'\. M!,-YJ&A0X^3RFT1R.L6H^P*
MHSQA/!Y^SZ'P;!^E@Z?\\?T/%6]ZE.U4A%[#T[5;K<2=<-S*/";UG4=T"F*
M/TV;)8YNV%6'6GS)$(,O[J%RYCMPRJ>!;W$P00MDD37
*MT,##)K$/0Q\HKWA8B9LJ/Z&;QD\'>EQ5E8\X@D_A$#)Z333?H]"L-J0CX'J@ ME_V3*A]*
*[5P^?V"#&#J6@DT9C%ZCX\>[BTZ%RB[TF. 8E,$VPVT_V,W6L:#W@ M*Q[#"*
*[_F6WZT&W"0D>=$U<)^0?N .V"Y!ZEIWD5UAY.2:*2N +_ 3KW34,# M& *\U./@\Z@"-*
U)Z.^;2K8=KUVBOS#TJB#T3^LZ3 O8[O;D['U]\E8-B & MA\20]DODVBRU#3X&XH4H0[
*:311 3[[);)1 <(VI9Z"P5*CU;#BVA7Q[R, ? M$V45L)XM?P .G,]J[>.[(\8,X;8L8"5*
"I/O6&/1L75? ^'N4+:(IY Q5C>"
M.UB=F#,BLAV(^_\#68W6E&T]V>QCP.4N6KA'P08,MD/'"^T7;DFYRJ5M\[Z? M._Z3TM-*
*'((=1"3#W]^/E>0^/'YQ_CW_JPLH$+P#8//JPV/HSSQ+0]5UJ'R+\H&%GPHTA+@*3TQ+9*E*
M'^ 1SYA.&HAU2V=V9&6A.@)RGIV=\%:'1@(;AOK*8-/.3A[SK(?U=MN?3&,.!*
*<0#_0+T=R MP4>B"?+" R/1*F!'L+$N@_+"L=O@Y-.?*
>'^*N@A2[!67]9Z^CJG&AFXK_7AO M ?DD/,J=32?QV#HR0&\("@B?'R M)I0X@!5C@ _
:]OT:S"0);5="_%OPU-D&].TJJBC'9C91\$U069;.24LMO,41 M*
*K6C0>FGM)HU[.GPQ_@H.+" /10<3Z;=1R <*G;*O_C0V.X=XH!;^*
CMDQCX(5W+8IW&VAZ E/J#),@&]CK MH=RS[!TIQ3?N%V1<@@") XQAX+;C H&'GPK-
Y8%1!633;<287 M^M0T@(UQK"X/Z1C\ R,R01[1?8;^H>UR&X>)=J9 0%@3C2WDH?
*@:#+"G[M!V M4)2Y)[C88H*I95N?*
Z6OPFP)>&7BA8,@%\L_U?)U)!\\&LQS#%:AN6>,6>6+) M'&#/NLPIX,8@?
*Y(+,8/5YD4$@NB%9PPP!8&VF!P'ZN8I7NL^ZCX,A5A<*D?7 MD-TM!B*
'1X;234,JA,.+]0O4(QK5@9'/I4^($!S7(H-)V.P>RTV;I23'A^" M9CB:/X()@R^"V . ^PVC,]*
*(OTV;#!#D_ [B2IC+$P,;2+_BQQM"&??>ZR,%8(MM*8;THX/=TQY,X&%C8\G/ ;V+M=08?*
8[O@Q\#4W8/E/"@9C@M,#1>3S,AU3D M7 0/,?,7!\@UC
*L(Q3EA9_50OIV*L%Z';QV"ZX84H ,8%FMG!*-\0CK@!PS0 MK)H7N!LN(XMGHQ1^";1:;-*
*:!!L 2A D"KCN!J#.*A(Q8_]FK?9A]M"7 7QG"*
MM,/0N;47S.2TN&%XYG/(/*:H>/HL54D2$7YRP<_,_R3,W+$C968HL=WP;DP M8*
BA/D.3!N"#Z'YRH'<,_)0;6C@S@3ID QZ!^Q$H;LU@V(+I"D57,/9 (!L! MMS)!!B(7-
*[%%4^;W88Y1<"#XIP;)&*NN@V^$)IM#@:VPCX%-:*.3" QA/7$D*
M!S,P"8=!K2?.LW$\A(9.: 'AE\]@?#JIQ+QS?/T;M4O6XBF2XB3^,J"7G" M#>R5I,3
L;U@/SA0K#DY@Q]V"@T/FE]W\&'X8F$Q,"G6'?GT/]B.S\53+5% M#?)B>,/ /X3!*
*("8C%H2N$\OX3TSVZ[W!N4'X_@9,%T)9IR:9N.G*=-_ <2$*P(3X^ M]'Z_NP:X??*
IP\40=H\J3\'I@K%0PWP0W[!31" M?)X/E1_,I.W60&S!E[B\PD_%)0=Z.E:QU"G,N?,T[A"*
*KDRDN M3?0^LM##>6 S-23F()B#UNY+#I"%_]_SG:F$AJG6*5J<"&A_;%NS\AOE9SSV*
M$&@@'I(.\@-G"1X94:P@V69%"?@Q[$,0 MP0C&AVK70K& 9C5+= Q#&'H0@
YVZ(0BT8U%^6>C-S-#-0T-EPJQ [QGW"ZA
MH($6C3$,6L>^%/0LQN33['B,9/C<1IPJ_IV'8(_-\P-P/QVA!FO48BJ,6;S

*MN.B\Z,#\KLOMT+^G9\=TT[8C+Y='3GGJZP5QL!Z5V]/ U>/AU',*OH$QK8C6*
*M7CY+IA6KB*8VZH?J7,8,V$&FB0, 985GH3+'!T4A&Y0%,U&K'2J7 ;(ME&G*
*M5=Z0^03(&.GS%DT988>IXL0MFK8\3DZYH1[/*_H.C;U[LMJ'\Z=V):A_-I5^'$,".*:ZU9*
*M'X(!(C8W 2N!:V=@U '\(_X& WVN,@,)!;&@T'6-W*0SU370W$ M]&FK=CA?7"%$T-*
P%:V:=D;5A9$>'\SG/D:#9HM$!76!1:)V> M;BX_\/(Q/6,N)3]PYMWAH
KNUOQ%#8V_MQ,/5\TU["13]78X\W#Y67R\/?MN
M6#_3DQ43/QA@0[3,8"=]1\L<6)=,Z4XY61/'&,?N;&^R<)JS'-AUL'48QFR(/W\UZ')
*7KH3WSU'D,%;B*6B&MD'K;,PGA]=.I, M9LCHH(3MR"-G-*
*@#Z[@9S7'EH%92SP_)]0+T;W(6+-#KH8A*LT\&4V"Y/D, - M1C '(')MS&2::MKXJII.,9:*
:4=TYYVNF)T8GV<,1;-$/8_P6'5\/9]$RW # MC
=1[K]'<706@XD;4K$%F#!Q(0A$!EYWPLQBS\4MJZGQSLD13U)MQ,&$K)S M+-*
@BX9Q1&SWGLI 308\+D7AD;HYR0,F@7./5MO2:0=N!FXR8W UJPS+:R M#<=S9N)&*
<62BIBQ;ATL/.)]A)/3N(K9RQ,(D+WA$>&1;CTUBH7DY-:QGTR6 M*T">*6H]]#$C4<'"%2
FXB)CNNR\[$X"%KX':XY!_A-E9=OY M>(.QLB[.K^_'UKAF%GF2N1YN%)^:^E"(=,L-
5MN0/\(LL(PD("2FJX" ,(TP M[^$EGK(2<$XPN6^I 9393$0!;)DG-
M,2]G":5A0ZM16%LH5LQK,@YN%_ZYX,_ M8BG1Z&K'(#D=I!._> "6TT7YB\Q1U^M5?*
_!'@N67/&MA^K__O_LO6ES
MV\::/SYYE>@,CES[2I($3=1BC.NHBW9T<26="7YY)U/4R#0)!&# \6R3R_M_GV6[@9*
*@A2IA01(I&);(H%>GWU5L?NW&=$!'E(%&S#M80Q=",5E)'LS**
(%KH6/JW/@,2+Q68C#B@K M'")K"U?I+E3XFH'$4O$7),]%:M,8?
$*.0!I>,\B,7&*>RK2A$K@E2(/HD MGH.R?"@L0EYXY^_$9Y.;C@T"\3A!1>?1\90L%-J47")*
SX9WXIE:3\#;(LD,;2/&.E09-J]DKGUJQP(K9W4ZL)1A(05*
MX"UN3DU]OD0B2_[.]BU"9CV=%4BZIZ?=9NNT?73:;74Q(_[UA9-Y9KNPZOPN M<-J[-
(&."2_2(2+)?=IU'E$G,# >!D=2$U'&I1Z3(UV]3;VZ*J\'PD_*I-$ZEXP2@H,>_T MN-ENG;0*
*Z[I'WS*84G/XO&B: M!KCHY%R5ZV0R2F/T- =!LT-1HKCRZ&82=X:81PFS2EHQ(<1*
*M.0Q4I^@<##"D#A#NT"B\1SG"F/DH$@A@U_,6*Y4 MOL>R.@=]*
*MC]UD3+01A6&AOL"D"B1['/,K*1<<",HC^4&R+Z)!/7.<)* !,A"7(>@E5@>*
MK7IHN3)VEQWLG&+E3TVY<<^668DJDDPG%>3"\(VQB$>!@V'SN9EF%Z+X"7^G
*M0M27"]0S$O@N6.]5+"P+C'":Z)L1#QSH**/[.;1?AGQRYL8\&@*B]V,%9U,6*
M4%U6CGTC\4-US11"I#0>NHB04J4#]HN,,3))Q6Q:\IH.T.!W '> E +T+(PQ
M=T.VO6)./CJ9YB?AKW0,N,;D#$,F]9E$XWO709E=KQ^6CH(!FQJ)S.71JX\5
*M)0Y1*_$H1Q0VDAE7B3HZS3!=.TL72<0:,+!90!1060Y"P="M3:D#[5O#8$/$ M*
*4R_#R7X6FEGI0-*MX>:O-[=$[8F";60X7,<2)2]<-P8$3RDZH(<<,5 ,@,.'+%3&#FS*
M5:ML'9:0#4LXJ<,2JAF6\'R=X1-@^#^1PGP5%@;C([:SSE"LO'=.&L>-;KMQ MOYG]@A(!
*M!A21:$5L6OKA2L$XC;5GC9K==*F5S19DWJ.(2;3C^BP\&Y3PZW)B(W:\&*"T M8'BJK+*
4.X@@<,46U10#AHT?,.A$B>5<96U#V@W'I"/,/RQXE20T:2'OT+B:7T.H?RPZ2KY#
*M7!9L&'>HDJ_T_:67)9W1!7R$N3*N\AZ*P%9Y:N MEPY!N0?B ET9W<;CB4PF[%/B\RC-*
9'SI[>K+JB\]ZY='Y M+L6?U)VAWF)9!L_35.$!&&Z$ [2?,N<*
*MS.>0J>SIVM""*0RL4&K@UMT8$W1E=;J\3?PV9Q.71>O89)B&2V785;$:O4/! M3IEWG*
MA41PGH(NB3>!^0S/C]^@' MRL>9\:Y$^;",20!G:RD2UD+G2>$.R7I!$,&3T=I,B
*MR/.*2Z:F@0*_HC07.%=^[T;ME^K]WN%S+C&_D[&1)DPJA2_<(F5PVUJATKN%#@[!I<:^*
*:\:[;+C MU>]]^?^\NL"@JOYL&53KNZL"39P+7:W)W3Z1NV:-,>MBS%T06UZIL*0&FPJ*
*MC;1!UX!3 \Y3 *=9 TX-.$\!G'()=#7@5 !P:@FG!IM:PJD!IY9P:L"I ."4*
M2\+)FJPV9)\JB!+'JVL>M4VCV3J!OSH=?8&O<"S2L]@\^L>FH20#$;GXY[Q;
*M\H!#HC_.^+FE\SKGZEX&1KO88GYYZ_CNICO'+^@(WVXU%]<*_5_M@?\PS;CU*
M/F%@,?;&Z_UPHX.B /Y(N^2_D@G\?W7;XPL=DD0OIX!SC7"#P3,:CX@T/#K*
MRVN6]E3@5&?@\BB[$H]9J M>*1__$/%$1.KS:,2.\SIBX;"H'U Q8'[0S@'_Q9A,
*(N%,D*U1L/RHF$YV-F2 MBN7/0L,!J6@R,6-8-H'32:!ZW& M?*
N#08^RL87:/VS4>E1>/RL'.NJOA4:W@U>QL-]&P'.SLY'70L%;P:HY8'50L M!T<\?
1U4K!6\:G#$$OEC.QURQ;ZV/W9[/EB8^G-1FO".>U57#:!X=%4;EU]6
*M3SHKI*WMHVVZ9;_=IL#6DX5^\^2L!%)*X]3L=N>[V6X*-(LB5O9.='E1_-PZ*
M,JXA^[27M JOA#6@'"A>7NFG1N^]9K\K1D65ULI0#O2N.?A^H?C6\7D=#OY M*
5L;LUZ4 \5K#KX_Z%TI#EX4"+8QMW5 \9K][@]Z5XK]KAAU5BO0-0>O4;R:'/R5
*N)J!;K2'+Q40;RM+> M:E2 K"BSTU$ CQ*S%A S)TBPG/<,U2U53./JRUY*
<8MB'U\Z&"K DW[V#PZ M;I6&XK7V4:!Y16S;_AK7D6^*PAM+Z.*OQ9,:6?*
>>-796C)?;MKVAYJXUPM;< M%1'VE0+H7MIZ4'/7&EEK[EH4#O?
2SO3MLL83L]5IUMBVH]BV_36NPQJ+(M- MZ!JO66.-K#5K7#'.;+\5SYJ[[C+";G^-*
*ZW#75PH\JQ7/;2*K]#K_!/]R=]Q? MJ;OO?&/R*G>I_IKK\>[ZCGOO.HGE9?*

+!J3FU)R+J9.\;@2^,J;!"DRIR8P]I M:QR$,4R)];FYL[3EY0=(>\\[V=;2U++5F.^,22//]3H\-
'JRL;V+%>8%3!7"
M,^X]]5P&9"QNK>UBVVS;2QQZ$1>;8!O9S*LXVP.LY9=B[&XNI(/T_3GN^E$$,
*[*_5S([:1/7/F+D7$55)X?42/MTG(%AW7LA(>.WYP$>W5PK^\[Q?"O[5X&%W_OO.X?8*
*82WO^[? M\'I/TN]T8[JA2(5QI#?/E6QL;1XAQYR$0&)"F(90YBD\$-Y;0*T[2YC;ND3S*
*M(\B:@)2;8S6=):QFLXM_/<*_R3*&5OV;V=B$D1NW".*/T> CH\V1X".GT> MY$:B72 [?*
PEC K<9.!A"_3%'\X10;/ZR6TBF'W-#Z^.!0^B *X"2"(&(,-_:G MM,J/P7AB^?*
*AS&"3#$:HC'BR1"(DUM%P?)P(9%'26.'&FOX*R\C<@(:SB/G!M M))\A#*
(J+A3&3";QEPXB>H %@':!VWM-S<#I].)0P !U.(>& A5:(.#.@.6O84%18_@&?<>.3Z+-*
*NA@@(GGW2J[9I% (>"]^ MD +U'LF":NU^_?G#GS_/:NU'1_\H,KG(3\B*0A\A?N?*
&^G1WL[2C6F:"F7=' M@X,P>)C_T!:@A%Y_OOSV]?%6;7,1TLKJ.(M@/[_E?
0P_\]/OX]T:/IU[_/Y MP8>;\]Z?![U/=^77W\XOK??\YSA)_B%LI:)F!G>)@]CE@7=&B*
*M5U!:$O>8A=W\8@H8Z6O(X==A "0JGEY[@%P@A9__*W$GJ*LL$;^/FYOC?MWG*
M<3^U/:[>F^[P MS.Q-J9R807_@K%<:5/AIX7O" #.D-$>D@B>"]Z.UOFR7,*
MKP2K&R]9)>.[WH%1.'ZLZHE>N,.J\?EJI):@U# M%8"A.6-"J4!H_S(XE:S=W6J?
79CZ4Q+Z;@QB9UZPV;?\SN4A!XUF69I1=)=Y M&Q<;!^FVDNF[YL\:S_PIY6<8*
O'_AP&T9/+,3:W5TIB[Z-Q@/RRSS&-RP-S2D! MS.TMB!=E1**
[#64L"XL!6R]P=ND1<=1_J$WT15B1&@><8[AB=K1SKO-N<]>5]
MPFV>.CVS[N/)LL8)JQ Q#2\7&7#9GGY0=R>H$6D[B+0L";1&I'TJ8[@QY7N7 M24DI:
*<1"Y"]**ETIT/=5D+?9J9L!EVBZ\H#IDE3*;8!IJU%>,"T1/]D/M3.* M,/TB&2<:'YS0**5-*
*1V8"7&V4MAY2P#*O SQXX#D>IQ MZBQ]OI" /54^/MI>7;[Y6RB.$GE;X\O.X/_.*
M.W+UG\;)8Y'B.RX&O%+!E^T3N75+-)T\.6UV(=6Z%$]F])WM*2EU':0:+3)H M\>2$[-=
BRWJ[KM0<6A#"7.J),RU-<7-HI#')0Z^N%;?];@ U>+1"FE;18Z.T?M.F^NSIM; M-
*D>=\U2H?M5YW,=<(1LJ;;GK,895S2#J'*WMHZ&:5%** M4S=]B]5_/N(]SQ8#6U/Q-*
)NG)8Y6KH&V)$"[MJ/D-8&VV:G3UFIO!T]](R! M557)P>%@(=:*
*;'&ZTMEN\\%2NF474I&U/1%9*J)NNN<[UVP%$$(UO>)R&>*
*M24Y.3K<7G;MG'+!:X+JVAV CX'KQ#65RG*T5B2*
*MKKWB%JK*Q,)69+S_&@0+4K*+RL>GY8X"Z8$8+.W4+HD MH7@;4%I;,&L=CJ>FWD>*
[S<_V(L=D =U9.YC%E<(L5N.JR M'ON-#6NG3+\R-E#>=,6PH43\>>>5T-
E\JKL@!E74F@\CWG$&7J>-* KVG!3K M1Y,'GD?)6B:%E9:$F-7I57N-)\])K7YE/&F8W>
*[V@M[J?*O5&P6+*!+B:B)" M*X8CHYINXR:=U_%VPQ$;!$EOI M$EN;7&*WN"?Q?)-*
B;\J+'ND< M]9D'==Q>M_-TI]EZ@8M^J>4?%R\?*
KW7MZYQI06W\L^AB979GOC&Y'8S'V% W M%!9P7NS@ZU-?8'H%6_I&24@?
X%0Q6AV,AY&+0:8)1/+=4 ?CE2#7=A#HI(N MX%7]FZO[^7K P8)PDRUP7X4?*
K7B3'_VH(F!GT03"WN4XS]FR#TVBCQ7W% M*YQ=6R28*/%T*@]K6IQFVRIHH%K]--*
O]\!.IA^3SI83OCA_=+\L3F73D!<) M5JTG5Z]=2E5 ':8:UC<".180BJO!)Q=Y\/*
*(*WRJZ;OV0M=6;DU1.KM-44KI*
M3UM(1(H<92]'1,X2<0E#WST([UY\)7G[J,:T1HDJ=Y:8ANQ#) N Z'%-0\I#
M0Y[LJEJ5AJ#HM?BA24>W)AWE(1U%WKN7)QVC4(@G$X_3FGC4
M[33SV.&2P]>3RQ>N0HD]!\B0C2A6C:4M$G?9!M.&00?:23"34[3BU
MJJ[MMJCDPXL2FZ>&]IW4NE(M[A0$)%.G)_1@AP]W-AR9-*
=+0>R%,%3I6!TJKFA:40V2)T1(:FKV5!FK50>%5R H_#8.[._8V5N$$;9>
*MB:>702P6M]WHM LBKEXK/KQQ]+P \=N1%0JY.1[HI-GHXC<&[W4'0\9[23P**
*M0GC=,>"27-26(SR&:!?BQ\]>.76Q% M J0*8R7AX_N*
F,,6>6#,3DP=23D[T!N@=W&,,6],"S8!O5\G5@AL]E#XV/F M;0E=%*8)G-B-*
/7@V#HQ0V,%]P%/74?X#D5N H7TK$P*Q:X;&$ >9;[M.+LZQ*J80;?Q]C9H?"'!D'O&6 C:+*
WJ3PW Y- "YN+Z M5C@U AAL@IT6YUZH=GSM/$8PJAMN%&&6J9.$>"BKQD?O
M9<^<9_)[#59H?W M9!H/!&("01&TW0 8J:TBDB=):(]0=+2&H1!D:#$>W'A$:;J
>S&]#?)6 EPZ=(# 2GH=8:0WA2Q!)A;% ?FD7YP<<'S0[V1]O MDW[D.BZ \JV%C7F(D?
5^N-'!=>C>P_C7GF73^K_2C69D'V(+A8SP@F#DC$#D M&EAJX-"S$9P]?14]
*(5#_XO(3Z'!FMWE4'*V?HT6(VE9Z!Y,0TW^ ;BW(1F@O M"&QZ[@F!= C;+SXG6B*
'=8!\O(3QV.0T M/25 [83.RIK 9S]@W%AXTX4GU]WDR5&1BT>/+=M>
<.V3FU=MTI.S!D!8X14G ML6/%:11@ @_&"K,BVB2/A96'[:7..(]JA*
JW>'Z\X<_BU,=YG52^0DIO_01 M2OVYL3[=W2QM09298.;=T> @#!
[F/\0L#>/Z\^6WKX_W-EJ8ES'+.MG!2,I3 M_I^??A]IB]5U[_/YP8>;\]Z?![U/=^!M//L:[JX]?
7/_[SWGUL>@? FP% M+C/ 4VSCFH/6%6T>$K1F]Y@%WMG%O(IT=.$C;?
(%$RP2=1!EF6-@9M4<[YF7 MGY 1#=TH#CEGB_D2B4HX\U-]NL;_KJGOGZ;SJHEJ
<$JX'KB?2U;S[)9;>H MJD0@Q6II#B6O\Q\@3/A#TA?&+A7=,]{%FZ>WVC %

<6L@YEP[!&FIZS:-W:GBT":9W35\VWL%P M:C]+MT!G!7HG;&1@X?
SK;P,P/.G_#3_CR[8(8PN@ 00W4+H1&@%Q09V"=R,Z MK@=@D$8?80GTL9 /;F)-#
<^%WQW2L1UK; T%21=Y9$ 9$/XG+PI>4#+!9QI' M_U"WQ8^F-@_38+! *S\>8?*
&7W#R7A3(FS-Q0/@^P)8, H\"RM%I05.<.R[M
*X8:5%QP&*7I9\]WV3$-0/+0IY)MD4K6!MX[@$6X.6&\E(VP+17M!G0L6)V*
M!PIB2<^ZP(!PL1X D/B!QHAEMYVM75ZM/RLI[:;B[3+DW6SSW-*$(F62S5%*
M@(D8M"(17H,"?.3E<9&U^RV"T3-O,9(R?;2N$$IU'A&B W]A.)./88)@%Z M0KU*
*N"98(>V4 7#!D9T^Z\A6TJ_IRRLF%N<_1&B[H+<]]=BZ1V:W2*5"Y"0^9S;7\W*
*MC:_AH7%FW;N.\9<%9_==:*O5(D+265 CI7W0.,K^>(>F[ZO!A4^V\\3RR)*
*MBU)KDDLJA67O^*28W&2/2YOHYXU]68OHRG:_3E$1E9<]R@**M. @_XE>D>><*
M(Y:LZ2RPC@+9770&Q37(7V+C&[-]-@Z/E]D^JTV3LYZ'AB)!)?8\=(H\#RTR
M33:R/U;+\]!HF$?PIWTT'_+Z+-=#I[CX\+./:)/HUSIL+T,_KV M%Y"K,U"3;01VK-
+,U"K:\GD5] /)NVI0PK(MEJ!)=[4P^L^=<%":HW9$B!G(M/9DOZ>-I92C-
*^CZ>3I&GXF5IP 9]/*WN86=3/IY.D6;]:B?WVCZ>UO%A :27 MU\>S#&\9KPWC9B?*
*1ZAO'6 M(L-XI\C*N[2NZ9J&\5MMA;X:G E@E>$+FK&M%V N;Q!WY&*D#/N8 M.?RXR+;*
*[D@?UHAZ$IGERO!D/0K41:=Y^S)>!FQ4AJ!"[8!'^F+MUM3-R;0R2 M.)% P*5Z:^8<+K-*
*M@IS$5TL&XXS5?<^Y+TWQY3Q3(@:$1)?DD*P[7L@.Z220 (9: MRBS\19FHQTO*?*
*_QO[\$*G;OI1)#I+QO?<)7$40R7##B[FO\DP_,_LI*K!>EB M*
>#I21S'K:;9;M5UGNO\^\>)UR(M,U69:EI5&EK575()9(96:>,%7CHYR4C
*M4\V3MGE25S@JD[156B*UKI6G)EGE(5E+"GW,D*PBD^+-[;>2T:V.>5J7OZ]%*
*M*WGXTOYJW5NN1_2*([#1[YLZFGIC]G,@^4(@)V=9\ZAQ:ER-?;>?1,:%CS8)*
M="U>>]:.%T&J%OEJKDR^[D8"[U1>J;Y1O-"2D3 ,K>^8K=,256PK,1G;!^%K M)3(&D-
\PSLF>1>+7A>\D,D1DG^C77I2B7$ -BX+9EU##9B,%EQ1:2DT:.UVS
*M4]B5MJ[N70M]1<5XJ=3W?E&\Q<4>*T#RUJU4V5VMM>-VR=:)V3PY-ANM[9G3*
*MZF*6*Q>S/+="'X,559[#7)!'M[/!XI6-YQ6OO!2Q\073%F W!FVG\M4J88:_ M!,5H)K&@9*
.^C)T DE_R@43T22) 9[ZD3<4WXB08<5!^%;%+3]0T1WA'%C
ME:VAR%1ZS(>X!:E3D<=RA!^,79]'RV0'3R@2[]"X3:VE^?1A?H -IBJ0RK)E MY.[<M-
*QO83"BB7T MSR0PG5_?PBHB(W+A JU0Q1#/#-*W(L*
*Y>%9&)^M%9$*AW%].Q24Y4L!P52; MQY"W(X\>"1:.2WW=P<7P MRWP_A\85*
*(LZ!]R$&W&(,I 'C&-+=^3B,N+X'M@"*EARY+SB%@_;E*
*M<*PRYS1Y=N+1<9DX(GSFAC+B&V<#>'\W%7@&SZ^R0M;&E=/D@-=14 VI:-*
=344%/3FAIJ]H[6E"@P8<,9 MBYWFEC,6+Z6!
<,=#$]9L.WZZ^<#2XJZ^QT<+NLUTUZF^#)=\X=O!6 +]FDM M,*
(T(#@)^^OG]L=GLMLL4$KH8>YYK;W];8T5)L6)!?;[NPKHUKXT5;;/=G2_= M4V-
%C14;Q(JUFQN\-E8TCLU.NU3,XFT-M.4"VL;:) VC;6:!MF\WF]F[*
*MEP%MB12EG8_@IO@^&>*F(O+F_"H&4+S'<=D45U2CA_8<1[Y8LDM&R=$S\MM*
M.6X4]?U8JH\5AGPKR.HQ8%U2N.'5@ ,U,T5C"KER25>FF:WTS [W?FBB>5.*
*M5*F194>094%GE\5JVO:0I=4U3]NG9KO9K)&E1I9M($OK15K3;0993LWCH[;9 MZ&XO-*
[Q&EKU&E@7MC58L7+U99#DB,:S5K!JRE$C;W(?
*J"A]F=9!7K/,'MMZAU5F&JPQ.I66HF.SILS/=CVAZ@%&46UUZ0&A6? MCXK'3_*
U;AP5MZ>UUJA8H^*F4'%!,,Q2!^>F4;%=?E3<&R?HWB+@OB8I4[5 MC2-*
*B:HZ/X8HY:I LY'T\FPIBT6E*ZBDAQ_$JG:&;A2Y6(/-9JA'L\4G,B.J*
*M\A,532_OP7&I+:3=&\]E*0YL\OHQK5DRGXT^EWG>.*TSS^NEZ;:0JE7L5&BNEOKPO\\T:*
7Z8%@]_4(4T/1\YS+P%<1D.^ZN MUBGDF6OLC0%]XQUNO;M]L-
],+%LM9Z+&LL?;EQV?GIB=,G=AW#[8[RV6K99L M46-9SO&THV3WH7TL?
5LCQ>E3[^Q5!1 B(X<'\(Y^#?(@QFZ@F]ET4VRDO
MM@_3>RMBK):=L2=%JN15[@D@U+ZH6"I6#%ZV6 M=;$G%1Y7E0BC78?*
RA\LTF@G^*&(8T^,L;4I]H@5 Q%BAUIV%".,UTIM>:C@ M@BJTFU1JSR2$T)/?
$#ZJ0!!/VN;)28F2XLH'Y/N*4ZT%17(W]>56$Z<:+?/T
*MJ$1U2LH'Y'N+4PO"F3:I\%83IVH^5;+IRH-3"X*7-JD!5Q.GRLZG2J0,[[-[*
*M%Y7A>Q'%6)0!XZ;SBC$\&X>N'=>J<4G)XX*HLTVJQC<:1B@&A@CDS>VW'"M#(*
MCGE:Y@"8[M:FY5 MKNG@U8+(I8VJ2-7%ZU*SJW*52>P8%+'O==/X,\O4?*
7NS(UL+XB24%P-\.J% M']'=WPC/ A#
[&$1QI"I'"N?:FJ^&LV5N&MUYTO]^#V\+*CFAN0+J!5VHTCQJGQM78 M=_M)9%SXF/*
/U,"X]BPX K?:1R K89ZYUE?AN+9EP&\A0"40/)LV>VBL>R;& M&RLR+/G2
*"BD$<,*C3B@?TTJF4FOX\-OC0=\V@DF.&I_2M]^'"*S001O/F1L* M.P["R'A#G[TU@+-\M4)*
[9#0P2@1'P659DTD8W/, 02+;XX"SQ'PJA739_1P MS_<3RS,^"Q]VZ1E?*
A2#K$DQUFWUE)#R'IYH:S29/=&C<)OU(_"M!^Q-MCS";

M]@5KGL!F3$Q&F(0N(@K\X]ONQ/**0X/OX3"BG R?-I*XE$0PATYRNS%R0SI
M2%0;=+5]-9MT"$BS%FPPFMWAX2X K08B++@Z=N,H!1{3"$+#HMP0-XZ%P%^C
MI)_^#D^&(AB8>'U##")3]X@$SO*G%/G8?1<9 B0H%|V1*IL*.&:N@(.C810O
MP19A;+D^&I*3[D:87+E'TSY*UX[2)$9%EV@Z_F()W6 M VRTZ LRA!IO0,:)WIJ%
43&FS/^$@Z.!!)8CQZO<'?R6UI]@(?'L'C0)Z[M7QX:?PEYF')#>*@Z)2=?33>%]_0:
:+]P/!$A#=I<7'=@>6&*(I\%[%Q;WF) M0%#&+V@ ;XH8E1_9BM0C#I
J_)G6=&C(%#C^%58-B].7.E^8([W7D0479<$B M?KCC!*@9 !N.^CM6QE&P?1)^\#]
<3!R'4?XOP&#/_WY?2R 0>!3[XVIL"2$ M#!DU@2R@;=L] X?&:I]]//[P!=J*%CV(\W?GX_-
*0F[MP^]D-/W&?[29, M!I#\(AMMY3:*0Q'5_1LN I=K.7\G44P. +AD)(UNI@RSAB-
F,6H;/O6Y4B Q MB]XSH).294
+=D4@:A0!JQL9Q3I/>\9"YTIILG/0;/XOOGH)W(,T$R!B.)YD
MHYJ+XC.K:2>IH)F5RWH8%3LD1\F'Z9PLVD-0R\ M()**$&2D3T'X*8E!+
[N06/MD]_1QU^QTYLU912<9RLEGR,5\&"_R6Z**"XZ[
MN_)Q+S5G5/7,BPV(JQXU$I7%CN*;1X[^9&/D8F/'V0)2W#%;I_/&(W6DH1B#
MF$K=WBW7(W]['JERKK1_,Z_5PI0V#JR,06%SX3F(+^>.N*?17OG$F;,E0B9\V
MS(Q>K93M^!&]?^4S,]YDOF*E'KCVP+)=ST5K NKU1H*;!4:N
/#4;Z8VEAU)ET;*Q6+3,,^2\ MA+](@)^!%--X&+GV*&=!D"KL8$9Q?
P4EO4@!7ZIBD[U"FR1P_HF+5B@&J,' M90M&C%!PUD_!&_"@0&R5,RP\#0-K: FNJ!8)7
%<#@!?99'0^*QL/%HP.!/ MPB2-3(>>CDDGJ>9[!+W@3?5;ZRUI!G#"'I FV,.AT?.B
"URQ81M ?XI"F 1 MP/&- GTCQ.3;E'=-1\X?T!&!FA$*W@+N*(E6@"!$4F"I$>G-
$5J;\%BPCQ!< MBHN-83!^4)F97G)!&<)VH"V&6LDJ)I C/%^MXC>.E)'@3HVGZ-
(28!E;4Z,O ME&D3SSF6_9 B^(06#V.G]EG8?=; FU4)Y\[T-13#SM%:DM[V2>E+:XF=TY4(
MZ:R.N$1X[C2V[\YO?#,M[L*:1*CJ.\!M//L:[JX]?7/_[MSWFO=]$_!- *7&: IS@*?
Y:5PP@*"C.@7O, N_L8C:A$5Z'+N I41!I&=\9 M_>\QA^[G"D$23NIH C3;G3, M=F-
]$:;H#G?-R,4[4^9XB>9H']X;RE9(QA8=B")G9[??,J$H):%H:E$O1]46 MDQYZA%%F
85IK6S^ M-#\N52>Q&M0K .I5[7U<*DBO6Q_7C27+ABQU.](:;G:@'6D--=6 FIK6U%!3
M=5I3HHI>^];Z&,VXE+&)-FI'W LOF*)=;Z6MZ9"C07EP((%W2UF]VQ5& LZ=1?
3&@L>P8(%W0UFBV)5 M%PO:[1+7UZFQH!18L*@?P6P-
JXIB01NPH%5W)JJ+,?/4JG(,I6W(5+?0BJG" MPTXK;*M:6\I7?&_EI2^@;PMZ0ZRC\4FH ?
+6R\%,*2@<|OG&]J3=(OO4WC'_M_<6N!5TBUM$DRXY=S>/M651J[-IK[%K09&
=#;7LV-4PC[9HL:SQ:Z_Q:T&W
M@75TW[+C5_>T:MA5(I5X'YKUW@4Q*,31@B2('5>+'Z4H+: H3I!0/9(\22F5
M=6_U92^@A L:1'1GTT6V1LO^E-N7(A@ CVZU")]'J1#M?+SU8VYJ1Z MX\'U/*[TV.?
$>ZXY(ZL7Q",KEH/*PON5KS[0,Z)D#)],,U42$;/NL8;LDKH"
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MVMBA- LIOBL1F>30)^/,X7&C1I<:71Y!EZ(2S,]"EU=$$RVRDL3Z1%_:2:M9 M7K0HD>"
[\TF),X7N/W-7AEK$+0]M*@H2+TC"*(FT2P 47?A MT>SFR6W!0 $JZFRZ1:
[RMD0@NOL8L0 A5@NO+YD$5H 7KR&&M0]/2FQAJ<6P
MTF^M1&+8OAG!/@7A0+BU&:Q*]6/+)7X5X,7K6,&Z%0F3J+*,4HM?M17L-:Q@3
!V7/QZN;I7F^=)*Z]] M@3#7*:KZO#0SOY@;
(1/#QM7".4M"UQ\R0^$,H6R^G@:II_*3[I'9+9,(MB" M>$?ELKU E068LJ!^\-
(:%J]H/&,|>E79K7%X4N5ZPE66>G9(H*M:BL7.&]EF
MTBJR38DIKZ*]7^+>XOHL%6!BZQ:7Z13%HZ\JY)4E_Z)M'K>:9KM5'N94%VQ:
M#SC+%8W^;*0JBEI_67EPV\D;K>TE;]2X5N6,CDY[5=PH>Z9&VSSI5]V>YEY4
M/;OP^1:I8E8_2&*8)+"_RR):D1&D@&!2K3#A4)DLK$9FXR]Q0!]CB:U@4" /
MF_GZ6[M53(M,=+TD'@4A%F2CFCD9B]TU* K1AVF.C=P@!LX5V^ITZF);KU-L
M2]>^@!,. 0#IY\;/+ZXYRD-N_X-+,BA [*_\RVM:$5*BNA&C15H]=)/3->:/ M?
HMGJN&N<53NHBMJ(ZW-EZM8K<97E@/],^5 YQD.A!]OK.K)=I#I43@[K@:8 M-
4Y*"F92X,E!&/%MY*4E *ZLE;=4C+7[NHQU/? J*1'3!AG
4B9E0]J42TQ;;\38VGORR(]5BQ#L4+>Z(YG7+NX\;STRE7 M6M+|S%^"!Q'R3^[8C9|>?
E^N4B\'2^8^??5@IV*(6S'U=MU9L!C6:5;=4-VM+]6.6ZN-2^4:V!W$O9*ENUI;J
M4DU7'FWB9.O:Q#QR5=%2W3*/FDWSY+1N^E6BZ6J%H@#-RFVK/EVJ4!R55J$H M
;3O#7+-\+#N]KVMZPN(%3=/5Z=.>8V,FT7&1@F1L8KFZ9-
NP^RR3[=J^W2IIBN/.G&\=75B'KDJ:9]N-\R3TUIG+]%TM3I1@&2EMDYW

MNTO5B49IU8D20/O>(-?;YT^.5HB3K8/6Z45)TMDG;Y]/3);]TP-X0:[:I; MI]NU=?
HQZ_1)J?PAVX.X%[).MVOK=*FF*XTZ<;*D6]?6D*N*UNGC;M=LG#1K
M)"O/=+4Z48!DI;9.GW26JA,GI54G2@#M>X-=[;5B
MKI&QQ,C8+2$R5M$Z78N3I9NN%BJ=8K-Z<1G\N7+V3X#0?'[#!@M*&J_B3;Q
MC05MXC=FXU]U00MPXK14KJ;MX<1+%?@^WJ:O:558*)VL]Y*'L%K#EE)*H"NO M?
0$N;[_JZCP"5]&YT#KIFD?-[04$UGB\7WAQN2^&L M\7>_\'>6#V_?
R;^^(%UQ%\GQ8>NXYMF%:S1.SV:WE[AJ/ M:[F[S(Z>T^.EZ/M8UM;:$F]; VG M)5C#
(^>P>RP(-F\X00+TJH(\:/'B%PB32T)Z*FY6;9O'K:;9;FTOEJT0K?9< MP-MM[%I#Q"N[L7-
9=$WWL%D6H6LO<>H9@%JNCH[/9E]+ZB7LCS6R==AJU$RN
M9G);P<&3HR7E[2MN(6R:C6[;;'6V5T>DQJY]PZZRB)#/MMN='"WKZ]TY/*Z6
M""GM=C_!O_W F>)J\6S>_S2[C9]^F@E&E6O^OS.K_;_OTI71PNC7>RMT+1]{
M$QZ<]TX&H^.>V_8GA4!W;K^_.'/V3CMQM'1/XI 4WY" M.$?_0R[R8UU^>VK'BR+-K8
X Q3&Q%-
L#SR=F;WL)T&D%68#3]/P]ZG^[.;WXS+._!FD8*D7XSX*C%S,PCP5MHXDU*"^=_'-
%_1<9/ M^=7/O\YN]X^SF\+MXIGEIDSO@C;_Q @J#N9N:%7AXC\Y 4PB2O,+7H!F,[>
MT[I+^KW__N+N_*O1//S]U_Y"L^[ROV&,K[U+@(2OYY=W/,Q)L]'%SV^-LXO;
MC]}N;R^N+HW>Y1G\Z7WYG]N+6^/JD_'IXK)W^?&B]\7X>'5Y=G&GGKDYO_WV
MY8X>N;H^O^GA%[#KJQSVW4@ EGE>\ $S?AJ^4"7QX";\KPBX\R-
M["2*4%H#O<3H^98WC=S(" ;&)]<'K<.U/ ,(N./&ZID;$25>3(]<38#2$^TW
MX!WB+$8RP>=L&Q JQDDGH0NC3#S8QU#X\+SG3?%[,0%68;B^$<,:OX$4"+_=
MQE8L:.0>P:5%$SJ\1O@"'QWH9=FY987ILH)T6S: MD7'AVX?T9I
=4GZD>NX<)2"7*IXE$H!#T";$P88SCM460(X(^P5%P_RI-& M"Q@T\EQZ$'YH'58?:N
VG10RHE&0>([1!Y%$6'1G%EYI>6(37B^ 7R1OSZ $_P$L'*$':Y!C"B\0#7)1@X("EA&(2
MA+&^*\OW0910G\(*/L$>@.P>_*EO#F4(>5%GPI;WU##Y>HP\5F0VBC(5R"P$ M
0]6Z!QX0? =G\FL/!Y9,:SL/O#NA>$C_0P26*(;?>==P;&($$>) 90.C2M<
M,,D^&D)M.DW"'0Q@52#] *034@S"8,P@OGAV"_Z7 R&DP].16#SY+8 OHGH3
MX,5]_]%*\,*L<&I7)^_97SRD K9:$=#"F.L'<@-36=[M>F>$HS^__-
EXB]R)>4<8Q49^N\2-8M@/H!7LN(_4*C;>1%,@]@*>>$LZBD0V M8Y3 V1NQ&T6),+
[#V^[W4(",W##>\$QP2C%\
/@>0C^'180*3(V;B.&;*T(!^QXC7Q&)!)J)##D"/@Y72E(5/VD@F C@?1'MYEZ8D
MV'CGHRDPW!A(/^*_8 VLN[Q!J(M^\D-JS<@GG@D1CY@!_<"R\S!4XJ088A M
L#/QF^!U(">=O:U=00\]F'DVB,\$SL)82FQ-U72 Q![^ 6 90:T8>D.#.L% M$YQ&PDX
FAV0W+$Q#.!!!(S 2.!^D+/ ^:/BXM"YH"X$RBXQM%C8(Q^4@R&* M!_""OA-Z[:-
$&"+.")Q U^72,O/3H(A3J#?#S?V;Z*4$+'VK^E0B1B4^JRQH M2@B3O$4>AL0IE]!JX55?
G]/U3#R$X0"(^3W:E24"@;03),,1S/6OQ V1BZO3 MC)%!T;[I5@#=T60P"CSWP.5M(
N>,*&MT"V *BU?#<:*Z$%KP\?9*Q4PX+LC0:EX(?K %K# M=W"1]A1OC^X"Q*@ UN*Y:
R%K=P#:!#&3P*8Q/TW47T@H4$(('G!Z[9QGPQX
MI@0O%T6\F&4RQ"!_1+#7!R$'9$20Q6BR?@"S&[Y(0I(QH@3X[SWB*8^K6<5$
M@.C5#RT$/,?%(X)56"'*4@&J&O BJ?2*846@7R@:?F]%?#Z!#11,ZSZN/W+[
MKCH4:Q),X@!5H3=Z-;;P@/X!!HS>(C7R)(V#S;M B'D-^N%0 (&&4Z,%,&;A
MY'"\XT!/X@_= +4BF(?.+LOP%ART M-[YZ.+=PP%N&H4CVQ+4&X=#R68*D-
7H6&G!@!1I5O:EFXK M=S#%?05)#&B- MLKL6#OHP>SHNL1>$?
BO&6>3CE4=MI+L2A7($?N).\,(%H7TD58SH-[D4M"0M M-
I5)TYK\^W=W#.#LH6%T#)RL=4 MEC]YC^S@>H1 U_RU!?
K*U_.S:=.X0W:$BDG5X4B*Y*D\@QHTTF7"K5!O.,^(MD7 P95@DUK%DL.!M8DGZ4$T0
JP)B;\.4*&A;QHA8&TP1D^ *3T1!\#6??B- MZ$(_.$ U&;B4AP2)Q\P1=OP*Z"=@R
\720%LK-4YTL*M :PHF>"CC:,C(LR1 M,?
2"/A(9ULUGED0*2>#C_J21@#DFXHT[AA^ES0I8 9X:+%5,<#GP/.@'P'^M M@0 Q>1P
HPM"IE(@T1K6 ;(Z 7-(UPDAMJZ(,ZA%$Z>1R512?7=9'X"0CL,
M:4U1F(_B8#)!2P?.WT);S?;Q@C..5+L-)64N9 MT70,;',<\47R)-+J'*40\#!";
<(6)$M(*84@%!CEN"] EAA/C3=?[\[2])DK MX04"[P;I_AZ%'B]EXI6LC=!.=)1D(+Q"
[78=E@:DB,^=H J6RHE0_\:.PZ M#MR/#5H(R!6>:6#4-?V(+_6M"*0,&
(!E#%1^\;4@DG(AG.:,-@BGN7TKS@1T PL!J'%R1F=LQ4Z'<_4CM$ZXE@FM'^8$U M6
N@VW@37_?HV CX2 %/@4J]=WEGV]-^)(../"FJ&H 'X$)WN:P%YA\1)8M
M%C!L+R"H@]WY(*'E]J57R;Y^ @8B84"_8'E("GX@\QY"G@R=$_%([DT,)T/[)&G.&CK-
'%9;I6%.4R6&8T$4AC$^6 M;3!C$CKQ.211^F4&DNO>KW#I>%Z_2B"\
(_$31YJBG#@)7%\9$36ST#R"= S;
M8M7S'E&'+3MLH@'I9@S"8()J(I!='.$!A..#K*V"'Y$0T;-Q8_G MC&_0N(.D>6J<@EH?380-

S[$M1$ZF;L@WX&DC I)'IWJ$9A;\!&FE_.3X+:FT M?0!-<2^1,4/ [EBRU:HG#
]ZV;U@'73BWA.1!GT+8)2=!_*J-;=5UFAY M?1D8V*1 ^VJNW$]WQ;[- E?
NS+NCP4$8/,Q_2.K2XS[BM=W"[052;_6**P2H2@F:WL@D!^1JT^5#1.RW'HN%)
<=$Q^A84-?0'F4"Z@$ X&7;%!D"2S9F= M28*486@1Z^% ;WSZV,9AR3'19;:?H.0U9O%U?
M$SY O].=JQ&2D)4Y)]
MD#0^(H<.*C*9%\VC<]=].KE0.Z=LF-.1,QF(MPT,GXKM$=\^FQ"(983)?V_M
2HB=7>\751,V*7'?!1]RUEIB$VM!!-920IXNXVVYIB,L-+DR\9[Q=#X%EF=
M0I,V1G%1L#'?L>2R!LF.I(/1D.E;9']"8!X,T*V*YB'8Y1#O@83J\00 ._4Y M2HN?
1)Y[D3UUN - "8MD2M;(I#TH546%-:;UTZM],H\A>AR 9A&1$(Y.3'F2 MA%
N>C2S3@<7%3R:$._"-/Z5 '%2OS+^:D0T,TXO1-&,*DA.Y7L*2T# 'H:P
ML+&.D^!#D3Y/VNO8EI)7WI6T.X#[7! M5QISR;4&8J45L@1+5N A3
7+8H,Q/($IFH;PA\RNF9!08Y+X1BLMPR,C[_MQS*-7H*RCN=RF,5G$0#IM0CVR*
])&@I)9?=N))P"8H%[>\!U2,5KCL2PGQ]= M0/1$/PGQX<#/$PM\BI8[!_@/0?@=M9
(9>ALI %%%*;81Q9,Z5+A\1C?+ >6 M#G!*N@V;ZOB,'9!=Z=,HF5 <
5DNOQW>2$<79Z]K #V.G# MB.$B$HKJD+D!-H\:I@S#L%P/;H)I'&N>A6^@X@R@[
CREQ3RT4I; ^=MG]=9 MW_^<85
"5&Y)QRX!31U51R8P2QA3LA0,X0/]*HT1M$$L5M[X_K
MFQ[%)@!FD^T.OSU$._!Y([A"#E03ZQ8SC MAN/;+#3IDXR 5,R(IE$LQL#L
IB#*>MWU_'%E)$+8R_"0Z,W& @V%;,Q]>0? MDFG0#I#2 ^WTG ?IU,L
$^+W!"U764&)8X@P. 'I(!G$) 5%KYS5GV9Y+SZ, ML[$48VJ'$1"F?
IA,>/_$346D>&3&KP6K&5LQ;A\=9&A<,/D@T+5V:-Q*&R()
MO]+BJ^(#1@(XESU"4>"">V2\:#X?X>X(U4V$!:+SVB4)+!V:$I@D2&?@PX06' MCQ+
((]"A,[D(90OAW?+AT^=ZO1Z>0B2MGA@X<@_D"Z.\I<&&(QG0&IR*DNDA
M\/7H$0!=)RL0R02H@^0NBHU'"%(0(!SA DA<3]A&*R#M8"%6<1* ?Q:7!
MZ0&G4XX\.IM4#HTIYB[OD$#&0$B7CSWA$$G$GL+PS= X!Y%V(J!-DME!HS0S
MIAN%=J1U/;(,[.PS7=,CFT;7D.XE8DG:2+ #\,-"(>Q]$.-^. T&(B83:SX(M!;T&4IR)X@-
VSF:?(;S!/">#7-B1BKU1HE+^!*1[Q?45\8DY!@F$N9Z66!!S
M'K*KMC)$@^VL(I14.CM2&#BDM+F^7 /?@^-2V"C(F4$4Y4[(_0-0= %"GF;
ML2PJ9_H#7" Z3&Q*SE#PJX^=+M$$,34F!6KV.3Y.>F@78)O4:Q6=BXHSWZ^B M7=
(;28$*RF.(L=7^ = \X9G /_PAN4Q0OU._'ECAV%1 04#&X7:!,_5AY38Q MAF!P
/^30C^)S169=J&[$XB0Q1!Y-QV*$,2*H?&'M"F8H.E,X(O@ =C1+6C/
M(^":&%9^:'PCGGEZ!$R2:#!J%M?G9E[(1PKO9\7NUE&JUM,K#!##,'B(,7 J MPD
:YG[2<",P/ I=-U+<)4>C'(. <=8OAU0>Q@)M%AU-N$,4D="1E]$W4'Q!
M2M[H*9[%1T72LN*8'D5J42 <'-*;_QS&[UIM$E2B5$Q!ECT4;S.1AW?!A&(8
MR'5*@I::"E589>DB=0I4&C*6"RF!>7-7FY$90!O(N!5A+ 01%FB0?D8S!'26
M>+"!23E.R$U)47_L?<2K>TC]JBIP&E^2=':LR$@2& F/CC(@ MD-RG N,X0
UM_TOC85RE[NC3K#J1^+W_/DT#V;%H:&*CR$0X+87#/LG8(7Q4
M/0GV59A/9'D44.\B2V>;%L*WL@K16$Q*I_I&[Z(V9@B'*40 M.4('L*B(<*09@*11*KO
DE'"1,RGN$48BHR1E+41S1\Q+Q)GDR\\H*3Z2^/X ML*.7@[O[I=$^;.I/%+M8*W?'1"J.-
XT @Q'Z=$%S;^@G086)3LEXX1S690W
M&U[ZI=%J'C;4<@!VDC[:8Q5C\3SEPY"@0G9VVA[;.Y3E7)U?>FR<@(/N_5S^ MC8+5-#
(^%YS&)@14*Y.,V9KUKO2Q-S?_"=K'N[.W.:,KP0YG;[%IU0$=2WI* MX4+??
*:7>F^UB&B#9(EVL2BPW31R808Q&*Q!LY)Y+8PCY*6)8N&H1(3*4]&_MA&28.HA(?9
*Z:TQYS6;LIAE/F=XKO3X#TDT"#8<>K7!-7A,,; D3 >!$ 0
M^,C)SNZYWP4'_\%J^YC_0&9I3'90$=MUA,%&(PPZ=83!GD08_$5A_^:0!-O
MM#A78)"0C=(70R:!MA6-.%,!#8TD43 6IWG-SR"AFB\4A#6D6A1^*7U31'TB
MJ;HX3R.=YLS6E6N9MHH.F22T%7OH8I:5&AYDP%FUS, NO MU9RQ$0[0J %
(HV%6;4]MM$A2S;AQ=7[17X(L*_)DT=2< D^$/IBL,)6QW+!N MA"8#5T7M/&0-
W8P#>GSA26DMM'#D^8% 1P2$&&!@XH,@YR_N>(R>3Z OWT6< M#>*A.!$8B"XVFT
M@WDHRN4^"%%KJ[RP^WO__4<5K\]%(H@B%-2,J+P=8=YI M>Y-
5J\XR,'TN)>U=\.!*#5']>,K<6*BFSIB1.3=Y-J^41%W,EQ*4(^!R&LD/
M:9+'*%W7UN$(892A=8_$@;S+A/U('B1'RWZ5]WSHH7,!0[35=QB
%:&2X"7/>Y4]#;Q3.+T%B MF.C@I>SR"Z)@Y(KUVK+U37*O*BM[MC)'?C:=:/I.;B?
6^=U9R8"YHTX/D<((MD@1D[C@WAGC)$(Y,QC;M^S__X^2T3:%^2#"8B:92"
A<%,B&V=-"!FS&2*#5 M@@EPA)W$&1:38RV8^:Q4.U[9G-
5$+D'F+D9H:/%XPUDV&UD>%8LQ@0WX8N J M*QUF1A]P)1P[4V2M\F2]%
[,XU0V6"1\VIQRX>0?TNGZ M63-6L?'J@=U6B4\F3D[%IQP+65P"ZU;
($BA327X05)5S@"TN%$E$H^-5YM/? MF7T3=JEP$PI-G:;K$\M$ZT@E6NA

ODQ6WRRXIX%>%/[1IZC'HH@7MCUDL9$J M5AYP[(>B;CKJJ5
[5^V!SF;2';*:-9>9!'M)"/H0 MUY_0M74P"I 2YP7%S*AHN,**495'U(RQ4>?"S)[60G.?*
%TOD A=&O)F?F!&DZ!@ %K&ZC)C1E 1XE;4FK^H#CYQ"E1#X' M@$Q""2K4:
(Z/K1\LAXMAJC=4G#/8]05@<(%>7U-&#;>!?SA3;ER4SZ;3Q"! MHCP&S7J]06?*
RA;2GH=A&0F$$:! 2A-5NDXVZ38YKM\F>N$U^[[_?%Y,>%7<#
M)5>7:@.94Y6%O<30DJ_L?CA_++1D%^CT7:YRJB2WR1@)]+]13
^.G%=8TWI,$2811_&]_V^")\G:94%&K""0 LEB_CV:6+;^G4D%"&-W*
*M^&HQ2UA.9=>H8T]TP*6Z-T@9?E##1FHDR?7HXS"SH#] I89EZB6]=HO)GU^K M-*
^$F^A\6SJ&;8!X_SD2WVUZ65ES,>IZSH!SR&!)[C(SR+(KXAU,01<33LU&*
M_@_U5=A<8\L&H4T-496#J$QT[W.RW_M];?,9K=97_^^7G^C:79.NO7]
*[^O]GYKM5GFH?XD$M4Z'9+37%M2V*IQ]7IPG MOA_BV0K3;8,FFZ='1Z7!R>U?*
P3[<^,E)I[[Q/;KQCGG M(DEK0R:QK4I:0Q\<]S8)@^+<_A[\-=GVY3K:WO>I-WW3"[K=/Z*
*MMO?FMIO-;:K';V=DJ)_@7X[;_97BCJL;-K[G53*R=3%D]G(<&+]T#H_F*E5R*
M2/PCD?!8Z)YK'?W2.FP]:8S6X7Q<'YUC>;A\9,*:696=WK8?LH0+4KJI0H1*
*MJETY)AACQ8$T%8Q*8D39EN:<;$!)@:H.E*Q)966+010WQ56E5V>+$\VU*TI/*
*M*9\BG,NNY+J9T_E]4-E2JJE$Q<*"P0!K%_>GO)=0R)[LN<3.F>Z]W_]'5U'' M=JQ4M31?*
_XG+,34^THOSL^^_7\R"]I,:R_(E'VNY$J9%91?=X#%.60U:9P+
*MR],'V)&+*GXY#I9G+FK'MJBS6::XV!S,95+ZGU PK:CI4K[@56$[MN*:5I&N M8+9K^:+*
*[FH$M:P0?GN:($/=1&ZQ.;NGD\+F . M*Y-.[$S&.)5]]8#K%=II-*
EN^RK"D"7W7U_0R0Y!T:>(*@4]FO:MD\6I=XJ;*
MR&)N:F4J1YMJ'#U6UMBS'J($&P0/+1@V-K#ISR75DO=T(Q>LI%]$6%-Z/9L[
M/S/KWS(-7I:6UX5==8G8//6GVDU8(W%AUC[-DJ6 <_!"U WKR0(Z" OHK17) MZV%BFZ-
YNT:5]B2+'>'RE^/&LOF0^3KE9@YP?CD^;/#3B#BE3MTAJ+M/"-ZM:((IO5AL_M.*
<+VB_NOQ'5:/JKU4^M[LX?SE$YB9W>1.0=7H3*O060LZ DAE MUI:?-A3:J**\NGIP-">*
(I/BG 6R%1@6J13&WFV1 Q:HNLELDMW"C'FNQY6'*
M&6S)F\A^;%@:B@\BJC.JZXSJ.G^/?8F5S8[(4XJ45)=NH77R3PW>ZT--CJ^6 M&
*]KK)*5R)"EUC[:4+U\BK43G8[>&/=J/5&A\2%NX"Z<421B'><&*\RW7;0KX/:04G0KP27*
*ML =WWC9A5:6Y\Q*1W'V(8&:2JTSPRG^X\\)P27&Q;39K\7>_KKQI=NO\D?T6 M>"F$*
8.X1(CMEYJ-[CO9D;PFPML@PEWS]+@6@O?]SCL-\ZA3'LY;(C\#T+P*
M7T'XG3H6<:Q!376W076/S7:W/&IH"2YA]^^\G&PSPZN0ZFXK\:?N7]/H
MUOUKRM>_IHX1>[98LXLQ8G6/A+I'0HT_3\>?.@BM#EVLH:8."=P'ZTYI0@(! M'#
JT/CD!0_&F15;FP,S5 .V)Z:!K=53U5?TE:G*A&EVWEWXDR*[T>5[88- MO.]=5#;Z4^--*
PHF>,LEL)XA>/4<]Q^O/42)2MO,N.?VG<4+KD.VM_:$J[;/S M\6E5B-5_T^B8Q^UM-
AG9T0)]U;C\MGE:CKJK):+,^R-D2LI\X=^+:\H&5?1 G1=N6U M-*
*QKF27=C4\32P*A$WV1^!GJW&ER).JY=B84ZT M(G,9MGP5C1WG,(\B6 L0S*
D2C(R;P;!R:>JKK_M-^VA["L0#GKKV9UE0W MC5^:AR=Z?
*F39!7NA$L2PY=/L@[.;X;7/%5#-ES2GRKM4395*E0MG_2UP(6\:*
M9&X)LL^$K/B+!9QI8.FU-H("1U!AV7'U]B0,;"&H0+$MW'M5:QWG_N_$%US1 M=1)B?
*P)A3#S+IM*MNU!+6(:,]TY]AO4X'NGN(TA66+EPW/$C[R"QJ?9"I]]GX@51I!NG6,X]-3;*
M-@AB$D1N; P2[$, ^[F'Y6)7!"S#'(2Q:B!0W'1&%B'G:UU0B=PL;A(I ?5!QJE8RI.E2
*X!_2!JLO;<(,MR[)%PFUD@%H(CWK ?7. M>Y'V+4*A!*
*(%UY'I**%&,7C5:DVWLSKXV3D\1;K"=$^" [[@.@ 4U)Z(Q_2 V MAM0F# FDY6,+-*
A!E$B&!3+V@"8;.07TDFQM!/06A-.QTII_A6,*@ZGEQ=/,YS!:E&";+Y=:BV3.1=\0*
M7G2B>IWP-NA2>,T@JLRV YS;3;8=X+)>6++_7WI6(V+OU%+4S+=B1->!$KJQ
MJ2$+%4QY(R&^%]T)0K&Y#)(RW19-
(K/441"&"FP2W<'FA6X_P5$JS\)ZMAV$"$4H"Z1GJ BA#UP^A_YH0L:-8\5,R?H(
MZ4)J.Y;ML)D,ZEQD7I?!K'@L20DS"*'F8.N5"2B)D8XS0.()0K%:,H"6"(H M7*
'FT!0)2W)A<< '0B%;:LW2[;$U-?HB0^OA6((P U4@&T6!YQP:/0_;& U' M>
(1$L@!6[HDIPDSVR!7W-$=$$I$?$;9B Z4(B#["N6Q92,V1^#F];PWVR'+Q
*M=OI"#4FKH7-*Y=0I2 US$C1 M?'8,2 A%8T)DBUI^9GL-RP%Q;-*
:O(S4X\+!@MC&R&,#)Q-%LLV)U?:M! K/8 M+"%C\C??O%D.FUT!$)=A:
*(TS]$SM2N%**I0H?"'!H0QHD#RC'VF8P'G1 *_1< M0?3)_CG53#,(\#*?2TB.YKX@Q1*#*
!@B025 MK"^$9=WZ0 :!JD7S)-=)7! MAV#)36$SM%P2 POX"5)-39XVR6#KZE.-
*D[KZ5/FJ3[V*X/<'2+%!B"Q92GZD MA3-I%TZ6#B'*SA@LI?([D#5Z9UV;W,@>!:.*
(>,F#%0)YD8X!F-;^#F/3P"ST M/Q2KG\A%)B$#';:1QK^!:%(D.C"W".K--,FD%&('RY;3:*
*(Y8.$L]!X 4(80*JJ2T1/90M+-S(')V-1R%)>GC,01(9DNF;3 M! M]I"G RMW1#].#7V1R>*
*(:OYXJ,P#^G@4KL=).\5+:-*QA*)@OTNJ \!M#E\PF M*?6.\N0;I4,2*
**^G]P.E(!"DIWT'"G1(W_WIK2-T*;X6:30UKWE>FK\A.18*

MF)MWGCDH;=LLEH3&0O!\/ID3T9SB2XG4LM'NE,X@3>ENE-%U 1[C$$#%'>2%
M3)!3+.9MP&_1/89'A49. *Y@#">=NN:SC,D1,0J.>!V55^SN HF&**0@3,P!
ML=;?)!QFS;@IY,+Q4.0IW@-!<8KK+ 8%#Z!_1R-WHILG:P$L6]5; X#C>@D) MT&
MD)8$=@JB%X!U++N<>]BO.43#!>[R7OA$HCP0)]EI&J(\"?*>K7VHJK,\QF98
MW^&T4,X9(#C9$E44YK/^,B/@T/$%V!M?36AA/$4P>F)P2<295#? 4 "Q"TNDEA.
(D/1$5XF[W]L@'66!(KTLE M05D^83T"Y&=3V]M2D3HHL
70IT/D/XJ81BF1(7#"M2&EZ(NL6JQHCB9U?/=(M,.>(FC48"-0*5=P-
ZD6)1H.\RQTDI7E:E>H"&1TF(C+))8U(J]OY.F,@V4 MVM@[;^/-S9"SKL UOU.T4-
)@R\&W=,9EC?S4[.QSL/FQEB\2ZW M:4_2!*;,F9PR%T0QS(=0A60HM6FE MU).^Q6>32
)BC!>%P#@0U#P<)1@1WJ-@*%VI(1$$^1X9/!)R@$HX%K"$8"J8 M&JA?"*Z
(ECLWAH'CCN82MKO",^:JK&R^OMR,_>[#%VD$+X,(60G@29T69.T
M6.HU0MFW=W%KH@%"4VK71]S(7 /*?23+IA8B)=P>F.\D%UP5M^1+8O$B[Y
M^A9@$(T@&YZ*4Y/ ;*N#L=*#F60/1JB#2*XR^X;GS1IK8UW.3,MB;2^GY!
(P9J?;WR"K1J- MHX,_4XW;18[$7L<7C(?(/V:M[L9&]UCIK0U*G<7V-5.*VQ)*S*+59A8 '6|
MN#O_:E!!5)YNW;]AB/_WK7=Y=W'7N[OXY[G1NSPSX(,OZO>SB]N/7ZYNO]V<
MWQJ]#U??[HROO9L_S^^,FXO;/W>!X/8B=,+#QQZ)UBK.F,5T-B>BC0B9>%:R
ME,23E'4OB,@EBY*)Q<8@,OBY0$%W@0,3C+6?!6,?KR[O;JZ^W!)\7=]00([N^.)
MWK'QQD*;Y(!\]O#&38)6]T;+.FATWHBW]'2CX\C?V*R-#/N;[Z(MXC8F,>8V
MM)G;#)&FWE(11P MH;Y/_>_R>U)H8#\1N6I$B*MBG0Z@UD(ONZ\,E'C9:!."T5"SQ*
4#X,X\$@\ MC-NPW8A4)\S."[-.>2<#L8?&56XOAF!D5N?,_G$R^\"*&)P9+-
/$HR5C.M@%^6'HAB#/A'&0.-%N&P M()SA V7DH,**8" T$3.?
NCU0TKQ4V&;B84MX^0R*78<_Y8/@B]/H(E M*$L)@)YV8Z#'-TIIQ=3PW.|
(FW$P__AZRZXM!I<9=W?UQ?F-<7'ZZNOG:N[NXNMP%$J8TW,;AL\[FR_GGWA?6;
<_/+BX_ M5U^YG4]F_ +*UY E#I*-KW-N3[3NLN.D%T6![9+.]AE0+<6]_TZ
"K,)%OY^@]_^>GW3PV1:X# >B"'16V,7\B:O?.,2 M. IQ,$QAA
TW325X.AC!+V)72Z[2,^0)BFC#0&B0-L7?B3/DA)PXMNR1\N4! M)TN=PTX XJ#*M)U01I
*Y]WLK9DJ/@U>(7<9ZQSI(9RH0Y 1!VRXAT8/63'ZZOS8DBIFT?OH7(4IB]:64? 6'"IETUG]
((E33T&7 MA&*Y:@ZKL#&H&C=($CE%"Z/LX"0VR]XX17;>CZGGGA?YYO+CQ[0A@Q0?
U%U!!!*DK MN/K('H%*YDD%8B0\NJFO!!R-XQ7\(Q5!P!XH+)[1E!X?4Y\H)@T0#B(LL#4
M!$.7+1 40* #Q)2&/9I&'/JBT"VK6'4:():&CAU,I@ 9'#M&JID(I=UL2,$F
MB/KD=_:4LD:A*+.9=M(NLYY0 M!EN$+5J](STT\#ACD:)8*"S?
X1@%LF84'8?:+JV2@C8I8@@P60>'80"ONHT! MRG1:+U=&>-
A#/Z0,;Z1X_M0(^I[B2:FRGCN[:1I(0W,7;@ZK4($*T[?0@TD1
MI!&E:Y#;,/'@BCQ%9UUT8.I9HU6FS9@MDH@(]7S0%$8L132WO&CXU+ 2#/F5
MITJC'AH P53NJ-%1 %RX(\E0?-31!2720D%,AJ!>HC]>E2(WFD#"
MA2A"KA4U&"+5QB0O:U>>/B!*J.U;CA,BU52I-9[ECCGIP['&UE 6-]"95#D"
MWE5E,^"Z/HE^F& R65<5$%M";\6*9!J"3 MO' $5AIE?IE$$=^XLN, KT\B5SNED6AAT-
>E)^$P?Y51AJ5L1W(T&80AS,"F0G#@CJ51[!/%(R"5E"$6DJS2J/WLBG: MQ)%41H+*@.-L
P$GBCX<3PQE(J;*,I#U/&2T7II:-PHBH9Q +I>XHI!OM$HB M9B*+Y!"]?@)W
EBOZ%TF)E"&VQ$$C4%.5 P]Y4AD-(+UH'ESDL08!GV;T"#R
MZ3"W1\H$3'PI$*19)VBNC>U@K!(A%/>;8 J(S:D$1)M3R[!YM)\IRS-R SA[($\ROM'B
RG$-UX]CHK WP?1/><8SV3E^4/ < [) :QZ MP"[JYO]VPXPLD)Q*XHD@]-!Q@3(-IEX
MP']T("1Y$1Z)P$#.!,Q".6]D]A3*HOBD#TL$G/ZNDT\!^E2^ 7-&?"'?G^7FY M>+'?JGY-
'F_NR3US.7\-^< MB66G'0Z<]27E&33=S";PS&?8Y#.1,"TQ
MC94_9"M:]>G+52JLG2JQ&IF2[P<))7Y**X=P)R3O%=:F05GDMO<',CPJM@)'
MR.6)ZM)0?DN+5JH"!(FM53F5AP^W[A]X
M5E]@O006!=GYHGX]L*ARC340,2>2R%23P)GZ<(ZV.8<+YHI+5T0.P]YC)10# M*K,J8-
Q-AR*$PQT:?P01)<686'@:O@"9PC1N04 9&;T!YMWR_GT9(B'%K&2" M)WIZ9#R
&*/LQ>?YNBDH!/M9R&T=*>E(&N=@V_QB.H/\2A-8B/[,V.X#M!F*"'VO2! ,5:@9"=+
M"3FN1V99M"I:"7HM?00X_&&FT!/5IO/QS'B<@;+7D%60,I,SIT#G-+*\@3R!
MZBL7S^5C2E6ESW5XCI4^J*1KLH)P\$P6]AV.?<#[R=2AN4B!W,RA/_,6')-R MB4
:0EZGRUVDX\X:R;+,<#'+.UB/Y67JCS_SMJ=THJ]&3TBI! MTPUS]6U#:6:*+;D&RB(EE/-
S56R"<*YD%V>T*CN$UI=5_IP,XLIEG1..J/I.
MICH8FEXG(_ZMLVDSBD]6%!D*WZ:ZP2A"!@IP5A8CS;5DR-FPK^=(D74QFXT5
MLVDVZF(V>U+,AM5QC$EVPF184 <02[=I>QL6ZB\2:U# >PA0Z+-@L[V+6\Y M
$WE#*E3)A^P4%/(5 F;88-(UU)ZE F;FRT[EG]/V5)?G*"]E%)L[(I6G-?$ MENLS2@-
=H1.S4T<> V*"VDQ-Y
M,Z9TV1T@*^\HK3PWCLQ_"%0UQ(8\R>5JMV4GJ$.BSP=K^L!!!=\%9X*S.4V@

M,P[EGMQD[+>3Y6ZE86&%:TGW@O(BU2R#F^]0VXNG.V0&EZ>32EOCD\'-9>
MG4#PKW1ML[>F;ZSXPLP52,B33E'"*8;,4"Q'^=D2TB%0!4N86%9$(Q418&0MC
M@(X0_V'"^UFN^%DI6R<3RJ-K#E58GH!!YDBUU\3#I;$):-B-HOAH)1=62!IN% MK47
!&)R,+>,#"NHA%#YJJZ@YO,\0=\N;\X_7]R"%'=^9MSVOIS?&E>?C//_
M]^WB[G\P0^3;S<7=Q3DG4WZ[/<ZS!M04&0?:2@,R'-0J2< M+]67+WN132%0)KY%V0,[
W.MY\'<.>=WKEL@6Q+9 M_H<7OJ;+(KUM/3YSI]#,ZTR>P.*QJ.\5=I?WSL-YP?Z-
@DB0%?CPGW5!DPO$ M,Y]@F(YE-^["8-A#6*$?#[W UH.@!XTOA[[UIT!
<^[Q@U62U0)RQ98YP"QY, M'-Q49TIVE?7(+J^I))C93A2Y7Q$4TAV:;(/: 7LQ^8]>8%
(7G#Z#&P0C+ :2 M[=&@[@BW$!]PAWA>$496'E;JZH-)?O^0LS&H]F@H NA^P9T*
]>V':\!Y%^& MU7_[CLK*.ZHK[S@I7* ;[4S"VRX6?LV2M@.'8Z$'$;X23W(?1Q!&"U 1B%(U
M!:7X4%J2>EP":QH(A9=)X(1"0Q)Y'TDZ"SF=)6 MHZYG@_+FB'-!HQAS"8]2 M,=
(-.R9N:O TRJU)$FI/0/TU)2/H78,6CXZ.CL[#OVR\79V$ UWAI1SVSL0I]/PS]IP:- MFR?
*:!I+#8K0;9E#SC;L/CX(5:Q]HSW $S^+*A(LRH7K*W0G1AQD1O9?VW_' M%^.NL6.X'
+,,DF$AB<>";\M\"-ERZ5AO@,4U4LGFMRR>9/>6:!+8U
ML+EWIK]/RII64\1!^%1([2Q@53!5I,&US^G<[H.NFHU9NM2*;K - ?KA3PGU
M;;@,VUS'2?(B)G%Z%PVF,D>.=B9L182UMFPC7I M-".JP#$""O7VSK*&FE_6&
(3AJ"%)S_/(K"#^.C_E?3 &B >MN38CV8@82B5
MI)1E12[+$@ABI:R=G)3KJB8K%465)6"N"EQ4ZN]A+ITC W(\C%]*1NZ
M)MR@GX$9X/%9NY&NRQ2[1!!*P>7 !AY[.0PY02-%% $$S"<"E"-H5;6NE&*) MMYOB0-
D#55E5W\/-31QPY!)%[EV&8-=-P/*F,/P2&*3EHEF2*/XH_J+ =CKW MLB6;&P[+/=!D-
8H3,M&G&1M@87
MO4;V/'#1@8OFN$C=!UU4SDP7*37R4S3$IA@SA*)5Y)5<4Y>K^\HUL2-V]SEG
M#_1/)3/]<^"4<15((^CL!==M+$IH+'3:L\%W&T- VSP+VSAZ&\
M*^,M6(XASQ9N>S3^]]?E_6V#%-T2ZQX?B_6=L/*9C;\B&"2;7)I#FDEH#!P'
M8Y>+;M1H20-C-OE4<2B&0(X)@]^SAXKY$SEY,'$5N9P[M<=.DV=Y=$[9O%*C>9%Y-
FA:&+RUWE-@"N6;;Z1H,"7$60U4NH=%C^&9GV1(] M;-
_YF*5L,=^U'8XL6A0FM%LA+JN/C8WV]X[>RTN =S=58/:#:8BQZA8,8OV4$I6.%
M:)@0"Q@*'OM%V#WAIW1*-CDK:2R1>]?Z V;>9#C>&HK(;L)[-=ENX&)>0YF MOL35O
?K4.S&901?3;^T-?,_B,&-BD'#@@&2&[_'&]K:"*[*>_9=)><%NS! MS!/"[_5A":LV'/U?
MRS8*5,@TA72<0M\';>ZT1-F#H.%&5>;S:0JOYE'!#_X M"@["I^'%_U!+ P04 "
#3@FU9/;3%?7 (#D, #0 &5X7SZ"+U/#4[0V/.99)%-^FLK=UDZSXIQN>C(8@S;CV'9/
M35F+__(Z3IV9!MB&D"4B'M?AT_=K V,%$Q[M* C9D3U@=[.61*L-344UI?W##\WI19
M+ 9I78E!9!H)4P.1ULD>-\1K=>XCX0D#1[6#6K/BM9J5K+7SP/P_+CGPXR8> M+$SX*?
5TUGALCI>MT<OW++Y=G[?[E]15T;WLWM^VK/O2OH7?[
MM0.U(U:N'>^Q?;CN0>TD*"YNK\X[/>C_VH&;SMEM[])_V;F!I_;H3_&__O9
MK^VKBPZTS_IP_05J_SPZ+D'[!MK?.NCDN?M^?MWM=\X7EF>]]10%;PL789=_
MA"C!,>RZVKW/[:O.3?GZ]Z^=?T]&/ZQ6#]]H*"S,<%F"GO#OH,OR6)? Y\J(M<
PF8J;^BFLSS(LY>%)A^CK=K6*BX7%<)('IM$:G9/20+S)"92-;$?
TOI\%A>A!$9FUHJ,@J5!CWZR?MJ;:_< 5C:A M!+:E!)HK$3:6$^"3>U([L/M!,U9,\(!?
D_SWBGY=0L2&'!0?"CY"KC&1T/!; MSA0",1Y#CV?(-B!3^(*=<:[A,_8/&|CKQ M4[5>_%M-
8NH%>_<(+2WM(JSP6[%GL!+@?_A"7_'/]S2H/S,-(8B!ETRAKM4
MCF(>#'C)Q:9R$1E(G#&5QNH6AE*"I6/(4Z-RCCZB;$HP5U"H,OSM,)8%*J:0 M^=BD0";
(^$8ZNQ6#E/M<:Z;&9)*P.X[SSHVIL2U 9W#*F"0%S4$&OE!^GJ!9 MBMW!JC481<*/0.?
TWZS_B"M>#$(+2(2.46%A^H.1,!$N4&%?-W1:I*RBPDL#O?IP' M."0B9"Y42X@N092288
3-@FS<3P#7Q'W>FEFQ'<@:. 26>0Q&B#B9$:U$;8Z M?WRF(PAC.=(3."H^$-
HH7#0P:BQ9._2R-(^_'-9^;N@".X4MS%Z"4QQBP:,;D'B&:,6N"8A+71$/<@L M0=
(CXJ/K0&@_ECK'?D2'2L8.%IF2/@^P6<,>HB#@""L7ZIU[/V+I@$,;F::7
MQUR[:+"UX,D>=Z[88I"NW*6@ZBQUF*1)@#AI#]H..N30\V8+]]WEW)0A3DG+
M7H8R6I!>K3\0M3OX2?7&0G$S'_6KF-CXY.+MU#5/9IF_*1L2T%ZSC5N*X:I M56E/ ZE$
M)GN=Z\"RDYCR,>BIF<-I0Y_L0Y\M!0:,MN:,53.PZ5Z#->G.=6 MQ6-F 5:
(PQDT2@7OTDV!'(F^:!F+P!X@ZMS3(A"X#;0 X22L)?N41LHUR4J;
ME[35H)8+I>;HD$'NI4X9HS#,8T84CLNR3LSD*?9P8G=>H^,WCY,ALBSVY\%?
MQ:KOC7VW,0%X;R(!;$QQ*WE@]F 31<*FUIQJ_#I<9XGVE?IZZR+"&-E+IJ5ZV#3AD
MD@AC.']$&G@2%3G=#P3Z9P?90W B$VMB>ORD2GZ24?CW7*#[-GODJ7T+1^_
MZV#K?3ZUWT;:W-;3K7:,91UNK$"4T?DIG59Y MV@+5/B^=/&QY%LB* R%WF+V&FUB
'36?4M.#@"S*6NR"J,*(+#GQJVE;\@37 MBQMB%U-(@K6/I9X2MJ^K71?
M_G_EY+8>^K11-88*,WL)HY1;4L(XMT_C"T"4 MG.@2Z5#&0T[**V6#XJ4"5?
83[)8CCG>'472D19;@!O"XP^1I2N[^/IZ:YM)

MYQEOS;F0L_3D_"C'/#1U&X)%@WU1M#X-RO7I81F?GC1&)@TH0OH$QW\LHE_Z
M;M\Y'5O4X0H#)O$P9FI'): 7@1]#F]O7LO,4PR&[!_N$ -3 VZN6@/[M-V"C ME55T9>
[EP@W2Z;I\MCCDP^GKZ;Y_WD;/+W)C[GBKB^TJI'Q2:Y9-SR+!0^C<
*MS#7M>=6V,*7EG^_I8(]$,P8^9UJ>[7]LW_7*W?=$I?^YU MVO^B]^?*
G[G8OOO1[2VU16%9RM-I(^16Z%U>WWV:SH07]$<":#_2B0G\4T&I6 M[%\W_]02P,$%
*@ TX)M6>IGN*9H" +3$ T !E>%\W-#,S-C,N*
M:'1M[5O_4]NX$O_Y^"OV\>;U8"9I$@+7NR1D)H7 ,=<"%\+,O9_>R+8<:VI;
MKB0GY/[ZMRLYWP.$:4O#E9E.P?)*VEWO9_>SLFE%)HG;K8BSH+WS4\L($_,V MO_O?
*N\-Z_9?Z6[S;JKC!G9_P_K_*93CG*5?,\ "\,?2C/ VX.I4)AVNI#(NA*
M#+5:Y:AR4#TXA%JU47O7.#R$ZX]0+K=;"3<,_(@ISS6WGL@_]^C=?NA"*
*MK<[*M<,]M@]7/:@=!<7%[>5IMP?]W[MPTSVY[5WT+[HW\)B/OHG^W;].?N]<*
MGG>A<]'JS.H_58_+$'G!CH?NZCDJ?O]].JZWSV=-^^[*(O.(C?3WL7C]MKU*
MZ@'I;7W9Z;WO7'9ORE=_?>C^=V+10;7Z4L-O88>+$MSXTACX@\4*$B]4RO=
<;\R76ATD@$)J*D5OU/$^S# M%IAW<4>H9G>4FC
[8_I6$_DAV>>SN(@),#*S4B04+"U:_\7J:6^N]0&L.*$$ M=J0$FBL1-I?3[J,^J;VU_J
*=*R:X1Z])UGU&O2X@8D,.B@\%'V&%,Y'0\&?. M%"(J'D./9UCC0*9PAI-QS?*?*
($,X%>PC#]#=6 ZQ-&8\1]]KN$C]M\UE._&G M:G_QLYK$U#?
T':S4TL)3L!+67]V\YWSD!UL:BN^9Q@#4O&\"F5HY@' UYR M$:E<' 82=TREL1R)
*(6UAZ1CRU*BE@F2&, M(N%'H'/Z;S9_Q!4O%B$#$J%C9'.8]& D3(0&Z@P)*
*(.U.ZV:HF@S03(PEQSOG MW/ *L6V'6/VE08Q#*%(,8L+#7-*
*"R%*7QKIJ[+5+7LF"O@K_[<1[@DHB+N0 M M(:8$E8\,PYH024B-XQGDBFC72SLCJ@-*
!"Y=((H]1 '$F,^J^<-3IXS,=01C+ MD9Z 4/&!T$:AT&F#"_#4.#EGMZWD7D!3'&+ 8QI0?
088Q6X)JHL=$0S2"S! D=%CJX# MH?
U8ZASG4>E3,G9@R)3T>8##&O8P]@..8'(!WKWS(Y8..'2PJO3RF&L7#;;' M/-KC3A7;9-
*5NQ342*4.B;0)4/V9 Z@##"GTM-W"?7QT+*
[,1_TJ)C8^$7DYG4[@)1M*4A/N4:W8IA:1O8XDI
M%GV6Z\VG$&OS..*AV,GQ0)GC(\ZQ^@R%MC4-I7AJUZ$F?%8-YRNJXC&S "N(MX
P:I:+:TDV!E1%UT3(6@3V8U+FG12#0#62 <'35EOB45LHU44B;E[3EF[8"
*M2LU1(8,5ER9EC,(PCQD5;C3+*C&CHCC#$=MY/HZ_>9P$L;;B?!Y\KUKZ]6KN M*
PEBBZKO-B8 [T4D@(U+W$H>V+PX;IP.,(4,14 H9UJFMMXPC1F"VDF"/E/! M!(:8&
*3S1"S,F'CONFTI*5G$6C"Z?+(@.L?L+>.X*PS*_PC)(-B6#3[7"/24ED6.]?D?_C(M_?*
4N1WARS.;7TD6/ P MI%=L0PQHO:9WG-+W#>J]NUS?3EJ@XT2LU=HUK9[,S?T:;,)
(V%2:4T<>/GY& M!-ZDU;>YBSM/H#Y-
*6OP5JS\L5H,MQ>JI@\$JG.B(MV@N[9VUF'U";2;J+7T_*
M5P2:.9Z[9M5$:H/C]'X1U]+X\.&S>S4">_=,"1']6#67I O%?<2D/9VF@^LT
*MG^JU[[2*F)XV!51O;;;@@24BUA\%21A#+#[QN#BJ7I(O?;&+'LH0K^WW<^/U*
*M:$OQ^O2SK]D14/'2,9A OC2K5E0\YV$W*UP$G">0]Y7^>:HBPQ[:2*6G?-D. MX)))(HSA_*
*%JX$EDY'0_$*B?760/P8F56%.EQY_4R4\R"O^<"U3?9H\\M5_W*
MZ/W7@ZV75C&W]6"K$V-'AXX5"# Z.J7C6%]P1$+!4<'3"/./A'E=!V>)9VV M-*
[6O12=O5YZ$K^(LR)UCKRE++,")FD^KTKU8+#I:G(PH@L.=ZKR2UY@O:B*
M0ZPQ!1M8^Q[J,4[[O+1U4>Z?RR2W];RG@X0Q5)C42QBEW-8CC'/[TKT 1,GQ
*M+9$.93SD1+I2-BB^'5!%">-)%LLQQ[NC2+IZQ1;@AO#X*HQTQ8O/7Q"V^3NP*
M)WP4YT+.EB>G1SGFH6G8$"P&[+>GC6E0KD\/R_CTI#$R:4(1TD>X_D,1_:6?
M[IW2B44#+C%@$@]CIE8O 7U;_!#:G%_+3E,,A^P.[,L!4 -OKUH"^K??A(TL
*MJ^C*PK>#&R34=1EM<='[$]CC<[^=JQ?-W+A^O%1S3R+!0SB;YJ KQ\U_,OW*
*MKMU!-1J]8O[^4Q+P-\R0@1B"'S.MCW<_=&[ZY>O.>;?\OM?M_$$?XL_=O3X_*
*MZ_>6QJ*PK.1H=9"R*ER?7]Y^G.V&$O37!&M^H!85^NN"=JMB_TSB_U!+ P04 M_"*
*#3@FU9FI6-!G,$!8$0 #0 &5X7S GE M;G*37LL7QMK5OFF?*
9V6W$IWR=BNA)&KOO6IIICEMT]F?[P^;S7>'-92VZN7B
*MWBN4_^(X<$X%5433"*9SF"2%B*@ZE2F%H52:<'# \^I']8;;. 3/];UCWW5A M>*
*F.TVZE5!,($Z)RJD\JA8Z=X\IB59"4GE1BJ5*BG8AJ&FHF105"*305J*TI*
*MIUDB!3T1LM+>:]7+H%M3&JSYMM^I9>V^+_\W8_T$$*P[?*
MB&F>!=_R\;P<0SPBJC:2[/9&DXNSBVYG:K,^;6] M8[BJC6O=&HQ[7:OI-
*8_<*G3&T#D=#">]TZU;[S=\<-_!X PFGWHP[HP^=O]] ML3/X_7/O#^AT)T;2<-*
*W&#UKF%0\751BQ\"L,2<'S*B14481A2)5F\;P*6:'R M*
*O>"EK!4UA),971E;4D.))*9@?'RGA5-4U09@TXHC(F:$D%S9S#C= Z=4!N) M*6H5Y<3N-*
7I3FEM).H>O0MYQ&EU3_P5KKLF48Q12(2F=5%RD#\KY N@/SWE& MPOOG14AW+-
)CWSEO@[ ]C5#7D./X&8S0PS(?DB/ZE[_UA0\)'S1_IA^9K6,

M4K1N]'@E3AUMT6N\MWI6^&2M8-85; K5+^D%9 MP'WOP%;/^-T>'2FT?*
%YTZ\'M/%G34%*HI!9^!Q&-,,! U+ &>JB"><+IJ=L MV]T\:&7H2D9 \?*
0B[&9L\'1*%32QY>U$PMX\9>221GAZ.+UPDF6TP*/,X4*$ M-=@WUDI/!Q*
7'"V&,LTXP\3NF$ZL-T5O"J9HBOV1&X,+T"!K[9,#P)"\H_WH MX $Z-*
"P4T\9";X:S3US3>_QX'YJ' 1 1K=[<0G.WZT@+P_!QO\8@DR4MS+3XN8V1IA*
;.&EZ1K!-FT:=H;E!1 M-6+".::)L&1X*T1!AC#)]W97S*
01H5E'@Q&SIA$&1JO@):AD9FZ9*,AW8'9+ MJ^ %T0Z#'WK:GYI[M@]}>5O2F-*
P'F*C_H@QE>]O96\;A MH?T')1,L Z3-48PA%":;AS6O-??*
Q'^9GS.56LO4SR5G$7C9#'YU[2_8;KI1 M:QC3];R^=#%[@K;^PV!W!K.=*
(9[;D,LI;F7HGR/5(9(1,W= RTS=A-$8!S@. M<\UN*0SBF.&M^Z>OPOY0,63J#*EZ(_F-F?*
6=J#=BMQ!RDN:-?D@[/SR:CM;4D=I2\VUPTM ;#_[5Y:,WU# ?'I[XPRCJYD,$ MOE_:+RI_*
U!+ P04 " #3@FU9=BSFMG0$ "F$@ #0 &5X7S]9O/]?@UW6_5R<>L-*
[O_B.'!"!55$TQC".4S2J8BI.I(9A:%4FG!PP//J M^_6&V]@#S_6]]]KPO ,'*?*
=RJ@F$*5$%50?5J8Z<0XJBU5!,GI82:3*B'9B*
MJFFDF105B*305*"TIISFJ13T4,A*>ZM5+YUNA3*>0Z'GW!X7VBG8W]1'T[D. MP"XD)&-|*
[L/;RZG4P81EM(^O8:1S(@H%P/(21PS<>&#RP2X-8^) **I*J3R M@4RU#(S-*
?,700N^:PN#6">N#?;PBBA&A?6'BXX&F,^T0SBZ$K]A%JH.,J LF*
M?"./@(3MWBQE(=/0;-0:K7K8;M7S]M8]]M^M.?#NWWBP8O"M"(L\>,C&TV*, M|*
IV@BRVQM-3H]/NYW)Z: /P_/1^+S3G\!D #;D4)G;;7L'<%X;U[HU&/>Z
M5M)K[KM5Z(RA15RS.@IG@8MX0ZP)=E* M_TIT20$DEKFA^=TS*Y(&5IF*
3BF,B0J)H(4SF'$ZATZDS8Z!M8K[Q)XU6@0WGYG2@-41RZ=:RE\9P"/'%P3*
\',K983B=:4'*W[J^!ZY MQ@_B15L@%4%NU*%@BJ6+,KA1GU'LQ*
M9C,F>!92!4U,>=NQ,#>/&#FC,=X>=C?L=#F=XE46<"JB&NP8;:6E74BF'#5&*
M,LLYP\"NF4ZM-44OITS1#/.C, H7I,&ZM4-V 5WR]G?BW1OJ4&PS3!L-O1GV*
M1G%!E_SQ/C;W B B7LNEIY=7TJO_]0EA6Q7+_UP.$VT;RFU6+#SN7]#LK+:K%-QK>J$.*
(+);*&] ML5?SMA\L,V6(3GG*+R1G,7CY#'YU[2]X4#N^(&P_2/^G9EN]J*\,E0\4X>\+*
MR\N&_1.&W$T93>#XI@H/DH3AF\-/$OW.4#&,.\? -R#8Z,.OJ9U\9QLQNX*(*
MDZ(XK'SIC"?.L'/2IW/Y@O(G=WAR?%DM+:6)HZ2UYN+IE3#*1_?G9K*
M#27,9YQO_*$7=?-9!]_'[?>I?P!02P,$% @ TX)M63 &R;T< @ AP@ M T !E>%\W-*
#,S.#$N:'1M[59-;YM $#W'OV)$U>02;&Q?*L!(3NLX4IS4 MFR*)O-Z5JZAB*
MZ#WX3PN8150)Z0YJJ'>E3S-4!,*4R +5Q%BKV/QD>#7*2883(Q8R(\J,4&&H MJ.*
&A((KY-I:(<,\%1PG7!A>SQW4*=U 1#LHU(Y5[ER9,Q 95W0WVC#T,J5 SF)*
(LH3VZ(<^D/*G3)/?@B>$9E0*
M;H.5;Z$R5[A5)F$TT:"D2:HZ0C8JNOZY%LIE56#K=HT*Z7G1?K2L0)OMDUI M0!6,^T-*
W$'CNH#32C]SKG6OQ4OTTN KU/%&6/=(L <+T<&E&$K2&_1]Y8D A*
MPR9R43*N>5#D3I. B/XZI>_NFW35NJHS!$R4A038SF_>S0."3KV?31G-*
[[LY6MY[HAN*!0,@(I0U*
M.3K25F>,RJ)Q;ZW%J+T5H_U2_#7MN]S>Y=8MMY;$QFV)C<](K%'_8OK--]^F*
MT:F6BZK@4(1^*;_\NL3J!^0/4$L#!!0 (-.";5E)2P1#D\H !SH * M*
:6UA9V4Q+FIP9^R[=U137=LF'J4C17H1B (*4E6:M$111.!!5 24%A60*
M$B&B(D%"HJ(@75! 48E2I!/I4B-=0*2$(CT) M(DH80#:1/?[YOWG37/.^MS M9LT?O_5;*
<\AF99UD[WW7Z[ZO;FXN'CY>/[/?@%]@CP\POR_$)"@L*[A'B''P"(J+" M0B*_W_]>Y/?*
TW[,X+R%^/GZA_^V#_1DDQK]K/]ON'AZ>=_P\?7SOW,W^%X(,O1^Q.,GD5%/ MHV.2G[]*
(24U[^2H],RL[YT-N7GY!67E%957UIYK:YI;6MO:.+YU= X3!H>&1 M[Z-*
C)/+,C]FY^9\+B]2U]8U-VA:PO?-;KUT@KEW__?BW>HEQ]-K-\0$WWV^] M=NT.^?*
T%,6Z> T=YQ4]>X+L6)*%\["&_I$72^](F 16]BQ2IZ[?[!:55]4D' MJ;]5^X=F?Z;8H_\CS?*
ZIV+_T&@,)<>WB.(]+# 0%,1F9,=L^,_8K-51E.BV. MBFE!/)H6N:NKX(\1OEMGY] F(S]1?*
57S&K'/A.%G MX@JJL@AU9?11B;QW);WY>;A7$$/6E,QGHSP0=)L-DD;KR:7]1>E]*
MJMO8)!VC_6X=IUK_2MQ"^N#G79)I7]I-G&6*,4T74%9$W&C4S(=RLNYNOUI8*
MF^Z#$.GAL>$(D;P1DV!*S5K&&%+'4'/[=MN!JW)KD)'%DAF=8R76&>6ARJM97&*
MHU/AX.FE=I3GO-.9=:,S'?M1-7(]/IOR$P5."^$C@0%AOB5U:9M//.:':8S> M*
G5<9.,ACA%X4*(6(6SP-' MDS2W\;=VZR78W3=J88,*
]5EL6V^,RV94I/ZXME4S#;M'&Z*RD)[TR3MUN5>[M*SS]=)-]9>6.S6NMU1B;G]VOC*
'MP<0ZQ:7TP-&]19V-,G@T3J68 AU7^L(ME+<2&CTM8J;W#E";Z3Z(BPPNYG-*
/IB[C5)]\>#2V)G#=XH/CF5U9-T EHFZ) MU85:9^1SY&*
[WKN/3+!:&XBV13R0O7);GD;QPXF]#B@I-9(.(!1[*E-QE6ZHS M.2?QD?Z*K3,03A5?*
^DQS.='P3.=#J?_Y4:TGCZ2O@'N^]?%_X6H(P?-"B9G# M&##:T*]6-*
W*CVX]QM)"A#7OJM+5VKCM8@0T*A%N5)IM_FZW[57KT??N(>LT$W>@&-*

M%:$C"^8KQY&52%51^I#HZ#[M-
*F4W["0N]U6.!OZZ6[<=%XN0^B'>_/**B]KY+\N2,^9!'E@,&\2C4$Z!,O2K MLLCA9*
":TWK,I0(CC] M:K&DRKU)&39P5=>:;RP7B.,2]SC\#3/[>D?A5--@GZY+?FH5=!/S
*MVBCH?O% S6JU?87IE$2&E$^K!Y29QA)=2E=[L-%SBHQIGPQQZ-=7Y*ETBK"K*
*MEC:2$3 8W#ITC*P? _JA(7V08G*CF*CIT35I4I)?"1QJVWSIPL)'5,_U5OGB*
*MXG%X8JZ'*L7JLWUB&D2'8IB2Q7!@8E?VUPU5P ,<2RH:;/:]K%^Z0ORT-D0S*
MX>UZ,9%SZSZUDFZ&:?IKAIG9>(A-:_N7O?6?0A),:EOWD MWX9F#\.+^A4O!-
*D+%+9^=.T(,8JZ&]9P[KAB3%&/D.Y^BS-GN4OT5F&'6*T8 MB@,;)(,*!RHI;%*
*SRY"2]FB#1'5H+D.6G_S$P4N80VJS[("QO**%3+20B-/Y*
M7=SQ7=V=WTP.7_._]+C@I"^>Q,&[P\-Q7ID[6/@%& ^Z'4]QFE9]\&DT;(+ MG-20>1R
*@E(#[?R%-0+X8,GK%_O'[?RDK757,@ZND9^U6GSTW"*8![G++*]S M@O(*
M;J##1IK:W5QO$.)O>[+]95;G\X'71I]D8MUJ\?I@2'4LXGQF284_&)"(@X M0^DC=?
*5!HPSRD;W0DD1C?8#!VQMKBEBX.V2ZZ^C'J*_@)57WV;-NSOFZ*XAP*
*MW96M3(8BJRE!$>H$A*K%QS/6RMR;-*8/5H^F:P5PB2:'>(G%=%TV*9T:AP4O*
MX:ZG(,T3@S(;PP>A-UG<+OR"N8$%M,2866@EAM1@,4,S(!
<.VUOOP9@2K\VZ([JPRZ+3Y_2 M#SWO9?WNLI?%"6Z;T(-V%S\/!]VVM42TN:-*
*W(V\1O&+- @QL_'B()28:YC! M UR@GP8Z6EG@M8K5AU,::2U.PS2]-*PK0N?*
*[9\BUQZ$':T[_DL$=+RFG!0'; MU/)6K*0RQ^5M]H]=0IYLK+C:FGS %@,85Y/BE*Q(T/U-*
*Y(DOW_?+ MO[JZV*YSL/DR_Z,$:P? &BTI.+TC7 M:@U[*_IGT1P]VB4C;F;[?*
[K(Y^6C.J]'HU/-A6KWZHJ66$8=S[!OI0:CRV& MJ$]FC.;+0?7,&) Z+@9Z$P\M\A59K8
M((EZ[JECL4Y4Z;QT5.KMU(CNNDBX^WK//H^_->/ MD^&I7[4^L4&I:Q6G]H/Q[?*
*[#69PIAQOZH,3TG8Z./3@N]PG@=0MO@*DKI;)^ M_EY:_LG[-TM44D\4.:EG\YX)SW[:?*
*LO/3-AK!5'9O;X,+7*H7!W@I-SBHN8, M4Y,EJ#@3KT<[+RGPEPH^);)LX!\Q\J.Y=83,Y?*
*T;U%D_>]R*5Z7KKQ'=HXM MJ5[]\>B87@*=)L#,,[M"/X_$. \R+(,I@8MC4Z;.54K<5-*
*LEWK9Y3!$7B3!84O1QK+&L'8;TABN^3U7?6]4=HM,F[]V4A\^7MS&]J*_ MQ?*
*#%3F&:0+Y'DZ6DD^6_T,LY%3V.J= >67Y/5T?.DPU27R.*W)%6=G!@.?=% MFV*34);?*
50&NC)9]^/&G1:F#0(O7C@_WG_K10UM\D>. R+W61BR- G#&^2 M/4\'&<<#"->'^4"?*
*U%OLE*0$(ZI.5!'.]JNT0#;DW!0* Q6N5MH_P5 N)XHP*
MK@VS03["^T[64,Z5DL%QOM.49+_[Z-
HT([1$TDW(P(5,MX_*)_J3]GM!]V2BFZ4PFH(/2QU-B93T)JM23G[8] M1[(KPC8(-$^%T?
>H>=.$HVZ<8@T<]HG;8(/&(SP 6Q*""VE!9XE=V?@Y7S%B M=CG=L(9\O"3ERB_]O$-
*QI\QN19H^?"&M?@*4?*
N'S<&#GW;G)FZ)B=L%+B%;9"6@K=@KW#NJW&HT70X.1/F>B2+D/BNOOD-
*T#F0&BX\$''1I:5%/I4ER]+5EH.34I>CZS_@Y-G%DPRRSEV*T. M)NO^TX^TN3_-R.,\B?*
*T**\2?[MNVZJ.5('RP75,]^]RXQ1!_W' &1H"9STJ4,2B#)M^-C]2-*
W/8XD/T)P^O4:IU.QL3Q]A">,-O9TJ_J_ MT!=CMN^0K1B2\\UX7KQ_HCP*0DTM)(GR?*
_\)$2NG2J>$%<,/>^H4F\U=#4A1
M_=RU#=^RAAK9=#1P=G\!CV>#N$N;^1,L\6JFO&U\J
*M?"YN42;VAG]H^CB+:SR]\F'1\DI#\?H0IFEE$'8YMZ!QA"%:\A/W F**:;)3 M*
4+HO$C1&:.H>BB\4#?Q T&K#S9E7O**M*W3)&K 6$SH/\E5J/+1(N1J4'HG MD,^! UEJ;
*[/N=^DM,:-E]=E<:IT4_'/3XF2>M?Q^E9*8U&'.VZ2I0RGJNO(Z:M+%%U79GYJ(.<*
*M8D!V;H;;[SY)5;$?W(2*JLH3\8,;0-&K$.$S4B>2Y*0&\ZVN?5KY,;_W8\J^*
M9>MD*'["],_G*OBG_*][%$4457HLB]8G"P$KBYD1LA=YEQN+ZJ;\/6=<][MJ?*
FGE0X(A>I;J<_%.A2TS6PN>S'%,1!!OAKB'&KUNF*W 3T?J1]6X8"I2>R*
ME"B@+1[NT%P[#CWQOM"YZ(>Y[V;[W?9:E:P%\2 MK'"]\"O\@*6D\]&\"Y:2(.?*
*QT1G>ZS(C<#C@;S0 X@[S2E)[9.ZA#^ MHEI6U65:YY]1K;2*F=KIZ] /4SL[43(B%/_*
[N[6U'"%FKA/M&H$B2@.5-@^ M8^<"'"6COE%SNP2C/&*
<-8C8T&'(<,M.PQ0;MP_DGP)Q>U_L31NHSV2#>4 ,] MP=O]!"R+2V7?C-
&R!!DK@70FLLI)B4_7L;$PGOJ9#T!::VH 1J16Y^J:KOB: MZMV LA)^]>V_A'R@]#*
[.?'GCLSJ@)5M=82#6]'& P:Z,5APH'9@\-M 1>V5 MBCHQ^.S!RGI#EJ?U;
*(>D]RF]U.NCYIH$#$F-F<<&_70$..4G(FR5963%4&6# M*L%,03POAH((9X/:EY*
DZE%KC8H-UD;8U%3:\+A.F5/L-KE0\YO3F%@])T=(\J2>N
M7+FB6/;X]ES%GTBZB"Z,GIVE]8U-
**]QKH"FRR@JJ^X>:]YWYH1*N)X:I4Z/'[)0ZZS\T67,=T!!8 MY@%+8YJ.;*
*()WH8P!/M%F>YG+OFA-9L;[NNK^$M3)7(/-R**T5);E]-CUZ!EO*
MG\Y;%QHOGNVP,,4"UFR0/W1'"BW$,=(4G0V[^? *W3%BJ,7K@G+V#>-H=;F*
M1+5FIU7FYFYEE:2.-
**;#^V!N684T3B?]V7N*#]QBEKVOMH[.,$LS__VCO5\O&+;FU7@NWB>Z_S8-=S7L(;0"*

MUSXMXPLY\ @JQ'#H\R;H]TB1[K!!_Q"M];Z8^/Q'P:MA+-B)YI>)(R:X_]F MQI]LT&,LC=-BO'!-TEZIMK_""$KC_4.7K_4QTI%[8COG4M9G-4OW MR.?

=,#83+M;Q&\IE@QY:AJ;9@L^E5_CULD&[DC8,I/YL M"8[B7KTL-(%C6;

(?,Q^\O05E[,>N@ SXX2 /?T"&]172/'AY.#6-",P\=_X MCOD\X<*6J/6_QQ/T[PE" M^XL-*

FE^!,D0._(]J2[&&,%51[OH*LC=O:T>ARC8YJK2AD97_K:4E=G6#$^5 M3UUOWUP3-*

*=Z82=_0%6%8,'-1MB2ZXIGI9CR?6;S%E.G++?_JIJK:2+E](B*B*

M^271%):ROJ>'0Y36:^OU#J=J>HFG NUQ05?<-8CO:.67#7O/IQQZ\3)]97HY

*MB\I%&D.6V]A.RS(N/B<+-ZR.JJZM7 MPF6*XELT?_/RXA/0P5:J:@F)9$-X M61-*

*828CZSXS]T2@]ZIX3&/O97FM?)WF" MP?^U+X*SWD>7_P[B,#IU";%VHO1%(+8L*

*SN9MCE(31RM9@GX476;I^0 T10^_T;#4:< M^'D4Y(K\B2:8(**

*(W7_[2!X\)DLJNU5..7:KR7@F><_-B_M)D3_P^Z*_$J4%HP,QUB@H22>1_F MH4X!+=E*

U$F*TW.=M)P%>>G80Z^DJU;DVZM=7OEEKZLZGK=HESIU5$51]!E MFR.F'HRA-*

=2H!-!&.D)DH+(,Z(P?XPK9W D>6SU@\/37+':E[Y27UV$N:^Y\ MV6?"T[7<\|=QB#\1^?

*WYUL*UH0^XAARI:<9DTXQZG4>*';1.=^E] P5.H'7 M)S8Z)RA6# DME#%G-XU%7EXA*

M3AU-]5VS5DO_1TD_@9#N._7;XYP0C68:G4CF9$L,Z*^0,]?8([>9^7^(?($

*MM_T3MJ*K_Z]AQ_^_(',-$<<&54,[>A^!Y=CR*

MZZH_1=R^E/L54SN!=NR/)#$L0^DF>A'W$#.N!T, 6;+>F.2!7B<)FP64Z+UE

MO,02/JZ1]S4YI%E4"O"?(IN:)N[]N77?R^%+3C)O.E^<,5?RKIO/S#6_8J[!

MOMLW84NA33@1/WG[R/J# >0E.W""7R/!3#W;A+$9UW3U(8\KJATOQR=D6B0Z

M>UVZ_R0)\ZZ$>_/9.3[)P"M@OO;/Z4_4O#T\S1!:@XTZL 2D=)>SC)H5PTX.

MU>OYS.!X%\<@;K+980?U9 C!-WLMVU%WV_6639.O'_VK!C4K@FCW68^0*NP*

M>J$5\]$,.T0>:M\02IN,V]>(ULH@K[?HX:.+R/77[>IE,GPO"7X"WTU\15<0 M/?

4G8I:\ZF_]]LO1KVYUU8I#FQS4R3_;AW/,H74JO2C. MR;0#D1(8,Z04"+ MHV

*$,SZB:$S&_N>MM+((H+]!=PES)"0T&J^O@$3^7J6^Y+*X#.AA/88_UF:UVG'QG MR<(X1*

,XUM&RUS4V9-)3?^]$^T!-[]?'W_BYWF@C.3F%(29(-7(T\ND&4U=*

*MJ3'712C_7;BB6BN-.GZ\FFIZY8HU''ZK$)MZZP(WIV#;*3B\Z M-N?V/!@9VJ X4F*

*M%=/,:J5.M#7?B%]@_B GI[U"$C*Y@)+ W4?FI(A)DS>BSQ<87K6XEV*

M@7P/=_<67%N0H-[KRU,650_-U8Q^,YJPI9!VWI')=R'[BHZM$WM M&FZ4GUJL_5

N7%R2=$?ZX_/)"7VB_LKAIYFI^Q-US8U+HOX <@MRA.Q.#]D, M3M[()BY-*

@5OV8H9&__IR;2T;?"?(]^(S#^:\Q ;]'\+ORY2H0R)J&:8)#X0 MMA?E0AV.

(K)!]QS'&Y;;@G&;ML MF8MR8U:8':2JN42TI%='H0Q(IM.BBA(7"!=_FA'<+#7^JFNR%"Q-

6<"^CHAP M_#=5X.]D,'?Q96SNROO,Z@[%8D]='=J8ATX?(7++'F$)7 P?XK5/04&+/.0*

*MY?91S4<9IVNH"75*KX2&+TZ-&K16'_G^^ WR?)"CD3AB<_1 M&G4 E'YB#*

(Y6I^B\)6,3[CM6I0XW2O>I#C#,<[;YNW1X:I(FYYZ''C,\;C]!:[E36]VWF@99^-

]G%"/J?;^S)7"1Z5(3.W&)(%'3-7 MJ8B6?E=L+2]0$?VVT-+*[G6R;.!KL>VZR"$.?*

66F1M3AC[I.R6-H7\"P47^ MLYO^KNDYYE-Q].$VM\@_.^,T,L@D9E_.!U3QA$?*

*ZL>)^2!=^D7H^B\,P/7' ML[/HAS#K-"R+;R]K,)%!Q[) O>_S**V%X9O_AK4K.M :KW?*

I2]_5IP4B5AJK+] MSY)XB-"M8>$?5'AN"9:@G.HMH"9S[CX;%/26+XH-

NH[@01UAODYA&[D)[- M'H?J!Y1D%'P[^8<7$0KK *"-5=[@CY*

*MT$/2%'8FWK4,7EHR/W 5VUK,Q-+LIJX_&)U.@UQ3G1^N8X/^Z-K!U'&WTPC_*

*MOA$,VKQX6\\H(7/E=W?8L8A,Q7&V@^.'*LVMR'N0Y&" &V5HO:4?-#YU1[%*

MVYUS=+SR67A\[(FKZX:K3>WWJ.[@%W)- (OTJ4.XT\ NB#%@V@N'5J6G/

M2O))CI^HHA'TTO'9[H=H1G89UQ)7S\J6T+A4<#E_!/S#!1F:K^S''6K'IQ)> M!XP'0$E?

*=H;V'*XH 4CM^/>NH0D3&V$*

*M[]G9U#187H0S1Q4[EJ,H^#8P+X3?;TJ6:H,4%*BX84B39HD2U @;W:XG9+KC*

MKZ=;@Y&F9>,U7\QOV^?^66_>:U:6_>/'(J&.Q;!3>=6LT?7F?ZLYO_"O]IJC MQ_^0")KS?

*W;M"?JO!!9=._X/,"MQ^15GRA@&4#CUK^S' MI:-_*VQ8KY+)&L%(L+20=1:4D-*

A@C,R2M,N'B#0;-6M=-"C@>-R3M:[FK1> M-*

*_WEN>3R)ZR]V*RQ4G]0H\G]"IVZ>>A*O/&5KA<;K!E-H(ZVB]"XGS6< 07B*

M<2VD\'L=;1EBY10:UCMOP3KDT"LS86.]R&=B$7,),GRSN".<=H^8+#.E"NC1

M(2ACJD\@/]3"=\>_Q?,%>;/%]3!#>:D';1.6?<)OC0WEB6#;I-/?+"!?5KV$R8>'-O=

MSS+VFW?%]6O[CT9CN<_[AR[K(571J)^WU;2 FYU9ZQ MG_)DN&

[FI=:]P#C0"8D*9K&SVDX^P_##F*:[F%^#*%,V2!/ M?>B.71#,A:'$!B5;D1!T;A?,SQ>X_*

[,EZ@]+!,LW6_]LNZV(AG3Q%$BT,1$ M/;/Q\L[Y?]V2^U\/W",H,6MZC=,:C\ZS\-

*K0C0;XZGU A27($>8PF)F!65KC MY*KM<&/68^B/JQP3DW_*U=*

S)AQ>"+.0XN9"246>)@!SL5^$' 98(>! M5.3AM7QP+C2\(;I.H0+&*>E@/?< M[16#A]P?*

*K/V1(1/A:"*4]R]Y!QWPPYB;M5%-W73X=< R\ERO^&BS'].!(RV M9OB6'@LPXMJ;?*

\E>U7V@@_;(..I-KK M[<9A@'&6#>'P!O1E1;N2>5A-T?DEO

M+H.#KM,/[X*!Y]\.U@P%I'NG'OK+6^;(62XE$;YBY-9R&&<*#0BEGT!) YTS MO?N
.VU@(3,H):U-[Z=P4-Z"<[+P!3.2<,$9LQ3/O+/S\._O0J]K/6RD&!"G M=_^N(= *7
M."B5)J2H,H!381T%Y(48PU(G$2Q7#@:^=A[5*9NO20A^^%VOU
ME'AR=/7&]18>"_$M!JF:@HTNTQX"+CIF<-+:$X0V58_5Q=_^Q3=T M*'7AQG.
[ALM9XF,!I\=T#MR[NOH5X7XKIT]]$/H\8S=S/(-[%YKXO9FG;MS
MLU%A+GQ'NB';S7>G/"[*9&[] M@A)3IDLQ3_$WF"%DGS@S3Z*H,"#1.KU71TOZ(E,/<
DDO%,*36B=B'K-W G8Z=R"SREV*& M:Z'=NP5Y$*6$0R@$#OYZ+Z
TIU0]1X!"B;IP,1HQQ M[<-"H]K@)G+ -#;TNH]K'7-]TMWPQS&)4MO
_2'[E6J(6$"W8YDPT^/0(NW4 MJ$JU*^Z--CO)!O$7/:(WWT\INJ^4Y[V658Y/(HF-
]:@P!^]U*CSCM;,C]0*: MV,?U_/@*WF(JU)5"2R.M/O:
VG,O=&===]I>1C]]8LX@7+K3HGPNKOG=5^ONQ M9WK/=JG,XSB@VJ2,/@I@B-
'WW1:^Q:I<_5%&@36 M?>NTU192);?'EJK&XM^D)L*&&W60N-,UE$L>:O9CX'/
*#%6VX)VRKNHQ1LQ M&YY '3@VO++_1HM&XP!?R0F^J>DRHY4<(G0<\7DLM8X(;W
KB4;O.!7F+LE; M?GN>
[V=D\SY.;WQ"^6Q\9'>91_!9=XAREMO7LS=\Q#+C'O"$:8,D+UB"I.99.LQ<,Q62 MJ!C,[]
BW6E0/T7<_]F"M(0_WUD+@>G;UYW$A';?:CW*M5_,N5$?6#I/B8S- MO>);]=$=/G6P4=
]IC=K+%NYC^A=M!KY\EJA4B1X7/-;*(_O-ZBE*OX+ DF6H M#Z?
4&W@7+Z8;/7GI"D0T#R]C2"K5SRKNU!5^[&GND0MQ"H$>]3:^X;)YZ[+L
M.9$&!Y7T#5%TNDN\|$$N' M %S6>,K(DTI["?B4!-W$O_I\C\
[;=Y>U]KYE@XRT@UZIM/=JE5X,4;?9Q(Q& MD=T[XNLE[W9O'Z@=K#<7+M+%
<"=0%OML$0H?W4LHBG\]_5QVI.OCM>0C[=3O
M@K0[5&N>@ZB4<=E]Z\T'1UO+L\8ENY6$T@W!E86AMG[:%2 ML4[,MY!C2+Z.=*%
[QY8\Q 82"KW2DN0"QBZ75.<%\]CJ6.T7V\0-IC.B.2WJ M&_R0'Y2FY899.
(ES>)0D4L_5ZR=-;/*SCF 7?[6@,<0$Q9H;=WLW0 MX 2G]C0;=' PGPWBLV+U?
X7^V$,I_/VP$(:1!DOO'*X5C8+PXX'7,Y-[6EPN
M/UCD0)#V1MU1_0RW,WX_+A/N7%UQ_WKLUBW-17S9D_&<_" ^XU0"O \F M"J)--
=]D@UH2);X#N[UB6VE3@Z'8 M!7/:2\??
VO9B*ZQ53(R:5QD2[I@U1U0^]3E+H(WJ2K2K;HZNC)?_MJ8;?\&U
MD^1,"+3[4AO:>N:XZK9S=]K-_K?U<8'&IG8A>SF+@"$ZEM3Y#IBH+HZEY%O;
MVQ*N1/ 860V&[F6FV594U""WLT&^OM1VD94FBYU!INWA"W-!\?C.\?4^;)'G
MJMD:4PT#BT"EP#@+2UM\ADXGQG9W/Z;1?4$"9FZT^HEV8'>5PWS
MN3/@LC^[::E)Z1]).HT7R M0F9J\A551(J*)77GX(80K&^0]ZY^935+R(>
VLX[LT(R;!AU2TAR6'#G! M_A+O>X8->@EM 3,D)CG>/(NEW-
Y:X>U@G6"#A#"4"__P.A'*L1[Q^;0L^@A# MOX]AE7V2^+/$S#'7MM!7"=Q
E90>8S7XR1[,K2I'O!H!)24?.[JH-R.?VY0H MA0PCW4B;"5L161MI3A]^#TGQSNNLL
H*YD5]/_&-V%TQOU]$6')MHN!V4)SR M&&&>J;:EI_%RN5W V,8:
YMK7/^5PY$Q%>,K'MK/DL,0,Y$BRJ_*Y$8HI^7?GQB) 0[_PV<,VM/Y7(-
CFU(%7VYSLG,=_&D^]4X" M&X3%K4)/CK!$+(&=Z75^ ,X)O- M^,#ABQJ+-.!S[
M'SN5<'9*_#>3"]3_.15:K2>ZS=2MIX^PE+4!#DL^\3]L#"4K3R="-P0 !,=L MA;_-
}B@OBPGKQL]_11-9$U^A\QN-ZZM_%_W[V(T"F8F;F+^PU81]#M'.&\& MZ+T-
F/]YAZQ_(P:@$0,=8M2Q4!V_1%>^_C]-_Y^F?Z1I,@<)C@!+BLWZM;HM MT9Y\
MD6UUZS=WILLW&;W#\NJ9>%,(\(]?6?QCU,O07C+KEC$^NK%CNH\0B?L1
M>Y+YN4ONB]7-4M(YR\T%=QP5KSC/=D MJJFGV3OO3B[C;PIE-
V]ZJ]>>HR;J$7S'ML(K^.>^&ZMW7G)Z4>/\!@?7VH(-"_J;"TEW9?%,6AUSN=JEPH(F-#V?
>#?L/M3F_!W2F><<0C MG7+%HOLP32?1^P CXHV(F1^#N@;Q1FWBS-?
6Y805QOC2:%.+A;+JM?Y&IXD3 M?%RJ93^NZ!BWBU_*\6.8(,*=IRK=A^L$YH"#A]N&G"-
W5@+ $QOH^X%AP5(_M8.56*Z])B6.
("T,5A9K"F!;TP;Y'#:RHDE%F\L[DOJSE3IY0N7F5VS^$6R!U
M;L@WVF[F5C;U;EZUT,]++60_YP\%_6GZLL;9H.>.
ME%5F7!\;M@%NY#2?"J!LQ)T:K>I^WDAUZ])*KO/60-
25GS8%OY!]XGDY/B5]@&WB5,TZ%L5Q^U7H[Y/%:('""0%VTU#5NH$$:< M'5$FZ'H3$&#
[^H39)W,_;;<3P1&-<2-#K3HG#F!:Q']'D9[0,$TP6)AY:(M M^,AI<188/0#E-W,EPQOV-3?
*C=S=%X:(AO$^)CL8C'6+>#WQ-.WNU% Y]LQ9 MD$MW#Z5D #,:QA+8IMN/(?
>0JUM%A5$GRYFYV@PCE#+UYL"BBT=&\,OKD=3W M-XZGSKI<4/V5NP(Y![YEP=<-
ML&!52H>V@I0#4EEP1] M#!&>!O M'H>P[3T?_!MUJ/L'O:=T*G=+3M8?/:()[XM_=^B(:
\;)(>'X\9$ M'0ALD \^UB0\IV>U'8X?C7!K'-SD?
7R0F?)^D&A=B0SX[)@^J]54&M9=KMJ==MW9?QDW# 74,+$,UYG5[R&DP-(9_%X T]:H
MC:=L5J1GU+S_ID;8C#8DNEON=Q0J4W?NRN,N_=RNSC6:]T_X^M>@3B>PE--:

M\!5\+85/^H.A8AU^/@43#2DQA=V^)ZKB/#3*U>^=U+2J0(T'*CRX=9*$0(&E
M.MH0"GZI+M\;J]7^U4E/\61(WR=MDE(2.I]X?U'=E@NF7>[1.M?5%_&76Y7CO^
M6:5Y5:TO$**$9$$!&X/C^ONH005-!D/?RZ@B43@(*/<-^UFLG37S?BDA]RX
M;W$I&]NH%S\[TN[6P-Q#2]Y6C2Z4WQ^=A*^_!#XYI1GVK-\CI [C"T:'*S?N M>W
0T[";C'^(!O^\U5/\$W((^+'LOZ401;>UY8:[9]H\"+C-/;([C.J1YQE M57GM/F]A^2J?
Y[$(:/7+&YP*N&<,TVR<6V0X(J8*&[,P+O&DGXB_O'T-='GP MB- ED2,\03!1E"6IL'S
KO5+PX1#I]*V857F,\N(%K9WP9''M@',' MCF./ZS04^%*V/3LO[[QY,2\
*QBI2PZ#>R5/D_GQIF<%IZ%4N6' =\M!(X#>\M M3D$AL4$Y691MDY%<=(=
(*6L$)GCEU07G=A-CK8Y=5N/7?F!MUB67G)3E7.CY M5NDZYKW*-
#]L*;9B_FF],#7,D@,I#Y">I)#(60JT]:V);R58BX+.H7EQFUE'[3?
TJVC!EKYI^QCQ*_&MW([<$P^)C8XGS4 MOU&IDC(5BS[@H#B92/[Q9@1#N^,
M//<\/K?7%Y5,KXD,^D:^/:7#S-7D]ZUQ.)RKV>#N#:M:,:,#)1C%@K) MS#&3TVV:Y/L-
J_57*&?FQJTI":^*O0$=YN'P',":NAOS&"9V-U%\U"]=I#@X:R+\@ZGYC29$D8[L
M;E"Z].>D,W<>W7\0YD3HRC%=[UK8*!_*^_1KG SFKM:VF4XZP0OWG$W3X:- MG-
JHICUCQJ&LO*D1)*/EYY3&>L1>QY^$NZ7!SO[;#ONB<>)
MJNL&:R_>SIT0E5/IQ!.+I@51[I0])+466"3-@WN0<93B2?JZY60B79@/&^T- M)
[^U077>"5.]93,G%5YT@5_VXIU'%HE)>%_1Q(S#S'R([A+$A%KRKA;[='-!
M])=WP@&ALWF/CL_$\PG(*Q<4[(AD_Q@Y+,^CX+->_+$F_++)[7S]E4(G^KFM MD-I?
[7]"D"#QFWZ9H1/)I M
S^BH95>=E!%6ES=15LQ>\Z?:1VU.YKD=2^^JJ2O[ISQ%X7U:5'6$2""@R2/
M$"CIZH%Z9R4<$0%B7+?3:R7T'"P(?WTZ]GSWY*;GSO>@W;/ MYA_MBJC#*?
JW!N5?/RMG!KZO9-^CV14>F%*Q%*X+K_M55/*\\DOHVY07]UVV M-M;&
[=YN^<\O^:P84&[WDC 1>-_P4QU]/^]QJG14AZC(TMXB9]J(>$]F0]?J
MR^QS/9+G7G^4/7P %B>X#+V)>3HMUBB%VLV)L),%$X"?OCE76X;L$$3^T)L=
M3$]V$S+YM%0 ZPY?U^[MK/PTA!RN_67F)<\'O):N [GR3ED!=Y\U:;K:)#^= MLZ-
V5CX47&+8!#TR?61Y^C;TR3>_T5P*;7;<7;?[QF;_<[.QB:ZCE82EZ=?A M!M6&L7:) [J
QN,I&<"*;N"?GOOX0WD2U+]7R@4Y9Q#K%V9W;_^_JF^"R0V: MGZA2%
(4QYY'9P$=+81;4N]*O(*O_&JJ_=!?NU5?Q<^.MIEW_Q@9A8T5G2$!9 M??]?
C^54,^RO]8',MN_';![[JO5Q0_+0J@X^F9YL^R/T58*R0:%QTY6[C.FI
M<:_^K4*QK0+J[_\X:Z4[$RGW!5-UAL0WI+3<"T]?[93)R]0V^'\S]?WRW-3R+#>
(6H3#G2CD (][W*R#U%&]*#FS274J!_ROO 6S 6NY, M##!CV:^+LBX8_^Y'2S,:J;[-
_ZZZ.CHGU4=ME^,E<6MST(^17U$,,4ZO0PBG
MRS'4&ZFZL<47ISLRCL:;+5T/,7SNFWO[A+W]T<2OP$\+74=5QI;$G"3ENURS
M_52ZGZX[>"(Q+.J(P5'9[S::DQ%V>+O&]94"#DN1A7K\\R;Y]IX9S]^775H8 M^XVY6(?
AC6S01N]Y' [>QNGRV:#O>I]AE4;Q&VS07N!]\/O\A=3K[7QEC88D
M3Y'5/JYO7H'APF%RAW2>"!*0D8/> NT+[B6^E6'N:)_G;Z[!G;.D3JJI?SM6 M?
L\^)1<^RK** PCGRZBZ#.FPII:6LE/FPTFDT+16W MKY^/-88 /'0S8*8-)LJPI(J2-
&X"T>^0JXX#!\>5K6AO(>2I@ZII!ZRC)SYV MSH0&VL0P]S#?LD%>]B!6MU-(-'%%
[&9@L$)X"W_H<9 M0>E] !_=&$#0 OL-PJ$MA^^G[LSEZN"":\8
SY)%US]/C>39!*IN'>)$OTM MA+N4SL;+S9JO_[*0
*],J+7KV@VF&1(D+HJ%P^3Y=T&WF UA[7SUM;J FL"
M)U,;1).@UQ$/[X=\!@/JO3'U4OY)G4JOB/M\ V+&U/?F&OIO' M'PX5-#.F^+
$)REW+"@E\=?>+QQ!GJ,.3PV;ORM-O-A=NOCUUK&OUL<51@;'
M=)=G2<5\M(=#K$.N.3^ID.K<#Z]O]Q@?D;UTFE=" 3R1:[P<;H=D57+"+05P MP
&9=C?("%G#S%]?#\EW!R8&J3XQO_B%ZJD;WNJTAN8MK-!"-S2VEIUVV,!/C9Y3GZ+A$^
R*-'\9+U MEAPXQP@%OZ":UUNU&MZ?
70K/:CF7GZ15^GYR=FWEE^QNWKZ.^<310I)AZ0QX M=.MSQH%^E#W)SK2-
I0@\"0LEP87]B2YC*6R+_6W\N=#7LD_R)*;.'.R+;R' M^IHET$OIGDF+D7 96]YT#;
K%F__16YFKHQ??")U7HL9PBAX5RUT I3!:\0(MHTLPC(H"MR&HC@=-5/9IR\M[@?
WT3P%P>Y7?27^UZ^)UN2V\D]OJNP-*D74 M6BYF\4_60"S5OE1$U&?GY-;] M6L31&I;\
D1?HGG'#B)S/_XQ2813PEC6X"?X93$_-BCS8J/-'SS]XI# M!B6)R#""H33"W$?
8FFDK9Q*6->%,F?^,X$*:=J2Q#@^8R9'L-%MWWBEO.9JAL27/,MN?"N3MDHZ9I?
L:UBO*(MBDIRGS,54*NC&'2 MXHZ742=3_&H?G_]Z+?FL=X,@R>UV
M+E\>KK_KWSTSA(T8OQ(!W];+AM?]-B@X)@,[F<9CWS&AO$.XGN:F%Y(\0Q MI%-WV*
VARC&/@Q=:Q<;I%S]E VBO*MA@\B%OW8TVUG#[9PN=S1\>0N2]]R-
AK1C@O!L;%'\38H)@=,"8Q:KH7..5-E6**_,.V-/S.Q MM$8C%KI[]?
I.Y#Y6..X3X(5I^F_LO7DXE/_[-SRAD"+[;BI*$=HL(9,*25*I MR#85$1.3;$/#A"S9QO)!
(9,D14RV[9CB;)%QCYF)CN9L5[,F'DN?;Z_[^_^ M?N[G?H[[..[C^>MY',?\,3.N]W6^S_-

UOL[7^9[K>E]5N.(E#N1[$56#!1W! MQ)[!C(_B!@,#4(Y-,,"@
M30S,0HS+#4XL86>#ZFG@ '8D :P4:8L&1KF<>Q M&RG;-].SF9N4* -
G;M/OR_/\%7',EF.LIS(+"<]2*,,P4V-1+T"WT>-CZ&
M'8S'?"^A"K&@=ICM*=;B2E16Z%V1,/I33[;FVH08!_+%DP-9WH0_E5QS%F4'
MFOPV:EOHSZ'-BNR]FUMI)JQO-AP(6T@=UI(!&R=S((,?,-_+\)CQ)1H+L7#Y"'NH
M%0S'3. \?%!'8V,56@F5P +[E><'",MJ"#*@AV.Y$ME\PDPM<-:KBRP%T/; M+"/80LV?
U=K[[*\-F*X/6U^!>DP#-SA=#N3D&-BRA%;_\W5YZ> ^#/T/_'*P)I1MB!ILQDW8D#-
T'MNT? M8CC&16-34I/,DK< '6LNAO%PABZSX8"HT/PCWNWU7FPL@4*$E:1N":0ML@5!
M#,O_O&>>3CJS[(R!Z+!XH]8T^+>7J,V:2'3*;C!;^RP?QL*_><'@4E&T&$P
M8!Q(*IN'R)0%,\# <5V1A@0>=\U/<"#G)[?=\Y$#:<'^3Y_4M;W%_ED&_\:! M<-
W;BGWV9U$]@5'.TG%9>_(_>L/D?_H$[M1CLC8)9B(,'#+X.+NE'M/U$HS+
M,%ON%/,,IKMR.PBS&$;V/][CB\&@_+=?,8YW85/?0<2"8DU0>BN#,/TOO_;\
MXSUI\/3UK!\?_M=S[[ZE_]1(R/?R]O;!AEG&8E=V['])%^D1"P*T$I?NE?= MX;?IK<^<@>
"LFV;S-#,ET;G< 'G$3_IJ:-'K^WB:C'5CUIW8\W1M5)]MM=, M/+>J3\]]4$Z]Q=
@0@7&IH_GI2;^[CB&7""W7V^#NK;'\QXS"8 0F"3;W>"A-N?]'3"9(J#6;*2M[U MQPP^
JK,AR@3FD)JH?U5]1J9TTAQ,F"@PS+Q='7;S!G-W6S],GCJA>*#;^J7 M
O.:WE()$$VR#AK<@:LJ.Z61!+F"^%% M68=-)_-
]5CW'VL#\L4/7>^CBS#9ESCKG;VI658:L*Q#KNZ:[3S$-ICI^FO,Q/>
M.GQ)_T"VR!]N=;_G_6Y7>=IYBN-?(CN,#X2;B /-
%/R@"ZY19:ELOP7X(*C57)]ZOJ79F%2F*FJ,F1]*Y@2%S/7M2MJBMG?VT;4_A ME0,=7W[;
<%4791[A7EN& Z\HA-TH5;:(O663C$(ZA7Q4F?VSJBY*5D.-4<2:
MO)MNJ\BK'1):W]WY75&O M^E[E CQV"#_O]0FMM14/FE-K!@=\&$AJ>3V>"VU(6B5+
,JWZ">)>;:#8\U' M>LE,KC._I89L1T[')8A\3V@_^4S.RI6!-$Z!A^%*"E/'R8.
[F11L8^S3YDS%
M/@5YD_J3J"Y+>OHG9)7WO9CYDFS>WX(K80YEI%XQU2A^Y]$$P,N&S 4#,Y.'
MA00\D52S%^_H^E9I*3GOAP91F;,_.G_/?)+OIU[Z>=CG86-6TH%BT!$HL?
#AQNC;JY1:=1KP0@0YP84V$^T[U$TLE1X(G]50:UMV/D@-_P M\/$SR];^#Z,S%EH\,0]P
Q?@#,96K+XFV.$*$O)0*M +>/P_TF.F3L#D^,BY^-A3 :28<_U^='4%_;-K,E?
[!./"V9WZP=R^>1 M$%UDIBL["W_Y/:"_AF_&A$%Y6?[TZ#5M #%N2PA.)1D(1=,6HR93:#
< 'S^J M*UK822E^9GEPF@-1J;KJA/KA+TZ)//%(+M1N,80#<=RZW\OF3Z>KU;A0A&(=
M)!D61*PL\,->V!&PA$9[!QY63:_DNI"/"FSPXF&_FS*XU$D<5_:\/8;H9%%
M*;0C'4LD[QVUR^7 M-!7&%,9QJQ[]>C=@'X*.H%G-+S.0=O3%>2(-_@*V$]Z0*?
9L,T'/$#1:0-M MK-0/=*28V]BN/X -A#]>B_5QF5A(]?)7>QG'J[@JN[8+
<*5J#%:S^0W'03Z^ M,PCT-BLZTEL#1R@D%S@!HU+ZWMX]D/3'D@0A9 M,T@+]N,X
;0N$%HX$\!^0<&U@&BV0!*=>0D(9.J0;5!^M_KTKS/-C/9.AE&
(>:YKJ3*WLEN4GJ97NKQ2 MO'@]OD*IO;W]V>?F()\@D 8BFC"RZ"?
=B]Y@)1LB!2LQH/4P:93?S5ZP?0L_M!5PP_K%ZAW[_!VO&S-
3WFZJG_F]TH]D!V'&'X37_K:3W0#D-_QP6[XJLXP.P MG8#?
^[DZ2493IB+=KL@@71V7@RV.+CGFQ"]F%13ZZ^11A.MTY^H.B;XEVR,Z[1?K^H+OO-
H] M'+=KW_.]Z]HL$4)0$1/-'@WH2&5%]I),>[VGM;:ZRFVF^V<"#&>JGQH+5;P1
MJIS^UX]6 (XM\&D/KI@4L>])!Q7U&+8P1JW# O<8$<0A"Z+%WB$[AZM)#>]M
MS\\>R[TK=:A8./XY-(TJ'. ^Y+-ICC4T'2_@_;E$HJ!/"M"G1R[="U& KEZWZ M:+!?
1F&3PYFY["%TORC;Q#K3?F/[]]/FZXQ6XLZ_ NMHQT["NCU@,^5,Z$HC MG/D+X_]$*,Y
2@E;/N+$A:&UT#Z#*L3KQR24"6:63U%_#_P4RA>#87%/%QB
M\HPE^A>6YA>>D^1&OFK[& XP*N:J;K&G/HEP(&1%YK<4H;@Z2837$4+%@*0_M[&
[%3+&TKC]FM)LZNHC9S_QVAM)1KBL@V\$S+:W&N69,&DA["W-"]D,[-@? M*?
1Y))"F5$3[C0F0WA6 ?K/RX+ H8ZKQFYNR]KK!=6P'+]-@ZO?&]6\9_O[, M)&-/4J)N". ^]?
P]H\?> V!:ZGT6 ML.*+XT4%D9(\Q' 'KLP-;4]HK^J@>?$U);MQU:
[#:!\>JWM&>L02)NCIG;ED
M.M@"/_G&P!%CT>YA\^S'?]5;S5O2,)G]0.=W3(&Q]$PPKLHP#VQ8"?JJ:[LJ
MV=T52[=%SR#GF1GS^_PW6E-QJVA:(8HY8N5HI/JO07/^'K0#'#3:MUMVD/7S
MY7#"VE$V@/NJJ'>"71*ST@KS2PNN.XNZ9XVBP",5:YIG:#+/)#2FF&$">.J8#VOG)1WJF,X
M&T@LZ7V9ZGFEU@,R>.QLFYB"/ [L^B)KZGUBG M0&706L@]4'=
[P%ZY8I(\K@%N@@KA^+ *;AC 5@7R>C;K70^PN6
MRH$H:,O[$:'KL%K]"VP>"Z/[4@:ZJ+OUQ2!('2'U6R&TK#OI;/]-0XVM)5A-
MY5Q^%)#*&+X$(L''H:0;Y#TS?(*Y]2@5YZ;>9UD#?H>NZV3-(',M+KF&\^O
M*%Z@XO##[G,TDL3>-3KXVB:S4[\WT6QSF26@QB 2CSQ&%IZ%@5COW]'59?L2
MLYB]U5]OH TX?95<($E[X*:UH2O#6]C->W^?V4"&=?50[DF:[7E%VW M*]X"4%;D0

2ZB'(<2.[(8[!_59"4UZHG+W?].\L8(/>(MJ0A(V'C63#(8H&R MO]JCPBS_UV\2=O.M+PYY?+V.\,S(X8=;M4 I5_OQ0)'>><9"_ZN'$C. M'-*

RD\2H,CB:T;=^>%131Q3!GOZTD9$(W;0R^0N5KU-V_$Y 5 Q\G1=<$XC+M

M3GHO+:\K_RLC>;)I5N%#/C%PB]IWPCO69+$U3HG'7%S6J?$NN9"5_9EY41O1 M?

R,7:N+JQX-9_@#JY1;I:*OS]/:3_C7<,SW41J"78N@@R1P&"*;OQ6' M-9"08"/7PEI3?*

VUL@%AG9E[N I.< [E=3RN\JANBXKF=@@'N[%%8QJ'CPFM'

*M&80NK>T4_'3C5*_,9,86N;K9&Q"G)F[Y^/=4T>:QG!%EFL-U'WN#C#^O>!0TXA-?*

O^C=S> M;>3JK('3OEG,-.Q3U\<=Z:H&B4./1^@/<=AY>)(4H:AG+DE@ AZL7I)9\SR:

*MVM8ZD*OHEQ9/ W.ZJ,\E]\PTO[SY/[(+E)]ABY1[$AQ(^8C[$FMD*P2DMQL=*

MN%7,2/@%[-JYV9O2)BWXO>G90L.YR]P;3F#^R=9\I8%LMM@AU55Y=H=BWK_G

M_2]:X6<,-RY=F!1@AJ3SO&+N;#5/@EEH,#]?QHSO]WFP$YQ-->ND=2CX]M[MQ-*

*8N6B%@R<2-96HPIS.C!N:.O*7/LSD08(?K^G:<(X$92J@(8?BWUI?C00V> M,R= G@B*-^-*

T-A%=3L.1 Y]2FJ2'?2 \'*@JG";MW2)W(@@=#?7W3;C]3H MP0ALB$T@!R($*(/U1Z"::'P-*

YX'SU.&>UU8H$?H=T/!W;MT%SQ+"SPQLX4H! M!Q*("]Z/V9C:&H[$++[5S7P)

M97,)&=^X#\>UX MT+VE7#H"&R16E7"IZC2._: EX+'2>/X(M20JK:U'E:JC4Z([M\N/*

*MGOY?Z3I+R^S"BSISG?]1?OY5SP@4;Y37PEOR0N]&RW5!@V8#[8V.7:=*H'/"*

MX0%W7;)VO0%CODJ!ET@32M7UBX1PN'DFKO+7BV6L!FSVJ\Y(F.Q\>.#M= /

M=OX.U]/!4G%F\%?;WV"_ZDG:+_B.>^ ?Q.X"]%(J?C_O.EY()ZX/6!-7S28

M\X2#>U:FSNXX" 4Q?(CB 3_Z.X=STO]'W MAV7P+'7"WJV/64QO]OVZ1K".D[Y'&52?6'\?

*@ZE_,6SW$ M /2*Z=O.V_!,6=J6(=7J ;/_A4#[/PA4!A%((.J#_&OWV)<#:8UMM>_&KY_U*

M.,B!U&'7;?G!K[\19;G!PN,ZPP[VY$#,"0,XTKM M=:F61?#<^D$TL%:@(MB;L-

%',+:D7WC-!':A=]%YB'? 0_=W,J9RCH>P_I6] M-)7_SW15I.'#VB6VT9_Z-

*_H/)+'!L/E2P8+!I9CW6409E$=MGA,",]\BA&GS MVE!4FQ*J\WO@]#OHL[-\RGG_3*

*\!!JVQXZ&+3%AKBN*RUYI QL+2VVV\KA^.*

*MH>&_FURKOT*0T==9%]@'(OXRB'C+K6558LP\F^5QJC?F_X:9H=@@<0G5)Z * M.?*

1VF8AQ&=GJ.G08S"@P"Z PK/M(2@\ M%:Y'=X)&=HTN.?V=^4<%=>F\-

W:\8I\&//1P2F2+26G]3X'AXZPQ)T]'O1/K M$X:9&4G=(KIY_TF"!\")#S>R'?Z0_1&EK@'U

'\O4Y#K1T/ JKV#._(24SC M ITTM ?N@0OX\@?R:%.2L\%#Q80/BM>]/,_"](9*;8NZO[-*

D?)U'O>]VY" M.^8*9@J74_':A,FK=]RP#,S(%U68[OQ=& M*\4GNN?*

7\EE[Q&7E[[4=2$F)DK5+)9\F!VF"(D;+UW1_W[B9,F1,RUPC&.04 $4PG[[42OL*

M;E+=P:TT) ?R,/L=^@A]M;E\T/+J2=3C\'X!W=KO/5VRIJ7[^J.5WA#CJT-" M%6'6'_#?-

;C8@SCQ.EFT"@"E1]<;-*

*MEBCB2WGJ%R6Y[W*7YU%7P7WNM\D.S>#4AK+7@K<^UNUWK1.DNY<_#Q)$X8GD*

MO2L8&2"SM3GMV.:GV+S9D_8F$DE?SE"/VV:5_-6FLZRT1=UIE^_$O5"E2@.+

M.>LIPTJ9B]'>,F]M26H-78<_']O: ,G:?V<<9;=W1NNJ\67[?N0?\HK:E

M6@^/#4BWEQ9,QNP?,ESF0/8&D:'2&$0'IA$LXGLUH3PL_6&=H.L4)2H:<'# M)*

(37D,,WOV,6KE)FD>+4N^E^15^Y']^PW;UC$W)UI];1VP^)V:K9>\(MXXW0 M>^FR:[^ -

*AI!-*AK"!N;2Y<;$]_*J9',6?4Q#?:F%KL7J@H..*

*1\[[B 'W [41>5!! .!_;FC4?\$*OV+05&V/7O MA:<'L/+@'7MWKI_^"O'[$WPV?';_(*4_L'_*

+17Q/\ MA?XM\1_M$>#CJ_PCUR3Q!H36NK/#$;EX&@;SD\H[TV,?E!'/?M0!YIXXL=?_M

&5O^#@V#2?@1\&?"_BB+3/V<[>R@\-VVM6WA2QTBS;Q%-(TD)\B1/\ 68'E

*MJBY\PMG@Y^7M,\3^+/B9\2?B7X!\86^H_#72OCE^UI:^'/B%8Z+KY:6VM#I**

M7'V%-1C$8V2RHJLP52X^5>2:^Z+;_@I%^P=#^VI$#X[N/!R>!F']

MKN;$:I:U,1'J"HBI+:R1HDML5" AD?<#G#8)% &K^V[^S%X&_X)M?M(?LI M^.?@7HS>

/$OBSXJ:7\.]'. ^5G M."/A";QG*/A-\ ?VM[WQ]^RV_Q!O/$GQS\8^'-(^*7PC^-

*FD_$C4/VE;7XD>._#,- MQ:>'=9\<>,;O6YO#5M, '@LU=!'&"H(\PJTV&8&1@<5<*_M7_*

!.;PO\ / MBY\,G^.G@C6/!_QL\0:KXG\26>IZJ;G=>ZB4:9H280(U1HT>/@E'0-G(S0!F M2?

#/6?AK_P %$O\ @FCX6\=:Y:>,-=TCX:>,+#5]5+K-!J$BZ):K(X?D2(02 M-

QR&7GO7F/[,_P"Q9/^"HO_!4]?&WPZ^#WPZ\$?LR?LT:PUOI6J^'_Q: M:;_PLCQ#$Z;V,**

[;BRMY(T91]UAMZ^:P7O;WXV_\$[]5\.?"^PN_P!I^*YE

M^$/A+6O!7AZ^;Q4ZWL.G:K:&SN-\RP M+'!M6%QM*;%)W$9KG?V??'W[!W[+

M/AOP]H/@/]NWXD>'O"_AF<3V6@VWQ \O3!^]\YHVB6T&Y'/#W[&/PC_:9_X+M?

*M&^&/B!\.?!GB[0-)^&7A.#3;/4M*BG33% M82Q?Z*<;H&"*JAHBI7:N","N#T+XD_L'^*

];\4W7@W]NGXB> K3QAK][XFU# M2_#OQ!-E8"^O)3+/)''}D;;DD #)X4#U-:?Q3^-

_[!WQ+^.&K?$BT_;5\7># M/&/B#0K'P_J]

[X8\=/IIU6WLXRD1F(MF8O@EBP(RS,0!F@#WK_@W_GUC1_V5 M_B9X-U'4=;U?1?

AE\7_%?@[PQ+JTC3W1TFTNU$*&=_FE".\J[LX&"@P$P/A? M]NS]GS6O#?QW_:,\>:Q\)

[/]I;X>(->DU^]^(O@_P 56\?C[X/+:00RW%G: M^>6^RM;L XBC0;XE_>'! 3[>_9C_ ."HW[*
['?P7TGX?#SXX_#S1/"VC^8 MUO;/JUQE>?&#XJ_\ !-?XQ_$7Q#K\W[0U MGX;M?'*
*6C?'3Q9 M)_P6S\%^-?@QX0;XW?\ "3?LJZ/=PR:[XF@\/W5SI\VL&5+Z69H'1Y6Q'NC6 M-
*Q#(-K;B17Z#?'3]OC_@G]\?OC9\+/B%J?Q_\#Z9XJ^$.
*MIS:IH5UI5^ML6:,,1RQ3Y@8R0LHQL^7J2"#@C \)_M8?\$Z/"_[/WQ9^&4OQ
*MT\#:SX1^-?B+5O$_B>TU35#=;KS42K3- ?) B"/&CQ\$QNH8$D T >$_$#]G MOQ+#_P
%(?V;/!/BGX5> ?VKO%/AW]F6+4M/\2ZI9V^GW,T>IHC7\UN;%9>(
*MUN/,MH(8WDDC2/)V9 4*2<"OSEU#QS_P3[.J^ -4T?\ ;/\ %WA77_AOX/'@
M32M:T3QN;349=(6X:X6WGD^RGS &@' ^6*,')7) ^@OV;_\ @K+^Q]^S?X%N M-#'[8 \?
*_:+UKW^T?&?B5M4OXMR(OE)((Q-F0N.KN<\T ?%G[>_P"SEKVE M?M'?
*M$>.=0^$UA^T[\&O$V1#5]1\:^&/%-NGC[X-_9+6*2>ULA.6^S/ P61(MXT!>)
*)#@@)ZY_P6<^#7P;^.G_!(OP!\9-+\,Z%XOUWQ+=^"([3QKKFBVLGB M34M.FO+5
*MSO>)9?VB+7PP?&SE M_&>D^&/&^H:/I7C@EE).I6\7RR,=N"T?ENZDJS,O%>A?M'_MY?
*\!/?]IK]F MO3?A-JWQV\!:+X*T:YTVZL+'0M0_L];/[!*DMM%&!RIIC4;0O08R.M 'G'
*M_!6[]F7X8_O]N#]B'POX5_9[\->,/"-WK?C6[N?AUX=T+2K:VUV9M(M@TGV
*M>X:&T9T\N.4F1@2(!@E@HKSG]ERX\/?%[X%_\%"OB/\ #+P9;_!7X4W/PXO_M
*M)\,BMO:7VG:W9Z9>B[O;K3X"4L'*MY:H/]=AG/*G'U!\8/^"D_P"P=\.U+ZA;"VG\^,Q'S!Y8&
*C:<]>E8?@ MG]N3_@GU\.?VK?'WQ>T7X_>"=/U_XHZ7%I?
*BK38M2VZ/K0CR%N);;R>;C:2I MDW98.^1\QH \P_:KM(I?^#O^";O[07CW7O$5_\M
*:7XH6\.$F!"J&=0DCA0K.RY4@'J7[??[)'P@\4_P#!
*M$[QOJ#1Z!\:O^%;?"76T\&>./$45EKNJ1QQ6$IBN(KY8\>8#''F2/:Q:)2Q+ M#-?-/[2/[-?
*P\^"?_!%#]D[7?!_@;PCX5UGQGXF^%E[X@O\ 2-)@LKG6YL1O
*MYMS)&H:9]TTK;G).9&/._V,;#X!>)OC9\/?$G MPUL-!L?
#JV5]J\YG>VLTC6W8S1JC"9##&PD3:VY0>'_P#!3B-6_P""RO[(MC,JX?
*P9\2D4D=QH\6<>^#^M?F-\%!X(UW_@EQ^SI\-=(_9UC^&_QN^+-U;V?
*M@OX[:A9Z3IE@M]!J33O.-2BE-UYWDHT*03*C3D[0"N#7WS\#OVA/^">GP7^(MQ\8W?
*[4MQ\0O&%OH]SX?TW6_&OC>[UFZT33YXTCEM[1'010[E09D"&0Y(+D$ MBH?$?
*QI_X)L^*O\ @G[H'[-E]\>/"EQX*F*71[IM;8ZQI<\5P]PEQ!=>3^ M[F#22+O50=DC+T-
&%^U!\)KKXD_\%_&MFW]/O@+]I.YLO@SHCR:=XLU"RT M^#3F^WS;J,W5M.N]C\I"J"
*QY[']*_V+OAK:?"OX :/IMK*_"OP5EE,MS= M^$/#LUO/I^F3-(V2DMO%%'(74*Y8(.6(.2,G\
*[?BY^T)^PC\5OCX/B=;_MH^ M)O!?C:7PW:>%;S4O"_C3^SI-2LK9F>/S_P#16W.78LQ&
*6Y '2O<_P!G7_@K M_P#L>?L^?#>+PX_[6MEXX,,\D_\:GBSQ^IZD^\YV--Y*91>BC;P*
/O:BO MD3_A_=^QQ_T<-\.__ Q__B/^']W['' $<-\.__ ,?_P"(H^NZ*^1/^']
*MW['' 1PWP[_\#'_^(H_X?W?L(4NKZ_MCO^(*O]F?_**%\;O_9Z;_\(-'_!!5 M_LS_
*/10OC=_X,]-_P#D&OV&KY1US_@H6?!'_!4#_A0>O: EKX;U/PYIFH:3
MXG1G91J]Y)J'EV%P/NQ^;#83M$_+Q^7RTD8H^)_P#B"K_9G_Z%\;O_!GI
*MO_R#1_Q!5_LS_P#10OC=_P"#/3?_
*)!K[F_9F_X*2:!X_P#VVI^S01JTTS^1:"5PJG;ENPKU+Q3^T?H6M M_LL:Q\3_;J6F^)-
*&MO#MYK^G7$$M/\7ZQ!##/<0>'[*ZCRMU=R(A6 MVM3(LB++,54F-LG@X
*/SW_X@J_V9_P#HH7QN_P#!GIO_,@T?\05?[,__10O MC=_X,]-_^0:_15?^"B_PCN-=O-
*&3Q'=OKMGXKA\%/I2Z/>F_?4YHO.A2. 1; MY(7A!F%R@,'E*S^9M4D7>E^'=3%G8
*MZ9:ZK3DQOY,,%Q;212RNP4&,R?+&0: /AG_(@J_P!F?_HH7QN_\&>F
*M_P#R#1_Q!5_LS_\10OC=_X,]-_^0:_1J#_@HA\(I?AYXZ\4OXH>WT?X;Z2N
*MOZ\]QIMU%-;Z8\+317\<+1B2>UEC1S'-"KI)L<*2RD";XV?\%_A+^SKK;:= MXQ\5'2+Q-
*(L==:/^SKJUT6#Q+=VFIW&N?\(Q-#J&CWMC_&=JQ4M'I]TTT2K;7,JJ3%'*5,H*;-V] M-
*WN$$ZW,0=>A_2@#\?/^(*O]F?\ Z*%\;O\ P9Z;_P#(-'_$%7^S/_T4+XW? M^#/3?
_D&OV&HH_'G_B"K_9G_P"BA?&[_P &>F__"#1_P 05?[,_P#T4+XW M?^#/3?\ Y!K]AJ
*/QY_X@J_V9_^BA?&[_P9Z;_\@T?\05?[,_\ T4+XW?\ M@STW_P"0:_8:B@#\>?\ B"K_
*&9_^BA?&[_P9Z;_/(-'_$%7^S/_P!%"^-W M_@STW_Y!K]&_VOOVE]1_9B\0?
#"_FTRQN/!'BKQ5#X7\2:K-\3>'?M<;I8W
*M>1E3&UX(+=MPP/M2,64*V<3Q5^VYI_@7]I7QGH.K7GAK1?AY*O"EOK?C7Q)
*MJ%Y(CZ7>WDS"TL@-HC&+>)YG)9F FMQM&\,P!^?_/Q!5_LS_P#10OC=_P"# M/3?_
*)!H_P"(*O\ 9G_Z*%\;O_!GIO\ \@U]Q?M"?\%1?!/PI\$V6L:)INN^ M+;[_(3K0O VJ:-
%I]W::II+:K<11Q736SP^:R-%)(L)MG.$1]QP-KPO_P4
*M:^&D!T6SU#Q3_:6L^*-5\0:9HMGI7AS4VGOY='N_L]Y:K#LDD\^!V2-LX61L ME!MZ
*'P'_P 05?[,_P#T4+XW?^#/3?\ Y!H_X@J_V9_^BA?&[_P9Z;_\@U^C M%Q_P48^#L?
*PJT;QK;^,(=1\.:Y9WNHV]Q8V=Q%/C+\>)KWPGK^K?"WP[+X5\4WD,-
UHVEZZ)/$/A.VD1&CO M+F279:700[A-# 0T89?+:XP<];YM+O4--DN4M)VL

*M/M]@C27>GBZ">2UY%&KN;<.92J.0IVG !^<'_$%7^S/_-%"^-W_(,]-_|MD&C_(@J_P!F?_HH7QN_|&>F_P#R#7WMIO|P5G^!.KZ-#J%OXLU-K6Y\/1> M+H2?#>IJ|VAN ?[55#;AFLDSB2<#9&>&(XKI?BY_P4-^$?P0|3'2O$'BAX[B M/PW'XQGEL]-NK^UM=$>=H!J4L|$;Q):AU.Z5F"JN';"?-0!^F__"#7Z2^&OV^/A-XG|,^+M93Q M=:Z?IG@6PCUC6I]3@ET];33I8FEAU "=4+V:3>0W5LVHRQ16$OV=HA,T%P|T8CF5#&W MS?-|C[0#|Z_^(*O]F?|Z*%|;O|P9Z;_P#(-'_$%7^S/_T4+XW?^#/3?_D&MOU!^$_[3W@CX_:SXDT7PWJTT^L^$IH(=:TV[L;BQO=-|]&>W>2&=$<),BEXW MQM=02"<''RW;?|%-?&?CCX@^,]'|%:3|+=5|3>"/$-SH$GPMU3Q6NF^.-;CM MYY4:Y@|XI;Q>;"J7,$95U>(@--&6^4^8O|B"K_&9_^BA?&[_P9Z;_/(-M'_$%7^S/_P!%"^-W_@STW_Y!K[8T#_@J%X3|(_&SXW>'?B'/;^%-(^%7BC3M M"BU1+2[GMT@O-,L+I+B^F6-H;8&YO# K,RKPO/.3ZTG[:WPRD^)DOA0>*;3^MTH-:'AF2@7-S87>KWFD7EIIWVNWOOL$UI'<2Q+'+<+;Q$SJNM1^&3I<=CHK?06=W+I]Y$T;PW&GW41Q+;3Q. |4R'AD@#|>?^(* MO]F?_HH7QN_|&>F__(-'_$%7^S/_-%"^-W_(,]-_|D&OV&HH_'G_(@J M_P!F?_HH7QN_|&>F_P#R#1_Q!5_LS_|10OC=_X,]-_^0:_8:B@#|>?^(*O] MF?|Z*%|;O|P9Z;_P#(-'_$%7^S/_T4+XW?^#/3?_D&OV&HH_'G_B"K_9G M_P"BA?&[_P &>F__"#1_P 05?[,_P#T4+XW?^#/3?|Y!K]AJ* /QY_X@J_MV9_^BA?&[_P9Z;_|@T?|05?[,_|T4+XW?|@STW_P"0:_8:B@#|>?|B"K_M &9_^BA?&[_P9Z;_/(-'_$%7^S/_P!%"^-W_@STW_Y!K]AJ* /QY_X@J_V9 M_P#HH7QN_P#!GIO_,@T?|05?[,__10OC=_X,]-_^0:_8:B@#|>?^(*O]F?_M **%|;O_9Z;_|(-'_!!5_LS_/10OC=_X,]-_P#D&OV&HH_'G_B"K_9 MG_Z*%|;O_!GIO_R#1_Q!5_LS_P#10OC=_P"#/3?_)!K]AJ* /QY_P"(*O|M9G_Z*%|;O_!GIO|\@T?|05?[,__$4+XW?^#/3?_D&OV&HH_'G_B"K_9G_M .BA?&[_,&>F_|R#1_Q!5_LS_]%"^-W_@STW_Y!K]AJ* /QY_X@J_V9_|MHH7QN_|!GIO_P @T?|$%7^S/|]%"^-W_@STW_.0:_8:B@#|>?^(*O]F? M_HH7QN_|&>F__(-'_$%7^S/_-%"^-W_(,]-_|D&OOCXH_MG:E\)OVE/B9 MX0U[1($\/>%/AK'\0=&U6$3,+P)-V]TMCX6M]-MKR]OKTQJS3R(+:U0Q@ M??>XC!P&!H^4/\B"K_&9_^BA?&[_P9Z;_/(-'_$%7^S/_P!%"^-W_@ST MW_Y!KZ(_:S_X+*Q_?P=JA\-^&4|97,7P:@^+&FZZ(KRVT;48YITB2)D,9DA MB=&,H=Y-P)6(C<>?HZS_."A'P?L+?Q,^I^,[?0?^$/L;75-4&LV=QIAALKI MQ%;7B+.BF2VFD/EQR)N5G!4'<"*/SI_X@J_V9_^BA?&[_P9Z;_|@T?|05?[M,_|T4+XW?|@STW_P"0:_2*R_;Z^%=U;6QE|13Z?=W'BNT\$-I]]I=U:W]M MJ]V-UK;S6[QB6(3(0Z2.HC9&#!L'-<3^T?|\%+_A|&/'WA_PYIFG:MXOU M2Z^(]E\-M>M["SN3)H-U=:6VII)M6%O//D>20D9Y$K?,#&RT?"?_$%7^S/_M -%"^-W_(,]-_|D&C_(@J_P!F?_HH7QN_|&>F_P#R#7Z"_MG_+17BWX)M>+?@QX;\(6GAV;5/BMXR;PN;K64GEM].C72K^_|."1.C.Q^Q!.;P/GSVKF_M!G[>A|"?%7XE^!OB|?#>B:C|-;?0[N36M'>=K+65UJXNX+"VAMY TRWC26WE MF%6EWM+'L8D[0?#W_$%7^S/_P!%"^-W_@STW_Y!H_X@J_V9_P#HH7QN_P#! MGIO_,@U^C>M_P#!0OX3>'/#>D:A=>([G?K7B4>#+?3X=)O)M236S;27(TV6MT2(S0W)AC9@DB+D;?[RYR_V@/VP&^$]_|%O$,.FQS?#CXEZW#H.L:K?13V5S MX?-[;,^FSR1NH9%DNEBMG255*O=1Y*;2& /SX_X@J_V9_P#HH7QN_P#!GIO_M ,@T?|05?[,__10OC=_X,]-_^0:^^?$?[<>D> OVD?'FE:S>^&=#^''PH|-6 M-]XN|1WMU*);/5=0G86E@HVB/(MXUD< L^;JW 5=P+Y_QU_X*&Z1X7T?PI<>M"X[+6=3U/XE>&_7B#2M52?3]1T!=4N(T,DUM(JRQRB&021JZA7!R"10!\+? M\05?[,__$4+XW?^#/3?_D&C_B"K_9G_.BA?&[_,&>F_|R#7Z6^!_VXOA MC\1]#^%NI:-XD-Y9?&B2>/P=)]AN4_MF_|R#7[#44 M?CS_,05?[,__10OC=_X,]-_^0:/^(*O]F?_**%|;O_9Z;_|(-?L-10! M^//_!!5_LS_/10OC=_X,]-_P#D&C_B"K_9G_Z*%|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|@F1XT^+%O\7[M"36O#VEV?Q&^6C?"JUN]\L[V>HVSZF9IWC"#,&+R(J0VYB&RJ\$\Q^T)_P3 MO^-W]3WQ"UE\K SMN9%;;RP_1:B@#X8^)?\P3M\>^+-?^)%U;WOAPP>+?C]X3^*%F)+N7*:5I4>*

MBK<1N/+^6X)T^;8@RI!CRXR0/N&S!VOD$9K^%+'X]?
*$/QAIWC_7=7L!=7NAMJ>FWMG/I]J! M)MN&LX[?3[6!ER& \S:1D8^Z**
*/@S]H;]@/XH_M$_&74?BM='P7I_B2WO\ MP/\ V7XX2:\:+F>X>9Q&RQ;(T"JRELM5_]F3_
*()Z^/OA M'^T-\,/%FKW/AH:?X1U_XFZOJ$-M>22RF+Q)JT-Y8)'F-0Q2-&$N2-K8V[P<
*MU]R44 ?EKX4_9Q\2_P#!/'78M3U2\T6^\3:[X)\6>'[JUNEOETNY2]\3ZCJ^
*MGFSO4MV62]"WSI+8[/.F+1F'<(W+?2_[//['=SX]_P""-?@CX$^/H[0KS4_
*MA/8^#=;C@VFXT^5M,2WF52#@LC9XSSMP<5]9T4 ?+?@GPE^TMJ^C?#[PUXBU
*M/P!X5M/#%Y;2^)_%/AZ22YF\5VMN?DM;6QFAQ8BX 3SG:5S&-ZQ;MP9?'?$/
*M_!,/X@ZQ^RWIWP(36/!Y\ ^'/&]YXPT_6O,N!JMS;MJ-WJ=G8O$5,:3"ZF19 M9\E&AW!
*(U<[A^@U% 'P#X5_X)H_$?1?"?AJSDO\ PPL^C_LMS?!B4K?3$?VV
*MRVP693Y63:_N6_>1R:]H&D1>(?A/X M-\):7=;I;@P:SH6JW6I;IX@JEK-Y'MU.UP[*90
*APU-_:?\ ^">7Q1_:K^)6
MJ>/]7NO!&C:\;;PCHNG:397EQ+;I9Z7XJMM;U"YFG:++22K;@01J@V!RKDD[ME^^Z/
O@I^SEX@^'G[<'QV^)-_-IS^'_B;;>&8=)AAE9KJ(Z=:W44XF0J% M4%IE;6;(SG'0^'_
*+2__!/3QU^TKX8\>^$_&WAGX1_$9O$,U[+X,^(&K1G3
M_$7@R*2226UCD$%OYDCV;2X@E@FC)"KY@W;I'^[: /S^_M:A\#'Q-HVO:[\8=1T&YT?
*5KZYEB:\^PZ1HUC<7%[A&\J::73IY"$\P?.O/) MI?
*%G_@G;\:/B#\7EUJ74_#NI6>D_&72OB%9PMXGO=/T_^R+741,O"?Q M!O?
*$GAGP#>ZEXX\3Z5JDFF7?B#6[_49=,T^WE@AA_MYYQ/!?GSG,=Q;QHL22
*M/"0ZL7'WS10!X=^P+\!/&O[.GPAU30O&_C/6/&-U=:Y:# M<>%[6STG5?[-
\8IK%A]I;5/#,\UM=7EG"?X9))]/LA@X!4N<_ W(_$7_@G' MXE\6?M9?
*%_QC;3^$/^$1\7^#=2C\-6+67E7^G^)M4L+?3K^[EF)$36NG68W
M+EB9I@5&P%_M:B@#\R_C[_P2<^*OC?X:/X&*G.!ZW^V5_P3O\
*&O[1W[5NL>/M%UGPSI4- MOX>\'KH)U SSAM7T+Q)*X_$O@O5].\-
*K>7#6K6'AZ:_N#;RWOE?\?-Q+J$V)5A M\M%2-
*2I(9FIZM_P3]^+>N_%S7OB!>1>!AJ<_QST7XHVFCVNKS^7/86GAQ-'D
*MMFN'MQLN!)F3[A1@F 5W#'Z 44 ?./[;_P"R#<_M=^.O@69[?2;SP[X | M(]?
*M;Z>2)KFT_L?4;-!%L&6D$]U"V"RC:K')Q@XW[5'["ES)\#(O#/P.MO#W M@:^N?
*$MEKVM21.UEJ&JV*E)DMM1\N62TO&01)'=;7:-%*C:&#+]3T4 ?GE\ M,?\
*@FQ\4/#WQJM]?OY?#<6GP?'JT^*6YO$M]JUR^EKX5DT>2W,US&99+A)]
*MAR[%61CAE"*I^M?VP?V>K/\ :K_9D\8^ ;R3[*WB'3RMG>;G'V"^B<3V=VK+
*M\RM#=1PRJ1R&C&.:]8HH ^(](_8>^+$7[$GC&QN=5\&Z?\>OB=XF7Q?XNU.T
*M>>33'G^T0@6MA<3Q236QBL;>"V@N3&[V[HLJ#*KCSK2/^"7'Q2N?C%XB\0W<
*MV@0VFM?$?X>^-HOMWBN_UR_CM-".+N">YN(C(\Y7!0AO+8D@>6*_2&B@#\^_
*MV<_^"=/Q8^&UA^ROX9UZ3P)-X:_9XN]:@OM4T[4+DWNMP7FD7]E#/%;O %B.
*M;N/>C2$@JQ5F& ;/[*O_3$\9_V_\ @-X9UJ?PYK/A+X&S/<0:I=^(=;O[MC49([6XL[%
[33GF6UL)8X)F$LG[Q&+,(XXU;_^^Z "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@
*HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH
*** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH ****
*"BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
*** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M ****
*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@
*HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $: M158
*G:;H[TBS*SE006'4=Q7PU^W'X^\0_LK_+5/CCQ)IMQK%YI_Q5^%$FE:
*M/I4,GF0OXFLKY;>V*AYDV2RQZM$
*D.W>MM*S'*H:\)O$]]YA^SQZYHVEZ.-2TV.\9+DW!MI+O5;%-V?WIM9$9=O4_4A M9E9L
*_Y_P*2*=)P=C!L=?:OQF_;K_:@^)7C+X+:I>Z;XF;PIX:UG]D?3?&
*MK^']+:ZB@L;^>_MU\RVD$X:-T#A!(0S>4I0Y)W#]$_@7^T9XZN/VUO%?P@\; M:?X2F?
*3_9IOC6SU30Q<1+&EU=W5HUE*DQ8R-&]H[B<%-ZR*#$A4Y /HCS% M^;D?
*+U]JB2_AE7*R*>,\'G%?F7^U+X1\=2_&/XTZQ>>$?'7QR\)OK*QZ5XR^ M&/Q
*BMO%GPJ$=O;&33+?26D1/M-M+FX'E[I)TGQ,I&$KTWX0_M]_$/XZ>,_& M5G\+)/
*_C3P+X_^'7AOQAIFOZ^+JUU3Q?)J%K>2>7((5$=N95LV8RB+]T_R^ M1('_
*'8!]U+.C/M#*6],TYG"$9.,U\ Q?\%D[GXI6FH:E\-O!\TUCX>\$:%X MU>QU/3=0NKO7I-
*6T_P#M(GL89H;1EMBI:XF+ RD(([FZ8=Q\+_P!N?XJ?
*MM47>K>*OAMX)T"S\%^$O%EAX3U70O%;2:?XBG9DMWU.X\P2>1:FT6[CVPNLK M3-
*;3KNC9XQ0!]B-<(C8+ $#/-G0J&W#!Z'L:_-[X6_\%1]9TCX#>#KNVTKP M!X4.J:?
*XJUF*U6/4-2FU.73=:O;=;."R@,ES#'+%;O++?2DQQ.VU(Y,L(_1?

MV$_V@+G]IW]O/Q=XO":AIFC>,?@=\/?%-IHLUV9TTM]0EUJ9UX^3S NQ&=0-
*MWEKZ"@#[>WCW/?@9I#(H&<|=*_+?XB>.?#'@[X[?MI^+OB'\)OB5|5?#W@GQ*
M7IL9N?#>H"2XT"T_X1O2I&6+[9#/$J-+).TENAV!G?.Y3C3^""[>7B3]DKX*
M?:I+X\;1_BKK?AWX0>$_$D7B/3M2>>X\2W&MZ]J-GIULUX3Y95: /TT%S&6(#J2O7':D-
U&"!O7+=.>M?E_P#MA_M0_&6_:O\.?"G M59_"$&I>!_B=\.[[2]1T9[[3X-<75H->,|-
[%YLA6W22Q"B-2P?8';[VR/I? MVDOVR?BSXH^'6LZ!9:YH?
A#Q;\./VC/"'P]N]:T:VN5L]>L;RXTNXR]LTPDC M5H]12:+SG$@AD*
=1("@!^CGGINQN&10MS&XR'5AZ@YKXK\._P#!1CQ-I'[7 M"_#KQU9>&O
MQJGBZ3P]HNC:S9:C8G6[(?+O+#6 LFGWMS+M67[OE/$DZ1 MM(9E*MZ^9OVE?*
*&^H_M:CX,?#>R*0^(+;P._C6]UCQ*;F2SB#WC6=E:I#;E M6?*
S98IO,.F9I}9U33+ ^RBDBE2)53^S9#%,R$DE"R8/=$T[5KGX;>(8/%/AZ6YE"?
*8M0A218W_VE^?=M/REDC8C**1E MZW^Q7\-/$OQ>\:?*
$&Y\.P2>+OB/X43P7KNJ0R,DM]I2^9^[4C]I(E 9U^8B M+)*
(C3'SY^WAH,OB7_@JK\#;1/AWHGQ01?AOXPG&B:K<6\-OO6^T("8?:$>,N MH8J. ?
WA.X#.?#_V&;WP<_Q:^+L/@"T^'$EE/J3?".[MM-,FN=1E>SAVK)/>)
TZ06Q$&9[=_,8&04 ?8/Q(_P""6WP>^*'@[2=#U/0]
M7.EZ1X'3X;!;36KF!KS08S&8K2=U;,NQXD=7)#!MQW'.]&-+_&@]*
M2^*/V:X7QAJN@6WA::[:YD,3V%O<3W,48CSL#B6XE)<#<00"<,?%?BS_@H)*
M\;8+Z+2!X1UJ+3/#_B2[TS5]>T3PVE_XAU.Q2QMKFWN(M FF6:-4-R1=LOF,
MAAC\F)ENE,?BG[6?_!0OXAKXD^'7QE^'7Q"T"YB_X4]K>I-96VDW;>']3ND
*M6Z%IDIEM+IH[B*11<.C+)B6!XI(PQ#.2 ?HCXH_8I\!>(OBSKGB^R'B/0=:\ M5!6\1#0?*
$%YIL/B$+%'"C7<,,@5R(X502%DV@C<037DWA#_ ()4>&]'_:$^ M)&J7$-OI_P -*
/$OA/PYX2T7PSHFI7FGQ0V.G0WT5Q9W<416.2VD%S#M&2WR.
M"5#,&\^^+W[:/CO]D'XU?'BUU=?"/CK4_!OA3P;<:1J T5=(FDN=;UW4-.A6
*M]DC9V>SM28)"%P=JS$89SC%_:_U+X[^$?C=\$O"?B'XH^%I+3_A;WAJ*PU'P*
M]8_8=4OXKK2=:-U'J%CYC(ML)K3]Q\Q$@+[@6@#, ?4?Q4_X)]?"GXVW%W/J
M6@RV46L:1;^'=5CT/5+C28-9TFW9S#IMS';NB26X\QUV8!VDIG82IL2?L"?" MI?%
[ZU%X76T:[OK#4K[3X+V>'3-0O+!($L+B>T#^3));K;PB,EMP:#OM+)+#7!I]O;V5DLJ
MQF1GF627S"055R,,V1RWPU_X?\ QD_:!\,?M!:[I$_@GPPOP'\"KK\EF=%D*
*MOH=;U2SNM=M[Q8IC,K)873:/E,J94292')5MP!]4:)_P2S^#WA:TMX=*T?Q% MI6W2;*
[0;B2P\17UM+J>G7=]=7\MI0>%=)\$I+=:C+=L-+TMK@V,!#DC,8NIEW_>(VY)Q7RS
*M=/\ @I!\2_AQ?Z?XHU."U*_#U? >E^)Y-6T_P .3^*-+L[RZ@::?^VS:O*
*M;=,M$PB121PR!U\V5Y,1LE?07[:G[3.L?!OX9^![OPWJ6BV5SXWUJUTO[0+**
*MYUB^DMY(9)7.EV%O&TM]<[4#*I7RTCDLFC:@#TGP/\ /"_PW\6_$#7M)TV*
*M1=0^)VI1:OXA,T[3Q7L\=E!8J0C$JJ>1;Q*57@X)/)->+3_\$L/AOX*^%/B_*
M0/!'A_2[&7Q9X73PB+3Q"UWJVC6VEQWMU>Q6 M1-&Z0+)?7(3RI$:(.H5L1H MM?-
WCO\:_\B!^U%X7^"%Q;ZQJ'@35?#_[3TOP\OY[2Q>T?6[>TL=299;FT ME;,6]0N^W8LH?
*YA]U *O[*7[3_Q'\!WVK^&!X]GU>7Q%\5?B'L4>&KOQ'K]M M#I^NRPPQV]G;*
*[@MB2S"6:9XXX*YM]?OB94W;D;>6#;0 ?H);_L*?#G1_&]IK M8TB[G%GKK>*+?*
*3I[Z:;3(=:=G9]42V+&,7A:1V\S& S%PH"RN'C:XM#)"Z[H9?*4,K9/4H5;Y]^8 MOBS_,%-*
OB+:>,OC!J/A7P=>WFC_8\4KX771?[$GE7Q6R1V&2XB"@["'>V@))4D>6,$9.> M2\4?
L3_#'QQXF\2:YJW@?0[O5_%LMA<:O.RL#?W%@7^Q73 $!;F#>=EPH65< M(
^%4#UJB@#Q/1_^"?OPG\.:-!9Z9X(TO2YH=0N-5&JV,\]OK/VRX 6YN6U!
*M'%V\LRA5E9I29%4*V0,57^)O_!.?X.?%SPYH&D:U\/M#?2_"]D^F:9:V;S:= M%;V;W$-*
RUL1;/&'A,]M;RF-]REX58C<,U[I10!YUXI_9:\">-_%'BW5].\): M-K5]X\T:W\.^(3J$9N8-
6TZW>=X;::%R8V16NKCC;SYA!) %8%S^PC\+;G18
M;0^"]/#6VL6NO0W8N;A=0COK5&BM;C[8)!<9AB=XD'F82)VC "$K7LE% 'C5
MC^P;=.^'WAGPQ;^!M*M=(\%O=OH"P2S1W.C&[D:2Z^SW*N)XUG9F$@5\.K*
M%&!7Y:ET?]AGX6^'M!\4:3IW@30=+TOQGX:@\'ZQ9V(>VM;O1X4N4BLEB1@L
*M4:K>7('EA3^^8YSC'L%% 'D.O_L-?"WQ)%;)=>"='DCM=*M]":(-(D5_I]LI M6VM+M%*
<+>01 MLCN1(JEB0 2:W_B[^S?X/\ CQINCVWBO08=1'AV^34=(GBG
*MDM+K2+E5*K/;7$+I-!)L+(3&ZDH[*^N[?S'O',EXFU)0ODW,A,D\&/*FDP[HS -7N=% '*
MA^D_\$\/A#HGPV\)^%+3P+ID.C>!+:YL?#T9N;AI]'M[DAKFW@N#)YZV\VU5
*MDBW['10C*4 6KD_[!OPGE^'7B[PDO@+1(?"_CR\M+_7=*M_,M[6]GM8[6*W< M(C*
1"..RM55(]JXA7CDY]DHH \@^)?["WPG^,OC?Q!XJ\ Z#K6K7US:WFH/ M-&?*
(U>:V79:R7L (ANVMU \K[0DGED IM/-5/B#_,$_?A+\4/B1<>+-:\$Z M?
=:]>ZCIVL7=S%RM8WDL44JQRW$&Q%65U+A%"9V?+7M5% $5K&Z M%RV!N.?_
**]2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !117&_%*

M7QOXG\%Q6C^'/!E[XS>>5EGBM]2M;%K50 029V4,#S]WD8YH [*BO-_A]\5?
M'/BKQ&MGK?PPU+PG8F)G-_<:W8W:!AC">7#(S\YZXP,-/".L00 M:#\.M1\76TL'FRW-
OK%E9K!)N(\HK.ZLQVX;<..<=: /0:*X3X9?$/QAXSO+ MN/Q!X!O_7' BM#)
<:K9WPNB.:QO%?QC^(>A>(KRUT[X M1ZMK=C#*5@OH_$&G6Z7*X&&$(]9\4^&%O-
>\/7'A M?4&E=383W<-TZ*#A6\R$E#GKC.1WYKSZY^.?Q.BN9$3X'ZY+&K$+(/$VE#>.
MQP9&+KQ9>>.AKF/"/QA^(.O\ MB:SL]4^$FJ^'M/N'*SZC-K^G7"6J[2=QCCD+MR
,*#UH]2HKA_B;X^\6>#X MK!O#W@>_\8OFWGJ*I?#GXI>-_%GB%K37?A
MIJ/A&R$+2"]N-:L;Q6<%0(]D#LPR"3N(P-O/6@#T6BO-/'7Q:\>>'/$,O$7C32KJ;Q'X.O/!M
MS#+LBM[C4;:],Z8!WAH&8 9R,'GB@#JJ*\I\3_&;XBZ+XAO;6P^$&KZQ903L
MEO>IXATV!;I ?E<(\@=01@X89&>:ZKPWXM\1:MX$;4K_ ,+W6D:PJ2,-'EO;
M>:5BI;8OG(QBR^%PT^Z2V 4D$QQ2%VR0%^4<;LG@5>^)/Q M+\:>$M7MX-
!^'6H^+;:6W\V6X@UBRLQ!)N(\HK,ZLQQ@[A\O.,YH]!HKA/A MC\0_%_C.[NX_$'@&_P#!
<<"*89+C5;. ^%T3G(@=BNW)W8!SQS69XV^+OC[
MP]XFN;31_A1JWB/3HMGE:A%KNGVJ7&5!;]W+('7!)'(YQGH: /3J*YCX5^+_M
!!XST.>Y\1>$KOP==QSF..TN+^WO6F3:I$@:!F4 DD8)S\ON*X:Y^.?Q.BN
M9$3X'ZY+&K$+(/$VE#>.QP93BN!?X[_%'83_PHS7 0.!_PE&D_P#D7\?PH]D MHKF?
&OBC7?#GA2>^TKP]XAU&/9Y>FQ7<-L\VYE#?O)2(QM!8\GG;@=:XS0O MC1\2-
4UZQMKSX-ZQI5G<7"1SWDGB/3)4M4)PTA1)2[!1SA1DXXH]9HKB/B?
MX]\5>#4L3X<\%7_C4W#2?:%@U*TL3: 8VY\]E#!LG&WD;>>HS1^'7Q2\;^+/
M$+6FN_#34?"-D(6D%[<:U97BLX*@1[('9AD$G<1@;?>@#T6BO.OB-\3O&_A+
M7X[;0_AMJ7BVS:W65[NWUFQLUCD+$&+9,ZL2 =P&.0!WJY\,?B!XM\9R7@\ M0>!+
[P6+<*8#VMA M\(-7UBR@F9(+U/$.FP+=(#\KA'D#J",'##(SS7=?
#WQ!J_B7PG%>ZUH%QX,X/(- &[17CK_';XH!F ^!FN$#.#_PD^E< M_P#D:N\E\4ZZ/
/]J+XS98RI/F[YV52 0%VYWFWGJ* .[HKSWX;?$[QIXOUN6VU_P"'&H>#
M[6.$R)=7&L65ZLK[@/+V0.S#(+'<>/EQWJGXU^+OC_P_XDN+32/A/JOB/3X@
MGE:A#KNGVJ3Y4%OWM,FU2) T#,H!)(P3GY?<5QFN_&KXD:7K=W;6?PF0K!?BSX\\3>*
(+/6 M?A9JGA?3Y%!@9R>!0!Z917G7Q%^)_C?PGK\=
MMH7PUU+Q99O;K*]W!K5C9K'(6(,6R9U8D [A\O(QWJY\,?B!XM\9RW@\0>! M+[P6(I@-
SJ=I??:L[LX\AVV[<#.[&=W'0T =S17E_C#XP_$#0O$MW::5\)- M7U_3X6407\6O:=;+
<@J"3Y[\0>%KKPA?+. MT:V-Q?07CL@"D2;X69<$DC&<_+
[B@#HZ*\BU3XV_$JPU2X@M_@SK%]!%*Z17 M*^)-,C6=0Q <*TH901@@$9&<'FNPM?
%WB.7XVYF,@ MSMB\\-Y.YL#YMVT9Y- '6T5XX/CK\4'(!^!VN1@D#/\ PD^E<9(!/^M[#)_"
MN\\?>*M>\+>&9;S1O#D_BB_1T5-/AO(;1Y5+ %O,F*H-HYP3DXXH Z>BO*?#
M7QE^(NL>(K&UU#X/ZOHMC<3*EQ?2^(=-F2U0]7*1R%V ZX49K;^)_P 0/%O@
MR6P'ASP+?^-DN!(;AX-4L[$VA&W:&$[+NW9.-O3;SU% '=T5Y[\-OB=XT\7Z
MW+;:_P##C4/!]K'"9$NKC6+*]65]P'EA('9AD%CN/'RX[U%\0OBCXY*>(?L MNB?
#/4O%=EY"2?;8-:L;1?,).Z/9,ZOD#!SC!R,=Z /1Z*XGX8^//%?C..\; MQ!X(O?!CVY7R4N-
2M;XW0())'D,VW! !#8)W#'0UA>*_C'\0M&\17EKIGPAU MC6[""3;!?
1^(-.MUNDP#N\N20.O/&&&>* /4Z*YSX> ^*]=\4>$'OM;\+77AC M4U=U&FS7UO=.P
^5O,B9D^;Z\=Z_/QW^*./^2%ZYT_Z&C2O_CU 'L=%#]+@GT#P?=^,+ MB2?
RI+6WU"VLFBCVDB7=.RJ1D!=H^;G/2L3P+\6?'GB;Q1!9ZS\+-4\+Z?(K MF349]..3X:?
$KQEXPU2YAU_X=W_(.@AB#Q3W&K MV=Z+A]V-@6!V*\9.6P.,4
=_17FWC[XJ^._"_B22TT;X8:GXIL4C1EOH-.?%'C&TNI/$'@R\\&RP.!%#<:C;7S7"XR6!@
M9@ #Q@D'GCC- '9T5Y%JGQM^)5AJEQ!;_!C6+ZWBE=(KD>)-,C6=0Q <*TH9
M01@@$9&<'FO0/"_B#5]5\!Q:CJ&@W&F:PT#R/I,EU#+)&XSMC,J$QDG Y!P, M^U &
[17CA^._Q1P?^+%ZYG'_$-&E?\ QZNV\6^-/$6A^"AJ.F>$[K7-5/EY MTB.^@MY!N(#_
+V1A'\G/?YL<4 =;17E/AKXR_$76/$5C:ZA\']7T6QN)E2X MOI?$.FS):H>KE(Y"[=
<*,UT7Q+\=>*/!UC:R>'_9>^,IH6266Q:! M0,AR9W4,">,#D?2@#M**\U\!?%?
QUXH\2)::W\+]3*V#1N[7\^MV%VBL!\J M;(9&?
+'C.,#O3_B'\4?'/A7Q%]ET3X9:GXJLO)23[9!K=A:+O).8]DSJ^0,'
M.,'(Q0!Z/17$_#'QYXK\9QWC>(/!%[X,>W*^2EQJ5K?&Z!!)(\AFVX((;!.
MX8Z&L+Q7\8_B%HWB*\M=,^$.L:W802;8+Z/Q!IUNMTF =WER2!UYXPPSQ0!Z
MG17/_#7Q/K7BWPP+S7O#5SX3U#S60V$]Y!>.%&,/OA9DY],YXK@+OXX?$VUO
M98H_@KK-S&DC*DP\3:6HD4,0&P9<@$<@'GUYH]?HKDV\7>(D^'*ZL/"]T^N
M_9A*="^VVXF\S_GEY^[R=W^UNV\'GI7%V_QR^)L]Q&DGP2UNWC=U5I#XFTHA M%)
+8$I)P,G'?% 'L%%N>)K*TU/X1:MH.GSR;9[^;Q!ITZ6JX/S&..0NWT49H
M]3HIL1)B7))..IZFG4 %%%% !110>E !17S/^U3^V1XF^!GQ6_L+2;'1KJU^ MPPW1>
[CD+AG9P0-K@8^7T[UYQ_P\K\<_] ?PO_WYG_\CM 'V_17Q!_P\K\< M_P#0'\+_/?F?

*_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ M /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[M1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F? _X[1_P|K|<_ M] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WY MG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM ' MV_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P M|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0 M'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F M?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P| MK|<_] ? PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?P MO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| MCM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17 MQ!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|< M_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ M /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[M1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_ M] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WY MG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM ' MV_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P M|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0 M'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F M?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P| MK|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?P MO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| MCM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17 MQ!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|< M_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ M /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[M1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_ M] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WY MG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM ' MV_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P M|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0 M'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F M?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P| MK|<_] ?PO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?P MO_WYG_| CM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| MCM 'V_17Q!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17 MQ!_P|K|<_P#0'|+_ /?F?_X[1_P|K|<_] ?PO_WYG_| CM 'V_17Q!_P|K|< M_P#0'|+_ M /?F?_X[7;?LY?MO>+?C#|9])|.ZCINA6]C? I,99+:.194*1,XQNE 'P?_P40_Y.-_[A%M_Z%+7AE?I/X_| V;?! M?Q4|1#5=? T"'4K_R5A$SSRQML&2%PK <9/YFL7_AB;X8_P#0HVO_(&7'_QR M@#||J*_0W_AB;X8_]"C;_P#@92OK/_(8F^&/_$*-K_X&7'_QRM3P3^RYX&^'7BFV MUG1/#T&GZC:AQ'.MS,Y3++#]H#P%|&_4FF:+XK|?Z7JNNR>(=5MS>6NB:=8-M;13216ZLIN+MI;VW$:.RQ!?,=BVT1O8TK6/CE|)?"_C8:QIF@_%:XTY[<>#9 M]-G&CZAK#3NJ-#J,3*8+<6[,&:XA9M|*LP@#@*X![_17QO|L5_'?X]?M9?L MI^%]HV4(TZ'"+!!+/L7;ND: M-S^[K%|._MZ_%/QU^S7|6->|"^'O"WQ,O_!?BJ_|->'? $]O>'2]!U>TLM/2> MYU2X.9CLAN5N+3%N)!+-$NT)&S,@!]Q45|5?L^_ME^/_-H_3/@!X+T[6M*T M3QC|0/@]:?%+Q+KLVBB>)MZV,2PVT'FA$,ES&]'O|PG|.6M? FJ>*O$FLZAI[W-O/?:?KEQH|D=JLDRA+(36, M|LK2$R"&X@"M$Y+@ ^^**_.GXV?|%6?B? X@_X)R^ /C'|,?!VDI%XE.F3>(/ M$E_=*VEZ4KZY;Z5/#90?/)=R3.|K1;_+1(,2,Y?;&WT'_!3']N[Q?^SAJ'AK MP[|,;6QOM93Q'X(-!2Q2TN+RV6YAMO.U"UMY':-B%;$)7,D#!&?)0 'V? 17SNO_!2CP!X9AUFV|76?BCP+K>E MZ-8>(8]&UK3RM_J%GJ%TUI8F".-GW3370$ MB5G65U1HU)K,TC_@IEX(@U+X MC:?XBTGQCX.U;X8:CI.BZEIFH6"3W>HZCJ<8:QM-/2VDE-W)+N55$>06;@D! MB #Z;HKR'X9? M4:;|4/%VK^&K#1O$=KXO|*7MI;^(O#]]}GM[W1(+F-G@O7S M+Y<]JX1PLEN|H9DD4 M&X6S^U?JOCG2/">GS^$]>|->#M%M)+B]|4^(]4@:[MGT;3HK:5]]I;XV2S&7RLF4[%C$OREBA !ZK17SS^P[^U3>_'?]CJW^)OBZ]| M.PV)FU9_[7L)&M["_P!-L[N>&+4'CE9FM3+#)7A=B82S*V"#C!T[_@IX>| M7>'K2ZTGPIXVMKSQ;X:G|3^!4U]PCTU?&L,,+2R"V$TJF.6.,"5H;CR9&A82 M(&7)4 ^I**^6OV0OC7|7_P!HW_@FWX=^)EE!HDGQ,^(_A^T|0:38:|L=MHFF M27<$3HG^B,|KV:;VD4.WVAU^5V1N5=^Q'^TOXA^+GQQ^,'@K4/%6@^/M(^%] MU8V,?B.RM/[.O'O9S'_+4'[*6I_%#XE^_B-X*|4IX M.^(7P|:[M[6XNK(7VGZQIMYY1N]-NXMROY4C00.'C=7C>%6&1D&[^S]|%?%G M@'QWXM|8>.O&|_BS7O%9MX8[*TBDL]$|/6MOO$=O9VSR2,&8NS2S.Q>5R.%1*

M54>QXS1CF@#XQF_X)U^-]_9+@^%&A?$/2(M(U'QGKWB/Q.LUAI M7NH? V7YT$ZS6Z;KI(Y7C;=+'&Z QB0X]D^'/P%U3P]^S/J'PYN;7P-H%G_9$ MV@:3;^%M-GM-/TNS:V,,:B"1V/REF/RD CWR:]JQ1@ T ?*GPU_8"U7X(>$_ M@S>>$_%NEV7Q ^%'P]MOAK=:O>:0;BQ\0::D5JK;H?,$D31SVJSQ[9.I9'+* MV5Q]1_X)? 0>'_AQX.\/>&]7\,:G;^&["[M+F/QGX4@UNTEO+Z]-[>ZQ# IC$ M5Y)-) <$H#Y#"50R$1**^PR,T4 ?+?Q,_X)TZ3K__ 3NL_V??">JCPYIU@^E M20:C2*0D*556FR%PNVF_ML?\$MO_[6&@ZQ>V0F M\,^*O$GB/P_X@U? 5(KZ^\O41I=Y9S;'MXKB.,R-;6OD+)C='N5Q\RBOJ;&:* M /#OVX/V5'_:|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end XML 17 R1.htm IDEA: XBRL DOCUMENT***

Document And Entity Information - shares	9 Months Ended Sep. 30, 2024	Nov. 11, 2024
Document Information [Line Items]		
Document Type	10-Q	
Document Quarterly Report	true	
Document Period End Date	Sep. 30, 2024	
Document Transition Report	false	
Entity File Number	001-36291	
Entity Registrant Name	DIAMEDICA THERAPEUTICS INC.	
Entity Incorporation, State or Country Code	A1	
Entity Address, Address Line One	301 Carlson Parkway, Suite 210	
Entity Address, City or Town	Minneapolis	
Entity Address, State or Province	MN	
Entity Address, Postal Zip Code	55305	
City Area Code	763	
Local Phone Number	496-5454	
Title of 12(b) Security	Voting common shares, no par value per share	
Trading Symbol	DMAC	
Security Exchange Name	NASDAQ	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Entity Filer Category	Non-accelerated Filer	
Entity Small Business	true	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Entity Common Stock, Shares Outstanding (in shares)		42,760,582
Entity Central Index Key	0001401040	
Current Fiscal Year End Date	--12-31	
Document Fiscal Year Focus	2024	
Document Fiscal Period Focus	Q3	
Amendment Flag	false	

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||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| M;=/[KX.7S7WH+^3^YFK160VI>)%CW#P7J1.W.T:C:YSMB./O^KNOUA;L5R\W MOB,7&S_A#]0*[]N_[?:XQOE7=C?G&V-'^DZCJK '+YK[T%_)_F8V/0J3*MYXB-R8_\ A$-0""38)/M] MM@CS9$WXW9QM19,=<2J/O!@#E\U]Z"_J69IT5C_VIXE^QM)_PA.I^8(BXB_M M&TW%O*5]F=^,[F,>>FY"?ND&IOM?B'S]G_"(ZAM\WR]_V^VQM\UDWXW9QM D MQUVL!]X$4:S,&C1R5U2R&QF0,R',G522I 4/0E21D8HI\C[K[U_F+F7G]S/_]D! end GRAPHIC 13 image01.jpg begin 644 image01.jpg M_]C_X 02D9)1@ ! 0$ E@"6 #_X0 B17AI9@ 34T *@ @ 0$2 , M ! $ #_X@Q824-#7U!23T9)3$4 0$ Q(3&EN;P(0 !M;G1R M4D="(%A96B 'S@ " D !@ Q !A8W-P35-&5 !)14,@0 9&5S8P 2D!\@'Z @,"# (4 M AT")@(O C@"00)+

*E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL" MJ0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[/Y M! 8$$P0@!"T$.P1(!%4$BP1Q!*X$C 2:!*@$M@3$!-,$X03P!/X%#044%]@8&!A8&)P8W!D@&609J!GL&C := M!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L!F|\'T@?E!_@("P@?"#((M1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4) ^PH1 M"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP"\@+X0OY#!(, M*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-^ X3#BX.20YD M#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/!))$"800Q!A$'X0FQ"Y$-<0 MJ1$3$03QM%#8P1A}>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D M$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#%B86219L%H\6 MLA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 911EK&9$99MQG=M&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>'4<= M:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;'"8(,0@\"$<M(4@A=2&A(B>K)]PH#2@_*'$HHBC4*08I."HE*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>$N M%BY,+H(NMR[N+R0O6B^1+|<-J1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD= M26-)]4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\ 3TE/ MDT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/ M5EQ6J5;W5T17DE?@6"]8?5C+6119:5FX6@=:5EJF6O5;15N56^5<-5R&7-9= M)UUX7&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1 M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I!]]VM/:Z=K M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5&YXS'DJ>8EYYWI&>]5[!'MC>\)|M(7R!?.%)07VA?@%>9N"]Q(!]BT5\Q^!?^"B%A\3K:ZT_P MUX+[.]>T.CZ7KUE>6MR([:.ZE>&^B=HGV0S1]=K&5]F, R5S'Q0_;Q M\3IX;T?4O#FC:Q:Z=-XAUBWUI]2MK>VU+2[73]+>_:)+:0X9V"%3O(9=K \D M&@#[#HKQKX9?M,S_ !*\86EA8^$_$MSH-W+/IP|11^6]M'?6RDSQ31J=T* J MR+*WRO(148!1FQ?BA+|3K7]JKPKH&D_$2VTKP[XIL=1U V;>&X+F2U^Q_85$ M:S,X)$GVB0DD9&!C@4 >_P!%?+NG?M^W-[=W"6/@3Q3KMM97MM8W%Z+RRM2+ MB]U.ZT^S@CC9_F_?0*)')4)$X?YF#(OO'/\ P4A|-_#SPUI$NL6::3K%ZVI? M;M,OM;M+,VD>FW9M+XP3RLJ7+K,,1Q1_/(,'Y!0!].450|*Z]:^0#&G:I8R M2366I6L5U;R21M&[QR(&4E6 9201PO"XJ_0 4444 %%%% !1110 4444 %% M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% 'G_QN_9XT_P"-VI>'J0EUWQ1X:U;PS)/) M87^A7JVTZ":,1RHV]'5E90."O4 BN+|4?\$|/ 7B72+>UCNO%>ER+I]_I5[>M66LRK?:M:W\OG7D5QVFMI+MH!P|KQSR;BQ(W,7 M #DL?5]* ,+Q1\.]-\7^)?#FK7B3&]*WDE]I()(5"226\MLVX?Q QS.,'N0 M>HKSX?L0> QH6]::+?51::Q9&PN5^WR$F(ZC/])P>Q^T7$ASUVD+T KUZB@# MRWQ-^R)X6\0W6H7L%QKFC:QJ.KS:T=5TZ],-J;SS6|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|'^!7|-:I=ZEXWT+, M/D6/B9+:.^M]8EVHD48A5%4#V.,<8KTNB@#SCP;^R9X"_!*|^':>E:!:6?A M*_2Z2XLH4$0E^T.SR'*!2&RWRL,,NU,$;1C(A_8O|-6V@PQ1:QXNBUZ.ZFO) M/$L>J%-;N7F6-)E>X"_<>.&%"H4 "&,]%90P]>HH |^UW]FGPWK/P_A\,0G4M=)TC3H[-=(BT^?R&T%[0@P26K8)1U(7.=P8## J2#BW7[%G@ZX\Z3I*S>{8 M+-L+8V5[:1ZG)Y.OP,[RO'? Y|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| 9Q9ZG=O?:W/S;Z7: /,V>%+GI&I/\ >.>X!KGO MVT_VL3|"]MJ'T15N/%VMQEK>,_;&'D&=E[G(8*IZE3V4@_*>C7""/Q[8#Q M5;RS:Q%J3L=8+.SW,#O_ ,MLGYMP(RP]ACY2< 'I?Q&_X*'_ !#.L^5H^B>' MM'M1";A?M):YED&!\N24!.:1.UC/(H55N()HRI4P[$?,"#CJ*O\ MB+X N?!>@P268WV&FS]4R(YY#Y:_B&;/T% &;|+O^"D=$_9D<_CKPZ--LW;R MQJ&G,95R, EHF^;KG[I-?2O@3Q]I/Q'\/P:OHNIVFJZ9=@F&>W?*G'4'N".X M/([U\=?&_P""B:7:6&C6MH#!HT:VT"0K\U[J!52$&.R*=Q)[G'>N)\)^/=9_ M8H|:^99WKZM<2CS=:TY&)MI4W'/8[&3.=X'?GTH_1<'(XYHK!^'OCO3?B'X M-TS6](E-SI^KPBY@DP5+*W7(/<'@CUK>H @U2=K73+B5/OQQ,R_4 FLKX::U M<>(_AYH.H73B2XOM.MKB5P -SO$K,<#@$O^P+9_|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| M50Z'<7+?VO/:&_2TCADEE>WT' C8|X'O M33J:C;\C\'W/U^E %FB@'< ?6B@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ J'4)XK6QFEFD6*&)"\CLVT(H&22> MP J:O'/^'B7B._| !_['QQU?2[N>PU/2O &NWEI?L[?M/^'/V2_BOI7CCX;^)M3|'^*M&R M+:_T^3RW*-J^.0?=EC?'S(X96'!% 'JTGA_PWIF@V:Q6L**CKL ^]A\.R_9M7,6M0WFH+<;R/+N?*8L)6*X\ MD#<"/ND@D_A]^U%_P=&?M0?M/_LQ:;|-Y]8TKPE.|$MMXA|1>'X39:GXBC8DM!"RG;;KL.'\D*7/=02M?G2;YBS,1DN=S$:GXSYDZ_C0!_6+_P $'_ | @J]\ M,OVV-0\8^!/VH:C:W>A,VI6FE:JJPW)MO-\MIH4W'=&^4D(',9DPV,BOTMK M^3K_(-,/'=UX7_X+..>$;*WLC=0^)O#VLZ;<28)^Q(ML;GS./]NV1.>/WGKB MOZQ: *VM?\@:[_ZXO_Z":P?@I_R1SPE_V!;/_P!$)6]K7_(&N_\ KB__ *": MP?@I_P D<\)?]@6S_P#1"4 ?.'_!7"[ATSX8_#]YGD2"W@\=V$T\C'"HBK*6 M9O8 9/TK'_X*"_M$> OVA?@D/ASX1U_1/$7B;Q=?V\=ELN8UMM.\N19))YYG M(6)1&''7X_LU_!_1O@C\ M$_#_ (5S_$[,223SVI5\/_"MO&W[2?_!(/1W9 M]0U;5_#NJ/]5A%+&SSWMC"9(D$?\38B=B.I.S%?:?[*%QZTG]H+X%>'_ _!'I M+*1-;)#=V^[<]G<(H62)AU!!D#*D'H: .I^)?PVTSXH^]4\/:E#OL-6A|MF4(=K)W5U/.&5@&!QU4=:V[*U%O;H&R[A0&=L;F]R<#DUF?$'Q[I7PN\%:GX MAUR\@T_2=(MVN;J>9PJQHKWSZDG ZDD >10!^;/_;,W^G:!^PK\2XCA:;>VD$EOI_BK4L6AFNK7Y M5CN$BEM[O?.I(9[DE2V]C7FW_!'+_@E=\|/^"@G_ 3_ /C5)XU\$>'-0\3: MY\2/%.D6?BRWM8WU738M\1AD@GP<%"^]>H(SP037KO|P0& _:|\3?!7Q3K_[M#7QT*Z=\5/@H7@|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|9_@+]N3X;'QC\-M3U;7 MO"DDACMM5NM$O--M[TAF5O(-S%&955E(+(" >"<|5^47['GCCQ'^RYX?^/G_ M3ST&^DLO'LGCMM(^'TCS,SV/A/6T>]N[]&W _Z'8K<2Y7;_I%Q$.KG;^RG MPE^%.A__P"&V@>$?#-C%IGA[POIMOI.F6<8PEK;01K'&@^BJ.3UH Z.BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ KP[]O#]GW4OVEOA_P"%_#FGQ_NT M\0"[N;DL,6"K8WBQ7!4LI<)&C M>>)M?BT1;C7]1:PL+,-;W$YDDD5'.?W&P+CEG'- 'S3IG[//Q3@\._$?Q-JW M@B"7Q+|28-'O-:TPWD=X/W>HZD)K;;'-"ETUO8M9]F>.'"[RW"VZ7$D<"+;6EVRP1NPB" M,@ +*IJO|-_M?>(?'Z6GA[P[X;T34/&\DEV)YFU5E\/BVM6A22]AN5C:2>)I M;B*-46/=0$H)'EDMZ+|(_B_=>.;+7++5]-CTWQ+X2NQIVLVM4,9[;SC;QW"/ M!(54O$\4T;C M([CQ)XEBO8MZV!M]1AM+>XA$GV@)%YEK"@FA6,&-7B9UE#-WO|,7_!1VU^,. MEB_\27?@"WTJ?PLOB>:Y\/:W)J'}AJ7@06EX&B0K<.;@!%0$LT,@ SMSW+?M ME_#_ $**2\U<:MH$C+,MW_:6BS6MS;3P0"<6LXVY%P\!\R*/K*@.S/ (!YS\ M'0Y?"+Z:GA71[C3+:[DU_^S#O+17'GK]F2[GGEM" M6 ?9&Q/R.%KD_B+ ^SE\0O' C.VO[(\$ZKH_CZ;5->U3_ (3B?4;:%;.SO=+U M*+3K1RDIF9[9[DB@#"-DB:%I$+!BQ^COB7|>-6T*T\$Z9X497R83.K;AS)NC"C+X IX]\/_P!CU_%'[3^GZT?@ M_=^#?AY#J=A>2:7?W=]\<]MINK1-_[9M=1UV>[L]3CU)[0V>C+XN^TW*O9H;[?++D_:SU_3?VE1X%U;P7;VD-Y!]%Y91VVM0W>KM96@.-0>TC!5;>X(?:OPZMIK;2)/MNE+IFJ2>2VH,A5TN[C[M/$'D5\[I ,"/>X#'RNF,$ ^">$?V!=6UKP]XOUEJ+|':G'X9T.[UJXT#1]>,_MB/1###)*EOJ%F\;,DC-&83Y>[;*"!N7+#K? W[=OA7Q=?:183:-)>W]K;7%=M:3W)0()'%W @ SAI%5MIH]NHKPS]H7]I[7?AE]=M#*Z,OP]LUU#0[K6[B]\5:])ID)6&>'(0Q%8GW,?-+$G&T <'-6/ 7[=WA#Q MMHMU=26/B;2I=+TRRO\ 4XKK2)PMA->16\MO9>8%VRW4@NH0D,6YR6 P"0*M;Z*\]TC]LGP1J.FZAZ*VCZ7=:OJ-MJEC+;7&GPVNTW2RH5RLD*O${) MUV31.-RN#5GXH_'B_P##TWAO1_#.AIJ_BGQ@)7L+6_N#906<,4:O/VNJO>0Q7MEIZ+!;2/M)=37@4VPB7;EQ)NP". R2*<,C 'I]%<%^S#\:W_ &B_@'X4\;O%YH+>)M. MCOS872LLML6SE3D GID' R"#CFN]H **** "BBB@#Q']I> 'Q!H7QK^&?BK2?M"7B/Q;I_AYM5BU"#1_LIN(?M%LB1/MGFB5EW*0=K$CCC'->9:C\&/'_C;XH7 MNL:?H.K^' %NKZDVK6/BV^EMP-(T9[+RUT:3RY'D$B7!W&%>$>$GJZ)"PKW'X M_P#Q@\1_#"V\[0_#]A?6=A9SZKJFHZK?_8;&WMX=F8%D"NQN9-YV!E"81RS# M 4\|X?\ V]/!.O:[#I[V_B?2F^U1Z;=W>IZ-/\V&F7SVJ77V.>X9?+6812+D M E0V5+ @@ 'B^J?SQ/I7P;O[7P]\+=2T^2YGTVV\1V-_?1W\6MRPK,+J_AT MY;E+>Y9Y'B+/<3(;D &6-O)57Y/P_P#LE_$6QTGP=J%UX-OI]-_P#2'$4!L(2%ABDD$9Q%@ 5]/?"/]KW3_C/\:=6\+Z7HMVL6MAIN@VVMPW^HVDUF=02>YN(8WA21!OA80;UD#*]$MO"^HV>MW?A*_P'!2Z@-2BB'CO5)KFU>WO8I$E#G9$EW^\E M\IT%P$487Y?:/@_|'T^#_P 9?&D6G>$X=-|':A?:;H*BG??MZ> =.T2XOY\0M!YUM%8"+1+F6375N;B.V@GL4 M52US"|\L2"2,%1YB$X5E8@'M$8PB\8XZ>E+5#3M;.HZ?!*\; ^-7[7UU|*?&>M11:-8W&@^"(-.NO$MOQ<7I@NFCOY6A@ M^Q)L*2LK(2P=DR2%7+'@]SHKPWQG^W!I/@WXH^+]$?2;RYTCP1X6O\ Q!J. MK1M^Z>XM'@MEN,NZI/&78?*I=5!+!PO2? WXV:YXTUO7?##WB_0[#0/%_@' MSN)X+']-[;//;W:.T#*0HOSAXIXF&;/*2H)P5UR >G45|<>$_ ^"H.H:Q8^([U] M)\%:HNE:1XBU1--T;7WN-1TO^RO-VIJ"-$!#YWEA05W;6;&&'->XZC^V-X.T M^Q/-I6I-K%@\,5R|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|!5Y\:?*!*=<\.VVDQR6>D M,T]O>:5;WMTDY6R!9F>20(P*[,KU\@'\O' Y=_:U)_P"3F? ;_@W#_;+^-]W;O;_!;5_#5G,SI[]\475OI'QLG/S13.@" M,N,U_0-\ /V@_C=K_/P3]|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

M7579F"RHX!)P!DYO?\%-K+]I:_|-@WH?LP77@FT\8#Q!:/JS>(@"&TT-F58 M=P,>20H?<-WEF3RR'VFOHNQ#"TC#A0X'S;?NY[XJ] /B3X_?\$(?AC^T/\1= M!\? WGC7XM>$_BQHUC%IUWX^\):[%HFO>((D38#>M#"(7E*X!D2)&(5020,5X ME_P5B_8I^$'PO_9A^&/P9T_4/%6G?$;XG?%&PF\'>+[_,4W$VM6_B!0%.K7 M>I7!>60VJL2$BW!G9((HS&<,OZFUXM^W!^P!\,?^^AWPB_X05XG.:)}]=A,W2 MZAI]Y.3FUU'1[M>$N;:=/FCD X[]PX8,.*./B[]HI_@GC^TS\"@%XL\,Z-^ MWK\3GU+P-H=UJD"._H.FIITXMHS(5N^)VLjS,VW')SSS7=2\5_1/2+ 1QODF\>V7QAL_#-GK&G2:3K]UI-KH5Q/ GFS6UHA\N+[0BQR."#O+8 M(V@"O6_"'_!)CP3:0067C?QJ\9_C%H-K);S0Z#X]\72ZMI D@R8WEME2..XP M<';<"1-R*VW(S7T];:=`8I&L;JBQJ$4*H4 8 -'%`R-XH_X(Z^"]:\2^ M.[G1O'GQA\&^&_BK<3W?C7PGHOB-{]'\37%PI2[GE$L,D\$EPA(E:VEAW=>=# MS70_M67\$F?A'^UE^RQX.^$6I:7[_A7PU\.9,2Y\(W'AC4&L+_PQ-:QF."6V ME.X%E0D$R*V2=WWI--7T_10!\C_$C_@CU\._CM^3(>XC*^OC+\0_#V7E;[M4FUSQO=RW:MV""(UD0PUP?[37[-/@W]L'X&Z_] M#?X@G+Y>,'<<6I6*W4MJ;E(Y4F0>9$RR+B2-#\K#.,=*10!\X?L.? M1ZW=_.]\'> M/1]]!9>'/#VK&V\30&YV6DEA>*/(M,L?1S;S_9W!/W$,QYZ$ O\ CKX%MJ.H MZ3K'@S4['P9XA\/V3Z5.3KIBW5F+*1HW>Lo>U#@QJ4W1QL11T9608)4LIT_A=\ M(A\,]'U9KZ^EUC7_-!+<&\UG5'00?;[CREA!6-PTE-+ MELD40 33-YLHGD'V6 @$*F58E#D;,.K_ +#MWX[FO9O$WC2^U''YUF[36]2:S MTU+%9-7MA;KI=Y&! (QC6R%NCK$2ZR2X=R0H2JFG_ +3'Q&3X^:#\,)X/ TFM M#4G36M5BM[1+1[/[$MX!;0&5G$V#Y1\R0J-RR'(O$>KZ:8M2U.X:&>XGBCWW2*R62-]GE*S7!DWLC*$4(7H M] [^,GP%U+XS_H#TS9W$V+VJV]0M>7EYH<-WI^HSHHW2RV3,!RV9$"2J8W M P#%5N$|=?\$U_AQX]^&.B>&?(UG3Y/#]AI^DP.A8ZK=66 M.)M\O#F$G:- AERNW:H#OVX[KQ1J/Q!^%6A>&XO$=V-9U34OMUAHWB>3P])>)% M8NZE[E/FVJ^&V#J<>F'Y?X"Z]KWQ^FTWP3X[\8^)-.N/#/A_[53=NCH]BTSX#72?%72];U3Q7?ZSI7A MRXGN?#VG7%LOFZ=-<00#+YMR&+3J(I)$C#]"H?YFD(4C:^&WPGM?AYX>U_38 MK^[N(M>UK4]8DE!$,L#WUP\{(C*<_)YF%8<\ ]:\M\0>/M8O_P!E3PK\1M.\ M9MXLD\#W<&NZAJ>CVKZ;:>}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{ZU_"O[#N@>"/B#X%U MS3;[6!%X'T]I//[%-(CQ:O*&N&M[F=L9+#P&)KORA,WC?+E(RONE% '$?1J?" M:3X%_"K3/"7]HOJMGH*&TL)Y+<0RK:J3Y,$ M[H<.4!9EW2!MNY$88NJ?L=:,XQ\-W^GVNVNEW%/OBX^+:,WRH5A\R1K86\ML! MG*1L-QR"64MU.,U-^T;\1?\ A0'Q5|->.M8UF\L_;VEUHFOQ27#?8[.5@++B MTNO+Z"00"]OO[_:$7W7S'X?J"_QO\,8[C1=6MHO&?B@Z'<*=7O9[JTT.\UR MJU9E@:+<,6UK';Q1+'&59R A<<. #U3X(_LVZA!*_B->:WJ?C&?Q'(N@6GAG M3K3^RXK-+&RMI9(RS*&68B7:[9524!5$R0>CT+X(Q^&/A7XF\+_P!HW,L7 MB>_UB]EN#"NZ ZE<7$[JH'!$;3D#/4*,UX//^TG\2/#?QQOU2I-X3G,>@Z7H MT>F6%S1+<:=;ZO<^(;C3%OY) V4C9-CO;D&2/88O-8KO.I)^UEX\UGQ_J_A<6 M/A(OX+TG7+GQ@?1BZB_M"2R6S,8LE$F80X01N:1W,3Q\!YG# ZSP%^Q+%X(MU'18U\0WMYX67AZ[:"VU"5]-O)-.:[=I-0*'C\|A @*UU6VFL?%C:39:/=O((R8Y#M*PE3PYH ^F/%7PW\+>/[_2+O6]&TO5KOP]QG M!'[V,D?*V5'(]!Z5YS^T!^R'IG[1'C_0=8U.]MKG2M'GAEGTZXTF"YD?R14F M"VUPV)+8.R()<;]ZJ-HC;YSYLOQ)_P"%M>%OB)X\E^)&I>"HO 4Q;195DF73 M=.LS8VJW!=W^G*R-=+.)F)27!V@+*%L;Y]^I_#T[W6DPR.ZR-(H8LJ%%;(!R% M/*@^C$D=S0!X'/\ |$W/A_| |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{)?Q]\>?M3? _P#;$^/A&"3XG> M=)FT#Q!_ %5];6T^H:;*\I:!)DD>W64>=< L)>CQL"=A0@'K7C3]CO4/V%_ M%Z_&^T_:#^-L_P_/.AWHNK:GXP\) ^+?%/\]OV&_|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|UK5Y5\3/C-K]AJ7@K0?#EMI2TLHH(5GE$BQ,&>0J0BA6 SEB2%VMY7\.OVXO&'Q%|":=XDCTCPO86= MF^D:?K=L\DTDK7>IM D,EJ^5!@B:XC+"10T@63:4*C=5T\OK3A[1+3_-M+[V MFA\RZGU-+*L>-W7L.Y14=9 &4@@]"*\9^ G{3%|\=?%[:8-*@<L?|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|+7\OA?Q3K'B>#7[_3/#-YJM]<"U@G MUF\U&VMYY=*8H_V:UBB:X4X#J'\L1[Y(Y"0#Z/U_X#>!_%/CRP\4ZCX8T2[\ M22:5:WU)[93=1E"/+._JQ4C*ELE?X<5V]M#3U M\+ZS'XLU+6K#6KO0Y[D6L^K06!U/6? MBGJNC_$CP]#XCM-:UT_$73]+CGM[U/#XLM-ETS3[J:TLW;S7#XDE4$$R_O'E M7YE"D_^L%U"]B,-P.E?)D&H^(?%/@O1;?PKX!90^*[M-KS2M)T6747OO+U2TOKBWQ4[N3FZTU&5$3>J$j,*#+)&J23'LZ?%?Q;XC^- MUOJOB>\U*#2O^/B'Q!HVC62:HMS:LNF7%S'&IM/*7[*1'-()DD=G9F655)C M(/K:BBB@ HHHH *****"BBB@ HHHH *****"BBB@ HHHH *****"@G HI'. M%/TH Q=;^)?AWPS?_9=3U[1M-NM@?R;]^BADVGH=K,#@X//M53_A=?@W_H;? M#'_@T@_^*K\N?^"5?_!M7K7_5?_;#B^*- C\6M+!$0Q^=DO7+0 M/,QD\Q9T&&\T?+C(V[:`3?\ B!Y\3_| 1Q?A_P#\(Z7_.2Z /WW_P"%U<"#? M^AM\,?\ @T@_^*H X77X-_Z&WPQ_X-(/_BJ_ C_B!Y\3_P#1Q?A__P (Z7_Y M+H_X@>?$_P#T<7X?_P#"_E_^2Z /WW_X77X-_P"A MM\,?^@#2#_P"*H_X77X- Z&WPQ_X-(/\ XJOP(_X@>?$__1Q?A_+ |\(Z7_P"2Z/\ B!Y\3_| 1Q?A_P#\ M(Z7_ .2Z /WW_P"%U^#? ^AM\,?\ @T@_^*H_X75X_ Z&WPQ_X-(/_BJ_ C_B M!Y\3_P#1Q?A__P (Z7_Y+H_X@>?$_P#T<7X?_P#"_E_^2Z /WW_X77X-_P"A MM\,?^@#2#_P"*H_X77X- Z&WPQ_X-(/\ XJOP(_X@>?$__1Q?A_+ |\(Z7_P"2 MZ/\ B!Y\3_| 1Q?A_P#\(Z7_ .2Z /WW_P"%U^#?^AM\,?\ @T@_^*H_X77X M-_Z&WPQ_X-(/_BJ_ C_B!Y\3_P#1Q?A__P (Z7_Y+H_X@>?$_P#T<7X?_P#" M.E_^2Z /WW_X77X-_P"AM\,?^@#2#_P"*I\ A=?@W_H;?#'_(-(/_BJ_?_M (@>?$__ $<7X?\ -_E_P#DNC_B!Y\3_P#1Q?A__P (Z7_Y+H _?^\ X77X M-_Z&WPQ_X-(/_BJ#:O!A YFWPQ_X-(/_BJ_ C_B!Y\3_P#1Q?A__P (Z7_Y M+H_X@>?$_P#T<7X?_P#"_E_^2Z /WW_X77X-_P"AM\,?^@#2#_P"*H_X75X, _MZ&WPQ_X-(/\ XJOP(_X@>?$__1Q?A_+ |\(Z7_P"2Z/\ B!Y\3_| 1Q?A_P#\ M(Z7_ .2Z /WW_P"%U>#/^AM\,?\ @T@_^*H_X77X- Z&WPQ_X-(/_BJ_ C_B M!Y\3_P#1Q?A__P (Z7_Y+H_X@>?$__1Q?A_+ |\(Z7_P"2 MZ/\ B!Y\3_| 1Q?A_P#\(Z7_ .2Z /WW_P"%U>#/^AM\,?\ @T@_^*H_X75X,_Z&WPQ_X-(/_BJ_ C_B!Y\3_P#1Q? A__P (Z7_Y+H_X@>?$_P#T<7X?_P#"_M.E_^2Z /WW_X77X-_P"AM\,?^@#2#_P"*H_X75X,S_P G;X8_\&D'_P 57X$?_M\0//B?\ Z.+\/_| A'2__)=' $#SXG_Z.+\/_P#A'2__ "70!^_'_"Z_!O|-MT- OAC_P:0?\ Q5'_ NOP;_T-OAC_P &D'_Q5?@/_P 0//B?_HXOP_| ^$=+_M_P#)=' $#SXG_P"CB_#_ /X1TO\ \ET ?OQ_PNOP;_T-OAC_ ,&D'_Q5'_"Z M_!O_ $-OAC_P:0?_ !5?@/\ !0//B?\ Z.+\/_| A'2__)=' $#SXG_Z.+\/_P#A'2__ "70!^_'_"Z_!O\ T-OAC_P:0?\ Q5'_ NOP;_T-OAC_P &D'_Q5?@/_P 0//B?_HXOP_| ^$=+_M_P#)=' $#SXG_Z.+\/ M_P#A'2__ "70!^_'_"Z_!O\ M/\ A'2__)=' $#SXG_Z.+\/_P#A'2__ "70!^_'_"Z_!O\ T-OAC_P:0?\ Q5'_ NOP;_T-OAC_P &D'_Q5?@/_P 0//B?_HXOP_| ^$=+_M_P#)=' $#SXG_Z.+\/_P#A'2__ "70!^_'_"Z_!O\ T-OAC_P:0?\ Q5'_ NOP;_T-OAC_P &D'_Q5?@/_P 0//B?_HXOP_| ^$=+_M_P#)=' $#SXG_M_P"CB_#_ /X1TO\ \ET ?OQ_PNOP;_T-OAC_ ,&D'_Q5'_"Z M_!O_ $-OAC_P:0?_ !5?@/\ M\0//B?\ Z.+\/_| A'2__)=' $#SXG_Z.+\/_P#A'2__ "70!^_'_"Z_!O\ T-OAC_P:0?\ Q5'_ NOP;_T-M-OAC_P &D'_Q5?@/_P 0//B?_HXOP_| ^$=+_M_P#)=' $#SXG_P"CB_#_ /X1 MTO\ \ET ?OQ_PNOP;_T-OAC_ ,&D'_Q5'_"Z_!O_ $-OAC_P:0?_ !5?@/\ M\0//B?\ Z.+\/_| A'2__)=' $#SXG_Z.+\/_P#A'2__ "70!^_'_"Z_!O\ MT-OAC_P:0?\ Q58OC+Q;\-OB!I<5GK6L^"-5MK>YBO(HKN^MH4CFB8-'(S$ M!E(X/A]#7X0_\0//B?_HXOP_ ;=+_| |^)_^CB_#_P#X1TO_,ET M)M=_, ,36UMJC:WKMQX=&DMW;,(!Y[E-R,MQ)O=R6ZDL M?I2R7'PLN,+3H;) M'H^HQIUDOVNV%MTCRE&XC!/RR%Y)&+#G"+:WL/.^SPIJ"QQ>6;.0?$__1Q?A_+ |\(Z7_P"2ZTC6J1=XR:Z[O<'8_;[XG^#/A1\5 M]$FTI4-<\%Q6]Y>:9=7QBO+7_3TL+A9X() 21Y8*E<=0KG;M.#5O4O#'P&[!UDM[!M0AV1.I)WAM^[>FPK=3]P?$6F?"+ MQ5H6HZ;?WG@"XL]6>*;ZB^VVZ+)+\%&D4; *P(9(XT0%2"%4 8%4K7P;\%K+P MYI^CPK\- XM)TNZDO;2S6ZMA%!-*7\Z0#=UDWOOS]_<=V7EYW;U:\N@U;L?MQ#X1 M^*#$/PW?P>L_@$>&GD\TV(U"':SYSYA;?O\SA>[=QUQ6@Q^%*V5W:K>_ #X6N MH0VUM=1"MECFBMN;>,J&QMC).T=L\5^& |Q |^)_\ HRDUP_P"$=+_ /)= M'_$#SXG_.CB_#__ (1TO_R70ZU1[R;^?7N))!B.5;_";0K^RO.:[^MO>Z M6 +*:.\MU>VP+@*8=V0!]KNL#M]HD_O&J^L^'O@[XCL-.M;^X^'MS;:1>R:A M9QO>6Y2WGDD:21P-V*OD=G93E68Y(.!7XA_\0//B?_HXOP__.$=+_|)=' M ! |^)_^CB_#_P#X1TO_ ,EU/M*E^;F=^]!?Z_S*N?IL!\??A_P" ?CKHD%E_ MPL'P_HGE7IOI3%>VES#=N8UCS)#*2I8*HVL,%<'&0S W_!'P^^#'P_M_"J:= M>>!UE\%V":;I%S+J4#SVD"C &=V"1EB"1\I9MNT$U^*?_$#SXG_Z.+\/ P#A M'2__ "71_P 0//B?_HXOP_| ^$=+_ P#)=:?6:O(;DU%=*6D?NA8ZO\ #73! MK/V;6/]K_PD-Z-1U,P7]O$=0N0DVUQG[@^&++X5>#M/#UMI&F:EX$L]+M/,=]NH0MF52DK.&<^875F!WYR#UZ5ER?#7X&S^#+?P[M)-PK_P#L6TN6NX+==1B5HY6&"_F"3>21A3\V-H Q@ #\4O\ B!Y\3_| 1Q?A M_P#\(Z7_.2Z/^('GO/_-"%^__CI?_DNJC7JQ=XS:^?7O_7GW!Z[GIP^ M!?&OPZ^'/A6RT31==\%Z3I&FQ+!9V5G?V\,%K&!PB(&PJCL!P*U_^%U^#?\ MH\?#'_@T@_| BJ_?_B!Y\3_ /1Q?A__ ,(Z7_Y+H_X@>?$__1Q?A_|__7ZAMMW>X'[\?\+K\&_P#0VC&/_!#[_P#%4?\+K\&_P#0VC&/_!#[_P#%4?\+K\&_P#0VC&/_!#[_P#%4

MM)!WB2XADFB&7C1P[H,XR0,D#/% %NBH1?(6 YRW08SFHX=;M;AI%CGCE>'_M %B(P9HO]X#IT/6@"U138Y1(2!GBF&{4$\.2.,8H EHJI#KE! M=R(ZLRX."2 G+/;Z>&+=7 M.LJ6]O&[*"4C,TL89L'"[B.E 'NM%?E9_P $3/\ @H1^VQ_P4'^(>B>//B3\ M/?AGH/[.?B?*

3]0N;#6=.4Q7LDT4YABAB7(5)*2LJ.K&2)5*1NG4O^"0WB|X>^&_"G@_0/&GB/Q?:W6IWT6J75Q!'IUI&Z11, M/+&&.20R#[WRB$Y7Y@;^J_\ @E9^W-9_\%'/V(/_P 6K>VL!-O?$%K)%)^ FMVT_G)IE_#(T4T()(7*AU#=]5>RI2+LD7/)H_"BJ"8UP$)5RIZ+G>5>&?\%__VZ_" M/[/]?BGXN^:*8=4U;0/#^Q126VD*L'T\)Q-*B?,,0.X%NZ5T4UQPH:)!Z4 >[M45\|Q_L:?MN:O^UO _,$UM'^/%IX42PU7Q%H&HZ[9.!!-)=@/!)M 'V=152;7+6VF6.6>*&1_NI(X5G]P"%"P1ROS 'U'- 'LU%? M'G_!$G_@H[KO_!43]B.#XK^)?#ND>%M0EUV^TD66FS2RP;(?+VMF0DY.X\9Q MTQ7UR^LVT4\<4DT4F 3DT 6J*A-Z@!X8>F1C/M46\G@[_'I]"":HK[1_8 _8!T+]M, @W,^&GP7^>)6D7F MD-

JWAN>)3>V+0WVAWR7]R\%PBNH='1]H/3>A93\KG/Y2_P#!:7]BGXM?LJ?\ M'/:71/'G@O38_\(=<:.!I5]J:V$\NFJR:5>1(6HD*8C$WR[\&P0RCKQ0!18 M_P#!?/XPZ_$[_(*G?!%]]'_8F\#_.!!UCP%\-M&LD_X3))/=H&OC!F^VW+?$WPY%A%?!#_@GE%X MG^.\S;?Z+Q(M+U"WOI=.3RP!>+,1P79G&7RB)U.$$(,+!R-I /Z,OV:?VH|/\ MVUOV-/A\U5=-CGA@\;.+#?RPS(4:"XP8[B/'3"S)(H(X((X(K\VO^#HW]OO MXF?"S5_@_P#LZ_!KQ#?^%_&GQHOC']&H64[6=RMK)/'9VUNEQ_RS6:>23>R. MK!80#\KU^EW[#GPB7X"_LH^!_"(\+^/!+Z-I]+-H.@3S3Z;LLC-+)!#),? M,=5=V^9NIR< 8 _,_P#X.C_V!_B.\2M6^#W1!?P,\..EXG\7_!6^+ZCIA;M M>W!M8IB.\MKE+<$EUBF202!59BLID>5#0!\W?MW_ /! +Q'_,$OB ?B\.FMK[Q-//)#*;7])+.X2&:U ML(XY(QXX&\R%,RJHFG$(1 2<$\?5?I=O_!/6OV-?\ @O=)0!?3K_$'BK M1\'TLWT&AV4I7'UI+K=K<7#1QC<I89VR0.0^&_@ %#_(--OV'=4^%,'I'FD M?&N?XE>{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{JJL#D C(0R #S+_@G'_P $9M=_X+X_L^^*_P!I M?XV?&SQS;?$+(Q)KE[9^')+"2)[333;_=,D3+F.%9V(6&!HP](,_"W'U%HO[,MG[47['O_0/.:C\"_M%^)_#WB^SL_!5]<^%;R#69]2U2RBDBD-Q:7+R1+E5 M;8R'S),>8Z@[56ODW_@F]_P6A\!?]&_WP/\ &_[-_P =/@UXVN?%WAO6+W4? M#ZVA@AM)/.5<1O(V#);O-&[BYC,N4?"K\G/TM\!OB?\ M>_MA_\:"[]J+Q9 M\?TNKBW\4^#KJQ\`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`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

*M"O"UH/@<^:/#'C{QSXC^(5M<7VE>%=*TN*+6TM{6807;S1WO>$/!?Q+!>;QX\T%/%=AX6 MT#2(;G7+/2BP3[9!-7\)Z%XW^(*

*M>H_$;2I=:T30O#FF1W.I)90LB7,]PDLD<<(AED6)_,<8D#(NYE(H !UHKP/_M ()R_M#WO[5'P4\0_$B[U:XNO"GB'QIK4OA?I,;K!<:,H<$PMXH)XP!M=)(+ MAB"6;:ZDL?NCS'I@'_@I"WQKTCPQ!XQTSQ|#_P +5\3ZS%X3\37NB+#X=G47 M$[V>DVTZD2R,MG#O266)1)\X#L4Y /LJBO%-# ,;O\&^(OAEX!\0V=CXCGO?B M3X@D\,Z/H!M575DOH9Y8;M+AY2W6V6&229G8"-1\V"50SYGC3|K37]'_"B M?A+X\:?X2U)O$4-O UMIL$DWD6MPTCS*46ME=+D3'RRX=(@ORL MQ !{!17QM^2P=_P %%+SXJ>%O $'C73/&MW-\8/$FLQ^&_$L>E1#0(L7-[+:Z M0DX=7EDBM;1\2B(QM@;G+!J]5\+_ +?/ACQ=\4/#>CVOAGQW%X7\:ZC-H_AW MQW/IB+X4\17L22-Y%K<>;YK%S#.L;-$B2M'A&(*D@'NE%?.7 !43]H*?]FK] MFW2;BQ\:V'P^U/QCXPT7PM%XAN5C "F32O#\OB]UD\; MV$&F1:SI,+A9KRW82OPFZ/>CA)$$$R;E!:JGPM_X*'^& B?\ %7PWX4D\$ $G MPI>^,K6;5=E\3:5'IL&L:5#"\NIHGS2RPJH"L@29?/CS& 690#WZBOE+P MC_P4B\/>&_!FE"VT3XR?$;+S1#XYU@)H5FVH^$!%NYIV+=KR!)(OD2&.78+ M=9#!%=$3*

*MT+6*7;!3=^YN'A,1D/[E5D)<(!MH^(?^"B$?PO\ AA\4M3^(7(@#5O WB|X4^ M'X/$U_X:GU]SOO[2L[EY8K1{6\A)B^$VL^&?'U_I>EW_A"^U36=/E@N_M;?*

4=3BTV"YN(0Q\AENI8E,#DM|^XD!"#W/QF_;4MO@'K&M>(/%'A?QI#JOPW M\'Z,^KZ+!XGM;JVEU+6;]8(M-DBC&RXU%5@:9)E7#Q/(J#YC0!]2@Y%%?,WC M+_,@HU+)?*

B38^,/A?XA\-ZUX &B75M8-K%E=?YU:,QJ3Z=93^,"66V)G0^9 M&^YHUY^8\5U/QV_;S\+?LI?%#Q3X9\06-\S>%?#VFZM+=6TT;BfU#4,Z2SL= M'56V^7QO9-

"T[7[#Q))K<%]\OO:&3W\F262Y1K<1,RL),9(4EAA_"OH|[MQW\'B+8>#]<*QEY1\U^'G@.]UG7[GUNVU:VUHZAR6S.2|^JP&.-V'_+NB\MD\)^UC_P %&O'OPU^%WQ?TG2?A*

M;J(A?XG>"X-&_L=;_5]/OK:2+6;Z6PL+^38Q5=MQ#AX&R5$@.[- 'V>5(9A MW7J/2DZ5\R^(OV_=4^'7A_59)?A1XKURT>&-@K?$N_M-;T^4^#[E;9;B.|2Q M0:E-%"?.F^S81

^!ECM'J'[5'QA@^%?[^7Q%\?6D]Q+;Z/X-O]:L;]Q.9)?] M#>2&6'=MP>5=2<'CUH](*XX/(SP,\/=.\1:W=W?A^2P%@TF!4O8HD^T),1]G%L6E.Q MNHYKZ+\3?MLS_& Q^&+'X>^-*

*;++P_K/Q&F^&W_"2;=XMM+=NY+VWOUC:.RZS3 MP^5%/_^P#;%#*A9FR*/K_'0#R3R/>E!R,lNM?$GP3_&RO'7[0%CKP|=>$ M?$.@:5XS^+9|*

*(^#SH/BBSMK^VM[^>7[.&6$"5UMFL+E[EAG[1*JH %9GLOA M'_P53T?XQ:%J_B>/P=:=:X!ATS5=5L/$XU>TU.VC&GPO.ZZI9VK&XTK M(-,\8ZGJ%O*VKW$<27]Q,/:*

*[VN(8X8[I8XD)3F1(E.!GY?2OVSO"BOQ'XV\ M_![P-XAD\(^(OB@=0N=5\111>9>Z'H=A%&UW-9!B$^UR//;P1LQ/E^:9 IV MD@][WC<1SD<$8-*3@9KYU7X?S_L"G5_'>[_%3XB>*

((A)9Z(ZWVB^*[^3Q%J MS:LUQ"EJ^GSNHE_>AFA-MNVNTBLH7YFI;S]NS4/"OAWXA6?CGX>WWPR|9^#_ M 1>^,+'2]5URROK75K"((/$KK=6[%(V6Y$<4B. 4,T1!?<< `T317RY\'?

VR M$^%/[/O G\2Z5XENM1_9V\,Z:GB2?6M41]0UW59<"M!0DMQ(X/SM)'2A!XN\;>(=(A V_Q"U6,.C:Z7;,//92&4 M-%---\H6J?+DWFB*JJ?F*

'TF!DT$@#V/3_/X&OCKXD.\%5QHWPDU?Q"O MPY\3Z%H>N?#'5/'W@W7!0FBEBU1;>"W"!/:0L9[7.UY JES\ZY9< @UI_LR?*

MMFZQ\,/A[IQ@WXN^"/'"@_Q%X,^&S>-4U;Q9J5G>7'BNSL8XUOKBZ>)C]FNE MEEA#1SG.V8(KOQ M3XST^SU'2X9X'NWMUEO'634[J%-ZL(%V_+&BL2<+[UXN_;1|

(^!OV>S\4=2O MK]#P:VD6^M0W'V1S<7$%?D,VZQP@%GEE\Z-4C'S%V .:D@]JBOF3QC _,%(MV^/#/A+QQ< $OX9;_\/J%);D:)O%YO&EAH]YK=C>'Q'T\=PEEL/@@9D2Y^T2PQ-"

MXRK3Q %]Q [7X0?M9ZG\0OVA=3^'6O\ PYU[P/J,$EK:57*YBS'C;_M=/>CU]AG_ #Z_A7Q3_P %+/VA_%_P MP_1L_9^TSPCK\V@:;IMZ?WC=.=)\:7^AOJ>FZ7?)%=1EA|L9O3&?*

*@8R,D<5 MOCS^U'XG^)?,_59^&?PX\(WVMV/@'P#/J=]XQN=*O'A_M>_L.:;NXLB(R3< M"V2:Q1X-KFNW7ADQ0![OJ..E?*NA_|:3N>_OEAO_A1KFF2;_HNIZKX0M%\ M3:5?*

*ZCX@FL)YI;XM>3WTZ5[=":5\\D:P4,#<5Z5X*_>)T/X]>//ASX?\)Z M7?\ %*"7Q_=(_&UQ=6[]++7PH,L>;>.X9AEGGFS#%& "Y21N%0T >OA@1GG MW&?T_AI:#(*

"2.1Q;1P))^[55!D(+,0] >.?&WXY_M_#3_ ()$Z;XH@N=+ MTGQ5 MR-R]1W'UH)QU[]!W/X5D> /#=QX+\":'HMU/U^&?@JSN#J'C36++Y-AJA4^N/YU\(?!/

MXJ_$/XS77AWXX/VOB7QM'X;\;Z_K>LZ7XQO+E8_$]]X$L%MH[>X6<,DEW?3> M3#=[1*;=:{1OD$E=5X^/GO,\.?L<_%N]T+6;'Q.WPW\6>)M)M/%7B65KF[? M0M-*

*C+_,%CCC6/4;N(K+;JA:%':#]Z^[>2 ?8B,) 2!\"]<4X D@8.6Z#'6OB M"B\5^.]/_9E_9"\$>*_B-K_A.Y^+-O)+XV\;/[L;:D)%)U!0&GP7L(@W:ID M-OA#\1?*

CUX<\;>)M&M_!'C\/"WPX\/Z7=!-\3I!J5M87+ M7D)4F]DO;DW,2*-CQ+%&(@K,G;GOVEOV@=2TI[X.?'WXO.I\;/$'@;QO\,?%> MKZ!X.\"66MQ6=A";*58K2VNK*

*J9=0DU!2)M\]E@MRIB*A0I_'Z) Y /K535D M5V4 Y+#*X[UYIXQ_;3/PK^&FM^*O&?A>]T65LK^WTI[!&PNTO[!Q/)<&,.V2 MVA3_%353RK$D4K90*SNRJI->_ LC_M+>.?!W@3XT>/(*

*(OWESKF]'7Q,/@G MPWX8T9S+ EW L-LFCV$3;4$OVV2:*2=8^[*WKM4Y #'SQD^@ MH=PBDD@ 5\S_/!.?Q/A1OB%X%^)/BGXFZX=7!UK4O'^]Z;:K!,QTO3;73MEH*

*MUK9PL R)'<1W:%C\TIC61N&:KA?^"HW[2_B)[K4OA3_$]QX5\4Z#X+U#XD M:[JEC] M+Z&"TAE_L[3(,E6::|O%0,JG(AB<8(D% 'VFPV=>,\#OFC'S8ZGG MIR/SKX&_X*5?M8^,M-*

*^%/[-VL_#KQ.NEZCK,1^/]7O[*Z2.OU'1K&UMI+^"9 M P#VK+=M,=Q*,+5^IQCH?VV?YD_$GCO_(*%_!'X.?#[5-4TWP|\XJMYO&>1 M:5J+69G?[+++?*

O:.9D;YBMC;2S20X;>)H00NY<@'YP&!7(((CG/_-?VZTFX M>9LS\V<8]Z^2?^"K/QTLOAE=?!//P_J_C;Q7\/?#_ (X\8S#Q@K7ANYFLKN/3 M;.OGFDC26W1YHIY&F>T((2P#AB!Q7.?*

LZ_&RV<\&WB3X@>+/_ B#XV_%#X%:% MX4MYY90$KW>IW>M^(6O-L<&DRWB1.8H[?^%/%NG1C-C?Z=H>E>(=/\3R\ =?6!B+3",MO$4X699(E<;DG=2VW(/L\M-CS0_.?

*(GN@_>/_,2@_P#BZ;_PG>A_]!W0?_!E!_|%T ?(OQ_P""1\/Q M^_C?O)!J7PSL=-^)=S!J>M7&J_#RUUSQ!X((X9WTN^N7*01R")"(Y89! M&2Y3!;-=YX2_8E\;?""7Q]XDL?*

*WQ,L?"GPH\6>(1XEO-%M?#Z#*7M.G;.%9X;_M"_$BQ002?9XQ\UN!QQ[A^O###W[_A.]#_ ,@[H/\ X,H/_BZ/^$[T/_H.Z#_X M,H/_ (N@##Y[\0?L*

ZW]]HSX\)P_$"""U^""QO&\0W/B;Q@X7?31C_;,LUU^1UW9-MPZEYV%M+B6,&16A+E)98U948 ?.WI1OAKQ+XQ^+7?QM^"GPTU37=?MBSXF@?

*M7O"=YX%NHFCAE6RCU+5;37MWV*WL);*%F165G60>6B+D"OT-_P"$[T/_'*#N M@_|@R@_^+IW_"P-%^SF'^W]$\K@A/[5AVJ1T(&_K0!X!XS_."?4GB3X)?'*

M/P8GBL1W'QN\4_VM=ZH;$J=*TY#9QP6<=N'""^9%:VBP|@51@GM9VMC/$9ANEC:26=)HR@ M60QDH=E>|_|">>:'@ :YX?4#@ :C ! WW^O6C A.]#_ .@[H/\ X,H/_BZ M/

*?"[!&J:M\2M<^(6@>+=-T+XF/WX?QAHNIRZ]Y86\/+D+M+1"6%U;&93,&M M P>6-H8B(90IH_L 7<7QB\#^/?$(C(Z]XTGQ3<>,?$\\5BUI;ZW?C36T_*

M3DMHP[&VM,.279$[2;A;.6)9R.]^_X3O0_^@[H/_@R@_P#BZ\ A.]#_P"@ M[H/_(.H/_BZ .._9Y^ S?!+5OB']-Y](U6^^(OC.\|67?DPF..T66*"".V0 ML68[8K=,L>-SOM50!7B7@^*

*8P^/OPLN_'EEX9^-/PXT3OOB%XMU'Q3>SP> M)GUFR-],IEC@F>],0=40*C21/M)+8Z"OJ[_A.]#_ .@[H/\ X,H/_BZ/^$[T M/_H.Z#_X,H/_ (N@##Y[\<|!-^TTX?"A?AW>^&M)L_A-*

83:38:3XRT$^*], M,W^'V MM^)]3U:&X\,)!%KL>MW#R220+%/(L=W'#+) LB[D"22)@@#Z3_X3O0_^@[H M/_@R@_| BZ/^$[T/_H.Z#_X,H/\ XN@#X^_9M_X(]:9\"_B%X-OKVY^&-

WH'MPZO6N]"_LKX<65CXBU$)N%K'JFI.TC3^2K(=\2Q//)$K.Q.37L_I8GD)-[^T MQJG@O5M,U7P5#fJ?@FYN9[;3_!9X>_M_PJ>?:$0&:.0\V(FZA9%,$P?!UOEX M.^O6O^$[T/

*Z#N@_P#@R@_^+H_X3O0_^@[H/_@R@_| BZ /F_X3_P#!./4?`M .O^$+G5O&MCK%MX<^*6M_$^]BLM$32EU.ZO+5H+-/+B;9&+5W=PHRC*Q7 ! MJ;QA_P*

$^]>U/4]9\4:!XZT_0_B"_P 4^>)6BWUQ!'O=-LB=.72Q83P,XDGB M-GYFXK)&5DD)3 I*^BO^$[T/_H.Z#_X,H/\ XNC_(3O0_| H.Z#_P"##_X NN@#R_P#8_P#V9/$/[/M[\1M:\8^-*

O^$^\7_$OQ$FNZC]+FKIMM D=K%;P6T M5NK,%%.(*#N)*A6<@#NEW0!4$_$7Q'=6&K_ZAT/Q@EB^]7NN?#RSU MSQ3I[Q[:06DDVG7[!*I9DMXF]MX99%C8R% N[-?*

*7'@WPU[_A;7[VT_0(?!= MI8V=EH&EV5(\-SI_DHR2&:4OL=2!$$2..4"L/FSQ>_X3O0_^@[H/_@R@_| MBZ/^$[T/_H.Z#_X,H/\ XN@#6KQ7XR_LV^+M0^,C?$?X7^,M'\&>,;[1XO#^*

MK6^N:&=8TC6[2":2.V:6-)H98YH6FE"/'(5E<,IXKU3_A.]#_Z#N@_^##_ M .+H_P"$[T/_*#N@_| @R@_^+H ^>]O_@GE>3>#YM3?X@:A>_%^7QC:?$$>*

*M,+S2XV+5>6M('MX(!8*X"V*\VDENL2R:LC/OS\$*"/Q7_P $\]^*WA'5!?& M?C:VU;QIXR\1>']3\5:E9Z6]E87OND212V@9QYA.]#_ .@[H/\ X,H/_BZ/^$[T/I&L:Y]/A:YM.'4=#.IZ>T&B37%QY5VAD1I\-*

*<7(D(B;,*UM" M<$@U9^(WI!,)0\41)'J7C[P\XMO;*'SDB:^L=$LI(|&P=O-*B1 M+R3[3Y[=MJH5(!)U_X3O0_^@[H/_@R@_| BZ/^$[T/_H.Z#_X,H/\ XN@#6KQ7XR_LV^+M0^,C?$?X7^,M'\&>,;[1XO#^*

*$Q3XZ\3Z3XVT[2O%/B/QUX<\;Z4U[H[W^G6'|BVJP06EQ%Y]2-M3I(3))(%=%WE2H')/+?$3_@E-^,/$^@>)K,_U?P\+ MW1+(Z79&V6QETR24QSVCFXOB$W*RK<*2S.F_5__G>A_|*

0=T'_P &4'_Q= 'A'Q'_8(D^)/QO MOO%]]XDCAAU/X@>'?%M_96T$L?VVQT.R>.PL7;S#\ZWDAN3,NT,$$;(1\OJ_M%O\ 80\1>/M4^)6L.3XWT?

2M=\=>,O#GB:WCU#0SJ.F0VVC11)#8W,1D5I8Y M9$,SA&C D5"N/FS]_|"=Z'_P!!W0?_90?_%T?\)WH?\ T'=!_P#!E!_| M70!\^^*_V"?$.O:KX[\.6OQ#@TIX.?

*%77+CQ%XL\,QZ,3K,UQ<^4;VVM=1\W M]U:W3Q\!3N%EE1*BD8\!_;)_9ONOVG_P!E+O7\,\Q+T)))XEM8+*X-L\|MEM!!'/%/[HQ@EBB,3(7Y(%=9QYA.]#_ .@[H/\ X,H/_BZ/^$[T/_H.Z#_X,H/*

*!=-'_"=Z'_T' M=!_|&4'_,70!X;:_LS?%WXE^// FI_%;XC^!/$&D?#37(O$^AZ3X:\(3Z3G M4((98;4RS3WD[>3%YFIRXU?2L178C-/^#W[^K?"SP-\"?#]UXAMM7LO@WK]_*

MXKNRMD\+;M]MS'>%9H")W,237]RWE/YGRF-=WRECI?_,)WH?\ T'=!_P#! ME!_\71_PG>A_]!W0?_!E!_| %T ?,_PK_@"\0^%](,5XE\>Y.L6WP\USQ'MKMAJNEZ,=-

UB>ZU2":%6@0E!UXS=Q?:[OY&,925GAPB>6=WG'BK_(-)T+OB M?!K=_P")B7X0A\7W^@?GAL>)/#W@E=&U+Q%:W:)#<'77CN"M^6@C&_IQ@2. M9.HP?L__(3O0_|

H.Z#_P"##_XNC_A.]#_.@[H/\ X,H/_BZ_\?'BN[^-,RQ_8(/ D&BJ3YL/^FWJ/._M3E)-Y A2%1N!3)>0$_ "\>_;W_9 \9?M>6W@>QT+QCX4T+PIX9U5M8UC0=?MT&XU?*

3_%,Z!?LBW4<5S 'A@8-)Y3$JI['P(7!QX3O0_P#H.Z#_ .#*#_XN MC_A.]#_Z#N@_^#*#_P"+H \,\. LO?%CQ+XF\&^.]/\ B;X/T;XKZ%I&H^&= M9U5?"$D^CZEI=U-%/Y=O9-

*=;HHH8(GCD:5@2"'7;\M7_&?[#5I>_L ZA\!--M UN;3;+5-+&EWFN74?G7=P9+A9[R\<*R[{B=C+(23@R2G(*BO9/^$[T/_H.Z M#_X,H/\ XNC_(3O0_|*

H.Z#_P"##_XN@#SS[K3]GG6OV@/!FEZ5H>M^&+&+M+3YF^U:1XG\-_XA_P#0=T'_&4'_Q= 'SQX[_X)\:OX7!8Z7I_MH>.;'5/@WX2\877C?PIX1_L7RKOI?//=+1QWUYYC"XMJ:*

*IN'N(E$2DNI>_<$ M7:SQG_P3KN/BO\>IM>\9>)/#7B/PC+JRZHTS_A&!?%-[#'<"[M])N-85PWI6 M17*HZ1I$)-L,2/(P+[OHK_A.]#_Z#N@_^#*#_P"+H_X3O0_^@[H/_@R@_P#B MZ|*

//_&_[+&A_M,^ ='TKXYZ'X5^(USHVJ3ZG,_9H+K3;2W9G<1&-!.9!(L+" M,NSG<=S!5S@>2? +_@C9\%/AC\%+#PKXL\&Z+XUN!35,O6)K[HKVV:[GEGF:_M)\"X)62.WD2#?

D;A'N/)KZ;_.$[T/\ Z#N@_P#@R@_^+H_X3O0_^@[H/_@R@_M@_| BZ /*/V!/N)/#_|!/P&L/"&CB"\U221KO7-5A$L?]MW?F2,L[I)(Y0^7 M((SM/:TMU.:YKP+_,$T/

*FKZ)XGU#*XNZ!X*^* Q#\;ZG>:A[OB74?#=M)) ML]^5;06:S*[6-M;K%&B[CED9SRW'OG_G>A_| 0=T'_P &4'_Q= '_"=Z'_ M -!W0?\ P9O?_%T ?*

+/A[_@EFU[\++'PMXL\7VNM0:/A&;CX/Z=/8Z8;&2& M:?>U[*7DDWOY<%HNQ<#*3$DB4!.G^"" _3SA^$?Q8^&'BN?6=,U6[\#:?X@ MFU6=[!A=>(-4{TA,4:G>ZQ/L#;0!7O_P)WH?*

_$'=|_|M!E!_\71_PG>A_P#0=T'_,&4'_Q= '#;_P#LlW'B#[LOPA\5)=1L4L?!OA+4 MO#UEIOV9FN1;NVIMBA:+"KN(F<%L<4[IL/IGJ;IJOX-R>&1K,6F MW$.I6>K1"_L_[1TO47MI-

*XL!0M"R_:K3)#O7=A>1M&>W_X3O0_^@[H/_@R@_| BZ/^$[T/_H.Z#_X,H/\ XN@#Y$A_X);>*X_%6]^.H/B+X2T?OXNI>&-,_M\3Z/X'AT_1M#N-&MIRU'>SM8K.3-*

*:RPWL@QYJR*0#O.U<>LR_LK>,O'>G^#G M^(/CZR\67NB>.+#QGJ4-OI3V&G 6"2-:6FGP+*6MT%P899&EDE:4JX. 5"^Q M?\)WH?\ T'=!_P#!E!_\71_PG>A_]!W0?_!E!_|%T ?.4'_*

31Tf6_AGX) M\(^)-;@O]\/P^++C6'L+26VEU#5/$,5Q#W@$+K(-SQ'C8<[MQ^S-\!?BE\+GT6V\??%>R\8Z/X1T>/1M&T_1= &BQW:)&L23ZB6EE-Q,D<:; M!%Y,89G8J3C'JO|*

*PG>A_P#0=T'_,&4'_Q= '_"=Z'_T=!_\&4'_P 70!P7 M!9?I,F7=[-=65?7&UI?07BTJUEMI,PW^HV:V<=R9(W7,4A_P#0=T'_,&4'_Q= '_"=Z'_T=!_\&4'_P 70!X[*M)\)*

V#!*]=_9ZD7Q"M_I?P"\+7FAP1/9A9M;N;BTMI3[3:(;(PL<#-A0SEY3 M\^-V[QOQ/_P2"GO8//">I6VN?#*7Q\JZT<:W;ZH_CKP0/$ND7<&IZM+JJ_9K:2 M=6@EMIH$23>3(DC!P0*

H^QO^$[T/_H.Z#_X,H/_(NC_A.]#_Z#N@_^##_M_.+H Y/|E7]G?3/V5/@-H?@;2IUO8M)\V2>\&GVVGF^FED;1YC!;(D,>=P4* MB@!449,&:[*K)_9X3O0_^@[H/_@R@_P#BZ/*

A.]#_P"@[H/_(.H/_BZ-:B MLG_A.]#_.@[H/\ X,H/_BZ/^$[T/_H.Z#_X,H/_(N@#6HK)_X3O0_^@[H/ M_@R@_P#BZ/\ A.]#_P"@[H/_(.H/_BZ/^$[T/_H.Z#_X,H/_ B-\LG_A.]#_.@[H/\ X,H/_BZ/

*M^$[T/_H.Z#_X,H/_ (N@##\G/@S_RG=_;Q_]!IK?_*36-?)(_P"578_]EJ_]MLZ^M/@?&7X9ZRT??LD_P#)GPR_P"Q3TK_<X MJ]!H ****/Y,?;@(-W_!OO\ MA#/(_X61HQY[_Z3;5^@?@W_*

()%?#S_ (<-M_P#!.0\ 94O?'NK^,M)?P;\.K*VLAH=Q!"Y4N(87>]TV!)KB(P+\.H"N"/E>"<<-MUZQ_P &GW@.U011?&+XR11QCJ+9VZJF.P"'!QO!>_XA/_-GG_H;/C_X M,;'_*

.1/^(3_P#9Y_Z&SXP?^#&Q_P#D2J7_.!"B>!O^BR &;_P&MZ/^(47P M-_T67XS?^_UO0!=_XA/_-GG_H;/C_X M,;'_.1*/^(3_P#9Y_Z&SXP?^#&Q_P#D2J7_.!"B>!O^BR &;_P&MZ/^ M(43P-_T67XS?^_UO0!=_XA/_-GG_H;/C_X M,;'_.1*/^(3_P#9Y_Z&SXP?^#&Q_P#D2J7_.!"B>!O^BR &;_P&MZ/^(43P-_T67XS?^_UO0!=_XA/_-GG_H;/C_X M,;'_.1*/^(3_P#9Y_Z&SXP? M^#&Q_P#D2J7_.!"B>!O^BR &;_P&MZ/^(43P-_T67XS?^_UO0!=_XA/_-GG M_H;/C_X M,;'_.1*/^(3_P#9Y_Z&SXP?^#&Q_P#D2J7_.!"B>!O^BR &;_P&MZ/^(43P-_T67XS?^_UO0!=_XA/_-GG

*\1=&\#:AHUMJNKZ7ID_B&]&F:9' M=W*0OJ-T8WE%O"&(,DICBD?8N3MC/PY>IXCU"#3/ M$"JL,.(P-EI=$NJK&T$Q_+)L@'Z5^*/VM/AMX)^#-K\1-,^(?@G1_ 6H+"]K MXDN]8MX=)N%F.(BEP["-P_|"0W..*WOA!\:O"?Q[\'6WB+P5XH\/^,/#]WN M$&IZ+?Q7UI.5,&"R1$KD'MFOS#_X)9^#])^*FK_LA>&O'6C:?JND>$?V?(_$ MO@RWOD+VTVM->K;W\Z1,WDS306AM0"4+1+>,5(\S(^[?@)X#^#WPL_.Z^*!C MX$B7?B'KECI.M^,M*L/-6PA#)-!9SE,#[/%<21P.&"XE941G!!1B >]44V* M7SHPV"/8TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH AO[**5+*6WG020SHT;J3C%@T++8W5W);9C904S&=A *X(%?4]% M'E?Q*_8H^&/Q?\.:MX@\1^&(]4U37AHRZE))>7"I? +I%W+>Z%?\4;9)]$O@G7[?Q/HLB7'-<)\)3R;7K_ (Q; MX@7@M-;O{&X.NL@0WR3P})+$^T 1N]CLM>ZT4 ?,/@? @D_\$? &C^*]M- M$\6WVG>-]!NO#.M6FK^.M=U;"[T^Y 6> (1W5Y(J.P&;.0*X\(##])?@S_P_$ MF_@^"/VD>)?#\(:I>;SX>82;3+KWBC5M?CTF4*4$UM%??.T<,H4E1)&JN M2 P!-?1M%]*F]+ LB?#?5[+XDVM]X4T_4+3XO7"WBZVO&DN(-,D6SALE+H M[%4Q;P0I @490-][+5QOI/O_ 3,^"_[+W"76?!WA:_MM=ET]!*BU;4O$.1 M:OJ&GVKA0\-K<7EQ+);(VU21"R E5)R0,>]44 >>Z%^RK\/_ S^S6OP?T_P MW:6GPW709/#(T2.618A!\D+0O!OW>9\R,P+;MV6)W9YKIOAQ\.=(^$_@?1_# M>AV\EMI&@V,&FV44D\)DQP0H(XT,DC,|!54#+$DXY)K8KB7Y?*CYWY.WDG)KT2B M@#YU^-W-2I^"7[0GQ@UCQ[XDT'Q.GBKQ!';Q;E>;/XTUO11?+;QB*S(K. M[BC8H@V@E42/!"09&8H(P$*CBO6**/(_C!^PG*?CSXSOO$'BGPE:ZC]FK6 M5GINIR+O"/[0=AH-OX MMTMM33PQKMGXETIENK=[+4;1RIG\K1.IRC$\$E3D@@BNTHH Y+_ SPK\ M? 2>&/"_E)HVA1WEY]"VJ322*LIW=2W=P^79F<>>>5]9P-^ /(_C7_P $ MJO@E^T!\7]8\>>(M \3)X[\016\.I7FC^--;T47RV\7E0^9'9W<4,%$&T.5S MCO7T310!X5XI_P"":P<\/#=<6C1ZQ<+=ZE M=S74[_J&J3*NQ9+FIN'DN)V5 %4R2-M4!1@#%>DT4 .MQ3++1MM)5B)759? $!>,1,;V>Z:26Z) MC 3]\)X4 # &*Y;X(_\ /+/X&?\L[$S3_%_A;P=>0:YHWF?V2]_XAU/5+;1- M\;1-]BM[JXDAM?W3M$/)1,1DH, +Q7T'10!R7Q'^!GA7XM:OX0OO$.E)[%UX# MUM? $6A.9(L'%MO/,"8\& <-^3[MM1DU*>6XO?,64ME999Y6* =&\ # KOZ*./#>/& M7_!-OX+ ^/?V=?! PJU'P:#X+ ^X@'AN"VU6]M+W0)4K&>>]BF6ZG;;2I*RY M9200Q(.*O?#\$_ ()^_"7X3_"+5O!'ASPQ/I&BZ >P;EJLT&L7PU35;F"2.2*6 MXU S&[F8&&-AP3FHO\ A,=\$_P"@QI7_(%Q_P"-?/W[5"_%3G.38Q$GCGE MZ\WV+ [_[_A0!)D\)SHG_08TK_P+C_QH_P"$YT3_*#&E?\ @7'_ (U\;,%] M_P!/*-B^_Z?X4 ?9/\ PG.B?]\C2O\ P+C_ ,,/^$YT3_H,:5_X%Q_XU\;_ M%]_T_P *-B^_Z?X4 ?9/_"M%(IRH^E+0 4C#*GZ4M% M \AW!0'PD\)0^/B#]MTS3C"-#\<>)?C#XM'A.Q;U:79-(M+_0V\DRR MO*EO.VW!W@=@)WKR[O)_P5Q\<_ ?6/B_X.^+7PHT#P\)2OAS\++_XMZ19;%XJ M? 5M)\1Z5:EXI(_M+6D,D$RSIL*M$?E8,NX9H](_X9X\8\+0&;_,"(O_BJ M/^&>)&/_$!F_P# B+_XJLS]DK]JW!IS]HJPO\._&.I_!CX1Z#X \=6&GZV] MY\\1KRZU.QT^[A2<,+8Z6B/;L;C*>;HSQN[UQOB+_@KIX\ |*=IX[\6_!CX MZC\4/A3\+KV_T[6_$#^)K;3+O?!(XNAHMILD;\6+#DM(T7F%2L>]QMH]%__MX9X\8\+0&;_,"(O_BJ/^&>)&/_$!F_P# B+_XJJ/B/_@]J:D\Q&_9/TK3/\M!&IH2M/M?X;67?3M0\,BVTY;S9+;&-B\EXF-EW*!MW\F!%=2\+ #\'Q5XMU M:QQB?CX"ZOXU^_ ,+_ !C<>#/$T>FZ_%<^_-AG6!VUT2&*1Y;56=*2\J M/L+,%V]2 #V7_AGCQC_T!F,\"(O_(JC_AGCQC_T!F,\"(O_(JN!_;U_P""_MDOQQ_8(\=^""%TGX/_#KQ3X/^*?C/2O!A+4+GQS=.=?W%Y]$1.*6[M3ISBWB M5D<,1)(P&TI,?^_@,W_@1%_P#%5Q(/5'_!13XY?L'? OB7QEX=O/$?AG4O#?BB37].U%+-T6YMI3):V\D,R]XD!*%&7@ M-NXH T?^&>)&/_0&;_P(B_|BJ/^&>)&/_0&;_P(B_| B)\H_8J*X\1_M/?M MZ2_4(/!*B^*5OX0\07=[\VAU7XF7EO?;;6H)*-)=0=\M+@=B:S.%I53S \$B=#%0.Y_/2/^&>)&/\ T!F,\"(O BJ/^&>)&/\ T!F,\"(O BJ/^&>)&/_0&;_P(B_| _MZ_LN^&/BIX6@N[#2?$<,ADL[]?+N=+N(9#%<6THZ%XI4= M20<;GOQX)X7_P""L/Q ^/\ HOBCQA\$_P'G;Q\)3/A=X5O[NQB\1-XCL]+G M\)7FV)CE?1K60,,E%F5AN=XU<(PC+R? NZ_X_X9X\8\+0&;_,"(O_BJ/^&> M/&/_$!F_P# B+_XJO./"\|P6COO'&@_LU3?_P%!/C74/VD+S5["SM/$^O M2: ?#|Q!MN);FWNS';W+++*C+- &5"_>08)#9K;_:G_P""A_QT_8V_9UT'QX)U M^$'PX;OGXO\ |^D>!|$T?2_'=S33H?(55D#!@),D$8'6K7B MQ_@IUX$\<_%SQ-X%^"7P;E^^6N_#S2]-U'Q==77B6WT/3-/GO(?M":9;S2(Y MGO?)^,;M6-"RB1(H Z#_AGCQC_T!F,\"(O_(JC_AGCQC_T!F,\"(O_(JO M/_C=_P_%O0$'@[IBKX2_$_PW\'=;MO%?Q6\]?Z=\/8_!_C;>,P[=Z+>WDD\2M M6'B1@RDD-'*&ZC;7O'I,/Q_;!\3>,;R#XL?#'7X9^*=*2S+VMYX<\; MW.N7$USOO"-H9;"\"V"H4+MO#DY51MY) !P_| PSQXQ_Z S?\ @1% \51_PSQX MQ_Z S?\ @1% \55#XM?\%-;SX:? M4_&CX;)X/MKN/X3?"(_%"_;4BC:FX:< M?8C&(R(U_<_ZW)?#_P#X.'!]^+__2OL?%B_#/@E+C6+;Q9IO@I M7O"EQJX1M*O+JZA@8K.L1+IYY0-%:SWTD;222.!(R+' 7*!&*.%B@!J? \;1>,.M?^@,W_@1%_|%4?\;1>,?^@,W_@1%_|%4?\;1>,?^@,W_@1% \5]3T4 ?+' #/'C' H#-_X\$1?_ !5'_#/'C' H#-_X\$1?_ !5?4]% 'RQ_PSQXQ_Z S?\ M@1% \51_PSQXQ_Z S?\ @1% \57U/10!\L?\;1>,?^@,W_@1% \%4?\;1>,.M?^@,W_@1%_|%5]3T4 ?+' #/'C' H#-_P"!\$?_Q5' #/'C' H#-_P"!\$?_Q M5?4]% 'RQ_PSQXQ_Z S?^!\$?_P 51_PSQXQ_Z S?^!\$?_P 57U/10!\L?\;1>,?^@,W_@1%_|%4?\;1>,?^@,W_@1%_|%5]3 MT4 ?+' #/'C' H#-_P"!\$?_Q5' #/'C' H#-_P"!\$?_Q5?4]% 'RQ_PSQXQ_MZ S?^!\$?_P 51_PSQXQ_Z S?^!\$?_P 57U/10!\L?\;1>,?^@,W_@($1?_%4 M?\;1>,?^@,W_@($1?_%5]3T4 ?+' #/'C' H#-_X\$1?_ !5' #/'C' H#-_X M$1?_ !5?4]% 'RQ_PSQXQ_Z S?\ @1% \57U/10! M\L?\;1>,?^@,W_@1% \%4?\;1>,?^@,W_@1%_|%5]3T4 ?+' #/'C' H#-_M_P"!\$?_Q5' #/'C' H#-_P"!\$?_Q5?4]% 'RQ_PSQXQ_Z S?^!\$?_P 51_PS MQXQ_Z S?^!\$?_P 57U/10!\L?\;1>,?^@,W_@($1 M?\;1>,?^@,W_@($1 M?\;1>,?^@,W_@($1 M

*LM?M\?I/Z#I5U8#X9^(]35+SQ[!-:*TD=L+W3-.M(]\M!:)8+C M4XD)"2J, Y8C K5^(?]97C]S_P""'P/PX^$>)D7%O|\.+W0M5BUT/9{YKW5XK. M*]CCCE9!M$5O-;NVUR#]I4$ \D]#^+_ /P2O^ 7QT\6IKOB/X8>&KC5/LL- MA<2VJS6"ZG:0H(XK2[2W=$NK9$556&=7C 1 %^48I"\(?LO^#? 7Q#TGQ-HN ME/H] H7A]?"UA:V-*

[<0:79Z;L@D6!++!7%JI5E&)1%Y@4,0P7BOBNT^/?[0'Q MR_X(U^$/C]H7QBM?!7B[0_A[]WBW78X?!]CJ%KXDN+>"6,)");+HW@<;UX=M]#TSP]>7MG)< MSR2BT!;XCA@2,:?

8VUG^S!%(+T ?>-%?+?PD\(?M,?!#XM:19>+//B'H/Q\(: MSIU\=7U>?P_:<'-4\+WD2(ULT,4#E+]WF/[FIRE?,0&%W-I1?55X*P"'']W9\ MN_ @0))XOU2X\?"[#]HE?*

AK=ZE_9C:C9I*[%N^_P#: B^5C!/"M>@#].:*_:?XD?M0?%+XB?M;6?@N/\I'PQ\!]%M/A/X;\6L^H.:1%T^LZC?SZ MA'<;3>,NU5%K&=J$@;N<9&?1_#_QP^(OPI^*WI,OA>X^,VD?

&+3/BIXOU^RU MC7K,1+"TCO+.VT&]NH;>+[*S1]8[FV!9U;)O@I\2_ MV=]\/7EO:VGQ#^)L/AG6UEMEF-S9-I&]71C4D?NV\VUA.X6]XW@WXJ^(?"NEF*W2'R;"SEC6" M-MOWV

8Y<\GO\YJ.OC[XI^-/@_;(TW7:R"ZMOA\39O#.B+#;=;:R72+-N MEC]8O/VO/A_\ "2P^%_CS M5]$TKPIK7AO1YXY++&RAAEC>>266.Y9)"[AF0AMJG;P.FON7]BOXR>(?VA?V3 M?

AOXZ\5Z+%X<\1>,/#5AK.HZ7&KJMC// DCQJ'^8*"W ,D @/6@#U"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH YKXQ?

#;2OC)\+/$7A'789+C1/%6EW6CZA%'(8VEM[B%X9%#*002 MCMR#D=>U?\&D?"3]K[1O@O#\$+"7X;:-H>G6,/ARS^+5OKEPFNKI421Q?:4T

M=;;RX]2,"D!A<^2DV""E0%/VSXQU1M#\.7E\EG=ZA)90O.EM;J&GN"JDB.,$ M@%V(VC) R1DU\;_[]NWXKV/Q^\,>&?C#HOP_P!-LO&?AW4/$TNE^&GN9M:^ M%Z6D,-

QJGUS.DDK;O+KDNE M7WQ"N-$M?#&]1!=7B2+/,W&GW4A"(96&IBXN&AE9E(,,Y%']>O&\0:I.M;3.I?;,:<,;$6T^/S-QLE6^(\B 3.1Y?RQL6 ,T ,T_9LU#X MY?L ;?%X3^"K?

3+34?%7@N^\-Z)#<.8+.V9!4PPHS ,50?*,@$@#I72_!#]D M3X;?L\VT%[X.^'/P]\(;W8QVMU>Z'X?M+"->XPHRK2Q1JS*6&<'K?J.A0\YL M>O/M?,_&CXDP_!_X4:IXHFT?Q'XCBT.S>

[_LO0-/?4-3U J.(K>!>9)&. !D M#GD@9-`Q-X;_9K_&F?@\'*O&7P)^'V@_"34_AOJ]YK'"^&_'&M^(+N/4= L M=4GGNI(KO3$MV^V3PRW,RJZ7$2R#RBRKAL]3-

^5E\;_%=?)U+2X\/WPUTS+)%=&*V@{QQJHT2X\/?8+ +[(T\5RM+1W,5V&SH,L+]OA]QVV\3-?\ 6-IX[TGXCW_P[\/>#1]2P=+ 7_/:D>GV-IU1Z) P %)/"GPU_9Z^+'C/Q8WP;^+4/@?RK72-

6^&>N[-/U# M7)[E+..+P[/#+++/!=_:)<>>3Y,+E67P_M?#'C#PWXJ-M(+:|:+6+""UB\A53#$%'+$D;> M.O2N"T?_(*2^\ X5_!OXU>,O'=W\"OB!IGPP\/SZC_ &A\/?$)-MI.L*"(

MO#M_%+--,)\)#"%NE5$;S&W1)CGUW_@G5^UAXW_;YT;7=5\2K\"9M*TXQ6RM M\//',OB>2SOB-T]I>;K:*,&2,%.%=\DGL 2 >>W'A_!;4G^%1^%GD_!1;E[M(Z/_

,+9_M2Y.WD8V?:/H'V'78;OR0!L^U>3YWS8\OV*]\$DO!7_#4UA<> M)/ ?@'Q?*/"OP?T7X>Z#9ZIEOJ%Q;W-I>WTDS"'2-DB#P3PY=&<))>&!M#K

M4^*'QT_:'^)7[=7Q"^%WPBU#X,^'!$^'OAK0-9GN?%VA:EJ5U>2ZD^H+MC^S M7<*HB"QIJ?2?.]JV_'7I0/Q@_9O@^ ^B^.YOASKWB?XH_$E?".L7>@:9>6-A; M6#Z9J-

XC6\4UQ(ZSAK.-2SNRD,WRCC !J?L%?LO^*?V*+3QA\.GU"UU?X3Z1 MJ2W?PY=KAGU'1=.F3,FC3!EW-;2*?)E+LS12]C$>6*\) ;:0 P"'"=GQ;\5>(

M_C+XN\!ZAH6F>, ,$'Q,LO&'@ZX>]2(QV3>%[;0+U)W>"3RCM,\@C56$I@A5B M QQI*_M)?M&ZU\% V-@(@#X6T^QTZ[L?BOXNO= U22[C(O@E:.+9Z7=1_$GXDV/@[43>

(I&VM9[^_N M'EAVL,2AK5 "V5PS9!.*./E;XA?\$I/%]E\,_CYX2\KX$$GO MC#Y=IX<-BMRLX5"(CLM6V!=P;C!M?3WI2WP!\0?%C]JO]G7QEI/GC1_A9XC MUC5=;%Q.8YC!=.'?6,1A4

A5YUQ'D$KA".54N-SPR\938W MT!WQS\40_L^6^AMFE;3XGCW"1WE0QOL M,[@RDJ"=H /+_C;\$OBS\$OYIM;^+OP2T3P.XUD^(VG6&D^,/"WB/?9=%65[

M!9Q9ZC:WBP7&D@DYBD@,95E5&!+;B>D^+/+GI'WQR_;*_9(=Z9XWU_P_=W5-MQ[XU\,>(K7P_;WTI\ ^$-+TI5--N&LO(!(]TIAM!)92BK--)PD:8JE^S!^ MV=\?_C/8^!_&\,GP

^)/@7Q;=V4>K>'O =S, 'Y)\'_ + _Q*^%/C+XD+?? MLB_LO?&-?$_C[Q#XHL?$WB;Q+!!JES::AJ4]U!%*DFCW#*T< MQZI\'O"O@C18?A'9_%J;XR7_PHUO5KC3M0

MNO#$PM!'N=6%W:P)+,'XB^\"O#.DW1A?>/Y-(.@WVF,;VFBC9=/F\^(M?;5?$9Q%G:-V {QS MX(_;2*_MJVWO(!)?"OX,^)) $GPOTGPIKFC7_Q ETU=&U"VU"_O)!#.-/E^

MTQ8NT4.4B)VD[!TJ;]HWX[_M, L6_L>?%WXF^/M4^\'BF7P?X=:^T.RT#PWJ MM@K7@FC4?:3/?2[X=K\Y8IC9Q\W:O1_A+X9_:QLOB)!$OQ \6_L]:EX125O[M2M] |*:O9ZC-

&5.U899K^2-&W[>64IA #8S50!UWQ+\,>-?VA_P!B+Q?X?L#:Q>'S]XF^$,P\,Z?>_"J_\ T'B.R^(DNH2&Z_I=[*WE-J=.CQ&\NPO M^]C5B?GGO@LU+XU?ME6OI;

<'P8M_$OI,RSWO@^Y\;1:BWA+6B$MHM0AL_(9!-MJ S(?.5MX(7Y3\O.:_^^;2#9"A=4\S:_O7!GOC/;K0!\>_#^T_:5\;? 74?A? MXR^$GPV)Z1/X'NO#]OKNG?

$675)?N_L#6\''C'3H<([X);S"4!SA][_/81-M_P""??@7]E+X%?#6!?AW\-]&^(GASPEIVCZUK6CZ#:1W5U=1VD,=RWVI8DE< M/*C,6)!?@GFOH<0([X"]!Z8]\TX# P. *

&00F%3EBQ)S3Z*"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH *;+&)8RD)&>XZBG5'=.8K6(Z_7%-M 'R/X\=^OOJ_9,_;2\<>,_@KX:_*$?PS\6KJ'6O$?

A_Q'XBFT"YTC6(+6"T M%W:W26UR)(9[>WB1X?0;&A5D.'<5/\#?V4OBM>_&(P\X1^*_BK2O%%YX9_;=_;>^-/[/M/B?QCKNB^&O FG_#SX$OA-X9^&/Q/\ AAK6

MN7VN:!!KWB2X\/:GX0^VW#W5U:RLEI+=4TJP^PV=S?SB--D$9)80P00P0(S MDR,D"EOF)KRO]LG_(*6:I\%M/\ A7-\// ^L>,.-^(VJ^&)+CQ7=6K1^'=* MTK5M4M;)"9BZ-

+>R+BVEY?B*U]IO+0 :WB$OFF+;S0KG/R M;=H) %5OBS\&?C3\|_VR?%GO5^#7ACP-\0=(^.'C;;8^*$\2>)(Y] N;"'TT M2I:W=K"?!D/B:RO?$EFUIJVJ]-

1OI.XO#!O8QV9%F6B5T65PI?&U MT% &)X1_8R^.GP>^#%YK7A3QMX.B^+OB/XB7?Q&\6Z7]FF7PKXD%Q"MJVD"1 M@US!"MM'!MG),\(D="C%!YSX]_X)^_%G\U/5?

C#XVUGX=_"7X.^*O&7PC\0 M_#FUTKPWXAEU(>*+R_A1;>\U2Y6SMU\NW\ORXL1O(@FF);.54=7^OQ_P4/\ MBA^T\3/"-Y.);BXTIP3,^(2+\>6W MA\32Q0^)',TJQ202*D4OV58

XCN$/F%E*4 >H M;?L7:\O&O^"=%E\.?#EAX M:B\V0P.1%6D?AGH[,?CQ^VWXC^&?A-?V?U\. ^'?%EO+6+5/B#+;^+I6M M;,JE_>6>DK:OO,HN8@'D0.UJYSL <^]?

!%&/VB_'WI/7@;X;VWPTB\(+XK^ MQ0!TWP5!<>);.XO-/LDNHKES.T4$L4C%3 N ' ^8T >,.^(O^"77B;QWX<^% M_P#PGI\ _$/Q%<-&_ $SXH"72U@T?

48VTB]T^.WMK:59/.2W1K**,3?.R0%V M(;@^C_"C]A%OV/OVSI?%OP?T_P ,^&OA-X_T^6+QOX0M(EL;6QU6%5-KK%C% M&FQ6D1?(N(DV*P\J3#,AK(^+/Q3-

&H/V3_V9OC#\2_B%K7P\(>O&O@/P%]VO MZ58^\?#>]ZJ?)+J-K 9HO/>>>^E#6V"\'5 KDE<.,'MWQ:^,&]^ OV-_$_P 0 M!>UT]H8T?5=>(X8IS:[+\>16#W(1E4]O+WJ<-G!/,>;

/(OVXOV&|;.:U^ M/EAJ:OHOX6D^%'C#P1>32.C7=M>ZK+ICVD\43HR,(VLW<,WW76,X/;S!]F' M_@GO\3O WQO^!OQ(\;2Z!/XKTV^\8:]\1)8M0$SR7VJ6EE9V:V[++#&)U2WLH

M(VV>,_P']OQ#X8 X)8ZM\^>;!V :,_;L^(?AOQ1\'//"/A>7X5^!]1^*'A,3Q))XM\)? MRW*Z#'<1+;,=*M8HI8C-=NL\DJTZE88)&P^TB@#1^'"7[%OC7P!_P15?]G_4 M#HG_GS?

#75/"@:*\9M/-[_LB M_"33=%U+1M*^*?P6;1]?\.W-V'GTM|5L+)K66WN-N&-M<0RW%NSJ-Z+-YBC> MBUVW!)OCWXG>,- UZR^*N@Z!9ZWH-[';V6O>&W9M"\6VDEM#.E].)*

]RPX:2 M2)XW)27P9VNZL&KYQ/[<7Q^^,/@@^)VO M*?5OBS\&?C3\|_VR?%GO5^#7ACP-\0=(^.'C;;8^*$\2>)(Y] N;"'TT M2I:W=K"?!D/B:RO?$EFUIJVJ]-

M4KVMND5G$))'$0#.TJQ.6 3!YOX=?L M_^)/#7_!$4_JIL"C_$IOA3>>$!<*X.R_M&7 3Y;=',_EIO+\OU)?;D#)P36

M,^WS^TY^TA\"/@+HOQ5\$6WPG\/Z!>0^';34?"WC/0[^\UO3=1U74+:Q=`GM M+U(0L#7<9*JK9\F0!SN4BQ\Z3=68EBNHM-41R&6 M[>1D%M@[3ELL2*GQE_X*"?'G]CO2OC-H_P

1H?A-XH\6>$?A-[QO\,7CA3 M=0LK#%E-JGEM-0M[BYDD&'26%HFD7>JW P#'D^U?!C2?VN;SQ9<0]OEXN_M_9UN_"4SQ3:Z-Z*F?]LR3CCK4@:P7^T MS^RO\=_CI=>"?A-\-

/'WA;XG>.W\8:??ZE\0Y=$NH4?3=/LC \ TZ<9!LBV[M?SY@&!C)^N/@=;>-K'X7:7%\1;[PMJ7C)1) ;-SX68H9Y99$Q M'L!W2-E@0& 0!U7V:,?P+^5 'R)^RS_P37\+>$?B-

\6_%GQ, ^//PP\2^)?%W MQ.U:#Q;H6KW>CVN!WUI8S);?9D)^6'S(Y(Y("%4D+G(/-?7%K9K; =V] .% MZ=.E2>2N0=HR.G%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M

HHHH ***** "BBB@ HHHH **** "BBB@#*%9V!Y=>';N/3[F%SU%X76TN)(? M.2"8J1&Y3(W\6P2N1D#&\7Y_2"[IF]X?M&_&SPC](COX):%\&/&FB3W;_$[MXBZ#>;>+;XH636%QI[6-

LEO(UW+!,SVUTOV!5-0]DC4!VK]!/%FH?V1H5W=^ M6)3:023A2VT-M0MC\<8KXW\.?\%5KGXI?!;X'KX\"Q^)OC1\%?"WI.VMZ7J5YXS_M^SFTWQ#'HMM+#IW]GQOR-=%YG-

M)*+F"%519P# MNV9^@_'_,&/$GB+_@IO\)?B#9;,)-XA-> ?%&C:C]!GC M[N\O-&EMXBA; M>V]+:?"SX3_ P\2V/PMDTFUU'5/$/C MF[T=[F>]TZ&]Q%#%HP-

B^:5R6!.!Q7=^"/VI_&^G_N@?]SX7^/?!?AW0_%' MCGPIK_B;4FT7I=1LM+;,3;RPMXX(GDMX6F$L=\KLS)'L9"H#CY] .X ;=_9E

MO/VDK#1X+3XH_%/X9'29)9&E\%ZG:V4FH;PH"SF>WF#*NW*[0N"S9SV1,2#[M+81QF620Q*JF1S\[XXR2!U/TKQ7]L#]JC6_@AKW@[PAX&\#7WQ$^(_CV2Z72 M=.%Z-

/TW3;>W13<:AJ%V4?I/;QF2%25C>1VE541F/'C'C;_@HO\ %X$^&_& M6G2?$OX,.;I/C?3/!V1^,/# T/Q5+]OA!Q5'I\'7G7>GK>FTCF@O4C <1O;D.K M91B%?: >?

>/O^'=/CCXJ_L,_&7P9J'AK2;K7=1^..L?$K0M!U>]C?3_%=C'K M@U"WM+B6.N88KN%#&2<,GF#<%&;Y,XQ?\$\]'Q'>F?%#Q$?A5;_)BUSP+

MIGA:U\#Z5J=H\/BJ_P!.UFWU>WDNSILDD$-J!"]DLBDS[+R';*\N+&TMY]RHT,I%WJ-NC@R)M0 M2."VW;>>_,%_X*WZM^R?AJ^(O^%&I^*O#G@+Q;X;\(F!L=1Q>.YWA MM8?

+V,UK 8<(9,R.[*?+ 4L >;:_^R[\6?VAO$>J_$+PS\ ?!?P3U+0_AO<> M#8_ WC5],U;2?'L]7EI=PV\]O8RM;K9VR07,44TV'#WQ/E*[']^OG\'?%_ MC3]M2?XS:I\(I_V?])M-

\$3>%KG4+&XN=>G%['=0W;)82R6RPVJ>?%$S'S M6^URC:BJ-WI7B/\ ;>TAOBI^SSI'A:WT[Q7X:^/K:C+8Z]:WQ\[VM[;2I-1C MFC7:?-$H14QE=N<\D8KF=%_X*6:9+_P4ENO@1/I,-

MHPMGT^3\227;$,AXBC MM8+^?2HXQ&@_W=A/"%,H??E/+QAB ?.?[<'!%__GO_!23QWXY\'_LH>*/ MVA?"VN>$O#^F.%]&D>

(=.T\:5<6LFHM=QO'<7!LQWBXMB&PP^0@8!}3\6/AC MXRTS]F[[FR_^&Ol-?C/P!%\/BA_;LWPZ_MW26U.VTX:=]L#3).!XUNP;:^1 M@IGW?.>!C _0B0}\#.H#';<=LU\?

_$;]LOXWZW^U=\3OAO\ "7X3?#OQ9;_"-M]3=(NM2OO$GC>XT6:[DU""6>..&..QG0!1"P+,ZC)';. #B?VC?'GQK^-WC# MX%?$:R_9D^)%E=_"/Q_=:C?

>&;C7_#_]EA97&@:E9"YAD6^-QM2:ZC#*\JO MUP",:ZKXRK\4/VSU^!6L77P9\6?#F?X>?&7\3]=U2PUV5M*GG&E0Z7]$;WRFU MN95*"6YCCV9\PG)V[>;EM_|@IUK/Q<^_ P9U?

X3_##5/%?CIXVV,^IZ;X?U M?4/[/L/#UI:LBWUWJ_&DHCMXW=8XF2-S.TI>Q<$[?4?V2OVE_&_Q+!9^+?!

MGQ.^&5S\/O&'A&*TNOM6GWLFK^&]>M[E7*R6%\T,)=XRI26)XT=&*G#*P:@# MYN_:N^#_(T^*GB?Q7H'QB_9-\-_M,Z?=:G<_P#"$^+= N])TN\T32Y662"R

MN9+N:*\LYH)#@SVKR>8%,FU6_=6WOX+_ ?^.7PS_P"""<>@^"?[\A,+]+O/CG MI'A&.P3QKB,3ZC9#55B&U\V)/.J-^]PY+,=Y4JY*UT?[>_]2FJ_L:LL^*?B MGIOAJ'Q3;>#EAU'5;+

[2]NZZ:)T6[N%*JY9H(&DGV[?F$3 $$BH/C_VMK?X M1ZM\)=%"+,3;3Q1KWQB\2V^B;1:B]\@"S\B6\O-0.%8O';VL+R84C=$HO($(65I#M=_C?4'QP^?B;Q?_P

%#/V?/'6GZ8]SX6\$Z#XO ML]9OO/B7[%+?)I8M$*%@[!S;RC*]0NSYL9&#O@)H.AZ MQJES]\VIV^O;_);S6NGZ'<6NG1WZ6D4CILNIWCD1G6,XB6126W$*>;M_^"]^-ME^

_AS\8V^(?A:Y_$;X-Z[%H5SX4L+Q;]X\1O?R\$;$VG.X7S\]*[-(=CD M696_U3&@#E/B=_P2>\'?M??M\?U^/QC\7O /IL>&M?_^&M)\)ZNFJ26MQ%)%*M'WYA\B57B>-

I+8AY%QG:5S@UX=\7O^"?\ \2+#]FWX6?"_Q)\$A\9_"OP3 M^+-U?FWT*\TS2)_'/AR;2=12UU"7=-:HM^EQ=1)= E3)+907A-?H%XL^,_MBCX4_LBW/Q\!\8> +^Y\8.;H*ZC?

>#O#$SZSWCOP;XS\]7^$OBU\+]#\&^,]'\":A\1-$@T?Q.=;L!8TZS<15P2 MS&VA;&YCEE@##:T;"=2COM< ^=O% [*EYX]_8%,;.^'7PK_&/_ !C\%>-\ M>>%5A@&[^)=

(NHO$EO'+B.U4Q:C<>6X624[GV)@G+9Q7=?L2?L^:^%?@W^TAX M=U;P]^PKX_\A#?MYU]_BN\\4:1>6^DQ/$RNSOQ:I-(R0PGR1LWS9P"1T?P M?_X*4_&*ZMO@;XA^>)P<\&>'O

/Q]NM.L-#U/P[XUFUGA=.NM0LVN[/[3:36 M5OB(HC+(T<%0372W"_!2#QCX> ^+6G7>L?".XTGX.ZOX\B^&^G^(K_4I MK7Q!<:C+,9R0*^D(FW1@],TU#&Y90H M^4Y(V\=?_K5)0

4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %17IQ:.TI=1D#FI:9<*6B(% 'PQ^W?\/OB\4?B;XE\)ZS^S\X8^. MO@?6I/1OA_XACN-/L+OX?:E)$T-

S)>RW4HGC"OY,T=S8HTJJK+M+*M<'8?LV M_'O]FCX.?%?X,Z1X(N?C#?XB/KEI:65GJUYHEH>IW.J0S2)<+'YU-MJ]PBVT4Y*?2!22X(KW_QQ_P

%+/"WP4^*/QWTOOW!%X>\,_!FW\/S)?"3M=?? MB&XU6WGDCM+>V"@M/ M_C);Z_K&&@>(_&KN0=

M4D@5]" &KX92_&+X9:IX;@\3^*//DVIHBKK7AVYBMM4L=KJ^Z&26.1%)"[3E M&^5F'&%=-M?#?C*YU5)X] M5U2&PFGE>6QMRAA\|)%0*WF8(+)C->W_ +5_]06G_LN?

G6O&NHZ9KFO+IGD MP6FCZ+;_ &C4=9N|B9+>VM+>/(W2RSRQH,D ;MS$*":. -?X(_"F;X)?"FQ\- M7/BI[Q?XYET\2EM:\3W4-UJEWOD9_WLD442';NVKA!A54')Y/A6Q_+-_B3QA

M_P %%_B)XFNK>+U\"^_@UW@N/54FB9UOQJ6J2S1"M,NW)#=1.&*[JN -]:\ M%8EY^VW\;_@MJ,B.S\9/@?H_A?+ZJ[5MIDVK>&?&\)\0:CX7:Z<1P3;E;&T@ M-M181(\<//B!-

X$M%\;>#/'JY\.H?#8 MU6:6UU/4H=3%E$_VE+&?LT?L(?$'0?#7P!^%$_P1 MTSX6G[GGO/;ZO>?$O3M7LY+'Q?:VTM-J4WCSP-\,/A;\

8/@E9^#HO@WX\T[Q1#\8;'5K(6OB"SL;S5VG6.07 MYO[ZU=K66&6-84\Z8AS&D<;?1OQ$_P""FQTSX?\ P[\3>%/!4^OZ3\2/ASK7*

MQ+O9I[_LOA_3K#2X;M(YEC20F6:>Z@@&2]KB8Y9D"')T7_@KMI7C#_@EKK_ M .T/!A*1=>\)6T$>O\ @JOO*N=(QVEMU:VEE56(4Q7$4\;[.R121M@;B M>:.?%;]F/XN?&2_]

$GPNN_@<X-\+:A=_$FW\8:=\9_#9T_3=/CM(-0@O4O9; M:.4;@VKM!&]K(-NQ\'+&41G%>M?\%D_V:]<_:6^ OP[]TS2/AU>?%;P\/_$C2

MO$&O^%K/4\+>QGU+2X8KI9D22XFA0,#)'QYB^U;__4'_P""C^-G_+"7B?X? MZ;<:1%K%KXDO)+SQ)>/=O%#X5T&*YM;.YU.01QNS;9KRV558(C9DS(NT_4>

MG,EQ;B1"LB2?,K@A@X/.01U% 'YF67)•W_]/W1!?@<%:?L<>,_@CK_Q$^&6 MKZ1•W^]>)•%X-9NWMI(K:Q'E:C<%'9IF8.P6,]4YR(=1_$GXDV/@[43>

M^%VI_LV_$;P!=:G\/-2T>TU;6-|$4 %M>R2 R.P 8H%'5BM=[^_MVS^UIX^^!GQ@^$G@#X;^!/"_C3Q5\5+G58X%\QO[#-HUE8I86BW4C&6*VN&8L MK$;.HZ\UQ?

A'_@IOK6@_##XNS?$CX9W^G?$%3X.ZW8>'[OPUX3U#^WH?$E[J M44$FG0Z;.T<+,\OVF%762-#"2S-\H)H \VLM=^./Q0_X)-]^S_??LR_$?PK MK-Q\'_P=#K>H>(/#\NG2Z@FA26L20WSR@33A45B@ W@MM)'>?'.P!\4=# M*^)UGX(>%?X2^)A#0#TZQU?'P+,FF?VOH^O6X %XG]HNMI=0LC>65\R-M?4JR;I*TT^.,T^..B_&#P;X?5

T_PI9^/4GCT_6?""B2;Q-8Z+;]MGU0FT@^S>8,I*ADB,@*EAN4GZGMA')9Y."AR2>>?ZB@#Y-_X)5?IV>(?V<_M 7CNWO?"M[\-//OB3Q&-4[' _ZNM735G\%6'V2!)HO-

CDDC0SW(N)_(C=HX M?,V]QYKPG]JG]G;XA_'C2?$OA;X1_LH>&OC=X[,EY,^#_BIX;U/2M#6PM7FE MDTUIHYI4U'3Y;4R*%N)QB/S%+EV0?37[-/[=]A\5_V=?B+XU\<66G^";OX0

MZ_KVA^+K/[:\L.E_V7(|>>)61&*26HAG&%X\[;DE37E_QQ_X*_+^SM^QO\/O M*VM^ =5D^('Q T2T\16_A*R,\QOI5C<7=K$TU[?B(QP)"EY"&)'SRML0,"'" M#I_VO/V9?B-\0O)

@F+X9^&\%$\0OB/IEQ*.KZC),D#ZQ/\^LZ9<:A>,ZK-M*ID)2WGEP6R<8&3@%W_!?]AZW_;9_:-_9VA\1^#X?%WPV\^ZQKM]XCFNO(2 MV672)8K1B%D25LW)C&(UXZG"Y-=[\8?

VM;KX"_M@_#SP!XE\/QV?@KXJPS:=_MH7BU+SW25X10QW/&8]H8@F3]CGJKFZ_;,G\8>(]#\.Q M6?POL=4,2?"/B10*N(119T\N&0NS3\??:,JI2P!\??&'_@E MOXK_&?/AI^TI\-

/@WX,LM=^'7QO^&^ICP\[7%O_ &MX?U[RY$&D-\= M>,D\#Z)KE[KDD?B)+R>ZDM+.ZN])>V0PVMS-&JIB9I56>)W15+%>5\8?\%,_MC;86_P AW,4_P,_M?

A)>>,=$TGP9!X]\1:GXAU23PY!!8RHTBV5I,T$D,VHB)&=XD)(HX@T6Z3YC MM^D?@M\6-(^//PC*^-=$6Y&D>,.'M-;L1=6[0S"WN84FCWHP#*VUQE2 09&>,;214E &.E% !1110

4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/X]C:?PAJ<4:.\LMG. MB*HRS,8V]217Y/?L3?L(^_|@E[^SE\"/CEX$\(_$'O)XQU?

PWINB?&K MP/=O->ZUJUI(]"&2UAD!,,VE.=J6Z! UNIC)W+N/ZU^(M2M|&TJ:\NI8X+.T MC>>65SA8E52S,3V -?%VE?\%.?BO>^!(/BJ?V;M=E^!UW<126.H6^N&3QE=

M;;+,D4>I#01;O*8/YWE?;/.$.'V9RM _\?/AOIVD?\%(_C_XC\;>#?VSS MTBV?P_/X?U#X2+XAAR\U"';.&4SG3I(U;5)E=/W@+++C%>G>)0DG-\'OVC M_PF\SXH;0+?VE?

$0@C1OASXJ],2QW^A+4]9\3V%Q+?Z1Y']HH(6N%>5;*9P M\I)<-DYS7O_/P4;_X*:=^P5X#!)ZQ_P (_+XJF\2WI5S36J7+P&PTFUFMN_M]0U)PD&_V%-9^#VH:MIEQXA\&?%#5)[>

M^UZQNU,6@626[S_VFRX*RVR*RM(P8;(MSC=C:0#@?B1\1/%.K?'[X MPD!F\B.VN9Y'F?8"[1!-VUZ]PU3]]>.3]MCP[\([,28KFWU[P)?^-HM;2[#* M!,?UG:+ L07YPXN_,$F\

>6!@ILCS_]9E_X*1Z1^T=^V7\1?A.FD+HZ>$5. M/#VJRWAD;Q:CIMY'GB[@:,,:Q3SEC!E%JR-MMNW&NP\.? +QYXB_93^"WB6^\(^(^&)+^)GB^T?0I;&ITRW>]E3S;R

MWR?),%@#:)(V%7"*Q'$$GU31O^"AWQV^(NH?$G5O!7[/GACO3X)^&_BI6_#$ MTZ?$(VN:=*N'AF>WLFL3&99-A\|N-[A0Q(!=0':?V!-%^./ MA+1KGQ6OC&TTH^&=

:X6VNM6OM2EB@MK%R@D,:O_P3;_:*^&_{)6F?&2#QU?ZO\2=%\??!+ZE^ M&$?@^VBNH|=G9I;S2S?6Y-S)(;.>>R\"C*MA4PL8 7|.?V2OVAM%_:Q_9M\&__M$;P_-;RZ7XMTR*_1(9#

(MK(1B6 L54EH!0\9RH.4.0.E>BXH SO"VKCQ#X5I_M-06"YM1?VR7(@N8FBXFW@[V.C ,KC.*& ((((!K\N/VK?@#|-]3 _."F/OLU M_P"-'|/?QM^"F@^(=*\-

V_AG4O"7AO5]0LF2&TN$O(G:RE12P9XP5<$]<=Z_M5BC H _/]G'X=?$[]C[3_A#\;M6^'7CWQ/HFD>$=7^'UQX.T[3UN_%OA/PW M<;TEWH!:T0@W$EM:0PV|S&K-*@"M^|

(D(^N?V9/C[\0_VC_BEXCUN^\ ZW\/ MOA/8;=,:0: OBO36T_P 1:W1>1KJY;V.A:VM8T\J-4FC$DCEW!"8W?0=!-

M&&XR\);7X^\"ZEH6MZ?!]>C:U9R6%]93INCN8)4*21L.X*L1CWKX&_X)>?LT M_$.P^-EA=_%/2-2M[3IFOPQ/*_UQJ-D8_[9C>\8R:S"^Q4VR:?:Z5#F(LN M[SDR"F7_$1HH ^7OVG?

AUX@\5?\%$OV5[=TV4-3OM"\+R>+/]9O[> O;:2) M]}2*8G'">8_RKG]1CM6%^TS^S!X?_X*P?IU>/H?"%$]-AX7T#Q1%)FLI"[MVVGS".T&FB<@[-X-Q?\ D[P2#)*5YZ?7U% '#?

M+?%'4O@C\ O%GBW1O"VN^\M.-8\/:9->6'A[1H&FOM:N%4^5;1A0Q&]RH+ -'1+8(%?_[';^(_C)_CGX M@\;^#/C;=?M _$;P'?\ ]HWWB/P/?Z'H6E6XAD6U\/:-YXV^7%+<'UEN'#RN

M>BK^F-&,T ?B_P#LI?LW^%_#'AC]G>+X5_LY?'KX>_M#>&;CP]#WC#Q'X9U M6ST/2HDBBB\0--+>2-,^5-9 ;856./Z9S;+YEC->136SQ//OE,:@Y5A^E MU% %:P 7<

3CMG_/U]LT=** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HEPVCA) +'T%/LL=@0LW04 ?F7^E)_P2]N?VX ^M*%/\0?CB\)+&$/$?

A[3O"5[\)_$!FECT6SU^UMYY1J'@YBNG@FCAB?<&VQ3 M2(,%\CE/VI?%7C/]JGQ!^S)X^^^/P>_;5\)\7/A.T\7Z+XSL?AK;:HFKZ9J9_MLR*&6*XL"DV%R89I(W5MCJ

*M^B[&C4/&\@A9XY-C2!P@_]1+N[BCQYDD<1 M;>ZKD98 @9YQ0!^+_P#P4"_8K^*FH_'KQ?XL\-_"CQHWB+QSX-\,Z?)X<7P MCIOQ \$>*K^TT\(=-\UV2XT:&W8O$)&9(9&C\PL-P1_TW_9:U^WTV3X<>'?$ MOPJ?P+\2$^'UI=7[:5H32Z%H**R))H\6J!3'F.7++;"0G8N_! S7H'BS\]_X M4^*

]"TC4M=^(_@'1M,\2]TNEW5]XBM+;#550@,8'>0+%++G82!N&>HK0^\7 M[0'P]^+VG;G?^$O'/@_Q19Z'\^HSZ1K=O>Q6&59@9FB=A*\]L?FQPI/;@##M* M*Y/X7_'GP-|<+*\N)?7C/PGXOMM/<1W4NB:O;Z@ELQ&0KF)V"DCG!OOGI_$ M/P_=-5AN3HBUS1Y?#(M&U ZNE[&UC]F52S3^<#L\U"2^=#\)<5AS-P/Q _:MM^%OPFU"TM/%7Q*\>&;N_MEO+:'5?$-I927$##9VRHLDBED.TX8<'!YXJ_X(M_;#_$VQTZ\}-^./"'B&VUBZEL;"73=9MKM+VXBC,LL,31N0\B1@NRKDJH) M(YH Z^BJ&M>*M+|-W.GPZCJ5A83:O.'\,:C\4?AW8>)(fE;-M)N?$EG%?+.S!5B,+2!PY8@!<9) M(&*\]##AC@$$_6@!;*** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HH MHH ***** "BBB@ HHHH ***** "BBB@#SW]K+QKKOPT_9B^(GB7P08MJ?B;PIX M7U34]\(LA$\INJR&SED@C'\)S%I%487DYP.:^_ A[^P=^S0W_ 2V\-^)_%6E MZ+IND3^&+'QUK?Q(6X5O$2WA6+49M5_M?:]RTQF!8N&)(.Q5VD+7Z!RI.-^W M!]>AKY9F_P"""0?P/;Q_-JXTCQ3<:.VK+K?\ PA[^M0?P?'>K(LJRC2#-]C& MV9!*$)O8KC(7M0!\^_|!37XH7NN:K\6==T35KS^R_ACX%T#PM/[=I>PQ3:0 MOB76+7^UK_S(U6XLYH-)ABF\XE45)=Y7 -=_.^WY^PW\"O@E_P3L\8:Y%/\#> M#O!6H?#'PX^N>"MM>:_#JF+N._P!UK#:>2R."! ((401$;0"WJXUAX)_MX)!_ _P9XPT6Y2Q\9ZWHWABZAN]#!*ZYXQU/5?#.B30D-;R6VFW$[VZ&'GR_MD(CW':!@8 */_!4^_O\ 6?\ @C;\=[6K6K0;K%Y\+-2GOK,#Y+2=M/9U(V"M^N67]>G04OOGI_.94\6?'SXQ_ 3U^/\ p3:_?MGXMOO%=GK.C7& MHZL!PVD)?JGPQZ<@WB3;'\Q)%&.X MA5 !)ZI*/A[_@G T.G?\$2M620U"EI!XJ6<2 1B C6=8+!P?N\'}W?C7@G ML/.I.6H>,_A1\&_& P -_"/P5^.?C#PS\#O!GA;Q7X \?W1M9O"JKI?VRTEL M!#;W"\6\MT)2)(YHAO$4!##H%/U_X^_X)&_!/XE?$GQ)KVIZ=XM^S>-]1;5?$ MGAFR\6ZE9^&?$5XRJLDUYID4RVTSR;$9]R?O&0%@3G/3_'W_ ()V?#/]H;QO M#XJNX?

*%/A'Q9#8IL,FN>" $=]X.U:\LXR3';SRV4L9FB1CE4DSM(&W\2'@#X5 M\<>)]-E_9A^ G_"F? $_AKQ+X?\ VGI+5_A_XJU<06'AK7EM=7:\TV.XMXYH MX;)7D>2,VZ.F)>%&X@)_P4.^-/I1'@KX\>__%WC/X?\ P^\+>)?"/PW^>]>I> M$O\ A$?%-YKUQ>7B:.;'#!|.V>/MC92A9B<_=QS]^Z#^P5\,O#7@#X?^&-.

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|-)*EAKGA??[$O-9@A<%9(/M-CJ7JH2,PS:?;*]%#(2XD)!51M.XD>-R/%=YJWARUEO&_MZ\W1%+T>>/+/R9;@[>.,.5^F'OF^!GA7 MXY;AX*NO$<#W4_@'O),:^*M&,=V\'D?\4,\$3O<7$]6\%RD<9>6 M1F(50,F@"G^RYIUOX?\ :^"M/!0]!.:=,Z,;VGPV\

*00V=LBK%;(DFO 1]% 1 M5084 8&%XX]IX7"R?\%O?&TJK\W _HWP^A.WGC7]9./U_G5_P")W_!*WX^(VK:3-J=K8^8+.[48)T^T2*9I3YDF6) MD@^&;7PE'JFB_$75M.OK[3[>6::M)+N:"=7N!)-*QDE+.Q8DF(@*73]OJ5;O!A?XTQ%3\;@+700P['3KC]^\'^> MT?\ \NSXA@*#R_|.AG.=,XRA!-,,?2OHW2/V?? #^G?L\3_#&ZO!;UGPQ>:/ M+>:]^?^^/OPQ\$>:,;!1(-? M^-&I^&|1\/W?AF71-9^).LZEI/ 9US;/,"MM-.T2[89&$9"YC(4K@B@#L? M&0Q_P2\U1'I6,?"J8E@I(_LU?!G[*W]+/B[|IC]DC!GG/1=,_9;\&__M"==&M?!OB(_%%=9TAM1EM[#['=22V\-FOVLSWD2-'ME9 $N)=[9 5OMCX5?\ M$L_ 7PE-S':>)?C5K.G7>D76A/I>O_$C6-5TX6D\)@=:[,SSM&I6-B$8+N3C: M0:]]^%/PNT;X-?"[PUX0T"VDM=#*:5;Z-IT.DK2O%;6*OQ(SL25@B>DDD MXR: -RR \HI1@$D_G4U-CB6(:, G)IZ=0 4444 %%%% !1110 4444 %%%% !4- P#\]>K<@5-39618R7*A1U)Z4 ?

$WP*^" _@C][C]O MG]HI[7OB5X4T+QAXF^'FL;=X2T"RUZ :A!I6A2:59WJ$V!I,&2$W-W+=%YD4> M;!FV@_NS7/CX??#+PM=?#'\G[X4Z;[PS-\7K[4-;T8WMO/!H<>DK_;-WIL4 M,\?-K'>R:>GE0[C"9PH==I]_P#VF?\ @GQ\.?VG?B1I?B[5IO&GAKQ9963: M8FM>#O%5_P"'-0O;4L'^SSRVW,=S=RX,"?'/@[7_ !$8 MVUZ?P9XPU+PVGB-D01QO?1V# M? GA[3_#'A?0(1;W&G>7Y<-NF2OXZL P#69B2222: /R3^ GP'\4?M' M +/(/Q1+|#Z# R;X&\43^+_ %]4 0VDZ8CZ>5SU6O80$WA]M' ;3_ &'S-48E>0" >17L/Q4_X):?#'XO?$&Q\6RZO\]2 "N:,?XS>L MO"@N_"?CS5-!^T;?;-*]O%,+69!*8VGD(9\M\U0^)O\@E;\-O&?PI\->'=4 M\2?%^\'@_6;C7!'UR7%ZCNVO6%S/&VE":AY_P!H$30LR^7OV@.W'S&@#-_X M:$/\:OV/QM)/_"[;+O MA-J?@[5?$?O?

*UBST+Q.GBW3=4O/B-J]QK6FZ@ML]JK07SSFXBC$4L@\M7"Y= MCC)->D?LU_LQ:%^RSH^JV.B>(_'^OQZO<+/-+XL\7WWB&>%E7;B*2\D=HT(& M2]D!CR1F@#R/_@DG&L6F?M'A5"[_(]>+B<#FJ?/AYIW_32;9\8_P!K\K&2 M&^-USR!C)_X1!0P]Y5=N_P#@DC\,5XC^(O%FF^)OC1X0 #FQ$_P28^''CZ%XJ>+/&$6O_!H\;KX

*MVU(:OK4/AGXCZQHEEP>77DQP>=]GMITCWF.&-20.X1>;/CKX1> =:|=_$KJ MK2-+_9&\%_&N+6/B]XBL_P#A+-&;#1KW426O)H(%C>0%B6*D@X). M<5I_!?]GCPY^S_/X]/AFUN[9?&OB&X\4:OYUQ).9]0N%B2:4%R=H80Q_*.! M@D#)-=]%;I#G:H7- #Z*** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ M HHHH ***** "BBB@ HHHH ***** "BBB@#*\;123>%%%[=1.CS26\B1W^U6^P ML4(5Y^4[#4I\G&X^?GBOS*)?0?!$\OVQ/"5IH7AOQ!X9T>3P]K.FW/CK4]4

MBU2/X_:Z=.6\@6\B@F8V]T'MKRX%Q+&KR&:,/"N<_IWXFTFV\0:+VT% MY8W\3V]S!.@>,.>)U*LC*>"&!((/S#^SI_P2R\)_L\>*O#++XT^(GC'PQ\

*M.9'G\!^$_$E!+=.1X(D*21*]HJ0[/\5O+)!$\S+,8HY'"D%B: /F'X1_!_P MJ^SK\#OV:_C]X;T:]7XL?&#Q'X7MO&VNS7UQ-=^)(?$%G(UXM\^'_(+?$_P_]\'CKXFZ[X8\ M##W=S>^#-=]VI0RZ\3FGCEA9X"D*7,VR*XN(XUN9Y5C67=OJNN?LY:/ MXH_:A\(?2%2NXM6CU_P &:!GANTMU=/L)X/"'B/5,%DTK7I=,74DTN5Q\EQ]F=E64KG(5B!G&E13S@P_+YF>, ##?D: /R)E\5^*/@?_ ,$L/B]X;TG7O'FOZSK_M .TCJ7@&ZU;3KU8O%&J07GB:*UN&MI5.4:WL\9=%(\M%,O&T $4/CGXIC_87

*M^'WQW\#^%_A]XL^:'CCQ)X>T>XTSPWX0\4MK.E:AU_K|KHTNJV+F.(Q>($^ MV")T#[':[*=\##!9?T"?_(0V^ M3^ ?O)^'%_+K^HZ\!\2_%.I^+]0G^Y"&^T MS4KZ[^V>=9S1!6A:W\G"O$W+*4&2W-8/AC_@EWX.O_[C*S^(_B7QS\9I6\;Z M&?#-YX@\6W4 U.YTH.LJVMJUG# D $X62S$3S6E6-F<^7'M /C_5OAJ0[/U MC\8/AC\//A-K'P9^*GQ0^&MY/X1T6R]>I=Z+XG1;B^UM=1N;J18UMO$-HKC M)D\YU<2P_OI9IV#3.)O#NO%YXLUWQWX\'+'C:73%T.W\2^,)66]T_3=Z5&RA%M!#&]-*

*MJR2,4,DC+'N9A&@4 ^(_VO//!PP\;_!:7OXO)\3/V=/"?I0<=GX$\)'3%\/ MZ!']Z>'BTVL>9Y@>YA$9FVIMQNW>0V<;>?2/B+X#\&_#?PA^Q3;_#[X,ZM\(-M/#FH?&];K_A%=1LA!Y8R-HFO!_/A22159R@?&]@0RG@\5[?:\;_^"=%U\3?V ME_$/Q1*?&OXN?"S6O%.CZ?H^K0>%SI+6E_%8M1DG%^%3]O$M;_MD_L.*CNHE^),JAP&(W#_A%=:.#ZC(S3O\ @J-,M\(C?JE())&)/CH*/M8C>OJE:N=]]1P.*\+_+ @E!J?Q$T3PS%K7!1?QTU M#@X(1OXDT'Q.[.(NJ:5(UA<6B:KIP@:%X;J7=OB9MQX8#BNIT[)!4T MOP7!XT^+'Q1^)5YX|

*<6WCK2[_7VTRXCN8;->U2U86MI"IMRMS(Y&W?N/WP M!MH_^4?VI_V6+2W_ &F_B3X\^(?I/^L?M9^#-7U5;S3/$/WQ4D'*&_M*VGTFWTM[B-P\,L;W(>R/FNTQ##*K1*3]7?!B?2O'W_!,S11X-^,.IWNEZKX" MDM-%^)&KND5]$K6;1PZE<$^7^^A.UF+[6W1$1=V36)XK_P"""8FFI\0?$^M_# MWXK?&'X.6WC?4YM:\2Z)X-U&S33M5OI0HGNE2ZMIVM9I<$R/:M$6=MY^2#5Z MGIW[(/P[M/V4H/@F AFTO?AE%(\. V-<%GCGLQ&$*R,/F+MPYDSN+DOG=S0 M!^>7P9^ WA']DWXT_">R^(OP-\9_

*;XB#Q)I^F6_QB\/:[YAATKQY?B7RC:: MC<^8UPL>J# YWL"GS9EPRR1H]=U^U7_P3'_9^\2?\%5/@3:7_P)O!|S:?$C M2_'&L^)X6MG&>M7L/ER13SKN^:1'N)R">AE?UKWKP#_,$O:#1O$_A.:Q!\ M8_C7\0_"/@:4+75- \)^)=5LKC2[&YM2#9R2R1VJ75V8#AD^TS2?.J.VYT5A M[%XW_9ST:QY^T?\ #_XE7=UJD6N?#6PUC3I,M8I$%K/'J:VHG,P*EBR_9(IF MU@!N.%)9>" "_-^RK] KFY^<&I?$#X#^-O MCYJ.M^!_AWHBT>,6X'F5S% 8[F7>%,8W9VX+!@G)OD)^Q3\#'2V>_-^&D= NO"?[%'Q M+'_?B32_,O++#QSK

*{/@7^STYQ$P(\Y+R4B1E+(OR\);"6OG?$__!;B^^(G MP0\?^ /B!\?_(U-$/PY\0M'.BSQZR=&C?2P9%?[1;-,6$)$PV 9DWK@GY<|-MUO?"']BCQK|-_B1I.NZA^TU\=O&]C!Q>71-

9301IVH#;R(}3;Z=%+M&0WR2 M(K/PC M-X-2V$I.?V$VDM[%>,Y&W5/-\R%0#NV[:]/C!$8!Z@4 .HHHH ***** "B MBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH *AO\?96ST.*FJ.ZY@;C M/MQ_6@+#\ |-@!J^/XC?Q\2M$\/\ BOXI>-]PP2TF/6+'6;:T?X%QVL!9 MM0LH1+'<3NI,\V$>]Y@P+$0$;N-F^'W@;JOGX.?M0_'K6_M'B7O?\/-BIM?

*MAKXLL[V>WETBUTIP[8ZA9W^F=/LK3W%P]PQ08+2>U?5?QP_X)F>&_BS\;|-M;Z9X^^)7PXE\=V%OIOC;3_"]],VMCXMTH<:W:7FPR212+#))#YUN\,OEOC= ME0PJ_$7_ ()^"_ '6MWL.A>+/B'X \$;_IECI/B3P3X:O[>VT+Q+96=JEG!#M(A\>>W7[)%';M]DFAW1QK_$-U 'AO_!0)/"7OQ_9B_9R^*I[XXO=|\-:EXB^_M&^H7W@G3;&,.#4-

5OM>TQWGN;MRTIP1).5CFOO>[L^%?5OKXU?&KPQ^SO\M,M4|9>,]8M/#_AC0T22_U"YW>5;HSK&I.T$\NZC@=Z%;HO|FS1VO?D^&_M=VB)\M&.:,%F=Y'M>90?

*LTZ#'^U1]_P 5WN-1GU_7 M:""5IX-GLY2C6/V*VO+FI5@FS<79[N0,2Q4J%&WJ2 ?F=^P+%;_#FW_9M^,?C M,X?>//#.M?%UK*WE^)TOBWI7K?BW6=3MY9HI+6+'9(!HL[$+,'S2\?E6A,.M"O?B5XGMGU'XJVOBPSZ]=7NK7)? W@S5&UCP MEX#UO48+00?!U(N=HI+4>2MS(/,D6!)Y14BW#: 40JO@'_@E1X2\">/8;E/-M&7Q'U+X>:=KY\4;/\-+[4O?

*#&C:EYPN8YH$\D7.R&Y+3QP/.88Y"K+&-B8 M/E?4_#OBCX_M3>++?CK\/-"N?C%H46J M>&--@%U=Z[8+[=;1Q%T$I) .TN =O7BN[L?^^3/@:U^)&LW2^*_'Y^'6O>(

*M3XROOAB;RW;PE)]S3+:,,^7CY:I) ;% 8\I/VT?_ MAS1IGQ7XL\%:AX/\26GBK2=:\,O;+?6=|;)*D3#[1%-$5Q. ^0T9SQTH _^$_B M7\) @SX3_P"""?G[5VO\ PV_9:\>'L_>

*(K'X0Z .:OK'B#PU%I!U"""2SE=H(*C MN9BV&B1F&!T4YK[6 ;30V | P2^^($H=[X^%>H _&(;(TB0YSZ^]*_ASX_\'>__V@_C9\1O#7Q#|*W _(6OK'7!HJ1V<5Y'Y3W;)M;'%A.]!PNX

MLGSME&XP[PA_P3JUGP_X8UGP_P"(OVA/C7X\\+:]XPBD\U$8[_6N!_:J_9KU;XZ:)\#=+9/@2S_;$^'_ <%MK/PFG\41:0YFN4MFM]>5)Y5 M@N6B^SS0!)RH'GLZ-O0J?3O"O_!*"

*IT'X0WWPZU?HCX]^*A_]?A&]\&/X? MU\M#%*8W%@=JB-K0Z?'-OAC<,A+D;D7<'&0>Q^*_.!+P_\ 5'_B3PSXP M^('PQ\>>>%@#T/A6+Q07X5OK>&^O!

*2HR"MI=1W$,UO<(K!G3S(28VD=D*EC0! MR7_])O4_4'P[\>.9X#LO'/O:UTGQ"%[']PT\5P^3<_#2[-E:EJ*$9?_$69 M0MU!MD>(B,]TA"R!TK]!OV7_V5[_&6=%\0"

*MWUKQ/X]\2^,-1&L>(O$WB.XCGU36[E;>.W1Y7CCCC18X8(T2*-%2-0 J].\C MUS_@DQH$-WK^F>#?BQ\9_ACX$\7W5U>ZSX+\,ZI:PZ/=RW1+7GD&>VEN+,3; MF++:S1 ,

*!N@5V4 +>#?\%5?V2O@Y\;O^'<_A/XW6FZ\3?$X_X0/2=.\?WU MOMOI/B\I[^ MK#X&S^+_ (93>+/$MU=> ?"FE+=RZE.VB2D3+.O+&K^GCF6(Q+C CR 2 *^W?

MC)^QOX.^,/[+^E_"5UOO#O@S1YM$-A!I&R%K*/2;RUN[6!-R.HCWVD2$;<[" MP!!P1K_%+]G+1/BG_AEV_U&IU.#5_A5>:E=Z3!!)&MO=/?64EE)@5)95C MD++M9<.!G(XH_)

!Q5HW@>[_&>?VS?$7P^'>L?!7X=^'_@WK/AOQEX3U?R MK#4YO%'"%IK:=]/2XE>V\JS,P,YV+<+=O[2XAROTA^PW\[_V=9_CGX*N/#G[# M_P 2OACXEL\?MEXMUOP=;V-AIE\

<+.)&G6\D=2Q7:IV'+.H/7-?1_P"TS_P3 M8\$?M-> &^O:A]?B/0K_P")7@2Z^:]?FREFAED21'47%LSRF*7 M&0LSHV]<'^D"?]&_Q4_\+_&>B:O<_M4

*O\\7:;HLR2OHFK+H/V'48U&/)E,. MFQRE".NR16]Z/SY^$/PS^!WB]XJ_'N[^(?[*7Q1^.OB(?&+Q;&?%.C>$X-4 MM)(5U.41VZS27<1S$/E*A.%(P,U[O_P54_X)T_RZC_9\UO_

*(55X;@U^ZOB M?X-\(7CRVI2>31@IMQ\\##8\M8(XXROI@'+*HL?^^66]>&/%WC#4O!7[27 MQX\.9XT\27_(JNM%T8Z')86UY?3-/<&(W.G32A#(Q(#2"%>N_%#ID_3OC=

*MX)^&FB^)O$/B74KGX9>(=(\4VNIR/ EW]U\IN=CW06,(5E8E!&B+)+?+L'% M'_]X(>$_VRWM1)(TKA1DXR[NQ\V-=+93 M+==")D>\6_'M3Z_BBB@ HHHH ***** "BBB@ HHHH ***** M "BBB@ HHHH ***** "BBB@ HHHH *****,?Q[-)!X-U5XBZNME.RLIPRD1M@ M@]CFOR)_X)S?MB^(/^"G7@WX"? V;QCXX\$^%M$^'NG;[XI\1WB^/-3\.^-

_@!;Z6LMO&D$^ZW M\P\%U &BE@,A5E89R5% 'RY\;O''P@D_P"""F'!0^B_&;Q9^'I7;0.!/X%/VZ?V;?#W@3 M7_'!Q\.M7^%?C#6(+7Q}[6]37EZQU+1'BENUU!OM+2QBYF5/M

WQJY0;1Q72 M>+OV#_C'H_[3GQ(^(WPR_:!TGP#'\3WTRZU?2+$S=QZXD4[E8162O^*]Y$RJ MRQ!MNTX)QD]:3XE_L&_&;QYX[^&'CS3_-H'2-<^)O@#0M8\/7^O'X=PW5IK MEMJ-

*U:W!Q9&\46S1BS@3*R/NP2<9Q0!?_:/N!8_:'_&^WP"L?&?BKP-X_M)_LU M:Y^S3XHTWX4^ /B=\3QX<_;'\/\ B+PS8Z=KWX4^ /B=\3QX<_;'\/\ B+ 7=,\3;2<,/5;749

*M96O84_T=XY8E=U=FB^JN&W>W^._V#O&WQ2\+^#-,UOXQWEM\P_HFAVTSH[Q)#8Q22!IF4I&KS2R.=L.JHI-V0#X MD^._[<'CCXH?#WX"?%/PWK?B6UTSX1^

*O#WQ'\=VT9E6751?:M:Z=>6MP8V^ MRR21V]KJYEBG \ARLGRE"5O?MF^)?B7\6M6\<>+/A]\4O&7A"3QE\??"GPX\ M&7D5^TFFZ9!86ACFG@C21H9K:?49[@3 IE_)9'#;%5?JGX&?\$]?"GP=^#WQ MV\)%27<6KZ#\;+G4H)HX1--)IFEW23K'I[.)2]R(7NKIA*S(S><1@=:?PK_P M3$M_#/[_P ?AZ_B]&N_A;XLO'IY]MMH26W_'1WT%\/=S;X5D*PF=[@[F# M,1C.#G

*/+/#7[:&M?M(_M1?LEQS#5/:OB>T\4>+/#/Q'\QW4T<-GJUGX>G MD-O(IVB>#=Y=Q;R.I#R12+R>)O!W_!1Y=9_P"""JD'CB%XD:3<^!_OQN?M@1;^#F\1)-

*;006P\K6DL8967$^LPSP>;?)%O\F2(^9Y3#;]DZAIUY'!8K-9:W/-I[Q8VE[<('C8W%]MRX5IVY MXPL>5 ###$1_\$6_A3]'[''O_ IVPT70-.UZ#0(=-MO'L>A6RZ]'J46R1-8: M5-DC7/V!<,;(S$@G!-'V!;YDM>,[/0="\;=:U:VM=&:.RN&F$L=K>00I)^ZHREU;.OL9S^]'A M.3K[3?"MA;ZG=17VHPVR175S'&8TN90H#2!"S%0OR=I85OSC]ZU\nCXM M1?

*M7^/OBA\\+?CHOP]_X619Z3;;KI>H> H=» ?3H98H9$E>[A(R)7++#;Z8- M'SK^SMXT\8_MX^\"_V5YY]>YN#Y@B1U,+*A1 MQAM_HW[,'[%^K?![XD^(_B)X[\?7_P 4?B?

*XHL;;1Y]9ETN#2;'3=.MGDDBL M[*SC+ ^1$9)6DD+22-)\)(Q(50 ._X*7?!_Q?\8?V(_'UC\.M1U?3/B)I]B-9 M\,S:==/;S3:A9R+=0VY9""T<[1>0ZYPR3,/0CQ/Q)^U;1[FOFW]B?_ ()PZ-

*^O9X_^(>OV&L3Z!)XQO7&DPW%MY1\,Z6;JYO%'T MR0M![HEN;RX<%5C^4QIMQ6F #S+XV:I\5_#W_!7SX#0:WX5TV/&>(9_$UMH MWAK1X9H?.C@T2*5KG4Y&?

*<3>>7|M%01QH%.2[?+YWX_|0_&_P#99^-FO?LS M>$-4US5W^.>IW&L_"WQIJ-PUW+X%TQRTNOQW.LBMN:P+QM9(P8,+RWC9@(N?

*MLKXJ_LL#XJ_M.?!_XD3:T]B_PE.LLFGK:B1=5_M&S6U.YRP,?EA=PPK;LXXZ-MT_XH_LNK\2/VL/A=\4?]:DLW^&>F:JJ:8+8.FI#5$LU9VDW QF+[(" =WF M',_<@#/%?

*L,NL^&_V1Y_AS\/O&^M>'-<@T,:)GBS5VDUO5+1MFPW+2AQX#^&.J1^*=12_Q>ZY M'H_C0!GABLKRX9BMPMP]FNHHF\N%OLN%C8#M]W_H+7#+7_C-| O%GA+POXNN M_

*6O>(],ETZT\16EJ+FXT=I%V&>)"Z9D52VTI@5;# Y%?.WI)_| P39\>?LZ M? +6_A3JOQ9\-;_\,K[PM>>'M/TO2?A_#H4UA<7";&OY)UNY6N)2&E+[P&D>

M4NSYZ@'PI^QKX_D\+WO]OB/P[%^U9X&U;Q)=:.;^,/%?Q)U;5+OP/XAM;G3 M&,\"B\NHH1->W7DK:O'''^\E3#+D?2OVAM&\;_LL_M,>" _$fK>//BE<>)O%

*M'CJTN\5\63O>V7PPT+PO/>/"NA7-OYTEM'<^6L<44PC1WN);>224(TBGT/X> M_P#!*_XK6_@7X,?#_P ??M#6OC3X3_#BXT.>/PW8_#ZWT>YU1=(:*2PBFO1=_MRN$2>WMY"*(&

*(?^"4^L^+?$GBGPUJ7Q?U_4/@%XQ\1'Q/J?P^O- M+CN+HW!FCNFM(=6:3SH; W422>0L>Y5+1K(JG@_^Q(OS,]#$_5Y-2U#\Q- M&[E@ #CZD^O^?2!J "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ ILR"2,,@YYIU,N$+PD*6!Z[\&?:@#\H_VR/^"G'B?]C;|OC]H? MPCHDVI7FM>)8O |KHVIZO%N7Y&8X8$EG@)0%3,X!;Y59A M=_;?^'?

*A+]DKXI?LP>!OB+\|3_CYXB\&;]8^,-4\3:SH>N>()M:\2ZL%TIXKF M1-()G$(:2;9#&H@A5@ !U/VO8_L/:)=_&WXY^(?$'Z=_P2P^)?@W0?A$?"O[1]Y:^)?@FN

*MOZ1H>MZ]X.CUR4C\:>797"M=1^9));:IQK,"""GXRH0(!Y=XQ\0?#0?Z^>A;]1^*=2

*[X1>+?!?QT^_M,$'Q)T?Q!%;2Z1=>'_"B>$]1\,WEO+YT=_;7,5S,WVB.587C.!M,?.X,10!Y M-^U7^S"?^":OP1U7XY^__B7\9;K6_A^\&L^)+37_ !=>>(/QK8B9%0+::SN MY3!!+*CR/'+;K${10N!L&RO.O$_BCQM?_!SXD_LX6'C#Q2/&6K?'J3PAINKW M.HWTE[IFA7T1\01-'=(XNX8H|)9K9;@DKYL,HI* $?0UG_P3[^)OQ,UG1+'X MN_M"ZW\0? GAO4[35X/#|AX5MO#1VKW%K()+4.I=P2.UU&LBQR-'&L*2R("P MV?NZJ8?L%;2Q_!1+_AH&.^MOM4GAT.5+1+:,YCF^4-$NH+=&3*$6C-;^2I>T MABV[)- 'Q7;?M2>,OVI_@5\/-;B\2^,M.U?X3_ 'O5XH\:I:W)LX;[Q$MJ^C M0"[2"16BG2>VU6>.*1<+R0JR197E|._&^(_@;_@D#XV^''COQ5KZ_%70_ &_MB>+_ CXOCNYK>]\6:!=SV)%P+A0I^UVCS&UN K%B## (6;SB:^SOAK_P2[T' MX9:1^T5:Z?KD,:?'N._M5FCT@)<>'+>|%/))"9&E+7(%WJ-W<#=LP9BH &,4 M_P!J_P#X)$^%OVO/V-/AY*M5U^]TG6OAEI^GZ?H_BRTLH_MBQP0107$3Q$| MV]U%$!)") "PC.3Y8H ^?2\ @M-^VIJ?@S]HBV\->$_B#HWA+4O@-X3D^+=_MIU_XCCTV+QA?'[C2QT4H)HY9S);V^.I.82'C)DMMZ?-&:_2#X, $32OB_|+/# MGBW0I? M&B>*=+M=7T^7##S;>XA6:-L, 1E7'!_/]!7CG@\.XO$^1/'>OO) M\9^-.]!*2$0O+1/$;:TUYKV@6UQ+I5HEO#;6NG0-*)&$,,<.EU_1-'U&_DT1I=H7TW3YIJ2>"P^:60NMNLGDH MV1E(T^48Y /EC_@L]XC&G?M$_LSZ']%O\9M:|*ZY[B0ZMH/PRU*_L]:U8PZ M=') 0+,>"1XXI/G(WX SP>E>/;?"#]I'Q=X!^#_Q+^OA?O\6/ $GC'X}^\/ M O@:S^(BM]? C+P!:.O#%|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| 9R_:!\3^.(/CYH.M1^/O$IU]Q5%=_#B$ZKK- MOYF4TX:@UZSPV\,/[F!50I"N2J9)R^;_ 0N?&[P/XL^*]CCCE$-U)=]_J(U*EHB >2IZ4 <-^W%X2\7>,?@Q MH?Q7G\:? %SXD:WEG^@)-;'_?M[MS(XK[#_9 1=W/Q-_9G^^OWWB;PIXPU+5O#MA<7VM:$5-IN[W)MT7)^>WW M,(FE$A4, PZ_ 0/@#+K_(OA>(_A- >^"YO@1\8M;^$D7A?P?9^![KRQN]'B\1 MV&JV%GC[-.L$\[/++>IF0>>-P96560A!7O_[,_P"SKX>_93^"_AGX?^$X+NW\ M.>%;$6=H+]?SYY,L7>21S]Z1W9W8C W.<_# !Z!1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110!Q'[2?Q:@^ ?[/\ XV|=W4$MU:>"=_U#7YX(L;YTM+:2X9!D@9/EXY(`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|+V\6ZA\7? CKH'C2P^+/C#0!!NM,^(&IP;=HJ6>H2166 MS3_-^R/"" G[IXRC!<,"#BLGXB_|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`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|@FIX-\&?M1?#+'XH?#?2_"?PQO_!":E8ZU9Z%X?ALX2%F MGWL'(UM.(#$N8YHH9D=EDVM$ S9 /I.-MR G&2*6DC78@'H*6@ HHHH **M** "BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH MH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ M HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****" MBBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH MH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ M HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****" MBBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ** M** "BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH M

WF64US"D;@G;+I4UE)LNWDFC9FN+[[,J$A><=]-M)O[$OO\ H'WG_?I__B:/[$OO^@?>?]^G_P#B:ZO]H7_@L;\#OV:/'WP5T'Q!
MKFHW"_":?);PEJ5A:";3HHH8(XYIIBRB,FYB.XCA22<8K8_|%3OA/XN_MX*%ZS^S)I[WK-S\3- T\ZE>[++(-IT48@BF9?/#??594!7;PV1U% 'GG]B7W_ M $#[S_OT_P#\31_8E]_T#[S_+]/_P#$UZ3I_P#P5'^>$&I_\%!;[IF2'6KMO MBKI^D'5Y;3[/_HQ A6#OV$_%,MCXU^'' MOQIN=+2;SM(O$&C^$GO-&NKFZ*K#;OW&\!I6=@FW&=W%)?V)??] ^_P"__M3_| Q-'IB7W_ $#[S_OT_P#\37H'@0\ X*2^=%GQ2^%O@G6/"'0?\<@V, M*$M_P"#-"O9-,U/GDR= $_B_#-*
A>)))Y8MVOX[=HF+$.1(A:'$;9D4E0P!F_MV)??] ^_P"_3 | Q-'}B7W_ $#[S_OT_P#\37]7Q_X*;?!_P"$G[37PM^% M&M^(VA\1?&:P.H>$KN*'SM,U1"
<1H+E25#2Y'E_POE0#EE!ZOX_MB>#OCG^ MT-\5_ACH3:HWB?X-3.9!XB$]KY=N&U"Y:YM_)DR?,_=J=W VG [T >!?\)?? M] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??| 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_3 | Q-'IB7W_ $#[S_OT M-P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_3 | Q-'IB7W_ $#[MS_OT_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10 M#\??V)??] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??\ 0/0/ M^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_3 | Q-'IB7W_ M $#[S_OT_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37 MVC10!\??V)??] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??| M0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_3 | Q-'] MB7W_ $#
[S_OT_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__M ,37VC10!\??V)??] ^_P"_3 | M ,37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_3 | Q-'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_3 | MQ-'IB7W_ $#[S_OT_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ MOT__,37VC10!\??V)??] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\ M??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_ M3_| Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??| 0/0/^_3_/O- 'IB7W_0/ MO/\ OT__,37VC10!\??V)??] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC
M10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??| ^_M_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_3 | Q-
'IB7W_ $#[S_OT_P#\ M37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)?? M] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_3 | MQ-'IB7W_ $#[S_OT_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ MOT__,37VC10!\??V)??] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\ M??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_ M3_| Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??| 0/0/^_3_/O- 'IB7W_0/ MO/\ OT__,37VC10!\??V)??] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC
M10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_M_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)??] ^_P"_3 | Q-
'IB7W_ $#[S_OT_P#\ M37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??V)?? M] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__
,37VC10!\??V)??] ^_P"_3 | Q-'IB7W_ $#[S_OT_M_P#\37VC10!\??V)??\ 0/0/^_3_/O- 'IB7W_0/0/\ OT__,37VC10!\??\ MV)??] ^_P"_3 | Q-'IB7W_ $#[S_OT_P#\37VC10!\??V)??|
0/0/^_3_ M /Q-=I^SQO=I_?J;6XA1$FRSQLHYC8#MP#0@!%&%%+110 4444 ?GG M_P %R?'NA?##]H#@'T__ !-K6D^'M!TGXQO7;IWD=1:6#2V%QF2260A$4
M9'+$#FOEK]N?QYX3_:S_ &H_VN?BG\+_ !!HGC'P1X*_9(UOP;KVN:.3<6-Q MJ]S+/=10QW48,-PZ6\8WE7;R\JO4,%_8SO9X$T3Q[9QV^N:/I6LV\+;TBO[2
M.Y1&QC(#@@''>]^G_#K1=%\/RZ/8Z/I%IHTP99+ "*TCCM9%?I%,2J$.[)SQS MWS0!^*_[,/A/XN^-/VXOAFOP2\=>%_!7C*U_8O\ !MU_^NZ#_:]C]P$Z[+9L M2HT :0QGSE$A4#
!AS7GGQ\:7:/XU_P"#'%I:UK5YKNB?&O4_C!IE\\7XM8C M@M;K1O$/IL6*2[(5 CBM5C16B!7HK\BQ4D_0:8> =+TJ^ANK73=.MKF"V2SB MFAMTCDB@4V6$,%SY:GHOW1V
JM/*/#VH#45N_#^@3QZO(DM^CZ?$RWSH25> M7*_.RDD@MG&3WH_/GQC'9?M ?LX?&SX>?#[]MRU_:+\>^.?AYK.DZ!X7??? M#/FQ7;P$K93NE?8N)&97^5\?HGH/P2\
M(^$-62^T;PIX9TF]C1E6YL]+@@F4$8(#*@.",#SR*V;,PQ96WB*355LI-=0F M@6W>[$* ,'C!)$9?&XH"20I.,\T ?!?_ 7=N1$G[1E=4+_ +3'A",$G&<__M:^A/?CM69^F/\0-
+_8U_X+%3?5BI,-!^&7CSX6_P#"&>`_!/>1L=)T+6(M=0:YFCNKAAY=EYT!&)&(5PN&(-]KO]$*U&6QO]3-;F^LK.]^Q3+<0"%AX640R+ MG;(FX':XR<,,$9.#R:L:UH]MK^DSV-
Y;V]W:72&*;&>-9(Y4/!5E8$,".Q&* M -/R" ;O^(>C_ +8G[77[3WQ9^%\XUOX8> OV8O$?@OQ#XIM(RD:[]\R374, M5K< >7>"&$'=(I*ID $@BO'Y(_B1X'_91_8-L?CQXYM?
$_]<B^UI*W%VVA^ M'(M+NO#5_#;02:79ZGC7.D:,//H*HD=A+9QR6]*G M"@1L-H"C@ #CMB@#X<_X.:ID7_@C%\2W+H%_M7PZY8'Y)M"DT('5-)>-<[O.BC#+M
M4R9C(3YF&/W!UKP=8^)-+:PU&OT_4+%BI-O(=<_:1U"33M0N;$:E%IHK[N_X* MQ_;XR:3^P]X4UOQSXLC^-=K\-_BYX<|>>(XO#W@XZ5*_AVQFS=PBQ2><7>P
MMYQ#,!M1B1\@S^A]E\-M$L+>S@AT;1H;?3N5I!+68DDR1@*-CG)^88 M//N<[] Y?:]\%/?VM_AO_P %#_#/P0^&?P-\3V'Q)^?B7XC:!XELVT$&Z;P MG9V-
REQ=75_(HWZ:R0[E*R!9B=R[.&Q\C:=-^T)X2_X)!?M8>,?AGXKL;WX5 MCXU^-++QMX0L?"T4WB&/1);P)!5[8WCLGG);2$!)(=]*KON.W:?WBTWP1IN M@W>H7&FZ?
I^FSZI,;B[EM;9(7NY>?GD*C+MDDY;)Y--M/ VFZ=I=S96^FZ9# M9WS2/=6Z6R)%C_">=K[P MGH?[/WBS7/ =P]O]NNQ)I=A:7EF1&"/B+\0M;N+RR2&[@T^VOX[>WCPZ MH?
BK+\6[_P 9-XATUHU"U!"8/I@M=V_R?)2(H#E5!+;,$+7Z;?\%)~G M>-.?^" #OBH>E2O M.8-EU-X;$<+;U^9 *9?$(E%]#>=>U\U=@%988=++(RY2:=B5MGK?IC,YF=E(DW_J-
=^#K&_U:UU& MXL+"YU&Q#"VN98E:6VW#:WEL1N3(X.TC(X.;) ;EA<^(X-9ET_3I=8M8C;PW MKVZ&XCC.2463&\+DGY0<')!. /P4U_+)E^(OC3X^_8]^"/CB:ZT'XI>&_V
M>=8U+0[H7TL<_AK7;>\CN-/:1N&S Q2-T.57:X&=H-?2G_!MY\:O'?QY_;#_ M &S?$'Q0T%/#?Q*74/"&D>)]/4D#[;8.?=V$EP 0,"8VYEP,KF3Y25Q7ZL2^ M#
[&;6HM3>QL)=3@1HH[N2%3/&C8W*KXW ' R <'N*=8^%/3=:N=0@M,"\O MRAO+B*%4EO"B[4\Q@,OM' R3@<<#B@#4HHHH ***** "BBB@ HHHH ***** "BB MB@ HHHH *****
"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH M***** "BBB@ HHHH ***** "BBB@ HHHH
***** "BBB@ HHHH ***** "BO#OVN M/VV[+]DWXG_!?PS=^'[S6I?C/XP3PC,3P7*1+IX8NH';1@\].]C MU?Q#;;'9S7-Y+%:VE]CRW%Q-(L<4"(NYG=B0%4#]3P* +U%8D?
Q#T:?7G_;R MZGIAT/R#<_VB+R,V@B'5_-!V:1@Y;...M>>?M3_MQ?#W\CQ)G:[.*7C/(5DC\ M(P:,Q6]O9.ERVI37*BQP16^&VR.[,,'<9"AF8A5)-!Z]17E_[4'4&F_LV?L
ME>._BV+,^(])\$^'+KQ(+>SND'I]0P0--MCE^9<.HX;D-?',]E+J4'@S0;[79+2) MQ')=+:\DYC5CPI8)@$\#-?./[&/_!07XP_M>;/X:\!5']FZ?PQ\-/'UA!JUO MXDF\?
Z===/;6<\'FQ2M9H@E).44IPP+<|#0!]=T5YK\$/C_/\0?AMIFL^*I,T M,P5]FJ7]Q80Z>OB2TU2.5HY72/9<0D)(IHF_RURR9*D9!KK+KXEZ+8:AI=K< M.H4%SKF3IT,E[$LNH
*&)@4G,HP1S/&>M &]17DW@_]M?X?>=/VM,%7P4T MO6{[GQWX*TFSU;6+7&VE0_/,< !P< NHQR M2 #ZQHKPC]GO\N;3 C_^TW\>/AK!X?N]+G^(.1,HZ7!HY].UTCQ:I]NLS=!T4
M&,1],'<3GKD5ZQ9_$[0=2\,?VY:ZQI-SH05W.I17T3V85"0[&4-LPI!!.>"* M -^BN>;XI: (KV0:O!)BTT1->R?;X=EF)0&B,AW?('4@J6QN!&,YK2U+Q+9Z M,L+7EQ!.+
<31V\1GE6+5)9&VI&-Q&68\!1R3P!0!?HJ&UO/M(^XR'G@]1@XK MXX_X*2_\%FO"O_!-/]I3X*_#[Q1X6U#4[;XPWQM3K45\D,.A(+FW@::,2,HS2 M*/M *M'TKP:FE:O=V''
MB*UU*!H(I-D5P\T1"1&3KY3'"?L8?MWZ?^V';_%Z6+P[>>&8 M_A%\0]6^'[X]Y=QRK>OIXB+WBD !(V$N=K#-3U6#]E_0=%U^YN8-1B$/B:'4[,W48@.T^6%48W'<&R"*
/LRBN2^'/Q>T M_P"(@?PC[Y\K3[,&.F0:G96,]KEZ\,&:U:G9(]%G:-1D%V16^;;, #-8!9?I2EK^Q MU^RGX, BG?.5<;Y;> M$N-:FT^WF$4EVL*;C&KD$*3ZD'%_'E%?$FD_P#!=X;X?^-OV-?
@A!9_"WA_5M/=*^'ITXW.<%WX=O!R66&03_>#>2\1^48 MWJZ_" PK[$N?'.E6GB>/1'U"P769H3,1.O=,G08; MVQELK5I4GN$N4;&%HBRS*$@X5HRCA@3\I4YQBK&@>
(,+Q3ID5]HUW:WUE"/B]^R#XRN-*\1ZAX>\$_%>/5];N-(T M2\U:33[5;&=3*\5K')MRP'"GDUR7_!4/]KSPK^V^>PI=3^ OASXA^*,E:1X
MST.W\2+K_@<,@:O!%X=LI)6+ZFVENEI/JT<00]UM$Q5O-R^%&#^@_C7XP^&-A_ MXR*>'=7U>UL=<\<7<]CH5E(6$FIS0V\ES*0>_1E((I)#G'"&MY8/M0$@=QR M2.3QVH_GQ\'?
LR>,]9_9Y^_,A2?P |&+0+#1_C9I/C#2K6Q^%B+I.FV$U@ M[3WEQX7GD\N;2-QD_P!$@:5U*PET8@]>C\6_LV>/_B_P2 ^/N@R? *R,,F^
M,_#OB+0==\.>#M0TF'QS8I=I+=7]OH5R#-9^3,>;K"&*-&BF,;1@(0?WM6SV MX&\D YY\?_UTS5+Z+1M&N+]YE"06D+32R'/RJH))XR> .U 'R/\ M[?V7\2_
M^'"%/QA>0@^'OAN^L=$ZCG#X9T.WT9J&<6S64B6T45Bs#P@IL V0E%=00I13E M1^6'!07 _3O^*Of,5]*RHJOP!\,.G/\'OC#KGPZ\0>.@#EEH\KOX0#\Z,'; MK)>F)1_HRW*2SF8E
#)"_F$'RZ_>[X:^--(^+'@72?%'A^^74-#\0V<6I:==_M]CHMU!,@>.0*P# %6!PP!YZ"MB:U,*%PVY_RS_GC\[/P# X*?\ P]\9^*_V MJ_B[X@T7X->(_'"BKP!4=%U>PUC0/
6HZOJNJ:9%)"HUAO$7GLEK:2QO<'[M#:0@]RH'/#UL_MV_L=2^+OA# P %%_'M!--:OOB); $SPWJ7@36[;1KIM61 M5EL0UQIKHOF<++<;GA[,VXX48_53XU?
\%;/V=/V,2JBE(65R8V#84GO[U9\OBOX?^/7P^TCO?X4U--9\,_; M_:M.OT22,3Q[BN0DBJP&0>H!XZ4 ?EA\3OV3O'OPQ_:R_,)\"?LY>&+WQ?XA0K%_%B2"+%%)8:9?:TS/#/)#
{W!KIP9F#$O6-_P3,TO5OVN^$_AO\/OA9>V7CI=$^"FH^%-+BN+9HIFMK\SWJWVC&WVIM M#+J,5SIF.]FB& 6OV1)XQ"?N*TN5* $FONZQTZ'3-/BM;9$@MX$$< M4:+M6)0,*H Z #
]J1K(M_'@!^,@F@#\)?@C^RQK/CK_@GS^PWX5\3_]U
M]4+"\V_;2U"\U[2[S1;@"WL6O]3837,93,CZ19^&/!_B;7S>*/#WB:2WMR/L/A_5M/T2\?0M4^!6MVEAXE.GR20>'=8&HQR6=S', M!M2XC9=X4,&*;AT:OU"@LQ;N<,21.<4Z;-S'[Q
QT]_6@#\!_@\X+_.!T+]D MS]OB3XR?!W5OB++1\W5?"^F:A9O9WMO;:W,65L]HV]Q+;O')?I'!%'?##2]7'\'Z5;_#FZ\&Z5]\AM; M]*YFTO1]TGDJ7\D%2QF?*LXR<#]\39Y).\Y_A\\ =I/L.%
#L O(QGKZT ?C M-\-O^"O!YIYM3N)#D$ M]^?QIT ?%G_!+_XH2_LR?LA_L\]?";XKZWXUA^)?C2QU&TT*V\2Z#+9:G-%9> M;FVKL?54M8+G3X_/*E(9)+B",+N*LPR%
OS7ZCZG\,]%UGQ=I6OW6G MVT^M:%#/!IMXZ9EL4GV><(SV#B- W]% K8^Q;7!#L#CG_;IZ /O'_P"""-'P1 M*\C9V(M MOBEXX|
(^,=*\0_$OPIX\]^)Y M4MIY$TZYN]5COM('FD7=`FVMX MMD4K%P,],K&3^SO\#?$?AFW^-OB+XE?#KQ;K_P"S_P"%OC1\2;!QUX=/AZXU M..XGNBHT6_GT14:2Z@1_-
"R".1$,BDC!R/W.-CG.78ANH/(-!M&SD2L=,,G M\Z /PD_9]^ 7CGO!^Q!XQ?3/A/\ $+PQ\,+7]K>X\5>-?A_=:5-;ZG<^"A'; M&2U:RR7O(HW$1>*)I P@;&_;13I_AO'XS^'' !4;]^&_P<|<>
!OC'PEX;B M\(:-<^%+C2VU18[.X5I;.U* [)6(E6-5#(DJADC/RC|V!8E"'"LA&.!D9 ^O M>G+9@.6W$D#"]?EH_!G]JS]FIXLZG\1O'[>)-$U.6W\9#OPSIOPND@^%=_MXPUF%
{=']&BUT]@<N$T6_BN_-E=KC;OS&O9@NQOT;_X*&^$O&7B#_@AE\2M M$U--=\2>-[GX4-974[\ 9NS4-2OS8]LI-O"9)7DW9G\"DD L.3]DKIX P7 M8@L68>M32OF2/
8]>Q':@#^?_P"/_P#P3S^)_P"R[\7OV4+_.'GAW5)O@A\ M6?&GP[\5>+M!T[1Y"/!7B33XX(Y;DQ(/I&CN(YIGE8H 7B;>05CS'_P4-\[^ M,==_;_ B5XFTWX-^(/!'BOP9$M'U:#5=\
ZCJNI:AI*30H-8E\2>%D#!B/EVGWZ4)8^7$4$C#DXZ\9- 'XF_MY_L?+\ M6_CS_P %.O%MW\--1UW7:;PKX-NO 6K?V-/)/]L33-SR:;(]_/,DD<(9HLLN MW:2 64I\:OV2/B?X,_:
\5:1^S]X3\0>%(?'(\)NI;**>RMJ7\1MJ=O'.MTT[X0ZLUD)D621A."P8?>K]M\(/:4!F"KT)&*7[']E@2Y'032 MWVJ1!IBTL,&@F621?-???ZE_LXZGX4U?
X*>&KGP)I<.B>"!I.ADT/3XM'?2$ ML[0K^[C%H\<;VX_Y9M&I7H0*[$6."/WC8'3U_.GV]MV#.3@!?&7B(DGH/^*5U2N,_X*A_M'>/[%.WPS^$?@6P^+C0^,MU:Q!?WO
MPVGT6WUV3[^]]&EK#+]S+,(F;EI9-N^8K&H50N]Al,?M,_L<,"_]LGPYIND?:M%'P1H/C?3=\NC>65OJD)E2UF*%"Z8(PQ4D?0UQ%K_P $]/V=K+X(7?PVC^$/ M@P>!+
[51KDVBM9EX;(6,7*Y.Y)-B^A92,KD\'0H ^(1_P4?^.7P$ ^%_G_$ M;Q7-XK;PIX2-'M MA1G.SL_V^/VIOC7\1\?MOAWXS\37.H>*?V>_!OB2'XF:U9V!OO%NM:\+MK;22
MI9074VD4]S\R1B1FC=,JK^/MN;]B?X3S_"+PYX!/@+#PO'X+\(W]MJFCZ+#8K M#9Z?=V[F2*XC1<8D5RS[NI9BQ))))KHM&^_7@[PYXH\8:W!_AW2;/5_B#)#)X
MEQ(K91/KABMQ;1>>_5PD(V*#P%SC&3D _)F#][S]HGQU\#/"'7CR'XB^/[6T[MPW\))/"WB6^?X7=]XCT2^19[]"0]\L?V2;,/& BQEF9E_7 M'X1>/M/^+'PG\,>)-
/U*UUJP\1Z1:,LWMO"\4-[%"DJ3+&_P R*ZL&"MR M0#R\F\>_P#!+G?XICPE_PDGP>\'T? FFP:-H!N=-5CIMC!CR;53WA3'R MHV0.GCDY1#^&?I/FB"KXD^-_%&F>9'?
>/;NSNM0C4!(5-K9QV<(51P"(HE! M/<*H_A% '4Z_ 4PE,7QE_9!56*@_&RVN >#_P 4]KH_K7!?M[_$OQCXP_:= ME\#>#O'/Q=TV'PUX>M-5 M,^DC>M<=\;?V)?A-
^TGXMT#7O'_P_P#"GC#6?##.=,N]6TZ,Y>U#$%D&X89" M0#M8%0648#97D?A9_P5)^+/PI_9RL/B/XXUJZ\0CX MC_"K4U\- 6D<=K+XTT?5IM,CC4*C+$^H13V4I1B(5>UF(X-
M&0=`LJ[6.6XMX22=L;O%2O3]VN_8KQOQ__M_$_U\4?%KX0Z-IFD_#WP+ SX/;J\&.EZ';;;*^3;ZIO H!8^3%;AKLW& MV093+&!]QC0!X5\?O$?Q4L_%6B?*#%N_&75=?!
AOX$TG4/&$W@:#0M(-I? M3QW9?5]7U+5MT7V69K28);6L9.8C9G;&T5]JZ=*=/;1N?FC.X,9$R,[7#*"'6P.3GL_A\(?#GP(^'NE>$ M_',E6NA>&M"MQ:=-IUJ"(+*$$D1H"20HR<#.
.]P!0!TM%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!11 M-10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110
CN$]3GTIC7"K(JX;OU@262RL9+B^BU5TWR>=*D2:+\S(0$(;[N6+ \3"N&)'/%-$ZL6 !.TXZ M<5^4_P"OJ^W-XI_8Z_X(3_LO:[I+?#9+OQ/8)IMSKOQ"\5MI6FZ7F:=PY1$D
MN+QV"LHBA&X<$G:#5SXV6%B9Q(. EQ&"N2"N1N(!^I9ND),X #))'&/6I 6/B?6?A?X&'PO7X[7GP3N[JQU^1V[Q>4J MJX)E#2$L"-JIC- 'Z=TV6584+,<_5^:_[5G_6L^^'P_P# O[2?Q
^&GPR\ M&;!_V;M4;P?JUSXAUR>QU34-#[GPS+JU MO+-X:6WN(8M E>U69I8O.\KR0)8UV?,,!2 MC 'I"JV1D TBR!CCD'WK\Z?VT/V\/"Q(\&?M&?!WX8^#=*U&/X-?"W]7XIU
M76M=ETZX)U30[F>WXTQ8H9-[I&HE:24HF*F,8)#CB/V0_P!O;XH_"7X% L*? M!OX>>>$?"'BW5OBS\Y-7EOOS<]:-@MI+8.=[,C9V(M MC'+9VSR3+M+K)*+.1QM
"F_\0: &_:M 4\"N<|@O2B.Y65RHSN'4$$5^7.]_L;_#G\MS_@O#^T5H/Q;%Q%I^@_#[P MO<:3MU.[LY=)GE$R/-\$B-')A5(<'(*@@@UYG^RS_P5YU?]AC[E:Y\>+O%
M>F>)_&$'QI\8?#/PIXG^(NL7%K9VVF:2$G-[]MX%EDD*>Z=?^7-,R7-I=&.+[1:SPO'(N44C)##(!/=_"?_(*9 M3_L],?\ $OQ9I7PO\)^'_.F_M1ZO\//B#?VU[=,]I;R&WA7Q%*SEE1S.\2R
MQJ3!7!3EJ/U&HK\V_BI_P7FN/AKX\=>(;CP]X1TIPS<_%%_A9\.]7UG4Y M!+3=4FMHW_M#5KZY$;]+*'5?$499_+*]+F>,_P#@2K'NIOV+0B\%^&
M#/GBKQE\,_&NB>$KJ"RUN>X\/:[%J4L20WUG>^3&WEN6E3:R%HGA<-N^!8 _M3>BO@_Q[_P %7O'7[*OI07CKP?\ &_P3X/T"QT7X7:E\2M!O=!U:YOH]4^P3
MND]DSM"I#>687W^6NWK;AW_$ M8K\ROV OV[/%^C?L^_LF? CX,^%-$\4_$35_@IH/Q_U>^\]3:Q+I^GVVD1F&U M9(WCBFDENYI2RKE0D?#L6'RUXS_P3._;X^('[)G_
2U_9BL/#OAC1/%WB+X MP?&36?!-Q#K>L301V7FZGJ#[O<*CD[/+QDH6@<+<]#K_@OU+^S M)\6O%7@?6-*^%5KXK^3GZ2UT+QGI&H^+KBSN=?
U&XM)+A=.T'_1&^T.JK$^^ M8(&-Q'& &)<87Q=_X.)KCP[^T-9>'-%\/^ O#6@WNEZ3]^B#XCZM?^&;CQY. MZC;131W-A>&T>RMH8C(5>$? ?@M-.TG3]6AN/'NN7FFVGC;
[5")8M+U&&UDLH5MG#Q/=.%D?A%XY M^W_A[XQ^(GC+QGX>\;T_P $;=X$U?PS%=7<%OJ4MJ]UOJ[N&\N*5$%M-9B$ MG$@(=FP0H4T >F4444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!

*M6*YO;J~LI(9$$,/E+,6L+&%08H(D4#@8P,.^G[5G|3^@^(O!NH?$WX&>&<+3·MPAXZU.'3&M_!VMW6L;_X*^T!VBN-3A:V2%X8\+':\$C"-FW#32K&]T+55AOO&VM2ROCPI87=_#INGS%4!.;UY*,,NU'';SMN·M)3:0#P__(+5_L%^)?\ @!U^TI\!/ &E>!=>M(|\%ZZ==\5>.I[N*VTB+19U·M\]\TF%5F$\|QJY4>Y1& JA?FPS;?NOX\?!B3XY_SQ3X%76-1\,6_BO1[G19·M-2TQE·[813Q·$SP,X*K(\$8[6(.TX(\%>&:?M-_M1?&72OVS-$^#_P@\!+?#'5]·M2NO!5QXTO;[OA]]H811!'?QV8BC%K!,68M*K98·8!YK@?&G_5%<)7P&^_G·M|0.WQ"\$>"4^*7P&AT?4IK'0-6NKK0|9L-5<+:,RI/=+'-(&CNE>-)EH\+1:\3X$>-?\%-:\MMX+B1HV+L!SYKXQGC2·;_P""·G@_]H[4_%.HR>.?B1X*U7XD^';7PWX^N?"V·MI0V\;PVMNT·M+=HT3A9(JWWH2FZ/,+[XF93[1^VW^U"G[&?[+7BSXDR:%=> M*\-10;--M[A+4W,D]S%;(7F<%88E:97DE8$1QJ[D$+BO-_@;^T/^T#;_$_P MQI?Q3^'_.,GPKXW@G>P\3_[UR]U>RT.2* W"#41<6L02&=,K'/&Y7>H4·M_P"M0T <]_PY\|#:9X+ ^&5GH'B[X@>#_!-\,?!4?P[M_%F@:E%9;O]^@ IY·MMA=-Y3)ARA=9(U22&1B\;(P!K,^$O_!$/P!\'@<0"F>+?&MUIOP#>2^ M/&kN:W>YU&[DEN)3!2U>)26W$@uI[%/[4,H·MWG_!0,^-+79-I5K\;J;QLNJB9O/>:74KBS,&S&W8%A#ALY);&.Y\E\:?M8·M_M%?$;]L7XL?#CX/^$/@Q6EK:S)M3:4Y M/(0T /C)_P1G\#?%BSU'2[/QO\3_"?A/Q#H5AX8U_PUIVM)%=-\&O|GGL%$)7RI{UIVC·TUP(U$>#-Y97G9N^:O)+'_(*=/]7_ 3CUSXW·MOX.GTSQ%IEW]'AV#PM)?1W7VK7[?5)·(CLH[A·HE2:^151E4.RN,+NXK'\5_M\%0M5T__()6ZQ\>-)T+1+[QIX<9=\U3P[///!96>M1ZI'IEU;LY3SECCF9F·M4L@!OB#XGM_!PU#P5X@·MU.]U'3M0NTD^QNT%U:1(\+S(L;E7W() V'%-9)]_P5P'AGP1XX:\|^/KOQ!M·M?B9K?PV\">"]#F\W4?&=58L@2;+ "'(*^:^XF;!U;HI8DDJI /M6BOC?7*?^ P#]3F]XV'QI^P> +_Q%JOPA\6>&O!T=FNJ·MPV:^(+O7$TTP.DCJ5@5'U!%8N#_JV.0#0!\]6W_!*WXR_L=?L}?"/X@Z#\0/M%OQ+|\>?!K7(O%\G@)-!TJ"*^N=2FQKUO%(/$>H?%+X8^,O%/Q,OK_P (ZWIGB;4+&U-G]@TW|/=G M3H[A;2XC:5)DD\V+/\ 3M8\AU0F-/LT,8=MYPN0?ESDU0^O_!1/PW\=_VTOB/\&[+3+C3[WP·& MS6.HW%TNWQ$UNT<6H?9XMN56UFFAC9BS!V8I?N·@ ^6OAWJ_O$_9S^(_[.WC M'6?V;_'-NGP]^'WBOP'X@\,_#G1HKRSTF^;_T@PS6JO.BFQN$LY9HF#L=KA6 M^8-CUK]ISXD^(_VC_AAX8U'Q)^S'XG^(GP.UB.\A\6>"=U3QKIE]#/&;"·M_ALGN/*F@W)*"(Y1,/.20?*C"NA\0_|·07XJZU^T!\3/_PU_9W0/B*HI]W$\,$BQLZJ"9=?X^_P#!3F]XV'QI^P> + _Q%JOPA\6>&O!T=FNJ·MPV:^(+O7$TTP.DCJ5@5'U!%8N#_JV.0#0!\]6W_!*WXR_L=?L}?"/X@Z#\0/M%OQ+|\>?!K7(O%\G@)-!TJ"*^N=2FQKUO%(/$>H?%+X8^,O%/Q,OK_P (ZWIGB;4+&U-G]@TW|/=G M3H[A;2XC:5)DD\V+/\ 3M8\AU0F-/LT,8=MYPN0?ESDU0^O_!1/PW\=_VTOB/\&[+3+C3[WP·& MS6.HW%TNWQ$UNT<6H?9XMN56UFFAC9BS!V8I?N·@ ^6OAWJ_O$_9S^(_[.WC M'6?V;_'-NGP]^'WBOP'X@\,_#G1HKRSTF^;_T@PS6JO.BFQN$LY9HF#L=KA6 M^8-CUK]ISXD^(_VC_AAX8U'Q)^S'XG^(GP.UB.\A\6>"=U3QKIE]#/&;"·M_ALGN/*F@W)*"(Y1,/.20?*C"NA\0_|·07XJZU^T!\3/_PU_9W0/B*HI]W$\,$BQLZJ"9=?X^_P#!3F]XV'QI^P> + _Q%JOPA\6>&O!T=FNJ·MPV:^(+O7$TTP.DCJ5@5'U!%8N#_JV.0#0!\]6W_!*WXR_L=?L}?"/X@Z#\0/M%OQ+|\>?!K7(O%\G@)-!TJ"*^N=2FQKUO%(/$>H?%+X8^,O%/Q,OK_P (ZWIGB;4+&U-G]@TW|/=G M3HIA;2XC:5)DD\V+/\ 3M8\AU0F-/LT,8=MYPN0?ESDU0^O_!1/PW\=_VTOB/\&[+3+C3[WP·& MS6.HW%TNWQ$UNT<6H?9XMN56UFFAC9BS!V8I?N·@ ^6OAWJ_O$_9S^(_[.WC M'6?V;_'-NGP]^'WBOP'X@\,_#G1HKRSTF^;_T@PS6JO.BFQN$LY9HF#L=KA6 M^8-CUK]ISXD^(_VC_AAX8U'Q)^S'XG^(GP.UB.\A\6>"=U3QKIE]#/&;"·M_ALGN/*F@W)*"(Y1,/.20?*C"NA\0_|·07XJZU^T!\3/_PU_9W0/B*HI]W$\,$BQLZJ"9=?X^_P#!3F]XV'QI^P> + _Q%JOPA\6>&O!T=FNJ·MPV:^(+O7$TTP.DCJ5@5'U!%8N#_JV.0#0!\]6W_!*WXR_L=?L}?"/X@Z#\0/M%OQ+|\>?!K7(O%\G@)-!TJ"*^N=2FQKUO%(/$>H?%+X8^,O%/Q,OK_P (ZWIGB;4+&U-G]@TW|/=G M3H[A;2XC:5)DD\V+/\ 3M8\AU0F-/LT,8=MYPN0?ESDU0^O_!1/PW\=_VTOB/\&[+3+C3[WP·& MS6.HW%TNWQ$UNT<6H?9XMN56UFFAC9BS!V8I?N·@ ^6OAWJ_O$_9S^(_[.WC M'6?V;_'-NGP]^'WBOP'X@\,_#G1HKRSTF^;_T@PS6JO.BFQN$LY9HF#L=KA6 M^8-CUK]ISXD^(_VC_AAX8U'Q)^S'XG^(GP.UB.\A\6>"=U3QKIE]#/&;"·M_ALGN/*F@W)*"(Y1,/.20?*C"NA\0_|·07XJZU^T!\3/_PU_9W0/B*HI]W$\,$BQLZJ"9=?X^_P#!3F]XV'QI^P> + _Q%JOPA\6>&O!T=FNJ·MPV:^(+O7$TTP.DCJ5@5'U!%8N#_JV.0#0!\]6W_!*WXR_L=?L}?"/X@Z#\0/M%OQ+|\>?!K7(O%\G@)-!TJ"*^N=2FQKUO%(/$>H?%+X8^,O%/Q,OK_P (ZWIGB;4+&U-G]@TW|/=G M3HIA;2XC:5)DD\V+/\ 3M8\AU0F-/LT,8=MYPN0?ESDU0^O_!1/PW\=_VTOB/\&[+3+C3[WP·& MS6.HW%TNWQ$UNT<6H?9XMN56UFFAC9BS!V8I?N·@ ^6OAWJ_O$_9S^(_[.WC M'6?V;_'-NGP]^'WBOP'X@\,_#G1HKRSTF^;_T@PS6JO.BFQN$LY9HF#L=KA6 M^8-CUK]ISXD^(_VC_AAX8U'Q)^S'XG^(GP.UB.\A\6>"=U3QKIE]#/&;"·M_ALGN/*F@W)*"(Y1,/.20?*C"NA\0_|·07XJZU^T!\3/_PU_9W0/B*HI]W$\,$BQLZJ"9=?X^_P#!3F]XV'QI^P> + _Q%JOPA\6>&O!T=FNJ·MPV:^(+O7$TTP.DCJ5@5'U!%8N#_JV.0#0!\]6W_!*WXR_L=?L}?"/X@Z#\0/M%OQ+|\>?!K7(O%\G@)-!TJ"*^N=2FQKUO%(/$>H?%+X8^,O%/Q,OK_P (ZWIGB;4+&U-G]@TW|/=G M3H[A

%G2}2@TS3_$MO)), M+G1I)HHYK;3R',4P@N5$FZ1GBP%=FD_9A^,/BGXS_P#!,_X^WGB76=\;6^F MIXDTK0?'EEI"Z6/B%IT.F#RM4DA7";R[20>9&/+E%JLB?(ZD_=U|MQJD/EW M-O#<1A@VV5 ZY'0X/>G+:Q+ (A'&(E78$"C:%QC&/3% 'YQ_'#Q9XE7_ ((. M_!'X=>]J*V^(OQN\$^%?AYX<=Y'B2"2]TV 7-Q(\;M)'"%9IA]Q0!\H_!V?=_P62^.DCC;O\ A9X*R!GC_B8> (?\ M&OB#X1?M*:,!*OC5^T7I%Y^W!X-_9XE'QC\2RCPGJF@Z+=W&&N$Q=F2\ _>D2 M@^0!6;,,L!G@GN.3^=59O"^F7$S22;=8R2,=S,UNA+ M'U)Q0!^=!6OQO\ @OXT^-.EZIXG_<,OCIFG/\A$-.G\,?&71=5M-.7*TAF MZ=<1RR&W$LD5 ,6"4+W<9QN6\(V=C[$?\SF?C!XL^-_[.V]ZUXKNM,|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|_PVR?]N-3T7K^7\Z_3R6TBF=6>*-V0$*64$ M]#C('UP/RIHTZW6U6 00B! <8CV#8,=,.E 'Y_P#_ 6P\?0?#CXU?LKZS/\ M%73?@E!9^,]:5, &VHV-M>6VC%O#|\H#1W7[DF4D0@MT,N1\V*\?_ &M/VEO# MOQ0_X)7_ !_MHOVK_"'[2%W17(@ZC-)IFGZ98'P[:KK%IO:1;+AE?&=SCCRS MCC-2]J?:1::FH%S:V]P%.0)8P^#Z\BHH?#FGV\'],TZ& MYGN'O)H0RVXGXMXPY'FO+M^Z'(]> _P"'"K/B3P)I/PE*6/Q-T;QE;^"]1U)1 M/X|\,3;/W'PPNT@F-KK)C=#2VX1OW%@H&@-G/]6ST@,+2TMK4/ MC=Y42INQTS@=LG\ZGDB6:-D=5=6!5@1D$'J#0!\ ?|\$W/V@;KQG^V'XD*>% M/C6GJ3GPIL/"9U6+QQ=VMG+J7A;4'O%0.:)]%[%!=K/%YD^P(^A%LFX8DC)-M]" _9!\16WA+IN#IMK5;Z:WM;&R\6Z!,!5)Y..#G&* M^N+-#3+,2X3':V\%M&6W%8HPBD^N!WD=(M)EE5[6W<3_ .M#1J1)QCYN.>.. M: /Q4U+P-^T%9? V'|L" P##/PYGT'3?B& Q^EG35[T>,4\/-!]D;3/(EM?L MR(NB!?W?F@AH58AI!AONS[L3Q)8^,OVH? V(-9TRXG7VO\'-H7UK,I+B6^3P MEK#(P(R#E6!3OD-[2*6 Q-%&/&T3+M*%05(QGC&/3%)'800I"]0PJMOQ$ @.MBXQ\OIQQQVH _,# (*$_&*P^$?_ 5ZL[NX ;1T#]FI,WX- V<*:OJ^EZ??1 M;T!K=Z?LR++>X163JY*?,01V%,_Q9_:_^%?Q_ 96\|++XY^,6K?&/PPOBF[MKC MX[^\Q9Z7_P *OU6.W.MK<2/9*ZVA,"*UMWJ)00\:1*]OD8.0!@Y% 'PO_P3"^/6H^/_ M_ JKQQX6\,_%V+]I/X5:.X:MM0L/B%<65[=0T:^GO)@VB27UJD<-Z/*3S\JB MM%A5-0V6GP:,#Y=M:#;QYW;8T'+GUP*FH ***** "BBB@ HHHH ***** M "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M "BBB@ HHHH ***** "BB@ HHHH ***** "BBB@ HHHH ***** "BO+OBQ^UWX3^#/B)Z}K&>M/>B!+@_9;(S)M:./ MF!Z\'BN:_P"'B'@#_GAXG_|:6W^- 'NU%>$_P##Q#P!_P \/$__ (*V_P : M/^'B'@#_)X>) | P5M_C0![M17A/_#Q#P!_SP\3_P#@K;_&C_AXAX_YX>) M_P#P5M_C0![M17A/_#Q#P!_SP\3_/@K;_&C_AXAX_YX>)__]6W^- 'NU%> M$ | #Q#P!_SP\3_^"MO\:/\ AXAX_YX>)__ 5M_C0![M17A/_#Q#P!_SP\3_P#@K;_&C_AXAX_YX>) P#P5M_C0![M17A/_#Q#P!_SP\3_/@K;_&C_AXAX_YX>)__]6W^- 'NU%>$_\/$/'_/#Q/\ ^"MO\:/^'B'@#_GAXG_/!6W^- 'NU%>$_\/$/'_/#Q/\ ^"MO M\:/^'B'@#_GAXG_\%;?X MT>[45X3_P/$/'_/#Q/_X^V_QH_P"'B'@#_GAX MG_| !6W^- 'NU%>$_P##Q#P!_P \/$__ (*V_P :/^'B'@#_)X>) | P5M_C0![M17A/_#Q#P!_SP\3_P#@K;_&C_AXAX_YX>) P#P5M_C0![M17A/_#Q# MP!_SP\3_/@K;_&C_AXAX_YX>)__]6W^- 'NU%>$_| #Q#P!_SP\3_^"MO\:/\ AXAX_YX>)__ 5M_C0![M17A/_#Q#P!_SP\3_P#@K;_&C_AXAX_YX>) P#P5M_C0![M17A/_#Q# MP!_SP\3_/@K;_&C_AXAX_YX>)__]6W^- 'NU%>$_| #Q#P!_SP\3_^"MO\:/\ AXAX_YX>)__ 5M_C0![M17A/_#Q#P!_SP\3_P#@K;_&C_AXAX_YX>) P#P5M_C0![M17A/_#Q#P!_SP\3_/@K;_&C_AXA MX_YX>)__]6W^- 'NU%>$_| #Q#P!_SP\3_^"MO\:/\ AXAX_YX>)__ 5M_C0![M17A/_#Q#P!_SP\3_P#@K;_&C_AXAX_YX>) P#P5M_C0![M17A/_#Q#P!_SP\3_/@K;_&C_AXAX_YX>)__]6W^- 'NU%>$_| #Q#P!_SP\3_^"MO\:/\ AXAX_YX>)__ 5M_C0![M17A/_#Q#P!_SP\3_P#@K;_&C_AXAX_YX>) P#P5M_C0![M17A/_#Q#P!_SP\3_/@K;_&C_AXAX_YX>)__]6W^- 'NU%>$_| #Q#P!_SP\3_^"MO\:/\ AXAX_YX>)__ 5M_C0![M17A/_#Q#P!_SP\3_P#@K;_&C_AXAX_YX>) P#P5M_C0![M17A/_#Q#P!_SP\3_/@K;_&C_AXA M

R[=V17P_^W)_P2Q^,?C7|KKX\^+?"D_B_P 8 M>%?V@}(L---AI'Q%7PIIVC?9)/ELY+?5X7AEDN[%P|.IM3O!FF0QC>91PGQG_M_P""0?

Q^\'>+-0NOA+H=YX.\4W6C:'I^D>)?"_Q3D729;O3[&-KCQ+8:A;O M]N<-&$CEMHV;3RHV9(B6<@'Z,_&/_@]"\ O@%XNAT/Q5\2]$L;Z2U@OIVMXI M[ZVTRVG4-*

*!/>W$$;PV<4JG='>/B3IGA31];,5= M5UKP^OBFPEM+*XFT^[TY!:&LR7]QFU)9B,1^,YA7Y@NWFOS+`,-9_X)A?"_QS M\=-=\;>#M'CTWQ[XL\-Z+IK>,/ /C\^:,;U;TLEAFN-=T]BD@N;17#K#]G M5I4B\M2A8;T 0G]GK?2B?XRAC MEB:,&.0127%NTB*MS %&KLBF: R1@NGS?,N?1/B=%83^-\6CU6VN+0I2GLIQ>PV MZR--+!Y3>8]+'^\9BN0 G5I'/.*_-*

-]5=5L+GXN_LZ^./A?XF\)^,?A5XDT?5 M?!_P4T#PM8RZ5]'@HW.A2,+ZX:25VNX$%@8'22. 6SSPEE9UR #[3^%O_!17 MX)_&SXVWOPZ\+>/=+U?Q=8-.GV2.WG2&Z:

XF2VN7C6"Y;/#;E@D<@(Y(PK$ M>@:C\;O". D?&+1_A]<;S;1>,]?TNZUNQTG;QGFL[;2&;?@855>>)?F(+%CM MSM;'Y^>_-8M-*

6_8_P"">NG^$=0\/MXKC\5^%@\=C+;K*&M]\NAKXCP PB6 M^$VW!:,HY+8/#]LY>#O@=?\ \%O?AIKOAS2FMM;^(O@/QKK7B'49[J6ZNM1G M%]X>2-3)*S%88E+'.%-*

*L<89MJC<<<@'UO\=_CWX-_9C^%FJ^-?'NOV'ACPMHJ M^2\0\LG8FY@?*JJ"SR,Q551 69B H).*Y3]FO]N?X3_M=#5%^'GC"RUV\T38 M=0L'MH'4+')')"226MPD:[NM35BB:RL?$*

TXC1I'=_P#5/DW]QNO">:T8SYABKJ?B-\;O@AX$ M_;%DU'4DT^Y^*A[X>:CJVJ:[;$-_P (_P"&K;=)76^E5\1123%VB5U.XPS$ M8V$T ;>MZ+^SS^T7^UQ'/AWXM^,/PML[>^EEOM

BNM2\/Q7_/[B'7_"=V;#5[:U\-:M?+ M87"JK-$\D%f]>X*ZD@,WB5YIW"Y8K&C$"QP 37P-^P!;^#?#_[0W[{5UX0\7P>+?#6N?!"7X@:XF MM-;?VF: M%\3+/X8?'?38M6U7X>ZU?*

*Z2NJ:/?0E+>+4|/EC=XXYGE@"L(XY4G587D1E56 MW_M7?9_;'>3"@=?\ 8FR/S&^OUQW*QR6W] MO#CS57+,K#*D$|W\"?\ @4'|*

_VE_B###X4\&_$+?3M2\07BNUE97-C=Z>VJ!-M2YM3&K22;0_%'A)IKV:S^W6LID>WEM;E87GAW2!8KB-RQA8D?4O_!6OQCX5\5_ MLV>#-/T35O"%\}2]<\;>'I?A:9#'?

2+K:A;2)7'EK$6WG:V M" ?3/PP_;,\"?&7QCXPT#POXDTS5]>^'^IC1_$5A"Q%SI%T8UD5)$8!@&0Y5 MQE&VL Q*L!<^$GQL*?'CP)%XE\(ZM!KFA3WEWIZ7<,;JC3VMU+:7$>'.4G*

*MAE0\8)0X\Y#P;KWP!^//[2'[3/@BRU#4]4\|_&?5=+|=:%; R2>*O" MAL-)DF*]U5[NP9Y+]L?NBXB&3*\7U!_P $-V=U=$>W2=U#+XEU.2.1>F59&4C@<4*

;/AW_@M5^R_P")O$\.EV_Q4L() M+B[:Q6\O=(U&RTT3+(8RK7LUNELO|QO2@+2 %L"20*]K^-?[2_@]G;3-!N_M&GB&ST.W\4ZS;Z!1DCDE-]?3DB*)5C5CS@Y8@*H&6('-?*

F;^PA^SY^T#^UY M_P $KM+^%R:A\%=#^"'"CF+6]'NM0DBU.Z\40Z=+]MZL^V'"VOGL?,57W14W* M^&*[3J_\%,O#?B_JL7]K3Q!\+/"7P]\6_$WP=\)?AS=Z"TN@ZMIEDWA_Q1K5

*ML@M]F5]NZMR\EOIZON%C.0+PYR)!0!]^_M2_MU_"\]BRWT*3S3;R_FO9(4#8RG]Q_!0d22, &N7^Q_>1^/O2^&_CKQ;HWO"*

MMGT+X:62:EXFEN]+OK&;2+9PY2=X)X4F,;>7(RHP)C8 Y!%?$3_ +3'Q-_: MAU[]A+Q+X+A\|*K\9K'_A+]\267C!{]"ST_6+'2TMM4AN!;AI?,$1A4 7 PVY M6X!XXO\;-

\4>+OBI\._VS=1^-0T#PU\:?A_\%)_#EKX7T"&;^RM3T&ZNY+F M/68+J:1GNDFEA6+:8XFM6CE5@3#0!^JGQ>_:H\ ? ?4_"MAX]\1V^F:EXXO M3I^@6*037-*

*Y]TRQF5_*@B1Y&1(U+/)MV(,;F7(K U^,Y^$&C_L\>'_ (LS M^.-,'PY\42VT&F:ZD4TEM<23R8<*2%0NAWAE;>]^C64.?MVG'QQ^O!%XJ^:?_M 4HU0?*

*M0'PWJ'QC^,FA0W/P]\4Z8)1HVGV,,,F\\)Z>)EQ#+;N/M#%3ONXY M!(WS)M'E7A3]ER^_:?\ $6L?LDW6GF'P!\(-<^(5Z);&YBMA:ZE;^7H2)<(MPD<*FO7,_P T-YAM)65CL7(!^I6H?*

M!>#=+^-.E?#J;7K3_A-M;TB?7K/245 MY)L&&\(Y+@E051 \BJ"Q&XY"YVMBO\ !3]#CP+^T7+XH3P3XAM?$' "&:W- MX&OBUX"MO"=Q=ZW]NG:A#X@\9;9Y|Z\VAL

*MKJ9(9+N&XOF(=8|$0@,2^'T _2/P!^U?\.OB=|*=9(\:/XLTR7PGX)<>*<$,)B9&W;P:HGH0:Z'X3?%?P !+\:*8ZM%XR*Z@-5\|- M>):*/4M,O1#)"\+]WD4,D@2115[*

MV^_$TOP5^+GA_P"&GQ_\->$-/LO$VF^+/#9U32_$6AM)=36+0HTT$H\FXFE# MSVTA4&8)*KLJ!?"_AQ\;[/7_ (P_L[^-_$7A;PC\.9-"^/GC#PJXUU;1;UI? M#.KZ_/H-]9K?

*VMS+@E+NX,.%0X!\\21G++D@'Z(?&A .T^'?P U>]L/&'B. MVT6[TIPQ['C*YCD@FD,6D6#1+:=W9*(PV1&>+('S'>,*><>?_ +1G_;5,X" L MEZ]9;.\0O'3^'KG4;"WU.W8Z%]5U*

]O<,R0MYT-N\8+LI 4L&R5&/F&?D+_ @ ML+XBL0&_QA^+XTN]LM3?PC^RAX^BUP6RV#Y:3[2?+:9+2Y X+"% MCT KW#_@]26@_P""4FDLKNI&M^ /XO\ J9-&H]:U_\X*Z?*

*L]^%OA3H/C74 M?'D]IX>\4:E#*78_LO_ +>0 MPK_;+U'5]3X<^(KW7)!BBFOEGT+4--$*R%E0@W4$0?)1N%R1C6&1GYW_P""_MJ-*

*_XXTW]M'!D:.X<2^#E\8KX@\3BQ'BN:XBTC;_8$_FB9K<&4'R]^W QNQGB MOHO]E#6_B_JUAK"_%^7X2OI*21G3E\"WE]<0B(@[S^*

.@"&W8V[1C&B>&O$%]"EQ]FN!*ZV4.C%8Y;J1$:.TC=E<(] MPT:N4?:3M;'=_%;X[^$?@?INCWGBS6[70[?Q!K5EX=TUIU8F]U"\E$-M;HJ@ MDNIL .,9)(

)'R#^WIK>F^,OB!\0V>_@IX=T)_BO\ ';1TD^(_B2]5ETWP MGHDMM_9ZWI\X6GZ:W1XK2V0gLR%VVHC%L; (=?LD>!?!WAW]GWQA%IUS]_M/BGP7\0OAWX/T;4KZ^EN6L+!?*

$%H&,2%O*2;53B294$DBA5+%0%H ^GOVD/^ M"A7P;_9&\4;7HOQ#\<6/A[5=7B^IPVWV6YNVA@W;//G\B-Q;0ELXEF(=C_-M\C8!?*

*TS5+;6;**YM)HKFVG198I8F#QRHP!5E8<$$$$$=017QSX*UW1?"O[<' M[9+?$6^T&WTF70?#M[FIR0M_P 4XND7"2[P03]E%VFI_(V?F,QQAP3Z5_P2 M>T_Q%IG_*

34^}@ZTZHKYME{(>N!G'K0!XY\9O^"A'P6_9W M^*&D^#?&OCW1O+QB/68XW@M]J.79 DCE(FN)E0Q6HD<%4,[Q[R"%R:C^_W-!

M13X)_1_&"P\!>,0'FEZ%XHU$0O]EDM{B2*S$$[(ENVAA0YZ&X>,$?-TY MKYB_:^\.>$?BAI/17A;X>>,/ 7@;Q@="AO?C+9Z]HTZWGBC2#8.+2&*]DE1*

M+=&MTN81=Q1SB'>2%6117 ?!GXO:#XR_X)^_MLZ_XQAT_P -7OB6UGUM=\0 MO +[2M)O/!VFMI%M=@I=BDHJN"P96!YS0!^C7Q8^.'A'X&:#IVJ>+=9L]"L=

M6U6RT.REG#'[3??DZ06UN@4$L[R.H&!@#). "1U%]=P:?:R37#QO0QJ6=W(' MHHK223P ,DG@8K\Y/V_OV9K"[_9;_9T^)?C[2[6C4?C%)\20#?P[<]#H]227

M!TV:3Q!I1OFCB#F!+B20NKSHN]T&W<4XKZ)_X+$^M7?_!-GXIQ:)92ZBSV%-MN-4M8H/M#SZ/L@.JJ(P"SYT_P"U_*@+G^ %MM &!\#_ /@JI^SY^T=\1[;P MEX-

^)FC:MKFHR2Q:=$]MD_$/I7P M-/B/X-\(>(=>MM-\2?$&YEM/#]@T4CR:E)$F^0#8I"*JD?,Y5-O'$?PGBT_P!\,_%.@ZKI= MK;:#K6E7L6K;JQ2:ZBN96>\BMK9_*1Q_HA78SH P!]W?*

M/?M-_LR_LB?M.Z1 MXA^(!>'^^^LZ(R6&I'^%;G5:;DTN.8H5$UM;RR1P"5R,$@:GI^>N\%?\%) MO@?\0/@%XF^)^E>/+&7P1X,NOL6NZA+8W5L^DSGRL)-!)IZB>(C.?(D!&1

MS7QW>_M">/OVH?\ @HI\)?B+ ^SQ>\-[^X\8_L_W&J2KXRDOK:RCM7UJT\Q%% MJK2K<)-A&5QA=KCJ\H^./BG5_BC^P)^W)XU^(#6.@_&YV/#WAOOQKX0L,4#QLD>Q3 :*

/UT^(7Q$\/\ PE\$:GXF\5;S MI7ASP]HT#7.H:GJ=TEK:V<0ZO)(Y"JON3WKR7]G?_@I/\$?VK?&TWAKP)XX@ MU;Q0!# UTFG7.FWFFW-S"I >6!+]&(SHA9-[1;@FI-Q&Y!?&?AW2GT77?

#&H0:5(9Y[FR M\Z:%[6>(F$SQLB+++<1*R*'2@#WKXN?\ !5[[GGX%?$R\\(>/B;H^G:Y1<@A MU-8[6ZNK71Y",E+RZAB>"T95(9EGD0HI#-A2#7H_B3]J7X=>#/'W@/POJ7B[*

M1+/6_BA'<2>$H&G!7Q L$<093K(Y8V #98-E=W-?,_ 27^>)'PWT7_ M_OCZ$NLZEX/T2Z\,V%W%\5[:\,-F++Q H9]!,_M%'(VRK4R.YD&OHV5ES6R5 M@^*?2

*V9K/[JNV_92\%17TOAS0=5T_P""><I_#/5]*ADL[GPO81ZI87/AZ]M@P M22-X(#,,%."R':258T ?K?;?&?PI(Y-+\MQNGR3O; MK<9V[-IFC=<9W97!CFO(OCK_,%6/@'^S9\7-*

3\"^,/'$MAXMT6<"}_T^U\/ MZGJ+VBSQB2(NUM;R(N]/F +9Q]*^:?\ @GQ^T3X@_:!_X*V^*K;QSID&A_%# MX??!ZS*^-M.MTV6\>I1:W0:LZ'UG\LVD[(L4GEA/-&YI$&W9NRV"!S7

MPE^UO\&/$O\L 7[(GPA_9G\:/>?%GO5\4_%YXE\9:=HT=KIAUC28]1=6=;% MLEU,L-0;//<6UN!)<1W 3<696KQ;OY\1_$@O=W_@=EY^UG\$_%A;6/ 7B?P9 MXHL?

%GA7PWBNHKJ6VT'6?$%M=68:XMYIHY8XKS[7"3'(Q"HN<,2H /T=^"/ M_)6#X_M$?%?2O_A3QX[UXJUSS?[.L+[0=2TQKYHHVED2)[JWB1W6-'?8&+

M,48XP#CTBQ .M^'5_P"!?&OB=?%NE0^'?ASJ%_I?B74;AVM[;1KFQQ]K25Y MH'EY&2,@YX)KXB^,/B7XT>,?VS/@%X _:27X:^$_"MUXQ@\3^$]<\#K?74&N M:[IT%S+%HMQ-

=.ALG=6,RMY3K<)%$FKYEU_PEXUA^(GQ0^(OCNUTGO9^-R M9\,/VC/$&H>,//]M'ZBS3QAM:OE4,MQ9Z9,;>;,[+C:R12R.&V(/U<^_" M?]>/PE_:%#^)o?&?QO?[QJ]NE^#8DN-*

;+V5S:3Z;$]L+N.22"=-)0CVY$B,$(-M=<[2<&I+?]NCX37?P1\)_$:/QKIK^#/'6H6FDZ!J CF_XFEY=3&&"WCBV>;Y MK2!@4!DV.6"A6(^$_VY'EU#]IOQQX6\$-%K.A?MI^!?#-*

E8:G9QR7>GSO#J M:6%]<&:(AEC?1;Y'C:!B$%L\A7)!9?VWECR0HP ?H5XF ;6\#^# _C MKX,^&>H^(+:W\=^+K*YU'2='$-?"^G6NK:EI1ADCFAM+HN()U+%D1FC=>+/M)^'?*

CS3;OP/XOTW5=-BTV+PIX7EN M8=3@6#[4EI.EU)/K08)$^[?%M7<#CZM_X*R6D/B;IG#P!^U\'O0%$6@>-]. MLI2O#OB6&W,\6H:+XFNK33G66,,AE5/MD%W#N;Y);92.&8$ ^T?*

A5^T3X^. M&J>*K/PCXAL?$$W@C6&\/ZV;3<|=C?I&DCVYDQL9T61-VPMM8E3A@0&_'[]H M[P-^RU\/I?%/Q!\3:9X6T..5;=)[MSON9FSL@AC4&2:9L';9$K.V.%-5OV=/*

MV??"_P"RW\&?#G@'PLDUOHWA^#(/;FXG\VYO969V)Z MUX=_P4K'A+Q;K/P=\,.GXZ/PR^)U_P")K[X9>)+)C2UOM-LM<@L9T\NY28B" M036UQ-$D+.LCLY,1#H&4 [3P/_P5_^*

_Q%^$7C#QSI?Q#L)/#?P_A2\1RW%^MC=VESH\,A(CEFM98EN%1RKA&\O#[\VD[6OZC\3_C?X6^+#&D:9?\ BC5HM\[-M9UBRT"SEFC=A/?WDZ6[M H)#22N[@G@$\D#-?

*EM^W/K_C[Q,\OVIOA[\1O M#_P^\?\ Q4T7X-KJECX\\"6L]K]KT(ZD[_8+ZSDDE-K.CQ2SH%ED5T25@058 M'Z=_X*3?%/PS\7_A^!+?PMXAT;Q%/XU^+?@K5/#\6F7T5S)K-*

*LZG;WMQ/; MJK'?%%:1O.IC@(I)(R*_/9?BA_P4D^"WP;\/ZQ]FO^,FALO#_B.7P=J+VFCW M]^UG]T5NES):NMO!(P*PR(V[&SY@-V>*YGP'_P %A_V16]K.6CR"-95>2W42@NP*

$6X]!*YO_@FDS+XC_;X8.R%? MCAK6"IP1_P 2?2.<]DB9/\-!*QT4Q"3/EA_M5MM+8Y" M@XSCG%'VE\%_P#@K)\!?A/BCI?@SPEXQU/4Q$>AN\=G;2^%=8LTE9(VD8& M6>U2)

*<*C'YF&<8') KT;I[,IKCX<_L?>$+37/B/XHM/#=A]-5]CLE:&;YN;^_M;!8QP6)*/-,P4,Q$:-M568X521YU^SEXI_:3U#XI6T/Q0G_9T/A5X9?-7PAJ M.JS:H9=0FLO(MP@CVY^]DYQTIG[??*

OP\%?LOZCX+\;W/@U_'?Q@N9+OPQ\.-% MLP'[6]7EXB//!%(Q\NW@V6Z23W$GRQO0L>>%8]9\(_M'>!?'OP57XCZ-XHT MG4O C6$V[?VY!-OLA;0[_.D+]O+,<@8'!4HP(!!%-

&GE9HCYFU8RRRH&9@ K$?-EM_P3 MNT6X_P""^*&NVNDWEPGA\;[=BZN&ACAWCS[.%IL)' M/N5WB61E!P!Q/[-=]-INC_\:],R_U.ZM(/#,GPPN8'][EC1'UJ3PSI[6FS=[

*MPF^RH@5EQA3**?F (!Y? SX^>$/VEOAQ8^+O NVVOB'P]]=8;]I60JZ,5 MDBDC+:)%(C JTCZ,']6 G(D^W\+,)-W)D#@GJZU154 %%%% !1110 4444 %%%% !1110 4444 %%%% %;5)4@@WRE5C3+LS$ (,[LGTQ7A?I-WP,^ M 'A"5,B_P#";PY\+K'_(36*>[U'QAX:L[79]\7FM),YNHLJR>:K%\'!9&S MRO'LOQ 4'P/K,>"+"XP0<$?NVK\>?*

*^":7C=?@G_P3U*_L]V=VUI>?'#0?!6 MK>&4M75;BWL_$:VL?$^CQV:W7BURC3S+;SH?]{8K!([,DB)V.=IKT/P_M7_M .PI^SQ??$UFN9?@W\;_ !1XST+QTI#2)X6\0#7-*

*4L].UD!8V*6US'\!97#, MRI&ZVK]"^ #]0_$?B+X5?M9^>;GP7=WW@;X@Z-XHT"#5I]$N+?48M3TFY8^_M1>&'++>9;R-&=DN-I9/E;(K5/3_A)^RG^RO\!CXA^&;??2@O\/O*

=LT=CXZL M)K\Y=634-$F.Q\"Z@0*CJN4GB@8$'.K\0_CE!{2 M_P 2^VKOB#X"TY/$MCXG^,GPHN].TS4"+!KJX4>&XVL:GS%;R'6=&@D$B'RV M5\f0.$ _1;0_VE_V9/VT=-

D^$^D_$?X(_$VVUFUV?\(IVOV&]"Z@@Q(_+6) MR2D?EJ_ PNP'C%>B_#&3X>>&;?'OC7PSX-D)VGBJ^[BUWQ9I>F7$0OXKJZA1 M(K]\A4[U>6&!-KN/G6$8)"UX_P#!+XB^-?!>K>

(/$?Q._9P\|?!CPOX9T2YU M67Q'I?B^QU:<&<(4A3]0_$VH:9;W&G7>H,EQ<2"MWE<-&]PPBD8A1O)#=6KT;XA_LY?IP_!S]D<^%/WA/X.>&O@A:W O$M-9ALK M?P[#+,V\2H9<1

[LQPRD$ECZ_+G@B[^(L?|>G[7=MX,_9U\ _&"PNO'6F)= M:IK_(HM-):QE/AG2!]G,,MG.\D>TARP8 ^8P R"3-^Q3^Q)H?P4 ;&<^%WP5 M^)\?A_Q--)?A$FK^#(KG>VG2ZK>ZM?

*G67L>?'K:PFR@CQ_9W^9_LU:C<_"$?"_S^$*0W<^I77AI(Z%Y:*WVIKAXLQ$*@8.9#P MJD'Y1BJOPH_92_9P_9.M-3^5*7@W%)?'_$^GOJ5IXIT_3K2PA6R*-*\YN0 M$A*,6+*

A2IR>^5O^"C7@;PU\/(CK\8[3X<:7X>TNZ\:?LX^-+WXC66G3+"=MIK;0Q:-->36B,]>8WFWT*S%"[)&5SM05ZM^UC ^_X-[?'IV\|\ KI5\'0?V > M/SH*

]Y\3_$#X. LC^%M4\3:]X@^'OPVT?OJC;K?:GJ6HVVE6NMW\L4<,3/) M(RK+\<<0SR2]+VK6_9ET]X>5X3 M"3'\TDCN<=W)QS7R;\:?@I-\5_VB_AKXA^%F]?"3Q+\9_ ?*

*PXM[+4?!/Q!BF MET[^P;]U*WT#PH\EM<_:+79Y@20/N1@F58^F?\!++#Q)H^KV?0?L?\A7+? M"?X@Z5XR">/?#5I]W:C0:MJUG*+G3W3;&(+BV>VF(5<;>9(Y=2Y9B ?0WP*

MZ^%&@?!CP19^O"NBZ7X=T#33(UM!|A^(;> R2-(^U ,#<[LQ]2Q/>L3X+W? MP\3Q)XW3P9+X6GUK^VV_X2YM'EBEN!JGE1J5O2A+'X$0B&V3D($QA<5Z%_ T M9!K\A?

@+^'TIW!//8'[2OQ3U-XAH?COQOXWT>_C=T1!]4T.UMM2TY0S=Y,> M74(>6C0&.(;DLN #]/"UA^SMX3\8W_BK39/A79;MH/C\MI$4X;BU673/$\N*

*MI>7;W4+ON_=7UR&B1T.)'W("#D9Z7XZ?"_X3_$KQ/IEO\0-%\%ZIJOB:SO/" MNGV^M1PFXUBWFC.]U'\8?YID9+[_&:;"7]ECXP_#'QO M!/J+4ED*RW=SJ=KX[0?%WQ3IO[*

M;'[+GP,^)U[/?_$GX1?$N_6WU>="K>-?#\OA?6ET_6%/EI&TNU3!Q B.>]B,QR'0 M&!'!P^!,2[0&^8?+Q\WMS7Y*P?#+_ (9N^(/CC]C6=$_9G^-_A.Y M^,#37FI:?X=-*

*WXPTI9]3M]+M'@U*8A++.Y\&^S1O9QO89HI7\X22$@__0?3_@ MO\$-#:?PE:-)\,;9YO$Q\4MHJ?9@TVN&3S?MK09RUUY@#^]B"VY5/4 B;QMXS M^#?Q8^-6B^ /$6M_#W7OB'X.O(?*

*%6G>';G4K.;6-'F1"([Z.W+^,&X25@KA? MNR$?=;G\]/AE\(W_ &5_'L M_P!FVMU#JD!!8WLYGM[:2RCA'ES.)=Y,/7?M4_#_P %_"6RT'XF^!U\'ZY\ M>Q?*OQ7@\]^,_%&GZM->^,*

[,Q"=6:"ZMX9'C9!)IX8KB#S5D\AKB%$> 9< 'W-M!X\'+WP3,]HPKXQ_Q1\,H_G\#MKTJU2UQO%%!=HIG%M_7\X+,ELI. MU?F$(ZXJU8^'_A)\OC]X\87>OZ'I7BKQI8Z,87T=S?

6]L\T%E]H^SY4E6=_MLW4WS-DX@<**^"OB+X-CU"_()7_M4>,KW0-$F^+=K\1_$]_:W5;Z6(%LCS08OE;S?FS?VK_@+=-_^T)^TF^TE=Z)^R]\:O#_P-*

M8[&XU7P[XB\/MJGB32K+2=-CN+G3H[B4K!ERNZXN$?RYS.)H ^U8TH _0W] MHC]CSX5?M?V5C;_$SX<^#?'D&DR%[4:]I,-XUL2"#Y;.I90.?A

M%X9^)/@2/PSKQ#Z3K'A^2UF73KNW62V#VLL+O'?P8^'']E0?K#[K/@4"O1]>^]H#QQ3X4T70M3\/,/&C>'+FROM+L9X \&GSV3I): M2Q>$;%XT9"/NE017844 >5_'|*

8M^%W[3VMZ)[7Q&^'G@GQO?^&G\W2;C6 MM)BO\+!BRL=C."0"R<=*5%>G6=]+52JJB+Q@*,?Y\/PJ:B@ HHHH **** "MBBB@ HHHH **** "DD?RT+8)P.X'6EID\:R1D. 1UYH*

\0^*?P^./]3W]0= MB/%?A?X9^-OB=\/(8+N%-0M+6^U?08)',D$C(WFN'?YK>/(\B-)@<%-ME-?'_C?Q59_L_P#_ 7*^)?Q:O+F&QTK3;KP;X#\032$(HT[6=-NQ#(3AC^[

MU&VL>@!VRR%G5%(/@GO-GD\:_;!?|O'XB74,|=+%[X";+XWDCG=9BM[?|U M=/CRLDBE5T^&S VG&:T!R P.T+XFA^_' P 9]?NO"6JR>&?$!]JXBR#E:O:O\O

UF+D3^,O#%NVGZU%X:;H-C(#Q3*K$$, R.A4C*D4 M?I%\//V1?V=_V4?B]9.]X<^'WPG\!>/O%\3^)O]6DC M(_X2_19O"&K_ HSL1-T]*89UCR(|F&4' 95YNXGY=^>: /M/0/A3\&*

MOV3O$'A06.D^ /A[]%^)/"GAKY,>PFNQCQA?V=@?$MA,2>8L#^>ZBYCBDER <M(#)VW<_"'_!6SXF^(_VA?VP/'NB>#_"WQ=U_4/@-X1B@\%.MX+\)W6]VUEXU MNH[34F-US62[T

S'SYK>53+!#"'4A8)?]HA@<'U!^U?=R7*REX2*.GXV^#?@CX+O>'0$6ES;9J.M^&+>RGT_4K$E7F@#FECS$\.Z-"RL2 M/E6$>9N%8_L@Z+XLW/I-\?PB;7UB1=9D\!S.=*

*<7L<1)VK*8&9TC+ |< MD=\#=(U8SZ)I-A9;-=) M9QWETD=O%))?:E!.I*I0QR@PQ'<6./H;_@I'\}_!OPP@^#*7BWPMX=\+:-\5] M(^(^@Z;X--L(+N;R*[OH(-3LU\LQF>)M--*

U(\))?$"L02@H]/\5?L< LY? MM6_$R;QYI_PY^$WC_P 4Z']+;?<;U-I-I]%S;7E]^U[>:0?WT3KM99,E2-I M'&*

[+4M8^%VJ:K+XVO=1\$RWGPH^VZ1)KD]Q;K_PB1DC@:\MGET:,DQK;%T8 MK\HC)&,5XY_P26MO^*^.IVL"OQU\OF23X5>&_CKX>^/O@W4?

*M%GAOPQXMU+]J>XU#P/;^(+#8W>D;_KMEH^F7EO8WMN"#/;2+%(74,K?*I4E@J MD_^ZOV>?B+\#_P!H?XDZS\0?AGXB^&7CKQ)IABT/4O$'AG4;/4;H6T;F6.UG*

MF@9CM5GWA6/!:O0M+^%6@>&?&GB+O)INC:=8:[XJ%N=9U"WA$=SJ9MXS%!YS MCE_+C)5<[:^O/V6=0U/PK_P41T_P_\ %OX0>"_ 'Q7N?!.HR>'?$GP^U>2? MP]XGT>

JLC=P7$#QPS)/;SS6YC\Z-QB>8QLNYPWW&P!4@1":.: /-M0'PX_X: M'TQ+N?PM_P +3&ASG3HI9HO[972C.IG:&,GS!;F8)O91M++@8G %<{\2?A9\ M%?B]\<[S0O%FD> =?*

^(>K^%XX[K2]X0S:K>;%/;O"Q\QI+1'U:;M67H< MDU\3?\%*!8C^%)\ P5W\+?%H2>5-\&/AA9>(;AN#OTN;Q&=.U-,$-G_0K%N0 M *5%H45<%/MPV_P!EWQ)9_&O_*

(+>VGQ4MW-Q:^*_ WC/0\'F$BR1/LCZWHM:MC"\161QY"/"\L_M^CZIAACDLO$+WR S7,H&4G\|"I9CD.#W!K\=OV5-JZ)+^S/X[G\\?#

MVWM(_!OQ$\/RZ_=64MS>2SO)IE#1QQ178@MT2\=I&B-O*JQD.]>:.W\.+?\ MX*U^+O@+XO\ !&G_ +.-AIVB?"1]0TSX;?$?PX?$4GAU+R[BA:>&QA:)[8K M9Q6T7(!JZ:E\1?*

@C^5?\>U!+|#"'4A8)?]HA@<'U!^U?=R7*REX2*.GXV^#?@CX+O>'0$6ES;9J.M^&+>RGT_4K$E7F@#FECS$\.Z-"RL2 M/E6$>9N%8_L@Z+XLW/I-\?PB;7UB1=9D\!S.=*

@X?LO$OC".*\U5U:H:C;.MLTK*33&6QLO-E4%2I&00L@!/LGXI^"O!6M^/?'CCQ'I^E6<_@FIN[!0;N MXNX8$;2ZLWM]'\;60PSAJGYLH3G:*Z'XB?#SP1^T_\;G0?$FC^&_'/A'6*

*MXR);6^MX=0L+U.02 =RG&3AAR#T:;_*GX9?LNZU^V;\)/V8?"%KJWP%DB\ V M?C.\T?PE\0M!EU^WNM*35Y++#2M1MK!)(UO;>+3UCB#23:1]HAF^=PE??O_!+*

MOXI6'Q0_96M(;+P1X>^,W@C6M6\&:EX>\/Q1QZ-8W^FWTUE=-9", "W>:-W M0$9 ?!R>2 =_ \ZO/AK^RKX#W;$SCKM%>I44 >??"+]E[P\ _A1)X&\%>#/#GA;P=

*M*9R^B:=9K!8MYV1-F-1CYP2&JZ?:VM MC:^'KS3HYM/MH;8*+=$A8;5$810F,0*])HH YCX2_'#P[\#? NF>%_".A;/ MX9\-Z)$;?3], TNU6VM;2+).U$4*

+R23CJ22OP076D7$5UM^R2QNDY8X C M*D-D]AC/->$?#S]EWX#__W\)_#/XC:"-$M/#?P>\)R6'A+71XBEDTG2]%.W M"M(TIF,,T8A!{GE+E5+$,,DGVOQ^GF>"=77!8M8S@

#)\)MN /6OSPT2XBA_MX-0Y8VEA5U_9WN+,@NHQ(_"NZ]MQ"M[K%P;I[2<2R%DEN\KT/'$Q M#*$SQI 4XK6^*/P]\:1?\%&O%'Q05^&-G'H"U#/"5P:;#]N_V^065D MP>,?*

O&#,3ELG)/K7FGQ%MO$>B?\%/C5;>"?V=/"OQP@MO '@I*2+4-:TW2 M(O#]+)K0C2$74,F5D /$>T(1G.5P =E:_LS_L1>%/AQ/XBNOBM93>"/&MI> M'^9+W6?*

CGI5_HNM12(([NU\N=1>"1MC;75?F4,1QFOIS6?#?PB_;^_9X.@VN MI:\X[^MQ=6S0W'AI6UEMUGL+F> QW-D)E'BG@C(VN#F/\XR*^6OBQX\(\8 M_MB_L36'B_X4>&?*

\EY/XVN+_P ((+34{'3Y1I0V_/%&LA("ON"#\;'45W7 MP>\ Z-\&_P#@L_XLT?P-HNEZ)HGB3X1V>K>[73+..&WBU"#57MJ-D=8P%BD MDMFO5Z9E6V'40\ 'L_B.?X1?L5:KXK\:>*

*(O$7A/X=O\ &KQ(+_6=4U_Q!'86 M^IW\5G<%1E6N950.+1]B"22>#_:^N?V8?CM\.?"&H/%KQE\+-+,0[MZ9[WPEXBF\8PZ+,SE))=,U*&>*5=T; /Y$O*L*

V0PSY]^V=\!KWXK_MTQ^, M_A8OP8^)'O1\$>#8=#U[P\0GD^56&EW=Q<7%M?6LL44S6US)/"R/NB=98HU M!,952W) !G0OAS\5?V _VD(^$EMX#!3>%K_,2IXF(ZJ;?

5K+PSK[Z3%/. M=;D ,2VTT:V!R#"J O.L;H&2!([Z^-Q-=$>49(XM\GRJ"$QMXYIX3_P#!,W!F'3P+ MK[^&+S7O$?A"?2-2\);JLGQ1UK5M'CLV@>TO+5XY+Z2",QQET:

KQ%C6^E:0C7>M:\U>V%M;6:F)-JR MXFG+[<$G#!\5G#]\NO(_ ((R?$'3?@;^T=XW_9_BTOXBZ/X-UGPSI?B,PE;^/5 MYH-U>7-M;02<K;PPW<;O+&{QVMRWS-@W$A)8LY.!*

{7\9M>_8F_;O/"=EKGQ M6^$.HZUHRKI&@7VB?$N'2[;A5RB_98+NSNX[EHY"L8,0N1YTUX]U\[^"_P"\!6?_!83XT6B>"/!L=MIGPS\%W5I&NB6JK:SMJ&OYEC 3"N=D>2 MN"=B?*

W1CPK]E=_'5M\|2/VC1X;_9/\'?&?3S\:?%#?\)\%[/B;2M.G:3[1'NMS M%/$OQ(\ ^'?#'B94;2-8U/Q#9V MMA]JNGF(T$TD@24,GS H3E>1Q7$VW|$?P4^,_@8W%H-IKGAWQ%XS3XG"ZT_ M7+A[74|8*J5O%EBEQ)$ZJN8@3"P"$$Y^?\ X_+ f/M_XT_;"N?&/PAT+X%> M//B-X/\ !6F>%_%7PZ\RM M_P#!)SQ)X1UWX#^,+;PMX(U?X97>C>.|9L?$W@^[ODO+7PUK0D22\M|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}>NZGXOM?@SXW^ M'OBJ^UK6I_$_B/\ L#Q-,ZU<27MUM5[F;9+(R%EA1%!P@2%44 +BF^%/V0Q@ M[^R(++QE9Z?9^%K;P+;Z[+!]%_K4ZVFCVNK7D5_]>6GD\N..2XA67YN$(;;M M#$'QO]OOX+>$_@U\6W\!D)"5YC>.%P**A& .U\1_%/X#_M;?L]^+//]1 M\5_"KXB_#"&VEM_$=P=9LM2T6TB1!(WVJ02-%&% 5RS,-N V1@&O"_V6?!G[M$OPY^-FB:I\.?B-\-O%/Q#N)EX>,4]8DWBS4K8RC;)%I=[.N^#OBA\#__"7PR^*.]> 9D\W$_;$L MC20F&%OV--//&@%Q/HHH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BNH M&G"[7V%3GI7S6O\ P2%^! ^)ESXF;PMJ;_J<>82V,G-?3-% :%:3^S_X:T/XU^(/B):VLT7B_P 4:38:'[5[M]HD(GM++*2YEMT$9;8A5[N<[E)W\DX&/.[7_ O]_!O3-+\56-AX0@TNR\;^ M- ++XAZO;V5U\;PW&NVDUO/#=A%*. ,(\8?L^^&/' MGQ=\%.,M4L6G\4> DOXM$NUGD06V+O+,M,4D#O1SC\&X(9(F7%??\)\62_[E]>7TNHVTQV_9)55\)(.*Y.[KQ5W1F3]O3Q;\3+K0/#OC: M_P#AWX>\.:.7\2]9^'.OQ6=I>R67BBXLM/EO4,1F:0F)O*,3R?:"X3R;],995 M:N:\??\ !)?P?^UU^WO^T'XK^+_@:[O?#_ B+2/#EXA1UR#5Y,.XC,-E1*K))'(T1#2KC(&,C-8/P0_8Y^+7@'5/V=/"&L>$M+,3/@A4-9+\RON !J+.;A_P4O^$-[\5_$7PV MT7X@>&K[XEZ):7TB:(S2@W,JK"9)((Y=HBFD3^..*1G7:X(!1LK:A8RZ?] M*+97D4-IHL2NUW%J,TDT>\SQQ^7OG4O)N$A@^$?[$?Q-\->"/V&[<>$],L]5 M^$OPKUWPYXE&!/+:../JESH=E;0PW*QN6FB>XCE5S#N\!"L<\@D ^C_!/_)5+ MX _$37_$6E>'_BIX5U6X);:;=ZOJ+6[3&$VEJA>XF@F\OR[E8T#,WD0-(0%)Q MP:L:1_P4^:\NN_O6/B;9_$00+KP%HFI1Z3/K*17'D2W3I&Z0P#R]]PS+(C# MR0X(S_=;'YU?$+|CC|H_XF^$O!6GWWPV^)MQ=>'=!\4:1]$6H^(_#T>@Z?>7 M?@^_TFV30M.L6C&$FO=7(6-Y<311D*5PS%/KWXE_L\>/? 7@_P#93\>Z%X/N M/%NK_L_Z,\G]_@>SNK:UOKS[7HT5@[6DLTB6IFMG!.'=0R-(%<''"N >G?\$\ M?VX%_;IT/XG:!IMQH.H^&?"WCV[\,.!?Z6) NI6,5E93K/)O)/G>9,_ ND?&W6OB#X%N?AWJ7Q'^*Nl>+-/T:>^MKZ2*RN M+#3HXW>2V9H[|-#N&>'|#C+##-]6T'%%%% !1110 4$9%%% $0M5'X&[*U3 MXT$:!1G }3FEHH **** "BBB@ HHHH **** "BBB@ HH MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@*

*HHHH ***** "BBB@ HHHH ;)$LH&X9P:KZWJR:'I<|W(CO';Q/*P7KA5+''X"O@GX.?\''GP^^,WI!:7Q,_:"L|. M\8,;X;^%N10:7]6CWR64>L74L_E"$PQ"X*%9#(P7=(18PR\?+R ??QMD.WY0 M-AR,<8HLHBFW;Q[$UYC^QW^UEH7[:WI,W@SXI^&-/U:PT/QOIYU"RM=12-+ MN&/>R8D$;.@;*'@,1[]JZ3QY\3=2|'>*?""^G6?@WQ'XB@\07S6EY?ZDC2QC72Y[55,VIOON5+6* MEU&Y-TQ)XBKZ(-T0N|RSMQG(.>* '&U0C!!(^JH-I&<_+UXZTT7+-]V,D9QG M/>GSSK;Q%V^Z,M #5LXT! 4>^N;BV1- /OC$T27"0.\+EH9)E1MZ('0=18\&P17%W;:5$CWXDKDGN>;3[''@#;P.@STKD_0=1$:=/^%'P.\1>/\ 4K2^DTGPSH-S MX@NH(%5KAX8+9KAT0%@I?:I RP&>^.:.H? LR_M$:5^U1^SMX(^)6@6.I6>C>/ M-%M==L,:^5%NH8+B(2HLH1F4, <'#$9Z$T =XELD9! P1[U)4/VLB-6,,'/7 M;R!Q^M)'?"9%9%+!C@'L.)Z*KI>LZ@B)L$<<]:/[14 DC"J<$DXQ]?2@"Q1 M0#D ^M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 44AV63RT)]/2% #]*^2OC/_P %9+/X8?M2>+/A+H/P M7^,? O+\0^!=`L>>URʔ7PI92:NG1QNT%[J#NL,DOF. MF(5Y$L5W..RFU\^%_P 4-1\?_P#*1#4O!WB3PBVAZQ<,7;C5C;-_,,,6W;?V M_D2R?Z-)D[/-\N3Y3NC7C(!V%%0)>%]OfM@2H./3- (M_N('EL&8X /'Y^E % MBBJYO)K#',;@$@9QT)[']WJ6&<3$X&,4 /HKY<'^'W_ 5R^%?Q)_X*6^*?V6=/ M_ML? $'PIHU">ZEMU73KEUCBEDMHGW;S*D*_&NJ6]W']+4,/1?'FB6NNV$% ^)EZYINBZEJ%_IT=OJD<:7*/9W4MM(S"-W4*7B8KAB M<$9 / /9**@6\+[L1D[?KU].E+,W9N(@^P@- TQSWH FHJO%?F521&PP0.?4 M_P!*6.]$@!VD L5/L:)Z**** "BBB@ HHHH ***** "BBB@ HHHH ***** "BB MB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M_GQU@^#=6!Q_P >4^[_VS:OYBOV_.V?]>U30/V;/&,!OI?#_X\^%4\9^^*M_)L(S82W/AF[UYC'-&R$2[P+$R,YW _F<5Y_ J%O6 C&0!"\@_YYJBJD18H MOE\8VB+$?CVZ "@#\.+KQH_AG_@BA\L+>'/$OA.XU3PYXE>;VU+4=8U*68 M/"">E/%YTD.,]VFE@W%XUQ*%6WA*[?.1B2!D'&_86\8>+M;\-?L8:1KVN^*=8 ME\)? M&>)=")C75%O(;FRT^*R9K:"2&Y9KB&,*P*13DLBL%SQ7[P,@C0+=)%LM]#YW_!2.]+^4 MKIYMOY(R3C[T6<9/W:Q?#/PZ_P"$/^%MG\6]+F\4V/Q'T[]MN[\/6NJPZK>@ MVVDW>H>7=6R0^9P2J18#X3YP!DD8K]\I+58<*0!0!2\>OU_Q[9%[8"WE0<- MP 1V^!)H _!G_@JC;6&C'0"GNC6/C=+XUL?CQ-KS9OMMPPC;75(HI/!*75@UI M]C%L1;- :"1!?/9LXD91-AV7/[" 'K]I&T_9# P"""">>M?$Z]072>" _!JZG%"W M/VJ=;92)BQD$EY2BX!R=W'>< M,?\$E_!W[4_C;Q+?:OX]^*NF^%O'!Q;7' MC+P? 8:VIT3Q0UH%$"NDT'M/@\!+^+;K M7?"B>U\2PZAJ6M:7XLN(A<>)IRVL?E^4DB%%6XD\N1W. &8!_P5AUO3[K] MF?\ ;'C^,L/CS5OCUJGEC6W^&QA739>/P,;K3Y+&;$6Y%E,9I!!,%/,=?T B/\ A9<_I_>S4TUFR"%,1\|/%E0@C'&\1|/YQ0!^,W_!1C6[#3 M_C3^TR_QYM_'U[H;?"W3((@#:Z;'J3023RZ+DK+I=IM65K=_MT8C.[Y2<$COBOVF-GNMSNSQD[<[#CGG_ #UIL5D9"=ZJISU"CD>GZT ?@O\ M'+7_ (Z:1^U\5O{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|ZDNK-0<R Z\#!&!CW__%4 ?AOX\TKXN^,OV"|, M^/EI9WMOH_[3/Q=-/B[XB6^IS?QMM$\'+YUOIEC>O#[-=C3O+2)KCRA@"4AE1 M-^>?^-%)XS\?? \$H?C):W7B5|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|TSQOH-F_A_6+/6_&7G&7O%AOM/^//B!=.6I@'D1W. MHM+M7M!R?S98X681W$4897-? IOXA\/VGBG2+G3[^&.ZL;R&2WN()5#1SQNI5 MD8'J""1BOF#]G+_@E-HGP$\1^$5U#XC?$'Q]X, ^%\SW'P^\)^();233_ ;(M8Y88WCEBA2XN7AMYI8(FNI9?+CD8#DA@ ?,? P>^&>B_L^_!K]D/|H;08|>E^ M*7QN\1>&;?QQJ=YKES*WB.#Q!9R/)=,\I^ _&$^AZ);6"6.G^'K"&^T)88L!F>XN297:6X MD;YOE5$0#'|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{CT;X]7T,GB[3-*U*YT+1 M;#[#IP2":ZBN(X8-DDDC-N ""8,Q .1^E?QR_P"""=W@CXR?L'Z?\'+5IOPMH M^@PZ6NB.GID4*W^C2Z;-!+;SQ.4VB56@7YL?Q-TS?3__P#9*T+XQ_$V-,N M\UVW^^OBF[\5.O]G,2356BYLI;UEMU0* 82EL#M?<-IF^_N.'X2>,I%MIM374)(+'^V=%;3(9IXW>,XG@L'@B.97<.R MNP=@VX^M_P#!5+X$>)_CD?AU+8.%]?^O2\'>';Z\N/%?PPTWQ(-#NO&5M*D4_M-PDAEBCF^Q2,)O(ED2- S(1+AE0&"U_X(ZKX!L/AK%\.?C;\3?AY#1M1NK:Y_LYS>VTRO'|FUBCB$DMR0T2."-M&7-'QSX9^(OASP=\;M<^%GPGU#XT? V[^(_Q!\+> =;\":L_DZM*Q>B[EN M=01TZ;9[A3%?$=Z>:,B3=GV'|C]B3P+_P $Y?A/%\/@I_BSPK MXJ\&ZJ!4^HV6DZY>7J^.+2XOX+2XL+/Z.>99A(EP[K)L\R.4'C^S:1_P2-MK\(> (_AG\0M'^)GBKQE\5_$'Q06P37?$^KSP6.IQC3W>33OL?V***'.T^RR.T ML9B4'S6>0Y+MEGAG_@FA=ZM\0/#6K_$[XV?%XOZ7X&U2'6_#FA:[_9UE86-_M] 2,>ZG^Q6L#WDL)VLAN&<*Z'|L;F@#Y8_9S^.WBG]DW]M?X]_$;7]*?C7<^!O$D%U,7MO^H&TTT:=JJ%V"PVL\EU]EN2&/C!H M>IF|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`O2YI+*/6(IFU75-2BDU2_M]@**MY%! M90;F7#^>N"NW%Z_;8UOX>P_$SPW\0M2^+_A"V^*IS6%_'>/H M_B62X*;QISON)RD4MEL7;HV0N0H*2,?K/P;_,$B__@K]F_5/A7;ZWK"^$=_M:\;6OBN]@CM+2%[I2UG@FMJ&)2(!K)!;0Q88,!0AD+$,37]7O_8WT'XY_$7 MX5^+%O;KPYX@^$^WB0^(--.N]@A#W2266TUM)?$UO"VX2%R.MT\#V14,L3WS_+"_H/\'A=H'P$^$WA_P $^&O;'0?#%A%IFGPRW$EQ)%%%%!H50TDA9W; Y9B23DFL#XA_LRZ5\1OVE_AQ\3[G4=1M]5^&NG:UIME9Q,/LU MVFIK.+*TN5+,;D^QIMVD#YVSGC%WPUX<|56?QV\6W^HZX]YX/U2RT^'1M)=(1 M_9MS%]H-U*K*@7X;U)FT"ZCF8S,+1_MN"9F%H8@"45#7UM\;_|+@GFOCCXV;E\2OAY\3O'GP9|>>(K*VTSQ!'AQ;*[MMOS%M;AA;BXM+Z"> S1!M]3HBR!,H6*G%9%__P $L_"Z? \7/'@=M+R!MU/[*Q+N(Q%,R#SHV]'V2#!"SJ&;#=1N//-/_X*]_L9_#?X M@_L/;%\4=;\,B\\>VS^!]"CUE-1NX)A9SZ[tT$\.(Y57:\5U<(3MW8E;G(!'MO.O_ 2HTSQE\/OB=9_$#XF_$'XC^+_BCX/N_MWXIUC[%%"W*V@R9 [D1DRM'&7+!0!ZM^T5^R/HW[2[-MM\,]3U35=/T]UN]%O%N[3R_ MM),;+ UO8@=RE<.]HBMQ]UFQ@X(/@[_ (*6_LN?"#]FKQ[^RSX!M_A;XK\1 M_"RY\5>);O4?!GA-=0U2^U28Z+(Z2+$DPF<1R*DA&_"A"<5I)_\ !+[X5?!W MP9_PEV]?"WX(_$;X-SW1M[74$\7Z-?Z9- JBKO=A6ZFDWHA=LE<8+ 'M7>_M ME?L0S_M6>*_AYXDT?XC^+/ACXL^&=_>WVCZOH5I8W4IH-W:-.3(|=Y!-$5,3L M/N9&<]<&MO\ 9D_9Z|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|_"7[>/PB_;>^/FHZI]VL>+/A9/>VGPX\2Z1K4UO' MH\&G>'K&_MK[3DC(CC,]S<-<-O60$N:I7 %? 6'QP_X)C6'O0^.7B+QMX;^)WQ M$^&G_"P,'VTOQWI?AZ2T^R^+[>W5HXS(9X)+;,R9'B,ULTI9C)\ECCF(2"-4+2?,[L $KZB_X*A_'+6?V<_P!A,OUX MH|.W5SIVO*MEI&GW]ND;RZ5/[%_;Z>EXJR*R,8#=>-<%88;R\'&W16P,[2<$'!KK M?BK\+/#_ ;_ (;ZYX0\5Z7;:WX;\2V4NFZII]P#Y5Y;RH4DC;!! *D\@@CJ M"#0!\F:#_P $G/A2 ^RWJW@[Q;X&\7^>)OAMX]\.ZS9SZUX]O=?GO)O'*N[136 M6IBJY$,WVR656^5599MACP<"OD;_(*_P#!0_0/!O[<^K:A%\0_#OA_6OV3 M--TC6=,\..EJD<6WWK87=Y;5]N>#/^"6TP M6>&\)B?ZA8ZC\'##K$4PSRS6:\. ((_L\KHZR6\[&-1("WZ[_L@_|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f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|C^TUCMY(MY(YN4\K?NC7/R;?.@#P;A7X*? LX#HS0!0$_LM?&_X9>+Z=?L=?\5>&= M6TW3[5O*9&4RSW#Q!V1V55*G))QC&;!T_P""DWP8^&GCSP58^+?CAXMQ-*^# M7P^L!S4->T)FV2RTW6IG$2V\ERT+I- *T+*_DP+D22S(=K.D>-'X-_L@?%7X< M_$W2M<\0?M0_$[QWI%@[MH@QLH5Y++;PCF7#,'&R1>4 /&08O MV^?^"">W_ W5K/PYOF^')BOP(_PUU:37;"'2[#3K^UN[[8$@N)X;VWFC=H!Y MACRN%;0MC2V.E/++!=9?3=#TT6UO(-3LK"TO3%.C($$=K!%"|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|C^TUCMY(MY(YN4\K?NC7/R;?.@#P;A7X*? LX#HS0!0$_LM?&_X9>+Z=?L=?\5>&= M6TW3[5O*9&4RSW#Q!V1V55*G))QC&;!T_P""DWP8^&GCSP58^+?CAXMQ-*^# M7P^L!S4->T)FV2RTW6IG$2V\ERT+I- *T+*_DP+D22S(=K.D>-'X-_L@?%7X< M_$W2M<\0?M0_$[QWI%@[MH@QLH5Y++;PCF7#,'&R1>4 /&08O MV^?^"">W_ W5K/PYOF^')BOP(_PUU:37;"'2[#3K^UN[[8$@N)X;VWFC=H!Y MACRN%;0MC2V.E/++!=9?3=#TT6UO(-3LK"TO3%.C($$=K!%"|&K':=F3_ M !$UP6O_/!.S3I/V:OA%X$\,>._ &/@[7? @AIUEI_A7Q=IOV5)2MQ!8?V>)2 MQ31/;3":W+JZ/$4W,K*%9%(.;_X)DPQ #0QA\>OA/IO]HCP!\'_!TFD>&H M[!V]>Z>RL+O2=/U(6B,_S>3#)=2)$"6*IM&3BOJ^O,_V6OV9K+]E_X? W.DQ;_MK_B5S]9U.YUS7-=UF2-]W6=0N"IEG=8U2*(8556*)<14554 5Z90 4444 % M

M_P""HOQ1\6W^-NZOK'P&\&>'O"%AXST,M).GAV/4EOMNO6Z!68+!+ %N53:## M.TK9\D8Y'|1+XT_%?O3X!^,NF^"/BAXB\->(KG|]G0/"/AK6/MCW$&C6MS8:
M,5@"$E6LC+,S/#@H_FR94[N?N+PA^Q_I^E_M$_%_QKK%W8>(M'^+OA[1/#M]·MH5S8#R(X-/BO8I1(S,PF2=;T@H5 5@2V>/!?@G_,$8K'X%?"D>#-&^(6HW M>CV/QFTCXJ;:-
J&G"2>TLI-6Q2#1RXD&\+%9K$LX VIM!0E>0#*$G_;F\1_'S MXE?'LS1K+J_@CQ3#XN\5>%OB1X6@NYDAL=5LO"VHS&VEX3SX/-2&ZMWQM=&AD M7V^=_P#@G!\4?@+|
<_@I\%&\4?M&?M7WWQ9\5:?1U*T'BWQDMA<:0*$8D>%_MYK|H^+O_!,I0_B5^W|X*^/NF:U-X:US0+>]MM>TN*T
M62U\4M)I=YI]I<3,"I2XMH[R1%D^8M&1'A< UQW[-?[%?[3_.R_\(? O@+1 M_P!HKX77/@_P)!GHEK%\B2WT8JLBR2[K&W MU24Q;6C9VMRX'R$VO^"EO[1Q@75/VL/V>?|
A,/BQ\5_!"PD\;>_O$&OQS>¦ M=7UJQFU6Y\[1FLD)%TU#.Z^3/<$;T"KNY(O /T5X& X)C?#6Y^)/Q)\;?$WP MGX%^*OBSXA^)I=8-_P"(//"MK=3:59+;P6MGH.#3+
{_E0PP*=P(R\DAP!@#G_M -D/_@FA??LM>_A-?R>/)-?L?A!X\;\3>$~M;"2.27J=3U&SN[2%Y6F<_Z M%%9I;AL'S%$9.TJ<@'SA\,OCM\2+K2KSP\A #[XE?$]Y%=_;9X-^&'C?
MQCILUYK^G6:Z+<:C<<\#:A"/,@:TEAMIKD)-LKOPRQ)>Q?&GX-;M_P3,E\' M_$SPM\7/B_KOAY_%NB^'O%OASOCXAN/%5OKMKJE_!I\;P=-/NLKF">YCE#0L
MJ,H=71_D" 2G[6_[*&E?M9?"RUTBZUG6_"VO:)]$&N>'/$FCRJN!>'=2AW>5 M=0EPR-\KNCON"DD$|9^-?QJLO&^A>!-336]*_M^%?"O_".66H7R#|S/]3-=7#W(@/SQQ(8H_,PS]Y5
H!I_P#!,SQYK_Q$\'_& M6;6]9K6SM]3=(:,,L3MBC4!40<*. *^?],\5?&GXE M_!3]II?_B'QMJ%QX.^/DUK?VNB7BGQ ?"\-AIDMYIVBM/E(;EED#?&7CG5/&DVCZK\.IK^_MCJ-VUS-
M;BZ74H_;&ZJOY0QZ"%;.K_\ !-&\;#QK?;'\3>\,>+=<'$^D_5/#^LZ=:K 9GPW8OOX4T&QT7|2L1A%%)GMTA\|P MED0VS.W0>Q&30!\0_!2+Y2Y
&"'!L*RTGP_#^?YHWPL\/^"#]M]J7PJTO2 M9A>WTEVX=I;C4HVBS:V\#%K>+?/+]JC*+B-LX7[67QR^)'Q:\6?!+_A3VO\ M[27BCX27?P_GURJ\83"^PT>>
/\5W,DMM%;&XGU&);6&6***>9XU"O(UQM2-= MA ^E/V@_V1/B?K/\09}?_"?XU3?#N36](AT3Q!H^K:#_ ,)%IMPL4I>&]LX& MGB6UO55Y$,A$D<@$> ^,E,GBW_P"";7BSX$CP
GI/GQ;O_AO\X+*#PA=;9D MTN3Q3I6K622B6.Z;W^T6XCOUD+GST:#)(5*850 #QK]HW7-5^/I+WAKXR>%_M_C#^ T)X\ ^\7A&&R\$+\.+.Y'B"
]UU%N&EU;6UMHDAD4/#'#)#/;BWA>-PT> M9&4=3X(NM;_X*,?'+0O!'B3XH^*=,TOP=\)_#GB[4;WX7^)IC1[#Q^K.K2W4 M4EU%=VI+.]M$+ "81PN2C?:"S*&05V&A_\$Q_&?
[/5YXOJ<<=OY\"6U^T]Q<$NF8F215,6(UJ[8?\$S-< _9UM//! M; L\ $>#X=WWAKPN/"&H'Q%X> X22VUVQ2YDNXYY42>V9;N.XGN65]YC"W4R MB,9! !\X>(OVG?CS\?OV?_V=%\-
R?'_55FE\5:?XU\1?#32[)_M/6KC1KZ32 MX=99+Y?L%;D2>2C#'(I(E#.ZD?>'[WQ/T'XN?LO^&M6>]V>-/%'CVU19[M.ZU3Q-
-%%K@NXIF2XM[^.*.*.,Y@D#1.JQJ!Y8QD88^2:C_P3I\5_#'PO\,E M^"WQC7MQXATC^W-*\7PW4GVB>XO[&*:V4WINLSK<(RN&FF! M#]_'M_[(G]-
UE^RS*3X=M4OM>U#4|2OO$.MZK=HL6OR0K M)/*Y6)?E1<*,XR0#U.BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH M**** "BBB@ HHHH ***** "BBB@ HHHH *****
,KQO<2V7A34KB%BDMO:32HX M/*L$)\]l.M?&6B_M5?$"X_P"#=Q_C/)XCF;XFCX'S>*Of<<SP^9_::Z0TXN?+
MV>5N\!T!MNS;GC&.*<U=>M%U#39;:0!H;E6AE!)&58$'I5W]5\$V7_\C]HI? MV84+S]F4>,?A);_.%|D|*0:^MA?2^+T\-,/+ ^P-;$"T^T?92UK]!\TG $NPR M<4 8/Q'_ .'C'Q"_9U_;
],WBK4(-1_9]TSX?>#Y?PP1R>%;W6;K48(M;_ MGRL;836T<5POS!%F20*HC$OC]X \':0!; M0.+/2=23P\;RU *999?MMQEF)<>:=K+A9)-Y5E)]AG2?(VM%)%?HH(8M\KY X)^=OA;_P
$&OC(_BG4KFSMM/\/NNAK8PV]Q M\;VC2:4#.R'S3(Q5%^:.2>2_: ^/,GA3_(*`>+_AI\0?VTM;^ V@>"_ MWA>YT5]B^\.:=+XIN[@ZC'?74AOJ1P\E;.W+++"%13*?E&0*^P/C5^S7K/Q/_
M &T/@+]' $VSOM-M]'^%UMXG@OI.;S/M-V=1MK>&$0484A6A8MN(X(QGG'COQ MR_9#^-NG_MS>./BE\-]^-7BK1O'%23&0&FM/*TH(H)=:=)SWS%H?(MI4VR"_M1/4?A-
-'^('PCOM>-QHR7V]Q>'KBUU&U6VC\F1+;,SA*HW,P.8 M7)X)Y->F?\H_LP_$>U_;3\1_&7XRZEX*NO&VI^'%/"6E:3X5ANFTWP\[h=P] MS/LN+G;+-)=2M'!YB0+]GC49P68
\K_X*A_M!>+O@[\?_"UGXD^*/C#X$_ F M_P!"'>1O&?A3PU%K%[7M-2ZTCXI_%7 M]@O7_&6D?M07U_;>#],6-9*^-? R:1<'QKI<=H);7^UELY(M(I8YHI!:A M
VTL=G,8X_9OVA_A3\??#WQUN_"P<\8^$=?L=0]&ED:63:I?8 #EOV4?BCKW]+W_ M 37_P"&@/BW\??'GQ-@<U;X>;;XVO(:.LM-CBTF5M/%R\-FMG;P,WFR3*@65 MG^XGS+\Q*?|
!+C]H;XK_$.W(WPG^-FHWI'Q:!*6NF>(?M@CABD^P:S8K.@ M@B\["TNUNI8"2-B/)CWLS,U;_O/_P""=VL?&/\ 81^"'P#\07N@W?A+PK%X M_O)3KUG*D^"_QCOO|
@HKXV^&U_P#M6_&G4_#7@+PKX:\5PI-IWAU)=2DOK54XYK>= MDTT?N=EA&!LV:/;?YNF/;/"_[4NF>/?C+\;+?XC_+?6H_[4O"?O)UOP_I?
MA,:MX51L19Z7;3*MLX2_1V+A@P9OG8R&V^U?=7=2)3G'6/=0"Of=_P 1/BO+>V$V MB^,O!GA_PW;6<7?:X)]/N=6287P*A=C+?1A<$G*MD#C/SAX0_8P_;/^!OQ% M^*/?'>K>,;.
{\6S;JFJP1WLJN()1%9R)\@4#AB.:.,C]M_MX\>*?@#\2/!>B^-_V@/'_P +/@E+X0M&TIXC^'_#-EJU_P"+-=0SFY&H7(L[MB"UC-JL,R*EM$DS2R%7 B*5]5_L
^(_$_BS]GF" \2>//"WQ3M9]0NCX>\@Z M%%)'XDT??\ Z)<7 A585N@N8Y1#E"T18;2Q1?-_%OPA_:@\(>._^$Q\$>*O MACK-5XIT/3[#PQ%X%\4RZ@GAS0[VWB827.D74$33+%
(697AEA^2Y?WIMV'NO^_M^'>)-Y^R!\&\]>TW5IK0Y_$/C/Q3J7E<8-!M'M-$T^]O75FMK"%R62WC5&& M6^9W\R0A3)M ![U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M% !1110 4444 %%%% !1110 4444 %,N$+PD @9]1GCO3Z",T ?-7[. Q?\ M$WC7_@H9^TAX,U'6)KOP[XLO".?A/XIU/ MQ7HFN^)|'^>M?%+QU>I92V,&IW-
HMWIBPV,&9!&D*26B 2."RP,Y)=B" 4 MKC]ON?XY?'OX/;O\-O%$W_"N/B!\/(&/BS[+Y$08W]C<:5%#Y\0S1S6SSW,3 MQAL"0.&!*C'CGQT>?&K?O\ @C[\)/VB-(:!^(?
A/Q7J'@GP6=5T_3=.T>3 M3]6O-2O+&"YOI5GLY)%F9;UCMC=(P8TP@^8-[9! P2OU'P9_P41\0?%KPIXE ML;/P/XI\)^(+&Y\+7*3$Z=KNK/9-'X_%/A?0_">DW&IR>
<=/EDTB\T>>9D(3S-KK:. M$RHV9<@#. #S'|N57?%?I&;_+P=XC_:P_%$+#WCGQE]UOXD^(>O'0+.\M; M6+1KFYM(7S)+)...W,$:AC#0QE*ICE0.#XT_'BY^&/_3]^-7CKX1_MFZY
M\<|;T5-'L8[!+OPWJ0*RW.IV\)E06-FBB22*24 3AU.W(\'-?1W_!0OJE[X MB_'OQS\/%GPYM?AQJ&L?"'S7M0U:?2_'#72Z9J.5UIES8;"=0\30:=)H5QX4N-3>WDNK;_AN6 M%Z)+6-
A'MAV@QAFRQX YH N>,+3XJ?|\ !/GXR_"/4-4^.7C/XO\ @?XA^-;7 MP/KNE^+=*TO[78R7L$XLKJRFLK:UV%;E$$PEVWAHV)4!D ;TO_@JA\3/B)\(_MV<+'6_ %
/J6BV4.O68^,M=TK11K6J^/#QCF-W?65F0WG3HX@_=R;$=Y/+< M1D5Q^C&_|I3XV_#O5?CG>?!W1_!OPR\0+X]M$\&-J6HR;_J4<$T=HUQ M-=I"(*($MI)1.H19"\BKG:%
{;V'JL#X/\ Q%^(^G>%)[:^%OCM/!_BSP7J3:G%8 M:C |QH/B>-H7A>RU",,B41E7+))+&2T4@5]CE0M 'SU^PSXOUG|HH^-=,\"_M
M5W7QA\"7>B2VLFO7=KIUKXV\":VS[8RMNEC%%Y$D!=T^TP9$D.0)4D.S*_8I M^%WQ<\1?ML_&?0?$/[3'Q:\3^'_@IXFTBPM-,OK#0HX->@N=&L]0D2\;+3TD
M_P!9:0G8?"']G+Q9\OCO^T9XWM;0KR3 MXMZOI^,ZP;EY(L,6NAXGA+]C&V TIN7R@?" ,#@G*T ?/%S_P %_&<7_!2 MF+4&OIS^SW-
XS;X&10^7%;V7B9;,WC:@S2)YDG^Ef^G*4E$>Y77RS)L+W_V_MZ_AU\62#W#I8/P:T[PQ^TM\62"N@?&GQG>Z)>:38Z?H4EOH=0!HE_?]+1HK!Y
M,F6S0$RO)\KOWP1S,G_!OM\/[3|CN2RTVQTRU'.;02R_MB#XBQWE_O\ PE@E M^U#4_++.$3[8 Q BRL?"@8&/IWXQ_LV^+/C5\3OVOKGPYIUUXJU4ZG=6\DDSWMFT)D\F-
"4@5!QG;_Z/XO\ MQ<\5_##]BS0?%'PV_:-\3_%KP'J7BUAXT^<%G=:I'B750"^@K;2), =/@L+=:. M>0I=QPHTAMYWA6>:.1D98\+WW!5GD)?QD\0_MSP?%OX9:3\$/$EI+X$@\'WFG
M>/Y+Z,V\D6H7%WY\'V>WF&&$RKR0?E-:%]\'/VE=?\">%=:MO$/PI^'/Q \" MZU=WEMX;\.?:KGP5XLI9[98_L^HAXHKB.82%W2:)6$1YV2$D K_/!.7XLW MWQ8\4^)!GPW^T)8?
M%?#*"&RBB74=5BM;/Q5X;UA9I%FM+FWMK6W46\D6QT,L M.2*T;8#]^'Y?L2OEC]D;]D[X@Z5^UEXK^,'Q8'PXTOQKKGAJV)1:7X%CN_L$ MEM%=27+75W/*?"X0?$OQIX\-
{X3]>Ix=TOI_D9LF+!,,Y?A3UR/RKD/^&=/CE_T5F'_M ,B?_$?]ML?MKW?!)WQ<-7A>U\.VVM1?&?QPGA">XDO&@;2D:WDF\|5'MY MA_=XVDJ.>M>T>:?
B7X=^%/A&^UWQ3KND>&|$TJ,S7NH:I=QVEK:H!DL\LA"@ M =R: /_^&=/CE_T5F'_,B?_$4?\,Z?'+,HK,/_)$_^(KUJT.:N^%U]\&' M^(\/Q$\#R_#^.)IF\2KE=L=)5%&23<[_
"ACO\W%>4?M:?\ !4SX0_LH?LD7 M7QIN/%6C^+O!S7%M9:=+H&]6UVNJ75R0(88I%?R^5)D8D_+&CN<@4 , X9T^ M.7_168?_ ")_\11_PSI\+-+%M](RU!&.W:>
{OW$88>7(H!#J&X(/-?*G@?\ X+XZ5\7_ M /@GQ\(?CCX4\))PW5S\0QB-I/PXUS0+G4BLGAN\NFBF82(A,NT\)4!5=Z2I MG:(+2.]&H.FI+3R2X?SF7D1XW$=!0!VJA_PSH\Y?
#SXV^#/B[!JDOA3Q9X:,31:)=/8ZB M^E:E#>+87"'#0RF-5;@@Y5L$8-1_#;X\>[_C+%>R>$/&'A?Q4FF7,EG>-I& MJ07HM)XW9'CD\IFV,K6C(;!!4^E 'B/_ S!\R?M(_%9_@7^SIX^\/!
2K;7&N+++OQ]% MWK5G:7$ EBQ;MIR1-+EE#+YP R<,<8(!U?!_PSI\,_@YH(OVR_A!X1UGPSIV]_%+X=Z; M?^-+<7?A^WN?$5I%)K<)4,)+)8-(#,A4@ADR"#O0!YA_PSI\,?V?-
*UFSE\;>#=(M-4N@]M["$NWG#2&VMH]V^5XH1'++*5&U!.@)SG'F'!)UU#RSI%W)=-;P))"5VM"SA0S[P5WYP0IH]#_.&=/CE_T5F'M_P B?_$4?\,Z?'+_**S#_Y$_P#B*D_9Z_X*
0_%?]WH!+P-X@T_1_"NB?L M_;GI-D^N7,J!8K^,JL3=-+'*54@"'''' >8'KD5ZEX3;,X^%?CSX0W_P 0-#^(_M_@;6? NE1RRWB0&QUNVN-,LTB)$C27",8T"X.2S#&*_/*?| AG3XY?\ 168?
M_(G_,11_P,Z?'+_HK,/_D3_P"(KT2W_,K^"-WI>MWT7Q>^&,EEX:%[=6N% M\3V1BTP7*AK;SF\S&?FJ04W8W#IFN!\>?'GP-\+=%TK4O$WC'PMX>T[7;B*U M4TVZU+5(+6'4)12!%'"
/L:(S[EP%))R*./$O^&=/CE_T5F'_R)_+$4?\,Z?'-M+_HK,/\ Y$_^(KZ3L=0M]3MXYK:;*XAE19(Y(V#(ZL,A@1P01R".H-?"?_!5 MQ_@LS/\ \$R_VIO@9X%G\#P^{]
^+%VR:M]XO98Y0#]LEW:P,L*1/YN%N"V M,KD]!GF@#UG_(9T^,7 _5$F'_R)_P#$4?\ #.GQR_Z'S*$ Y$ \ B*\D^%' _M 62N/BQ_P %HO%0[*5EX*B&B>%=-N+!_%;7LR33W,$%O)-
MNT>TA9)\NX2 M$$*#CFOH\X62M=Z/;0^J:1XO2\TB!(1=B1W-U M.D*Q7G;2#!V:\H9NM'+_P##.GQR_P"BLP_^1/\ XBC_(9T^,7_$5F'_R)
M_P#$5!^PC_P49PB1"02YP"5&!ACFO/(B#_P %M(-(@_;^O_#'A[P%XNT'!FOPWH!/B+1M4 MT_Q!YUMXNCU*R>Z/SQHR1*FW:&1I-W7CI0!|-_PSI\D^#?VK_9<^$OA]-
XH\3^$_OB/XB:,ZKINC7VL0P MW-V9(SED2!)&5Y0FXC*KVYQ5/)NQHF3]D'IC7XD_%2RTJ#?]CP#H%SK<>G2-#^ZD<+6ZW,4,30.DBE9D!1LG#'!K MTA98I$#!
<@X(^3M0!^%7_!3+]D[X]?&?XJ?&);+X%^);2*R^)VB^*(G\$>$ MM)&F;_IMO+$(]6N=3)_M*ZU#RS"+J/00^J;M;12V)EELG*[RL8-P6*G W29ZM7[:Q, MDH)4#KSQCFO,?
V;/VQOAS^UN?&@\|Z['K$OP|\27?A'7XFMY++>6PU"V8++&4 MD4,5R?ED */@[2<&@#\ZOCY_P3S^')'B+]JG]KG3/A)X37X?67Q*^.!FC>'- U
M;VM1IFD7^](1S6HEC78)3;CR=V"45A\RCD8\!?P>\>[D_+047QD\9^%O MC5I?A3X1"P\N^7/?A\$^?#L$@MA%+_94-I8'SM32(#I\L-TI,64(1R'>OT?^ M#*?|>?PU_:!\(6NN>#+
]6?$.D7?BZY\#BXL]#WCY(X=1M_;\S,1_N[=?*8?:& MQ%DJ-^67/JNOZ5IGBW0;K3M4LK34[-U&)[>YM+NW6:&ZC8$-&Z,"'4C(P001 MF@#Q_P#:/U67]H_
(}L^/K[PHNKWTWC[X:ZC<;/8-:-%?SM>;?(T$)A/S+ M,?,1=AY#''6O"/\ @CQ_P3NL/\;/V??@IXDUF[^+VD^.[']P78PZMH.N>--6G MTS3K[5$FA.ES3FWBV,6"H(P(CC;C%?6?
P!^/?A3]I3X*^'/'G@V]>_)*+'M,7FF7#VLEL98EO>ZDZW5U$X(6#;)$P9AC#]OG6_P4 MA_8%^&B_M8?%G5_8--_$^H^(%)K'2;,3&0M@*A^+O OCNXM(&Q?VET8GT
M:/,P$L868&0'^O NJ-2>2VDMV,]G>36=PNR10V%GMY5SC#!T>"_M/%%QV%O):F_L8'/E7=Q%:1PNB,_L=?&&7X>?M_:OAM\6$NOC1\,-)D*C7/#>GZ;=^)+F*UN89E6UTO-K
M;3Y:("UXG"XWC(;OW,\M?[!]>U*(U X4#G/3OO!^3/@3_@G/+8_MR?"N^F^'MMI%X0L?V5&\/;H\OAN$6,>O&1$%I-\FS[7Y32KAOFVNPS@FO ?@O^P3^T+\,
M_A/^51XIUKP_]1++P_X<^$EYX'O-T?SP1\?BO6="U:,6IY1/IEJ82&"ZM3;.MQFXCR46$*_EQ.6/R&-2.?%00?:D.2L>54_A0!\3_/\-/Q=_L(_LR?LX?;
MQ_I/Q#MO&OBVRU6TTZ+4XK;4ET9;(27?V6[NI,FWB5;=E2'&050+P17BW_!< M/]B/QO\MG?M4^!{3P_X.UO7-&D^$?CK2VU"V5X[2RU:.TAETV*:9?\ 5E[F M&+:#]X@C\&;_3.Y\
-:=>;[;ZI-I]E+]=C%)\;7;P*T]O\(5,B(Y&Y5* M_A)XO\4>"/AO\7/B1]VN^-#HM.2XU2[35MJ;5]\%A.RI12>4N<[5SC&<4 ?B'\$OV#OC'KO[*.NZA=_!36_"FG:!^UG-|
M4M8^%\@MUEUOPPD=N39VD(*VEZB/AHTW"*0VQV$G;F]KG[-7Q-^+7A+_(*8 MZSI'|/GC;X=6?QA\,>'T%:!-I,,5SKABM+A))(XK?*>?(2LLL0R\;R[*S(& MK]KC$K')522,=.U*$.
<=#]/PS_&F/^">7QSOO'/Q02]_$?Q)HWQA\!^ M&]!\6'ASPCH6L;%L]'6"}3+R^U'$FB/%=>9*LJ#9F3>&K9%4?H/^W?\$_&? MB?\ X(F_$'X?
6MEXD\?>/+/CX7MHPMY/+O=5U2_%FD;!S#\DD|R!L^6-I.=O& M*^Q0@'8<^U((U4Y"J#!*/PO_:_X)*__'_]EGQU_#6LW'@+OIXB\M:S\5?"NGZ=&\:.UH\=O$-2>,?-&IA>Y$S(
Z,7+&1<5_+@H1^RC\>/BW^ MT+\2I(?@9XGLH-%^,>C^,-,E\$>#M(72-7TJ&6%8]7FU+/\ :=[J#0F?S;: M8C=@QXSG]V1&H&-HQ]*01*.BKQ[4 ?CO^VY^P7XM^,?Q5_X*7:W_
,*DU+Q%-M=^.?"/A.#X?ZA-H*W,VK7$.G#STT>1EWEHYHX=ZI@AXT)Y450_:*_P"":WQ6 M\9_&{6=(^$_@B;P1\B%-K&%Q4?H>IFG2ZJ[_:=NTNGW,R+M%U):)-%E^5
M60<@/28;"P_?:@(\,8+D9B8DHC%6;/Z<_\3Q/:>-O MAAHNL6.@ZKX7LJ3M(IB'2-4T[^SK)3589$,UQ_RR=>A7M74I0#T'-* !0 44 M44 %%%% !1110 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-
!T]^*6B@# MXX,/GU72_AW^WE^S/XW\>75GIGPOT#_A(;&3==1D2/3MG\175O;0:9-/*V%A M+P#48$D>JO"ZBGP,XON M-3\2^,%K*#3O-\^]B6%8K;SRENA99&42#"DG&?T0\6^%-
/\;^'KS2=6L++#5=*.MU&)K>\L;VW2MKNN-AADDC<%64G]""#7'_##]E;X;_!&PU2U\%_#OP'X0MM;0 M1:C%HF@6FGQZ@@! 6988U$@&6X;(PQ'>@#\'T/A/^WJ/@KX)>+KKQO|
%R\'T M>]U?]D#PAXGT"36?$1@DO=8?3]6^UW]L97'F7;2FT\R1,N6,.3DK4?PX^ %M M\;/VO_[,U_QK\4AK'BC]D;0},U^6S\9W]H[\D)IFMY,;)!M50+!P].(.DEDQO M=B?TV\2_LP?
#WQM!WAZSUSX?^!=:I,_"<7V?1+>_T*UN(M&B*\"ELKQD0KL55 MQ&%&U0.<"MBQ^$OA_2!]JUT#0+6XCTM-$26'3XDD2P0DI9A@N1\;J22(ON_D MD"@#\M/^"/WP9O?
%/C_X):)\2OC"OA;P?\ L\^_O'MIX?C\97;Z;W6I M&7SH]WSVP6%(DML^2(P$*D)'MX?X"_MG?&3Q;\3_ \0]435=&\;>+O&EMH M^K;/JGQKBDL%-J)MH]*7PD(#)!-% "$VHLZ/)9)"/-+?
L#X7^$'ASP1=P7 M.B>'M#T>XMM.@TB%[&QBMS#90;C!:*44$01%WV1CY%+,54$FLZS_ &$?"S+H^JR:[8H=*MR+'47=W>\BRG[NX9)&,RX$LA M^\R^2,C-
>@_L+_$/0/$/BK]GOQUKOF1WC[_C)\7K64^+OA_K+:KI-U?'3GN M+S3VTHY&C"QGCV+(B1LAA\]1F:4D_H+_ ,*?\+&E>+5V0+51M_9D.8
M!28,K7H^7BY8.P,P^347AKX$>$?!GCK6O%&C^$O"FD^)?$A4ZMJ]EI- MO;W^J8'!N)T022D=M[&@#\C/V$]4UG]CGIF7!C_QYI/Q,^), ^F_$WPSXHA\2 M:+J6QT_3!AC(Y8):*,((-
CS*75V+_'G[77P MMCT+Q=XL\6K\2=%\27NH;3XA^*&=!M_#\-CX9\-V<7A,NVB);Z,#$FC;XVC?I* OI@LCNL> MW^NP/!-8OA/]DOX9>
]4M[W0_AQX!T2]MK^758;G3_#]I:S07DJ;)+A6CC\$ MK* K."&8<$D4 ?EE^PW^UU\6=9^/?P\3WMSJ\ PD/Q7'UBUL_%-EK'QO@UV-MVN8[BWEFO((/#44&[39K5HRX1%B;
6K13.K5[QX<_9S\'^# _B3]?C/2/ W@W2?&&M@C4==L]%MH-3U#<06\VX M5!*^2 3N8YP/2NC\&> "[,\ Z+ 9VCZ;INDV FEG6VL+9+:.!9)9&DD<(@ #/(M[NQOEF=F/)- &M1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M%%%% !1110 4444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 CN(U+,0[J,DDX %8=A\4/#.J>';G6+7Q%H5SI-DVRXO8K^)[:!N.'D#;5
M/S+U(<>M6/('SX,U?_KRG_|1,5_+)^Q=!XCT#_.GPWL;MA>,K|:;PFT'Q?M8.EW;QO!9P7.IQZR\4+#]XJHHT0;TX3D2V$JGY65MS*

*MP57N;2.X1I[<,,]70'?$*RO=5_:R\5>(//"?B_P MH+_[1=^\+>;ZA7PZ\MN"3"2T21DLTBI&%V8#G;](?\%?_P!K_P")?[:?_:-# M]LNZT'3O!&A_":X3^+'^"%_9:A'>(H;BYN?$3;KH%S<+!9^2ZK;+%"NXO()"IKLV!27'$?LD_M;?&#X M?_"O]@'X+?"Q?AQ!%\4?@Q-J5]>>*=/NKGI))8:=;21-&8)4)!+\H>#UR,8(-M!^M!8*.2!2Y!/45^3_B__@O]XEIOBG\0;G0O#-KX@\,_#COJ/!%QX3T_P;X@-MU#6]=\B>W@U#4;?4H(6L8_*9Y_*M)?G=(@S.C.BM;_:H_P""ROQ5_9V_;'\3 M>$]>LO!7PM\+Z-K]MI&@S>.?#FK2;+X]M9A'LU%O$%HSQ6;D_[*V;V<0,'D-M0[L`ZJE@-XM8*]Q7Y8_MN-\%DOBI^R[^U9XA\;ZAI_@KX;>#-$.GC0=8\5 M>&=6U?P_XQANXT+W+ZW8L4TY8G,NQ#;3>)Y7S&/=&?#0P%\/#XSU_QA!KUWK_@ MR_|FI:!.2VFG:5:23SI?,\ETFH&4)/:LAQ&OD*Q&&+'.T 'IM%(AR@/]* M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1_NF@#U[XM>%?"VMHIFI^)O#^FZE(5"VEU[,,,[;ONX1 MF#'/;CFM_<,>1QU]I_/3?V3OAE^UE_P7P_::T;XF>_/"/CO38?AMX6$":UI MD-X]F91,CM SJ7A=E &^_]PVCG@5X#^RK_P4>\0?\$_/\9:;X06=_=//]WQT M\<3<:-60:U]+!(CT\@F@>'=(VS-<-60-UJ+I+/(T'%@Z\=2\#JFC7DZP69A=4MEBA&XR2"1G MD7;L5"7_!^CNEZK;GTVW97-O>6ET@EAF@D$D*{;BILQ81206:6,,$#HXFEE+!G;,&IW*LC#8?%@\ M@G/^V#\3/Y5O^"6O[*_B_#VS\#MKOQ:^-^L^#-1.N6]Q/8V4VIZC(SO&)TD M&UHQ@G.0,8&<@_;?<"">HXHW#U%?E=^T9_P6K^(/P4^/'Q#^'=CI_A#4?%?P M0T&QG\06=MX/\1;JGCO6KFTDNA9V,UE'*NEQ*GE%9+HONDD*<(CR#)_:_X+ MH?$[X9?%\//X=T3X-^_[G3M'U+P]1I M5\]Ef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|-_VJ_CU\/?C?\'|'-^,FA_#?3]*<^ M.+W5K9^'M!BNO[:\#7$&FRZ@4NYGF>&]C"Q-9++$D:QS/$J^8L@8<_\ #O\M;V^+,K>'OAY\;=;?X9?*#^^?B6TT+2M-M+>[37M&LM0NVM-+U*2\;5H[CSY M?LI:V6VB:,?N"_[EBP!Z%;?\$C?A'\?=M=QIXG\'YXQR?')=VK$JOB610K,? ME_X]L=(:X._;<^,_@?!;:!*V?B:P[X&TIPOX\!:GPIO@.,N_CNVT!]D<\M1.\5P\+Vl%N;B6+R4\B!G)E9HBK_%?^T'\6KCX)_"""^\1V?@_Q7XIQ;9K>& MVT+PI:K<:A?2S3)"@4.RHB*SAGD=@D:*!L0%-`YJ_!3'_ 08_%3]HOQU M\8/#/@OX:Z/9>&_C9+9./$6A^;/G1M*LID:V>XU'7-'9]MY?#R62%K9"DBOF M,Y@KC]$/CS^S!H7[1'[*6K_"/Q'>ZJWA[Q:HR:)J4NFSK:W=Q;!560*Q#;-X M4J<\,0"#R/(/V4/^"B_9Q_X*.ZS>?\ !,WQS|>OB_HNB^%-;\"W MOBB'4|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|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f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|-\A({22SU?2=`OS?;=';VZR&\%Z]16*3>;"D65NB& \LGU MC_@]/_P4.U/]C3PQX1B\&Z!9>(_$VL?;]?U/3+F&2;XMO#FF6C76I74<*/&Q MF,,,>6P)9U)#*KX[7XB?M@2Z3^7+S1H?A5=`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|MFC?'3XT:EX]_83OOCA>^+OB)K.OZ9XIA\4Z%)=:,<2]UM'Y=Q?12H54'(9! MR?>NNU[_(*K?'KPO\+_ _!]\4$\UGIF_4O#'@3QIK'A^/P&T6H6_B_7+>PU]7-M35@@F-VT?VVX$8,0^S,KO(B[?FR/TYLKIKJ)6:-HBRAL'J,CH?<4 ?F#^U=^ MQAJ7Q9_:.L/B'XK_ &-]0^,7A74OA9H&AV6C#Q/HUO-X-U"VN]1ENK1S->1H MY6.YMTWQ,Z,4.&/4_0>@?!34]?|^"5/Q.^&GA3X(7?P5N!3\+>(=^T#P5D!4[B< BL_\X**_]H/+IFOQGX9U#X?ZC\$ MI?!WC?QCH?@NPM?$.@ZG<;I97.I?VQN)98+N.)XTD)<([!BO&[/-=`I$1_ MM8QV_(QX3T?3O@QXF;3:O5?$GC6^TS4[_#$;+=".VTZSLTNC=&X:)B\DLDO MEH(\@/OVH>X_L[^%+_X?_LV^.?#VJ6_V:5M%\-Z?HY;AU$K M>2"..XL;A=1DC(8R1>8ES;R%W\PAE3RT!R?BE^WS\>-X[*YMYX!Y,C6LWERR(',22)]FY(KZ4 M_9'O?C!K'@;.^U/B]FOPXU*[U2.'[TO\ X0_2[W3X((B#%9A=7$Q=]S<,I48 M'(SB@#XF^*7_ 3$^,,G[?P&\,PW5WJWC#1HM8\">,?(U^&_?3O"6O/(MQ: M&ZOF7?7]86Z6D0RAEF^S1N%|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|M1/B%\/;?PC\1_#US/H5EX?\ MXGL?$&J-=`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f4?AN.,5XM2OS%]5CJ>H"XG=;/4X\RVIS:3Q,J2#:=N MX,I#(.?1?OS_,"FU\'_P#=@HOX8^&,&GZ=>_,#Y*XTG0O%VM,2W%SI>N:WI ML4&D6N4<"%6:TC$C.CAC?6X!4YS2_;0_;)^.D?!=`BCX6^_/%GI/W@?1O"7@__M1O$4U0W\0,2]GN-0GO{C48FCA:&\MU"1BR4GY2?WHH \C_;/_&3_!-^'79V-M:X0<*'CK]D6^^-.B77PLL=%N-!'B?2+;7PMK0U"XN+B,M<7<*S*$E5!)&6!P M/%?7]H7]BS4?BI^RU\%M"T;]C>^TKPC\/?B=<:O]_P *Y?$^C>9]-A)I%]&+ MN.=;PVVTW=W&3&TP?,3';C!/VE_P3M_;3UK]KO\ 9&\']?$++7]%LM#U?7XKE;MP^PN6N;"Y:"ZEMA=6LC@,]K<"'SX6)AFC.6ZFK^WKXK^,/P[^%=_P"'%A+]+J7PUM&\+Z9?ZMK4'B[2;V<6]A@MS*D=O]FN(2C$HX8ON!!7 &-#D \Z_X)F_";.M3?@OXE\5VNC?LEZC^S?8ZM;0S75_-KVDZA%K$L3,1<.RSNYW5E621LLJKC/.M<5VW!'P6\3?",X[_M(ZOK>GBRL/B%\0X=?T*43QR?;,)=`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|:(OPS^VK'T^T#XX^.'PVO;%O'T'AY/#.10ZRUM]&EJF@VT-V(3;$S)+ M!=_]X.D4@LF1O0\JEH/\ P4&_:^)5]\2J;\$? ?P+XE\# #;0?K?AE@WCV.V M\0:T-+N'AE-O:&R,/G2;#Y;/<-%B6&)M)?"%%I2^%=_FN!;WHZGJ4-M8R%!(5D224B8(KM&(9CM;810!;_P"":_,FI\D M\=?!KJF]+X;?$3PIH-E>^!-1O-'M-3TBUMK73O%>GF5I8-16V@-6&6:.7%PA M1\O_?B+PU9^%:TB:5)+O3;?R"D)FU.[F MC.824):XSP3@$ \C]5_9}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|J=FTD O@>H_M'\%--+_9Z_;,^OPHN\AFT?Q&+=/$ M?B*2[=-93YKQ!5 93,0D]{OV@?VROC#HW[95Q\(/ MA1\-/ 7BZ

*MM9M2DU*WC74;I $+7,6UXB0ZHN3V'ZBT4 ?,/_!+KX+ ^,/@E^S+\)8>,.';P:B~M=3\1:KJ^B>#__+5#=+X&TF>Y9K/2%EA9HF$,6#B,I{,,.:¥5 3ZK^TYX/O\ MQ]^S?*

*\0=#TBV^V:OK7AK4K&Q@W*AFGEM9(XUW,0!EF R2 ,\FNYHH ^-_'%E M\>?V;,+@D/\-_#?PI\"/KWQIT?PCX>\-M8_:+%QX?F2S@AO+O\ ?SQ03-;A M)-B>9M>3R\Y3<:WO^:"5OPON/@_| "#5O#|S\)OB1\,KU-2_M75=8\;ZQ!>IZ MSXZU*Y&;K4KB;ON9PTI*(&W[%\M(U"(/JB@#¥Y_X)I?_Q)\"?@1XHT?Q M;I/|E:AJ'Q&\?ZY;PM+%-YEG>Z}>W5K+E&8#?!+&^:"=PW8(!! XK]O70_B'K M?Q0L-,'U>IGSPU^TK\%=3TX2OZ(1ID>]>'==C=@MS) ;,R0//:{P62+!|$$X?·MA@XQ]=T4 ?$OO>_8 @-#Y6.?(VL?\ !#'QG\$|/4?VI? #7Q,|\?LV>';7X6^!O"GC2VT8V5AXB\ M"7R00KK^A>1Y%W8V;R,EO%.J$%!*?*=59#C(-?1-% 'RC_P3;_9^\4_";4?B M/K]QX+7X. ^"/&E]83^&?AE%/:RX3%O T-U<%,1WM87NY"DAAMV9 (E8G?(X M'U=\110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 <+^TW\(T_; _9U\=^ I+1UM-B\;^' M=1T'[H8Q(<7=&K) 7"GAMOF9P>N,=Z^/_'[9OQ>^'WI.VC_FT/JGF'X'MZ>&-%M"]!>WFB,W@1;J&&*#^T_!7,B12V 4>?L#+<2*!CVfY^:7[WFA$R@$G M YX/6F/9) (,')H _/?XR?L,_%?\ ,C _;]\?>*1XSNOAAX=\#^$(_AGIDEYX* MM=5M?%<=]$EUK%U;)=L#^$SM#:AESN$,H$A4X'%_LU? OXE?OB7]E7X?>/?! M7B/5;#X'>)?&G@+6M9O-/G.GZUHR:%0L2X)&.&QCZ4 ?E;X7^"7QM_8-_:S\91Z#X1\2^/O!O MPN^#.OZ3\)]6MX)+V2]-[JNFRZ?H,!19":BTDC:-9),"2V1', CM2>'?^"97 MQF_X)R^/V>/'VE_$74?*

*B[%\$]5&G7OA73_!D=G=2Z;KLJ0ZU.);0R3W3)+(`MEZPF#9-KO8EE^;]4VLD<8);;_=!P*D:(-%LY Z<<8H _.7]FC]J/Q+^QO^/C=-MX3F^!?Q_\3>*M5^*_B_7O#[:9X*N9-'UF.\OY);*

*(C46VV\<,H*9E=@J DD@# M-LM:OOAU%\[_#$OC_6?=$GAVUUS3O^$RWS%:*3(1 M,1#*UL+K4)(N_&R\1L9WU|U%-9I/)N8'=C;D'MG-2F %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4RXB,T+*,#<;,\ P-\; M-*

*=A\9:9J_@;P_+KTVDWL>G6=AVT)\R(%;2*6*559'WRJQ5D53P/[1'PY M_:!_X*/+\)_!VNZ->?!VQG\9WOQ"GNVT*#5O^$;TS2FB&B:?J222O:SWMU'&LUFUF348+?4M/\B'=*

DSK;PW05'"'P>5B M#GY?4_V[_P!BOX@> OVO/A|K_P ~"U#7_AE\2_BSX5\]3^-]LP\|:MI^H M1.^MHNXW@N;9?+N%5]R6\4I;YWS^C/(/[3L_"E]X.MS=0PZ%/L\/%QBMW ";2& MZ*

159#<,=GF,Y;KO\|'5GC#P/^V3X?\ C/XX^|_QR5?B%\/#= TN_L?#?@;4- M6.AZS#JNI2WEE,JH'B9/-0C?lY74@D$$_LL"I#L PN,8I@L(P,8/8|<=/ /MS\^*_P"/BU^TO*

*!/X]2VO@WQAX!U/IL/QYH_AFU@NM/CEO?"'?A2VL+:TN- M8OH@^(*EMH+G]Q(Z.C2PK]\E*!]X(_LI_%G]A?\ X*)>$-> U'Q3?_%?P?\6?*

*M#+ ^"O$%YIOA&'++,PB=*C:XT>>6*SW0>41)=6H=U4H98@"%#5^@"62(01G*I M.?TIT|LEP1N&=N1^8QO MO\ ZA,|=H[YI] &!CTHH **** "BBB@ HHHH ** M*** "BBB@ HHHH*

***** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH ****1ONGG'OZ4 +17E?Q7^.WBSX*

*M>^+O[/TGX;ZYXJLS;QS"!LY@D:L<[HS\AY&!^=/?^B)>*_| P*'_M ,;H]YHKP;_(:N\>_]$2\5 P#@4/\ XW1_PU=X]_Z(EXK_ / H?_&Z/>:\ M*\& X:N\>_| 1$O%?_@4/_C='_#5WCW_*

*(EXK_\"A_\;H]YHKP;_A[fQ[_M -$2\5_^!0 ^-T?\-7>/?^B)>*__*'_P ;H]YHKP;_A[fQ[_T1+Q7_P"'\ M0_| C='_ U=X]_Z(EXK_P# H?\ QN@#WFBO!O\ AJfQ[_T1+Q7_ .!0_P#C*

*M=' _#5WCW_HB7BO\|"A_\;H]YHKP;_A[fQ[_P!$2\5_^!0_^-T?\-7>/?^B)>*__*'_P ;H]Y*

MHKP;_A[fQ[_T1+Q7_P"!0_| C=' _U=X]_Z(EXK_P# H?\ QN@#WFBO!O\ MAJfQ[_T1+Q7_ .!0_P#C=' _#5WCW_HB7BO\|"A_\;H]YHKP;_A[fQ[_P!$ M2\5_^!0_^-T?\-7>/?

HB7BO_P"_QN@#WFBO!O^&KO'O\ T1+Q7_X%# _XW1_PU=X]_Z(EXK_| H?_ !N@#WFBO!O^&KO'O_1$O%?_ (%# _P"-T?\ #5WCW_HB7BO_ ,"A_P#&Z />:*\& X:N\>_P#1$O%?_@4/_C='_#5WCW_HB7BO_P "A_| &Z />:\& X:N\>_]$2\5_| @4/_(W1_P -7>/?^B)>*__*'_P ;H]Y*

_@4/_C='_#5WCW_HB7BO_P "A_| &Z />:\& X: MN\>_]$2\5_| @4/_(W1_P -7>/?^B)>*_| P*'_ ;H]YHKP;_(:N\>_] M$2\5_P#@4/\ XW1_PU=X]_Z(EXK_/ H?_&Z/>:*\& X:N\>_|*

*1$O%?_@4 M/_C='_#5WCW_*(EXK_|"A_\;H]YHKP;_A[fQ[_-$2\5_^!0_^-T?\-7>/ M?^B)>*__*'_P ;H]YHKP;_A[fQ[_T1+Q7_P"!0_| C=' _U=X]_Z(EXK M_P# H?\ QN@#WFBO!O*

A[fQ[_T1+Q7_.!0_P#C=' _#5WCW_HB7BO\|"A_M\;H]YHKP;_A[fQ[_P!$2\5_^!0_^-T?\-7>/?\ HB7BO_P"_QN@#WFBO!O^&KO'O\ T1+Q7_X%# _XW1_PU=X]_Z(EXK_| H?_

!N@#WFBO!O^&KO'O_1$ MO%?_ (%# _P"-T?\ #5WCW_HB7BO _"A_P#&Z />:\& P"&KO'O_1$O%?\ MX%# _.-T?\-7>/?^B)>*_P#P*'_QN@#WFBO!O^&KO'O_ $1+Q7_X%# _XW1_P*

*MU=X]_P"B)>*__ H?_&Z />:*\& X:N\>_P#1$O%?_@4/_C='_#5WCW_HB7BO_M_P "A_| &Z />:*\& X:N\>_]$2\5_| @4/_(W1_P -7>/?^B)>*_| P*'_ ;H]YHKP;_(:N\>_]$2\5_P#@4/*

XW1_PU=X]_Z(EXK_/ H?_&Z />: M\& X:N\>_| 1$O%?_@4/_C='_#5WCW_*(EXK_|"A_\;H]YHKP;_A[fQ[_M -$2\5_^!0_^-T?\-7>/?^B)>*__*'_P ;H]YHKP;_A[fQ[_T1+Q7_P"!\0_| M0_|*

C='_ U=X]_Z(EXK_P# H?\ QN@#WFBO!O\ AJfQ[_T1+Q7_ .!0_P#C M='_#5WCW_HB7BO\|"A_\;H]YHKP;_A[fQ[_P!$2\5_^!0_^-T?\-7>/?\ MHB7BO_P"_QN@#WFBO!O^&KO'O

T1+Q7_X%# _XW1_PU=X]_Z(EXK_| H?_ M !N@#WFBO!O^&KO'O_1$O%?_ (%# _P"-T?\ #5WCW_HB7BO _"A_P#&Z /> M:*\& P"&KO'O_1$O%?\ X%# _.-T?\-7>/?

^B)> .P#P*'_QN@#WFBO!O^&K MO'O_ $1+Q7_X%# _XW1_PU=X]_P"B)>*__ H?_&Z />:*\& X:N\>_P#1$O%?_M_@4/_C=;OPU_:\\7^.?&=HNI_##Q@*X;L9PYOO[F8/'#A2PR-*

*@ZD!>O>@#UR MB@=** "BBB@#SGXX_M5^"OV=?&/P^T#Q7J4]CJ?Q0UT>&_#L<=I+,MW?&-I! M&S(I$#VHQW.0..M>B]^]-P!^G>OS]_X+8>)=.\'_ +2G[$&IZM]%CI6G67QE*

*MBEN+N\G2"""\!87&6=W(51\DUK?\!?,]N7P=X5_8VBN/#'Q+UD?!)#XMTOPL ME]\/_%&G6312W;M^ZO=4D65-,MGC2?===85T*KM.3@@'W-]O4OLVMOVIMN,<5 MA?*

$OXN>)/@SX,U'Q\ZUC3_#V@:1%YUXJ\9_,L,%NN0HW,>,EBJA>K%@ "37X M5>"OVZ?BYXC_&4OB;X=L_CWI-IH7AGXW:=X;T8ZCX_FN%UC2+]RDE?0U\61 MO"6+#<_;I"F3!

(JS?,N//%MQ-IWASP9IEQ]^K3QPO\!%M"ADD<(@+.0H/"@DI.M>977_!3C MX,P?LZ_#_P"\/BO^T/ 7Q/UFQ\/^:=3L;*>Y%Y?7DCQ0P,B(7B82H\;[P/+ M=&5L$5YQ_P*

%)4T^R_X(B?'&W\-ZY<>)="LOA;]JG8ZM#[^ M>[60^&-946QUBQ)V[G2:2Y29 Q4*/N[CYAH_I--WM!RC+C.>^/RIJ:BDK85 M7SC(^4X(^O2OPC_X*0?\%(0%G@@/IL'X@>*

*(/AS\6O'>C:¥\/OBCI?A$:?XC\< MVEE:M%YD:7=G9>%T@S=VC"@CP?I=KXA8:)9"9K2*6.6U8%98)%N7W0L?+)53MSN) /W/23*

M='NP!BF0W/G/C.RY&1FOR4^(_P"TS\9_VOCI^V%X1\#^~/'WQ-_X1'X/:=X M^\-V/B65=9NI.U>+XIYX2(IWDJ,S_9P/^4H0JHG ;_P2G_;5^(+_M,^'/#^ MO_$/1[_P-

*K_PWN/%6NPZ_P#%FR\7W8G66.7^V87AMHQ8Q.TCQO:M(L2*P.;(M(B" ?JO\3/B'I7PB^'':B#Q9KI[VNA^%]-N=6U&9(VD;&WMXFEE8*H+,0B,<*

M$G&!7S]^SQ_P5I^%_P"U)XA\-6/@[1/B_>6OBY%ETO5[KX;ZW9:-/&T9D24W MTMLMNL;/E178_M[ZK:K7_!.KXUWM<6]Q:7?PYUV:&>*0212QMDID MY5U89#*0001P0:^;?*

^""/AZ5QR[;"K4/A6 _@+3P:.18>%KZVU MR%K*,6RR7CWKPLZ';O(&4/@X"T ?9OP:^->F?'+P-#X@TJP\1Z;9SSSVX@U MW1G2+U&BD:-BUOG^<5^:"?P@ .;(^)-*

MQ7_8&_8I-U\6_B38ZK\0/VB+_P -:WK=EX@F74K_ $X7NIHMI\SEM\81$54< M,H"K@# PO !1/]H7XB?LO_M2?$FQB^-/BOQCX0^#^A;/+:V6F_$X>$_%_A" MV^9Y6L[N$6?

B&68;'L@N-NI:%$N0P!^T^G_ ;\:.K\2[SP=:.Q8S^*-.T^ M+5:O3$E#7-K:2N\<4TB_PJ[QN%S@ML;&0":X/XD_MV_"[X1?M4^#O@MXB\30 MZ3\1/B!H\NH^'|/N()%CU)(V92BS:?

+$I^/M0L&;:< G /X\ P#!-74O"'C/ M_@-N\'?\)8^,OMGBSX_:,EBJA>K%@ "37X M5>"OVZ?BYXC_&4OB;X=L_CWI-IH7AGXW:=X;T8ZCX_FN%UC2+]RDE?0U\61 M0"6+#<_;I"F3!

[PI%;U2^T/XA>&_@MJGBKP/J%MB"^W$ 1OGN#P17X"_LB?\%#]:U7X# M?\% /C%X57QS/&=[KGA+2=7B*S6RZEI>K1V:Z=+B:YB:*UA>XA8O*RGRH MV;;2R@GI_@O^VO*

$C_AF/\ X*# ^%K/XG;MJ6D?"WP'8:QX0FMOB"?&-[X9N MKFVNFN4CUT)'+<.)8E)P6$391&P.0#]TAJ2,>$D/)'W<=.M*M\"V"C9!P<*/$&]MH^N_">Z\7W MFMP?$"R^'>(]*

*<@UB2U/FZA-;O#.UI:01Z/:*LAN&>561=I /WBKP?I[\MX*3_ B_8Z^:'PW^'^Q \076C>*/DS>"PI\-0+ITIQ%>2F>**#RQI4B'I31C_MA48.1_&GQ=$0UKQYXHTZX1+O23=0C=?*

*$0MIGC M-S$NR(NYC5&E'1@*S'@#%? O_!S+|\'T^-/[7/PHM[=('UCPW\+//BO1W>:K MAHKW2XK6_B*1J1O=C;E .1\^2& Q0!^D^C?!%)OA+XA,;AU+]G.RUZYG^+>D M:*

*<-5N|*_L^<010>5'-G[3L\DD)*AVAB..X1'>%CRD[@HXY4D5^(7_ 1@OF^-/_!7,X;? M'O4HX_[<_:$\/>._$\IDL_LMPEI#J4-C;12(&,9VQVO8,@ /F'EL9KL/V=_V*

*MNOB\0M8^&W@KQ\)7O&?AZC4^_ C#\2-/\5>+CX@DT^ZM/[,YX-1\(U:1O\ M0X7(/MVEL[FZT\"L;RHBJ_EK'LMW= MRH3=6%_P6C_8\0\ J#3_ (+&?#

*{(GQ/X>NX/V%/&.NV|UH_C@^#_"}>N6GA7Q#XYCTA6\.Z!K-P]O&EC<2> M8)0Z/=0K+(L310LP1W#'%97B7_@1[X&TWX[^*? ^@^"/B5X]_P"$$U;_ (1[MQ'J7AC3(-0.FZEE ;=;$3C4+A0TB*TT-L*EN7P"1\|_$S_@W%L-?^,_C>ZT M6;X177AGXB>+9_&>H:QXK\'R:WXFTF:>XBGN=,M\W$=I+:R,DFUY8_,B$S ! MSAQI?MN?\$$O%'I6_P"T!XF\41^-? AS1#/CYXD^'^B>"?B5X_U'P- M-,6GBB7PUID%Q-HUQ=1QO;PK8R3QWUVS>;@8VL$HBW?.5PQN))6P,+R6E^U1W"+\SB2%5 .-Q8%1\$?M_ M\$'O$_[9?QV%Q;B|:63> MS+=CY-P 9U4)7W*/ _(--T/6-:T/Q+X)<)T3PQ9:?#]!T9 -$FU35(@=3QQ%:?#]TG0_=2&|S&;/% 'IRG*CO2TBC"C.,TM !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R>,21$'C MW]*?3+B,RQ%1W]Z /SC\?0?%;]J?_@L)\ _!6@:SH5MX M=BTZ6UCO;L2'1YX[FVE.];D4E R9RPW#;$W['O\ P5VUZ/\ 9DFL_BU97GCW MXTZ7\3_$'PGTW2_!^GPQW'CB_P!+#3-/;PN\<5O$MOS))(Z1ILW$KN"UV/Q(M_8B_:)\ _P#!0_XD_&_X/:[\%S#\1?#.D^'Y;+QC%J;R6)L5?$]"U(5@S.3@ MGH!TYKS3Q]_P;S6GBKX"> (+!Q%X4\.=2M$FA-'X=\;:GKAS M?I>VEO(LI2 L;R*2.0F.0+E'% &Y^WI_P %+!_&?P?^'OB'X1>(?\ "U]/ M^T9X?^&_&'3NGR6UU"U0W$T5!HMU%(&V!@(SE#\RE65L&NH^#_| P5/\#?#[MQ)K\%_<_%WQ#I^M?M :E\'WU+?UTZ6W\-.L AAAB\CRW32F;Y(I) \JLQWD@ M@UQEC_P0TUOPY^SXY#*Z3KGPST€4M"^,.C?%W4TT/PP^C:,';6>=VFP*KRR M3.HPJ3SMO8#Y\&M{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| !9CX-G1-%TW1TU;X M=^.-3U#[%9I +N\FU#P_YEQ,4 WRR;1EVRS;1DF@#W'[K_\:Z\-_L;_ YL MM?U^'5]5N]9U&'1=#T'1;3[9J_B349L^396<.Y0\S!7;YF5$1'=F55)KD_V= MOV_M'\GQ3UX>ZUX(\ /PM^(=EI0UZ/PUQWLL(+N\TPR&'|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f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|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

*[<3?:8;]^23SHO/V+=6T0C9O(MRS?*AKSN/XC6 MW[5WQ5^!WC;XK?&GQE^S#\6-9^#;:C]DMK6QTS3+A)KZ-[B2TN\3CE$GPR_9SF\-VVI7&N^(-0\56 M#:KIVF^%/#=[XCO);!=FZ_-O91R/':AI(U\Y@%+2* 237QMX=_:CL/VJ_P!G M[2M0\8?$?PU^S)\]_'G@MM2UfQG<^&K2&#QEX>BN;ZQC:UGO70B*0".IV(_F M0+<(4.UPYV?^"=/Q\T+P.!\8\>'MH-\0R/?>"\67S[F#4'DM6#2P+"K[C]G=QN*Y59'Z9(KU_X*_%_PQ^T%\-M) M\5^$M3CUSPUK]NT]C>)%)&ET@.RNX]/;VVQ>2 M^S231]57,/C]^R ;ZSXUN;5]3T[6=6T*U\0N\76-`MC?2VUKKs:?<=VW<,;R@I^];<63"D"@#Z$&GO*"%C554$!5X7GKP.*3%L(QMVC;CZ5-10!%' M800N&2&)6'0A "*2ZT^"^QYT,4VWIO4-C\ZFHH B2QAC7:L4:J.Rf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`]6>Y?^"KW[(@W+_$-[I M<3:YY(M_LUI<^9N_>;MXS;M3!.3@ ZB/XJ_\M$_QA5\,M^%(4-K^SYH/AOQ9<76D:9JT'A6D$&TW$";,<.P7Y"PQCI7I) M\)/CG\%? ^"@/PNOCX4USP[A_%+PH95BOJ11#?P1R(X=%GMY 2A#QAU\Q!JT, MO8U\]_%N\\9ZG^WK^Q-C^,W;QL=3M- OYK_3H7_L@!1%--%%(X*;_M"=T:X)(Y !/2>"TAC_X+A^+SX>^R>3)\';^-S;! YU :K)_9/VCOYGV4ZAL MQ_/FX$= 'I_]0'[4?P,_89D;5OB!XJ\#_#V[\77 G=[EHX+S698XUB\YD0> M;-LC1$,A:"]$4D?**XSX_?MY_LJW'[/NA:W\1O'/PRUGX9_$ R#3I=52/4]* MU5K' VAO"/@ M>VT_6|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l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f:UT]+9KIUDN LF%.^>2-"RK\TKJG#,!7A/_!3=X\ MA=Of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l.36+-R8DN_+@B&Y28 MRH9AGY_=J])\,?\ !23X$>,/@+]GQ0L/BGX1?X?Z->/IUWK]:^+NC?\ !:6YD^#_ (=^'OB/5Y(@E8#48O%V MNW>D010_V!?%6B>VM;AGZ_'X_ M) ;HMM^$_A;PE+I3Z5X;T#3'T+3SI.F-::?% =.LSL)MH2[CRX28X_W:87]VO' M KY4_9 !<^*1_P %"_&'A3XQ>#? 8^,MEX%MK^#QMX(GNTTS6M!;4)EBMKJS MN'9[6YCGW,@9I=RF0I(&2OLN@#$TSX:>'-%)%'PU9Z!HMIX<:WDM#I4-C%' M8F&3=YD7DA=FQMS97&#N\156EI6C6F@Z3,?8VMO96%VUO&(HH(E4*J M(JX"[% & !5FB@#D?B/\ #P)\8Y-+?Q?X*\)>*WT.8W.FMK&D6]^=/E. MTF2'S4;RV)522N#\H]*?\5/@3X^.MA9VOC?P;X5\96NG3?:+2'7-)M]1CM9 M<6\R-9D8*V.,C!KJZ* .3^)OP&\#?&I- -7QEX,\) ^+5T:8W&GC6M(M[\6,AQ MEXO-1O+,Y5Y7!X'I\5O@+X&^/&EVMCXY\&>%/&=E8S_&]VM]=TF#4HK>7! M7S$69&"MM)&X 'I Q7644 +0_&?A'PQXNT6"59X)/UK2X+^ MUCD4%5<1RJRA&08 @3 =]:Z#3M,MM(L8+6TMX;6VM8UAAABO)"B@!551P% M X %3T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% (5#8R <*/$KMXNU5(;RUOM7M7AD@OW"D S{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f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f>U:)#X1O;*22:W-J=N)(EFDSYVZM_3(^') M&EV^C?'F'5OBS\00%%_^T7X-L_"WB?4-6M;%KB*2UCDBCN;588HHX46.5U6W M";% 7!.* .,\.?! !7WXV^(_BG:^!T_9_P#"47B_Q9+K?XK>%XV\>C(')V MS%U%>3?90R3B8HD:1HZL) 7=0K,(=0 X.&?!GB/PO\ (0]"TSP=X;U?XF^$'\ M>74'Q"\:6 AFQTC3H[UK\+R((IHY%GNYYHK>0H%5=L)>0H.GT!H'_ 3#T+P_ M^T)X1^(2>*-% M?@W\.?AG9^^OB)XP\+^- OAMX7D\&KXO@L+'"\GUG1I;Y[QK2>UNH98 4DD&"@C@U^8__!S#XR\=_#_]MW]G3Q-X(0:YILOP[T+6_'MW86! MFD75(=*N,"YEC>%&"R 1+(Q\SY0[ONXS7Z#_ Y_9H>_LZ^)O@EX4\ >-=?:MN?A9X+M-5C\8#@))#]VJ>(Q)$#8]URZ+_LJ3N[HXRJ$VLIRNVM^,Y_P3/\ M#'[;@Q%X+/,O$VLZU.IH?@!Q%X+FTNT5!#]P%GK5J+,X9Y.'5D7)7.1SUXH_ M.?\ X)^?'#OQ7^TE_P<9ZL\2I/$&OGX??$#3/$]EX;TF:1X[46NCFST\7?*(LC M02!I5F =,Y*,21VV@Z)X _%_PFLHOB/\3_B;XSTK1*U'Q7=_MMH_EZ/(KZAJ5U>S)-- 'N#ILMX8V&7PH50:]C_8H_X(L>"OV'O&?P&\N+F4]4<2$X5/E XZU#X,_X(H>%?AMX:TN MY\->/O&N@?$#PSXP\0>,?#GC&S@M6O-';6B/MUD;>6-[>.WD0*,2(6!16#+!C M! /FC_@G_P#\% M<_9@^"_QQOM?\,ZMK_P 0_B/^UAK?@PKX

*4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 444R?=Y1Vl:`T5\,_%G_@H!\\=M5_;V^(_P4 M^$/PO^'7BP_#+PYI?B*[G\0^+;K2+G4UO5# M4_W%O#J$DL;744D8=9&C,1PF0#SDC%=7\'OVPM$UGQ7K6B^+?&OPEMM3F\;: MAX2\.6FA^*/MTM|):(K_&2X$L'7I=8MUTV229PD2"X+>7EF8 #=R30!WM%<#X!_:K M^&/Q4US5],\,_$+P7X@O!|M1?:C!IVLV|RI(,EG3SI CG;'NCD7>>~ 489R#6 M|\-/BSX8^,W@?3O$WA+7|)\2>'=70R6.IZ,)/"MGXCM}!U+5=!7/5-8B ML9}?GM+2:Y$$2L=[;A"02JG SQGB@#V:BOG|H<}O#PS\1OV;?A)\7/'VM>% M?APOQ3T73;^&VU+67X%<MB*KO-/WVR-&2UADF*>8VZ15 R?2N\)8# _*K7A3|H5C^BD\>52B+]/@WX6R>,O$,1^'M.M+ [7HTM[R>UO+B!$AEFV>8[I 7V@=,XX% `MUO17 :I^U:|\+]#E|\+I>_$7P-:-XW@^T^'A-KEM'_ &Y%L+^9;9?]\FP$[DR, M5#\0/VO?A3\)_B)I?A'Q3\2? OAOQ5K4;2V.D:IKEM:7UTBKO++#(X<@+SG' M2@#T6BO//B;^UO\ "SX*^,=%/>,/B/X&\+:[XC!.EZ?]VN6UG?$^V\$P^*= F\7WFC_P#"00:,E]&U]-IWF"+[8L0.XP>8 M0OF ;2S&- L#'N>/QK^?+IE_+3)"]*PO) MX,FU#QY'<^?!=Z;K&BW0DXID;J&Q$76|LBB?\M2O:YMW1#TTB1@:^1WSOCX*E*S"U>9M-2_T M:-9)' GE?F)!&<9Y')?L-_L(_Z? ^R_H^J_"_QSHB_#S|H7Q-KNK1:C;P MRMLE7-H?L|S)+!_H[1MNVEX/W9<-MQTK]?_ G^T|\,O'_O2UKP-H?C_P $ M:UXU\,JS:KH%CK5M<:GIH5E5C-,HYDC 9E!W*,%@#R:71/VH/AGXC^,=_P## MK3O'_@]^^(&E1&:|\,V^M6TFKVB*JL6DM5>$:MD"V0GD]>M9J_|\$[O'}M^S>;B+ MX0:JOC@?MF?!)C]H714&I'P^-1,@O_-_W_9? +)^,,,$CI7[3:GKECHNG3W5Y M/#:VMK$TT\LI"1POJ-S.S'@=*23P,55I-/O@;X^$#|>1^+_ T?!#V8U!|/$_M0U*:^RFMB0!,+G=Y1CR1\}/$_M@U^:^RFMB0!,+G=Y1'R1\}/$_MQ^:^7[+W_!0?2%'P_B^(GB7 MQQXQ_P\$OTSQOIS:=J<7AO2I9M:%K87LTDHNK,>W!98[O\ @/P_J0B?QO0Q@U3X?TO3;8SW5S?M:*EN$3.V=LC* MQRI "G/&37(_M0_L*?LRZWXHO_C\\5_"G@ZPFTHP7^L; [K&H2:,IER\)6.VF MU&,2QVUT8CM6-[I7,?RA2.*[!X;_\%"_@%\:?&6G^&/"7QI^%'BSQ'JJL;/2 M=(\56-]>7@5&=O+ACD9WPJLQV@X"D]: /R7T_| X)1_M/?L6_LO_LX?$W1- M:TOQWXP^#'B>/Q9=^%=#*\?O$7[9WP=\& %]W\;D1H|AGU^%M:+\+7N$7[1?#MAXUM_#,FKZ5'XCN[*74;?&6NG6 MMHV1))TA)WM&K.BLP& 74$Y- `YD^!>M?'&V^/_PT MT?P]X%%A'9W*^%9K/2IX;RUN3'[;5],N===TB""ZOM.BN$>ZLH9RXADEC!W(DABDVLP ;RWQG: M:\^^+G[>GP.^ 7C"3P_X[^+_ ,,?!>OQ1+FWEY\.?B!X)\>VFGRB&[F\.ZU:.I';.5#;9&@=@IP0>*<=10!^2?_!0#]A+ MXW/^TE\5M<^&_P .?&D>K?$@Z-=QZ,-/T+QE\/?'EY96T1<7Z7S12Z2D+1HB M>861C%E,EME?!1+#*7O$7[9WP=\& %]W\;D1H|AGU^%M:+\+7N$7[1?#MAXUM_#,FKZ5'XCN[*74;?&6NG6 MMHV1))TA)WM&K.BLP& 74$Y- `YD^!>M?'&V^/_PT MT?P]X%%A'9W*^%9K/2IX;RUN3'[;5],N===TB""ZOM.BN$>ZLH9RXADEC!W(DABDVLP ;RWQG: M:\^^+G[>GP.^ 7C"3P_X[^+_ ,,?!>OQ1+FWEY\.?B!X)\>VFGRB&[F\.ZU:.I';.5#;9&@=@IP0>*<=10!^2?_!0#]A+ MXW/^TE\5M<^&_P .?&D>K?$@Z-=QZ,-/T+QE\/?'EY96T1<7Z7S12Z2D+1HB M>861C%E,EME?!1+#*7O$7[9WP=\& %]W\;D1H|AGU^%M:+\+7N$7[1?#MAXUM_#,FKZ5'XCN[*74;?&6NG6 MMHV1))TA)WM&K.BLP& 74$Y- `YD^!>M?'&V^/_PT MT?P]X%%A'9W*^%9K/2IX;RUN3'[;5],N===TB""ZOM.BN$>ZLH9RXADEC!W(DABDVLP ;RWQG: M:\^^+G[>GP.^ 7C"3P_X[^+_ ,,?!>OQ1+FWEY\.?B!X)\>VFGRB&[F\.ZU:.I';.5#;9&@=@IP0>

*MX$I:51@C{X8G/D/{)OQV^-?PM^.?[4VG?#?X!Q_%'09?C1JEQ+J[>.K+0S%<_M-INEA[?R)XV<[55#O!P=^_/E-?0/PF_X)<^%/AQX_P##7B'6?B#\8_B-_%CZI8>'{GRWB6>*,1H9I4BE9%DN6E90<@ALL?8O@1^SSX?|\ V?|\ M4/"MYH3ZK)+|1O%5QXOU07DOFA+R;"WMW6+"C9%LM8*.+*P*3^5>RQ6Y$1R M:[\.W.E;M=|)S=2):WBBZ9;&66)@R_*K%|V$((QG],8B-@ /3]*\A_;$_8_T+]MGP)H& M@ZWKOC#PK-X7U^-U\3Z5JOAJ_2RU&QOK=)%CD21XY%P!,^05YR*L?LQ?LN77[M-EEJT-S\3_BE\3#JLL4JR^-M5@U"2PV!AM@,4$(0-NRV0V=]J\X!C?MY_;P M_P#M'-"_2/#GB;49I=,CUB'4QX6^WVU\;>/9K8-+%H|UYZL)+:9U7?&!\P49 M^4$'X_95^VA>//A=|\8O@IXWCN/@P+7Q[I/B&;X3Z?]MHVE6&F7,,4EGHL- MXP:*XL=3DL+AIH(EC"DW,"HL8!?[E_:T_9)|*?ME_#"'PQXJ;5K+^S]1M]:T MC5](NS9:KH&HV[H|>]LYP"8IXVS@X(()!!!(KS,Z_P""4WPYU[X%>*//GB'4 M/&/BS4_&-W;ZE]?C/5]7,GBJ?]LVW:?=1WL:((7LR%_C143YOE)DD+@'A__M3N\\"Z[X+U:]HGX6V6FK^S5XNUF*R\0^\/!.FI;:YIG@6SNK-[*+5;*1<6\ MWGW5I.SVX6-(Y+?&P[RI[YO[#7P%T[O]!^R\^U9\-?$'Q.\7Z#IU\9->T34/& M.FK6]OK=RKQ:%?C3KU_P"(O$MC]4_[*!S>)$LHA955HE7R(V3!+(PR M&SB@#\W?C?\ "/7_(0^(/B]X$_"76/@UX>\8:=H6K3?#/X>W\5Q_PEWA/ M2]9">(M2LGM3&L-[-9WD5N]G$(Y'C:-@TCNP3W3_(0F>+?AEI7_ 4DU_1? MV=_"F]^$/@CXK^&:Z[=PIH5UH^B:EK5I]45HMS9VTZHT4H@E>&=Q&@F>%.7: M%F'N>F_|$A/ DG@;7=-\2>-?BWX\U_5K.#3K'O?XB\3F?O)X9@@FCN(5TZZCMBC^5%;B*.8N$+R.B>8SJJJ/2_P!EK]B3P]^RSK>OZY!XB|=>.?%_BF&VM=6\ M2^+]:,4M3O;>V,IM[?A4ABBB\Z7:L4:9,C,VYB6(!|+1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M% !1110!C^/CL\%ZLP)5DLIV4@X(/EMR/>O@C0?'6N2?\&N;^(?!9U5O$G_# M/$^H#4_MDGV[I1_8;N)_.SO\S=\V_.<\YK]",ZS2^@,(IOX_:IH7BV!U#1I M_P!I#X7Q;1=V&J/+:OIU%X6=T@='*^1,)I"RH=K^8VN*\)^__11 M\$?"'7X;>,/"'AKQ/K|AX=\3?$W1?B3:VDT:3C16TR>QFBTV$G'^BYLE1:P8HMV"KG8,@'EOJ9'_!/CX8:U_P5$^!6F/;^-XM,^+)\9:MXKM+7Q[KUM!J5S;VU-MK/"P2.\58%22:0A(0B?-C;@ #@/VDO#_,'-&_X*>?$+PG\3_"_QY\7^&_"7-MP\\(0>%[!P0?%>IKI"EM42)KGX<^*/A-MLOC33M&UC7;O5E\.7MKJ8M+CI-+=22S&.Z6ZBD=&DPCP$!J/WAVZGQ/\ ^""2S*^0 D:X#@;CG M)KT3]E+]BN]^ WQ&\3>/O&7Q$\0?%3XD>+;"TTB]UO4;&TTZWM;"TDF>WM;6 MTMD6.! T\C.#_BQ\8O@M;>'VL+ MKP1\,_$L&:61-6GABNK5[N)X5$"CS_P!TRN1&^_CA?#OP*^$_[5'__M 38^(6]V'C/XE^,-#^'C^(KKPM8:QK>MZ#XA^'|=BK-HM]BZ2YG>VECW(+ MO<5CDC4!E =_IS]H/]A#6?"?QON?B=\,?BOXH^#_ (]U?3+?1-,NK2QM=9TW M6[*!WD@$UC=]T:SQ-)($FC*L%ED4A@W&E\)_V%;/X:?L]_$'P?=^+-:1^(? MBK)]%]X]\47T$$=WJ=_>VBVKW AB5(8TCBCACCB5<+'#&I+$%B ?,_P$UKP% M_P $N_|+@C(OQ_M8-;N-G:QJOO2^ ,I?$S0/BXVBZ5I7Bf'Q#I7B%=5-|-3 MM!'JL#W$,TBHT6HQ7! 21=J7*!%157/T_K__3UTGQ;^SY\$OAC]GB*^O?" M?P>N=$N;FU>TB*^^$_P"R;81VL5VIRGE&=(IW3:06B0#;@,-#O?|L&>'-3_: MF^&?Q5|\.SVO@_5?A_;ZKIUY:;?IL4,/B.POXHU>UN-A7Y4EBCF4X.'0'% 'R M=\|$?^":,?PDL/^"]_Q)*16?CF3PWX&\|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|% ;W_9"L?VI],\ M,7D'B;Q'X&\:> M2;6?"WB71)4^TZ3=M"\+[X9%:&X@DBD>.2&52KHS#*D[@ M ?) [!G@SX4>-_B]X_|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|T57XA_|@>?\;]YHH \&_P"&)[___**K\0___// M^-'_ Q/?_|15?B'_X'G_&O>:* /!O^&)[_/Z*K\0___XT?\,3W_/T5 M7XA_^!Y_QKWFB@##P;_AB>_|^BJ_$/\ \#S_ (T?\,3W_P#T57XA_P#@>?\ M&O>:*/!O^&)[_|Z*K\0_|P//^-'_#$]_ -%5^(?_('G_&O>:* /!O\ MAB>__P"BJ_$/_P #S_C1_P ,3W__$57XA_^!Y_QKWFB@##P;_AB>_P#^BJ_$ M/_P//^-'_#$] P#]%5^(?_@>?\;]YHH \&_X8GO_/HJOQ#_/_P"-'_#$ M]_|]%5^(?\ X'G_!KWFB@##P;_AB>__.BJ_$/_,#S_C1_PQ/?_P#15?B'M_P"!Y_QKWFB@##P;_(8GO_\HJOQ#_|_XT?\ #$]__P!%5^(?_@>?\;]Y MHH \&_X8GO_HJOQ#_\#S_C1_PQ/?_15?B'_X'G_&O>:* /!O^&)[_P#Z*K\0_P#P M//\ C1_PQ/?_ /15?B'_ .!Y_P :]YHH \&_X8GO_P#HJOQ#_P# _XT?\,3 MW_|T57XA_|@>?\;]YHH \&_P"&)[___**K\0___//^-'_ Q/?_|15?B M'_X'G_&O>:* /!O^&)[_/Z*K\0___XT?\,3W_/T57XA_^!Y_QKWFB@#P M;_AB>_|^BJ_$/\ \#S_ (T?\,3W_P#T57XA_P#@>?\ &O>:* /!O^&)[_|MZ*K\0_|P//^-'_#$]__-%5^(?_('G_&O>:* /!O\ AB>__P"BJ_$/_P # MS_C1_P ,3W__$57XA_^!Y_QKWFB@#P;_AB>_P#^BJ_$/_P//^-'_#$]_P#]M%5^(?_@>?\;]YHH \&_X8GO_/HJOQ#_/_P"-'_#$]_|]%5^(?\ X'G_M !KWFB@#P;_AB>__.BJ_$/_,#S_C1_PQ/?_P#15?B'_P"!Y_QK MWFB@#P;_(8GO_\HJOQ#_|_XT?\ #$]__P!%5^(?_@>?\;]YHH \&_X8 MGO_HJOQ#_\#S_C1_PQ/?__15?B'_X'G_&O>:* /!O^&)[_P#Z*K\0_P#P/!\ C1_PQ/?_ /15?B'_ .!Y_P :]YHH \&_X8GO_P#HJOQ#_P# _XT?\,3W_|T57X MA_|@>?\;]YHH \&_P"&)[___**K\0___//^-'_ Q/?_|15?B'_X'G_&O M>:* /!O^&)[_/Z*K\0___XT?\,3W_/T57XA_^!Y_QKWFB@#P;_AB>_|M^BJ_$/\ \#S_ (T?\,3W_P#T57XA_P#@>?\ &O>:* /!O^&)[_|Z*K\0_|MP//^-'_#$]__-%5^(?_('G_&O>:* /!O\ AB>__P"BJ_$/_P #S_C1_P , M3W__$57XA_^!Y_QKWFB@#P;_AB>_P#^BJ_$/_P//^-'_#$]_P#]%5^(?_@>?\ M?\;]YHH \&_X8GO_/HJOQ#_/_P"-'_#$]_|]%5^(?\ X'G_!KWFB@# MP;_AB>__.BJ_$/_,#S_C6]\,OV7KWX<^-K36)/'_C+7([4.#97!V9+>7Z6[-M_M#4D M9I8;V2,K(#!$T4+*$*3Y+U>_;3 ;V^*_P[_:_^!?@FP\(Z9HWPZ\;>+#X>UO M7+^]6>[U:9M%OI_[-90(ORP1-;J'N9&1F=-BQE=ST ?7=%?'?L;OI2WQ<_94 M^&GBOQ]X\;FX>"*WMY+EG1TOI7,I1($,<*Y9_.M+)?\)?M6?%36/^"!EC\\+=9\-.;X6^&M_X+U!6-*:;[6ZU;6Y]/U'3;47LBHN MRV@873F*,.[2(P=Q&0$H^M:*_/V^_X*D>+/"'[,O@O]H;4;>QU;X=?$77KO M1[/PE9Z:T6]V<'^GK!\BW)E(:YDEM4$X93&%E'E@&,F7I?@=^WMXQ@\<_L^: M;X\U?PCXHOOVBO"%YXBMM&\-V7Y>YT2XM].CO\6X>=FELVB\R(O*2WYC9A@C M[(P#[=HKXT_9%_;D\=^+_BQ^TA_PNC3__\.=!^%$6B;G;::MW]K?0M/N]- M>\D^YW*]JR3@*"ZQADC8.B/(,.=7_@G#^UU\1/VK?B1\W)^(=_M;B\.Z,8O+O=.TR[T>UOX5O&R]LIF:YEN&N75Y(T:)>(WCPK$;_MAP1H?_#_(*D_P#"7?LS>%/%GC/P/XJM?$ESX*_X3GQ39:+IDK67A_2EEFC%MZ7G96(E2$S1VR&2=X\LJNJE]-/LJBOE;XW?\%6OA\'O .N^+;.V\4^.O"OA M&RTN\U[4?#EFEQ%I"ZHL+V"2'22-B\L4\,Q^AO)BEC>78)$SU7Q+_P""@G@/ MX7:[XMAN_P"V[!0/AU<06?C/Q'96+3Z5X2FF5'6.ZFW9)2.2.68QK(+>.1)) MO+1@: /?Z*PM$U:ZU?4-05M.NK:SM7C%K?-/%)'J2-&KF2-5=F"JS%3Y@4DJ M< K@GY6^,?[2_P 7_P!GGQ'\,8_$FJ_#W4?%?Q1*